PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sone, M; Akiyama, Y; Ito, K				Sone, M; Akiyama, Y; Ito, K			Differential in vivo roles played by DsbA and DsbC in the formation of protein disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ALKALINE-PHOSPHATASE; SITE CYSTEINE RESIDUES; FORMATION IN-VIVO; ESCHERICHIA-COLI; PERIPLASMIC PROTEIN; FORMATION INVIVO; BETA-LACTAMASE; GENE; IDENTIFICATION; MEMBRANE	Several Escherichia coli proteins participate in protein disulfide bond formation, Among them, DsbA is the primary factor that oxidizes target cysteines. Biochemical evidence indicates that DsbC has disulfide isomerization activity, To study intracellular functions of DsbA and DsbC, we used an alkaline phosphatase mutant, PhoA[SCCC], with the most amino-terminal cysteine replaced by serine. It was found that the remaining 3 cysteines in PhoA[SCCC] form a disulfide bond of incorrect as well as correct combinations. An aberrant disulfide bond was preferentially formed in wild-type cells, which was converted slowly to the normal disulfide bond. This conversion did not occur in the dsbC-disrupted cells, Overproduction of DsbC stimulated the formation of the correct disulfide bond. In contrast, the inefficiently formed disulfide bonds in the dsbA-disrupted cells, and the more efficiently formed disulfide bonds in the same strain in the presence of oxidized glutathione were mostly in the correct form. These results suggest that the DsbA-catalyzed reaction can be too rapid for some proteins. DsbA may simply oxidize available pairs of cysteines, which happen to be in an incorrect combination in the case of PhoA[SCCC]. In contrast, DsbC stimulates the formation of correct disulfide bonds and corrects previously introduced aberrant ones. Thus, DsbC acts to isomerize disulfide bonds in vivo.	KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University								AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; ALKSNE LE, 1995, J BACTERIOL, V177, P462, DOI 10.1128/jb.177.2.462-464.1995; ALKSNE LE, 1996, J BACTERIOL, V173, P4306; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Frech C, 1996, BIOCHEMISTRY-US, V35, P11386, DOI 10.1021/bi9608525; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J. H., 1972, EXPT MOL GENETICS, P431; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	34	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10349	10352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099671				2022-12-27	WOS:A1997WV26200005
J	Akinbi, HT; Breslin, JS; Ikegami, M; Iwamoto, HS; Clark, JC; Whitsett, JA; Jobe, AH; Weaver, TE				Akinbi, HT; Breslin, JS; Ikegami, M; Iwamoto, HS; Clark, JC; Whitsett, JA; Jobe, AH; Weaver, TE			Rescue of SP-B knockout mice with a truncated SP-B proprotein - Function of the C-terminal propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; RESPIRATORY EPITHELIAL-CELLS; BOVINE PULMONARY SURFACTANT; TARGETED DISRUPTION; LAMELLAR BODIES; EGF RECEPTOR; BEIGE MICE; II CELLS; DEFICIENCY; LOCALIZATION	The function of the 102-amirno acid C-terminal propeptide of surfactant protein B (SP-B) was analyzed by characterizing the phenotype associated with loss of expression of Shia peptide domain in transgenic mice. A construct encoding the signal peptide, N-terminal propeptide, and mature peptide of human SP-B (hSP-B-Delta c) was cloned under the control of the 3.7-kilobase human SP-C promoter and injected into fertilized eggs of the FVB/N mouse strain. Founder mice expressing the hSP-B-Delta c transgene were bred with heterozygous SP-B knockout mice (SP-B +/-). Offspring containing the transgene and one allele al mouse SP-B were identified and subsequently crossed to generate a transgenic line that expressed SP-B-Delta c in a null background (SP-B(-/-)/hSP-B-Delta c(+/+)). Expression of hSP-B-Delta c in SP-B(-/-) mice was restricted to type TP cells and resulted in a 2-fold Increase in mature SF-B relative to wild type littermates, These mice survived without any evidence of respiratory problems and had normal lung function, normal alveolar surfactant phospholipid pool sizes, and typical tubular myelin indicating that the 102-residue C-terminal propeptide of SF-B is mot required for normal structure and function of extracellular surfactant. However, proteolytic processing of the SP-C proprotein was perturbed resulting in the accumulation of a processing intermediate, M(r) = 11,000, similar to the phenotype detected in SP-B(-/-) mice; furthermore, lamellar bodies ire type II cells of SP-B(-/-)hSP-B-Delta c(+/+) mice were much larger than in the wild type animal and saturated phosphatidylcholine content in lung tissue was significantly increased although the incorporation of choline into saturated phosphatidylcholine was normal, Collectively, these results demonstrate a role for the C-terminal propeptide of SP-B in SP-I: proprotein processing and the maintenance of lamellar body size, The C-terminal propeptide may be an important determinant of intracellular surfactant pool size.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229; UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509	Cincinnati Children's Hospital Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056285, R37HL056285, R01HL036055] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36055, HL56285] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLARD PL, 1995, PEDIATRICS, V96, P1046; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; Buckingham KW, 1981, TOXICOL PATHOL, V9, P17; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHI EY, 1976, LAB INVEST, V34, P166; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FEHRENBACH H, 1991, J MICROSC-OXFORD, V162, P91, DOI 10.1111/j.1365-2818.1991.tb03119.x; GIESELMANN V, 1995, BBA-MOL BASIS DIS, V1270, P103, DOI 10.1016/0925-4439(94)00075-2; GROSS NJ, 1988, J APPL PHYSIOL, V64, P2017, DOI 10.1152/jappl.1988.64.5.2017; HAMVAS A, 1994, J PEDIATR-US, V125, P356, DOI 10.1016/S0022-3476(05)83276-7; HILL BT, 1975, FEBS LETT, V56, P20, DOI 10.1016/0014-5793(75)80102-5; HOOK GER, 1982, J BIOL CHEM, V257, P9211; Huffman JA, 1996, J CLIN INVEST, V97, P649, DOI 10.1172/JCI118461; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; KULOVICH MV, 1979, AM J OBSTET GYNECOL, V135, P57; LAI YL, 1986, RESP PHYSIOL, V66, P147, DOI 10.1016/0034-5687(86)90068-X; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MASON RJ, 1976, J LIPID RES, V17, P281; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STENGEL PW, 1980, J APPL PHYSIOL, V48, P370, DOI 10.1152/jappl.1980.48.2.370; TAKAHASHI A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P43, DOI 10.1016/0005-2760(90)90216-K; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VORBROKER DK, 1995, AM J PHYSIOL-LUNG C, V268, pL647, DOI 10.1152/ajplung.1995.268.4.L647; Wang ZD, 1996, J LIPID RES, V37, P790; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; YU SH, 1988, BIOCHIM BIOPHYS ACTA, V961, P337	40	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9640	9647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092492				2022-12-27	WOS:A1997WU03900011
J	Kessler, E; Safrin, M; Abrams, WR; Rosenbloom, J; Ohman, DE				Kessler, E; Safrin, M; Abrams, WR; Rosenbloom, J; Ohman, DE			Inhibitors and specificity of Pseudomonas aeruginosa LasA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ELASTASE; PURIFICATION; PROTEINASE; PROTEASE; GENE; ENDOPEPTIDASES; QUANTITIES; FRAGMENT; MUTANT	LasA is an extracellular protease of Pseudomonas aeruginosa that enhances the clastolytic activity of Pseudomonas elastase and other proteases by cleaving elastin at unknown sites. LasA is also a staphylolytic protease, an enzyme that lyses Staphylococcus aureus cells by cleaving the peptidoglycan pentaglycine interpeptides. Here we showed that the staphylolytic activity of LasA is inhibited by tetraethylenepentamine and 1,10-phenanthroline (zinc chelators) as well as excess Zn2+ and dithiothreitol. However, LasA was not inhibited by several serine or cysteine proteinase inhibitors including diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, leupeptin, and N-ethylmaleimide. LasA staphylolytic activity was also insensitive to N-alpha-p-tosyl-L-lysine chloromethyl ketone or phosphoramidon. EDTA and EGTA were inhibitory only at concentrations greater than 20 mM. Without added inhibitors, LasA obtained by DEAE cellulose fractionation was active to ward beta-casein, but the same cleavage patterns were observed with column fractions containing little or no LasA. The beta-casein cleaving activity was fully blocked in the presence of inhibitors that did not affect staphylolytic activity. In the presence of such inhibitors, purified LasA was inactive toward acetyl-Ala(4) and benzyloxycarbonyl-Gly-Pro-Gly-Gly-Pro-Ala, but it degraded soluble recombinant human elastin as well as insoluble elastin. N-terminal amino acid sequencing of two fragments derived from soluble elastin indicated that both resulted from cleavages of Gly-Ala peptide bonds located within similar sequences, Pro-Gly-Val-Gly-Gly-Ala-Xaa (where Xaa is Phe or Gly). In addition, Ala was identified as the predominant N-terminal residue in fragments released by LasA from insoluble elastin. A dose-dependence study of elastase stimulation by LasA indicated that a high molar ratio of LasA to elastase was required for significant enhancement of elastolysis. The present results suggest that LasA is a zinc metalloendopeptidase selective for Gly-Ala peptide bonds within Gly-Gly-Ala sequences in elastin. Substrates that contain no Gly-Gly peptide bonds such as beta-casein appear to be resistant to LasA.	UNIV PENN,SCH DENT MED,BIOPOLYMER ANAL LAB,PHILADELPHIA,PA 19104; UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; VET ADM MED CTR,MEMPHIS,TN 38163	University of Pennsylvania; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kessler, E (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,CHAIM SHEBA MED CTR,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL.		Abrams, William R/A-5782-2008		NIAID NIH HHS [AI-26187] Funding Source: Medline; NIAMS NIH HHS [AR20553] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AULD DS, 1995, METHOD ENZYMOL, V248, P228; Ayad S, 1994, EXTRACELLULAR MATRIX; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; BRITO N, 1989, RES MICROBIOL, V140, P125, DOI 10.1016/0923-2508(89)90046-6; DAMAGLOU AP, 1976, ATLAS PROTEIN SEQ S2, V5, P98; DUMAS BR, 1972, EUR J BIOCHEM, V25, P505, DOI 10.1111/j.1432-1033.1972.tb01722.x; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; GOLDBERG JB, 1987, J BACTERIOL, V169, P4532, DOI 10.1128/jb.169.10.4532-4539.1987; Gustin JK, 1996, J BACTERIOL, V178, P6608, DOI 10.1128/jb.178.22.6608-6617.1996; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KESSLER E, 1993, J BIOL CHEM, V268, P7503; KESSLER E, 1982, INFECT IMMUN, V38, P716, DOI 10.1128/IAI.38.2.716-723.1982; KESSLER E, 1995, METHOD ENZYMOL, V248, P740; LACHE M, 1969, J BACTERIOL, V100, P254, DOI 10.1128/JB.100.1.254-259.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SL, 1990, J BACTERIOL, V172, P6506, DOI 10.1128/jb.172.11.6506-6511.1990; LOEWY AG, 1993, J BIOL CHEM, V268, P9071; MAEDA H, 1995, METHOD ENZYMOL, V248, P395; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; OHMAN DE, 1980, J BACTERIOL, V142, P836, DOI 10.1128/JB.142.3.836-842.1980; OLSON JC, 1992, J BACTERIOL, V174, P4140, DOI 10.1128/jb.174.12.4140-4147.1992; OZA NB, 1973, INT J PEPT PROT RES, V5, P365; PARK S, 1995, MOL MICROBIOL, V16, P263, DOI 10.1111/j.1365-2958.1995.tb02298.x; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; PETERS JE, 1992, MOL MICROBIOL, V6, P1155, DOI 10.1111/j.1365-2958.1992.tb01554.x; SCHAD PA, 1988, J BACTERIOL, V170, P2784, DOI 10.1128/jb.170.6.2784-2789.1988; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TODER DS, 1991, MOL MICROBIOL, V5, P2003, DOI 10.1111/j.1365-2958.1991.tb00822.x; TSAI CS, 1965, CAN J BIOCHEM CELL B, V43, P1971, DOI 10.1139/o65-220; WOLZ C, 1991, MOL MICROBIOL, V5, P2125, DOI 10.1111/j.1365-2958.1991.tb02142.x	33	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9884	9889						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092525				2022-12-27	WOS:A1997WU03900044
J	Parameswaran, KN; Cheng, XF; Chen, EC; Velasco, PT; Wilson, JH; Lorand, L				Parameswaran, KN; Cheng, XF; Chen, EC; Velasco, PT; Wilson, JH; Lorand, L			Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIII(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; HUMAN ERYTHROCYTE TRANSGLUTAMINASE; FIBRIN-STABILIZING FACTOR; PROTEIN CROSS-LINKING; TRANSAMIDATING ENZYMES; ALPHA-2-PLASMIN INHIBITOR; TISSUE TRANSGLUTAMINASE; PURIFICATION; PLASMA; LENS	N-epsilon (gamma-glutamyl)lysine cross-links, connecting various peptide chain segments, are frequently the major products in transglutaminase-catalyzed reactions. We have now investigated the effectiveness of these enzymes for hydrolyzing the gamma:epsilon linkage. Branched compounds were synthesized, in which the backbone on the gamma-side of the cross bridge was labeled with a fluorophor (5-(dimethylamino)-1-naphthalenesulfonyl or a-aminobenzoyl) attached through an epsilon-aminocaproyl linker in the N-terminal position, and the other branch of the bridge was constructed with Lys methylamide or diaminopentane blocked by 2,4-dinitrophenyl at the N-alpha position, Hydrolysis of the cross-link could be followed in these internally quenched substrates by an increase in fluorescence, In addition to the thrombin and Ca2+-activated human coagulation Factor XIII(a), cytosolic transglutaminases from human red cells and from guinea pig liver were tested, All three enzymes were found to display good isopeptidase activities, with K-m values of 10(-4) to 10(-5) M. Inhibitors of transamidation were effective in blocking the hydrolysis by the enzymes, indicating that expression of isopeptidase activity did not require unusual protein conformations, We suggest that transglutaminases may play a dynamic role in biology not only by promoting the formation but also the breaking of N-epsilon-(gamma-glutamyl)lysine isopeptides.	NORTHWESTERN UNIV,SCH MED,DEPT CELL & MOL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NEI NIH HHS [EY-03942] Funding Source: Medline; NHLBI NIH HHS [HL-02212, HL-16346] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003942] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016346, R01HL016346] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; BASKOVA I P, 1985, Biokhimiya, V50, P424; BENDER ML, 1971, MECH HOMOGENEOUS CAT, P503; BERGAMINI CM, 1993, BIOCHEM MOL BIOL INT, V30, P727; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; BRUNERLORAND J, 1966, BIOCHEM BIOPH RES CO, V23, P828; CHENG XF, 1996, FASEB J, V10, pA1110; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; CROALL DE, 1986, CELL CALCIUM, V7, P29, DOI 10.1016/0143-4160(86)90028-X; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fradkov A, 1996, FEBS LETT, V390, P145, DOI 10.1016/0014-5793(96)00644-8; FREUND KF, 1994, BIOCHEMISTRY-US, V33, P10109, DOI 10.1021/bi00199a039; ICHINOSE A, 1982, BIOCHIM BIOPHYS ACTA, V706, P158, DOI 10.1016/0167-4838(82)90482-4; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LOEWY AG, 1993, J BIOL CHEM, V268, P9071; LORAND L, 1985, BIOCHEMISTRY-US, V24, P1525, DOI 10.1021/bi00327a035; LORAND L, 1971, ANAL BIOCHEM, V44, P207, DOI 10.1016/0003-2697(71)90362-9; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1992, BIOCONJUGATE CHEM, V3, P37, DOI 10.1021/bc00013a006; LORAND L, 1963, ARCH BIOCHEM BIOPHYS, V102, P171, DOI 10.1016/0003-9861(63)90168-1; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1992, BIOCHEM BIOPH RES CO, V186, P334, DOI 10.1016/S0006-291X(05)80812-5; LORAND L, 1987, BIOCHEMISTRY-US, V26, P308, DOI 10.1021/bi00375a043; Lorand L, 1980, Prog Hemost Thromb, V5, P245; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; LORAND L, 1971, ANAL BIOCHEM, V44, P221, DOI 10.1016/0003-2697(71)90363-0; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; LORAND L, 1976, HDB BIOCHEMISTRY MOL, V2, P669; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; MIMURO J, 1986, J CLIN INVEST, V77, P1006, DOI 10.1172/JCI112352; PARAMESWARAN KN, 1981, BIOCHEMISTRY-US, V20, P3703, DOI 10.1021/bi00516a006; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PISANO JJ, 1969, BIOCHEMISTRY-US, V8, P871, DOI 10.1021/bi00831a016; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; STEWART JM, 1969, SOLID PHASE PEPTIDE, P62; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; ZAVALOVA L L, 1991, Biokhimiya, V56, P115	50	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10311	10317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092583				2022-12-27	WOS:A1997WU03900102
J	Roberts, BJ				Roberts, BJ			Evidence of proteasome-mediated cytochrome P-450 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; RAT-LIVER; PROTEIN STABILIZATION; OXYGEN ACTIVATION; TURNOVER; INDUCTION; CELLS; FORMS; ACIDOPHILUM; EXPRESSION	The cytochrome P-450 family of enzymes performs an incredibly diverse range of detoxification and oxidation reactions within the cell and constitutes between 5 and 10% of protein in hepatic endoplasmic reticulum. In this report it is demonstrated that constitutively expressed membranous P-450s are targeted for destruction by the proteasome, in a process which is ubiquitin-independent and is demonstrated in vitro to require prior labilization of the enzyme. This process was specific for P-450s CYP1A2, CYP2E1, CYP3A, and CYP4A and was not demonstrated to be involved in the turnover of CYP1A1, CYP2B1/2, or NADPH reductase. In reconstitution experiments using purified proteasomes and microsomal fractions, labilized P-450 conformations are protected from 20 S proteasome degradation by substrate addition, with proteolysis occurring while P-450s are still attached to the endoplasmic reticulum.			Roberts, BJ (corresponding author), NIAAA, CLIN STUDIES LAB, 10 CTR DR, MSC-1256, BETHESDA, MD 20892 USA.							BARMADA S, 1995, BIOCHEM BIOPH RES CO, V206, P601, DOI 10.1006/bbrc.1995.1085; BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V297, P228, DOI 10.1016/0003-9861(92)90666-K; CORREIA MA, 1991, METHOD ENZYMOL, V206, P315; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; ELIASSON E, 1990, P NATL ACAD SCI USA, V87, P3225, DOI 10.1073/pnas.87.8.3225; ELIASSON E, 1988, BIOCHEM BIOPH RES CO, V150, P436, DOI 10.1016/0006-291X(88)90539-6; ELIASSON E, 1994, J BIOL CHEM, V269, P18378; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; INGELMANSUNDBERG M, 1993, ALCOHOL, V10, P447, DOI 10.1016/0741-8329(93)90063-T; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KOCAREK TA, 1993, MOL PHARMACOL, V43, P328; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MASAKI R, 1987, J CELL BIOL, V104, P1207, DOI 10.1083/jcb.104.5.1207; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROBERTS BJ, 1995, J BIOL CHEM, V270, P29632; ROBERTS BJ, 1994, BIOCHEM BIOPH RES CO, V205, P1064, DOI 10.1006/bbrc.1994.2774; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; SADANO H, 1983, J BIOCHEM-TOKYO, V93, P1375, DOI 10.1093/oxfordjournals.jbchem.a134272; SHIRAKI H, 1984, ARCH BIOCHEM BIOPHYS, V235, P86, DOI 10.1016/0003-9861(84)90257-1; SONG BJ, 1989, J BIOL CHEM, V264, P3568; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WATKINS PB, 1986, J BIOL CHEM, V261, P6264; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	40	96	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9771	9778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092510				2022-12-27	WOS:A1997WU03900029
J	Yamashita, T; Shimada, S; Guo, W; Sato, K; Kohmura, E; Hayakawa, T; Takagi, T; Tohyama, M				Yamashita, T; Shimada, S; Guo, W; Sato, K; Kohmura, E; Hayakawa, T; Takagi, T; Tohyama, M			Cloning and functional expression of a brain peptide/histidine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-TRANSPORT; PROTEIN; METABOLISM; MEMBRANE; DNA	Here we report the cloning and functional characterization of a rat novel peptide/histidine transporter (PHT1), which was expressed in the brain and the retina, The cDNA encodes the predicted protein of 572 amino acid residues with 12 putative membrane-spanning domains, The amino acid sequence has moderate homology with a nonspecific peptide transporter found in the plant, When expressed in Xenopus laevis oocytes, PHT1 cRNA induced high affinity proton-dependent histidine transport activity, This transport process was inhibited by dipeptides and tripeptides but not by free amino acids such as glutamate, glycine, leucine, methionine, and aspartate, Dipeptide carnosine transport activity was also confirmed by direct uptake measurement, By in situ hybridization analysis, PHT1 mRNA was widely distributed throughout whole brain. Especially, intense hybridization signals were found in the hippocampus, choroid plexus, cerebellum, and pontine nucleus. Signals were located in both the neuronal and small nonneuronal cells in these areas, PHT1 protein could contribute to uptake of oligopeptides, which function as neuromodulators, and clearance of degraded neuropeptides and be a new member in the growing superfamily of proton-coupled peptide and nitrate transporters, although its structure, localization, and pharmacological characteristics are unique among these members.	OSAKA UNIV, SCH MED, DEPT MOL NEUROBIOL TANABE, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT NEUROSURG, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University	Yamashita, T (corresponding author), OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.			Yamashita, Toshihide/0000-0003-4559-7018				Becker J. M., 1980, MICROORGANISMS NITRO, P257; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FROMMER WB, 1994, FEBS LETT, V347, P185, DOI 10.1016/0014-5793(94)00533-8; Ganapathy Vadivel, 1994, P1773; KONKOY CS, 1995, J NEUROCHEM, V65, P2773; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; MANTLE D, 1992, CLIN CHIM ACTA, V207, P107, DOI 10.1016/0009-8981(92)90154-I; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; NAIDER F, 1987, CURRENT TOPICS MED M, V2, P170; Payne J. W., 1980, MICROORGANISMS NITRO, P211; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAL CJ, 1991, COMP BIOCHEM PHYS B, V99, P679, DOI 10.1016/0305-0491(91)90354-G; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; STEHLE P, 1991, ANN NUTR METAB, V35, P213, DOI 10.1159/000177648; STEINER HY, 1994, PLANT CELL, V6, P1289, DOI 10.1105/tpc.6.9.1289; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILLIAMSON LC, 1992, J NEUROCHEM, V58, P2191, DOI 10.1111/j.1471-4159.1992.tb10963.x; [No title captured]	32	177	186	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10205	10211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092568				2022-12-27	WOS:A1997WU03900087
J	Kung, HC; Bolton, PH				Kung, HC; Bolton, PH			Structure of a duplex DNA containing a thymine glycol residue in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; ESCHERICHIA-COLI; OXIDATIVE DAMAGE; NUCLEIC-ACIDS; POLYMERASE-I; NMR; LESIONS; DYNAMICS; INVITRO; SPECTRA	Oxidative stress, ionizing radiation, and other events can induce the oxidation of the thymine in DNA to thymine glycol. The presence of thymine glycol can have significant biological consequences, and there are specific repair enzymes for thymine glycol in a wide range of organisms. The structure of a duplex DNA containing a single thymine glycol (5,6-dihydroxy-5,6-dihydrothymidine) has been determined by the combined use of NMR and restrained molecular dynamics. The duplex of d(C(1)G(2)C(3)G(4)A(5)Tg(6)A(7)C(8)G(9)C(10)C(11)) paired with d(G(22)C(21)G(20)C(19)T(18)A(17)T(16)G(15)C(14)G(13)G(12)), with Tg indicating thymine glycol, has been used for these studies. The structure shows that the thymine glycol induces a significant, localized structural change with the thymine glycol largely extrahelical. This structural information is consistent with the biological consequences of thymine glycol in DNA. This structure is compared with that of a DNA duplex with an abasic site in the same sequence context.	WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University								BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; CADET J, 1986, BIOCHIMIE, V68, P813, DOI 10.1016/S0300-9084(86)80097-9; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DEMPLE B, 1982, NUCLEIC ACIDS RES, V10, P3781, DOI 10.1093/nar/10.12.3781; DEMPLE B, 1982, J BIOL CHEM, V257, P2848; DEMPLE B, 1991, OXIDATIVE STRESS, V2; EKERT B, 1959, NATURE, V184, pBA58, DOI 10.1038/184058a0b; FEIDBERG EC, 1985, DNA REPAIR; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GEORGE AM, 1987, PROG BIOPHYS MOL BIO, V50, P121, DOI 10.1016/0079-6107(87)90012-5; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; HARE D, 1986, BIOCHEMISTRY-US, V25, P7456, DOI 10.1021/bi00371a030; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; JOSHUATOR L, 1988, NATURE, V334, P82, DOI 10.1038/334082a0; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P294, DOI 10.1021/bi00427a040; KAO JY, 1993, J BIOL CHEM, V268, P17787; KUNG HC, 1996, MAGN RESON CHEM; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; MORDEN KM, 1983, BIOCHEMISTRY-US, V22, P5557, DOI 10.1021/bi00293a016; NIKONOWICZ E, 1989, BIOCHEMISTRY-US, V28, P8714, DOI 10.1021/bi00448a007; NINKOWSKI EP, 1990, BIOCHEMISTRY-US, V29, P8714; RESINISCH KM, 1995, CELL, V82, P143; ROUET P, 1985, CANCER RES, V45, P6113; SYMONS MCR, 1987, J CHEM SOC FARAD T 1, V83, P1, DOI 10.1039/f19878300001; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; VONSONNTAG C, 1990, METHOD ENZYMOL, V186, P511; WAGNER JR, 1990, METHOD ENZYMOL, V186, P502; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Wang KY, 1996, J MOL BIOL, V260, P378, DOI 10.1006/jmbi.1996.0408; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WEINFELD M, 1993, NUCLEIC ACIDS RES, V21, P621, DOI 10.1093/nar/21.3.621; WITHKA JM, 1992, J MAGN RESON, V98, P611, DOI 10.1016/0022-2364(92)90014-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Young MA, 1995, METHOD ENZYMOL, V261, P121	46	89	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9227	9236						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083056				2022-12-27	WOS:A1997WU03700061
J	Lin, TH; Chen, QM; Howe, A; Juliano, RL				Lin, TH; Chen, QM; Howe, A; Juliano, RL			Cell anchorage permits efficient signal transduction between Ras and its downstream kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ADHESION; FIBRONECTIN; ACTIVATION; INTEGRINS; PATHWAY; REQUIREMENT	Cell anchorage strongly affects the signal transduction cascade initiated by peptide mitogens. For both epidermal growth factor and platelet-derived growth factor, activation of the consensus mitogen-activated protein kinase cascade is impaired when cells are held in suspension as compared with cells anchored to a fibronectin substratum. Upstream events in the signaling cascade, including tyrosine phosphorylation of the mitogen receptor and GTP loading of Ras, are similar in anchored and suspended cells. However, propagation of the signal to Raf and subsequently to the downstream kinases MEK and mitogen-activated protein kinase is markedly attenuated in suspended cells. Thus, there seems to be a distinct anchorage-dependent step between Ras and Raf in the signaling cascade initiated by peptide mitogens. These observations may have important implications for understanding the anchorage dependence of cell growth.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKE GD, 1970, NATURE, V227, P798, DOI 10.1038/227798a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUDDON R, 1995, CANC BIOL, P101; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	28	182	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8849	8852						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9082999				2022-12-27	WOS:A1997WU03700004
J	Mellado, M; RodriguezFrade, JM; Kremer, L; vonKobbe, C; deAna, AM; Merida, I; MartinezA, C				Mellado, M; RodriguezFrade, JM; Kremer, L; vonKobbe, C; deAna, AM; Merida, I; MartinezA, C			Conformational changes required in the human growth hormone receptor for growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CULTURED LYMPHOCYTES; SERUM BINDING-PROTEIN; TYROSINE PHOSPHORYLATION; EXTRACELLULAR DOMAIN; CYTOKINE RECEPTORS; IN-VIVO; PROLACTIN; FAMILY; IM-9; IDENTIFICATION	Growth hormone (GH) plays a significant role in normal growth and development. Signaling to the cell is believed to require growth hormone receptor (GHR) dimerization, which occurs following binding of a single growth hormone molecule to each of two receptors. We have developed,human growth hormone receptor-specific monoclonal antibodies, one of which was used here to characterize hormone/receptor interactions. This antibody, GHR05, is directed against the hinge spanning subdomains I and II of the receptor's extracellular region. Antibody binding to the cell surface receptor increases upon receptor binding to growth hormone, but not when it binds a mutant form, hGHG120R, which does not trigger receptor activation. Growth hormone binding thus appears ta lead to a conformational change in the receptor epitope recognized by GHR05, giving rise to the active dimer configuration, necessary for signal transduction. Using a chimeric receptor-expressing, growth hormone-dependent murine cell line, we find that GHR05 binds to the receptor in the absence of human GH and delivers a signal leading to cell proliferation. Finally, GHR05 treatment of IM-9 cells, a human cell line expressing a functional human GHR, leads to cell proliferation mediated by the generation of GH-specific signals, including phosphorylation of the JAK2 tyrosine kinase and activation of STAT5.			Mellado, M (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,CAMPUS CANTOBLANCO,E-28049 MADRID,SPAIN.		Kremer, Leonor/L-5445-2015; Mellado, Mario/M-9893-2014; Frade, Jose Miguel Rodriguez/K-4266-2014; Merida, Isabel/A-9713-2014	Kremer, Leonor/0000-0002-2235-2010; Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Merida, Isabel/0000-0003-2762-6241; von Kobbe, Cayetano/0000-0003-3895-3790				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHEN WY, 1994, J BIOL CHEM, V269, P15892; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GENARO AM, 1994, EUR J IMMUNOL, V24, P2515, DOI 10.1002/eji.1830241038; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; Harlow E., 1988, ANTIBODIES LAB MANUA; HOOGENRAAD NJ, 1986, METHOD ENZYMOL, V121, P375; ILONDO MM, 1994, BIOCHEM BIOPH RES CO, V202, P391, DOI 10.1006/bbrc.1994.1940; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Mellado M, 1996, J CLIN ENDOCR METAB, V81, P1613, DOI 10.1210/jc.81.4.1613; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MILMAN AE, 1950, ENDOCRINOLOGY, V47, P114, DOI 10.1210/endo-47-2-114; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; SWISLOCKI NI, 1970, ENDOCRINOLOGY, V87, P900, DOI 10.1210/endo-87-5-900; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WELLS JA, 1996, P NATL ACAD SCI USA, V3, P1; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; YOSHIDA A, 1992, ACTA ENDOCRINOL-COP, V126, P524, DOI 10.1530/acta.0.1260524	37	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9189	9196						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083050				2022-12-27	WOS:A1997WU03700055
J	Park, IS; Walsh, CT				Park, IS; Walsh, CT			D-Alanyl-D-lactate and D-Alanyl-D-Alanine synthesis by D-Alanyl-D-Alanine ligase from vancomycin-resistant Leuconostoc mesenteroides - Effects of a phenylalanine 261 to tyrosine mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-FAECIUM BM4147; GRAM-POSITIVE BACTERIA; PEPTIDOGLYCAN PRECURSORS; ESCHERICHIA-COLI; GLYCOPEPTIDE RESISTANCE; LACTOBACILLUS-CASEI; GALLINARUM BM4174; DDLA GENE; PURIFICATION; PROTEIN	The Gram-positive bacterium Leuconostoc mesenteroides, ATCC 8293, is intrinsically resistant to the antibiotic vancomycin. This phenotype correlates with substitution of D-Ala-D-lactate (D-Ala-D-Lac) termini for D-Ala-D-Ala termini in peptidoglycan intermediates in which the depsipeptide has much lower affinity than the dipeptide for vancomycin binding. Overproduction of the L. mesenteroides D-Ala-D-Ala ligase (LmDdl) 2 in E. coli and its purification to similar to 90% homogeneity allow demonstration that the LmDdl2 does have both depsipeptide and dipeptide ligase activity. Recently, we reported that mutation of an active site tyrosine (Tyr), Tyr(216), to phenylalanine (Phe) in the E. coli DdlB leads to gain of D-Ala-D-Lac depsipeptide ligase activity in that enzyme. The vancomycin-resistant LmDdl2 has a Phe at the equivalent site, Phe(261). To test the prediction that a Tyr residue predicts dipeptide ligase while an Phe residue predicts both depsipeptide and dipeptide ligase activity, the F261Y mutant protein of LmDdl2 was constructed and purified to similar to 90% purity. F216Y LmDdl2 showed complete loss of the ability to couple D-Lac but retained D-Ala-D-Ala dipeptide ligase activity. The Tyr --> Phe substitution on the active site omega-loop in D-Ala-D-Ala ligases is thus a molecular indicator of both the ability to make D-Ala-D-Lac and intrinsic resistance to the vancomycin class of glycopeptide antibiotics.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM49338] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHUR M, 1992, J BACTERIOL, V174, P2582, DOI 10.1128/jb.174.8.2582-2591.1992; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BILLOTKLEIN D, 1994, J BACTERIOL, V176, P2398, DOI 10.1128/JB.176.8.2398-2405.1994; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; DAUB E, 1988, BIOCHEMISTRY-US, V27, P3701, DOI 10.1021/bi00410a027; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; ELISHA BG, 1995, GENE, V152, P79, DOI 10.1016/0378-1119(94)00692-L; EVERS S, 1994, GENE, V140, P97, DOI 10.1016/0378-1119(94)90737-4; FACKLAM R, 1989, J CLIN MICROBIOL, V27, P724, DOI 10.1128/JCM.27.4.724-730.1989; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; FAN C, 1997, IN PRESS BIOCH; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; NAVARRO F, 1994, ANTIMICROB AGENTS CH, V38, P1788, DOI 10.1128/AAC.38.8.1788; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1962, J BIOL CHEM, V237, P3128; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1477, DOI 10.1128/AAC.33.9.1477; ORBERG PK, 1984, APPL ENVIRON MICROB, V48, P1129, DOI 10.1128/AEM.48.6.1129-1133.1984; Park IS, 1996, BIOCHEMISTRY-US, V35, P10464, DOI 10.1021/bi9603128; REYNOLDS PE, 1994, BIOCHEM J, V301, P5, DOI 10.1042/bj3010005; ROBINSON AC, 1986, J BACTERIOL, V167, P809, DOI 10.1128/jb.167.3.809-817.1986; RUOFF KL, 1988, J CLIN MICROBIOL, V26, P2064, DOI 10.1128/JCM.26.10.2064-2068.1988; SALYLE R, 1995, RASMOL; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEGEL IH, 1975, ENZYME KINETICS, P64; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; Walsh CT, 1996, CHEM BIOL, V3, P21, DOI 10.1016/S1074-5521(96)90079-4; WRIGHT GD, 1993, BIOCHEMISTRY-US, V32, P5057, DOI 10.1021/bi00070a013; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; WU Z, 1995, BIOCHEMISTRY-US, V34, P2455, DOI 10.1021/bi00008a008; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	37	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9210	9214						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083053				2022-12-27	WOS:A1997WU03700058
J	Minamide, LS; Painter, WB; Schevzov, G; Gunning, P; Bamburg, JR				Minamide, LS; Painter, WB; Schevzov, G; Gunning, P; Bamburg, JR			Differential regulation of actin depolymerizing factor and cofilin in response to alterations in the actin monomer pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; TUBULIN MESSENGER-RNAS; CULTURED-CELLS; BETA-ACTIN; NUCLEAR TRANSLOCATION; INCREASED EXPRESSION; BINDING PROTEIN; AUTO-REGULATION; F-ACTIN; BRAIN	Myoblasts, transfected with a human gene encoding a beta-actin point mutation, down-regulate expression of actin depolymerizing factor (ADF) and its mRNA Regulation is posttranscriptional. Expression of cofilin, a structurally similar protein, and profilin, CapG, and tropomodulin is not altered with increasing mutant beta-actin expression. Myoblasts expressing either human gamma-actin or the mutant beta-actin down-regulate the endogenous mouse actin genes to keep a constant level of actin mRNA,whereas the gamma-actin transfectants do not downregulate ADF. Thus, ADF expression is regulated differently from actin expression. The mutant beta-actin binds to ADF with about the same affinity as normal actin; however, it does not assemble into normal actin filaments. The decrease in ADF expression correlates with an increase in the unassembled actin pool. When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are downregulated compared with cofilin and 19 other proteins selected at random. Increasing the actin monomer pool also results in nearly complete phosphorylation of both ADF and cofilin, Thus, ADF and cofilin are coordinately regulated by posttranslational modification, but their expression is differentially regulated. Furthermore, expression of ADF is responsive to the utilization of actin by the cell.	COLORADO STATE UNIV, DEPT BIOCHEM & MOL BIOL, FT COLLINS, CO 80523 USA; COLORADO STATE UNIV, MOL CELLULAR & INTEGRAT NEUROSCI PROGRAM, FT COLLINS, CO 80523 USA; CHILDRENS MED RES INST, WESTMEAD, NSW 2145, AUSTRALIA	Colorado State University; Colorado State University; Children's Medical Research Institute - Australia			Gunning, Peter W/E-9058-2010; Schevzov, Galina/G-5117-2013	Schevzov, Galina/0000-0002-0793-2279; Gunning, Peter/0000-0003-0833-3128	FOGARTY INTERNATIONAL CENTER [F06TW001856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035126] Funding Source: NIH RePORTER; FIC NIH HHS [TW01856] Funding Source: Medline; NIGMS NIH HHS [GM35126] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; BAMBURG JR, 1991, METHOD ENZYMOL, V196, P125; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; GLUCK U, 1992, EXP CELL RES, V202, P477, DOI 10.1016/0014-4827(92)90102-E; GREENBERG ME, 1988, CURRENT PROTOCOLS MO; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYAKAWA K, 1993, J BIOCHEM-TOKYO, V114, P582, DOI 10.1093/oxfordjournals.jbchem.a124220; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1987, MOL CELL BIOL, V7, P2457, DOI 10.1128/MCB.7.7.2457; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ONO S, 1994, J BIOL CHEM, V269, P15280; ONO S, 1993, J MUSCLE RES CELL M, V14, P195, DOI 10.1007/BF00115454; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PARDEE JD, 1979, BIOCHEMISTRY-US, V18, P2245, DOI 10.1021/bi00578a017; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; ROSENBLATT J, 1997, IN PRESS J CELL BIOL; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3, pB15; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; Samstag Y, 1996, J IMMUNOL, V156, P4167; SAMUELS M, 1993, J CELL BIOL, V121, P909, DOI 10.1083/jcb.121.4.909; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; SCHEVZOV G, 1993, J CELL BIOL, V121, P811, DOI 10.1083/jcb.121.4.811; SCHEVZOV G, 1995, DNA CELL BIOL, V14, P689, DOI 10.1089/dna.1995.14.689; SERPINSKAYA AS, 1990, FEBS LETT, V277, P11, DOI 10.1016/0014-5793(90)80797-M; SHIMIZU N, 1986, J BIOCHEM-TOKYO, V99, P751, DOI 10.1093/oxfordjournals.jbchem.a135534; SHINAGAWA Y, 1993, ZOOL SCI, V10, P611; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	69	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8303	8309		10.1074/jbc.272.13.8303	http://dx.doi.org/10.1074/jbc.272.13.8303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079652	hybrid			2022-12-27	WOS:A1997WQ63500035
J	Sastry, SS; Ross, BM				Sastry, SS; Ross, BM			Nuclease activity of T7 RNA polymerase and the heterogeneity of transcription elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID POLYMERASE; PSORALEN CROSS-LINK; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; TERNARY COMPLEXES; T7-RNA POLYMERASE; STRUCTURAL-ANALYSIS; NASCENT RNA; TEMPLATE; PROMOTER	We have discovered that T7 RNA polymerase, purified to apparent homogeneity from overexpressing Escherichia coli cells, possesses a DNase and an RNase activity, Mutations in the active center of T7 RNA polymerase abolished or greatly decreased the nuclease activity. This nuclease activity is specific for single-stranded DNA and RNA oligonucleotides and does not manifest on double-stranded DNAs, Under the conditions of promoter-driven transcription on double-stranded DNA, no nuclease activity was observed, The nuclease attacks DNA oligonucleotides in mono- or dinucleotide steps, The nuclease is a 3' to 5' exonuclease leaving a 3'-OH end, and it degrades DNA oligonucleotides to a minimum size of 3 to 5 nucleotides. It is completely dependent on Mg2+, The T7 RNA polymerase-nuclease is inhibited by T7 lysozyme and heparin, although not completely, In the presence of rNTPs, the nuclease activity is suppressed but an unusual 3'-end-initiated polymerase activity is unmasked, RNA from isolated pre-elongation and elongation complexes arrested by a psoralen roadblock or naturally paused at the 3'-end of an oligonucleotide template exhibited evidence of nuclease activity. The nuclease activity of T7 RNA polymerase is unrelated to pyrophosphorolysis, We propose that the nuclease of T7 RNA polymerase acts only in arrested or paused elongation complexes, and that in combination with the unusual 3'-end polymerizing activity, causes heterogeneity in elongation complexes, Additionally, during normal transcription elongation, the kinetic balance between nuclease and polymerase is shifted in favor of polymerase.			Sastry, SS (corresponding author), ROCKEFELLER UNIV,GENET MOL LAB,BOX 174,NEW YORK,NY 10021, USA.							ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BONNER G, 1994, J BIOL CHEM, V269, P25129; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8999; CAZENAVE C, 1994, P NATL ACAD SCI USA, V91, P6972, DOI 10.1073/pnas.91.15.6972; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; Chamberlin M., 1982, ENZYMES, V15, P87; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHEN YH, 1993, J BIOL CHEM, V268, P5849; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P5301, DOI 10.1093/nar/19.19.5301; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAUSMANN R, 1988, BACTERIOPHAGES, P259; IKEDA RA, 1992, J BIOL CHEM, V267, P20153; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KRUPP G, 1989, NUCLEIC ACIDS RES, V17, P3023, DOI 10.1093/nar/17.8.3023; MAITRA U, 1967, J BIOL CHEM, V242, P4897; Maniatis T., 1982, MOL CLONING; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; MULLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; OSTERMAN HL, 1981, BIOCHEMISTRY-US, V20, P4884, DOI 10.1021/bi00520a013; PAVCO PA, 1991, NUCLEIC ACIDS RES, V19, P4639, DOI 10.1093/nar/19.17.4639; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; RASKIN CA, 1993, P NATL ACAD SCI USA, V90, P3147, DOI 10.1073/pnas.90.8.3147; RASTINEJAD F, 1993, J MOL BIOL, V232, P105, DOI 10.1006/jmbi.1993.1373; REINES D, 1992, J BIOL CHEM, V267, P3795; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RICHETTI M, 1996, BIOCHEMISTRY-US, V35, P14970; SADOWSKI PD, 1985, NUCLEASES, P23; SASTRY SS, 1993, BIOCHEMISTRY-US, V32, P5526, DOI 10.1021/bi00072a006; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P13519, DOI 10.1021/bi960982d; SASTRY SS, 1991, J MOL BIOL, V221, P1111, DOI 10.1016/0022-2836(91)80115-B; SASTRY SS, 1995, BIOCHEM BIOPH RES CO, V211, P106, DOI 10.1006/bbrc.1995.1784; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SASTRY SS, 1997, IN PRESS BIOCHEMISTR; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SHI YB, 1988, J BIOL CHEM, V263, P527; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SKOOG JU, 1993, NUCLEIC ACIDS RES, V21, P4055, DOI 10.1093/nar/21.17.4055; SMEEKENS SP, 1986, NUCLEIC ACIDS RES, V14, P2811, DOI 10.1093/nar/14.6.2811; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SPIELMANN HP, 1992, P NATL ACAD SCI USA, V89, P4514, DOI 10.1073/pnas.89.10.4514; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	73	31	31	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8644	8652		10.1074/jbc.272.13.8644	http://dx.doi.org/10.1074/jbc.272.13.8644			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079696	hybrid			2022-12-27	WOS:A1997WQ63500079
J	Thain, A; Webster, K; Emery, D; Clarke, AR; Gaston, K				Thain, A; Webster, K; Emery, D; Clarke, AR; Gaston, K			DNA binding and bending by the human papillomavirus type 16 E2 protein - Recognition of an extended binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PAPILLOMAVIRUS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TRANS-ACTIVATION; GENE-PRODUCT; E6 PROMOTER; IN-VIVO; ENHANCER; DOMAIN; TRANSACTIVATION	The human papillomavirus (HPV) 16 E2 protein (hE2) binds to four sites present upstream of the P97 promoter and regulates transcription of the viral E6 and E7 oncogenes. We have determined the relative binding constants for the interaction of the full-length hE2 protein with these sites. Our results show that hE2 binds tightly to site 4, less tightly to sites 1 and 2, and weakly to site 3, Similar results have previously been obtained using a C-terminal fragment of the hE2 protein suggesting that the C-terminal domain is the sole determinant of DNA binding affinity and specificity. Using circular permutation assays we show that binding of the hE2 protein induces the formation of a significant DNA bend and that the hE2-induced DNA bend angle is the same at both tight and weak hE2-binding sites. An alignment of the four hE2-binding sites from the HPV 16 genome suggests that this protein recognizes an extended binding site when compared with the bovine papillomavirus E2 protein. Here we show that the hE2 protein binds tightly to sites containing an A:T or a G:C base pair at position 7 of its binding site but weakly to sites containing either C:G or T:A at this position. Using site-directed mutagenesis we demonstrate that an arginine at position 304 of the hE2 protein is responsible for the recognition of specific base pairs at this position.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, CTR MOL RECOGNIT, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol			Gaston, Kevin/K-9237-2019	Gaston, Kevin/0000-0002-7349-5513				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; PHELPS WC, 1987, J VIROL, V61, P1630, DOI 10.1128/JVI.61.5.1630-1638.1987; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SPALHOLZ BA, 1988, J VIROL, V62, P3143, DOI 10.1128/JVI.62.9.3143-3150.1988; Stubenrauch F, 1996, J VIROL, V70, P119, DOI 10.1128/JVI.70.1.119-126.1996; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; Thain A, 1996, TRENDS GENET, V12, P209, DOI 10.1016/S0168-9525(96)90022-0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994	35	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8236	8242		10.1074/jbc.272.13.8236	http://dx.doi.org/10.1074/jbc.272.13.8236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079642	hybrid			2022-12-27	WOS:A1997WQ63500025
J	Bambara, RA; Murante, RS; Henricksen, LA				Bambara, RA; Murante, RS; Henricksen, LA			Enzymes and reactions at the eukaryotic DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CELL NUCLEAR ANTIGEN; CEREVISIAE CDC2 GENE; POLYMERASE-EPSILON; CALF THYMUS; SV40 ORIGIN; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; PURIFIED PROTEINS; CRYSTAL-STRUCTURE; STRAND SYNTHESIS		UNIV ROCHESTER, MED CTR, CTR CANC, SCH MED & DENT, ROCHESTER, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), UNIV ROCHESTER, MED CTR,DEPT BIOCHEM,SCH MED & DENT, 601 ELMWOOD AVE, BOX 712, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM24441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; Bambara RA, 1995, METHOD ENZYMOL, V262, P270; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; Brush GS, 1995, METHOD ENZYMOL, V262, P522; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; BUDD ME, 1996, IN PRESS MOL CELL BI; BURGERS PM, 1990, EUKARYOTIC DNA POLYM; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FISHER PA, 1994, PROG NUCLEIC ACID RE, V47, P371, DOI 10.1016/S0079-6603(08)60257-3; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUBSCHER U, 1992, TRENDS BIOCHEM SCI, V17, P55, DOI 10.1016/0968-0004(92)90499-Y; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; HWANG PI, 1995, FASEB J, V9, pA1398; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAGUNI LS, 1988, BIOCHIM BIOPHYS ACTA, V950, P87, DOI 10.1016/0167-4781(88)90001-2; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Shakibai N, 1996, P NATL ACAD SCI USA, V93, P11569, DOI 10.1073/pnas.93.21.11569; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SITNEY KC, 1992, ANN NY ACAD SCI, V665, P52, DOI 10.1111/j.1749-6632.1992.tb42573.x; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STILLMAN B, 1992, CIBA F SYMP, V170, P147; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMMES P, 1992, J BIOL CHEM, V267, P6063; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TURCHI JJ, 1992, NUCLEIC ACIDS RES, V20, P6075, DOI 10.1093/nar/20.22.6075; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wang TSF, 1995, METHOD ENZYMOL, V262, P77; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	73	285	297	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	1997	272	8					4647	4650		10.1074/jbc.272.8.4647	http://dx.doi.org/10.1074/jbc.272.8.4647			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WJ855	9081985	hybrid			2022-12-27	WOS:A1997WJ85500001
J	Koyota, S; Wimalasiri, KMS; Hoshi, M				Koyota, S; Wimalasiri, KMS; Hoshi, M			Structure of the main saccharide chain in the acrosome reaction-inducing substance of the starfish, Asterias amurensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; OLIGOSACCHARIDES; SPERMATOZOA; DESULFATION; MOLECULES	The structure of the main saccharide chain of the acrosome reaction-inducing substance in the egg jelly coat of the starfish, Asterias amurensis, is composed of the following pentasaccharide repeating units (Structure I), A polymer consisting of 10-11 repeating units has been observed to induce the acrosome reaction in starfish sperm at high calcium concentrations. GRAPHICS STRUCTURE I The identities and linkage positions of constituent sugars were established using sugar, methylation, and sulfate analyses together with one- and two-dimensional nmr spectroscopy, The structure was supported by the data obtained for desulfation products and the Smith degradation of the polysaccharide.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology								ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HEY GW, 1965, METHODS CARBOHYDR CH, V5, P377; HOSHI M, 1994, INT J DEV BIOL, V38, P167; IKADAI H, 1981, DEV GROWTH DIFFER, V23, P73; IKADAI H, 1981, DEV GROWTH DIFFER, V23, P81; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA K, 1970, DEV GROWTH DIFFER, V12, P179; KELLER SH, 1994, DEV BIOL, V162, P304, DOI 10.1006/dbio.1994.1087; MATSUI T, 1986, DEV GROWTH DIFFER, V28, P339; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nishigaki T, 1996, ZYGOTE, V4, P237, DOI 10.1017/S0967199400003154; NISHIYAMA I, 1987, DEV GROWTH DIFFER, V29, P171; OKINAGA T, 1992, BIOCHEM BIOPH RES CO, V188, P405; PARK JT, 1949, J BIOL CHEM, V181, P149; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; Ushiyama A, 1995, ZYGOTE, V3, P351, DOI 10.1017/S0967199400002781; YAMAGUCHI M, 1989, DEV GROWTH DIFFER, V31, P233	23	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10372	10376						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099675				2022-12-27	WOS:A1997WV26200009
J	Chang, LM; Wei, LN				Chang, LM; Wei, LN			Characterization of a negative response DNA element in the upstream region of the cellular retinoic acid-binding protein-I gene of the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; THYROID-HORMONE; RECEPTOR BINDS; CRABP-II; EXPRESSION; CELLS; MICE; BETA; INDUCTION; CDNA	A negative, regulatory DNA element from the mouse cellular retinoic acid-binding protein I gene promoter was identified, This DNA element, located approximately 1 kilobase upstream from the transcription initiation site of this gene, contained a pair of direct repeats (DRs) separated by 4 base pairs (DR4, TGACCTTTGGGGACCT). By examining a series of reporters deleted or mutated within this DR4 region, it was concluded that the core sequence of this DR4, including both repeats and the spacer, was required for suppressive activity in the mouse embryonal carcinoma cell line P19, From gel retardation experiments, it was concluded that both repeated sequences were essential for specific protein binding, but the spacer sequence was not as critical. Specific residues required for protein binding to this DR4 were identified, In P19 cells, retinoic acid induced the binding of nuclear factors to DR4 and suppressed the activities of the reporters containing this DR4. Co-expression of retinoic acid receptor beta or thyroid hormone receptor beta 1 (T(3)R(beta 1)) significantly inhibited the expression of this reporter in P19 cells. Gel retardation with in vitro-synthesized nuclear receptors demonstrated specific binding of this DR4 by T(3)R(beta 1) monomers, homodimers, or heterodimers of T(3)R(beta 1)/retinoid receptor X beta. A biological function of DR4 in crabp-I gene regulation in P19 cells was suggested.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46866] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTROM A, 1991, J BIOL CHEM, V266, P17662; BASS NM, 1993, MOL CELL BIOCHEM, V123, P191, DOI 10.1007/BF01076492; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BOYLAN JF, 1991, J CELL BIOL, V112, P1965; Chen AC, 1996, J BIOL CHEM, V271, P14971, DOI 10.1074/jbc.271.25.14971; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; JONES KE, 1993, MOL CELL ENDOCRINOL, V91, P113, DOI 10.1016/0303-7207(93)90262-I; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMPRON C, 1995, DEVELOPMENT, V121, P539; MANGELSDORF DJ, 1993, RETINOIDS, V2, P319; NUGENT P, 1995, IN VITRO CELL DEV-AN, V31, P553; ONG DE, 1993, RETINOIDS, V2, P283; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; VAESSEN MJ, 1989, DIFFERENTIATION, V40, P99, DOI 10.1111/j.1432-0436.1989.tb00819.x; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1992, DEV GROWTH DIFFER, V34, P479; WEI LN, 1994, DEV DYNAM, V201, P1, DOI 10.1002/aja.1002010102; Wei LN, 1996, J BIOL CHEM, V271, P5073; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1995, MOL CELL ENDOCRINOL, V111, P207, DOI 10.1016/0303-7207(95)03570-W; WEI LN, 1987, MOL ENDOCRINOL, V2, P526	33	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10144	10150						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092560				2022-12-27	WOS:A1997WU03900079
J	Richon, VM; Lyle, RE; McGehee, RE				Richon, VM; Lyle, RE; McGehee, RE			Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; GENE FAMILY; CYCLIN-A; CLONING; PRODUCT; ASSOCIATION; INTERACTS; ELEMENT; DOMAIN; MANNER	During 3T3-L1 adipocyte differentiation, growth-arrested, postconfluent preadipocytes are required to reenter the cell cycle and proceed through a mitotic clonal expansion phase prior to terminal differentiation. The retinoblastoma proteins (pRB, p107, and p130) are thought to be critical in controlling cell cycle progression by binding to and regulating the activity of the E2F transcription factors.We show here that p130/p107 protein levels, p107 mRNA levels, and E2F DNA binding complexes are regulated during 3T3-L1 adipogenesis. The predominant E2F binding complex in day 0 preadipocytes was p130 E2F with no detectable free E2F or p107. On Day 1, during mitotic clonal expansion, there was a distinct switch to free E2F and p107-E2F complexes associated with increased p107 mRNA and protein along with decreased p130 protein levels. Following differentiation, the day 0 pattern is reestablished. The switch is not just a consequence of reentry into the cell cycle, in that p107 protein levels are both detectable and unchanged in dividing, serum-restricted, or serum restimulated preconfluent cells. Interestingly, hormonal stimulation of 3T3-C2 cells, a related nondifferentiating cell line, also induces a mitotic clonal expansion phase that is associated with the p130:p107 switch in a pattern very similar to 3T3-L1 cells, suggesting the block in differentiation observed in 3T3-C2 cells occurs after clonal expansion. Combined, these findings suggest that the regulatory mechanisms of the p130:p107 switch are not specific to differentiation but may play a key role in regulating the mitotic clonal expansion necessary for adipocyte differentiation in 3T3-L1 cells.	UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; ARKANSAS CHILDRENS HOSP,RES INST,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Memorial Sloan Kettering Cancer Center; Arkansas Children's Hospital					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034522] Funding Source: NIH RePORTER; NCI NIH HHS [CA0874823] Funding Source: Medline; NICHD NIH HHS [HD34522] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GRANA X, 1995, ONCOGENE, V11, P211; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; MCGEHEE RE, 1993, MOL ENDOCRINOL, V7, P551, DOI 10.1210/me.7.4.551; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; RONCARI DAK, 1984, TRENDS BIOCHEM SCI, V9, P486, DOI 10.1016/0968-0004(84)90318-9; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1992, GENE DEV, V13, P3975	28	121	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10117	10124						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092557	hybrid			2022-12-27	WOS:A1997WU03900076
J	RuizGomez, A; Mayor, F				RuizGomez, A; Mayor, F			beta-Adrenergic receptor kinase (GRK2) colocalizes with beta-adrenergic receptors during agonist-induced receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; SEQUESTRATION; TRANSLOCATION; PHOSPHORYLATION; RESENSITIZATION	Rapid regulation of G protein coupled receptors appears to involve agonist-promoted receptor phosphorylation by G protein-coupled receptor kinases (GRKs), This is followed by binding of uncoupling proteins termed arrestins and transient receptor internalization. In this report we show that the beta-adrenergic receptor kinase (beta ARK-1 or GRK2) follows a similar pattern of internalization upon agonist activation of beta(2)-adrenergic receptors (beta(2)AR) and that beta ARK expression levels modulate receptor sequestration. Stable cotransfected cells expressing an epitope-tagged beta(2)AR and beta ARK-1 show an increased rate and extent of beta(2)AR internalization compared with cells expressing receptor alone. Moreover, subcellular gradient fractionation studies suggest that beta ARK colocalizes with the internalized receptors. In fact, double immunofluorescence analysis using confocal microscopy shows extensive colocalization of beta(2)AR and beta ARK in intracellular vesicles upon receptor stimulation. Our results confirm a functional relationship between receptor phosphorylation and sequestration and indicate that beta ARK does not only translocates from the cytoplasm to the plasma membrane in response to receptor occupancy, but shares endocytic mechanisms with the beta(2)AR. These data suggest a direct role for beta ARK in the sequestration process and/or the involvement of receptor internalization in the intracellular trafficking of the kinase.	UNIV AUTONOMA MADRID,CSIC,DEPT MOL BIOL,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Ruiz-Gomez, Ana/ABF-3079-2021; Mayor, Federico/N-7644-2016; Ruiz-Gómez, Ana/H-2092-2015	Ruiz-Gómez, Ana/0000-0002-1646-3072; Mayor Menendez, Federico/0000-0003-1434-8449				BARAK LS, 1994, J BIOL CHEM, V269, P2790; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; GARCIAHIGUERA I, 1994, J CLIN INVEST, V93, P937, DOI 10.1172/JCI117099; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HAGA T, 1994, J NEUROCHEM, V63, P400; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONG GH, 1994, J BIOL CHEM, V269, P13084; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; MAYOR F, 1987, J BIOL CHEM, V262, P6468; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MOORE RH, 1995, J CELL SCI, V108, P2983; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	36	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9601	9604						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092483				2022-12-27	WOS:A1997WU03900002
J	Vindevoghel, L; Chung, KY; Davis, A; Kouba, D; Kivirikko, S; Alder, H; Uitto, J; Mauviel, A				Vindevoghel, L; Chung, KY; Davis, A; Kouba, D; Kivirikko, S; Alder, H; Uitto, J; Mauviel, A			A GT-rich sequence binding the transcription factor Sp1 is crucial for high expression of the human type VII collagen gene (COL7A1) in fibroblasts and keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; ANCHORING FIBRILS; BASEMENT-MEMBRANE; PROMOTER ACTIVITY; MAMMALIAN-CELLS; IDENTIFICATION; PROTEINS; CLONING; SKIN; ACTIVATION	Type VII collagen is the major component of anchoring fibrils, structural elements that stabilize the attachment of the basement membrane to the underlying dermis. In this study, we have dissected the human type VII collagen gene (COL7A1) promoter to characterize the cis elements responsible for the expression of the gene in cultured fibroblasts and keratinocytes. Using transient cell transfections with various 5' end deletion COL7A1 promoter/chloramphenicol acetyltransferase reporter gene plasmid constructs, we determined that the region between nucleotides -524 and -456, relative to the transcription start site, is critical for high promoter activity in both cell types studied, Gel mobility shift assays using several DNA fragments spanning this region identified a GT-rich sequence between residues -512 and -505, necessary for the binding of nuclear proteins to this region of the promoter, Point mutations abolished the binding of nuclear proteins in gel shift assays and drastically diminished the activity of the promoter in transient cell transfections, Supershift assays with antibodies against various transcription factors including Sp1, Sp3, c-Jun/AP-1, and AP-2, and competition experiments with oligonucleotides containing consensus sequences for Sp1 and AP-1 binding identified Sp1 as the transcription factor binding to this region of the COL7A1 promoter, Indeed, recombinant human Sp1 was shown to bind the COL7A1 promoter GT-rich element but not its mutated form in gel mobility shift assays, In addition, co-transfection of pPacSp1, an expression vector for Sp1, together with the COL7A1 promoter/chloramphenicol acetyltransferase construct into Sp1-deficient Drosophila Schneider SL2 cells unequivocally demonstrated that Sp1 is essential for high expression of the COL7A1 gene, These data represent the first in-depth analysis of the human COL7A1 promoter transcriptional control.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOL MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University			MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [T32-AR07651, R01-AR41439] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; CHRISTIANO AM, 1993, NAT GENET, V4, P62, DOI 10.1038/ng0593-62; CHRISTIANO AM, 1994, P NATL ACAD SCI USA, V91, P3549, DOI 10.1073/pnas.91.9.3549; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; CHRISTIANO AM, 1992, HUM MOL GENET, V7, P475; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kivirikko S, 1996, J INVEST DERMATOL, V106, P1300, DOI 10.1111/1523-1747.ep12349019; KIVIRIKKO S, 1997, IN PRESS J MATRIX BI; KONIG A, 1994, LAB INVEST, V70, P203; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REGAUER S, 1990, J CELL BIOL, V111, P2109, DOI 10.1083/jcb.111.5.2109; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; WETZELS RHW, 1991, AM J PATHOL, V139, P451; WIHINEN T, 1996, J BIOL CHEM, V271, P12532; WILLIMANN TE, 1994, J BIOL CHEM, V269, P332; WU RL, 1994, J BIOL CHEM, V269, P28450; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	47	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10196	10204						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092567				2022-12-27	WOS:A1997WU03900086
J	Zhang, P; Liu, B; Jenkins, GM; Hannun, YA; Obeid, LM				Zhang, P; Liu, B; Jenkins, GM; Hannun, YA; Obeid, LM			Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; HL-60 CELLS; CERAMIDE; MEDIATOR; DIFFERENTIATION; PROTEIN; MECHANISM; SYNTHASE; SIGNALS	The activation of sphingomyelinase and generation of ceramide have been implicated as important regulatory pathways in cell growth and apoptosis, Bacterial sphingomyelinase has been used in many cell systems to mimic the activation of endogenous sphingomyelinase. These studies, however, have been complicated by the inability of exogenously applied bacterial sphingomyelinase to perform many of the effects of short chain cell permeable ceramides, indicating that there may be a distinct signal transducing pool of sphingomyelin not accessible to exogenous sphingomyelinase or that endogenous ceramide is not sufficient to induce these changes, We cloned the Bacillus cereus sphingomyelinase gene by polymerase chain reaction and subcloned it into a mammalian expression vector under the control of an inducible promoter, Upon stable transfection and induction of B. cereus sphingomyelinase, there were increases in neutral sphingomyelinase activity, cellular ceramide levels, cleavage of the death substrate poly(ADP-ribosyl)polymerase, and cell death, In contrast, exogenously applied B. cereus sphingomyelinase, despite causing higher elevations in ceramide levels, was unable to induce poly(ADP-ribosyl)polymerase cleavage or cell death, These results support the existence of a signal transducing pool of sphingomyelin that is distinct from the pool accessible to exogenous sphingomyelinase.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DURHAM VET ADM,GERIATR RES EDUC & CLIN CTR,DURHAM,NC 27710	Duke University; Duke University; Geriatric Research Education & Clinical Center				obeid, lina/0000-0002-0734-0847				Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BORCHARDT RA, 1994, BBA-LIPID LIPID MET, V1212, P327, DOI 10.1016/0005-2760(94)90207-0; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JI L, 1995, BIOCHEM BIOPH RES CO, V215, P489, DOI 10.1006/bbrc.1995.2491; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIM MY, 1991, J BIOL CHEM, V266, P484; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; Santana P, 1996, ENDOCRINOLOGY, V137, P2480, DOI 10.1210/en.137.6.2480; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STRUM JC, 1994, J BIOL CHEM, V269, P15493; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; TAMURA HO, 1994, TOXICON, V32, P629, DOI 10.1016/0041-0101(94)90211-9; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Walev I, 1996, INFECT IMMUN, V64, P2974, DOI 10.1128/IAI.64.8.2974-2979.1996; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	33	154	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9609	9612						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092485				2022-12-27	WOS:A1997WU03900004
J	Bostedor, RG; Karkas, JD; Arison, BH; Bansal, VS; Vaidya, S; Germershausen, JI; Kurtz, MM; Bergstrom, JD				Bostedor, RG; Karkas, JD; Arison, BH; Bansal, VS; Vaidya, S; Germershausen, JI; Kurtz, MM; Bergstrom, JD			Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUALENE SYNTHASE; INHIBITORS; BIOSYNTHESIS; SQUALESTATINS; MECHANISM; OXIDATION; PHOMA	Farnesyl diphosphate, the substrate for squalene synthase, accumulates in the presence of zaragozic acid A, a squalene synthase inhibitor, A possible metabolic fate for farnesyl diphosphate is its conversion to farnesol, then to farnesoic acid, and finally to farnesol-derived dicarboxylic acids (FDDCAs) which would then be excreted in the urine, Seven dicarboxylic acids were isolated by high performance liquid chromatography (HPLC) from urine of either rats or dogs treated with zaragozic acid A or rats fed farnesol, Their structures were determined by nuclear magnetic resonance analysis, Two 12-carbon, four 10-carbon, and one 7-carbon FDDCA were identified. The profile of urinary dicarboxylic acids from rats fed farnesol was virtually identical to that produced by treating with zaragozic acid A, establishing that these dicarboxylic acids are farnesol-derived, By feeding [1-C-14]farnesol and comparing the mass of the dicarboxylic acids produced with the ultraviolet absorption of the HPLC peaks, a method to quantitate the ultraviolet-absorbing FDDCAs was devised, When rats were treated with zaragozic acid A, large amounts of FDDCAs mere excreted in the urine, The high level of FDDCAs that were found suggests that their synthesis is the major metabolic fate for carbon diverted from cholesterol synthesis by a squalene synthase inhibitor, A metabolic pathway is proposed to explain the production of each of these FDDCAs.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK RES LABS,DEPT DRUG METAB,RAHWAY,NJ 07065	Merck & Company; Merck & Company								ABE I, 1994, NAT PROD REP, V11, P279, DOI 10.1039/np9941100279; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ASANO M, 1950, J BIOCHEM-TOKYO, V37, P321, DOI 10.1093/oxfordjournals.jbchem.a126200; BANSAL VS, 1994, ARCH BIOCHEM BIOPHYS, V315, P393, DOI 10.1006/abbi.1994.1516; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BERGSTROM JD, 1995, ANNU REV MICROBIOL, V49, P607, DOI 10.1146/annurev.mi.49.100195.003135; BERGSTROM JD, 1992, Patent No. 5096923; CHRISTOPHE J, 1961, J LIPID RES, V2, P244; DAWSON MJ, 1992, J ANTIBIOT, V45, P639, DOI 10.7164/antibiotics.45.639; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; GONZALEZPACANOWSKA D, 1988, J BIOL CHEM, V263, P1301; HILDEBRANDT H, 1901, ARCH EXP PATHOL PH, V45, P10; Kuhn R, 1936, H-S Z PHYSIOL CHEM, V242, P171, DOI 10.1515/bchm2.1936.242.3-4.171; Laclau Ernesto, CRIT INQUIRY, V13, P330, DOI [10.1086/448393, DOI 10.1086/448393]; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SIDEBOTTOM PJ, 1992, J ANTIBIOT, V45, P648, DOI 10.7164/antibiotics.45.648	18	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9197	9203						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083051				2022-12-27	WOS:A1997WU03700056
J	Holland, J; Owens, T				Holland, J; Owens, T			Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line - The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; MAP KINASE; INTERFERON-GAMMA; T-CELLS; MONOCLONAL-ANTIBODIES; HUMAN NEUTROPHILS; CROSS-LINKING; PHOSPHORYLATION; RAF-1	Intercellular adhesion molecule 1 (ICAM-1) (CD54) is an adhesion molecule of the immunoglobulin superfamily. The interaction between ICAM-1 on B lymphocytes and leukocyte function-associated antigen 1 on T cells plays a major role in several aspects of the immune response, including T-dependent B cell activation. While it was originally believed that ICAM-1 played a purely adhesive role, recent evidence suggests that it can itself transduce biochemical signals. We demonstrate that cross-linking of ICAM-1 results in the up-regulation of class II major histocompatibility complex, and we investigate the biochemical mechanism for the signaling role of ICAM-1. We show that cross-linking of ICAM-1 on the B lymphoma line A20 induces an increase in tyrosine phosphorylation of several cellular proteins, including the Src family kinase p53/p56(lyn). In vitro kinase assays showed that Lyn kinase was activated within 1 min after ICAM-1 cross-linking. In addition, ICAM-1 cross-linking resulted in activation of Raf-1 and mitogen-activated protein kinases, as determined by gel mobility shift. Activation of these kinases may represent important components in the cascade of signals that link. ICAM-1 to various ICAM-1-elicited cellular responses. These data confirm the important role of ICAM-1 as a signaling molecule in B cell activation.	MCGILL UNIV,MONTREAL NEUROL INST,NEUROIMMUNOL UNIT,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,MONTREAL NEUROL INST,NEUROIMMUNOL UNIT,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University; McGill University				Owens, Trevor/0000-0001-9315-6036				AHN NG, 1991, J BIOL CHEM, V266, P4220; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BERG NN, 1995, J IMMUNOL, V155, P1694; BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GEISSLER D, 1990, EUR J IMMUNOL, V20, P2591, DOI 10.1002/eji.1830201210; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P185; KIM KJ, 1979, J IMMUNOL, V122, P549; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MOMBURG F, 1986, J IMMUNOL, V136, P940; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUNRO JM, 1989, AM J PATHOL, V135, P121; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; POUDRIER J, 1994, J EXP MED, V179, P1417, DOI 10.1084/jem.179.5.1417; POUDRIER J, 1994, EUR J IMMUNOL, V24, P2993, DOI 10.1002/eji.1830241211; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; ROTHLEIN R, 1994, J IMMUNOL, V152, P2488; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANHORSSEN M, 1995, EUR J IMMUNOL, V25, P154, DOI 10.1002/eji.1830250126; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	47	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9108	9112						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083038				2022-12-27	WOS:A1997WU03700043
J	Kramer, EM; Koch, T; Niehaus, A; Trotter, J				Kramer, EM; Koch, T; Niehaus, A; Trotter, J			Oligodendrocytes direct glycosyl phosphatidylinositol-anchored proteins to the myelin sheath in glycosphingolipid-rich complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CENTRAL NERVOUS-SYSTEM; ENRICHED MEMBRANE SUBDOMAINS; CULTURED OLIGODENDROCYTES; DEVELOPMENTAL EXPRESSION; MONOCLONAL-ANTIBODIES; TYROSINE KINASES; SURFACE ANTIGENS; LINKED PROTEINS; PRECURSOR CELLS	The myelin sheath synthesized by oligodendrocytes insulates central nervous system axons and is a specialized subdomain of the plasma membrane, containing a restricted pattern of proteins and lipids. Myelin is enriched in glycosphingolipids and cholesterol, a lipid environment favored by glycosylphosphatidylinositol (GPI)-anchored proteins, which associate with these lipids in detergent-insoluble complexes in many cell types. Since proteins regulating oligodendroglia-neuron interaction are largely unknown and GPI-anchored proteins are often involved in cell-cell interactions, we examined oligodendrocytes and myelin for their expression of these proteins. Oligodendrocyte precursors and maturing oligodendrocytes express a similar pattern of GPI-anchored proteins, which unlike the majority of oligodendrocyte plasma membrane proteins, accumulate in myelin. To elucidate mechanisms underlying the expression of GPI-anchored proteins in myelin, we analyzed detergent-insoluble complexes from cells and myelin using TX-100 extraction and sucrose density gradients. In precursor cells, the GPI-anchored proteins are not incorporated in detergent-insoluble complexes. In contrast, GPI-anchored proteins from maturing oligodendrocytes and from myelin were isolated as complexes associated with glycosphingolipids and cholesterol. These results show a specific association of GPI-anchored proteins with glycosphingolipids and cholesterol during oligodendrocyte maturation and suggest sorting of these macromolecular complexes to myelin.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Messier, Claude/A-2322-2008; Eva-Maria, Kraemer-Albers/AAP-8805-2020	Messier, Claude/0000-0002-4791-1763; Eva-Maria, Kraemer-Albers/0000-0001-7994-1185				AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; AVELDANO MI, 1991, J NEUROCHEM, V57, P250, DOI 10.1111/j.1471-4159.1991.tb02122.x; BARRES BA, 1993, DEVELOPMENT, V118, P283; BAUERFEIND R, 1995, P NATL ACAD SCI USA, V92, P7342, DOI 10.1073/pnas.92.16.7342; BHAT S, 1986, J NEUROSCI, V6, P3348; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BURGISSER P, 1986, NEUROCHEM RES, V11, P1261, DOI 10.1007/BF00966121; CAMMER W, 1980, J NEUROCHEM, V35, P367, DOI 10.1111/j.1471-4159.1980.tb06273.x; CAMMER W, 1985, DEV BRAIN RES, V20, P89, DOI 10.1016/0165-3806(85)90090-2; CINEK T, 1992, J IMMUNOL, V149, P2262; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; Doyle JP, 1993, CURR OPIN CELL BIOL, V5, P779, DOI 10.1016/0955-0674(93)90025-L; FANARRAGA ML, 1995, GLIA, V15, P95, DOI 10.1002/glia.440150202; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FRA AM, 1994, J BIOL CHEM, V269, P30745; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; KOCH T, 1997, IN PRESS GLIA; Koski CL, 1996, J NEUROCHEM, V66, P303; KUHLMANNKRIEG S, 1988, DEV BRAIN RES, V39, P269, DOI 10.1016/0165-3806(88)90031-4; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEYERFRANKE A, 1994, CURR BIOL, V4, P847; MIKOL DD, 1993, GENOMICS, V17, P604, DOI 10.1006/geno.1993.1379; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; PODUSLO SE, 1975, J NEUROCHEM, V24, P647, DOI 10.1111/j.1471-4159.1975.tb03842.x; RATHJEN FG, 1984, EMBO J, V3, P1; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHACHNER M, 1981, DEV BIOL, V83, P328, DOI 10.1016/0012-1606(81)90478-4; SCHAERENWIEMERS N, 1995, J NEUROSCI, V15, P5753; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P457, DOI 10.1016/0165-5728(81)90023-0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SMITH ME, 1969, J NEUROCHEM, V16, P83, DOI 10.1111/j.1471-4159.1969.tb10345.x; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TISDALE EJ, 1988, J BIOL CHEM, V263, P8244; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; YU RK, 1989, J NEUROSCI RES, V23, P136, DOI 10.1002/jnr.490230203	66	108	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8937	8945						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083015				2022-12-27	WOS:A1997WU03700020
J	Lin, CY; Wang, JK; Torri, J; Dou, L; Sang, QXA; Dickson, RB				Lin, CY; Wang, JK; Torri, J; Dou, L; Sang, QXA; Dickson, RB			Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells - Monoclonal antibody production, isolation, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTATIC MELANOMA-CELLS; AMINO-ACID-ANALYSIS; HUMAN-TUMOR CELLS; IV COLLAGENASE; BASEMENT-MEMBRANE; UROKINASE-RECEPTOR; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; ACTIVATION; METALLOPROTEINASE	A major, apparently novel extracellular matrix-degrading protease was previously identified and partially isolated from hormone-dependent but not from hormone-independent human breast cancer cells (Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E., and Dickson, R. B. (1993) Cancer Res. 53, 1409-1415). Although initially the 80-kDa protease was identified from breast cancer cell-conditioned medium, immunofluorescence staining of breast cancer cells with anti-80-kDa protease monoclonal antibody 21-9 showed that in addition to its detection in intracellular compartments, the protease was uniformly localized around periphery of the cells with more intensive staining on the pseudopodia and membrane ruffles. A surface biotinylation technique confirmed the plasma membrane localization of the protease. In addition, the 80-kDa protease could not be washed from the membrane fraction of homogenized breast cancer cells with high concentrations of salts or with EDTA. The 80-kDa protease may noncovalently associate with other protein(s) to form complexes, the 95- and 110-kDa proteases. Both complexes showed gelatinolytic activity and bore the epitopes recognized by monoclonal antibody 21-9. Furthermore, both complexes could be converted to 80-kDa forms by boiling in SDS in the absence of reducing agents. Expression of this novel, integral membrane gelatinase could allow breast cancer cells an alternative to other previously described matrix-degrading enzymes for degradation of the extracellular matrix in close proximity to their surfaces.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	Georgetown University; State University System of Florida; Florida State University					NCI NIH HHS [1P50CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; CHEN WT, 1984, J CELL BIOL, V98, P1546, DOI 10.1083/jcb.98.4.1546; CONESE M, 1995, BAILLIERE CLIN HAEM, V8, P365, DOI 10.1016/S0950-3536(05)80273-2; DUGGAN C, 1995, INT J CANCER, V61, P597, DOI 10.1002/ijc.2910610502; EMONARD HP, 1992, CANCER RES, V52, P5845; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Imai K, 1996, CANCER RES, V56, P2707; JONES PA, 1980, CANCER RES, V40, P3222; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KRAMER RH, 1984, JNCI-J NATL CANCER I, V72, P889; KRAMER RH, 1986, CANCER RES, V46, P1980; KRAMER RH, 1980, INT J CANCER, V26, P639, DOI 10.1002/ijc.2910260516; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; MUELLER SC, 1991, J CELL SCI, V99, P213; MUNEMITSU SM, 1988, VIROLOGY, V163, P643, DOI 10.1016/0042-6822(88)90309-1; PUENTE XS, 1996, CANCER RES, V56, P9444; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHI YE, 1993, CANCER RES, V53, P1409; STETLERSTEVENSON WG, 1994, INVAS METAST, V14, P259; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1990, BIOL CHEM H-S, V371, P305; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOUS GI, 1989, ANAL BIOCHEM, V179, P50, DOI 10.1016/0003-2697(89)90198-X; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; YEE C, 1986, CANCER RES, V46, P1835; ZUCKER S, 1987, BIOCHEM J, V245, P429, DOI 10.1042/bj2450429; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	40	120	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9147	9152						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083044				2022-12-27	WOS:A1997WU03700049
J	Lin, SJ; Pufahl, RA; Dancis, A; OHalloran, TV; Culotta, VC				Lin, SJ; Pufahl, RA; Dancis, A; OHalloran, TV; Culotta, VC			A role for the Saccharomyces cerevisiae ATX1 gene in copper trafficking and iron transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; SUPEROXIDE-DISMUTASE; CANDIDATE GENE; MERCURY-RESISTANCE; MENKES DISEASE; FET3 GENE; YEAST; PROTEIN; ENCODES; MUTANTS	The ATX1 gene of Saccharomyces cerevisiae was originally identified as a multi-copy suppressor of oxidative damage in yeast lacking superoxide dismutase. We now provide evidence that Atx1p helps deliver copper to the copper requiring oxidase Fet3p involved in iron uptake. atx1 Delta null mutants are iron-deficient and are defective in the high affinity uptake of iron. These defects due to ATX1 inactivation are rescued by copper treatment, and the same has been reported for strains lacking either the cell surface copper transporter, Ctr1p, or the putative copper transporter in the secretory pathway, Ccc2p. Atx1p localizes to the cytosol, and our studies indicate that it functions as a carrier for copper that delivers the metal from the cell surface Ctr1p to Ccc2p and then to Fet3p within the secretory pathway. The iron deficiency of atx1 mutants is augmented by mutations in END3 blocking endocytosis, suggesting that a parallel pathway for intracellular copper trafficking is mediated by endocytosis. As additional evidence for the role of Atx1p in iron metabolism, we find that the gene is induced by the same iron-sensing trans-activator, Aft1p, that regulates CCC2 and FET3.	JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA; NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Northwestern University			O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [R01 GM054111, GM 38784] Funding Source: Medline; PHS HHS [R01 5016] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, R01GM038784, R37GM038784, R29GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BYRD J, 1988, J BIOL CHEM, V263, P6688; CHANEY RL, 1988, J PLANT NUTR, V11, P1033, DOI 10.1080/01904168809363867; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CULOTTA VC, 1995, J BIOL CHEM, V270, P2991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; HAMLETT NV, 1992, J BACTERIOL, V174, P6377, DOI 10.1128/JB.174.20.6377-6385.1992; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; NULPE C, 1993, NAT GENET, V3, P7; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; PETYRUKHIN K, 1993, NAT GENET, V5, P338; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rose M. D., 1990, METHODS YEAST GENETI, P97; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	44	342	354	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9215	9220						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083054				2022-12-27	WOS:A1997WU03700059
J	Liu, L; Damen, JE; Hughes, MR; Babic, I; Jirik, FR; Krystal, G				Liu, L; Damen, JE; Hughes, MR; Babic, I; Jirik, FR; Krystal, G			The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; PROTEIN; KINASE; INTERLEUKIN-3; ACTIVATION; RECEPTOR; GRB2; BINDING; FAMILY	In this study we have investigated the role that the Src homology 2 domain (SH2) of the 145-kDa 5-phosphatase, SH2-containing inositol phosphatase (SHIP), plays in three of the properties that have been associated with this protein following cytokine stimulation: its association with Shc, its tyrosine phosphorylation, and its inhibition of hemopoietic cell growth. In vitro studies using this SH2 domain revealed that it was capable of binding directly to the Tyr(P)(317) motif of Shc with a K-D of approximately 290 nM, in keeping with other specific SH2/Tyr(P) interactions. In vivo analysis revealed the SH2 and NPXpY motifs of SHIP acted together, with the Tyr(P)(317),and phosphotyrosine binding (PTB) domains of Shc, respectively, to ensure a high affinity SHIP Shc complex. Expression of cDNAs encoding hemagglutinin-tagged wild type and SH2-inactivated forms of SHIP in the murine hemopoietic cell line DA-ER revealed that wild type SHIP becomes both tyrosine-phosphorylated and associated with Shc following interleukin-3 stimulation, as expected, but the SH2-inactivated SHIPs do neither. Moreover, while the growth rates of parental DA-ER cells and cells expressing these various SHIP constructs are identical, the wild type SHIP-expressing cells die, via programmed cell death, far more rapidly than parental cells. Cells expressing SH2-inactivated SHIPs, on the other hand, show either a reduced or no effect on apoptosis, These results suggest that the SH2 domain of SHIP is required not only for the tyrosine phosphorylation of SHIP and Shc association following cytokine stimulation but also for its induction of apoptosis.	BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	British Columbia Cancer Agency; University of British Columbia			Hughes, Michael/N-6039-2015	Hughes, Michael/0000-0002-7925-6070; Krystal, Gerald/0000-0002-1961-6281				ANDERSON SM, 1995, J IMMUNOL, V155, P1660; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAWLEY RG, 1994, GENE THER, V1, P136; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MURTHY SC, 1989, BLOOD, V73, P1180; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; TOKER A, 1994, J BIOL CHEM, V269, P32358; TORIGOE T, 1992, BLOOD, V80, P617; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	27	111	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8983	8988						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083021				2022-12-27	WOS:A1997WU03700026
J	Singer, HA; Benscoter, HA; Schworer, CM				Singer, HA; Benscoter, HA; Schworer, CM			Novel Ca2+/calmodulin-dependent protein kinase II gamma-subunit variants expressed in vascular smooth muscle, brain, and cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL CAM KINASE; RAT-BRAIN; CALMODULIN; ISOFORMS; CA2+; IDENTIFICATION; CELLS; GENE; TISSUE	Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) gamma-subunits were cloned from a porcine aortic smooth muscle cDNA library resulting in identification of alternatively spliced CaM kinase II gamma(B)- and gamma(C)-subunits and a novel gamma-subunit variant predicted to encode a 60.2-kDa polypeptide, which was designated the gamma(G)-subunit, A clone predicted to encode a 62.2-kDa gamma-subunit, designated as gamma(E), was isolated with a variable domain structure similar to a gamma(B)-subunit but with a 114-nucleotide insertion in the conserved ''association'' domain of CaM kinase II subunits. A full-length gamma(E)-subunit construct expressed in COS cells resulted in multimeric CaM kinase II holoenzymes (470 kDa) with activation and autoregulatory properties similar to expressed holoenzymes composed of gamma(B)-, gamma(C)-, or gamma(G)-subunits. Expression of gamma(E) and related gamma-subunit mRNAs containing the 114-base insertion was documented in porcine tissues by reverse transcriptase-polymerase chain reaction, CaM kinase II subunits containing the 38-amino acid insert were identified by Western analysis of partially purified CaM kinase II from carotid arterial smooth muscle and brain using a sequence-specific antipeptide antibody. Immunoprecipitations of tissue homogenates indicated a comparatively high level of expression of subunits containing the insert in brain and provided evidence for their co-assembly with other more abundant subunits into CaM kinase II heteromultimers, Our analyses indicate the following patterns of gamma-subunit expression: vascular smooth muscle, gamma(B) > gamma(C) > gamma(E,G); heart, gamma(B) > gamma(E,C) > gamma(G); brain, gamma(E) and related subunits much greater than gamma(A,B,C,G).			Singer, HA (corresponding author), WEIS CTR RES,GEISINGER CLIN,100 N ACAD AVE,DANVILLE,PA 17822, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL049426, R01HL049426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham ST, 1996, J BIOL CHEM, V271, P2506, DOI 10.1074/jbc.271.5.2506; Allen BG, 1996, MOL CELL BIOCHEM, V155, P91; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Grover AK, 1996, AM J PHYSIOL-CELL PH, V271, pC181, DOI 10.1152/ajpcell.1996.271.1.C181; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; KARLS U, 1992, MOL CELL BIOL, V12, P3644, DOI 10.1128/MCB.12.8.3644; KWIATKOWSKI AP, 1995, GASTROENTEROLOGY, V109, P1316, DOI 10.1016/0016-5085(95)90594-4; LACHMAN PJ, 1906, CIBA FDN S, V119, P25; LORCA T, 1994, BBA-MOL CELL RES, V1223, P325, DOI 10.1016/0167-4889(94)90091-4; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; NGHEIM P, 1993, J BIOL CHEM, V268, P5471; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OHSAKO S, 1993, J BIOL CHEM, V268, P2052; OWENS GK, 1995, PHYSIOL REV, V75, P487; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; SCHWORER CM, 1985, ARCH BIOCHEM BIOPHYS, V242, P137, DOI 10.1016/0003-9861(85)90487-4; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SINGER HA, 1996, BIOCH SMOOTH MUSCLE, P143; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; URQUIDI V, 1995, FEBS LETT, V358, P23, DOI 10.1016/0014-5793(94)01381-A; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108; ZHOU ZHL, 1995, BIOCHEM J, V310, P517, DOI 10.1042/bj3100517	36	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9393	9400						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083077				2022-12-27	WOS:A1997WU03700082
J	Borges, R; Travis, ER; Hochstetler, SE; Wightman, RM				Borges, R; Travis, ER; Hochstetler, SE; Wightman, RM			Effects of external osmotic pressure on vesicular secretion from bovine adrenal medullary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CHROMAFFIN CELLS; CATECHOLAMINE RELEASE; HYPERTONIC SOLUTIONS; GRANULE MATRIX; VESICLE FUSION; BEIGE MOUSE; EXOCYTOSIS; CALCIUM; FORCES; CHROMOGRANINS	Secretion of catecholamines from individual vesicles of bovine adrenal medullary cells was studied with amperometry in media of various osmolarities and compared with results obtained in isotonic physiological buffer (315 mosM). Hypotonic solutions caused an increase in the number of amperometric spikes evoked by brief exposure to 5 mM Ba2+. Under moderate hypertonic conditions (630 mosM), individual vesicular events were decreased in frequency, and lower amounts were secreted per event. Furthermore, the events were temporally broadened relative to those observed during release in isotonic conditions. At 970 mosM, exposure to 5 mm Ba2+ evoked even smaller secretory events that resemble the prespike feature that has been attributed to the initial opening of the fusion pore. The lack of large spikes is not due to failure of Ba2+ entry because fura-2 fluorescence reveals an increase in intracellular divalent ions. After exposure to Ba2+ in hypertonic solution, spikes could be induced with isotonic solution transiently directed onto the cell, but this process was not accompanied by a change in the concentration of intracellular divalent ions. Thus, this procedure provides an unique opportunity to temporally separate exocytotic secretion from entry of divalent ions.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV LA LAGUNA,FAC MED,UNIDAD FARMACOL,SANTA CRUZ TENERI 38010,SPAIN	University of North Carolina; University of North Carolina Chapel Hill; Universidad de la Laguna			Borges, Ricardo/N-3250-2014	Borges, Ricardo/0000-0003-3413-4392				BAKER PF, 1984, BIOSCIENCE REP, V4, P285, DOI 10.1007/BF01140492; BRODWICK MS, 1992, J MEMBRANE BIOL, V126, P159; Cahill PS, 1996, ANAL CHEM, V68, P3180, DOI 10.1021/ac960347d; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FINNEGAN JM, 1995, J BIOL CHEM, V270, P5353, DOI 10.1074/jbc.270.10.5353; FINNEGAN JM, 1996, J NEUROCHEM, V66, P1414; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIGH JR, 1989, BIOCHEM J, V259, P485, DOI 10.1042/bj2590485; HAMPTON RY, 1983, J CELL BIOL, V96, P1082, DOI 10.1083/jcb.96.4.1082; HELLE KB, 1985, ACTA PHYSIOL SCAND, V123, P21, DOI 10.1111/j.1748-1716.1985.tb07556.x; HOLZ RW, 1986, J NEUROCHEM, V46, P1835; HOLZ RW, 1986, ANNU REV PHYSIOL, V48, P175; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KNIGHT DE, 1982, J MEMBRANE BIOL, V68, P107, DOI 10.1007/BF01872259; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; LADONA MG, 1987, BIOCHIM BIOPHYS ACTA, V927, P18, DOI 10.1016/0167-4889(87)90061-9; LADONA MG, 1984, NEUROSCIENCE, V12, P301, DOI 10.1016/0306-4522(84)90155-6; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; Moser T, 1995, PFLUG ARCH EUR J PHY, V431, P196, DOI 10.1007/BF00410191; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; ORNBERG RL, 1995, CELL TISSUE RES, V279, P85, DOI 10.1007/BF00300694; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; POLLARD HB, 1984, J BIOL CHEM, V259, P1114; RUDEN LV, 1993, FEBS LETT, V336, P48; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; TERAKAWA S, 1993, J PHYSIOLOGY-PARIS, V87, P209, DOI 10.1016/0928-4257(93)90032-O; UVNAS B, 1989, NEWS PHYSIOL SCI, V4, P68; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; WAKADE AR, 1986, J NEUROSCI, V6, P2625; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Winkler H., 1975, HDB PHYSIOLOGY, V6, P321; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1992, J BIOL CHEM, V267, P11326; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	45	83	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8325	8331		10.1074/jbc.272.13.8325	http://dx.doi.org/10.1074/jbc.272.13.8325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079655	hybrid, Green Published			2022-12-27	WOS:A1997WQ63500038
J	Day, ML; Foster, RG; Day, KC; Zhao, X; Humphrey, P; Swanson, P; Postigo, AA; Zhang, SH; Dean, DC				Day, ML; Foster, RG; Day, KC; Zhao, X; Humphrey, P; Swanson, P; Postigo, AA; Zhang, SH; Dean, DC			Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor E2F pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC GLANDULAR CELLS; EXTRACELLULAR-MATRIX; ANDROGEN ABLATION; EPITHELIAL-CELLS; PROGRAMMED DEATH; PROTEIN; CYCLE; P53; PROLIFERATION; EXPRESSION	Epithelial cells are dependent upon adhesion to extracellular matrix for survival. We show that loss of beta 1 integrin receptor contact with extracellular matrix signals the inhibition of G(1) cyclin-dependent kinase activity. This loss of cyclin-dependent kinase activity leads to accumulation of the hypophosphorylated (active) form of the retinoblastoma tumor suppressor protein (Rb). We present evidence that in epithelial cells deprived of matrix contact, the growth suppression signal elicited by hypophosphorylated Rb opposes stimulatory signals hom serum growth factors, leading to a cell cycle conflict that triggers apoptosis. This apoptotic pathway is modulated by Bcl-2 through a novel mechanism that regulates Rb phosphorylation. We present evidence that the Rb-dependent apoptotic pathway functions in vivo in the apoptosis of the prostate glandular epithelium following castration.	UNIV MICHIGAN,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; WASHINGTON UNIV,SCH MED,DEPT MED & CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	University of Michigan System; University of Michigan; Washington University (WUSTL); Washington University (WUSTL)	Day, ML (corresponding author), UNIV MICHIGAN,DEPT SURG,DIV UROL,1150 W MED CTR DR,RM 5510 MSRBI,ANN ARBOR,MI 48109, USA.			Postigo, Antonio/0000-0003-4605-2634	NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NCI NIH HHS [CA69568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DAY ML, 1993, CANCER RES, V53, P5597; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; RAFFO AJ, 1995, CANCER RES, V55, P4438; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; Wang H, 1996, ONCOGENE, V13, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	30	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8125	8128		10.1074/jbc.272.13.8125	http://dx.doi.org/10.1074/jbc.272.13.8125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079623	hybrid			2022-12-27	WOS:A1997WQ63500006
J	Cherradi, N; Rossier, MF; Vallotton, MB; Timberg, R; Friedberg, I; Orly, J; Wang, XJ; Stocco, DM; Capponi, AM				Cherradi, N; Rossier, MF; Vallotton, MB; Timberg, R; Friedberg, I; Orly, J; Wang, XJ; Stocco, DM; Capponi, AM			Submitochondrial distribution of three key steroidogenic proteins (steroidogenic acute regulatory protein and cytochrome p450(scc) and 3 beta-hydroxysteroid dehydrogenase isomerase enzymes) upon stimulation by intracellular calcium in adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; SIDE-CHAIN CLEAVAGE; INTRAMITOCHONDRIAL CHOLESTEROL TRANSFER; ANGIOTENSIN-II; MITOCHONDRIAL PROTEINS; ALDOSTERONE PRODUCTION; HORMONE STIMULATION; CORTICAL CELLS; CORTEX CELLS; LOCALIZATION	In adrenal glomerulosa cells, angiotensin II (Ang II) and potassium stimulate aldosterone synthesis through activation of the calcium messenger system, The rate-limiting step in steroidogenesis is the transfer of cholesterol to the inner mitochondrial membrane, This transfer is believed to depend upon the presence of the steroidogenic acute regulatory (StAR) protein, The aim of this study was 1) to examine the effect of changes in cytosolic free calcium concentration and of Ang II on intramitochondrial cholesterol and 2) to study the distribution of StAR protein in submitochondrial fractions during activation by Ca2+ and Ang II, To this end, freshly prepared bovine zona glomerulosa cells were submitted to a high cytosolic Ca2+ clamp (600 nM) or stimulated with Ang II (10 nm) for 2 h, Mitochondria were isolated and subfractionated into outer membranes, inner membranes (IM), and contact sites (CS), Stimulation of intact cells with Ca2+ or Ang II led to a marked, cycloheximide-sensitive increase in cholesterol in CS (to 143 +/- 3.2 and 151.1 +/- 18.1% of controls, respectively) and in IM (to 119 +/- 5.1 and 124.5 +/- 6.5% of controls, respectively), Western blot analysis revealed a cycloheximide-sensitive increase in StAR protein in mitochondrial extracts of Ca2+-clamped glomerulosa cells (to 159 +/- 23% of controls), In submitochondrial fractions, there was a selective accumulation of StAR protein in IM following stimulation with Ca2+ (228 +/- 50%). Similarly, Ang II increased StAR protein in IM, and this effect was prevented by cycloheximide, In contrast, neither Ca2+ nor Ang II had any effect on the submitochondrial distribution of cytochrome P450(sec) and 3 beta-hydroxysteroid dehydrogenase isomerase, The intramitochondrial presence of the latter enzyme was further confirmed by immunogold staining in rat adrenal fasciculata cells and by immunoblot analysis in MA-10 mouse testicular Leydig cells, These findings demonstrate that under acute stimulation with Ca2+ mobilizing agents, newly synthesized StAR protein accumulates in IM after transiting through CS, Moreover, our results suggest that the import of StAR protein into IM may be associated with cholesterol transfer, thus promoting precursor supply to the two first enzymes of the steroidogenic cascade within the mitochondria and thereby activating mineralocorticoid synthesis.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; TEXAS TECH UNIV,HLTH SCI CTR,DEPT CELL BIOL & BIOCHEM,LUBBOCK,TX 79430	Hebrew University of Jerusalem; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Cherradi, N (corresponding author), UNIV GENEVA,HOP CANTONAL,DIV ENDOCRINOL & DIABETOL,FAC MED,DEPT INTERNAL MED,CH-1211 GENEVA 14,SWITZERLAND.		Friedberg, Iddo/S-4793-2019; Rossier, Michel/AAW-2895-2021; Cherradi, Nadia/K-9695-2016	Friedberg, Iddo/0000-0002-1789-8000; Cherradi, Nadia/0000-0002-4292-774X	NICHD NIH HHS [HD 17841] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTA JA, 1989, J BIOL CHEM, V264, P2368; APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BRANDENBURGER Y, 1996, IN PRESS ENDOCRINOLO; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; CHAPMAN JC, 1979, J BIOL CHEM, V254, P6624; CHERRADI N, 1994, ENDOCRINOLOGY, V134, P1358, DOI 10.1210/en.134.3.1358; Cherradi N, 1995, J STEROID BIOCHEM, V55, P507, DOI 10.1016/0960-0760(95)00199-9; Cherradi N, 1996, J BIOL CHEM, V271, P25971, DOI 10.1074/jbc.271.42.25971; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; Court DA, 1996, FEBS LETT, V390, P73, DOI 10.1016/0014-5793(96)00629-1; ELLIOTT ME, 1984, BIOCHEM PHARMACOL, V33, P1519, DOI 10.1016/0006-2952(84)90422-2; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FAKUNDING JL, 1979, ENDOCRINOLOGY, V105, P327, DOI 10.1210/endo-105-2-327; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; FOLSCH H, 1996, EMBO J, V15, P470; GAMBLE W, 1978, J LIPID RES, V19, P1068; ISHIMURA K, 1988, HISTOCHEMISTRY, V89, P35, DOI 10.1007/BF00496581; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JOHNSON EIM, 1989, J ENDOCRINOL, V122, P391, DOI 10.1677/joe.0.1220391; KATSUMATA N, 1996, PROGR 10 INT C END S, pP3; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; LABRIE F, 1992, J STEROID BIOCHEM, V43, P805, DOI 10.1016/0960-0760(92)90308-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN S, 1990, ENDOCR REV, V11, P469, DOI 10.1210/edrv-11-4-469; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Muller J., 1988, REGULATION ALDOSTERO; NEWMAN GR, 1983, HISTOCHEM J, V15, P543, DOI 10.1007/BF01954145; Nishikawa T, 1996, BIOCHEM BIOPH RES CO, V223, P12, DOI 10.1006/bbrc.1996.0838; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; OTSUKA S, 1964, BIOCHEM PHARMACOL, V13, P995, DOI 10.1016/0006-2952(64)90096-6; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PORTATDOVEN S, 1996, PROGR 10 INT C END S, pP2; PRASAD VVK, 1992, P NATL ACAD SCI USA, V89, P4173, DOI 10.1073/pnas.89.9.4173; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; QUINN SJ, 1988, AM J PHYSIOL, V255, pE488, DOI 10.1152/ajpendo.1988.255.4.E488; ROTH J, 1989, TECHNIQUES IMMUNOCHE, P107; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; Stocco DM, 1996, BIOCHEM PHARMACOL, V51, P197, DOI 10.1016/0006-2952(95)02093-4; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1992, J STEROID BIOCHEM, V43, P319, DOI 10.1016/0960-0760(92)90167-H; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON JX, 1984, ENDOCRINOLOGY, V115, P1357, DOI 10.1210/endo-115-4-1357	55	148	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7899	7907		10.1074/jbc.272.12.7899	http://dx.doi.org/10.1074/jbc.272.12.7899			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065457	hybrid			2022-12-27	WOS:A1997WP59200051
J	Chicchi, GG; Graziano, MP; Koch, G; Hey, P; Sullivan, K; Vicario, PP; Cascieri, MA				Chicchi, GG; Graziano, MP; Koch, G; Hey, P; Sullivan, K; Vicario, PP; Cascieri, MA			Alterations in receptor activation and divalent cation activation of agonist binding by deletion of intracellular domains of the glucagon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING	Deletion of residues 252-259 within the putative second intracellular loop of the human glucagon receptor results in a protein with high affinity for glucagon but with attenuated agonist activation of adenylyl cyclase, The Delta 252-259 mutant has 4-fold higher affinity for glucagon than does the wild type receptor, The nonhydrolyzable GTP analog, guanosine 5'-(beta,gamma-imido)triphosphate (Gpp(NH)p), inhibits binding of I-125-glucagon to the wild type receptor but not to the Delta 252-259 mutant, Divalent cations such as MgCl2 and CaCl2 stimulate the binding of I-125-glucagon to the wild type receptor by increasing glucagon affinity, The rate of dissociation of I-125-glucagon is decreased 4-fold by MgCl2 and increased 6-fold by Gpp(NH)p. However, divalent cations do not affect the binding of I-125-glucagon to the Delta 252-259 mutant, The rate of dissociation of I-125-glucagon from the Delta 252-259 mutant protein is equivalent to the rate of dissociation from the wild type receptor in the presence of MgCl2. These data suggest that at least three conformations of the glucagon receptor can exist in the membrane based on their differing affinities for I-125-glucagon. Deletion of residues 252-259 appears to lock the protein in the conformation promoted by divalent cations and prevents the protein from normal coupling to Gs.	MERCK SHARP & DOHME LTD,RES LABS,DEPT MOL PHARMACOL & BIOCHEM,RAHWAY,NJ 07065	Merck & Company								CASCIERI MA, 1995, J PHARMACOL TOXICOL, V33, P179, DOI 10.1016/1056-8719(95)00002-Y; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; PADRELL E, 1987, ENDOCRINOLOGY, V120, P2316, DOI 10.1210/endo-120-6-2316; POST SR, 1992, J BIOL CHEM, V267, P25776; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; TOTA MR, 1995, J BIOL CHEM, V270, P26466, DOI 10.1074/jbc.270.44.26466	11	31	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7765	7769		10.1074/jbc.272.12.7765	http://dx.doi.org/10.1074/jbc.272.12.7765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065438	hybrid			2022-12-27	WOS:A1997WP59200032
J	Xia, WM; Zhang, JM; Kholodenko, D; Citron, M; Podlisny, MB; Teplow, DB; Haass, C; Seubert, P; Koo, EH; Selkoe, DJ				Xia, WM; Zhang, JM; Kholodenko, D; Citron, M; Podlisny, MB; Teplow, DB; Haass, C; Seubert, P; Koo, EH; Selkoe, DJ			Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E GENOTYPE; PRECURSOR PROTEIN; MISSENSE MUTATIONS; DOWN-SYNDROME; GENE; PEPTIDE; DEPOSITION; COMPONENT; TERMINUS	Mutations in the presenilin 1 (PS1) and presenilin 2 (PS2) genes cause the most common and aggressive form of early onset familial Alzheimer's disease, To elucidate their pathogenic mechanism, wild-type (wt) or mutant (M146L, C410Y) PS1 and wt or mutant (M239V) PS2 genes were stably transfected into Chinese hamster ovary cells that overexpress the beta-amyloid precursor protein (APP), The identity of the 43-45-kDa PS1 holoproteins was confirmed by N-terminal padiosequencing. PS1 was rapidly processed (t(1/2) = 40 min) in the endoplasmic reticulum into stable fragments, Wild-type and mutant PS2 holoproteins exhibited similar halflives (1.5 h); however, their endoproteolytic fragments showed both mutation-specific and cell type specific differences, Mutant PS1 or PS2 consistently induced a 1.4-2.5-fold increase (p < 0.001) in the relative production of the highly amyloidogenic 42-residue form of amyloid beta-protein (A beta(42)) as determined by quantitative immunoprecipitation and by enzyme-linked immunosorbent assay, In mutant PS1 and PS2 cell lines with high increases in A beta(42)/A beta(total) ratios, spontaneous formation of low molecular weight oligomers of A beta(42) was observed in media, suggesting enhanced A beta aggregation from the elevation of A beta(42). We conclude that mutant PS1 and PS2 proteins enhance the proteolysis of beta-amyloid precursor protein by the gamma-secretase cleaving at A beta residue 42, thereby promoting amyloidogenesis.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; UNIV HEIDELBERG,CENT INST MENTAL HLTH,D-68159 MANNHEIM,GERMANY	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Central Institute of Mental Health; Ruprecht Karls University Heidelberg			xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NIA NIH HHS [AG06173, AG12376] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006173, RF1AG006173, R01AG012376, R01AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOWING E, 1994, J BIOL CHEM, V269, P10987; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mann DMA, 1996, AM J PATHOL, V148, P1257; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; PODLISNY MB, 1997, IN PRESS NEUROBIOL D; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; REBECK GW, 1993, NEURON, V11, P575; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Selkoe D. J., 1996, Society for Neuroscience Abstracts, V22, P278; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	47	262	279	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7977	7982		10.1074/jbc.272.12.7977	http://dx.doi.org/10.1074/jbc.272.12.7977			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065468	hybrid			2022-12-27	WOS:A1997WP59200062
J	Kelly, SL; Lamb, DC; Baldwin, BC; Corran, AJ; Kelly, DE				Kelly, SL; Lamb, DC; Baldwin, BC; Corran, AJ; Kelly, DE			Characterization of Saccharomyces cerevisiae CYP61, sterol Delta(22)-desaturase, and inhibition by azole antifungal agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZING LANOSTEROL 14-ALPHA-DEMETHYLATION; CYTOCHROME-P-450; YEAST; BIOSYNTHESIS	Cytochrome P-45061 (CYP61) was a cytochrome P350 revealed during the yeast genome project when chromosome XIII was sequenced. Here we report on the properties of this second microsomal P-450 of vegetatively growing yeast. The enzyme kinetics associated with its endogenous role in sterol Delta(22)-desaturation revealed a K-m of 20.4 mu M and a V-max of 2.9nmol/min/nmol CYP61. The affinity of the enzyme for antifungal drugs was characterized to investigate its potential role in determining tolerance to these sterol 14 alpha-demethylase (CYP51) inhibitors. Drug binding induced a type II spectral change, which became saturated at equimolar concentrations of azole drug and P-450. Fluconazole exhibited slightly reduced affinity in comparison to ketoconazole as indicated by carbon monoxide displacement. These and K-i determination for fluconazole (0.14 nM) revealed CYP61 to have a similar affinity to azole drugs when compared with data available for CYP51, and the implications for antifungal treatment were considered.	ZENECA AGROCHEM,JEALOTTS HILL RES STN,BRACKNELL RG42 6ET,BERKS,ENGLAND		Kelly, SL (corresponding author), UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOL BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND.							AOYAMA Y, 1984, J BIOL CHEM, V259, P1661; BARRELL B, 1995, DIRECT SUBMISSION EM; HATA S, 1981, BIOCHEM BIOPH RES CO, V103, P272, DOI 10.1016/0006-291X(81)91689-2; HITCHCOCK CA, 1990, BIOCHEM J, V266, P475, DOI 10.1042/bj2660475; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kelly SL, 1995, FEBS LETT, V377, P217, DOI 10.1016/0014-5793(95)01342-3; KELLY SL, 1993, BIOCHEM SOC T, V21, P1035; NEBERT DW, 1994, CYTOCHROME P450, P3; RAGSDALE NN, 1975, BIOCHIM BIOPHYS ACTA, V380, P81, DOI 10.1016/0005-2760(75)90047-8; SAGGS BA, 1996, GENE AMST, V169, P105; VANDENBOSSCHE H, 1987, PESTIC SCI, V21, P289, DOI 10.1002/ps.2780210406; WIGGINS TE, 1984, PESTIC SCI, V15, P206, DOI 10.1002/ps.2780150212; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655	13	100	104	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9986	9988						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092539	hybrid			2022-12-27	WOS:A1997WU03900058
J	Tan, XQ; Martin, SJ; Green, DR; Wang, JYJ				Tan, XQ; Martin, SJ; Green, DR; Wang, JYJ			Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; MAMMALIAN HOMOLOG; GENE CED-3; ACTIVATION; REQUIREMENT; EXPRESSION; CLEAVAGE; PATHWAY; ENZYME	The product of the retinoblastoma susceptibility gene, RB, is a negative regulator of cell proliferation. Inactivation of RE does not interfere with embryonic growth or differentiation. However, Rb-deficient embryos show abnormal degeneration of neurons and lens fiber cells through apoptosis, suggesting that RE may protect against programmed cell death. Consistent with this notion, RE is found to be degraded in tumor necrosis factor (TNF)- and CD95-induced death, A consensus caspase cleavage site at the C terminus of RE is cleaved in vitro and in vivo by proteases related to CPP32 (caspase 3). Mutation of the consensus cleavage site generates a cleavage-resistant RE which is not degraded during cell death. Expression of this non-degradable RE is found to antagonize the cytotoxic effects of TNF in Rb-/- 3TS cells, but this mutant RE cannot attenuate the rapid death induced by anti-CD95 in Jurkat/T cells. These results show that RE is a target of the caspase family of proteases during cell death and suggest that the failure to degrade RE can attenuate the death response toward some but not all death inducers.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093; LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [R01CA058320, T32CA009345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09345, CA58320, R01 CA058320] Funding Source: Medline; NIGMS NIH HHS [GM52735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An B, 1996, CANCER RES, V56, P438; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATSUI H, 1994, FEBS LETT, V351, P419, DOI 10.1016/0014-5793(94)00897-3; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	151	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9613	9616						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092486				2022-12-27	WOS:A1997WU03900005
J	Tschantz, WR; Furfine, ES; Casey, PJ				Tschantz, WR; Furfine, ES; Casey, PJ			Substrate binding is required for release of product from mammalian protein farnesyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING; FARNESYL; TRANSFERASE; EXPRESSION; INHIBITORS; CLONING; ISOPRENYLATION; MEMBRANES; HOMOLOGY; SUBUNIT	Protein farnesyltransferase (FTase) catalyzes the modification by a farnesyl lipid of Pas and several other key proteins involved in cellular regulation. Previous studies on this important enzyme have indicated that product dissociation is the rate-limiting step in catalysis. A detailed examination of this has now been performed, and the results provide surprising insights into the mechanism of the enzyme. Examination of the binding of a farnesylated peptide product to free enzyme revealed a binding affinity of similar to 1 mu M. However, analysis of the product release step under single turnover conditions led to the surprising observation that the peptide product did not dissociate from the enzyme unless additional substrate was provided. Once additional substrate was provided, the enzyme released the farnesylated peptide product with rates comparable with that of overall catalysis by FTase. Additionally, stable FTase-farnesylated product complexes were formed using Ras proteins as substrates, and these complexes also require additional substrate for product release. These data have major implications in both our understanding of overall mechanism of this enzyme and in design of inhibitors against this therapeutic target.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOL BIOCHEM,RES TRIANGLE PK,NC 27709	Duke University; Duke University; GlaxoSmithKline				Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, GM18069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372, F32GM018069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Huang CC, 1997, J BIOL CHEM, V272, P20; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Pellicena P, 1996, BIOCHEMISTRY-US, V35, P13494, DOI 10.1021/bi961336h; Penefsky H S, 1979, Methods Enzymol, V56, P527; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; YING WL, 1994, J BIOL CHEM, V269, P470; Zhang FL, 1996, BIOCHEM J, V320, P925, DOI 10.1042/bj3200925; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	34	86	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9989	9993						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092540				2022-12-27	WOS:A1997WU03900059
J	Botling, J; Castro, DS; Oberg, F; Nilsson, K; Perlmann, T				Botling, J; Castro, DS; Oberg, F; Nilsson, K; Perlmann, T			Retinoic acid receptor retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; CO-REPRESSOR; TRANSCRIPTIONAL ACTIVATION; RESPONSE PATHWAYS; CRYSTAL-STRUCTURE; LINE U-937; BETA-GENE; PROLIFERATION	The receptor for 9-cis-retinoic acid, retinoid X receptor (RXR), forms heterodimers with several nuclear receptors, including the receptor for all-trans-retinoic acid, RAR. Previous studies have shown that retinoic acid receptor can be activated in RAR/RXR heterodimers, whereas RXR is believed to be a silent co-factor. In this report we show that efficient growth arrest and differentiation of the human monocytic cell line U-937 require activation of both RAR and RXR. Also, we demonstrate that the allosteric inhibition of RXR is not obligatory and that RXR can be activated in the RAR/RXR heterodimer in the presence of RAR ligands. Remarkably, RXR inhibition by RAR can also be relieved by an RAR antagonist. Moreover, the dose response of RXR agonists differ between RXR homodimers and RAR/RXR heterodimers, indicating that these complexes are pharmacologically distinct. Finally, the AF2 activation domain of both subunits contribute to activation even if only one of the receptors is associated with ligand. Our data emphasize the importance of signaling through both subunits of a heterodimer in the physiological response to retinoids and show that the activity of RXR is dependent on both the identity and the ligand binding state of its partner.	LUDWIG INST CANC RES, S-17177 STOCKHOLM, SWEDEN; UNIV UPPSALA, DEPT PATHOL, LAB TUMOR BIOL, S-75185 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research; Uppsala University			Castro, Diogo S/I-6217-2016; Botling, Johan/ABA-2586-2020	Castro, Diogo S/0000-0001-8178-9565; Botling, Johan/0000-0003-2226-3517				Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; Botling J, 1995, LEUKEMIA, V9, P2034; Botling J, 1996, CELL GROWTH DIFFER, V7, P1239; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOTAN R, 1995, CANCER RES, V55, P232; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; OLSSON IL, 1982, CANCER RES, V42, P3924; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SPORN MB, 1994, RETINOIDS; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	47	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9443	9449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083083				2022-12-27	WOS:A1997WU03700088
J	Casamassima, A; Rozengurt, E				Casamassima, A; Rozengurt, E			Tyrosine phosphorylation of p130(cas) by bombesin, lysophosphatidic acid, phorbol esters, and platelet-derived growth factor - Signaling pathways and formation of A p130(cas)-Crk complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; FOCAL ADHESION KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; CELLULAR PROTEIN; FACTOR RECEPTORS; CROSS-TALK	Treatment of Swiss 3T3 cells with bombesin rapidly induced tyrosine phosphorylation of the p130 Crk-associated substrate (p130(cas)). Vasopressin, endothelin, bradykinin, lysophosphatidic acid, sphingosylphosphorylcholine, and phorbol 12,13-dibutyrate also stimulated p130(cas) tyrosine phosphorylation. Bombesin-induced p130(cas) tyrosine phosphorylation could be dissociated from both protein kinase C activation and Ca2+ mobilization from intracellular stores. In contrast, cytochalasin D, which disrupts the network of actin microfilaments, completely prevented tyrosine phosphorylation of p130(cas) by bombesin. Platelet-derived growth factor, at low concentrations (1-5 ng/ml), also induced tyrosine phosphorylation of p130(cas) via a pathway that depended on the integrity of the actin cytoskeleton. The phosphatidylinositol 3'-kinase inhibitors wortmannin and LY294002 prevented tyrosine phosphorylation of p130(cas) in response to platelet-derived growth factor but not in response to neuropeptides, lysophosphatidic acid, sphingosylphosphorylcholine, or phorbol 12,13-dibutyrate. All agonists that induced p130(cas) tyrosine phosphorylation also promoted the formation of a p130(cas).Crk complex in intact Swiss 3T3 cells. Thus, our results identified distinct signal transduction pathways that lead to tyrosine phosphorylation of p130(cas) in the same cells and suggest that p130(cas) could play a role in mitogen-mediated signal transduction.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, J CELL SCI, V108, P225; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OKADA T, 1994, J BIOL CHEM, V269, P3563; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1991, CANCER CELL-MON REV, V3, P397; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VUORI K, 1993, J BIOL CHEM, V268, P21459; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	69	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9363	9370						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083073				2022-12-27	WOS:A1997WU03700078
J	Chadee, DN; Allis, CD; Wright, JA; Davie, JR				Chadee, DN; Allis, CD; Wright, JA; Davie, JR			Histone H1b phosphorylation is dependent upon ongoing transcription and replication in normal and ras-transformed mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN CONDENSATION; NUCLEAR MATRIX; PROTEIN; APHIDICOLIN; STATES; KINASE; CELLS	We have previously shown that mouse phosphorylated histone H1b (pH1b) was localized near nuclear sites that contained splicing factors. This observation suggested to us that pH1b was associated with transcribing chromatin. Here we investigated the relationship between phosphorylation of H1b and transcription. We demonstrate that treatment of normal or ras-transformed mouse fibroblasts with the transcription inhibitor actinomycin D for 70 min results in a dramatic decrease in the level of pH1b. Similar results were observed when transcription was inhibited by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). When DRB was removed, the level of pH1b was restored after 2 h. Treatment of the cells with aphidicolin, a potent inhibitor of replication, resulted in a marked decrease in the level of pH1b after 30 min. This is the first report showing a dependence of histone modification upon ongoing transcription and replication. Inhibition of transcription or replication may hinder accessibility of H1b to the H1 kinase, supporting the idea that pH1b is associated with transcribing chromatin. Phosphorylation of H1b may be required to maintain a more decondensed chromatin structure to facilitate transcription and replication processes.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Manitoba; University of Manitoba; University of Rochester				Davie, James/0000-0002-0420-6888	NIGMS NIH HHS [GM 40922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; ARABSHAHI L, 1988, NUCLEIC ACIDS RES, V16, P5107, DOI 10.1093/nar/16.11.5107; BELIKOV SV, 1993, NUCLEIC ACIDS RES, V21, P1031, DOI 10.1093/nar/21.4.1031; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Clemson CM, 1996, J CELL BIOCHEM, V62, P181, DOI 10.1002/(SICI)1097-4644(199608)62:2<181::AID-JCB6>3.0.CO;2-O; CODOSH LA, 1989, J BIOL CHEM, V264, P2250; DAVIE JR, 1991, BIOCHEM J, V280, P491, DOI 10.1042/bj2800491; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; JERMANOPWSKI A, 1992, J BIOL CHEM, V267, P8514; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LU MJ, 1994, CHROMOSOMA, V103, P111; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; Paulson JR, 1996, J CELL SCI, V109, P1437; PEDRALINOY G, 1979, BIOCHEM BIOPH RES CO, V88, P1194, DOI 10.1016/0006-291X(79)91106-9; PERRY RP, 1963, EXP CELL RES, V29, P400, DOI 10.1016/S0014-4827(63)80003-8; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1	27	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8113	8116		10.1074/jbc.272.13.8113	http://dx.doi.org/10.1074/jbc.272.13.8113			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079620	hybrid			2022-12-27	WOS:A1997WQ63500003
J	Chapman, RL; Kane, SE; Erickson, AH				Chapman, RL; Kane, SE; Erickson, AH			Abnormal glycosylation of procathepsin L due to N-terminal point mutations correlates with failure to sort to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; OLIGOSACCHARIDES; PHOSPHORYLATION; CELLS; SITE; TRANSFORMATION; MUTAGENESIS; PROREGION; PROTEIN; GELS	A single point mutation in the lysosomal proenzyme receptor-inhibiting sequence near the N terminus of mouse procathepsin L can result in glycosylation of a normally cryptic site near its C terminus. When alanine replaced His(36), Arg(38), or Tyr(40), the nascent chain of the mutant protein cotranslationally acquired a high mannose oligosaccharide chain at Asn(268). In contrast, when alanine replaced Ser(34), Arg(37), or Leu(39), this second carbohydrate chain was not added, This alternating pattern of abnormal glycosylation suggested that propeptide residues 36-40 normally assume an extended conformation having the side chains of residues 36, 38, and 40 facing in the same direction. When tyrosine conservatively replaced His(36) or lysine replaced Arg(38), Asn(268) was not glycosylated, But the procathepsin L mutant having phenylalanine in place of Tyr(40) was carboxylated at Asn(268), which indicates that the hydrogen bond between the hydroxyl group of Tyr(40) and the carboxylate group of Asp(82) is necessary for normal folding of the nascent proenzyme chain. Mutation of the adjacent alpha 2p (ERININ) helix of the propeptide or addition of a C terminal epitope tag sequence to procathepsin L also induced misfolding of the proenzyme, as indicated by addition of the second oligosaccharide chain. In contrast, the propeptide mutation KAKK99-102AAAA had no effect on carbohydrate modification even though it reduced the positive charge of the proenzyme. Misfolded mutant mouse procathepsin L was not efficiently targeted to lysosomes on expression in human HeLa cells, even though it acquired phosphate on mannose residues. The majority of the mutant protein was secreted after undergoing modification with complex sugars. Similarly, epitope-tagged mouse procathepsin L was not targeted to lysosomes in homologous mouse cells but was efficiently secreted. Since production of mature endogenous protease was not reduced in cells expressing the tagged protein, the tagged protein did not compete with endogenous procathepsin L for targeting to lysosomes.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; CITY HOPE NATL MED CTR,DIV SURG,DEPT CELL & TUMOR BIOL,DUARTE,CA 91010	University of North Carolina; University of North Carolina Chapel Hill; City of Hope								ANDUS T, 1983, EUR J BIOCHEM, V183, P561; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; ERICKSON AH, 1988, INTRACELLULAR PROTEI, P74; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; KANE SE, 1993, J BIOL CHEM, V268, P11456; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LI QZ, 1993, BIOTECHNIQUES, V15, P976; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MORRISON DA, 1977, J BACTERIOL, V132, P349, DOI 10.1128/JB.132.1.349-351.1977; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; Sambrook J., 2002, MOL CLONING LAB MANU; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; VARKI A, 1980, J BIOL CHEM, V255, P847	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8808	8816		10.1074/jbc.272.13.8808	http://dx.doi.org/10.1074/jbc.272.13.8808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079717	hybrid, Green Published			2022-12-27	WOS:A1997WQ63500100
J	Forgacs, E; Latham, G; Beard, WA; Prasad, R; Bebenek, K; Kunkel, TA; Wilson, SH; Lloyd, RS				Forgacs, E; Latham, G; Beard, WA; Prasad, R; Bebenek, K; Kunkel, TA; Wilson, SH; Lloyd, RS			Probing structure/function relationships of HIV-1 reverse transcriptase with styrene oxide N-2-guanine adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THUMB SUBDOMAIN; POLYMERIZATION; TERMINATION; MECHANISM; TEMPLATE; HELIX; DNA	Details of the interactions between the human immunodeficiency virus (HIV-1) reverse transcriptase and substrate DNA were probed both by introducing site-specific and stereospecific modifications into DNA and by altering the structure of potential critical residues in the polymerase, Unadducted 11-mer DNAs and Il-mer DNAs containing R and S enantiomers df styrene oxide at N-2-guanine were ligated with two additional oligonucleotides to create 63-mers that served as templates for HIV-1 reverse transcriptase replication, Oligonucleotides that primed synthesis 5 bases 3' to the adducts could be extended up to 1 base 3' and opposite the lesion, However, when the positions of the 3'-OH of the priming oligonucleotides were placed 1, 2, 3, 4, 5, and 6 bases downstream of the styrene oxide guanine adducts, replication was initiated, only to be blocked after incorporating 4, 5, 6, and 7 bases beyond the lesion. The sites of this adduct-induced termination corresponded to the position of the DNA where alpha-helix H makes contact with the DNA minor groove, 35 bases upstream of the growing 3' end. In addition, mutants of the polymerase in alpha-helix H (W266A and G262A) alter the termination probabilities caused by these DNA adducts, suggesting that alpha-helix H is a sensitive monitor of modifications in the minor groove of newly synthesized template-primer DNA several bases distal to the 3'-OH.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; NIEHS,MOL GENET LAB,RES TRIANGLE PK,NC 27709	University of Texas System; University of Texas Medical Branch Galveston; University of Oregon; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES05355, ES06492, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P01ES005355, R01ES006492] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; DeCorte BL, 1996, CHEM RES TOXICOL, V9, P630, DOI 10.1021/tx9501795; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; LATHAM GJ, 1995, THESIS VANDERBILT U; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P4334, DOI 10.1021/bi952086s	13	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8525	8530		10.1074/jbc.272.13.8525	http://dx.doi.org/10.1074/jbc.272.13.8525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079681	hybrid			2022-12-27	WOS:A1997WQ63500064
J	Huang, F; Gallo, V				Huang, F; Gallo, V			Gene structure of the rat kainate receptor subunit KA2 and characterization of an intronic negative regulatory region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN GENE; GLUTAMATE-RECEPTOR; 1ST INTRON; TRANSCRIPTIONAL ENHANCER; INTRAGENIC SEQUENCES; EXPRESSION; BRAIN; IDENTIFICATION; CHANNELS; SILENCER	We have isolated and analyzed the structure of the gene grik5 (glutamate receptor ionotropic kainate 5), encoding the rat kainate receptor subunit KA2. Six overlapping DNA fragments containing the entire grik5 gene were identified in a rat genomic library. grik5 is a unique gene composed of 20 exons that together span over 54 kilobases (kb). Reporter gene analysis demonstrated that 2 kb of grik5 5'-flanking sequence confers tissue-specific expression on a chloramphenicol acetyltransferase gene in vitro. We show that (i) the first intron of grik5 (3.4 kb) inhibited transcription of the chloramphenicol acetyltransferase gene driven by the 2-kb grik5 5'-flanking region; (ii) the negative regulatory element was located within 500 bp of the 3'-end of intron 1, and this 500-bp fragment selectively bound nuclear proteins isolated from neural and nonneural cells; (iii) the effect of the negative regulatory element on grik5 transcription was orientation- and distance-independent; and (iv) a 24-nucleotide sequence (CTTTCTGTGGC-CTCTGACCTTTCC) was identified as the binding site for nuclear proteins within the 500 bp fragment, as determined by footprinting and gel shift assays. We conclude that an intronic element that displays features of a silencer modulates grik5 transcription.	NICHHD, LAB CELULAR & MOL NEUROPHYSIOL, NIH, SECT MOL NEUROBIOL GLIA, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BAHN S, 1994, J NEUROSCI, V14, P5525; BELECKYADAMS T, 1993, J NEUROSCI, V13, P5056, DOI 10.1523/JNEUROSCI.13-12-05056.1993; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DENG TL, 1989, NUCLEIC ACIDS RES, V17, P645, DOI 10.1093/nar/17.2.645; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUESTER G, 1986, NUCLEIC ACIDS RES, V14, P1931, DOI 10.1093/nar/14.5.1931; HANIEL A, 1995, J BIOL CHEM, V270, P11209, DOI 10.1074/jbc.270.19.11209; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KOZMIK Z, 1990, GENE, V90, P287, DOI 10.1016/0378-1119(90)90192-T; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; Molne M., 1995, Society for Neuroscience Abstracts, V21, P52; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1991, J NEUROCHEM, V57, P675, DOI 10.1111/j.1471-4159.1991.tb03799.x; SCHLOKAT U, 1986, EMBO J, V5, P3251, DOI 10.1002/j.1460-2075.1986.tb04636.x; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Seeburg PH, 1996, J NEUROCHEM, V66, P1; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SZPIRER C, 1994, P NATL ACAD SCI USA, V91, P11849, DOI 10.1073/pnas.91.25.11849; WERNER P, 1991, NATURE, V351, P741; WISDEN W, 1993, J NEUROSCI, V13, P3582	41	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8618	8627		10.1074/jbc.272.13.8618	http://dx.doi.org/10.1074/jbc.272.13.8618			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079693	hybrid			2022-12-27	WOS:A1997WQ63500076
J	Jansson, M; Hallen, D; Koho, H; Andersson, G; Berghard, L; Heidrich, J; Nyberg, E; Uhlen, M; Kordel, J; Nilsson, B				Jansson, M; Hallen, D; Koho, H; Andersson, G; Berghard, L; Heidrich, J; Nyberg, E; Uhlen, M; Kordel, J; Nilsson, B			Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; MOLECULAR-BASIS; AQUEOUS-SOLUTION; PROTEIN-A; HEAT-CAPACITIES; COOPERATIVITY; ANTIBODIES; RESONANCE; THERMODYNAMICS; PURIFICATION	Details of the signal transduction mechanisms of the tyrosine kinase family of growth factor receptors remain elusive. In this work, we describe an extensive study of kinetic and thermodynamic aspects of growth factor binding to a soluble extracellular human insulin-like growth factor-I receptor (sIGF-I-R) variant. The extracellular receptor domains were produced fused to an IgG-binding protein domain (Z) in transfected human 293 cells as a correctly processed secreted alpha-beta'-Z dimer. The receptor was purified using IgG affinity chromatography, rendering a pure and homogenous protein in yields from 1 to 5 mg/liter of conditioned cell media. Biosensor technology (BIAcore) was applied to measure the insulin-like growth factor-I (IGF-I), des(1-3)IGF-I, insulin-like growth factor-II, and insulin ligand binding rate constants to the immobilized IGF-I-R-Z. The association equilibrium constant, K-a for the IGF-I interaction is determined to 2.8 x 10(8) M(-1) (25 degrees C). Microcalorimetric titrations on IGF-I/IGF-I-R-Z were performed at three different temperatures (15, 25, and 37 degrees C) and in two different buffer systems at 25 degrees C. From these measurements, equilibrium constants for the 1:1 (IGF-I:(alpha-beta'-Z)(2)) receptor complex in solution are deduced to 0.96 x 10(8) M(-1) (25 degrees C). The determined heat capacity change for the process is large and negative, -0.51 kcal (K mol)(-1). Further, the entropy change (Delta S) at 25 degrees C is large and negative. Far- and near-UV circular dichroism measurements display significant changes over the entire wavelength range upon binding of IGF-I to IGF-I-R-Z. These data are all consistent with a significant change in structure of the system upon IGF-I binding.	PHARM & UPJOHN AB, PRECLIN RES, S-11287 STOCKHOLM, SWEDEN; ROYAL INST TECHNOL, DEPT BIOCHEM & BIOTECHNOL, S-10044 STOCKHOLM, SWEDEN	Royal Institute of Technology			Uhlen, Mathias/B-3262-2016; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; 				BACKMAN P, 1994, J BIOCHEM BIOPH METH, V28, P85, DOI 10.1016/0165-022X(94)90023-X; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; Bevington P. R, 1969, DATA REDUCTION ERROR; CABANI S, 1981, J SOLUTION CHEM, V10, P563, DOI 10.1007/BF00646936; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; FORSBERG G, 1990, BIOCHEM J, V271, P357, DOI 10.1042/bj2710357; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; FREIRE E, 1993, PROTEINS, V17, P111, DOI 10.1002/prot.340170202; GUAL P, 1995, ENDOCRINOLOGY, V136, P5298, DOI 10.1210/en.136.12.5298; GUTHRIE JP, 1977, CAN J CHEM, V55, P3700, DOI 10.1139/v77-519; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JENDEBERG L, 1995, J MOL RECOGNIT, V8, P270, DOI 10.1002/jmr.300080405; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KENNE L, 1990, CARBOHYD RES, V198, P173, DOI 10.1016/0008-6215(90)84290-B; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; LOWENADLER B, 1986, EMBO J, V5, P2393, DOI 10.1002/j.1460-2075.1986.tb04509.x; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MCDONALD NQ, 1995, STRUCTURE, V3, P1, DOI 10.1016/S0969-2126(01)00129-0; MOKS T, 1987, BIOCHEMISTRY-US, V26, P5239, DOI 10.1021/bi00391a005; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NICHOLS N, 1976, J CHEM THERMODYN, V8, P1081, DOI 10.1016/0021-9614(76)90139-7; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; NORDMARK MG, 1984, J BIOCHEM BIOPH METH, V10, P187, DOI 10.1016/0165-022X(84)90039-3; OH Y, 1994, CURRENT DIRECTIONS I, P41; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; Siddle Kenneth, 1992, Progress in Growth Factor Research, V4, P301, DOI 10.1016/0955-2235(92)90013-8; SOOS MA, 1992, J BIOL CHEM, V267, P12955; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SUURKUUSK J, 1982, CHEM SCRIPTA, V20, P155; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; ZHANG RM, 1989, J BIOL CHEM, V264, P18472	52	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8189	8197		10.1074/jbc.272.13.8189	http://dx.doi.org/10.1074/jbc.272.13.8189			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079636	hybrid			2022-12-27	WOS:A1997WQ63500019
J	Shibagaki, Y; Chow, SA				Shibagaki, Y; Chow, SA			Central core domain of retroviral integrase is responsible for target site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING DOMAIN; HIV-1 INTEGRASE; PRODUCTIVE INFECTION; ESCHERICHIA-COLI; IN-VITRO; TYPE-1; PROTEIN; INVITRO; IDENTIFICATION	Integration of retroviral DNA can occur into many sites on target DNA with a wide variation in preference. One factor known to affect target site selection is integrase, the viral protein required for the integration reaction. In this study, assays that measure the distribution and frequency of retroviral DNA integration showed that purified integrases of human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus (FIV) had different patterns of target site usage. The integrase domain involved in target site selection was mapped by analyzing the integration pattern of chimeric proteins formed between HIV-1 and FIV integrases and of deletion variants of the two wild-type integrases. The results indicate that the domain responsible for target site selection resides in the central core region of integrase.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA068859] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGLUND G, 1995, J VIROL, V69, P3216, DOI 10.1128/JVI.69.5.3216-3219.1995; Goulaouic H, 1996, J VIROL, V70, P37, DOI 10.1128/JVI.70.1.37-46.1996; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; KAHN E, 1991, NUCLEIC ACIDS RES, V19, P851; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KATZMAN M, 1994, J VIROL, V68, P3558, DOI 10.1128/JVI.68.6.3558-3569.1994; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; PAHL A, 1993, J VIROL, V67, P5426, DOI 10.1128/JVI.67.9.5426-5434.1993; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; Sambrook J., 2002, MOL CLONING LAB MANU; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1990, J VIROL, V64, P5219, DOI 10.1128/JVI.64.10.5219-5222.1990; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P2433	47	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8361	8369						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079660	hybrid			2022-12-27	WOS:A1997WQ63500043
J	Jiang, W; Stock, MF; Li, X; Hackney, DD				Jiang, W; Stock, MF; Li, X; Hackney, DD			Influence of the kinesin neck domain on dimerization and ATPase kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RATE-LIMITING STEP; MOTOR DOMAIN; ESCHERICHIA-COLI; MICROTUBULE MOVEMENT; HEAD DOMAINS; ADP RELEASE; HYDROLYSIS; MECHANISM; PURIFICATION; MOLECULES	Motor domains of kinesin were expressed that extend from the N terminus to positions 346, 357, 365, 381, and 405 (designated DKH346-DKH405) to determine if the kinetic differences observed between monomeric DKH340 and dimeric DKH392 (Hackney, D. D. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 6865-6869) were specific to these constructs or due to their oligomeric state, Sedimentation analysis indicated that DKH346, DKH357, and DKH365 are predominantly monomeric and that DKH381 and DKH405 are predominantly dimeric at 0.01-0.03 mu M, the concentrations used for ATPase assays, In buffer with 25 mm KCl, all have high k(cat) values of 38-96 s(-1) at saturating microtubule (MT) levels, Monomeric DKH346, DKH357, and DKH365 have K-0.5(MT) values of 17, 9, and 1.4 mu M, respectively, but the K,.,,,,, values for the dimeric species are significantly lower, with 0.02 and 0.14 mu M for DKH381 and DKH405, respectively, The three new monomers release all of their ADP on association with microtubules, whereas the two new dimers retain approximately half of their ADP, consistent with the half site reactivity observed previously with dimeric DKH392, Both the k(bi(ATPase)) (=k(cat)/K-0.5(M/T)) values for stimulation of ATPase by MTs and the k(bi(ADP)) for stimulation of ADP release by MTs were determined in buffer containing 120 mM potassium acetate, The ratio of these rate constants (k(bi(ratio)) = k(bi(ATPase))/k(bi(ADP))) is 60-100 for the dimers, indicating hydrolysis of many ATP molecules per productive encounter with a MT as observed previously for DKH392 (Hackney, D. D.(1995) Nature 377, 448-450), For the monomers, k(bi(ratio)) values of similar to 4 indicate that they also may hydrolyze more than one ATP molecule per encounter with a MT and that the mechanism of hydrolysis is therefore fundamentally different from that of actomyosin, DKH340 is an exception to this pattern and may undergo uncoupled ATP hydrolysis.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HACKNEY DD, 1996, ANNU REV PHYSIOL, V58, P732; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; INGOLD AL, 1988, J CELL BIOL, V107, P2659; Inoue Y., 1996, Biophysical Journal, V70, pA36; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; PENNEY CL, 1978, ANAL BIOCHEM, V89, P297, DOI 10.1016/0003-2697(78)90754-6; RAMANATHAN K, 1996, BIOPHYS J, V37, pA37; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; SADHU A, 1992, J BIOL CHEM, V267, P11352; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	36	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7626	7632		10.1074/jbc.272.12.7626	http://dx.doi.org/10.1074/jbc.272.12.7626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065417	hybrid			2022-12-27	WOS:A1997WP59200011
J	Moule, SK; Welsh, GI; Edgell, NJ; Foulstone, EJ; Proud, CG; Denton, RM				Moule, SK; Welsh, GI; Edgell, NJ; Foulstone, EJ; Proud, CG; Denton, RM			Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells - Activation of protein kinase B by wortmannin-sensitive and -insensittve mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHOSERINE RESIDUES INVIVO; PLECKSTRIN HOMOLOGY DOMAIN; EPIDERMAL GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; GAMMA-SUBUNITS; ALPHA-ISOFORM; S6 KINASE; PHOSPHORYLATION; ADIPOCYTES	Previous studies using L6 myotubes have suggested that glycogen synthase kinase-3 (GSK-3) is phosphoryl ated and inactivated in response to insulin by protein kinase B (PKB, also known as Akt or RAG) (Cross, D, A, E., Alessi, D, R., Cohen, P., Andjelkovic, M., and Hemmings, B, A. (1995) Nature 378, 785-789), In the present study, marked increases in the activity of PKB have been shown to occur in insulin-treated rat epididymal fat cells with a time course compatible with the observed decrease in GSK-3 activity, Isoproterenol, acting primarily through beta(3)-adrenoreceptors, was found to decrease GSK-3 activity to a similar extent (approximately 50%) to insulin, However, unlike the effect of insulin, the inhibition of GSK by isoproterenol was not found to be sensitive to inhibition by the phosphatidylinositol 3'-kinase inhibitors, wortmannin or LY 294002, The change in GSK-3 activity brought about by isoproterenol could not be mimicked by the addition of permeant cyclic AMP analogues or forskolin to the cells, although at the concentrations used, these agents were able to stimulate lipolysis. Isoproterenol, but again not the cyclic AMP analogues, was found to increase the activity of PKB, although to a lesser extent than insulin. While wortmannin abolished the stimulation of PKB activity by insulin, it was without effect on the activation seen in response to isoproterenol, The activation of PKB by isoproterenol was not accompanied by any detectable change in the electrophoretic mobility of the protein on SDS-polyacrylamide gel electrophoresis. It would therefore appear that distinct mechanisms exist for the stimulation of PKB by insulin and isoproterenol in rat fat cells.	UNIV KENT,DEPT BIOSCI,CANTERBURY CT2 7NJ,KENT,ENGLAND	University of Kent	Moule, SK (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND.		Denton, Richard/ABC-9914-2020	Welsh, Gavin Iain/0000-0002-2148-6658	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Arch JRS, 1996, BIOCHEM SOC T, V24, P412, DOI 10.1042/bst0240412; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1966, BIOCHEM J, V100, P407, DOI 10.1042/bj1000407; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIORGETTI S, 1995, BIOCHEM BIOPH RES CO, V216, P526; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1991, EUR J PHARMACOL, V199, P291, DOI 10.1016/0014-2999(91)90492-9; LAWRENCE JC, 1986, J BIOL CHEM, V261, P669; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; MURPHY GJ, 1993, BIOCHEM PHARMACOL, V46, P575, DOI 10.1016/0006-2952(93)90540-D; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PARKER PJ, 1982, EUR J BIOCHEM, V124, P47, DOI 10.1111/j.1432-1033.1982.tb05904.x; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VANLIEFDE I, 1992, J PHARMACOL EXP THER, V262, P552; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WILSON C, 1984, EUR J PHARMACOL, V100, P309, DOI 10.1016/0014-2999(84)90007-4; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4	44	221	227	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7713	7719		10.1074/jbc.272.12.7713	http://dx.doi.org/10.1074/jbc.272.12.7713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065430	hybrid			2022-12-27	WOS:A1997WP59200024
J	Zhou, Q; Snipas, S; Orth, K; Muzio, M; Dixit, VM; Salvesen, GS				Zhou, Q; Snipas, S; Orth, K; Muzio, M; Dixit, VM; Salvesen, GS			Target protease specificity of the viral serpin CrmA - Analysis of five caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; FACTOR-INDUCED APOPTOSIS; DEATH GENE CED-3; IL-1-BETA-CONVERTING ENZYME; PROTEINASE-INHIBITORS; MAMMALIAN HOMOLOG; MICE DEFICIENT; IDENTIFICATION; ENCODES; CLEAVES	When ectopically expressed in animal cells, cytokine response modifier A (CrmA), a product of the cowpox virus, prevents programmed cell death initiated by a variety of stimuli, Since CrmA is a proteinase inhibitor, its target is probably a protease that promotes cell death. The identification of this target is crucial in delineating essential regulation points that modulate the apoptotic program, We have compared the kinetics of interaction of CrmA with five proteases that may play a role in apoptosis, Four of the proteases, all members of the caspase family, are inhibited with widely different rates and affinities ranging over 5 orders of magnitude, One is not inhibited at all under the experimental conditions, CrmA is quite selective in its ability to inhibit caspases, showing the highest affinity for interleukin-1 beta-converting enzyme and the second highest for the caspase FLICE (K-i = 0.95 nM), identified as a component of the intracellular signaling complex recruited by ligation of the death receptor Fas, On the basis of comparative inhibitor kinetics, we propose that CrmA is unlikely to inhibit the caspases Yama, Mch2, or LAP3 in vivo but that its inhibition of FLICE is of a magnitude for this protease to be a key target of CrmA during Fas-mediated apoptosis, Therefore, our results support the hypothesis that FLICE catalyzes a crucial step in the promotion of cell death.	BURNHAM INST,SAN DIEGO,CA 92037; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620	NHLBI NIH HHS [HL51399] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051399] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Salvesen, 1986, PROTEINASE INHIBITOR, P23; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	27	466	477	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7797	7800		10.1074/jbc.272.12.7797	http://dx.doi.org/10.1074/jbc.272.12.7797			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065443	hybrid			2022-12-27	WOS:A1997WP59200037
J	Korner, CG; Wahle, E				Korner, CG; Wahle, E			Poly(A) tail shortening by a mammalian poly(A)-specific 3'-exoribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION; YEAST; DEADENYLATION; BINDING; PURIFICATION; STABILITY; POLYMERASE; CLEAVAGE	3'-Exonucleolytic removal of the poly(A) tail is the first and often rate-limiting step in the decay of many eucaryotic mRNAs. In a cytoplasmic extract from HeLa cells, the poly(A) tail of mRNA was degraded from the 3'-end. In agreement with earlier in vivo observations, prominent decay intermediates differed in length by about 30 nucleotides. The Mg2+-dependent, poly(A)-specific 3'-exoribonuclease responsible for this poly(A) shortening activity was purified from calf thymus. A polypeptide of 74 kDa copurified with the activity. The deadenylating nuclease (DAN) required a free 3'-OH group, released solely 5'-AMP, degraded RNA in a distributive fashion, and preferred poly(A) as a substrate. At low salt concentration, the activity of purified DAN was strongly dependent on spermidine or other, yet unidentified factors. Under these reaction conditions, DAN was also stimulated by the cytoplasmic poly(A)-binding protein I (PAB I). At physiological salt concentration, the stimulatory effect of spermidine was weak and PAB I was inhibitory. At either salt concentration DAN and PAB I reconstituted poly(A) shortening with the same pattern of intermediates seen in cytoplasmic extract. The properties of DAN suggest that the enzyme might be involved in the deadenylation of mRNA in vivo.	UNIV GIESSEN,INST BIOCHEM,D-35392 GIESSEN,GERMANY; UNIV BASEL,DEPT CELL BIOL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	Justus Liebig University Giessen; University of Basel			Körner, Christian/B-6592-2014	Körner, Christian/0000-0001-7768-7638; Wahle, Elmar/0000-0003-2504-0677				ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KELLY JM, 1982, NUCLEIC ACIDS RES, V10, P4173, DOI 10.1093/nar/10.14.4173; KROWCZYNSKA A, 1986, J BIOL CHEM, V261, P397; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MANSBRIDGE JN, 1974, EUR J BIOCHEM, V44, P261, DOI 10.1111/j.1432-1033.1974.tb03481.x; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Pirrotta V, 1980, Methods Enzymol, V65, P89; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; Sheflin LG, 1996, ENDOCRINOLOGY, V137, P2085, DOI 10.1210/en.137.5.2085; STOECKLE MY, 1993, NUCLEIC ACIDS RES, V21, P1613, DOI 10.1093/nar/21.7.1613; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1993, J BIOL CHEM, V268, P2937; Wahle E., 1994, RNA PROCESSING PRACT, VII, P1; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x	46	192	197	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10448	10456						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099687				2022-12-27	WOS:A1997WV26200021
J	Ruth, P; Pfeifer, A; Kamm, S; Klatt, P; Dostmann, WRG; Hofmann, F				Ruth, P; Pfeifer, A; Kamm, S; Klatt, P; Dostmann, WRG; Hofmann, F			Identification of the amino acid sequences responsible for high affinity activation of cGMP kinase I alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; BOVINE AORTA; BINDING SITES; CIRCULAR-DICHROISM; BACULOVIRUS SYSTEM; TERMINAL DOMAIN; EXPRESSION; BETA; ISOZYME	The cGMP-dependent protein kinases (cGK) I alpha and I beta have identical cGMP binding sites and catalytic domains, However, differences in their first 100 amino acids result in 15-fold different activation constants for cGMP, We constructed chimeras to identify those amino acid sequences that contribute to the high affinity cGK I alpha and low affinity cGK I beta phenotype, The cGK I alpha/I beta chimeras contained permutations of six amino-terminal regions (S1-S6) including the leucine zipper (S2), the autoinhibitory domain (S4), and the hinge domain (S5, S6). The exchange of S2 along with S4 switched the phenotype from cGK I alpha to cGK I beta and vice versa, suggesting that the domains with the highest homology between the two isozymes determine their affinity for cGMP, The high affinity cGK I alpha phenotype was also obtained by a specific substitution within the hinge domain, Chimeras with the sequence of cGK I alpha in S5 and cGK I beta in S6 were activated at up to 6-fold lower cGMP concentrations than cGK I alpha. Based on the activation constants of all chimeras constructed, empirical weighting factors have been calculated that quantitatively describe the contribution of the individual amino-terminal domains S1-S6 to the high affinity cGK I alpha phenotype.			Ruth, P (corresponding author), TECH UNIV MUNICH,INST PHARMAKOL & TOXIKOL,BIEDERSTEINER STR 29,D-80802 MUNICH,GERMANY.							AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; FEIL R, 1993, FEBS LETT, V336, P163, DOI 10.1016/0014-5793(93)81632-A; FEIL R, 1995, BIOCHEMISTRY-US, V34, P13152, DOI 10.1021/bi00040a029; FRANCIS S, 1993, FASEB J, V7, pA1123; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MCCUNE RW, 1979, J BIOL CHEM, V254, P5083; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157	32	53	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10522	10528						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099696				2022-12-27	WOS:A1997WV26200030
J	VanEyk, JE; Thomas, LT; Tripet, B; Wiesner, RJ; Pearlstone, JR; Farah, CS; Reinach, FC; Hodges, RS				VanEyk, JE; Thomas, LT; Tripet, B; Wiesner, RJ; Pearlstone, JR; Farah, CS; Reinach, FC; Hodges, RS			Distinct regions of troponin I regulate Ca2+-dependent activation and Ca2+ sensitivity of the Acto-S1-TM ATPase activity of the thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CONTRACTION; BIOLOGICAL-ACTIVITY; INHIBITORY PEPTIDE; SYNTHETIC PEPTIDES; ACANTHAMOEBA ACTIN; CARDIAC TROPONIN; F-ACTIN; TROPOMYOSIN; RABBIT; BINDING	The regions of troponin I (TnI) responsible for Ca2+-dependent activation and Ca2+ sensitivity of the actin-myosin subfragment 1-tropomyosin ATPase (acto-S1-TM) activity have been determined. A colorimetric ATPase assay at pH 7.8 has been applied to reconstituted skeletal muscle thin filaments at actin:S1:TM ratios of 6:1:2. Several TnI fragments (TnI-(104-115), TnI-(1-116), and TnI-(96-148)) and TnI mutants with single amino acid substitutions within the inhibitory region (residues 104-115) were assayed to determine their roles on the regulatory function of TnI. TnI-(104-115) is sufficient for achieving maximum inhibition of the acto-S1-TM ATPase activity and its importance was clearly shown by the reduced potency of TnI mutants with single amino acid substitutions within this region. However, the function of the inhibitory region is modulated by other regions of TnI as observed by the poor inhibitory activity of TnI-(1-116) and the increased potency of the inhibitory region by TnI-(96-148). The regulatory complex composed of TnI-(96-148) plus troponin T-troponin C complex (TnT.C) displays the same Ca2+ sensitivity (pCa(50)) as intact troponin (Tn) or TnI plus TnT.C while those regulatory complexes composed of TnT.C plus either TnI-(104-115) or TnI-(1-116) had an increase in their pCa(50) values. This indicates that the Ca2+ sensitivity or responsiveness of the thin filament is controlled by TnI residues 96-148. The ability of Tn to activate the acto-S1-TM ATPase activity in the presence of calcium to the level of the acto-sl rate was mimicked by the regulatory complex composed of TnI-(1-116) plus TnT.C and was not seen with complexes composed with either TnI-(104-115) or TnI-(96-148). This indicates that the N terminus of TnI in conjunction with TnT controls the degree of activation of the ATPase activity. Although the TnI inhibitory region (104-115) is the Ca2+-sensitive switch which changes binding sites from actin-TM to TnC in the presence of calcium, its function is modulated by both the C-terminal and N-terminal regions of TnI. Thus, distinct regions of TnI control different aspects of Tn's biological function.	UNIV HEIDELBERG,INST PHYSIOL 2,D-6900 HEIDELBERG,GERMANY; UNIV SAO PAULO,DEPT BIOQUIM,SAO PAULO,BRAZIL	Ruprecht Karls University Heidelberg; Universidade de Sao Paulo	VanEyk, JE (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP PROT STRUCT & FUNCT,EDMONTON,AB,CANADA.		Farah, Chuck Shaker/G-5565-2012	Farah, Chuck Shaker/0000-0003-3110-6302				CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; INGRAHAM RH, 1988, BIOCHEMISTRY-US, V27, P5891, DOI 10.1021/bi00416a011; KLUWE L, 1993, FEBS LETT, V325, P83; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PAN BS, 1991, J BIOL CHEM, V266, P12432; Pearlstone J. R., 1995, Biophysical Journal, V68, pA166; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SMILLIE LB, 1982, MEHTODS ENZYMOL, V851, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRAUSS JD, 1996, PFLUGERS ARCH, V431, P851; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Van Eyk Jennifer E., 1993, Methods (Orlando), V5, P264, DOI 10.1006/meth.1993.1033; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WILKINSON JM, 1974, BIOCHIM BIOPHYS ACTA, V359, P379, DOI 10.1016/0005-2795(74)90238-4; YANG YZ, 1979, J BIOL CHEM, V254, P2084; YANG YZ, 1979, J BIOL CHEM, V254, P7137; Zhang R., 1995, Biophysical Journal, V68, pA165; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	66	67	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10529	10537						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099697				2022-12-27	WOS:A1997WV26200031
J	Bennett, BL; Cruz, R; Lacson, RG; Manning, AM				Bennett, BL; Cruz, R; Lacson, RG; Manning, AM			Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; JAK-3 JANUS KINASE; ENDOTHELIAL-CELLS; HUMAN MONOCYTES; MYELOID CELLS; DNA-BINDING; IFN-GAMMA; IL-4; ACTIVATION; EXPRESSION	Interleukin-4 (IL-4), an immunoregulatory cytokine secreted from activated T-helper 2 lymphocytes, eosinophils, and mast cells, stimulates the expression of a number of immune system genes via activation of the transcription factor, STAT6. However, IL-4 can concomitantly suppress the expression of other immune related gene products, including kappa light chain, Fc gamma RI, IL-8, and E-selectin, We demonstrate that IL-4 activates STATE in human vascular endothelial cells and that two STAT6 binding sites are present in the promoter of the E-selectin gene, IL-4-induced STAT6 binding does not activate E-selectin transcription but instead suppresses tumor necrosis factor alpha-induced expression of the E-selectin gene, STAT6 was found to compete for binding to a region in the E-selectin gene promoter containing overlapping STAT6 and NF-kappa B binding sites, effectively acting as an antagonist of NF-kappa B binding and transcriptional activation, This novel mechanism for IL-4-mediated inhibition of inflammatory gene expression provides an example of a STAT factor acting as a transcriptional repressor rather than an activator.			Bennett, BL (corresponding author), PHARMACIA & UPJOHN INC, CELL BIOL & INFLAMMAT RES, 301 HENRIETTA ST, KALAMAZOO, MI 49007 USA.							ARNDT H, 1995, GUT, V37, P374, DOI 10.1136/gut.37.3.374; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Banchereau J, 1994, CYTOKINE HDB, P99; Bell FP, 1996, FASEB J, V10, P4682; BELL FP, 1995, HEPATOLOGY, V22, P1098; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRISCOE DM, 1992, J IMMUNOL, V149, P2954; CARLOS TM, 1994, BLOOD, V84, P2068; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CJP, 1995, EUR J IMMUNOL, V25, P2961, DOI 10.1002/eji.1830251037; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; HASHIMOTO S, 1993, ANN ALLERGY, V71, P455; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; Manning AM, 1995, J INFLAMM, V45, P283; MOSER R, 1993, J LAB CLIN MED, V122, P567; NONAKA M, 1995, J IMMUNOL, V155, P3234; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PAUL WE, 1991, BLOOD, V77, P1859; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Pierce JW, 1996, J IMMUNOL, V156, P3961; READ MA, 1995, AM J PATHOL, V147, P235; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; SAMBROOK J, 1989, MOL CLONING LAB MANU, P43; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TEVELDE AA, 1990, BLOOD, V76, P1392; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THORNHILL MH, 1990, J IMMUNOL, V145, P865; VELDE AAT, 1990, J IMMUNOL, V144, P3046; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	59	122	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10212	10219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092569				2022-12-27	WOS:A1997WU03900088
J	Dong, ZG; Huan, CS; Brown, RE; Ma, WY				Dong, ZG; Huan, CS; Brown, RE; Ma, WY			Inhibition of activator protein 1 activity and neoplastic transformation by aspirin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN SYNTHESIS INHIBITORS; URINARY-BLADDER CARCINOGENESIS; SODIUM-SALICYLATE; CELL-PROLIFERATION; COLONIC EPITHELIUM; GENE DISRUPTION; EPIDERMAL-CELLS; TUMOR-GROWTH; KAPPA-B	Aspirin, along with its analgesic-antipyretic uses, is now also being considered for prevention of cardiovascular disease, cancer, and treatment of human immunodeficiency virus infection. Although many of aspirin's pharmacological actions are related to its ability to inhibit prostaglandin biasynthesis, some of its beneficial therapeutic effects are not completely understood. Transcription factor activator protein 1 (AP-1) is critical for the induction of neoplastic transformation and induction of multiple genes involved in inflammation and infection. We have used the JB6 mouse epidermal cell lines, a system that has been used extensively as an in vitro model for the study of tumor promotion and antitumor promotion, to study the anti-carcinogenesis effect of aspirin at the molecular level. Aspirin and aspirin-like salicylatcs inhibited the activation of AP-1 in the same dose range as seen for the inhibition of tumor promoter-induced transformation. The inhibition of AP-1 and tumor promoter induced transformation in JB6 cells occurs through a prostaglandin independent- and an Erk1- or Erk2-independent pathway. The mechanism of AP-1 and transformation inhibition in this cell culture model may involve the elevation of H+ concentration. The inhibition effects on the activation of AP-1 activity by aspirin and aspirin-like salicylates may further explain the anti-carcinogenesis mechanism of action of these drugs.			Dong, ZG (corresponding author), UNIV MINNESOTA, HORMEL INST, 801 16TH AVE NE, AUSTIN, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096; Brown, Rhoderick/0000-0002-7337-3604	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS DS, 1995, J CELL BIOCHEM, P18; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BISCHOF G, 1966, BIOCHIM BIOPHYS ACTA, V1282, P131; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CHENG LL, 1994, MICROBIOL-SGM, V140, P1085, DOI 10.1099/13500872-140-5-1085; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COHEN SM, 1989, CANCER RES, V49, P372; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEMELLO MCF, 1980, BIOCHEM PHARMACOL, V29, P311, DOI 10.1016/0006-2952(80)90506-7; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FISCHER SM, 1987, CANCER RES, V47, P3174; FURSTENBERGER G, 1990, CELL BIOL REV, V24, P1; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GOODLAD RA, 1991, GASTROENTEROLOGY, V101, P1229, DOI 10.1016/0016-5085(91)90071-R; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUNE GA, 1988, CANCER RES, V48, P4399, DOI 10.1093/ije/dym193; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lavrovsky V, 1996, IN VITRO CELL DEV-AN, V32, P234; Li JJ, 1996, CANCER RES, V56, P483; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARNETT LJ, 1992, CANCER RES, V52, P5575; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MCCORMICK DL, 1985, CANCER RES, V45, P1803; Meade T. W., 1992, P321; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; MURASAKI G, 1984, CARCINOGENESIS, V5, P53, DOI 10.1093/carcin/5.1.53; MURGUIA JR, 1995, J CELL BIOCHEM, V57, P630, DOI 10.1002/jcb.240570407; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; NIGRO ND, 1986, J NATL CANCER I, V77, P1309; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Rainsford K.D., 1984, ASPIRIN SALICYLATES; SAKATA T, 1986, CANCER RES, V46, P3903; SANTORO MG, 1976, NATURE, V263, P777, DOI 10.1038/263777a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1995, INT J ONCOL, V6, P465; TAKAHASHI M, 1990, CARCINOGENESIS, V11, P393, DOI 10.1093/carcin/11.3.393; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; TUTTON PJM, 1980, BRIT J CANCER, V41, P47, DOI 10.1038/bjc.1980.6; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1995, CARCINOGENESIS, V16, P2401, DOI 10.1093/carcin/16.10.2401	75	153	158	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9962	9970						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092536				2022-12-27	WOS:A1997WU03900055
J	Korte, T; Ludwig, K; Krumbiegel, M; Zirwer, D; Damaschun, G; Herrmann, A				Korte, T; Ludwig, K; Krumbiegel, M; Zirwer, D; Damaschun, G; Herrmann, A			Transient changes of the conformation of hemagglutinin of influenza virus at low pH detected by time-resolved circular dichroism spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION ACTIVITY; HEMOLYTIC-ACTIVITY; VIRAL FUSION; A VIRUSES; GLYCOPROTEINS; INACTIVATION; FLUORESCENCE; ACTIVATION; MECHANISM; KINETICS	Membrane fusion of influenza virus is mediated by a conformational change of the viral membrane protein hemagglutinin (HA) triggered by low pH. By near UV CD spectroscopy, which is sensitive to the arrangement and mobility of aromatic amino acids in proteins, we have monitored continuously with a time resolution of 5 s the kinetics of structural alterations of the ectodomain of KA isolated from different influenza virus strains (H1 (A/PR 8/34), H2 (A/Japan), and H3 (X31)). To establish a functional correlation to structural alterations of the HA ectodomain reflected by the CD, we have measured the kinetics of the virus-erythrocyte fusion and of the inactivation of fusion by low pH preincubation of viruses, At acidic pH we found a multiphasic behavior of the CD signal recorded at 283 nm. Upon lowering the pH we detected first an increase of the CD amplitude, which is associated with the formation of a fusion-competent state of HA. The initial increase was followed by a continuous decline of CD amplitude, which can be ascribed to a transformation into a fusion inactivated conformation that is in its early phase reversible as found for A/Japan. The half-time of the different phases of the CD signal depended on the virus strain, the temperature, and the acidic pH. The results support recent hypotheses that the fusion-competent conformation is an inter mediate of the fusion-inactivated structure of HA.	HUMBOLDT UNIV BERLIN,MATH NATURWISSENSCH FAK 1,INST BIOL BIOPHYS,D-10115 BERLIN,GERMANY; MAX DELBRUCK ZENTRUM,D-13125 BERLIN,GERMANY	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine								ARBUZOVA A, 1994, BBA-BIOMEMBRANES, V1190, P360, DOI 10.1016/0005-2736(94)90095-7; BIZEBARD T, 1995, NATURE, V376, P92, DOI 10.1038/376092a0; BLUMENTHAL R, 1987, J BIOL CHEM, V262, P13614; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GUTMAN O, 1993, BIOCHEMISTRY-US, V32, P101, DOI 10.1021/bi00052a014; HERRMANN A, 1993, BIOPHYS J, V65, P528, DOI 10.1016/S0006-3495(93)81054-3; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; HUGHSON FM, 1995, CURR BIOL, V5, P265, DOI 10.1016/S0960-9822(95)00057-1; JUNANKAR PR, 1986, BIOCHIM BIOPHYS ACTA, V854, P198, DOI 10.1016/0005-2736(86)90111-2; KAWASAKI K, 1983, BIOCHIM BIOPHYS ACTA, V733, P286, DOI 10.1016/0005-2736(83)90534-5; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; KRUMBIEGEL M, 1994, BIOPHYS J, V67, P2355, DOI 10.1016/S0006-3495(94)80721-0; LUDWIG K, 1995, EUR BIOPHYS J BIOPHY, V24, P55, DOI 10.1007/BF00211399; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; SCHOLTISSEK C, 1985, VACCINE, V3, P215, DOI 10.1016/0264-410X(85)90109-4; Skehel JJ, 1995, COLD SPRING HARB SYM, V60, P573, DOI 10.1101/SQB.1995.060.01.061; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; White JM, 1995, COLD SPRING HARB SYM, V60, P581, DOI 10.1101/SQB.1995.060.01.062; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	35	41	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9764	9770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092509				2022-12-27	WOS:A1997WU03900028
J	Miyako, K; Kai, Y; Irie, T; Takeshige, K; Kang, DC				Miyako, K; Kai, Y; Irie, T; Takeshige, K; Kang, DC			The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridinium ion (MPP(+))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-DEHYDROGENASE; RESPIRATORY-CHAIN; BINDING-SITE; MPP+; NEUROTOXICITY; PARTICLES; DEPLETION; MYOPATHY; CELLS; MPTP	1-Methyl-4-phenylpyridinium ion (MPP(+)), an oxidative metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is considered to be directly responsible for MPTP-induced Parkinson's disease-like symptoms by inhibiting NADH-ubiquinone oxidoreductase (complex I) in the mitochondrial respiratory chain, Here we demonstrate that 25 mu M MPP(+) decreases the content of mitochondrial DNA to about one-third in HeLa S3 cells, On the contrary, 0.1 mu M rotenone, which inhibits complex I to the same extent as 25 mu M MPP(+) in the cells, increases the content of mitochondrial DNA about a-fold, Hence, the effect of MPP(+) on mitochondrial DNA is not mediated by the inhibition of complex I, To examine the replication state of mitochondrial DNA, we measured the amount of nascent strands of mitochondrial DNA. The amount is decreased by MPP(+) but increased by rotenone, suggesting that the replication of mitochondrial DNA is inhibited by MPP(+). Because the proper amount of mitochondrial DNA is essential to maintain components of the respiratory chain, the decrease of mitochondrial DNA may play a role in the progression of MPTP induced Parkinson's disease-like symptoms caused by the mitochondrial respiratory failure.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Kyushu University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1019; KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KANG D, 1997, ARCH BIOCHEM BIOPHYS, V37, P75; KANG DC, 1983, J BIOCHEM, V94, P1301, DOI 10.1093/oxfordjournals.jbchem.a134475; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; Maxam A M, 1980, Methods Enzymol, V65, P499; MORAES CT, 1991, AM J HUM GENET, V48, P492; MUELLER PR, 1992, CURRENT PROTOCOLS MO, P1; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RAMSAY RR, 1987, ARCH BIOCHEM BIOPHYS, V259, P645, DOI 10.1016/0003-9861(87)90531-5; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129	23	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9605	9608						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092484				2022-12-27	WOS:A1997WU03900003
J	Seelan, RS; Grossman, LI				Seelan, RS; Grossman, LI			Structural organization and promoter analysis of the bovine cytochrome c oxidase subunit VIIc gene - A functional role for YY1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTION FACTORS; BINDING-SITES; IV GENE; NF-E1 YY-1; DNA; PROTEIN; EXPRESSION; ACTIVATION; DOMAIN	Cytochrome c oxidase (COX) subunit VIIc is one of the nuclear encoded subunits of the 13-subunit holoenzyme that carries out the terminal step in the electron transport chain, We have isolated the gene for this subunit, previously shown to be ubiquitously expressed from a single copy gene in the genome, and show that 167 base pairs of DNA surrounding the transcriptional start site contain the minimal promoter of this gene. This basal promoter contains two YY1 sites and at least one site for NRF-2, which show binding to their cognate factors. Mutation of both YY1 sites eliminates most of the promoter activity. Mutation at the upstream YY1 site significantly reduces the efficiency of transcript initiation at the major start site and thus plays the dominant role in COX7C regulation. COX7C is, thus, the second nuclear gene of COX that is regulated by YY1, suggesting that it is a third common factor, along with NRF-1 and NRF-2, to be associated with COX gene regulation.	WAYNE STATE UNIV, SCH MED, CTR MOL MED & GENET, DETROIT, MI 48201 USA	Wayne State University				Seelan, Ratnam/0000-0002-8925-1070	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048517] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48517] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUA MS, 1991, GENE, V104, P211, DOI 10.1016/0378-1119(91)90252-7; AQUA MS, 1991, THESIS WAYNE STATE U, P81; Ausubel FM, 1988, MOL REPROD DEV; BASU A, 1993, J BIOL CHEM, V268, P4188; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOTHWELL A, 1990, METHODS CLONING ANAL, P167; Breen GAM, 1996, GENE EXPRESSION, V5, P181; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KUMAR G, 1992, GENE, V110, P101, DOI 10.1016/0378-1119(92)90450-4; LATCHMAN DS, 1994, METHODS MOL GENET, V5, P44; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERS B, 1993, J BIOL CHEM, V268, P3430; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; Seelan RS, 1996, J BIOL CHEM, V271, P2112, DOI 10.1074/jbc.271.4.2112; SEELAN RS, 1993, GENOMICS, V18, P527; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SPJOTVOLL E, 1973, J AM STAT ASSOC, V68, P975, DOI 10.2307/2284534; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WAN B, 1995, J BIOL CHEM, V270, P26433, DOI 10.1074/jbc.270.44.26433; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353	50	45	47	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10175	10181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092564	hybrid			2022-12-27	WOS:A1997WU03900083
J	Kim, HJ; Okazaki, IJ; Takada, T; Moss, J				Kim, HJ; Okazaki, IJ; Takada, T; Moss, J			An 18-kDa domain of a glycosylphosphatidylinositol-linked NAD:Arginine ADP-ribosyltransferase possesses NAD glycohydrolase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; DIPHTHERIA-TOXIN; PERTUSSIS TOXIN; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; ASPARTIC-ACID; EXOTOXIN-A; TRANSFERASE; PROTEINS; SUBUNIT	Transfection of NMU (rat mammary adenocarcinoma) cells with NAD:arginine ADP-ribosyltransferase cDNAs from Yac-1 murine lymphoma cells or rabbit muscle increased NAD glycohydrolase and ADP-ribosyltransferase activities. The ADP-ribosyltransferase activity was released from transformed NMU cells by phosphatidylinositol-specific phospholipase C (PI-PLC) and hence glycosylphosphatidylinositol (GPI)-anchored, whereas the NAD glycohydrolase (NADase) activity remained cell-associated. By gel permeation chromatography, the size of the PI-PLC-released transferase was similar to 40 kDa and that of the detergent-solubilized NADase was similar to 100 kDa. Using polyclonal antibodies against rabbit muscle transferase on Western blots, similar to 18- and similar to 30-kDa band were visualized among proteins from the NADase fractions and 38-40-kDa bands with protein from the transferase fractions. Incubation of blots with [P-32]NAD led to the incorporation of radioactivity into the immunoreactive transferase bands of 38 kDa and the immunoreactive NADase band of similar to 18 kDa. These data suggest that proteolysis of ADP-ribosyltransferase synthesized in transformed NMU cells might result in the formation of aggregates of an 18-kDa NAD glycohydrolase. A fusion protein with glutathione S-transferase linked to the amino terminus of Yac-1 transferase, from which the amino-terminal 121 amino acids had been deleted (GST-Yac-1-delta 121), exhibited NADase, but not transferase, activity. The size of the recombinant fusion protein was similar to that of the proteolytic fragment seen in NMU cells transformed with transferase cDNA. These results are compatible with the conclusion that the NAD glycohydrolase activity was generated in NMU cells by proteolysis of ADP-ribosyltransferase, with release of a carboxyl-terminal fragment that possesses glycohydrolase but not transferase activity, i.e. the carboxyl-terminal portion of the transferase can exist as a catalytically active NADase.			Kim, HJ (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,NIH,10 CTR DR,MSC 1434,BLDG 10,RM 5N-307,BETHESDA,MD 20892, USA.							ANTOINE R, 1994, J BIOL CHEM, V269, P6450; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; Donnelly LE, 1996, BIOCHEM J, V315, P635, DOI 10.1042/bj3150635; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; FIELD MC, 1994, J BIOL CHEM, V269, P10830; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GODEAU F, 1984, ANAL BIOCHEM, V137, P287, DOI 10.1016/0003-2697(84)90087-3; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON VG, 1994, J BIOL CHEM, V269, P4349; KHARADIA SV, 1992, EXP CELL RES, V201, P33, DOI 10.1016/0014-4827(92)90345-9; KOCH T, 1994, VIROLOGY, V203, P294, DOI 10.1006/viro.1994.1487; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; LOWERY RG, 1990, ADP RIBOSYLATING TOX, P459; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; Okazaki IJ, 1996, BLOOD, V88, P915; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; TWETEN RK, 1985, J BIOL CHEM, V260, P392; UI M, 1990, ADP RIBOSYLATING TOX, P45; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352; [No title captured]	39	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8918	8923						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083012				2022-12-27	WOS:A1997WU03700017
J	Matsui, T; Muneyuki, E; Honda, M; Allison, WS; Dou, C; Yoshida, M				Matsui, T; Muneyuki, E; Honda, M; Allison, WS; Dou, C; Yoshida, M			Catalytic activity of the alpha(3)beta(3)gamma complex of F-1-ATPase without noncatalytic nucleotide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; APPARENT NEGATIVE COOPERATIVITY; THERMOPHILIC BACILLUS PS3; STEADY-STATE KINETICS; TIGHTLY BOUND ADP; ATP SYNTHASE; BOVINE HEART; CHLOROPLAST F1-ATPASE; DIRECTED MUTAGENESIS	A mutant alpha(3) beta(3) gamma complex of F-1-ATPase from thermophilic Bacillus PS3 was generated in which noncatalytic nucleotide binding sites lost their ability to bind nucleotides. It hydrolyzed ATP at an initial rate with cooperative kinetics (K-m(1), 4 mu M; K-m(2), 135 mu M) similar to the wild-type complex. However, the initial rate decayed rapidly to an inactivated form. Since the inactivated mutant complex contained 1.5 mol of ADP/mol of complex, this inactivation seemed to be caused by entrapping inhibitory MgADP in a catalytic site. Indeed, the mutant complex was nearly completely inactivated by a 10 min prior incubation with equimolar MgADP. Analysis of the progress of inactivation after initiation of ATP hydrolysis as a function of ATP concentration indicated that the inactivation was optimal at ATP concentrations in the range of K-m(1). In the presence of ATP, the wildtype complex dissociated the inhibitory [H-3]ADP pre-loaded onto a catalytic site whereas the mutant complex did not. Lauryl dimethylamineoxide promoted release of preloaded inhibitory [H-3]ADP in an ATP-dependent manner and partly restored the activity of the inactivated mutant complex. Addition of ATP promoted single-site hydrolysis of 2',3'-O-(2,4,6-trinitrophenyl)-ATP preloaded at a single catalytic site of the mutant complex. These results indicate that intact noncatalytic sites are essential for continuous catalytic turnover of the F-1-ATPase but are not essential for catalytic cooperativity of F-1-ATPase observed at ATP concentrations below similar to 300 mu M.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	Tokyo Institute of Technology; University of California System; University of California San Diego								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1994, FEBS LETT, V347, P13, DOI 10.1016/0014-5793(94)00497-8; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; JAULT JM, 1994, ARCH BIOCHEM BIOPHYS, V310, P282, DOI 10.1006/abbi.1994.1168; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V114, P171, DOI 10.1093/oxfordjournals.jbchem.a124150; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; Matsui T, 1996, BIOCHEM BIOPH RES CO, V220, P94, DOI 10.1006/bbrc.1996.0362; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; MUNEYUKI E, 1994, BBA-BIOENERGETICS, V1188, P108, DOI 10.1016/0005-2728(94)90028-0; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PAIK SR, 1993, J BIOENERG BIOMEMBR, V25, P679; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1995, J BIOL CHEM, V270, P21045, DOI 10.1074/jbc.270.36.21045; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	48	99	107	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8215	8221		10.1074/jbc.272.13.8215	http://dx.doi.org/10.1074/jbc.272.13.8215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079639	hybrid			2022-12-27	WOS:A1997WQ63500022
J	LeersSucheta, S; Morohashi, K; Mason, JI; Melner, MH				LeersSucheta, S; Morohashi, K; Mason, JI; Melner, MH			Synergistic activation of the human type II 3 beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; TYROSINE PHOSPHORYLATION; ADRENAL-HYPERPLASIA; P-450(11-BETA) GENE; GONADAL DEVELOPMENT; RESPONSIVE ELEMENT; KEY REGULATOR; FTZ-F1 GENE; NGFI-B; EXPRESSION	Steroidogenic factor-1/adrenal 4-binding protein (SF-1/Ad4BP) is an orphan nuclear receptor/transcription factor known to regulate the P450 steroid hydroxylases; however, mechanisms that regulate the activity of SF-1/Ad4BP are not well defined, In addition, little is known about the mechanisms that regulate the human steroidogenic enzyme, type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD II), the major gonadal and adrenal isoform, Regulation of the 3 beta-HSD II promoter was examined using human adrenal cortical (H295R; steroidogenic) and cervical (HeLa; non-steroidogenic) carcinoma cells, H295R cells were transfected with a series of 5' deletions of 1251 base pairs (bp) of the 3 beta-HSD II 5'-flanking region fused to a chloramphenicol acetyltransferase (CAT) reporter gene followed by treatment with or without phorbol ester (phorbol 12-myristate 13-acetate; PMA). CAT assay data indicated that the region from -101 to -52 bp of the promoter was required for PMA-induced expression, A putative SF-1/Ad4BP regulatory element, TCAAGGTAA, was identified by sequence homology at -64 to -56 bp of the promoter, Cotransfection of HeLa cells with the -101 3 beta-HSD-CAT construct and an expression vector for SF-1/Ad4BP increased CAT activity 49-fold, Subsequent treatment with PMA induced an unexpected synergistic increase in transcriptional activity 540-fold over basal, Mutation of the putative response element (TCAAGGTAA to TCAATTTAA) abolished SF-1-induced CAT activity and the synergistic response to PMA. Gel mobility shift assays confirmed that SF-II Ad4BP interacts with the putative element and transcripts for SF-1/Ad4BP were detected in H295R cells by Northern analysis, These data are the first to demonstrate 1) regulation of a non-cytochrome P450 steroidogenic enzyme promoter by SF-1/Ad4BP, 2) a powerful synergistic effect of PMA on SF-1/Ad4BP-induced transcription, and 3) the importance of the SF-1/Ad4BP regulatory element in the regulation of the 3 beta-HSD II promoter.	VANDERBILT UNIV,DEPT OBSTET & GYNECOL,SCH MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,SCH MED,NASHVILLE,TN 37232; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOL BIOL,HIGASHI KU,FUKUOKA 812,JAPAN; UNIV EDINBURGH,DEPT CLIN BIOCHEM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Vanderbilt University; Vanderbilt University; Kyushu University; University of Edinburgh					NICHD NIH HHS [P30-HD05797, 5T3-HD07043] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD005797] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BALASCH J, 1987, J STEROID BIOCHEM, V3, P393; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; BONGIOVANNI AM, 1981, FERTIL STERIL, V35, P599; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CSAPO AI, 1973, AM J OBSTET GYNECOL, V115, P759, DOI 10.1016/0002-9378(73)90517-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; HUM DW, 1993, CLIN CHEM, V39, P333; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JONES GS, 1976, FERTIL STERIL, V27, P351; LABRIE F, 1992, J STEROID BIOCHEM, V43, P805, DOI 10.1016/0960-0760(92)90308-6; LACHANCE Y, 1991, DNA CELL BIOL, V10, P701, DOI 10.1089/dna.1991.10.701; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; OLSON GE, 1987, J ANDROL, V8, P129; OMURA T, 1995, J STEROID BIOCHEM, V53, P19, DOI 10.1016/0960-0760(95)00036-Y; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SIMARD J, 1993, MOL ENDOCRINOL, V7, P716, DOI 10.1210/me.7.5.716; SPEISER PW, 1992, ADRENAL GLAND, P327; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; TREMBLAY Y, 1993, MOL ENDOCRINOL, V7, P355, DOI 10.1210/me.7.3.355; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANTANABE N, 1994, EUR J BIOCHEM, V222, P825; WEHERENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; YOUNG SL, 1991, ANAL BIOCHEM, V197, P401, DOI 10.1016/0003-2697(91)90411-L	55	150	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7960	7967		10.1074/jbc.272.12.7960	http://dx.doi.org/10.1074/jbc.272.12.7960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065466	hybrid			2022-12-27	WOS:A1997WP59200060
J	Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN				Liu, Y; Choudhury, P; Cabral, CM; Sifers, RN			Intracellular disposal of incompletely folded human alpha(1)-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC ENDOPLASMIC-RETICULUM; ALPHA-1-ANTITRYPSIN DEFICIENCY; MOLECULAR CHAPERONE; PROTEIN; GLYCOPROTEINS; DEGRADATION; VARIANT; ASSOCIATION; INHIBITORS; ALPHA	Protection of lung elastin fibers from proteolytic destruction is compromised by inefficient secretion of incompletely folded allelic variants of human alpha(1)-antitrypsin from hepatocytes, Pulse-chase radiolabeling with [S-35]methionine and sucrose gradient sedimentation and coimmunoprecipitation techniques were employed to investigate quality control of human alpha(1)-antitrypsin secretion from stably transfected mouse hepatoma cells, The secretion-incompetent variant null(Hong Kong) (Sifers, R, N,, Brashears-Macatee, S,, Kidd, V, J,, Muensch, H,, and Woo, S, L, C, (1988) J, Biol, Chem, 263, 7330-7335) cannot fold into a functional conformation and was quantitatively associated with the molecular chaperone calnexin following biosynthesis, Assembly with calnexin required cotranslational trimming of glucose from asparagine-linked oligosaccharides. Intracellular disposal of pulse-radiolabeled molecules coincided with their release from calnexin, Released monomers and intracellular disposal were nonexistent in cells chased with cycloheximide, an inhibitor of protein synthesis, Post-translational trimming of asparagine-linked oligosaccharides and intracellular disposal were abrogated by 1-deoxymannojirimycin, an inhibitor of alpha-mannosidase activity, without affecting the monomer population, The data are consistent with a recently proposed quality control model (Hammond, C,, Braakman, I., and Helenius, A. (1994) Proc, Natl, Acad, Sci, U, S, A, 91, 913-917) in which intracellular disposal requires dissociation from calnexin and post-translational trimming of mannose from asparagine-linked oligosaccharides.	BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			Sifers, Richard Norman/AGQ-7262-2022					BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BEITH J, 1978, FRONT MATRIX BIOL, V6, P1; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; BRANTLY M, 1988, AM J MED, V84, P13; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FABRETTI G, 1992, LIVER, V12, P296; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERS T, 1983, PLASMA PROTEIN SECRE, P1; PIND S, 1994, J BIOL CHEM, V269, P12784; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; Sifers Richard N., 1994, P1357; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SIFERS RN, 1989, AM J RESP CELL MOL, V1, P341, DOI 10.1165/ajrcmb/1.5.341; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TROMBETTA S E, 1991, Glycobiology, V1, P155, DOI 10.1093/glycob/1.2.155; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997	48	110	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7946	7951		10.1074/jbc.272.12.7946	http://dx.doi.org/10.1074/jbc.272.12.7946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065464	hybrid			2022-12-27	WOS:A1997WP59200058
J	Pennybacker, M; Schuette, CG; Liessem, B; Hepbildikler, ST; Kopetka, JA; Ellis, MR; Myerowitz, R; Sandhoff, K; Proia, RL				Pennybacker, M; Schuette, CG; Liessem, B; Hepbildikler, ST; Kopetka, JA; Ellis, MR; Myerowitz, R; Sandhoff, K; Proia, RL			Evidence for the involvement of Glu-355 in the catalytic action of human beta-hexosaminidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN; N-ACETYLHEXOSAMINIDASES; FIBROBLASTS; BIOSYNTHESIS; PURIFICATION; DEGRADATION; BINDING; SITE; GM2	In a previous study the photoactivable affinity probe, 3-azi-1-[([6-H-3]2-acetamido-2-deoxy-1-beta-D-galactopyr anosyl)thio]-butane, was used to identify the active site of beta-hexosaminidase B, a beta-subunit dimer (Liessem, B., Glombitza, G. J., Knell, F., Lehmann, J., Kellermann, J., Lottspeich, F., and Sandhoff, K. (1995) J. Biol. Chem. 270, 23693-23699). The probe predominately labeled Glu-355, a highly conserved residue among hexosaminidases. To determine if Glu-355 has a role in catalysis, beta-subunit mutants were prepared with the Glu-355 codon altered to either Ala, Gln, Asp, or Trp. After expression of mutant proteins using recombinant baculovirus, the enzyme activity associated with the beta-subunits was found to be reduced to background levels. Although catalytic activity was lost, the mutations did not otherwise affect the folding or assembly of the subunits. The mutant beta-subunits could be isolated using substrate affinity chromatography, indicating they contained intact substrate binding sites. As shown by cross-linking with di-succinimidyl suberate, the mutant beta-subunits were properly assembled. They could also participate in the formation of functional beta-hexosaminidase A activity as indicated by activator-dependent G(M2) ganglioside degradation activity produced by co-expression of the mutant beta-subunits with the cu-subunit. Finally, the mutant subunits showed normal lysosomal processing in COS-1 cells, demonstrating that a transport-competent protein conformation had been attained. Collectively the results provide strong support for the intimate involvement of Glu-355 in beta-hexosaminidase B-mediated catalysis.	NIDDK,SECT BIOCHEM GENET,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892; UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; ST MARYS COLL MARYLAND,DEPT BIOL,ST MARYS CITY,MD 20686	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bonn			Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; Fernandes MJG, 1997, J BIOL CHEM, V272, P814, DOI 10.1074/jbc.272.2.814; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GEIGER B, 1976, BIOCHEMISTRY-US, V15, P3484, DOI 10.1021/bi00661a014; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; IZUMI T, 1983, J BIOL CHEM, V258, P6991; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LICARI PJ, 1993, BIOTECHNOL PROGR, V9, P146, DOI 10.1021/bp00020a005; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; Pennybacker M, 1996, J BIOL CHEM, V271, P17377, DOI 10.1074/jbc.271.29.17377; PROIA RL, 1984, J BIOL CHEM, V259, P3350; PROIA RL, 1982, P NATL ACAD SCI-BIOL, V79, P6360, DOI 10.1073/pnas.79.20.6360; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+	26	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8002	8006		10.1074/jbc.272.12.8002	http://dx.doi.org/10.1074/jbc.272.12.8002			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065471	hybrid			2022-12-27	WOS:A1997WP59200065
J	Shibasaki, Y; Ishihara, H; Kizuki, N; Asano, T; Oka, Y; Yazaki, Y				Shibasaki, Y; Ishihara, H; Kizuki, N; Asano, T; Oka, Y; Yazaki, Y			Massive actin polymerization induced by phosphatidylinositol-4-phosphate 5-kinase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; MAMMALIAN-CELLS; RHO; ACTIVATION; PROTEINS; KINASES; FAMILY; BIND; RAC	The Rho family GTP-binding proteins have been known to mediate extracellular signals to the actin cytoskeleton, Although several Rho interacting proteins have been found, downstream signals have yet to be determined. Many actin-binding proteins are known to be regulated by phosphatidylinositol 4,5-bisphosphate in vitro. Rho has been shown to enhance the activity of phosphatidylinositol-4-phosphate 5-kinase (PI4P5K), the phosphatidylinositol 4,5-bisphosphate synthesizing enzyme. Recently we isolated several isoforms of type I PI4P5K. Here we report that PI4P5K Ia induces massive actin polymerization resembling ''pine needles'' in COS-7 cells in vivo, When truncated from the C terminus to amino acid 308 of PI4P5K I alpha, both kinase activity and actin polymerizing activity were lost. Although the dominant negative form of Rho, RhoN19, alone decreased actin fibers, those induced by PI4P5K were not affected by the coexpression of RhoN19. These results suggest that PI4P5K is located downstream from Rho and mediates signals for actin polymerization through its phosphatidylinositol-4-phosphate 5-kinase activity.	YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	Yamaguchi University	Shibasaki, Y (corresponding author), UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN.							Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; ZANG X, 1995, P NATL ACAD SCI USA, V92, P4853	28	149	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7578	7581		10.1074/jbc.272.12.7578	http://dx.doi.org/10.1074/jbc.272.12.7578			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065410	hybrid			2022-12-27	WOS:A1997WP59200004
J	vantVeer, C; Golden, NJ; Kalafatis, M; Mann, KG				vantVeer, C; Golden, NJ; Kalafatis, M; Mann, KG			Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation - Synergistic effect in combination with tissue factor pathway inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; ANTI-HEMOPHILIC FACTOR; FACTOR-V; FACTOR-XA; COAGULATION INHIBITOR; BLOOD-COAGULATION; COFACTOR ACTIVITY; FACTOR-IX; INACTIVATION; THROMBOMODULIN	The effects of the components of the protein C path way on thrombin generation were studied in a reconstituted model in which thrombin is generated by factor VIIa and relipidated tissue factor (TF) via the activation of the purified coagulation factors X, IX, VIII, V, and prothrombin. The influence of protein C and soluble thrombomodulin on thrombin generation was correlated with factor Xa generation, factor V(a) and factor VIII(a) formation/inactivation, and protein C activation, Thrombin generation initiated by low concentrations of factor VIIa . TF (1.25 pM) occurs in an explosive fashion during a propagation phase which occurs after an initiation phase of similar to 1 min in which only traces of thrombin are formed, In the absence of other inhibitors, protein C (65 nM) in combination with high concentrations of soluble thrombomodulin (10 nM) resulted in a reduced rate of thrombin generation during the propagation phase without affecting the initiation phase; the activated pro protein C generated failed to neutralize prothrombinase activity and did not prevent prothrombin consumption, In the presence of plasma levels of the tissue factor pathway inhibitor (2.5 nM recombinant TFPI), the protein C pathway reduced the rate of thrombin generation, initiated by 1.25 pM factor VIIa . TF, and completely eliminated prothrombinase activity at soluble thrombomodulin concentrations of greater than or equal to 1 nM. The neutralization of prothrombinase activity coincided with cleavages at Arg-506 and subsequent cleavage at Arg-306 of the factor Va heavy chain by activated protein C, Thus, the protein C pathway combined with TFPI creates a minimal inhibitory potential required to shut down TF-initiated thrombin generation, The protein C pathway constituents did not influence factor Xa generation or factor VIIIa degradation over the interval in which prothrombinase activity was neutralized, Our data thus suggest that the protein C pathway regulates thrombin generation solely by the inactivation of factor Va. At low initiating factor VIIa . TF (1.25 pM) and high thrombomodulin concentrations (10 nM), the factor Va heavy chain is cleaved before significant amounts of light chain are generated, The ability of the protein C pathway to inhibit thrombin generation was greatly reduced when the reaction was initiated in the presence of factor Va, supporting the hypothesis that effective down-regulation of thrombin generation by the protein C pathway, in reactions initiated with the procofactor, occurs by prevention of the coexistence of the factor Va heavy and light chains.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [HL-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BREGENGAARD C, 1993, THROMB HAEMOSTASIS, V70, P454; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON NL, 1982, J BIOL CHEM, V257, P859; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FULCHER CA, 1984, BLOOD, V63, P486; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRIFFIN JH, 1992, BLOOD, V79, P3203; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; IKEDA K, 1985, THROMB RES, V39, P297, DOI 10.1016/0049-3848(85)90225-7; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KALAFATIS M, 1995, ARTERIOSCL THROM VAS, V15, P2181, DOI 10.1161/01.ATV.15.12.2181; KALAFATIS M, 1996, BLOOD, V87, P4708; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LIN JH, 1994, J BIOL CHEM, V269, P25021; LINDAHL AK, 1991, BLOOD COAGUL FIBRIN, V2, P713, DOI 10.1097/00001721-199112000-00004; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MARLAR RA, 1982, BLOOD, V59, P1067; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NOVOTNY WF, 1991, BLOOD, V78, P387; OGURA M, 1990, THROMB HAEMOSTASIS, V64, P297; OHLIN AK, 1995, BLOOD, V85, P330; OSLOU ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; SANDSET PM, 1991, P NATL ACAD SCI USA, V88, P708, DOI 10.1073/pnas.88.3.708; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SHEN L, 1994, J BIOL CHEM, V269, P18735; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; TANS G, 1991, J BIOL CHEM, V266, P21864; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855	59	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7983	7994		10.1074/jbc.272.12.7983	http://dx.doi.org/10.1074/jbc.272.12.7983			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065469	hybrid			2022-12-27	WOS:A1997WP59200063
J	Perales, JC; Grossmann, GA; Molas, M; Liu, G; Ferkol, T; Harpst, J; Oda, H; Hanson, RW				Perales, JC; Grossmann, GA; Molas, M; Liu, G; Ferkol, T; Harpst, J; Oda, H; Hanson, RW			Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SITE-SPECIFIC DELIVERY; IN-VIVO; MEDIATED ENDOCYTOSIS; POTENTIAL CARRIER; COMPACT FORM; LIVER; CELLS; CONDENSATION; INVIVO	Electrostatic binding of polycations or basic polypeptides to the DNA phosphate backbone has been previously described as a one-step process which results in uncontrolled aggregation and precipitation of the DNA in solution. We describe here a multistep process in which the condensation of DNA in the presence of poly-L-lysine can be controlled to produce particles of discrete size and shape suitable for receptor-mediated gene transfer in vivo and in vitro. The first step in this process involves the gradual accretion of poly-L-lysine onto the DNA phosphate backbone, until charges are neutralized, The addition of poly-L-lysine to a concentrated solution of DNA in this fashion prevents intermolecular aggregation of the DNA, presumably by promoting the formation of a nucleus of condensation along the length of each DNA molecule. The second stage of the process involves adjusting the ionic strength of the solvent to facilitate the solubilization of compact DNA-poly-L-lysine complexes. Several physical and biochemical parameters have been studied and correlated with the efficacy of DNA/ligand-poly-L-lysine particles in transferring genes to the liver of adult animals by receptor-mediated endocytosis.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University			PERALES, JOSE C./AAC-3156-2019; PERALES, JOSE C. C/D-5586-2012; PERALES, JOSE C/J-7457-2017	PERALES, JOSE C./0000-0001-7363-2226; PERALES, JOSE C. C/0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; Molas, Maria/0000-0002-3215-515X	NHLBI NIH HHS [HL 53672] Funding Source: Medline; NIDDK NIH HHS [DK 21859] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BIESSEN EAL, 1994, J HEPATOL, V21, P806, DOI 10.1016/S0168-8278(94)80243-2; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BIJSTERBOSCH MK, 1992, ARTERIOSCLER THROMB, V12, P1153, DOI 10.1161/01.ATV.12.10.1153; BIJSTERBOSCH MK, 1992, MOL PHARMACOL, V41, P404; BIJSTERBOSCH MK, 1990, BIOCHEM J, V270, P233, DOI 10.1042/bj2700233; BLOOMFIELD VA, 1991, BIOCHEM SOC T, V19, P496, DOI 10.1042/bst0190496; CARROLL D, 1972, BIOCHEMISTRY-US, V11, P426, DOI 10.1021/bi00753a020; CHANG C, 1973, BIOCHEMISTRY-US, V12, P3028, DOI 10.1021/bi00740a013; CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; EICKBUSH TH, 1978, CELL, V13, P295, DOI 10.1016/0092-8674(78)90198-8; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; Ferkol T, 1996, P NATL ACAD SCI USA, V93, P101, DOI 10.1073/pnas.93.1.101; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; GOSULE LC, 1978, ADV POLYAMINE RES, V1, P201; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; KUPFER JM, 1994, HUM GENE THER, V5, P1437, DOI 10.1089/hum.1994.5.12-1437; LANG D, 1973, J MOL BIOL, V78, P247, DOI 10.1016/0022-2836(73)90113-7; LENG M, 1966, P NATL ACAD SCI USA, V56, P1325, DOI 10.1073/pnas.56.4.1325; LERMAN LS, 1971, P NATL ACAD SCI USA, V68, P1886, DOI 10.1073/pnas.68.8.1886; LI AZ, 1992, SCI CHINA SER B, V35, P169; LI HJ, 1973, BIOCHEMISTRY-US, V12, P1763, DOI 10.1021/bi00733a016; LIU JS, 1991, J BIOL CHEM, V266, P19095; MANIATIS T, 1974, J MOL BIOL, V84, P37, DOI 10.1016/0022-2836(74)90211-3; MONSIGNY M, 1984, BIOL CELL, V51, P187, DOI 10.1111/j.1768-322X.1984.tb00298.x; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Perales Jose C., 1996, P105; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; POST CB, 1982, BIOPOLYMERS, V21, P2123, DOI 10.1002/bip.360211104; ROJANASAKUL Y, 1994, PHARMACEUT RES, V11, P1731, DOI 10.1023/A:1018959231951; ROSS GF, 1995, HUM GENE THER, V6, P31, DOI 10.1089/hum.1995.6.1-31; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; SHAPIRO JT, 1969, BIOCHEMISTRY-US, V8, P3233, DOI 10.1021/bi00836a015; SHAPIRO JT, 1969, BIOCHEMISTRY-US, V8, P3219, DOI 10.1021/bi00836a014; SHIN YA, 1977, BIOPOLYMERS, V16, P225, DOI 10.1002/bip.1977.360160117; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1992, J BIOL CHEM, V267, P12436; WU GY, 1991, J BIOL CHEM, V266, P14338	50	120	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7398	7407		10.1074/jbc.272.11.7398	http://dx.doi.org/10.1074/jbc.272.11.7398			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054440	hybrid, Green Published			2022-12-27	WOS:A1997WN14700079
J	Li, GP; D'Souza-Schorey, C; Barbieri, MA; Cooper, JA; Stahl, PD				Li, GP; D'Souza-Schorey, C; Barbieri, MA; Cooper, JA; Stahl, PD			Uncoupling of membrane ruffling and pinocytosis during Ras signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE KINASE; GTP-BINDING PROTEINS; IN-VITRO; ACTIVATION; 3-KINASE; PATHWAY; RAB5; WORTMANNIN; INTERACTS	Activation of Ras stimulates cell. surface membrane ruffling and pinocytosis. Although seen as coupled events, our study demonstrates that membrane ruffling and pinocytosis are regulated by distinct Ras signal transduction pathways, Ras controls membrane ruffling via the small GTPase Rac. In BHK-21 cells, expression of the constitutively active Rac1(G12V) mutant, via a Sindbis virus vector, resulted in a dramatic stimulation of membrane ruffling without affecting the uptake of horseradish peroxidase. Expression of Ha-Ras(G12V), an activated Pas mutant, stimulated both membrane ruffling and horseradish peroxidase uptake. The Ha-Ras(G12V)-stimulated pinocytosis but not membrane ruffling was abolished by either wortmannin or co-expression with a dominant negative mutant of Rab5, Rab5(S34N), Expression of the activated Rab5(Q79L) mutant mimics the stimulatory effect of Ha-Ras(G12V) on pinocytosis but not membrane ruffling. Our data indicate that Ha-Ras(G12V) separately activates Rab5-dependent pinocytosis and Rad-dependent membrane ruffling.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Washington University (WUSTL); Fred Hutchinson Cancer Center			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1993, J BIOL CHEM, V268, P24475; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NOBES CD, 1995, J CELL SCI, V108, P225; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	34	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10337	10340						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099668				2022-12-27	WOS:A1997WV26200002
J	Ishida, A; Sasaguri, T; Kosaka, C; Nojima, H; Ogata, J				Ishida, A; Sasaguri, T; Kosaka, C; Nojima, H; Ogata, J			Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; GUANOSINE-MONOPHOSPHATE; RETINOBLASTOMA PROTEIN; BALLOON ANGIOPLASTY; POTENTIAL MEDIATOR; DNA-REPLICATION; CDK INHIBITORS; P21; PROLIFERATION; EXPRESSION	Nitric oxide-generating vasodilators inhibit vascular smooth muscle cell proliferation. To elucidate the mechanism underlying this process, we investigated the effect of S-nitroso-N-acetylpenicillamine (SNAP), a nitric oxide-releasing agent, on the smooth muscle cell cycle. When G(0) cells were stimulated with fetal bovine serum and basic fibroblast growth factor, DNA synthesis assessed by [H-3]thymidine incorporation started about 15 h later. SNAP dose-dependently inhibited this incorporation, and this effect was maximal at 100 mu M. This inhibition was attenuated when SNAP was added after 9-12 h. SNAP inhibited the activity of cyclin-dependent kinase 2 (Cdk2) and phosphorylation of the retinoblastoma protein, both of which usually increased from about 9 h, whereas it did not inhibit the activities of cyclin D-associated kinase(s), Cdk4, and Cdk6, which normally increased from 0-3 h. Although SNAP reduced the mRNA levels of cyclins E and A, it neither reduced their protein levels nor impaired their association with Cdk2. SNAP did not reduce the mRNA levels of cyclins G, C, and D1, Cdk2, Cdk4, and Cdk5, which were normally elevated from 0-3 h. The mRNA and protein levels of the Cdk inhibitor p21 were high in the early G, phase, peaking at 3 h and then rapidly decreasing after 6 h. In the presence of SNAP, however, p21 expression was enhanced, and moreover, the later decrease disappeared. SNAP also increased the amount of Cdk2-associated p21. These results suggested that nitric oxide inhibits the G(1)/S transition by inhibiting Cdk2-mediated phosphorylation of the retinoblastoma protein and that p21 induction is involved in the Cdk2 inhibition.	NATL CARDIOVASC CTR, RES INST, DEPT BIOSCI, SUITA, OSAKA 565, JAPAN; UNIV RYUKYUS, SCH MED, DEPT INTERNAL MED 3, OKINAWA 903, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, OSAKA 565, JAPAN	National Cerebral & Cardiovascular Center - Japan; University of the Ryukyus; Osaka University				ishida, akio/0000-0002-7822-6849				AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBINA JE, 1993, J IMMUNOL, V150, P5080; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GARG UC, 1993, EUR J PHARMACOL, V237, P243, DOI 10.1016/0014-2999(93)90275-M; GARG UC, 1989, AM J PHYSIOL, V257, pF60, DOI 10.1152/ajprenal.1989.257.1.F60; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI Y, 1994, ONCOGENE, V9, P2261; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SARKAR R, 1995, SURGERY, V118, P274, DOI 10.1016/S0039-6060(05)80334-4; SASAGURI T, 1992, EXP CELL RES, V200, P351, DOI 10.1016/0014-4827(92)90182-8; SASAGURI T, 1987, J AM COLL CARDIOL, V9, P1167, DOI 10.1016/S0735-1097(87)80322-4; Sasaguri T, 1996, J BIOL CHEM, V271, P8345, DOI 10.1074/jbc.271.14.8345; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SCOTTBURDEN T, 1993, CIRCULATION, V87, P51; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TARRY WC, 1994, ARTERIOSCLER THROMB, V14, P938, DOI 10.1161/01.ATV.14.6.938; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	62	145	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10050	10057						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092548				2022-12-27	WOS:A1997WU03900067
J	Pantopoulos, K; Mueller, S; Atzberger, A; Ansorge, W; Stremmel, W; Hentze, MW				Pantopoulos, K; Mueller, S; Atzberger, A; Ansorge, W; Stremmel, W; Hentze, MW			Differences in the regulation of iron regulatory protein-1 (IRP-1) by extra- and intracellular oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ELEMENT BINDING-PROTEIN; HYDROGEN-PEROXIDE; TRANSCRIPTIONAL ACTIVATION; KINASE CASCADE; FLOW-CYTOMETRY; SULFUR CENTER; DNA-BINDING; METAL-IONS; HEAT-SHOCK	We have studied the responses of iron regulatory protein-1 (IRP-1) to extra- and intracellular sources of reactive oxygen intermediates (ROIs). IRP-1 is a cytoplasmic RNA-binding protein that regulates iron metabolism following its activation by iron deficiency. nitric oxide, and administration of H2O2 or antimycin A, an inhibitor of the respiratory chain (Hentze, M. W., and Kuhn, L. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8175-8182). We show that 10 mu m H2O2 suffice for complete IRP-1 activation within 60 min when H2O2 is generated extracellularly at steady-state. By contrast, rapid cellular H2O2 degradation necessitates a 5-10-fold higher bollus dose. To study IRP-1 responses to intracellular oxidative stress, mitochondrial respiration was inhibited with antimycin A (to generate oxidative stress by leakage of ROIs from complex III), or catalase was blocked with 3-amino-1,2,4-triazole (to diminish H2O2 degradation); in parallel, 2',7'-dichloradihydrofluorescein diacetate was used as a redox-sensitive probe to monitor intracellular H2O2 levels by fluorescence-activated cell sorting. Catalase inhibition elevates intracellular H2O2, but surprisingly does not cause concomitant IRP-1 activation. Following antimycin A treatment, IRP-1 is activated, but the activation kinetics lag behind the rapid increase in detectable intracellular H2O2. IRP-1 is thus activated both by extra- and intracellular generation of ROIs. While extracellular H2O2 rapidly activates IRP-1 even without detectable increases in intracellular H2O2, intracellular H2O2 elevation is not sufficient for IRP-1 activation. IRP-1 thus represents a novel example of are H2O2-regulated protein that responds differentially to alterations of extra- and intracellular H2O2 levels. Our data also suggest that a direct attack on the 4Fe-4S cluster of IRP-1 by H2O2 (or an H2O2-derived reactive species) represents an unlikely explanation for IRP-1 activation by oxidative stress.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT INTERNAL MED 4, D-69115 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg			Hentze, Matthias W/V-3980-2017; Pantopoulos, Kostas/A-9668-2008; Ansorge, Wilhelm/AAN-8780-2020	Hentze, Matthias W/0000-0002-4023-7876; Pantopoulos, Kostas/0000-0002-2305-0057; Stremmel, Wolfgang/0000-0002-8545-1753				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGGIOLINI M, 1991, OXIDATIVE STRESS OXI, P399; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FERRER AS, 1990, ANAL BIOCHEM, V187, P129, DOI 10.1016/0003-2697(90)90429-D; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HERSHKO C, 1994, BAIL CL HAE, V7, P965, DOI 10.1016/S0950-3536(05)80133-7; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KHAN AU, 1995, CHEM BIOL, V2, P437; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEPOIVRE M, 1986, BIOL CELL, V57, P143, DOI 10.1111/j.1768-322X.1986.tb00470.x; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mueller S, 1997, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P338; Mueller S, 1997, ANAL BIOCHEM, V245, P55, DOI 10.1006/abio.1996.9939; MUELLER S, 1995, J BIOLUM CHEMILUM, V10, P229, DOI 10.1002/bio.1170100406; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHULZEOSTHOFF K, 1997, IN PRESS ADV MOL CEL; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1	59	140	145	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9802	9808						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092514				2022-12-27	WOS:A1997WU03900033
J	Soncin, F; Strydom, DJ; Shapiro, R				Soncin, F; Strydom, DJ; Shapiro, R			Interaction of heparin with human angiogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SITE-DIRECTED MUTAGENESIS; HUMAN ALPHA-THROMBIN; RIBONUCLEOLYTIC ACTIVITY; CRYSTAL-STRUCTURE; TUMOR-GROWTH; 3-DIMENSIONAL STRUCTURE; LIPOPROTEIN-LIPASE; ENDOTHELIAL-CELLS; DERMATAN SULFATE	HT-29 human colon adenocarcinoma cells adhere rapidly to human angiogenin (Ang) via interactions with cell surface heparan sulfate moieties (Soncin, F., Shapiro, R., and Fett, J. W. (1994) J. Biol. Chem. 269, 8999-9005). Soluble heparin inhibits adhesion, and Ang itself binds tightly to heparin-Sepharose. In the present study, the interaction of Ang with heparin has been further characterized. The basic cluster Arg 31/Arg-32/Arg-33 has been identified as an important component of the heparin binding site. Mutations of these residues, and of Arg-70 as well, decrease both the affinity of Ang for heparin-Sepharose and the capacity of Ang to support cell adhesion. Replacements of four other basic residues do not. affect heparin binding. Heparin partially protects Ang from cleavage by trypsin at Lys-60, suggesting that heparin also binds to the region of Ang that contains this residue. The map here determined indicates that the heparin recognition site on Ang lies outside the catalytic center; indeed, heparin has no significant effect on the ribonucleolytic activity of Ang. It also does not influence the angiogenic activity of this protein. Light scattering measurements on Ang-heparin mixtures suggest that 1 heparin chain (mass of 16.5 kDa) can accommodate -9 Ang molecules. The minimum size required for a heparin fragment to effectively inhibit HT-29 cell adhesion to Ang was determined to be 6 disaccharide units. The implications of these findings fur inhibition of Ang-mediated tumor establishment in vivo are discussed.	HARVARD UNIV,SCH MED,CTR BIOCHEM & BIOPHYS SCI & MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673	NHLBI NIH HHS [HL-52096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BODE W, 1992, PROTEIN SCI, V1, P426; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1979, ARCH BIOCHEM BIOPHYS, V195, P378, DOI 10.1016/0003-9861(79)90363-1; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HALLAHAN TW, 1992, BIOCHEMISTRY-US, V31, P8022, DOI 10.1021/bi00149a036; HARPER JW, 1988, J PROTEIN CHEM, V7, P355, DOI 10.1007/BF01024885; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HATA A, 1993, J BIOL CHEM, V268, P8447; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE FS, 1989, BIOCHEM BIOPH RES CO, V161, P121, DOI 10.1016/0006-291X(89)91569-6; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MARTON LS, 1989, J BIOL CHEM, V264, P13145; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOROIANU J, 1994, BIOCHEM BIOPH RES CO, V203, P1765, DOI 10.1006/bbrc.1994.2391; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLSON KA, 1994, CANCER RES, V54, P4576; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; RUSSO N, 1994, P NATL ACAD SCI USA, V91, P2920, DOI 10.1073/pnas.91.8.2920; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P1726, DOI 10.1021/bi00430a045; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1992, BIOCHEMISTRY-US, V31, P12477, DOI 10.1021/bi00164a026; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; SHAPIRO R, 1988, ANAL BIOCHEM, V175, P450, DOI 10.1016/0003-2697(88)90569-6; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232; SONCIN F, 1994, J BIOL CHEM, V269, P8999; STATHAKIS NE, 1977, J CLIN INVEST, V60, P855, DOI 10.1172/JCI108840; STRYDOM DJ, 1994, J CHROMATOGR A, V662, P227, DOI 10.1016/0021-9673(94)80509-1; STRYDOM DJ, 1994, ANAL BIOCHEM, V222, P19, DOI 10.1006/abio.1994.1448; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TITANI K, 1982, ANAL BIOCHEM, V123, P408, DOI 10.1016/0003-2697(82)90465-1; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	60	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9818	9824						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092516				2022-12-27	WOS:A1997WU03900035
J	Carpick, BW; Graziano, V; Schneider, D; Maitra, RK; Lee, X; Williams, BRG				Carpick, BW; Graziano, V; Schneider, D; Maitra, RK; Lee, X; Williams, BRG			Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DSRNA BINDING DOMAIN; NEUTRON-SCATTERING; P68 KINASE; TAR RNA; MECHANISM; PKR; AUTOPHOSPHORYLATION; IDENTIFICATION; HOMOLOGY; HEPARIN	The antiviral activity of the interferon-induced, double-stranded RNA (dsRNA)-activated protein kinase (PKR) is mediated through dsRNA binding leading to PKR autophosphorylation and subsequent inhibition of protein synthesis. Previous biochemical studies have suggested that autophosphorylation of PKR occurs via a protein-protein interaction and that PKR can form dimers in vitro. Using four independent biophysical and biochemical methods, we have characterized the solution complex formed between PKR and trans-activating region (TAR) RNA, a 57-nucleotide RNA species with double-stranded secondary structure derived from the human immunodeficiency virus type I genome. Chemical cross-linking and gel filtration analyses of PKR.TAR RNA complexes reveals that TAR RNA addition increases PKR dimerization and results in the formation of a solution complex with a molecular weight of approximately 150,000. Addition of TAR RNA to PKR results in a quenching of tryptophan fluorescence, indicative of a conformational shift. Through small angle neutron Scattering analysis, we show that PKR exists in solution predominantly as a dimer, and has an elongated solution structure. Addition of TAR RNA to PKR causes a significant conformational shift in the protein at a 2:1 stoichiometric ratio of protein to RNA. Taken together, these data indicate that the PKR activation complex consists of a protein dimer bound cooperatively to one dsRNA molecule.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Cleveland Clinic Foundation; United States Department of Energy (DOE); Brookhaven National Laboratory			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034039, R01AI034039] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1995, VIROLOGY, V206, P511, DOI 10.1016/S0042-6822(95)80067-0; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756	32	113	119	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9510	9516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083092	hybrid			2022-12-27	WOS:A1997WU03700097
J	Hatada, I; Nabetani, A; Arai, Y; Ohishi, S; Suzuki, M; Miyabara, S; Nishimune, Y; Mukai, T				Hatada, I; Nabetani, A; Arai, Y; Ohishi, S; Suzuki, M; Miyabara, S; Nishimune, Y; Mukai, T			Aberrant methylation of an imprinted gene U2af1-rs1(SP2) caused by its own transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING METHOD; EXPRESSION	Genomic imprinting refers to the parental allele-specific expression of genes. The precise mechanism underlying this phenomenon, which may involve DNA methylation, is not yet known. U2af1-rs1(SP2) is an imprinted gene expressed from the paternal allele and is methylated on the maternal allele. Here we report an artificial system in which expression and methylation of the endogenous imprinted gene U2af1-rs1 can be affected by interaction with its own transgene in the testis. We suggest that there is a mechanism in male gametogenesis by which the U2af1-rs1 gene is kept unmethylated to be expressed in the offspring in addition to a mechanism in female gametogenesis by which the U2af1-rs1 gene is methylated and is not expressed in the offspring.	SAGA MED SCH,DEPT PATHOL,SAGA 549,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN	Saga University; Osaka University; Kumamoto University	Hatada, I (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT BIOSCI,5-7-1,FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN.			da shi, xiang zi/0000-0002-2256-905X				ARAI Y, 1994, EUR J BIOCHEM, V221, P253, DOI 10.1111/j.1432-1033.1994.tb18736.x; BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; HATADA I, 1995, NUCLEIC ACIDS RES, V23, P36, DOI 10.1093/nar/23.1.36; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; OHLSSON R, 1994, TRENDS GENET, V10, P415, DOI 10.1016/0168-9525(94)90100-7; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SOLTER D, 1988, ANNU REV GENET, V22, P127; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YAMAOKA T, 1995, GENOMICS, V27, P337, DOI 10.1006/geno.1995.1051	13	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9120	9122						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083040	hybrid			2022-12-27	WOS:A1997WU03700045
J	Partridge, JF; Mikesell, GE; Breeden, LL				Partridge, JF; Mikesell, GE; Breeden, LL			Cell cycle-dependent transcription of CLN1 involves Swi4 binding to MCB-like elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DNA-SEQUENCE; G1 CYCLINS; S-PHASE; EXPRESSION; PROTEIN; COMPLEX; START	Two promoter elements have been defined that activate G(1)/S-specific transcription in Saccharomyces cerevisiae. SCB elements (CACGAAA) are activated by the Swi4-Swi6 complex, and RICH elements (ACGCGTNA) are activated by the Mbp1-Swi6 complex. CLN1 encodes a cyclin which is expressed during this interval, and requires Swi4 and Swi6 for peak transcription, but it has no consensus SCB elements in its promoter. Two SCB-like sequences had been previously noted and suggested to be the functional promoter elements. Our studies indicate that these sequences are unable to activate transcription of a lacZ reporter construct, or to bind Swi4-Swi6 complexes in vitro, However, a cluster of three sequences resembling MCB sequences are active promoter elements, sufficient to confer G(1)/S-specific transcription to a reporter. These sites are the predominant activation elements in the CLN1 promoter, and despite their resemblance to MCB elements, they bind Swi4-Swi6 complexes in vitro and require Swi4 and Swi6 for their activity in vivo. This indicates that the sequences that promote Swi4/Swi6 binding have not been fully defined, or that there are multiple Swi4- and Swi6-containing complexes with distinct DNA binding specificities. In addition to these novel Swi4/Swi6-binding sites, these studies also show that there must be at least one novel promoter element that can confer G(1)/S-specific transcription to CLN1, because when all the potential SCB- and MCB-like sequences are eliminated the transcript is still cell cycle regulated.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center			Partridge, Janet/M-9352-2018	Partridge, Janet/0000-0003-1102-6305; Breeden, Linda/0000-0001-7337-5434	NIGMS NIH HHS [GM41073] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041073, R29GM041073] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1992, BIOCHEM CELL BIOL, V70, P1073, DOI 10.1139/o92-152; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1994, GENETICS, V138, P1015; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOLL T, 1992, J CELL SCI, P87; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; Sherman F., 1982, METHODS YEAST GENETI; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1	39	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9071	9077						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083033				2022-12-27	WOS:A1997WU03700038
J	Uusitalo, A; Tenhunen, K; Tenhunen, J; Matikainen, S; Peltonen, L; Jalanko, A				Uusitalo, A; Tenhunen, K; Tenhunen, J; Matikainen, S; Peltonen, L; Jalanko, A			Expression and regulation of the human and mouse aspartylglucosaminidase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; BETA-GLUCURONIDASE GENE; TRANSCRIPTION FACTOR; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; GROWTH-REGULATION; HIP1 BINDING; DNA-BINDING; SEQUENCE; PROTEIN; ACTIVATION	Aspartylglucosaminidase (AGA) is a lysosomal enzyme that catalyzes one of the final steps in the degradation of N-linked glycoproteins. Here we have analyzed the tissue-specific expression and regulation of the human and mouse AGA genes. We isolated and characterized human and mouse AGA 5'-flanking sequences including the promoter regions. Primer extension assay revealed multiple transcription start sites in both genes, characteristic of a housekeeping gene. The cross-species comparison studies pinpointed an approximately 450-base pair (bp) homologous region in the distal promoter. In the functional analysis of human AGA 5' sequence, the critical promoter region was defined, and an additional upstream region of 181 bp exhibiting an inhibitory effect on transcription was identified. Footprinting and gel shift assays indicated protein binding to the core promoter region consisting of two Spl binding sites, which Were sufficient to produce basal promoter activity in the functional studies. The results also suggested the binding of a previously uncharacterized transcription factor to a 23-bp stretch in the inhibitory region.	NATL PUBL HLTH INST, DEPT VIROL, FIN-00300 HELSINKI, FINLAND; ORION PHARMA, ORION CORP, FIN-00700 HELSINKI, FINLAND	Finland National Institute for Health & Welfare; Orion Corporation	Uusitalo, A (corresponding author), NATL PUBL HLTH INST, DEPT HUMAN MOL GENET, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.		Matikainen, Sampsa/AAH-8654-2021					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLERC RG, 1983, NUCLEIC ACIDS RES, V11, P8641, DOI 10.1093/nar/11.24.8641; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ENOMAA NE, 1993, J HISTOCHEM CYTOCHEM, V41, P981, DOI 10.1177/41.7.7685790; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P493, DOI 10.1042/bj2720493; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; HUANG DH, 1988, J BIOL CHEM, V263, P12596; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; Matikainen S, 1996, BLOOD, V88, P114; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Norflus F, 1996, DNA CELL BIOL, V15, P89, DOI 10.1089/dna.1996.15.89; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; PARK H, 1991, FEBS LETT, V288, P168, DOI 10.1016/0014-5793(91)81027-6; POLLITT RJ, 1968, LANCET, V2, P253; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; RIIKONEN A, 1994, DNA CELL BIOL, V13, P257, DOI 10.1089/dna.1994.13.257; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SCOTT HS, 1992, GENOMICS, V13, P1311, DOI 10.1016/0888-7543(92)90053-U; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHIPLEY JM, 1991, GENOMICS, V10, P1009, DOI 10.1016/0888-7543(91)90192-H; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Tenhunen J, 1996, DNA CELL BIOL, V15, P461, DOI 10.1089/dna.1996.15.461; TENHUNEN K, 1995, GENOMICS, V30, P244, DOI 10.1006/geno.1995.9881; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Tikkanen R, 1996, PROTEINS, V24, P253; WAKAMATSU N, 1994, GENOMICS, V24, P110, DOI 10.1006/geno.1994.1587; YAMANAKA S, 1994, GENOMICS, V21, P588, DOI 10.1006/geno.1994.1318; YE ZS, 1988, J BIOL CHEM, V263, P7821	52	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9524	9530						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083094				2022-12-27	WOS:A1997WU03700099
J	Ambrosini, G; Plescia, J; Chu, KC; High, KA; Altieri, DC				Ambrosini, G; Plescia, J; Chu, KC; High, KA; Altieri, DC			Activation-dependent exposure of the inter-EGF sequence Leu(83)-Leu(88) in factor Xa mediates ligand binding to effector cell protease receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-X; MOLECULAR-CLONING; FACTOR-IXA; EXPRESSION; THROMBIN; MODULE; IDENTIFICATION; ANTIBODIES; UROKINASE	Binding of factor Xa to human umbilical vein endothelial cells (HUVEC) is contributed by effector cell protease receptor-1 (EPR-1). The structural requirements of this recognition were investigated. Factor Xa or catalytically inactive 5-dimethylaminonaphthalene-1-sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone-factor Xa bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of I-125-factor Xa to these cells. Similarly, factor Xa active site inhibitors TAP or NAP5 did not reduce ligand binding to EPR-1. A factor X peptide duplicating the inter-EGF sequence Leu(83)-Phe(84)-Thr(85)-Arg(86)-Lys(87)-Leus(88)-(Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of I-125-factor Xa to these cells in a dose-dependent manner (IC50 similar to 20-40 mu M). In contrast, none of the other factor X peptides tested or a control peptide with the inter-EGF sequence in scrambled order was effective. A recombinant chimeric molecule expressing the factor X sequence Leu(83)-Leu(88) within a factor IX backbone inhibited binding of I-125-factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma Ma had no effect. An antibody generated against the factor X peptide 83-88, and designated JC15, inhibited I-125-factor Xa binding to HUVEC. The JC15 antibody bound to factor Xa and the recombinant IX/X83-88 chimera in a concentration dependent manner, while no specific reactivity with factors X or Ma was observed, Furthermore, binding of I-125-factor Xa to immobilized JC15 was inhibited by mo lar excess of unlabeled factor Xa, but not by comparable concentrations of factors X or Ma. These findings identify the inter-EGF sequence Leu(83)-Leu(88) in factor Xa as a novel recognition site for EPR-1, and suggest its potential role as a protease activation dependent neo-epitope. This interacting motif may help elucidate the contribution of factor Xa to cellular assembly of coagulation and vascular injury.	YALE UNIV,SCH MED,BAYER CTR MOL MED,MOL CARDIOBIOL PROGRAM,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BAYER CTR MOL MED,DEPT PATHOL,NEW HAVEN,CT 06536; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT LAB MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	Yale University; Yale University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			High, Katherine A./AAB-9322-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131, R01HL043773, R01HL048322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43773, HL54131, HL48322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1995, FASEB J, V9, P860, DOI 10.1096/fasebj.9.10.7615156; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1995, J LEUKOCYTE BIOL, V58, P120, DOI 10.1002/jlb.58.2.120; Ambrosini G, 1996, J BIOL CHEM, V271, P1243, DOI 10.1074/jbc.271.2.1243; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; Bouchard BA, 1995, BLOOD, V86, P1788; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CLOHISY DR, 1990, J BIOL CHEM, V265, P7729; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; EISENBERG PR, 1993, J CLIN INVEST, V91, P1877, DOI 10.1172/JCI116404; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Gordon EM, 1996, P NATL ACAD SCI USA, V93, P2174, DOI 10.1073/pnas.93.5.2174; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; Grey ST, 1996, J IMMUNOL, V156, P2256; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KEYT B, 1982, J BIOL CHEM, V257, P8687; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; RIMON S, 1987, J BIOL CHEM, V262, P6023; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; VLASUK GP, 1993, THROMB HAEMOSTASIS, V70, P212; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056	41	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8340	8345		10.1074/jbc.272.13.8340	http://dx.doi.org/10.1074/jbc.272.13.8340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079657	hybrid			2022-12-27	WOS:A1997WQ63500040
J	Kim, DH; Magoori, K; Inoue, TR; Mao, CC; Kim, HJ; Suzuki, H; Fujita, T; Endo, Y; Saeki, S; Yamamoto, TT				Kim, DH; Magoori, K; Inoue, TR; Mao, CC; Kim, HJ; Suzuki, H; Fujita, T; Endo, Y; Saeki, S; Yamamoto, TT			Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; MEDIATED ENDOCYTOSIS; ALZHEIMERS-DISEASE; BETA-GALACTOSIDASE; MOLECULAR-CLONING; BINDING PROTEINS; MAMMALIAN-CELLS; NERVOUS-SYSTEM; LDL RECEPTOR	Apolipoprotein E receptor 2 is a recently identified receptor that resembles low and very low density lipoprotein receptors. Isolation and characterization of genomic clones encoding human apolipoprotein E receptor 2 revealed that the gene spans similar to 60 kilobases and contains 19 exons. The positions of the exon/intron boundaries of the gene are almost identical to those of low and very low density lipoprotein receptors. Fluorescent in situ hybridization of human chromosomes revealed that the gene is located on chromosome 1p34. Isolation of a cDNA encoding a variant receptor and reverse transcription-polymerase chain reaction indicate the presence of multiple variants with different numbers of cysteine-rich repeats in the binding domain of the receptor. We also found a variant receptor lacking a 59-amino acid insertion in the cytoplasmic domain, The transcription start site was mapped to the position 236 base pairs upstream of the AUG translation initiator codon by primer extension analysis, Sequence inspection of the 5'-flanking region revealed potential DNA elements: AP-2, GC factor, PEA3, and Sp1. The minimal promoter region and a region required for nerve growth factor inducibility in PC12 cells were also determined.	TOHOKU UNIV, CTR GENE RES, SENDAI, MIYAGI 981, JAPAN; FUKUSHIMA MED COLL, DEPT BIOCHEM, FUKUSHIMA 96012, JAPAN	Tohoku University; Fukushima Medical University								BARAKAT HA, 1985, J LIPID RES, V26, P1252; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ENDO Y, 1995, GENOMICS, V25, P760, DOI 10.1016/0888-7543(95)80028-K; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P11; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	43	70	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8498	8504		10.1074/jbc.272.13.8498	http://dx.doi.org/10.1074/jbc.272.13.8498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079678	hybrid			2022-12-27	WOS:A1997WQ63500061
J	Tang, J; Kriz, RW; Wolfman, N; Shaffer, M; Seehra, J; Jones, SS				Tang, J; Kriz, RW; Wolfman, N; Shaffer, M; Seehra, J; Jones, SS			A novel cytosolic calcium-independent phospholipase A(2) contains eight ankyrin motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; ARACHIDONIC-ACID; PHOSPHATIDIC-ACID; MAMMALIAN-CELLS; PLASMA-MEMBRANE; KAPPA-B; PURIFICATION; INHIBITION; MECHANISM; PROTEINS	We report the purification, molecular cloning, and expression of a novel cytosolic calcium-independent phospholipase A(2) (iPLA(2)) from Chinese hamster ovary cells, which lacks extended homology to other phospholipases. iPLA(2) is an 85-kDa protein that exists as a multimeric complex of 270-350 kDa with a specific activity of 1 mu mol/min/mg. The full-length cDNA clone encodes a 752-amino acid cytoplasmic protein with one lipase motif (GXS(465)XG) and eight ankyrin repeats. Expression of the cDNA in mammalian cells generates an active 85-kDa protein. Mutagenesis studies show that Ser(465) and the ankyrin repeats are required for activity. We demonstrate that iPLA, selectively hydrolyzes the sn-2 over sn-l fatty acid by 5-fold for 1,2-dipalnitoyl phosphatidylcholine in a mixed micelle. Moreover, we found the fatty acid preference at the sn-2 position to be highly dependent upon substrate presentation. However, iPLA, does have a marked preference for 1,2-dipalnitoyl phosphatidic acid presented in a vesicle, generating the lipid second messenger lysophosphatidic acid. Finally the enzyme is able to hydrolyze the acetyl moiety at the sn-2 position of platelet-activating factor.	GENET INST INC,CAMBRIDGE,MA 02140									ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; KAUFMAN R J, 1990, Technique (Philadelphia), V2, P221; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; REYNOLDS LJ, 1994, ANAL BIOCHEM, V217, P25, DOI 10.1006/abio.1994.1079; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; Vesterqvist O, 1996, CARDIOVASC RES, V31, P932; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; WONG PY, 1990, PHOSPHOLIPASE A2 ROL	59	265	277	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8567	8575		10.1074/jbc.272.13.8567	http://dx.doi.org/10.1074/jbc.272.13.8567			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079687	hybrid			2022-12-27	WOS:A1997WQ63500070
J	Kato, A; Takahashi, H; Takahashi, Y; Matsushime, H				Kato, A; Takahashi, H; Takahashi, Y; Matsushime, H			Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; GROWTH-FACTOR-BETA; CATALYTIC SUBUNIT; PROTEIN-KINASE; POTENTIAL MEDIATOR; TGF-BETA; P27(KIP1); ARREST; G(1); IDENTIFICATION	Cyclin-dependent kinase (Cdk) inhibitory proteins are involved in cell cycle arrest induced by antiproliferating factors or chemicals, High cell density also induces cell cycle arrest in which the genomic DNA is unreplicated, even in the presence of a mitotic dose of growth factors; this is termed contact inhibition. Although the cell cycle of the rat fibroblast cell line, 3Y1, was arrested in quiescence by contact inhibition, the Cdk4 bound to its regulatory subunit, cyclin D1 or D3, However, these complexes were enzymatically inactive, Phosphorylation of the cyclin D1 bound Cdk4 by the Cdk-activating kinase could convert the inactive cyclin D1-Cdk4 complex into its active form in vitro, suggesting that threonine 172 of the Cdk4, of which phosphorylation is required for its activation, was in part unphosphorylated in contact-inhibited 3Y1 cells. Although MO15 was active in cell extracts prepared from the arrested 3Y1 cells, activation of bacterially produced Cdk4 in the cell extracts was inhibited. Removal of p27(kip1) from the cell extracts allowed the MO15 holoenzyme to phosphorylate the Cdk4 and in turn activate it, indicating that p27(kip1) plays a role in inhibiting the phosphorylation of Cdk4 by MO15 in the contact-inhibited 3Y1 cells.	NIPPON ROCHE RES CTR,MOL ONCOL GRP,KAMAKURA,KANAGAWA 247,JAPAN; SAITAMA MED SCH,SAITAMA MED CTR,DEPT INTERNAL MED 1,KAWAGOE,SAITAMA 350,JAPAN	Roche Holding; Saitama Medical University								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8065	8070		10.1074/jbc.272.12.8065	http://dx.doi.org/10.1074/jbc.272.12.8065			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065480	hybrid			2022-12-27	WOS:A1997WP59200074
J	Lawrence, DA; Palaniappan, S; Stefansson, S; Olson, ST; FrancisChmura, AM; Shore, JD; Ginsburg, D				Lawrence, DA; Palaniappan, S; Stefansson, S; Olson, ST; FrancisChmura, AM; Shore, JD; Ginsburg, D			Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin - Implications for the regulation of pericellular proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; EXTRACELLULAR-MATRIX; HUMAN-PLASMA; FUNCTIONAL STABILITY; ENDOTHELIAL-CELLS; ALPHA-THROMBIN; PROTEIN; TYPE-1; PAI-1; IDENTIFICATION	Plasminogen activator inhibitor type 1 (PAI-1), the primary physiologic inhibitor of plasminogen activation, is associated with the adhesive glycoprotein vitronectin (Vn) in plasma and the extracellular matrix, In this study we examined the binding of different conformational forms of PAI-1 to both native and urea-purified vitronectin using a solid-phase binding assay, These results demonstrate that active PAI-1 binds to urea-purified Vn with approximately 6-fold higher affinity than to native Vn, In contrast, inactive forms of PAI-1 (latent, elastase-cleaved, synthetic reactive center loop peptide-annealed, or complexed to plasminogen activators) display greatly reduced affinities for both forms of adsorbed Vn, with relative affinities reduced by more than 2 orders of magnitude, Structurally, these inactive conformations all differ from active PAI-1 by insertion of an additional strand into beta sheet A, suggesting that it is the rearrangement of sheet A that results in reduced Vn affinity, This is supported by the observation that PAI-1 associated with beta-anhydrotrypsin, which does not undergo rearrangement of beta-sheet A, shows no such decrease in affinity, whereas PAI-1 complexed to beta-trypsin, which does undergo sheet A rearrangement, displays reduced affinity for Vn similar to PAI-1 plasminogen activator complexes, Together these data demonstrate that the interaction between PAI-1 and Vn depends on the conformational state of both proteins and suggest that the Vn binding site on PAI-1 is sensitive to structural changes associated with loss of inhibitory activity.	UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV ILLINOIS, CTR MOL BIOL ORAL DIS, CHICAGO, IL 60612 USA; HENRY FORD HLTH SYST, DETROIT, MI 48202 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Henry Ford Health System; Henry Ford Hospital	Lawrence, DA (corresponding author), AMER RED CROSS, HOLLAND LAB, DEPT BIOCHEM, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930, R29HL039888, R01HL039888, R01HL055374, R37HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55374, HL 45930, HL 39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FAY WP, 1994, BLOOD, V83, P351; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOST C, 1992, J BIOL CHEM, V267, P12098; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LOO RRO, 1993, J AM CHEM SOC, V115, P4391, DOI 10.1021/ja00063a079; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NASKI MC, 1993, J BIOL CHEM, V268, P12367; OHLSSON M, 1991, SEMIN THROMB HEMOST, V17, P286, DOI 10.1055/s-2007-1002622; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; Ukraincik K, 1981, Methods Enzymol, V74 Pt C, P497; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	60	101	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7676	7680		10.1074/jbc.272.12.7676	http://dx.doi.org/10.1074/jbc.272.12.7676			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065424	hybrid			2022-12-27	WOS:A1997WP59200018
J	Pasyk, EA; Foskett, JK				Pasyk, EA; Foskett, JK			Cystic fibrosis transmembrane conductance regulator-associated ATP and adenosine 3'-phosphate 5'-phosphosulfate channels in endoplasmic reticulum and plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING CHLORIDE CHANNELS; AIRWAY ION-TRANSPORT; EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; SULFATE TRANSPORT; INORGANIC SULFATE; CL CHANNEL; CFTR; GENE; MECHANISMS	Cystic fibrosis (CF) is characterized by abnormal regulation of epithelial ion and fluid transport due to mutations in the CF transmembrane conductance regulator (CFTR), an apical membrane-localized Cl- channel, that usually prevent it from exiting the endoplasmic reticulum. Defective or absent CFTR in the epithelium is believed to disrupt fluid balance in human airways and thereby contribute to chronic respiratory inflammation. Patch-clamp of the plasma membrane and outer membrane of the nuclear envelope of nuclei isolated from CFTR-expressing Chinese hamster ovary cells revealed that CFTR is associated with a regulated ATP channel in both membrane compartments, CFTR expression was also shown to be associated with permeability to another adenine nucleotide, adenosine 3'-phosphate 5'-phosphosulfate, the universal sulfate donor in cells. These results may provide a link between the ion channel function of CFTR and abnormal glycoprotein processing observed in CF.	UNIV PENN, SCH MED, DEPT PHYSIOL, STELLAR CHANCE LABS, PHILADELPHIA, PA 19104 USA; UNIV PENN, INST HUMAN GENE THERAPY, PHILADELPHIA, PA 19104 USA; HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	University of Pennsylvania; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Foskett, Kevin/R-2549-2019					ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1993, J CELL SCI, P229; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOAT TF, 1989, ACTA PAEDIATR SCAND, P25; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CHACE KV, 1983, CLIN CHIM ACTA, V132, P143, DOI 10.1016/0009-8981(83)90242-5; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Grygorczyk R, 1996, J MEMBRANE BIOL, V151, P139, DOI 10.1007/s002329900065; GUGGINO WB, 1993, J BIOENERG BIOMEMBR, V25, P27, DOI 10.1007/BF00768065; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HART GW, 1978, J BIOL CHEM, V253, P347; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KATO Y, 1989, J BIOL CHEM, V264, P3364; KING BM, 1992, BIOCHEM MED METAB B, V47, P260, DOI 10.1016/0885-4505(92)90034-V; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MOHAPATRA NK, 1995, PEDIATR RES, V38, P42, DOI 10.1203/00006450-199507000-00008; MULDER GJ, 1978, BIOCHEM J, V176, P959, DOI 10.1042/bj1760959; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PIND S, 1994, J BIOL CHEM, V269, P12784; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P689; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIDDICOMBE JH, 1995, RESP PHYSIOL, V99, P3, DOI 10.1016/0034-5687(94)00095-H; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Wine JJ, 1995, CURR BIOL, V5, P1357, DOI 10.1016/S0960-9822(95)00269-7; Zhang YL, 1995, J CLIN INVEST, V96, P2997, DOI 10.1172/JCI118372	58	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7746	7751		10.1074/jbc.272.12.7746	http://dx.doi.org/10.1074/jbc.272.12.7746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065435	hybrid			2022-12-27	WOS:A1997WP59200029
J	Song, HH; Shi, W; Filmus, J				Song, HH; Shi, W; Filmus, J			5/rat glypican-3 binds fibroblast growth factor-2 not to insulin-like growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; SIMPSON-GOLABI-BEHMEL; CLONING; FAMILY	OCI-5 encodes the rat homologue of glypican-3, a membrane-bound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome. OCI-5 and glypican-3 are 95% identical. It has been recently suggested that glypican-3 interacts with insulin-like growth factor-2 (IGF-2) and that this interaction regulates IGF-I activity. We report here that we have transfected OCI-5 into two different cell lines, and we have not been able to detect an interaction between the OCI-5 proteoglycan produced by the transfected cells and IGF-2. On the other hand, we have found that OCI-5 interacts with FGF-S, as has already been shown for glypican-1. This interaction is mediated by the heparan sulfate chains of OCI-5 because it can be inhibited by heparin or by heparitinase.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4N 3M5,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto				NOIRI, Eisei/0000-0002-9515-7582				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CULOUSCOU JM, 1990, J CELL PHYSIOL, V143, P405, DOI 10.1002/jcp.1041430302; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GARGANTA CL, 1992, AM J MED GENET, V44, P129, DOI 10.1002/ajmg.1320440202; HUGHESBENZIE R, 1992, J MED GENET, V29, P928, DOI 10.1136/jmg.29.12.928-b; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OGUCHI S, 1993, BIOCHEM BIOPH RES CO, V196, P789, DOI 10.1006/bbrc.1993.2318; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; WITTE DP, 1994, AM J PATHOL, V145, P762	20	111	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7574	7577		10.1074/jbc.272.12.7574	http://dx.doi.org/10.1074/jbc.272.12.7574			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065409	hybrid			2022-12-27	WOS:A1997WP59200003
J	Uyeda, K; Wang, XL; Mizuguchi, H; Li, Y; Nguyen, C; Hasemann, CA				Uyeda, K; Wang, XL; Mizuguchi, H; Li, Y; Nguyen, C; Hasemann, CA			The active sites of fructose 6-phosphate,2-kinase: Fructose-2,6-bisphosphatase from rat testis - Roles of Asp-128, Thr-52, Thr-130, Asn-73, and Tyr-197	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; PHOSPHATE-BINDING-SITES; AMINO-ACID-SEQUENCE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; LIVER 6-PHOSPHOFRUCTO-2-KINASE; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; TRANSITION-STATE; EXPRESSION; 2,6-BISPHOSPHATASE	To investigate the role in catalysis and/or substrate binding of the Walker motif residues of rat testis fructose 6-phosphate,2-kinase:fructose-2,6-bisphosphatase (Fru 6-P,2-kinase:Fru-2,6-Pase), we have constructed and characterized mutant enzymes of Asp-128, Thr-52, Asn-73, Thr-130, and Tyr-197. Replacement of Asp-128 by Ala, Asn, and Ser resulted in a small decrease in V-max and a significant increase in K-m values for both substrates, These mutants exhibited similar pH activity profiles as that of the wild type enzyme, Mutation of Thr-52 to Ala resulted in an enzyme with an infinitely high K-m for both substrates and an 800-fold decreased V-max Substitution of Asn-73 with Ala or Asp caused a 100- and 600-fold increase, respectively in KFru 6-P with only a small increase in K-ATP and small changes in V-max. Mutation of Thr-130 caused small changes in the kinetic properties, Replacement of Tyr-197 with Ser resulted in an enzyme with severely decreased binding of Fru 6-P with 3-fold decreased V-max. A fluorescent analog of ATP, 2'(3')-O-(N-methylanthraniloyl)ATP (mant-ATP) served as a substrate with K-m = 0.64 mu M, and V-max = 25 milli-units/mg and was a competitive inhibitor with respect to ATP, When mant-ATP bound to the enzyme, fluorescence intensity at 440 nm increased, mant-ATP binding of the wild type and the mutant enzymes were compared using the fluorometric method, The K-d values of the T52A and D128N enzymes were infinitely high and could not be measured, while those of the other mutant enzymes increased slightly, These results provide evidence that those amino acids are involved in substrate binding, and they are consistent with the crystallographic data, The results also suggest that Asp-128 does not serve as a nucleophile in catalysis, and since there are no other potential nucleophiles in the active site, we hypothesize that the Fru 6-P,2-kinase reaction is mediated via a transition state stabilization mechanism.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Uyeda, K (corresponding author), VET AFFAIRS MED CTR,RES SERV,4500 S LANCASTER RD,DALLAS,TX 75216, USA.		Mizuguchi, Hiroyuki/B-5676-2013	Mizuguchi, Hiroyuki/0000-0001-7055-316X	NIDDK NIH HHS [DK16194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGAIER J, 1988, BIOCHEM BIOPH RES CO, V153, P328, DOI 10.1016/S0006-291X(88)81226-9; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FURUYA E, 1981, J BIOL CHEM, V256, P7109; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HAZLETT TL, 1993, BIOCHEMISTRY-US, V32, P13575, DOI 10.1021/bi00212a025; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; ISTVAN ES, 1995, PROTEIN SCI, V4, P2439, DOI 10.1002/pro.5560041125; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KITAMURA K, 1989, J BIOL CHEM, V264, P6344; KOUNTZ PD, 1988, J BIOL CHEM, V263, P16069; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURLAND I, 1995, BIOCHEM BIOPH RES CO, V213, P663, DOI 10.1006/bbrc.1995.2183; LI L, 1992, J BIOL CHEM, V267, P4386; LIVELY MO, 1988, J BIOL CHEM, V263, P839; Muegge I, 1996, STRUCTURE, V4, P475, DOI 10.1016/S0969-2126(96)00052-4; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RIDER MH, 1995, BIOCHEM J, V309, P341, DOI 10.1042/bj3090341; RIDER MH, 1987, FEBS LETT, V2243, P317; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P4023; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; TSUJIKAWA T, 1995, BIOCHEMISTRY-US, V34, P6389, DOI 10.1021/bi00019a018; UYEDA K, 1981, J BIOL CHEM, V256, P8394; UYEDA K, 1978, J BIOL CHEM, V253, P8319; UYEDA K, 1991, CRC REV, V2, P445; Vertommen D, 1996, J BIOL CHEM, V271, P17875, DOI 10.1074/jbc.271.30.17875; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	39	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7867	7872		10.1074/jbc.272.12.7867	http://dx.doi.org/10.1074/jbc.272.12.7867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065453	hybrid			2022-12-27	WOS:A1997WP59200047
J	deTurco, EBR; Deretic, D; Bazan, NG; Papermaster, DS				deTurco, EBR; Deretic, D; Bazan, NG; Papermaster, DS			Post-Golgi vesicles cotransport docosahexaenoyl-phospholipids and rhodopsin during frog photoreceptor membrane biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; ELECTRON-MICROSCOPIC AUTORADIOGRAPHY; RETINA SUBCELLULAR-FRACTIONS; NEWLY SYNTHESIZED RHODOPSIN; BOVINE RETINA; FATTY-ACIDS; <1-C-14>EICOSATETRAENOATE 20-4(N-6); DOCOSAPENTAENOATE 22-5(N-3); VERTEBRATE RETINA	Post-Golgi vesicles budding from the trans-Golgi network (TGN) are involved in the vectorial transport and delivery of rhodopsin to photoreceptor rod outer segments (ROS). We report here that newly synthesized docosahexaenoyl (DHA) phospholipids are sequestered and cotransported by rhodopsin-bearing post-Golgi vesicles to ROS, Frog retinas were pulse-labeled with [S-35]methionine/cysteine and [H-3]DHA prior to ROS isolation and subcellular fractionation. After a 1-h pulse, relatively uniform [H-3]DHA-lipid labeling (DPM/mu g protein) was observed in all fractions enriched in post-Golgi vesicles, TGN, Golgi, and endoplasmic reticulum (ER) membranes. During the subsequent 2-h chase translocation of free [H-3]DHA from ROS to the photoreceptor inner segment contributed to an additional overall increase in labeling of lipids. The specific activity (dpm/nmol DHA) in ER-enriched fraction was similar or higher than in other subcellular fractions after both the pulse and the chase, indicating that the bulk of [H-3]DHA-lipids was synthesized in the ER. After the chase a a-fold increase in labeling of lipids in the ER and Golgi and a 2.6-fold in lighter TGN-enriched fractions was observed. The highest labeling was in the post-Golgi vesicle fraction (4-fold increase), with [H-3]DHA-phosphatidylcholine and [H-3]DHA-phosphatidylethanolamine showing the greatest increase. At the same time, newly synthesized [S-35]rhodopsin shifted from the ER and Golgi toward TGN and post-Golgi fractions. Therefore, sequestration and association of [S-35]rhodopsin and [H-3]DHA-lipids in a TGN membrane domain occurs prior to their exit and subsequent vectorial cotransport on post-Golgi vesicles to ROS. Labeling of ROS lipids was very low, with phosphatidylinositol and diacylglycerols displaying the highest labeling, This indicates that other mechanisms by-passing Golgi, i.e. facilitated by lipid carrier proteins, may also contribute to molecular replacement of disc membrane DHA-phospholipids, particularly phosphatidylinositol.	LOUISIANA STATE UNIV,CTR NEUROSCI,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT OPHTHALMOL,NEW ORLEANS,LA 70112; UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48105; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	Louisiana State University System; Louisiana State University System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NEI NIH HHS [EY 6891] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler R., 1986, RETINA MODEL CELL BI, P297; ANDREWS LD, 1981, EXP EYE RES, V33, P1, DOI 10.1016/S0014-4835(81)80076-0; ANDREWS LD, 1983, J CELL BIOL, V97, P749, DOI 10.1083/jcb.97.3.749; Aveldano de Caldironi M.I., 1980, Neurochemistry International, V1, P381, DOI 10.1016/0197-0186(80)90074-1; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1983, J LIPID RES, V24, P620; BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0; BAZAN NG, 1982, PHOSPHOLIPIDS NERVOU, P49; BAZAN NG, 1990, NUTR BRAIN, P1; BESHARSE JC, 1980, J CELL BIOL, V87, P451, DOI 10.1083/jcb.87.2.451; BIBB C, 1974, J CELL BIOL, V61, P327, DOI 10.1083/jcb.61.2.327; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; CHEN YS, 1973, EXP EYE RES, V17, P517, DOI 10.1016/0014-4835(73)90082-1; CHOE HG, 1990, EXP EYE RES, V51, P167, DOI 10.1016/0014-4835(90)90069-7; CHOE HG, 1990, EXP EYE RES, V51, P159, DOI 10.1016/0014-4835(90)90068-6; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; DERETIC D, 1993, J CELL SCI, V106, P803; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DERETIC D, 1995, J CELL SCI, V108, P215; DERETIC D, 1995, PROG RETIN EYE RES, V14, P249, DOI 10.1016/1350-9462(94)00004-3; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Deretic D, 1996, J BIOL CHEM, V271, P2279, DOI 10.1074/jbc.271.4.2279; DERETIC D, 1993, METH NEUROSCI, V15, P108; DETURCO EBR, 1990, J NEUROSCI RES, V27, P522, DOI 10.1002/jnr.490270413; DETURCO EBR, 1991, J NEUROSCI, V11, P3667; DETURCO EBR, 1992, INVEST OPHTHALMOL  S, V32, P705; DETURCO EBR, 1993, CURR EYE RES, V13, P21; DUDLEY PA, 1978, FEBS LETT, V95, P57, DOI 10.1016/0014-5793(78)80051-9; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; FLIESLER SJ, 1995, EXP EYE RES, V60, P57, DOI 10.1016/S0014-4835(05)80084-3; FLIESLER SJ, 1987, J BIOL CHEM, V262, P17516; FOLCH J, 1957, J BIOL CHEM, V226, P497; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1992, J BIOL CHEM, V267, P17977; GIUSTO NM, 1986, BIOCHIM BIOPHYS ACTA, V860, P137, DOI 10.1016/0005-2736(86)90508-0; GIUSTO NM, 1986, BIOCHIM BIOPHYS ACTA, V877, P440, DOI 10.1016/0005-2760(86)90210-9; GORDON WC, 1993, INVEST OPHTH VIS SCI, V34, P2402; GORDON WC, 1990, J NEUROSCI, V10, P2190; JIAO XD, 1993, INVEST OPHTH VIS SCI, V34, P1328; LEE J, 1995, INVEST OPHTH VIS SCI, V36, P2032; LOUIE K, 1991, EXP EYE RES, V53, P309, DOI 10.1016/0014-4835(91)90235-7; LOUIE K, 1988, BIOCHEMISTRY-US, V27, P9014, DOI 10.1021/bi00425a020; MARCHESELLI VL, 1990, J NUTR BIOCH, V1, P231; MATHEKE ML, 1984, J NEUROSCI, V4, P1086; MATHEKE ML, 1984, J NEUROSCI, V4, P1093; MERCURIO AM, 1982, J NEUROCYTOL, V11, P295, DOI 10.1007/BF01258248; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAPERMASTER DS, 1975, BIOCHEMISTRY-US, V14, P1343, DOI 10.1021/bi00678a001; PAPERMASTER DS, 1986, J HISTOCHEM CYTOCHEM, V34, P5, DOI 10.1177/34.1.2934469; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; REDDY TS, 1984, CURR EYE RES, V3, P1225, DOI 10.3109/02713688409000826; ROQUE ME, 1995, EXP EYE RES, V60, P631, DOI 10.1016/S0014-4835(05)80005-3; ROTSTEIN NP, 1987, BIOCHIM BIOPHYS ACTA, V921, P221, DOI 10.1016/0005-2760(87)90022-1; ROTSTEIN NP, 1987, BIOCHIM BIOPHYS ACTA, V921, P235, DOI 10.1016/0005-2760(87)90023-3; SELLNER P, 1994, INVEST OPHTH VIS SCI, V35, P443; SELLNER PA, 1991, INVEST OPHTH VIS SCI, V32, P1149; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; URBANI L, 1990, J BIOL CHEM, V265, P1919; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WETZEL MG, 1993, J NEUROCYTOL, V22, P397, DOI 10.1007/BF01195560; WIEGAND RD, 1983, EXP EYE RES, V37, P150; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700; ZIMMERMAN WF, 1988, EXP EYE RES, V47, P247, DOI 10.1016/0014-4835(88)90008-5	64	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10491	10497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099692				2022-12-27	WOS:A1997WV26200026
J	Loverix, S; Doumen, J; Steyaert, J				Loverix, S; Doumen, J; Steyaert, J			Additivity of protein-guanine interactions in ribonuclease T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DOUBLE-MUTANT CYCLES; CRYSTAL-STRUCTURE; ACTIVE-SITE; STAPHYLOCOCCAL NUCLEASE; MICROBIAL RIBONUCLEASES; AROMATIC INTERACTIONS; SUBSTRATE BINDING; X-RAY; ACID	It has been established that Tyr-42, Tyr-45, and Glu-46 take part in a structural motif that renders guanine specificity to ribonuclease T1. We report on the impact of Tyr-42, Tyr-45, and Glu-46 substitutions on the guanine specificity of RNase T1. The Y42A and E46A mutations profoundly affect substrate binding, No such effect is observed for Y45A RNase T1. From the kinetics of the Y42A/Y45A and Y42A/E46A double mutants, we conclude that these pairs of residues contribute to guanine specificity in a mutually independent way, From our results, it appears that the energetic contribution of aromatic face-to-face stacking interactions may be significant if polycyclic molecules, such as guanine, are involved.	FREE UNIV BRUSSELS VIB, DIENST ULTRASTRUKTUUR, B-1640 RHODE ST GENESE, BELGIUM	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel			steyaert, jan/GQP-7811-2022; Steyaert, Jan/H-4662-2011	Steyaert, Jan/0000-0002-3825-874X				ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1991, X PLOR VERSION 3 1, V47, P110; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Doumen J, 1996, PROTEIN SCI, V5, P1523, DOI 10.1002/pro.5560050808; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P6030, DOI 10.1021/bi00393a013; FUJII T, 1995, BIOSCI BIOTECH BIOCH, V59, P1869, DOI 10.1271/bbb.59.1869; GERLT JA, 1987, CHEM REV, V87, P1079, DOI 10.1021/cr00081a010; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; HAKOSHIMA T, 1991, PROTEIN ENG, V4, P793, DOI 10.1093/protein/4.7.793; HAKOSHIMA T, 1988, PROTEIN ENG, V2, P55, DOI 10.1093/protein/2.1.55; HARTLEY RW, 1980, J MOL EVOL, V15, P355, DOI 10.1007/BF01733142; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HIRONO S, 1991, PROTEIN ENG, V4, P233, DOI 10.1093/protein/4.3.233; IKEHARA M, 1986, P NATL ACAD SCI USA, V83, P4695, DOI 10.1073/pnas.83.13.4695; ISHIDA T, 1993, FEBS LETT, V333, P214, DOI 10.1016/0014-5793(93)80656-F; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LEATHERBARROW RJ, 1991, GRAFIT VERSION 2 07; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MAYR LM, 1993, PROTEIN EXPRES PURIF, V4, P52, DOI 10.1006/prep.1993.1008; NISHIKAWA S, 1988, EUR J BIOCHEM, V173, P389, DOI 10.1111/j.1432-1033.1988.tb14011.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1957, J BIOCHEM-TOKYO, V44, P753, DOI 10.1093/oxfordjournals.jbchem.a126717; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SEVCIK J, 1990, TRENDS BIOCHEM SCI, V15, P158, DOI 10.1016/0968-0004(90)90217-Y; SHIMADA I, 1990, BIOCHEMISTRY-US, V29, P757, DOI 10.1021/bi00455a024; SHIRLEY BA, 1990, J BIOCHEM BIOPH METH, V20, P181, DOI 10.1016/0165-022X(90)90076-O; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P494, DOI 10.1021/bi00216a027; STEYAERT J, 1993, J MOL BIOL, V229, P770, DOI 10.1006/jmbi.1993.1078; WALZ FG, 1979, ARCH BIOCHEM BIOPHYS, V195, P95, DOI 10.1016/0003-9861(79)90330-8; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; ZABINSKI M, 1976, ARCH BIOCHEM BIOPHYS, V175, P558, DOI 10.1016/0003-9861(76)90545-2; ZEGERS I, 1994, J BIOL CHEM, V269, P127	50	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9635	9639						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092491				2022-12-27	WOS:A1997WU03900010
J	Rebbaa, A; Yamamoto, H; Saito, T; Meuillet, E; Kim, P; Kersey, DS; Bremer, EG; Taniguchi, N; Moskal, JR				Rebbaa, A; Yamamoto, H; Saito, T; Meuillet, E; Kim, P; Kersey, DS; Bremer, EG; Taniguchi, N; Moskal, JR			Gene transfection-mediated overexpression of beta 1,4-N-acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; BREAST-CANCER-CELLS; A431 CELLS; GLYCOSYLATION; CARBOHYDRATE; EXPRESSION; CARCINOMA; BINDING; ACID	N-linked oligosaccharides appear to be important for the function of the epidermal growth factor (EGF) receptor. In a previous study (Rebbaa, A., Yamamoto, H., Moskal, J. R., and Bremer, E. G. (1996) J, Neurochem. 67, 2265-2272), we showed that binding of the erythroagglutinating phytohemagglutin lectin from Phaseolus vulgaris to the bisecting structures on the EGF receptor from U373 MG glioma cells blocked EGF binding and receptor autophosphorylation. In this study we examined the consequences of overexpression of the bisecting structure on the EGF receptor by gene transfection of U373 MG cells with the N-acetylglucosaminyltransferase III (GnT-III). This modification leads to a significant decrease in EGF binding and EGF receptor autophosphorylation. In addition, the cellular response to EGF was found to be altered, Proliferation of U373 MG cells in serum-free medium is inhibited by EGF., In contrast, proliferation of the GnT-III-transfected cells was stimulated by EGF. These data demonstrate that changes in EGF receptor glycosylation by GnT-III transfection reduces the number of the active receptors in U373 MG cells and that this change results in change in the cellular response to EGF.	CHILDRENS MEM HOSP,CHICAGO INST NEUROSURG & NEURORES,BRAIN TUMOR RES PROGRAM,CHICAGO,IL 60614; OSAKA UNIV,SCH MED,OSAKA 565,JAPAN	Ann & Robert H. Lurie Children's Hospital of Chicago; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Moskal, Joseph/B-7628-2009	Taniguchi, Naoyuki/0000-0001-5889-5968; Meuillet, Emmanuelle/0000-0002-2242-0810	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033383] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33383] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BARNES D, 1987, METHOD ENZYMOL, V146, P88; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; MIYAJI K, 1994, J NEUROSURG, V81, P411, DOI 10.3171/jns.1994.81.3.0411; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; Rebbaa A, 1996, J NEUROCHEM, V67, P2265; ROSS SA, 1995, INT J CANCER, V62, P303, DOI 10.1002/ijc.2910620312; Sauter G, 1996, AM J PATHOL, V148, P1047; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; Soderquist A M, 1988, Adv Exp Med Biol, V231, P569; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; WAKSHULL EM, 1985, P NATL ACAD SCI USA, V82, P8513, DOI 10.1073/pnas.82.24.8513; ZENG FY, 1995, MOL CELL BIOCHEM, V142, P117, DOI 10.1007/BF00928932	21	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9275	9279						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083062				2022-12-27	WOS:A1997WU03700067
J	Yim, HS; Kang, JH; Chock, PB; Stadtman, ER; Yim, MB				Yim, HS; Kang, JH; Chock, PB; Stadtman, ER; Yim, MB			A familial amyotrophic lateral sclerosis-associated A4V Cu,Zn-Superoxide dismutase mutant has a lower K-m for hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; TRANSGENIC MICE; MUTATIONS; GENE; SUPEROXIDE-DISMUTASE-1; COPPER; CELLS	Point mutations of Cu,Zn-superoxide dismutase (Cu,Zn-SOD) have been linked to familial amyotrophic lateral sclerosis (FALS). We reported that Cu,Zn-SOD can catalyze free radical generation and a FALS mutant, G93A, exhibits an enhanced free radical-generating activity, while its dismutation activity is identical to that of the wild-type enzyme (Yim, M. B., Bang J.-H., Yim, H.-S., Kwak, H.-S., Chock, P. B., and Stadtman, E. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5709-5714). The A4V mutation is both the most commonly detected of FALS-associated SOD1 mutations and among the most clinically severe (Rosen, D. R., Bowling, A. C., Patterson, D., Usdin, T. B., Sapp, P., Mezey, E., McKenna-Yasek, D., O'Regan, J. P., Rahmani, Z., Ferrante, R. J., Brownstein, M. J., Kowall, N. W., Beal, M. F., Horvitz, H. R., and Brown, R. H., Jr. (1994) Rum. Mol. Genet. 3, 981-987). We cloned the cDNA for the FALS A4V mutant, overexpressed the protein in Sf9 insect cells, purified the protein, and studied its enzymic activities. Our results show that the mutant and wild-type enzymes contain one copper ion per subunit and have identical dismutation activities. However, the free radical-generating activity of the mutant, as measured by the spin trapping method at low H2O2 concentration, is enhanced relative to that of the wild-type and G93A enzyme (wild-type < G93A < A4V). This is due to the decrease in the K-m value for H2O2, wild-type > G93A > A4V, while the k(cat) is identical for these enzymes. Thus, the FALS symptoms are not associated with the reduction in the dismutation activity of the mutant enzyme. The fact that the A4V mutant has the lowest K-m for H2O2 is correlated to the clinical severity observed with the A4V patients, if FALS is associated with a differential gain of the free radical-generating function of the Cu,Zn-SOD mutant.	NHLBI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; ORRELL R, 1995, NATURE, V374, P504, DOI 10.1038/374504a0; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	22	150	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8861	8863						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083002				2022-12-27	WOS:A1997WU03700007
J	Knauper, V; Cowell, S; Smith, B; LopezOtin, C; OShea, M; Morris, H; Zardi, L; Murphy, G				Knauper, V; Cowell, S; Smith, B; LopezOtin, C; OShea, M; Morris, H; Zardi, L; Murphy, G			The role of the c-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; HUMAN FIBROBLAST COLLAGENASE; CATALYTIC DOMAIN; MATRIX METALLOPROTEINASES; SYNOVIAL COLLAGENASE; STROMELYSIN; DEGRADATION; GELATINASE; PURIFICATION; PROENZYME	Recombinant human procollagenase-3 and a C-terminal truncated form (Delta(249-451) procollagenase-3) have been stably expressed in myeloma cells and purified, The truncated proenzyme could be processed by amino-phenylmercuric acetate via a short lived intermediate form (N-terminal Leu(58)) to the final active form (N-terminal Tyr(85)), The kinetics of activation were not affected by removal of the hemopexin-like C-terminal domain, The specific activities of both collagenase-3 and Delta(249-451) collagenase-3 were found to be similar using two quenched fluorescent substrates, but Delta(249-451) collagenase-3 failed to cleave native triple helical collagens (types I and II) into characteristic one- and three-quarter fragments, It was noted, however, that the beta 1,2(I) chains of type I collagen were susceptible to Delta(249-451) collagenase-3, which indicates that the catalytic domain displays telopeptidase activity, thereby generating alpha 1,2(I) chains that are slightly shorter than those in native type I collagen, It can be concluded that the C-terminal domain is only essential for the triple helicase activity of collagenase-3, Binding of procollagenase-3 and active collagenase-3 to type I collagen is mediated by the C-terminal domain, Both collagenase-3 and Delta(249-451) collagenase-3 hydrolyzed the large tenascin C isoform, fibronectin, recombinant fibronectin fragments, and type IV, IX, X, and XIV collagens; thus, these events were independent from C-terminal domain inter actions, In contrast, the minor cartilage type XI collagen was resistant to cleavage, Kinetic analysis of the mechanism of inhibition of wild-type and <Delta(249-451) collagenase-3 by wild-type and mutant tissue inhibitors of metalloproteinase (TIMPs) revealed that the association rates for complex formation were influenced by both Nand C-terminal domain interactions, The C-terminal domain of wild-type collagenase-3 promoted increased association rates with the full-length inhibitors TIMP-1 and TIMP-3 and the hybrid N.TIMP-2/C.TIMP-1 by a factor of up to 33, In contrast, the association rates for complex formation with TIMP-2 and N.TIMP-1/C.TIMP-2 were only marginally affected by C-terminal domain interactions.	CELLTECH LTD,SLOUGH SL1 4EN,BERKS,ENGLAND; UNIV OVIEDO,DEPT BIOQUIM & BIOL MOL,E-33006 OVIEDO,SPAIN; IST NAZL RIC CANC,I-16132 GENOA,ITALY	Celltech Group Ltd; University of Oviedo; University of Genoa; IRCCS AOU San Martino IST	Knauper, V (corresponding author), STRANGEWAYS RES LAB,DEPT CELL & MOL BIOL,WORTS CAUSEWAY,CAMBRIDGE CB1 4RN,ENGLAND.		López-Otín, Carlos/AAB-2106-2020	López-Otín, Carlos/0000-0001-6964-1904; Knauper, Vera/0000-0002-3965-9924	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; CAWSTON TE, 1981, BIOCHIM BIOPHYS ACTA, V657, P73, DOI 10.1016/0005-2744(81)90131-5; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Eble JA, 1996, J BIOL CHEM, V271, P30964, DOI 10.1074/jbc.271.48.30964; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GILLET C, 1977, FEBS LETT, V74, P126, DOI 10.1016/0014-5793(77)80768-0; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, EUR J BIOCHEM, V235, P187, DOI 10.1111/j.1432-1033.1996.00187.x; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OKADA Y, 1989, FEBS LETT, V244, P473, DOI 10.1016/0014-5793(89)80586-1; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; SIRES UI, 1995, J BIOL CHEM, V270, P1062, DOI 10.1074/jbc.270.3.1062; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WU JJ, 1991, J BIOL CHEM, V266, P5625	42	279	288	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7608	7616		10.1074/jbc.272.12.7608	http://dx.doi.org/10.1074/jbc.272.12.7608			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065415	hybrid			2022-12-27	WOS:A1997WP59200009
J	Sillaber, C; Baghestanian, M; Hofbauer, R; Virgolini, I; Bankl, HC; Fureder, W; Agis, H; Willheim, M; Leimer, M; Scheiner, O; Binder, BR; Kiener, HP; Bevec, D; Fritsch, G; Majdic, O; Kress, HG; Gadner, H; Lechner, K; Valent, P				Sillaber, C; Baghestanian, M; Hofbauer, R; Virgolini, I; Bankl, HC; Fureder, W; Agis, H; Willheim, M; Leimer, M; Scheiner, O; Binder, BR; Kiener, HP; Bevec, D; Fritsch, G; Majdic, O; Kress, HG; Gadner, H; Lechner, K; Valent, P			Molecular and functional characterization of the urokinase receptor on human mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; C-KIT LIGAND; PLASMINOGEN-ACTIVATOR; RECOMBINANT HUMAN; CHEMOTACTIC FACTOR; ENDOTHELIAL-CELLS; MEDIATOR RELEASE; HUMAN BASOPHILS; BINDING-SITES; HIGH-AFFINITY	The urokinase receptor system is involved in several biological processes including extracellular proteolysis, cell invasion, and chemotaxis. Mast cells are multifunctional perivascular cells that play an important role in the regulation of microenvironmental events. We report that primary human mast cells and the human mast cell line HMC-1 express the receptor for urokinase. As assessed by Northern blotting and reverse transcription polymerase chain reaction technique, purified human lung mast cells and HMC-1 cells expressed urokinase receptor mRNA in a constitutive manner. Using a toluidine blue/immunofluorescence double staining technique and monoclonal antibodies, surface expression of urokinase receptor was demonstrable in lung, skin, uterus, heart, and tonsil mast cells, whereas the low density lipoprotein receptor-related protein was not detectable. Binding of monoclonal antibody VLM5 (recognizing the urokinase binding domain of urokinase receptor) to HMC-1 could be blocked by high molecular weight but not low molecular weight urokinase. Binding analyses performed with I-123-urokinase revealed expression of 271,000 +/- 55,000 high affinity urokinase binding sites per HMC-1 cell, with a calculated dissociation constant of 1.29 +/- 0.3 nm. Purified urokinase induced dose-dependent migration of primary mast cells and HMC-1 in a chemotaxis assay without inducing release of histamine. The mast cell agonist stem cell factor also induced migration of HMC-1 and caused up-regulation of expression of urokinase receptor mRNA. Together, our data show that human mast cells express functional receptors for urokinase. Expression of urokinase receptors on mast cells may have implications for mast cell-dependent microvascular processes associated with fibrinolysis, migration, or local tissue repair.	UNIV VIENNA,DEPT INTERNAL MED 1,DIV HEMATOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST ANASTHESIOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT NUCL MED,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST GEN & EXPT PATHOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT VASC BIOL & TROMBOSIS RES,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT INTERNAL MED 3,DIV RHEUMATOL,A-1090 VIENNA,AUSTRIA; SANDOZ GMBH,RES INST,A-1235 VIENNA,AUSTRIA; ST ANNA CHILDRENS HOSP,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST IMMUNOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; Novartis; Sandoz; Saint Anna Children's Hospital; University of Vienna			Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Test, PV/U-9451-2019	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Kress, Hans Georg/0000-0001-8150-6019				Baghestanian M, 1996, EXP HEMATOL, V24, P1377; BAGHESTANIAN M, 1995, BLOOD S1, V84, pA76; BANKL HC, 1995, CIRCULATION, V91, P275, DOI 10.1161/01.CIR.91.2.275; BARTHOLOMEW JS, 1988, BIOCHEM BIOPH RES CO, V153, P540, DOI 10.1016/S0006-291X(88)81128-8; BERANEK JT, 1985, IMMUNOL TODAY, V6, P317, DOI 10.1016/0167-5699(85)90120-3; BIENENSTOCK J, 1987, AM REV RESPIR DIS, V135, P5; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BLASI F, 1986, J CELL BIOCHEM, V32, P179, DOI 10.1002/jcb.240320303; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOHUSLAV J, 1995, J EXP MED, V181, P1681; BOYLE MDP, 1987, J IMMUNOL, V139, P169; BU GJ, 1994, BLOOD, V83, P3427; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; CONESE M, 1994, J BIOL CHEM, V269, P17886; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DVORAK AM, 1991, BLOOD CELL BIOCH, V4; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GALLI SJ, 1990, LAB INVEST, V62, P5; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1992, BLOOD, V80, P3009; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; MILES LA, 1988, BLOOD, V72, P628; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; MOHANAM S, 1993, CANCER RES, V53, P4143; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NILSSON G, 1994, J IMMUNOL, V153, P3717; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SPERR WR, 1994, BLOOD, V84, P3876, DOI 10.1182/blood.V84.11.3876.bloodjournal84113876; STACK MS, 1994, J BIOL CHEM, V269, P9416; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; TODD RF, 1995, LEUCOCYTE TYPING, V5, P932; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1992, BLOOD, V80, P2237; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; VALENT P, 1989, BLOOD, V73, P1778; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VIRGOLINI I, 1995, ARTERIOSCL THROM VAS, V15, P17, DOI 10.1161/01.ATV.15.1.17; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WILLHEIM M, 1995, J IMMUNOL METHODS, V182, P115, DOI 10.1016/0022-1759(95)00034-8; WYPIJ DM, 1992, BIOCHEM PHARMACOL, V43, P845, DOI 10.1016/0006-2952(92)90252-E; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YURT RW, 1977, J BIOL CHEM, V252, P518; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	67	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7824	7832		10.1074/jbc.272.12.7824	http://dx.doi.org/10.1074/jbc.272.12.7824			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065447	hybrid			2022-12-27	WOS:A1997WP59200041
J	Udovichenko, IP; Newton, AC; Williams, DS				Udovichenko, IP; Newton, AC; Williams, DS			Contribution of protein kinase C to the phosphorylation of rhodopsin in intact retinas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; CALPHOSTIN-C; BETA-2-ADRENERGIC RECEPTOR; BOVINE RHODOPSIN; IN-VIVO; DESENSITIZATION; PHOTORECEPTOR; ARRESTIN; SITES	Similar to other G protein-coupled receptors, the visual receptor, rhodopsin, is phosphorylated by both a substrate-regulated kinase, rhodopsin kinase, and a second messenger-regulated kinase, protein kinase C, In the present study, the extent of involvement of protein kinase C in the light-dependent phosphorylation of rhodopsin in intact retinas was assessed using a specific activator (phorbol ester) and specific inhibitor (calphostin C) of protein kinase C, Kinetic analysis of rhodopsin phosphorylation following different illumination conditions revealed that hyperactivation of protein kinase C with phorbol ester resulted in a relative increase in rhodopsin phosphorylation that peaked 10-15 min after the onset of illumination, Following this period, the rate of rhodopsin dephosphorylation was increased in the phorbol ester-treated retinas, so that by about 30 min the amount of phosphorylation was similar to that in control retinas, Treatment of retinas with calphostin C, a potent regulatory domain-directed inhibitor of protein kinase C, resulted in an approximately 50% reduction in the light-dependent phosphorylation of rhodopsin, This inhibitor had no effect on the activity of rhodopsin kinase in vitro, Last, we show that frog rhodopsin is phosphorylated in vitro by protein kinase C from frog rod outer segments, indicating that this kinase could directly modulate rhodopsin in vivo, In conclusion, the present results reveal that the kinetics of rhodopsin phosphorylation/dephosphorylation differ markedly, depending on whether protein kinase C or rhodopsin kinase activity dominates, and that, under the conditions studied, protein kinase C contributes to approximately half of the phosphorylation of rhodopsin in intact frog retinas.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NEI NIH HHS [EY08820] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; JEAN T, 1986, J BIOL CHEM, V261, P6414; KAPOOR CL, 1984, BIOCHEM BIOPH RES CO, V122, P1397, DOI 10.1016/0006-291X(84)91246-4; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NEWTON AC, 1993, METH NEUROSCI, V15, P261; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; ORR JW, 1992, J BIOL CHEM, V267, P15263; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; ROTENBERG SA, 1995, MOL CARCINOGEN, V12, P42, DOI 10.1002/mc.2940120107; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHMIDT SY, 1983, J BIOL CHEM, V258, P6863; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STRYER L, 1991, J BIOL CHEM, V266, P10711; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; Udovichenko IP, 1996, BIOCHEM J, V317, P291, DOI 10.1042/bj3170291; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WOLBRING G, 1991, EUR J BIOCHEM, V201, P601, DOI 10.1111/j.1432-1033.1991.tb16320.x; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7952	7959		10.1074/jbc.272.12.7952	http://dx.doi.org/10.1074/jbc.272.12.7952			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065465	hybrid			2022-12-27	WOS:A1997WP59200059
J	Harrington, EO; Loffler, J; Nelson, PR; Kent, KC; Simons, M; Ware, JA				Harrington, EO; Loffler, J; Nelson, PR; Kent, KC; Simons, M; Ware, JA			Enhancement of migration by protein kinase C alpha and inhibition of proliferation and cell cycle progression by protein kinase C delta in capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NIH 3T3 FIBROBLASTS; IN-VITRO; INTEGRIN ALPHA(V)BETA(3); ANGIOGENESIS INVITRO; BLOOD-VESSELS; ACTIVATION; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION	Activation of protein kinase C (PKC) induces angio-gensis, migration, and proliferation of endothelial cells (EC), but can also prevent growth factor-induced EC proliferation, To determine whether these disparate effects are mediated by substrates of individual PKC isoenzymes, PKC alpha and PKC delta were overexpressed in rat microvascular EC. Basal and stimulated migration were enhanced in PKC alpha EC compared with either PKC delta or control EC, Serum-induced growth of PKC delta EC was decreased, while that of PKC alpha cells was similar to control EC, Phorbol ester markedly inhibited PKC delta EC growth but enhanced growth of PKC alpha and control EC. To determine possible causes for this altered proliferation, the effect of PKC delta on adhesion, mitogen-activated protein kinase activity, and cell cycle progression was measured, Adherence of PKC delta EC to vitronectin was significantly enhanced. Serum-induced extracellular signal-regulated kinase-2 activity was increased equally in both PKC alpha and PKC delta EC above that of control, while extracellular signal-regulated kinase-l activity was similar in all EC, Cell cycle analysis suggested that PKC delta EC entered S phase inappropriately and were delayed in passage through S phase, Thus, PKC alpha may mediate some proangiogenic effects of PKC activation; conversely, PKC delta may direct antiangiogenic aspects of overall PKC activation, including slowing of the cell cycle progression.	BETH ISRAEL HOSP,DEPT MED,VASC BIOL UNIT,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT VASC SURG,VASC BIOL UNIT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Simons, Michael/G-8553-2014; Nelson, Peter/B-2055-2009	Simons, Michael/0000-0003-0348-7734; Harrington, Elizabeth/0000-0002-3207-5301; Nelson, Peter/0000-0003-0398-2962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038820, R01HL051043, R01HL047032, R29HL038820] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47032, HL 51043, HL 38820] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BASSON CT, 1990, J CELL BIOL, V110, P789, DOI 10.1083/jcb.110.3.789; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HU DE, 1995, INFLAMMATION, V19, P39, DOI 10.1007/BF01534379; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KINSELLA JL, 1992, EXP CELL RES, V199, P56, DOI 10.1016/0014-4827(92)90461-G; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOSAKA C, 1995, ANN NY ACAD SCI, V748, P538; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; MAHER JJ, 1993, J CLIN INVEST, V91, P2244, DOI 10.1172/JCI116451; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; MURPHY HS, 1994, AM J PHYSIOL, V267, pL145, DOI 10.1152/ajplung.1994.267.2.L145; Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P; NAKAMURA Y, 1995, BIOCHEM BIOPH RES CO, V215, P483, DOI 10.1006/bbrc.1995.2490; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SAITOH M, 1989, BLOOD, V74, P2001; SOZERI O, 1992, ONCOGENE, V7, P2259; TANG DG, 1993, PROSTAG OTH LIPID M, V45, P249, DOI 10.1016/0090-6980(93)90051-8; TENNENBAUM T, 1988, J INVEST DERMATOL, V90, P857, DOI 10.1111/1523-1747.ep12462098; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WRIGHT PS, 1992, J CELL PHYSIOL, V152, P448, DOI 10.1002/jcp.1041520303; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; ZHOU W, 1993, J BIOL CHEM, V268, P23041	55	124	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7390	7397		10.1074/jbc.272.11.7390	http://dx.doi.org/10.1074/jbc.272.11.7390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054439	hybrid			2022-12-27	WOS:A1997WN14700078
J	Franzen, S; Boxer, SG				Franzen, S; Boxer, SG			On the origin of heme absorption band shifts and associated protein structural relaxation in myoglobin following flash photolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN EVIDENCE; PICOSECOND TIME SCALES; SPERM WHALE MYOGLOBIN; SITE-SPECIFIC MUTANTS; GEMINATE RECOMBINATION; LIGAND-BINDING; CARBONMONOXY-MYOGLOBIN; PROXIMAL LIGAND; HEMOGLOBIN; DYNAMICS	The role of the protein structural change monitored by absorption band shifts following flash photolysis of CO from myoglobin is discussed in terms of structure-function relationships. Evidence is presented that the Soret band shift does not depend primarily on the covalent linkage of the heme iron to the protein by using the mutation H93G(L) in which the proximal histidine 93 is replaced by glycine and an exogenous ligand L, which coordinates the heme iron but is not covalently bound to the globin. While CO rebinding kinetics depend strongly on the nature of the exogenous ligand L in H93G(L), the magnitude and time evolution of the Soret band shift in a viscous buffer on the nanosecond time scale are hardly perturbed in all cases studied. Comparison of the Soret band and charge transfer Band III shifts demonstrates that both have a similar time dependence on the nanosecond to microsecond time scale following flash photolysis in viscous solvents. We conclude that the nonexponential kinetics of protein relaxation probed by transient absorption band position shifts involves primarily distal coordinates prior to ligand escape. This result agrees with earlier measurements of Soret band shifts in distal pocket mutants of myoglobin (1). We suggest that the band shifts are primarily a response to changes in the electrostatic field around the heme (a transient Stark shift) associated with changes in protein structure that occur following ligand photodissociation.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University				Boxer, Steven/0000-0001-9167-4286	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027738, R01GM027738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CHANCE MR, 1990, BIOCHEMISTRY-US, V29, P5537, DOI 10.1021/bi00475a018; DASGUPTA S, 1985, BIOCHEMISTRY-US, V24, P5295, DOI 10.1021/bi00341a003; DECATUR SM, 1995, BIOCHEM BIOPH RES CO, V212, P159, DOI 10.1006/bbrc.1995.1950; DECATUR SM, 1995, BIOCHEMISTRY-US, V34, P2122, DOI 10.1021/bi00007a004; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; EATON WA, 1978, J AM CHEM SOC, V100, P4991, DOI 10.1021/ja00484a013; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GEISSINGER P, 1995, J PHYS CHEM-US, V99, P16527, DOI 10.1021/j100045a008; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; HAGEN SJ, 1995, SCIENCE, V269, P959, DOI 10.1126/science.7638618; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; OLDFIELD E, 1991, J AM CHEM SOC, V113, P8680, DOI 10.1021/ja00023a015; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; ZERNER M, 1966, THEOR CHIM ACTA, V6, P363, DOI 10.1007/BF00528464	40	44	44	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9655	9660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092494				2022-12-27	WOS:A1997WU03900013
J	Illing, M; Molday, LL; Molday, RS				Illing, M; Molday, LL; Molday, RS			The 220-kDa Rim protein of retinal rod outer segments is a member of the ABC transporter superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC MEMBRANE-PROTEIN; PLASMA-MEMBRANE; P-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; PHOTORECEPTOR CELLS; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; DISK MEMBRANES; GATED CHANNEL; IDENTIFICATION	Outer segments of mammalian rod photoreceptor cells contain an abundantly expressed membrane protein that migrates with an apparent molecular mass of 220 kDa by SDS gel electrophoresis. We have purified the bovine protein by immunoaffinity chromatography, determined its primary structure by cDNA cloning and direct peptide sequence analysis, and mapped its distribution in photoreceptors by immunocytochemical and biochemical methods, The full-length cDNA encodes a 2280-amino acid protein (calculated molecular mass of 257 kDa) consisting of two structurally related, tandem arranged halves, Each half consists of a hydrophobic domain containing six putative transmembrane segments followed by an ATP binding cassette, A data base homology search showed that the rod outer segment 220 kDa protein is 40-50% identical in amino acid sequence to the ABC1 and ABC2 proteins cloned from a mouse macrophage cell line, Photoaffinity labeling with 8-azido-ATP and nucleotide inhibition studies confirmed that both ATP and GTP bind to this protein with similar affinities, Concanavalin A labeling and endoglycosidase H digestion indicated that the rod outer segment protein contains at least one carbohydrate chain, Immunocytochemical and biochemical studies have revealed that the 220 kDa glycoprotein is distributed along the rim region and incisures of rod outer segment disc membranes, From these studies we conclude that the 220-kDa glycoprotein of bovine rod outer segment disc membranes or Rim ABC protein is a new member of the superfamily of ABC transporters and is the mammalian homolog of the frog photoreceptor rim protein.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia					NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BURTON MD, 1989, ANAL BIOCHEM, V183, P225, DOI 10.1016/0003-2697(89)90472-7; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; CONVERSE CA, 1979, EXP EYE RES, V29, P409, DOI 10.1016/0014-4835(79)90057-5; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; CORLESS JM, 1987, EXP EYE RES, V45, P883, DOI 10.1016/S0014-4835(87)80104-5; ELLIS RE, 1991, GENETICS, V129, P79; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; EWART GD, 1994, J BIOL CHEM, V269, P10370; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HSU SC, 1991, J BIOL CHEM, V266, P21745; JURANKA P, 1992, J BIOL CHEM, V267, P3764; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MOLDAY RS, 1979, J BIOL CHEM, V254, P4653; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; REID D M, 1990, Investigative Ophthalmology and Visual Science, V31, P78; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SHUSTER TA, 1988, EXP EYE RES, V46, P475, DOI 10.1016/S0014-4835(88)80005-8; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; SZUTS EZ, 1985, BIOCHEMISTRY-US, V24, P4176, DOI 10.1021/bi00336a054; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUKURA J, 1981, BIOMED RES-TOKYO, V2, P177, DOI 10.2220/biomedres.2.177; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	52	234	242	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10303	10310		10.1074/jbc.272.15.10303	http://dx.doi.org/10.1074/jbc.272.15.10303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092582	hybrid			2022-12-27	WOS:A1997WU03900101
J	Sharf, R; Meraro, D; Azriel, A; Thornton, AM; Ozato, K; Petricoin, EF; Larner, AC; Schaper, F; Hauser, H; Levi, BZ				Sharf, R; Meraro, D; Azriel, A; Thornton, AM; Ozato, K; Petricoin, EF; Larner, AC; Schaper, F; Hauser, H; Levi, BZ			Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED RESPONSE ELEMENT; TRANSCRIPTION FACTOR IRF-1; CELL-GROWTH INHIBITION; FACTOR FAMILY; GAMMA-INTERFERON; GENE-EXPRESSION; INDUCIBLE GENES; FACTOR-I; TYROSINE; IFN	Two families of transcription factors mediate interferon (IFN) signaling, The first family, signal transducers and activators of transcription (STATs), is activated within minutes of IFN treatment. Specific phosphorylation events lead to their translocation to the nucleus, formation of transcriptional complexes, and the induction of the second family of transcription factors termed interferon regulatory factors (IRFs). Interferon consensus sequence binding protein (ICSBP) is a member of IRF family that is expressed only in cells of the immune system and acts as a transcriptional repressor. ICSBP binds DNA through the association with other transcription factors such as IRF-1 or IRF-2. In this communication, the domain that is involved in protein-protein interactions was mapped to the carboxyl terminus of ICSBP. This domain is also important for mediating ICSBP repressing activity. In vitro studies demonstrated that direct binding of ICSBP to DNA is prevented by tyrosine (Tyr) phosphorylation. Yet, Tyr-phosphorylated ICSBP can bind target DNA only through the association with IRF-2 and IRF-1. This type of phosphorylation is essential for the formation of heterocomplexes. Tyr-phosphorylated ICSBP and IRF-2 are detected in expressing cells constitutively, and Tyr-phosphorylated IRF-1 is induced by IFN-gamma. These results strongly suggest that like the STATs, the IRFs are also modulated by Tyr phosphorylation that affects their biological activities.	TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT,DIV CYTOKINE BIOL,BETHESDA,MD 20892; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	Technion Israel Institute of Technology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA); Gesellschaft fur Biotechnologische Forschung mbH			Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FINBLOOM DS, 1995, ARTHRITIS RHEUM-US, V38, P877, DOI 10.1002/art.1780380702; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nelson N, 1996, J IMMUNOL, V156, P3711; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; POLITIS AD, 1994, J IMMUNOL, V152, P2270; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thornton AM, 1996, J IMMUNOL, V157, P5145; Thornton AM, 1996, P NATL ACAD SCI USA, V93, P383, DOI 10.1073/pnas.93.1.383; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	43	152	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9785	9792						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092512				2022-12-27	WOS:A1997WU03900031
J	Klebanow, ER; Poon, D; Zhou, S; Weil, PA				Klebanow, ER; Poon, D; Zhou, S; Weil, PA			Cloning and characterization of an essential Saccharomyces cerevisiae gene, TAF40, which encodes yTAF(II)40, an RNA polymerase II-specific TATA-binding protein-associated factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIIB; MOLECULAR-CLONING; ESTROGEN-RECEPTOR; YEAST; ACTIVATION; COMPLEX; DISTINCT; TBP; SUBUNITS; IDENTIFICATION	In this report we describe the cloning and initial characterization of TAF40, a gene that encodes a yeast TATA-binding protein-associated factor (yTAF) of M(r) = similar to 40,000. This gene has many similarities to other yTAFs described thus far in that it is present at a single copy per haploid genome, it is essential for viability, and the deduced protein sequence of yTAF40 exhibits similarity to previously described human and Drosophila TAF(II)s. Immunological studies confirm that yTAF40 protein is a subunit of a large multiprotein TATA binding protein-TAF complex that contains a subset of the total number of the yTAFs present in yeast cell extracts. Transcription reactions performed using yeast whole cell extracts reveal that of the three nuclear RNA polymerases only RNA polymerase II function is abrogated when yTAF40 and associated proteins are immunodepleted from solution, indicating that the functionality of the multiprotein complex containing yTAF40 is RNA polymerase II-specific. By these criteria yTAF40 appears to encode a bona fide RNA polymerase II-specific TAF, and thus the protein that it encodes has been termed yTAF(II)40.	VANDERBILT UNIV,SCH MED,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELLULAR BIOL,BERKELEY,CA 94720	Vanderbilt University; Howard Hughes Medical Institute; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052461, R56GM052461] Funding Source: NIH RePORTER; NCI NIH HHS [CA09385] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P428; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIU HP, 1992, GENETICS, V132, P665; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; POON D, 1993, J BIOL CHEM, V268, P15325; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; POON D, 1993, J BIOL CHEM, V268, P5005; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587	50	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9436	9442						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083082				2022-12-27	WOS:A1997WU03700087
J	Lee, SH; Seo, HY; Kim, JC; Heo, WD; Chung, WS; Lee, KJ; Kim, MC; Cheong, YH; Choi, JY; Lim, CO; Cho, MJ				Lee, SH; Seo, HY; Kim, JC; Heo, WD; Chung, WS; Lee, KJ; Kim, MC; Cheong, YH; Choi, JY; Lim, CO; Cho, MJ			Differential activation of NAD kinase by plant calmodulin isoforms - The critical role of domain I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; LIGHT-CHAIN KINASE; ENZYME ACTIVATION; ESCHERICHIA-COLI; PEPTIDE COMPLEX; TARGET ENZYMES; CENTRAL HELIX; PROTEIN; BINDING; RECOGNITION	NAD kinase is a Ca2+/calmodulin (CaM)-dependent enzyme capable of converting cellular NAD to NADP. The enzyme purified from pea seedlings can be activated by highly conserved soybean CaM, SCaM-1, but not by the divergent soybean CaM isoform, SCaM-4 (Lee, S. H., Kim, J. C., Lee, M. S., Heo, W. D., Seo, H. Y., Yoon, H. W., Hong, J. C., Lee, S. Y., Bahk, J. D., Hwang, I., and Cho, M. J. (1995) J. Biol. Chem. 270, 21806-21812). To determine which domains were responsible for this differential activation of NAD kinase, a series of chimeric SCaMs were generated by exchanging functional domains between SCaM-4 and SCaM-1. SCaM-4111, a chimeric SCaM-1 that contains the first domain of SCaM-4, was severely impaired (only 40% of maximal) in its ability to activate NAD kinase. SCaM-1444, a chimeric SCaM-4 that contains the first domain of SCaM-1 exhibited nearly full (similar to 70%) activation of NAD kinase. Only chimeras containing domain I of SCaM-1 produced greater than half-maximal activation of NAD kinase. To define the amino acid residue(s) in domain I that were responsible for this differential activation, seven single residue substitution mutants of SCaM-1 were generated and tested for NAD kinase activation. Among these mutants, only K30E and G40D showed greatly reduced NAD kinase activation. Also a double residue substitution mutant, K30E/G40D, containing these two mutations in combination was severely impaired in its NAD kinase-activating potential, reaching only 20% of maximal activation. Furthermore, a triple mutation, K30E/M36I/G40D, completely abolished NAD kinase activation. Thus, our data suggest that domain I of CaM plays a key role in the differential activation of NAD kinase exhibited by SCaM-1 and SCaM-4. Further, the residues Lys(30) and Glu(40) of SCaM-1 are critical for this function.	GYEONGSANG NATL UNIV, PLANT MOL BIOL & BIOTECHNOL RES CTR, CHINJU 660701, SOUTH KOREA; GYEONGSANG NATL UNIV, DEPT BIOCHEM, CHINJU 660701, SOUTH KOREA	Gyeongsang National University; Gyeongsang National University			Cho, Moo Je/F-1649-2010					BIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHEN YR, 1987, J BIOL CHEM, V262, P10689; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; HARMON AC, 1984, ANAL BIOCHEM, V141, P168, DOI 10.1016/0003-2697(84)90441-X; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1995, J BIOL CHEM, V270, P2186; Liao BR, 1996, ARCH BIOCHEM BIOPHYS, V327, P53, DOI 10.1006/abbi.1996.0092; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MUTO S, 1977, PLANT PHYSIOL, V59, P55, DOI 10.1104/pp.59.1.55; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; RASICALDOGNOV F, 1993, PLANT PHYSIOL, V103, P391, DOI 10.1104/pp.103.2.391; RHYNER JA, 1992, BIOCHEMISTRY-US, V31, P12826, DOI 10.1021/bi00166a017; ROBERTS DM, 1986, J BIOL CHEM, V261, P1491; ROBERTS DM, 1990, CURR T PL B, V9, P67; ROBERTS DM, 1992, P NATL ACAD SCI USA, V89, P8394, DOI 10.1073/pnas.89.17.8394; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Snedden WA, 1996, J BIOL CHEM, V271, P4148; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU ZH, 1994, J BIOL CHEM, V269, P16761; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WALKER RG, 1993, P NATL ACAD SCI USA, V90, P2807, DOI 10.1073/pnas.90.7.2807; Walker RG, 1996, P NATL ACAD SCI USA, V93, P2203, DOI 10.1073/pnas.93.5.2203; WALSH MP, 1980, J BIOL CHEM, V255, P335; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546	44	60	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9252	9259						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083059	hybrid			2022-12-27	WOS:A1997WU03700064
J	Alliegro, MC; Linz, LA				Alliegro, MC; Linz, LA			Novel characteristics of a myosin isolated from mammalian retinal pigment epithelial and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE MYOSIN; UNCONVENTIONAL MYOSIN; MESSENGER-RNAS; HEAVY-CHAINS; EXPRESSION; PROTEINS; IDENTIFICATION; ANTIBODIES; BRAIN; LECTINS	We have isolated a novel, high M(r) protein from human retinal pigment epithelial cells and endothelial cells by affinity chromatography on Sepharose 4B. Two polypeptides are present on SDS-gels of the 8 an urea eluent with apparent molecular mass of similar to 210 and 47 kDa. In the absence of dithiothreitol, the two polypeptides migrate as one protein band with an apparent molecular mass of similar to 550 kDa. ''Piglet,'' as this molecule is tentatively named, is present in retinal pigment epithelial and endothelial cells of several species, but could not be detected in the nonepithelial cells we examined. Immunofluorescent localization using an antibody to the 210-kDa polypeptide revealed a filamentous network in the cytoplasm of cultured cells. This antibody was used to identify a cDNA for piglet in a bovine aortic endothelial cell expression library. Sequence data indicate a high degree of identity with non-muscle myosin II heavy chain. We subsequently found that piglet had an actin-activated ATPase activity, colocalized with actin in cells, and reacted on Western blots with a pan-non-muscle myosin II heavy chain antiserum. The protein was also recognized by antibodies specific for myosin heavy chain isoform A, but did not react with anti-isoform B antibodies. Although piglet has several features in common with known forms of non-muscle myosin II, the distinctly unconventional features it displays suggest that it is a novel myosin.			Alliegro, MC (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT ANAT, 1901 PERDIDO ST, NEW ORLEANS, LA 70112 USA.				NEI NIH HHS [EY09533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY009533] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; ALLIEGRO MC, 1990, BIOCHEMISTRY-US, V29, P2135, DOI 10.1021/bi00460a025; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashwell G., 1966, METHODS ENZYMOLOGY, V8, P85; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CLARK VM, 1991, INVEST OPHTH VIS SCI, V32, P327; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; DANDREA L, 1994, J CELL SCI, V107, P2081; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; FENSELAU A, 1976, CANCER RES, V36, P3269; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI DQ, 1992, J NEUROCHEM, V59, P1344, DOI 10.1111/j.1471-4159.1992.tb08446.x; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; OWARIBE K, 1988, CELL TISSUE RES, V254, P301; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TIEN L, 1991, INVEST OPHTH VIS SCI, V32, P319; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASTA GR, 1986, J BIOL CHEM, V261, P9182; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392	38	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8759	8763		10.1074/jbc.272.13.8759	http://dx.doi.org/10.1074/jbc.272.13.8759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079711	hybrid			2022-12-27	WOS:A1997WQ63500094
J	deHeuvel, E; Bell, AW; Ramjaun, AR; Wong, K; Sossin, WS; McPherson, PS				deHeuvel, E; Bell, AW; Ramjaun, AR; Wong, K; Sossin, WS; McPherson, PS			Identification of the major synaptojanin-binding proteins in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; NERVE-TERMINALS; DYNAMIN; GENE; ENDOCYTOSIS; DROSOPHILA; MUTATIONS; AMPHIPHYSIN; VIABILITY; DOMAINS	Synaptojanin is a nerve-terminal enriched inositol 5-phosphatase thought to function in synaptic vesicle endocytosis, in part through interactions with the Src homology 3 domain of amphiphysin. We have used synaptojanin purified from Sf9 cells after baculovirus mediated expression in overlay assays to identify two major synaptojanin-binding proteins in rat brain. The first, at 125 kDa, is amphiphysin. The second, at 40 kDa, is the major synaptojanin-binding protein detected, is highly enriched in brain, is concentrated in a soluble synaptic fraction, and co-immunoprecipitates with synaptojanin. The 40-kDa protein does not bind to a synaptojanin construct lacking the proline-rich C terminus, suggesting that its interaction with synaptojanin is mediated through an Src homology 3 domain. The 40-kDa synaptojanin-binding protein was partially purified from rat brain cytosol through a three-step procedure involving ammonium sulfate precipitation, sucrose density gradient centrifugation, and DEAE ion-exchange chromatography. Peptide sequence analysis identified the 40-kDa protein as SH3P4, a member of a novel family of Src homology 3 domain-containing proteins. These data suggest an important role for SH3P4 in synaptic vesicle endocytosis.	MCGILL UNIV,MONTREAL NEUROL INST,CBET GRP,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B4,CANADA	McGill University; McGill University								BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BAVERFEIND R, 1995, PROTEIN KINESIS DYNA, V60, P397; CATER LL, 1993, J CELL BIOL, V120, P37; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; GROSS E, 1967, METHOD ENZYMOL, V11, P403; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MORRIS SA, 1995, CURR BIOL, V5, P1; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NAKATA T, 1993, J CELL SCI, V105, P1; NOVICK P, 1989, GENETICS, V121, P659; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sossin WS, 1996, J NEUROSCI, V16, P10; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935	36	149	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8710	8716		10.1074/jbc.272.13.8710	http://dx.doi.org/10.1074/jbc.272.13.8710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079704	hybrid			2022-12-27	WOS:A1997WQ63500087
J	Kong, DC; Nossal, NG; Richardson, CC				Kong, DC; Nossal, NG; Richardson, CC			Role of the bacteriophage T7 and T4 single-stranded DNA-binding proteins in the formation of joint molecules and DNA helicase-catalyzed polar branch migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-RECOMBINATION; ASSEMBLY PROTEIN; GENE-59 PROTEIN; REPLICATION; PURIFICATION; POLYMERASE; EXCHANGE; CLONING; PRIMER	Bacteriophage T7 gene 2.5 single-stranded DNA-binding protein and gene 4 DNA helicase together promote pairing of two homologous DNA molecules and subsequent polar branch migration (Kong, D., and Richardson, C. C. (1996) EMBO J. 15, 2010-2019), In this report, we show that gene 2.5 protein is not required for the initiation or propagation of strand transfer once a joint molecule has been formed between the two DNA partners, a reaction that is mediated by the gene 2.5 protein alone. A mutant gene 2.5 protein, gene 2.5-Delta 21C protein, lacking 21 amino acid residues at its C terminus, cannot physically interact with gene 4 protein, Although it does bind to single-stranded DNA and promote the formation of joint molecule via homologous base pairing, subsequent strand transfer by gene 4 helicase is inhibited by the presence of the gene 2.5-Delta 21C protein, Bacteriophage T4 gene 32 protein likewise inhibits T7 gene 4 protein-mediated strand transfer, whereas Escherichia coli single-stranded DNA-binding protein does not, The 63-kDa gene 4 protein of phage T7 is also a DNA primase in that it catalyzes the synthesis of oligonucleotides at specific sequences during translocation on single-stranded DNA, We find that neither the rate nor extent of strand transfer is significantly affected by concurrent primer synthesis, The bacteriophage T4 gene 41 helicase has been shown to catalyze polar branch migration after the T4 gene 59 helicase assembly protein loads the helicase onto joint molecules formed by the T4 UvsX and gene 32 proteins (Salinas, F., and Kodadek, T. (1995) Cell 82, 111-119). We find that gene 32 protein alone forms joint molecules between partially single-stranded homologous DNA partners and that subsequent branch migration requires this single-stranded DNA-binding protein in addition to the gene 41 helicase and the gene 59 helicase assembly protein. Similar to the strand transfer reaction, strand displacement DNA synthesis catalyzed by T4 DNA polymerase also requires the presence of gene 32 protein in addition to the gene 41 and 59 proteins.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; NIDDK, MOL & CELLULAR BIOL LAB, NIH, BETHESDA, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BARRY J, 1994, J BIOL CHEM, V269, P33049; BERGER H, 1969, J VIROL, V3, P171, DOI 10.1128/JVI.3.2.171-175.1969; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1986, J BIOL CHEM, V261, P5663; JIANG H, 1993, J BIOL CHEM, V268, P7904; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KODADEK T, 1990, J BIOL CHEM, V265, P20966; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MEYER RR, 1979, P NATL ACAD SCI USA, V76, P1702, DOI 10.1073/pnas.76.4.1702; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Mosig Gisela, 1994, P54; NAKAI H, 1986, J BIOL CHEM, V261, P5217; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; POWLING A, 1974, MOL GEN GENET, V134, P173, DOI 10.1007/BF00268418; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA S MOL CELL BIOL, V127, P249; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SUGIMOTO K, 1988, MOL GEN GENET, V211, P400, DOI 10.1007/BF00425692; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; TOMIZAWA JI, 1966, J MOL BIOL, V21, P247, DOI 10.1016/0022-2836(66)90095-7; WACHSMAN JT, 1987, GENETICS, V115, P405; WHITTIER RF, 1981, MOL GEN GENET, V183, P341, DOI 10.1007/BF00270638; WU JR, 1973, J VIROL, V12, P758, DOI 10.1128/JVI.12.4.758-765.1973; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	49	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8380	8387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079662				2022-12-27	WOS:A1997WQ63500045
J	Yu, JP; Vassiliev, IR; Jung, YS; Golbeck, JH; McIntosh, L				Yu, JP; Vassiliev, IR; Jung, YS; Golbeck, JH; McIntosh, L			Strains of Synechocystis sp. PCC 6803 with altered PsaC .1. Mutations incorporated in the cysteine ligands of the two [4Fe-4S] clusters F-A and F-B of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP PCC-6301; SP PCC-6803; ELECTRON-TRANSFER; CORE PROTEIN; SP PCC6803; BINDING; SUBUNIT; COMPLEX; MUTANT; POTENTIALS	Two [4Fe-4S] clusters, F-A and F-B, function as terminal electron carriers in Photosystem I (PS I), a thylakoid membrane-bound protein-pigment complex. To probe the function of these two clusters in photosynthetic electron transport, site-directed mutants were created in the transformable cyanobacterium Synechocystis sp. PCC 6803. Cysteine ligands in positions 14 or 51 to F-B and F-A, respectively, were replaced with aspartate, serine, or alanine, and the effect on the genetic, physiological, and biochemical characteristics of PS I complexes from the mutant strains were studied. All mutant strains were unable to grow photoautotrophically, and compared with wild type, mixotrophic growth was inhibited under normal light intensity. The mutant cells supported lower rates of whole-chain photosynthetic electron transport. Thylakoids isolated from the aspartate and serine mutants have lower levels of PS I subunits PsaC, PsaD, and PsaE and lower rates of PS I-mediated substrate photoreduction compared with the wild type. The alanine and double aspartate mutants have no detectable levels PsaC, PsaD, and PsaE. Electron transfer rates, measured by cytochrome c(6)-mediated NADP(+) photoreduction, were lower in purified PS I complexes from the aspartate and serine mutants. By measuring the P700(+) kinetics after a single turnover flash, a large percentage of the backreaction in the aspartate and serine mutants was found to be derived from A(1) and F-X, indicating an inefficiency at the F-X --> E(A)/F-B electron transfer step. The alanine and double aspartate mutants failed to show any backreaction from [F-A/F-B](-). These results indicate that the various mutations of the cysteine 14 and 51 ligands to F-B and F-A affect biogenesis and electron transfer differently depending on the type of substitution, and that the effects of mutations on biogenesis and function can be biochemically separated and analyzed.	US DOE, PLANT RES LAB, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; UNIV NEBRASKA, GEORGE W BEADLE CTR, DEPT BIOCHEM, LINCOLN, NE 68588 USA	United States Department of Energy (DOE); Michigan State University; University of Nebraska System; University of Nebraska Lincoln				Yu, Jianping/0000-0003-0466-3197				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; ANDERSON SL, 1991, PLANT MOL BIOL, V16, P487, DOI 10.1007/BF00023416; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1997, J BIOL CHEM, V272, P8040, DOI 10.1074/jbc.272.12.8040; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannan RM, 1996, EMBO J, V15, P1826, DOI 10.1002/j.1460-2075.1996.tb00532.x; MANNAN RM, 1994, ARCH BIOCHEM BIOPHYS, V315, P68, DOI 10.1006/abbi.1994.1472; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MEHARI T, 1995, J BIOL CHEM, V270, P28108; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SMART LB, 1994, PLANT PHYSIOL, V104, P349, DOI 10.1104/pp.104.2.349; STEINMULLER K, 1992, PLANT MOL BIOL, V20, P997, DOI 10.1007/BF00027170; TAYLOR LA, 1988, NUCLEIC ACIDS RES, V16, P358, DOI 10.1093/nar/16.1.358; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; VASSILIEV IR, 1995, BIOPHYS J, V69, P1544, DOI 10.1016/S0006-3495(95)80026-3; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; YU L, 1993, BIOCHEMISTRY-US, V32, P8251, DOI 10.1021/bi00083a028; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118	39	23	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8032	8039		10.1074/jbc.272.12.8032	http://dx.doi.org/10.1074/jbc.272.12.8032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065476	hybrid			2022-12-27	WOS:A1997WP59200070
J	Si, JT; Miller, DS; Mei, L				Si, JT; Miller, DS; Mei, L			Identification of an element required for acetylcholine receptor-inducing activity (ARIA)-induced expression of the acetylcholine receptor epsilon subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMUSCULAR-JUNCTION; MESSENGER-RNA; SYNAPSES; MUSCLE; ARIA; MYOGENIN; REGION; DOMAIN	Acetylcholine Receptor (AChR)-inducing activity (ARIA) is believed to be the trophic factor utilized by motoneurons to stimulate AChR synthesis in the subsynaptic area. Among the four AChR subunit genes, the epsilon subunit gene is strictly expressed in nuclei localized to the synaptic region of the muscle. To understand mechanisms of the regulation of synapse-specific transcription, we studied the promoter activity of the 5'-flanking region of the AChR epsilon subunit gene in response to ARIA. Transgenes containing the wild type or mutant 5'-flanking regions upstream of a luciferase gene were transfected in C2C12 muscle cells. The promoter activity of these transgenes was determined by assaying activity of expressed luciferase. Analyzing a combination of 5' deletion and site-directed mutants, we identified a 10-nucleotide element (position -55/-46), which was crucial for ARIA-induced expression from the epsilon subunit promoter. This element was named ARE for ARIA-responsive element, Mutation of ARE greatly diminished ARIA-induced transgene expression and deletion of ARE abolished completely the ARIA response. Electrophoretic mobility shift analyses revealed a DNA binding activity in muscle nuclear extract that interacted with ARE. Such interaction was enhanced by ARIA stimulation of muscle cells and appeared to be dependent on nuclear protein phosphorylation.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia			Mei, Lin/G-8755-2012		NINDS NIH HHS [NS34062] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Sambrook J., 2002, MOL CLONING LAB MANU; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Walke W, 1996, J NEUROSCI, V16, P3641; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; ZHU X, 1995, EMBO J, V23, P5842	29	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10367	10371						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099674				2022-12-27	WOS:A1997WV26200008
J	Gerards, WLH; Enzlin, J; Haner, M; Hendriks, ILAM; Aebi, U; Bloemendal, H; Boelens, W				Gerards, WLH; Enzlin, J; Haner, M; Hendriks, ILAM; Aebi, U; Bloemendal, H; Boelens, W			The human alpha-type proteasomal subunit HsC8 forms a double ringlike structure, but does not assemble into proteasome-like particles with the beta-type subunits HsDelta or HsBPROS26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; 20S PROTEASOME; THERMOPLASMA-ACIDOPHILUM; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; PROSOME ANTIGENS; CDNA CLONING; RAT-LIVER; DEGRADATION; DIFFERENTIATION	The eukaryotic proteasome is a barrel-shaped protease complex made up of four seven-membered rings of which the outer and inner rings may contain up to seven different alpha- and beta-type subunits, respectively. The assembly of the eukaryotic proteasome is not well understood. We cloned the cDNA for HsC8, which is one of the seven known human alpha-type subunits, and produced the protein in Escherichia coli. Recombinant HsC8 protein forms a complex of about 540 kDa consisting of double ringlike structures, each ring containing seven subunits. Such a structure has not earlier been reported for any eukaryotic proteasome subunit, but is similar to the complex formed by the recombinant alpha-subunit of the archaebacterium Thermoplasma acidophilum (Zwickl, P., Kleinz, J., and Baumeister, W. (1994) Nat. Struct. Biol. 1, 765-770). The ability of HsC8 to form alpha-rings suggests that these complexes may play an important role in the initiation of proteasome assembly in eukaryotes. To test this, we used two human beta-type subunits, HsBPROS26 and HsDelta. Both these beta-type subunits, either in the proprotein or in the mature form, exist in monomers up to tetramers. In contrast to the alpha- and beta-subunit of T. acidophilum, coexpression of the human beta-type subunits with HsC8 does not result in the formation of proteasome-like particles, which would be in agreement with the notion that proteasome assembly in eukaryotes is much more complex than in archaebacteria.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV BASEL,BIOZENTRUM,MAURICE E MULLER INST MIKROSCOP STRUKT BIOL,CH-4056 BASEL,SWITZERLAND	Radboud University Nijmegen; University of Basel			Boelens, Wilbert/D-8877-2012					AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRIANE D, 1992, EUR J CELL BIOL, V57, P30; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; COUX O, 1994, MOL GEN GENET, V245, P769, DOI 10.1007/BF00297284; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DESA MFG, 1988, J CELL SCI, V89, P151; EASON R, 1986, CENTRIFUGATION PRACT, P251; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GERARDS WLH, 1994, FEBS LETT, V346, P151, DOI 10.1016/0014-5793(94)00454-4; GRZIWA A, 1994, EUR J BIOCHEM, V223, P1061, DOI 10.1111/j.1432-1033.1994.tb19084.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; IWAKI A, 1990, J BIOL CHEM, V265, P22197; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MORIMOTO Y, 1995, J BIOCHEM-TOKYO, V117, P471, DOI 10.1093/oxfordjournals.jbchem.a124731; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; OLINKCOUX M, 1994, J CELL SCI, V107, P353; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PAL JK, 1988, J CELL SCI, V90, P555; PATEL SD, 1994, P NATL ACAD SCI USA, V91, P296, DOI 10.1073/pnas.91.1.296; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SAXTON O, 1968, ULTRAMICROSCOPY, V4, P343; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; SCHERRER K, 1994, PROG NUCLEIC ACID RE, V49, P1; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1990, BIOCHEM BIOPH RES CO, V171, P676, DOI 10.1016/0006-291X(90)91199-3; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Thomson S, 1996, BIOCHEM J, V315, P733, DOI 10.1042/bj3150733; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	52	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10080	10086						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092552				2022-12-27	WOS:A1997WU03900071
J	Gerken, TA; Owens, CL; Pasumarthy, M				Gerken, TA; Owens, CL; Pasumarthy, M			Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide - Model proposed for the polypeptide:GalNAc transferase peptide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGALACTOSAMINE; AMINO-ACID; LINKED GLYCOPROTEINS; EDMAN DEGRADATION; D-GALACTOSAMINE; SEQUENCES; IDENTIFICATION; CONFORMATION; INVITRO; MOTIFS	The heterogeneously glycosylated 81-residue tryptic tandem repeat glycopeptide from porcine submaxillary mucin (PSM) has been isolated and its glycosylation pattern determined by amino acid sequencing. Key to these studies is the ability to trim the structurally heterogeneous PSM oligosaccharide side chains to homogeneous GalNAc monosaccharide side chains by mild trifluoromethanesulfonic acid treatment. Trypsin treatment of trifluoromethanesulfonic acid-treated PSM releases the 81-residue tandem repeat as an ensemble of 81-residue glycopeptides with different glycosylation patterns. Automated amino acid sequencing using Edman degradative chemistry of the repeat was used to determine the extent of glycosylation of nearly every Ser and Thr residue. The Thr residues are all highly glycosylated within the range of 73-90%, giving an average Thr glycosylation of 83%. In contrast, the Ser residues display a wide range of glycosylations, ranging between 33 and 95%, giving an average Ser glycosylation of 74%. These data are consistent with the known elevated glycosylation of Thr peptides over Ser peptides for the porcine UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. It is also observed that the extent of glycosylation of the repeat correlates poorly with published predictive methods. An examination of the sequences surrounding the glycosylation sites reveals that nearly all of the highly glycosylated sites have a penultimate Gly residue, whereas those that are less highly glycosylated have medium to large side chain penultimate residues. As observed by others, glycosylation also appears to be modulated by the presence of Pro residues. On the basis of these findings we suggest that the acceptor peptide binds the transferase in a beta-like conformation and that penultimate residue side chain steric interactions may play a role in determining extent that a given Ser or Thr is glycosylated. A model for the GalNAc transferase peptide binding site is proposed.	CASE WESTERN RESERVE UNIV, WA BERNBAUM CTR CYST FIBROSIS RES, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, WA BERNBAUM CTR CYST FIBROSIS RES, DEPT MOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Gerken, TA (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, BRB, WA BERNBAUM CTR CYST FIBROSIS RES, CLEVELAND, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039918, P30DK027651] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078834, P30-CA-43703] Funding Source: Medline; NIDDK NIH HHS [R01-DK-39918, P30-DK-27651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; CHOU KC, 1995, PROTEIN SCI, V4, P1365, DOI 10.1002/pro.5560040712; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DIIULIO N, 1994, GLYCOSYLATION DIS, V1, P21; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P1485, DOI 10.1021/bi00302a023; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; GERKEN TA, 1997, TECHNIQUES GLYCOBIOL, P247; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HILKENS J, 1988, Cancer Reviews, V11-12, P25; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; LORENZ C, 1992, EUR J BIOCHEM, V205, P1163, DOI 10.1111/j.1432-1033.1992.tb16886.x; MANTLE M, 1978, Biochemical Society Transactions, V6, P607; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OCONNELL BC, 1993, J DENT RES, V72, P1554, DOI 10.1177/00220345930720120401; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	50	71	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9709	9719						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092502				2022-12-27	WOS:A1997WU03900021
J	Sansom, SC; Stockand, JD; Hall, D; Williams, B				Sansom, SC; Stockand, JD; Hall, D; Williams, B			Regulation of large calcium-activated potassium channels by protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; MESANGIAL CELL; SMOOTH-MUSCLE; K+ CHANNEL; RAT-BRAIN; SERINE THREONINE; NITRIC-OXIDE; BLACK SPONGE; CALYCULIN-A; KINASE	Vasodilating agents induce relaxation of mesangial cells, in part through cGMP-mediated activation of large calcium-activated potassium channels (BKCa). Normally quiescent in cell-attached patches, the response of BKCa to nitric oxide, atrial natriuretic peptide, and dibutyryl cGMP (Bt(2)cGMP) is characterized by a biphasic increase and then decrease (''rundown'') in open probability. Using the patch clamp method in conjunction with phosphatase inhibitors, we investigated whether the run-down phase was the result of dephosphorylation by an endogenous protein phosphatase. In cell-attached patches, cantharidic acid (500 nM), okadaic acid (100 nM), and calyculin A (100 nM), nondiscriminant inhibitors of protein phosphatases 1 (PP1) and 2A (PP2A) at these concentrations, caused a significantly greater and sustained response of BKCa to Bt(2)cGMP. Within 2 min, the response of BKCa to the combination of cantharidic acid and Bt(2)cGMP was greater than the response to these agents added separately, Incubation of mesangial cells with okadaic acid for 20 min at a concentration (5 nM) specific for PP2A increased the basal open probability of BKCa and completely inhibited rundown after activation by Bt(2)cGMP. Incubation with calyculin A (10 nM), a more potent inhibitor of PP1, did not affect BKCa activity, In inside-out patches, Bt(2)cGMP plus MgATP caused a sustained activation of BKCa that was inhibited by exogenous PP2A but not PP1. It is concluded that either BKCa or a tightly associated regulator of BKCa is a common substrate for endogenous cGMP-activated protein kinase, which activates BKCa, and PP2A, which inactivates BKCa, in human mesangial cells.	UNIV TEXAS,SCH MED,DEPT INTEGRAT BIOL PHARMACOL & PHYSIOL,HOUSTON,TX 77030	University of Texas System	Sansom, SC (corresponding author), UNIV TEXAS,SCH MED,DEPT MED,DIV RENAL DIS & HYPERTENS,6431 FANNIN ST,HOUSTON,TX 77030, USA.			Stockand, James/0000-0002-3817-4319				ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; ASHIZAWA N, 1989, BIOCHEM BIOPH RES CO, V162, P971, DOI 10.1016/0006-291X(89)90768-7; BARNES GN, 1995, J NEUROCHEM, V64, P340; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GANZ MB, 1995, AM J PHYSIOL-RENAL, V37, pF1081; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; GUO H, 1993, J BIOL CHEM, V268, P11193; HADDAD GE, 1995, MOL CELL BIOCHEM, V148, P89, DOI 10.1007/BF00929507; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAFFER F, 1989, AM J PATHOL, V135, P261; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V269, pF355, DOI 10.1152/ajprenal.1995.269.3.F355; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LEE MY, 1994, PFLUG ARCH EUR J PHY, V429, P150, DOI 10.1007/BF02584044; LING BN, 1993, J CLIN INVEST, V92, P2141, DOI 10.1172/JCI116815; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MITSUI T, 1992, J BIOL CHEM, V267, P16727; PUGAZHENTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1179, P271, DOI 10.1016/0167-4889(93)90082-Z; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1995, J NEUROSCI, V15, P4572; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Sansom SC, 1996, CLIN EXP PHARMACOL P, V23, P76; SANSOM SC, 1995, J AM SOC NEPHROL, V6, P3; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; STOCKAND JD, 1994, AM J PHYSIOL-CELL PH, V267, pC1080, DOI 10.1152/ajpcell.1994.267.4.C1080; Stockand JD, 1996, AM J PHYSIOL-CELL PH, V271, pC1669, DOI 10.1152/ajpcell.1996.271.5.C1669; Stockand JD, 1996, AM J PHYSIOL-CELL PH, V270, pC1773, DOI 10.1152/ajpcell.1996.270.6.C1773; SUGANUMA M, 1992, TOXICON, V30, P873, DOI 10.1016/0041-0101(92)90385-I; Tokui T, 1996, BIOCHEM BIOPH RES CO, V220, P777, DOI 10.1006/bbrc.1996.0480; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YAKEL JL, 1992, PFLUG ARCH EUR J PHY, V420, P470, DOI 10.1007/BF00374621; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	37	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9902	9906						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092528				2022-12-27	WOS:A1997WU03900047
J	Stroup, D; Crestani, M; Chiang, JYL				Stroup, D; Crestani, M; Chiang, JYL			Orphan receptors chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) and retinoid X receptor (RXR) activate and bind the rat cholesterol 7 alpha-hydroxylase gene (CYP7A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN-1; RESPONSE ELEMENTS; THYROID-HORMONE; MESSENGER-RNA; BILE-ACIDS; EXPRESSION; LIVER; SUPERFAMILY; CLONING; ARP-1	The cholesterol 7 alpha-hydroxylase gene (CYP7A) is transcriptionally regulated by a number of factors, including hormones, bile acids, and diurnal rhythm. Previous studies have identified a region from nucleotides (nt) -74 to -55 of the rat CYP7A promoter that enhanced bile acid repression of the SV40 early promoter, as assayed with a luciferase reporter gene in transiently transfected HepG2 cells. The rat CYP7A promoter/reporter activity was strongly stimulated by cotransfection with an expression plasmid encoding the nuclear hormone receptor chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) in a dose-dependent manner. Site-directed mutagenesis in the region of nt -74 to -55 altered this stimulation. Recombinant COUP-TFII expressed in HepG2 or COS-1 cells were found to bind to nt -74 -55 and nt -149 -128 probes by electrophoretic mobility shift assay (EMSA) and by supershifting the corresponding band with COUP-TFII-specific antibodies. The region of nt -176 -117 was previously mapped as a retinoic acid response region and was found to bind retinoid X receptor (RXR). EMSA supershift assays of wild-type and mutant oligomers using antibody against RXR revealed that the sequences between nt -145 and -134 were important for RXR binding. We conclude that COUP-TFII stimulates the transcriptional activity of the rat CYP7A promoter by binding to the sequences between nt -74 to -54 and nt -149 to -128. RXR may stimulate CYP7A gene transcription by binding to a direct repeat of the hormone response element separated by one nucleotide located at nt -146 -134.	NE OHIO UNIV,COLL MED,DEPT BIOCHEM & MOL PATHOL,ROOTSTOWN,OH 44272	Northeast Ohio Medical University (NEOMED)				Chiang, John/0000-0001-9360-7650; Crestani, Maurizio/0000-0001-9230-1078	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044442, R56DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09156] Funding Source: Medline; NIDDK NIH HHS [DK44442, R01 DK044442] Funding Source: Medline; NIGMS NIH HHS [GM31584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chiang J.Y., 1996, ADV MOL CELL BIOL, V14, P269, DOI [10.1016/S1569-2558(08)60347-1, DOI 10.1016/S1569-2558(08)60347-1]; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHIANG JYL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P337, DOI 10.1016/0167-4781(92)90175-Y; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; Crestani M, 1996, BIOCHEM BIOPH RES CO, V225, P585, DOI 10.1006/bbrc.1996.1215; CRESTANI M, 1995, J LIPID RES, V36, P2419; DENT CD, 1993, TRANSCRIPTION FACTOR, P10; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAUDET F, 1995, J BIOL CHEM, V270, P29916; GE RW, 1994, J BIOL CHEM, V269, P13185; ING NH, 1992, J BIOL CHEM, V267, P17617; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KIMURA A, 1993, J BIOL CHEM, V268, P11125; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE YH, 1994, J BIOL CHEM, V269, P14681; LI YC, 1990, J BIOL CHEM, V265, P12012; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; Sambrook J., 1989, MOL CLONING LAB MANU; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; Soosaar A, 1996, FEBS LETT, V391, P95, DOI 10.1016/0014-5793(96)00711-9; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang DP, 1996, J LIPID RES, V37, P1831	30	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9833	9839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092518				2022-12-27	WOS:A1997WU03900037
J	Eklund, EA; Kakar, R				Eklund, EA; Kakar, R			Identification and characterization of TF1(phox), a DNA-binding protein that increases expression of gp91(phox) in PLB985 myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; INTERFERON-STIMULATED GENES; TRANSCRIPTION FACTOR IRF-2; REGULATORY FACTOR-I; PROMOTER ELEMENT; INDUCIBLE GENES; CYTOCHROME-B; HISTONE GENE; Y-BOX	The CYBB gene encodes gp91(phox), the heavy chain of the phagocyte-specific NADPH oxidase. CYBB is transcriptionally inactive until the promyelocyte stage of myelopoiesis, and in mature phagocytes, expression of gp91(phox) is further increased by interferon-gamma (IFN-gamma) and other inflammatory mediators. The CYBB promoter region contains several lineage-specific cis-elements involved in the IFN-gamma response. We screened a leukocyte cDNA expression library for proteins able to bind to one of these cis-elements (-214 to -262 base pairs) and identified TF1(phox), a protein with sequence-specific binding to the CYBB promoter. Electrophoretic mobility shift assay with nuclear proteins from a variety of cell lines demonstrated binding of a protein to the CYBB promoter that was cross-immunoreactive with TF1(phox), DNA binding of this protein was increased by IFN-gamma treatment in the myeloid cell line PLB985, but not in the non-myeloid cell line HeLa. Overexpression of recombinant TF1(phox) in PLB985 cells increased endogenous gp91(phox) message abundance, but did not lead to cellular differentiation. Overexpression of TF1(phox) in myeloid leukemia cell lines increased reporter gene expression from artificial promoter constructs containing CYBB promoter sequence, These data suggested that TF1(phox) increased expression of gp91(phox).	UNIV ALABAMA,SCH MED,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), UNIV ALABAMA,LURLEEN B WALLACE TUMOR INST,DEPT HEMATOL & ONCOL,SCH MED,WT1554,1824 6TH AVE S,BIRMINGHAM,AL 35294, USA.				NHLBI NIH HHS [HL54000, K08HL0313] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BRADLEY TR, 1982, BRIT J HAEMATOL, V51, P595, DOI 10.1111/j.1365-2141.1982.tb02823.x; CASSATELLA MA, 1986, J CLIN INVEST, V83, P1570; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEWALD B, 1979, J CLIN INVEST, V63, P21, DOI 10.1172/JCI109273; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; EKLUND EA, 1995, GENE, V155, P231, DOI 10.1016/0378-1119(94)00898-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEY GO, 1952, CANCER RES, V12, P264; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KOZAK M, 1986, CELL, V44, P23; LARRICK JW, 1980, J IMMUNOL, V125, P6; LETO TL, 1990, SCIENCE, V248, P724; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH CIE, 1995, ANN MED, V27, P477; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TUCKER KA, 1987, BLOOD, V70, P327; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	63	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9344	9355						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083071				2022-12-27	WOS:A1997WU03700076
J	Geilen, GC; Bektas, M; Wieder, T; Kodelja, V; Goerdt, S; Orfanos, CE				Geilen, GC; Bektas, M; Wieder, T; Kodelja, V; Goerdt, S; Orfanos, CE			1 alpha,25-dihydroxyvitamin D-3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID BREAKDOWN PRODUCTS; PSORIATIC SKIN; DNA FRAGMENTS; HL-60 CELLS; TNF-ALPHA; VITAMIN-D; CERAMIDE; DIFFERENTIATION; IDENTIFICATION; RECEPTOR	Treatment of the human keratinocyte cell Line HaCaT with 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) resulted in the hydrolysis of sphingomyelin with peak elevations of ceramide levels after 2-3 h (Geilen, C. C., Bektas, M., Wieder, Th., and Orfanos, C. E. (1996) FEBS Lett. 378; 88-92). In the present paper, the mechanism underlying the effect of 1,25-(OH)(2)D-3 on sphingomyelin hydrolysis was investigated. Using the cell culture supernatant of HaCaT cells treated with 1,25-(OH)(2)D-3 for 2 h, it was possible to induce sphingomyelin hydrolysis as early as 30-60 min after addition to resting cells. Several lines of experimental evidence indicated that tumor necrosis factor alpha (TNF alpha) mediates sphingomyelin hydrolysis after 1,25-(OH)(2)D-3 treatment: (i) 1,25-(OH)(2)D-3 stimulated TNF alpha mRNA expression after 1 h, (ii) newly synthesized TNF alpha occurred 2 h after 1,25-(OH)(2)D-3 treatment, (iii) indirect activation of sphingomyelin hydrolysis by the supernatant of 1,25-(OH)(2)D-3-titrate HaCaT cells was abolished by preincubation of the supernatant with antibodies directed against TNF alpha, and (iv) preincubation of HaCaT cells with neutralizing antibodies directed against the 55-kDa receptor of TNF alpha blocked the ability of 1,25-(OH)(2)D-3 to induce sphingomyelin hydrolysis in HaCaT cells. These data demonstrate that 1,25-(OH)(2)D-3 activated sphingomyelin hydrolysis by an autocrine mechanism via TNF alpha expression. Furthermore, this indirect mode of action may serve as an explanation for the delayed induction of sphingomyelin hydrolysis by vitamin D-3.	FREE UNIV BERLIN,UNIV MED CTR BENJAMIN FRANKLIN,INST MOL BIOL & BIOCHEM,D-12200 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Geilen, GC (corresponding author), FREE UNIV BERLIN,UNIV MED CTR BENJAMIN FRANKLIN,DEPT DERMATOL,HINDENBURGDAMM 30,D-12200 BERLIN,GERMANY.							BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P72; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLDE G, 1992, ARCH DERMATOL RES, V284, P154, DOI 10.1007/BF00372709; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHIAS S, 1993, SCIENCE, V259, P519; MILDE P, 1991, J INVEST DERMATOL, V97, P230, DOI 10.1111/1523-1747.ep12480255; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OKUDA KI, 1995, J LIPID RES, V36, P1641; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; Wu SL, 1996, J NUTR BIOCHEM, V7, P642, DOI 10.1016/S0955-2863(96)00125-8; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	32	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8997	9001						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083023				2022-12-27	WOS:A1997WU03700028
J	Hamai, A; Hashimoto, N; Mochizuki, H; Kato, F; Makiguchi, Y; Horie, K; Suzuki, S				Hamai, A; Hashimoto, N; Mochizuki, H; Kato, F; Makiguchi, Y; Horie, K; Suzuki, S			Two distinct chondroitin sulfate ABC lyases - An endoeliminase yielding tetrasaccharides and an exoeliminase preferentially acting on oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASAL CARTILAGE PROTEOGLYCAN; SWARM RAT CHONDROSARCOMA; STRUCTURAL-ANALYSIS; DERMATAN SULFATE; PROTEUS-VULGARIS; LINKAGE REGION; CHAINS; POLYSACCHARIDE; ANTIBODIES; DIGESTION	Crude enzyme obtained from chondroitin sulfate-induced Proteus vulgaris NCTC 4636 has been fractionated into 1) an endoeliminase capable of depolymerizing chondroitin sulfate and related polysaccharides to produce, as end products, a mixture of Delta(4)-unsaturated tetra- and disaccharides and 2) an exoeliminase preferentially acting on chondroitin sulfate tetra- and hexasaccharides to yield the respective disaccharides. Isolation of the two enzymes was achieved by a simple two-step procedure: extracting the enzymes from intact P. vulgaris cells with a buffer solution of nonionic surfactant and then treating the extract by cation-exchange chromatography. Each of the enzymes thus prepared was apparently homogeneous as assessed by SDS-polyacrylamide gel electrophoresis and readily crystallized from polyethylene glycol solutions. Both enzymes acted on various substrates such as chondroitin sulfate, chondroitin sulfate proteoglycan, and dermatan sulfate at high, but significantly different, initial rates. They also attacked hyaluronan but at far lower rates and were inactive to keratan sulfate, heparan sulfate, and heparin. Our results show that the known ability of the conventional enzyme called ''chondroitinase ABC'' to catalyze the complete depolymerization of chondroitin sulfates to unsaturated disaccharides may actually result from the combination reactions by endoeliminase (chondroitin sulfate ABC endolyase) and exoeliminase (chondroitin sulfate ABC exolyase).	AICHI MED UNIV,INST MOL SCI MED,NAGAKUTE,AICHI 40811,JAPAN	Aichi Medical University	Hamai, A (corresponding author), SEIKAGAKU CORP,TOKYO RES INST,TATENO 3-1253,TOKYO 207,JAPAN.							BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CATERSON B, 1990, J CELL SCI, V97, P411; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CHRISTNER JE, 1980, J BIOL CHEM, V255, P7102; EURELL JAC, 1990, CLIN ORTHOP RELAT R, V256, P238; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HASCALL VC, 1972, J BIOL CHEM, V247, P4529; HASHIMOTO N, 1993, Patent No. 576294; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; KHANDKE KM, 1995, Patent No. 29256; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; OUCHTERLONY O, 1948, ARK KEMI MINERAL G B, V26, P1; RODEN L, 1972, METHODS ENZYMOLOGY B, V28, P638; RYAN MJ, 1994, Patent No. 25567; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANDERSON PN, 1989, BIOCHEM J, V257, P347, DOI 10.1042/bj2570347; SATO N, 1994, APPL MICROBIOL BIOT, V41, P39, DOI 10.1007/s002530050104; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; Sugimura T, 1996, SPINE, V21, P161, DOI 10.1097/00007632-199601150-00001; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1995, GLYCOCONJUGATE J, V12, P488; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	34	143	164	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9123	9130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083041				2022-12-27	WOS:A1997WU03700046
J	Szabo, C; FerrerSueta, G; Zingarelli, B; Southan, GJ; Salzman, AL; Radi, R				Szabo, C; FerrerSueta, G; Zingarelli, B; Southan, GJ; Salzman, AL; Radi, R			Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; ISCHEMIA-REPERFUSION; LIPID-PEROXIDATION; FREE-RADICALS; DNA-DAMAGE; SUPEROXIDE; INJURY; KINETICS; CELLS; NEUROTOXICITY	Nitric oxide (NO) produced by the inducible nitric-oxide synthase (iNOS) is responsible for some of the pathophysiological alterations during inflammation. Part of NO-related cytotoxicity is mediated by peroxynitrite, an oxidant species produced from NO and superoxide. Aminoguanidine and mercaptoethylguanidine (MEG) are inhibitors of iNOS and have anti-inflammatory properties. Here we demonstrate that MEG and related compounds are scavengers of peroxynitrite. MEG caused a dose-dependent inhibition of the peroxynitrite-induced oxidation of cytochrome c(2+), hydroxylation of benzoate, and nitration of 4-hydroxyphenylacetic acid. MEG reacts with peroxynitrite with a second-order rate constant of 1900 +/- 64 M(-1) s(-1) at 37 degrees C. In cultured macrophages, MEG reduced the suppression of mitochondrial respiration and DNA single strand breakage in response to peroxynitrite. MEG also reduced the degree of vascular hyporeactivity in rat thoracic aortic rings exposed to peroxynitrite. The free thiol plays an important role in the scavenging effect of MEG. Aminoguanidine neither affected the oxidation of cytochrome c(2+) nor reacted with ground state peroxynitrite, but inhibited the peroxynitrite-induced benzoate hydroxylation and 4-hydroxyphenylacetic acid nitration, indicating that it reacts with activated peroxynitrous acid or nitrogen dioxide. Compounds that act both as iNOS inhibitors and peroxynitrite scavengers may be useful anti-inflammatory agents.	UNIV REPUBLICA,FAC MED,DEPT BIOCHEM,MONTEVIDEO 11800,URUGUAY	Universidad de la Republica, Uruguay	Szabo, C (corresponding author), CHILDRENS HOSP,MED CTR,DIV CRIT CARE,3333 BURNET AVE,CINCINNATI,OH 45229, USA.		Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013; , Basilia/AAV-7582-2021; Ferrer-Sueta, Gerardo/C-3316-2011	Ferrer-Sueta, Gerardo/0000-0002-8663-8480				BAKER MS, 1984, ARCH BIOCHEM BIOPHYS, V234, P258, DOI 10.1016/0003-9861(84)90348-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Briviba K, 1996, BIOCHEM J, V319, P13, DOI 10.1042/bj3190013; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P8992, DOI 10.1073/pnas.90.19.8992; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Denicola A, 1996, P 3 ANN M OX SOC OX, P73; DOHERTY DG, 1957, RADIAT RES, V7, P13, DOI 10.2307/3570550; FAGNI L, 1994, PROG BRAIN RES, V103, P381; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HU P, 1994, AM J PHYSIOL, V266, pL628, DOI 10.1152/ajplung.1994.266.6.L628; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; ISCHIROPOULOS H, 1995, AM J PHYSIOL-LUNG C, V269, pL158, DOI 10.1152/ajplung.1995.269.2.L158; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KOLLMANN G, 1966, RADIAT RES, V27, P474, DOI 10.2307/3571966; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MATSUMOTO H, 1996, CHEM RES TOXICOL, V9, P262; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; NASEEM SA, 1995, J MOL CELL CARDIOL, V27, P419, DOI 10.1016/S0022-2828(08)80038-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, METHOD ENZYMOL, V269, P354; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SCHULZ R, 1995, CARDIOVASC RES, V30, P432; Southan GJ, 1996, BRIT J PHARMACOL, V117, P619, DOI 10.1111/j.1476-5381.1996.tb15236.x; SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; SZABO C, 1995, FEBS LETT, V363, P235, DOI 10.1016/0014-5793(95)00322-Z; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Szabo C, 1995, New Horiz, V3, P2; SZABO C, 1995, BIOCHEM BIOPH RES CO, V209, P739, DOI 10.1006/bbrc.1995.1561; SZABO C, 1996, P NATL ACAD SCI USA, V118, P1659; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; WOORALL NK, 1995, J EXP MED, V181, P63; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; Zingarelli B, 1996, J IMMUNOL, V156, P350; ZINGARELLI B, 1997, CRIT CARE MED S, V5, P138	66	159	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9030	9036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083027				2022-12-27	WOS:A1997WU03700032
J	Bockamp, EO; McLaughlin, F; Gottgens, B; Murrell, AM; Elefanty, AG; Green, AR				Bockamp, EO; McLaughlin, F; Gottgens, B; Murrell, AM; Elefanty, AG; Green, AR			Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-2; DNA-BINDING PROTEIN; SCL GENE-PRODUCT; LOOP-HELIX GENE; ENDOTHELIAL-CELLS; MICE LACKING; TAL-1 GENE; STEM-CELLS; DIFFERENTIATION; PROMOTER	The SCL/tal-1 gene (hereafter designated SCL) encodes a basic helix-loop-helix transcription factor which is pivotal for the normal development of all hematopoietic lineages and which is expressed in committed erythroid, mast, and megakaryocytic cells as well as in hematopoietic stem cells. The molecular basis for expression of SCL in stem cells and its subsequent modulation during lineage commitment is of fundamental importance for understanding how early ''decisions'' are made during hematopoiesis. We now compare the activity of SCL promoters 1a and 1b in erythroid cells and in CD34 positive primitive myeloid cells. SCL mRNA expression in CD34 positive myeloid cells did not require GATA-1. Promoter 1a activity was weak. or absent in CD34 positive myeloid cells and appeared to correlate with the presence or absence of low levels of GATA-1, However, promoter 1b, which was silent in committed erythroid cells, was strongly active in transient assays using CD34 positive myeloid cells, and functioned in a GATA-independent manner. Interestingly, RNase protection assays demonstrated that endogenous promoter 1b was active in both erythroid and CD34 positive myeloid cells. These results demonstrate that fundamentally different mechanisms regulate the SCL promoter region in committed erythroid cells and in CD34 positive myeloid cells. Moreover these observations suggest that in erythroid, but not in CD34 positive myeloid cells, promoter 1b required integration in chromatin and/or additional sequences for its activity, Stable transfection experiments showed that both core promoters were silent following integration in erythroid or CD34 positive myeloid cells. Our data therefore indicate that additional regulatory elements were necessary for both SCL promoters to overcome chromatin-mediated repression.	UNIV CAMBRIDGE, DEPT HAEMATOL, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA	MRC Laboratory Molecular Biology; University of Cambridge; Walter & Eliza Hall Institute			Elefanty, Andrew G/A-6066-2008	Green, Anthony/0000-0002-9795-0218; Elefanty, Andrew/0000-0001-6448-8314; Gottgens, Berthold/0000-0001-6302-5705; Bockamp, Ernesto/0000-0002-6181-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1991, ONCOGENE, V6, P1477; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOCKAMP EO, 1994, BIOESSAYS, V16, P481, DOI 10.1002/bies.950160707; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CROSS MA, 1994, ONCOGENE, V9, P3013; DEXTER TM, 1979, NATURE, V277, P471, DOI 10.1038/277471a0; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DZIENNIS S, 1995, BLOOD, V85, P319; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HWANG LY, 1993, ONCOGENE, V8, P3043; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEONARD M, 1993, BLOOD, V82, P1071; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MAY G, 1995, EMBO J, V14, P564, DOI 10.1002/j.1460-2075.1995.tb07032.x; MITSUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V11, P131; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG F, 1995, BIOTECHNIQUES, V18, P1034	55	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8781	8790		10.1074/jbc.272.13.8781	http://dx.doi.org/10.1074/jbc.272.13.8781			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079714	hybrid			2022-12-27	WOS:A1997WQ63500097
J	Frech, M; Andjelkovic, M; Ingley, E; Reddy, KK; Falck, JR; Hemmings, BA				Frech, M; Andjelkovic, M; Ingley, E; Reddy, KK; Falck, JR; Hemmings, BA			High affinity binding of inositol phosphates and phosphoinositides to the Pleckstrin homology domain of RAC protein kinase B and their influence on kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; INSULIN; AKT; POLYPHOSPHOINOSITIDES; 3,4,5-TRISPHOSPHATE; ACTIVATION; RECEPTORS; FAMILY	The influence of inositol phosphates and phosphoinositides on the alpha isoform of the RAG-protein kinase B (RAC/PKB) was studied using purified wild type and mutant kinase preparations and a recombinant pleckstrin homology (PH) domain, Binding of inositol phosphates and phosphoinositides to the PH domain was measured as the quenching of intrinsic tryptophan fluorescence, Inositol phosphates and D3-phosphorylated phosphoinositides bound with affinities of 1-10 mu M and 0.5 mu M, respectively. Similar values were obtained using RAC/PKB expressed and purified from baculovirus-infected Sf9 cells in the fluorescence assay. The influence of synthetic dioctanoyl derivatives of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate on the activity of RAC/PKB purified from transfected COS-1 cells was studied. Phosphatidylinositol 3,4,5-trisphosphate was found to inhibit the RAC/PKB kinase activity with half-maximal inhibition at 2.5 mu M. In contrast, phosphatidylinositol 3,4-bisphosphate stimulated kinase activity (half-maximal stimulation at 2.5 mu M). A mutant RAC/PKB protein lacking the PH domain was not affected by D3-phosphorylated phosphoinositides. These results demonstrate that the PH domain of RAC/PKB binds inositol phosphates and phosphoinositides with high affinity, and suggest that the products of the phosphatidylinositide 3-kinase can act as both a membrane anchor and modulator of RAC/PKB activity. The data also provide further evidence for a link between phosphatidylinositide 3-kinase and RAC/PKB regulation.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	Friedrich Miescher Institute for Biomedical Research; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ingley, Evan/C-2401-2013	Ingley, Evan/0000-0002-8112-9134; Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P310; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLEY E, 1995, PROTEIN KINASE FACTS, P95; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	41	349	359	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8474	8481		10.1074/jbc.272.13.8474	http://dx.doi.org/10.1074/jbc.272.13.8474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079675	hybrid, Green Published			2022-12-27	WOS:A1997WQ63500058
J	Gacad, MA; Chen, H; Arbelle, JE; LeBon, T; Adams, JS				Gacad, MA; Chen, H; Arbelle, JE; LeBon, T; Adams, JS			Functional characterization and purification of all intracellular vitamin D-binding protein in vitamin D-resistant New World primate cells - Amino acid sequence homology with proteins in the HSP-70 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; 1,25-DIHYDROXYVITAMIN D3; SQUIRREL-MONKEY; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID RESISTANCE; SOLANUM-MALACOXYLON; LOW AFFINITY; RECEPTOR; METABOLISM; MARMOSET	Most genera of New World primates exhibit resistance to vitamin D. These monkeys harbor high circulating concentrations of the prohormone 25-hydroxyvitamin D and the active vitamin D hormone 1,25-dihydroxyvitamin D, Previous work from this laboratory indicated that resistance is associated with the overexpression of a 60-65-kDa intracellular protein that binds vitamin D metabolites competitively, In the current studies 25-[H-3]hydroxyvitamin D-3 (25-OHD3) was used as a competitive ligand to investigate the ability of a number of small lipid molecules to interact with this intracellular vitamin D-binding protein (IDBP) in post-nuclear extracts of a prototypical lymphoblast cell line from the common marmoset, a vitamin D-resistant New World primate, Only those vitamin D metabolites with a hydroxyl moiety in the C-25 position were bound by IDBP, Disruption of the C-25 hydroxyl obviated binding, whereas more proximal alterations in the vitamin D side chain did not. Modifications in the A-ring of 25-hydroxylated vitamin D metabolites, most specifically hydroxylation of C-l, diminished but did not abolish ligand binding, Of more than two dozen other small lipid molecules examined, only the C-19 17-hydroxysteroids 17 beta-estradiol and testosterone, and the C-21 steroid progesterone were found to be capable of binding specifically to IDBP. Using a combination of physical and serial chromatographic techniques, we enriched IDBP 25-OHD, binding activity 17,588-fold in extracts of B95-8 cells. Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis of this purified fraction demonstrated a predominant 65-kDa molecular species with a pI similar to 4.5, Seven different peptide fragments were isolated from the 65-kDa protein, each possessing sequence similarity to the hsp-70 family of proteins, Ligand binding analyses confirmed that human inducibly expressed hsp-70-bound 25-OHD, with approximately similar affinity (similar to 10(-7) M) as did purified IDBP. In summary, these results suggest a novel action for the hsp-70 family of proteins as intracellular vitamin D- and gonadal steroid hormone-binding molecules.	UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI BURNS & ALLEN RES INST,LOS ANGELES,CA 90048; CITY HOPE HOSP & MED CTR,BECKMAN RES INST,LOS ANGELES,CA 92714	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope			Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NIAMS NIH HHS [AR-37399] Funding Source: Medline; NIDDK NIH HHS [DK-07682] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037399] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JS, 1988, J CLIN ENDOCR METAB, V66, P224, DOI 10.1210/jcem-66-1-224; ADAMS JS, 1985, AM J PRIMATOL, V9, P219, DOI 10.1002/ajp.1350090307; ADAMS JS, 1985, ENDOCRINOLOGY, V116, P2523, DOI 10.1210/endo-116-6-2523; ADAMS JS, 1984, J STEROID BIOCHEM, V20, P857, DOI 10.1016/0022-4731(84)90396-0; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BOLAND RL, 1986, NUTR REV, V44, P1, DOI 10.1111/j.1753-4887.1986.tb07543.x; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BOUILLON R, 1976, BIOCHEM J, V159, P463, DOI 10.1042/bj1590463; BOULANGER J, 1995, J CELL PHYSIOL, V165, P7, DOI 10.1002/jcp.1041650103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDON DD, 1991, J MOL ENDOCRINOL, V7, P89, DOI 10.1677/jme.0.0070089; BRANDON DD, 1989, CANCER RES, V49, pS2203; CHROUSOS GP, 1984, J CLIN ENDOCR METAB, V58, P516, DOI 10.1210/jcem-58-3-516; CHROUSOS GP, 1984, ENDOCRINOLOGY, V115, P25, DOI 10.1210/endo-115-1-25; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; Coe, 1985, HDB SQUIRREL MONKEY, P191; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; GACAD MA, 1992, AM J PRIMATOL, V28, P263, DOI 10.1002/ajp.1350280404; GACAD MA, 1991, J CLIN INVEST, V87, P996, DOI 10.1172/JCI115108; GACAD MA, 1993, J BONE MINER RES, V8, P27; GACAD MA, 1992, ENDOCRINOLOGY, V131, P2581, DOI 10.1210/en.131.6.2581; GACAD MA, 1990, CLIN RES, V38, P120; GACAD MA, 1990, J BONE MINER RES, V5, pS198; HAMMAMI MM, 1991, J CLIN ENDOCR METAB, V73, P326, DOI 10.1210/jcem-73-2-326; HAMMOND GL, 1994, ENDOCRINOLOGY, V134, P891, DOI 10.1210/en.134.2.891; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; KLOSTERMAN LL, 1986, ENDOCRINOLOGY, V118, P424, DOI 10.1210/endo-118-1-424; KOCHA T, 1989, BIOCHIM BIOPHYS ACTA, V991, P56, DOI 10.1016/0304-4165(89)90028-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; LIBERMAN UA, 1985, FEBS LETT, V182, P385, DOI 10.1016/0014-5793(85)80338-0; MALLOY PJ, 1989, J CLIN ENDOCR METAB, V68, P263, DOI 10.1210/jcem-68-2-263; MARX SJ, 1989, J CLIN ENDOCR METAB, V69, P1282, DOI 10.1210/jcem-69-6-1282; MOORE CCD, 1993, ENDOCRINOLOGY, V133, P368, DOI 10.1210/en.133.1.368; MOOS M, 1988, J BIOL CHEM, V263, P6005; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKUDA KI, 1995, J LIPID RES, V36, P1641; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PHILBEAM D, 1984, SCI AM, V250, P84; RAO US, 1990, J BIOL CHEM, V265, P7227; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SHINKI T, 1983, BIOCHEM BIOPH RES CO, V114, P452, DOI 10.1016/0006-291X(83)90801-X; SKLIAR MI, 1992, J STEROID BIOCHEM, V43, P677, DOI 10.1016/0960-0760(92)90293-R; TAKAHASHI N, 1985, BIOCHEM J, V227, P555, DOI 10.1042/bj2270555; TOMITA M, 1986, J CLIN ENDOCR METAB, V62, P1145, DOI 10.1210/jcem-62-6-1145; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WASSERMAN RH, 1976, SCIENCE, V194, P853, DOI 10.1126/science.982048	50	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8433	8440		10.1074/jbc.272.13.8433	http://dx.doi.org/10.1074/jbc.272.13.8433			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079669	hybrid			2022-12-27	WOS:A1997WQ63500052
J	Morrisey, EE; Ip, HS; Tang, ZH; Parmacek, MS				Morrisey, EE; Ip, HS; Tang, ZH; Parmacek, MS			GATA-4 activates transcription via two novel domains that are conserved within the GATA-4/5/6 subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING FACTOR; SERUM RESPONSE FACTOR; HEAVY-CHAIN GENE; TROPONIN-C GENE; DNA-BINDING; ENDOTHELIAL-CELLS; DEVELOPING HEART; MAMMALIAN-CELLS; SKELETAL-MUSCLE; CARDIAC DEVELOPMENT	GATA-4 is one of the earliest developmental markers of the precardiac mesoderm, heart, and gut and has been shown to activate regulatory elements controlling transcription of genes encoding cardiac-specific proteins, To elucidate the molecular mechanisms underlying the transcriptional activity of the GATA-4 protein, structure-function analyses were performed. These analyses revealed that the C-terminal zinc finger and adjacent basic domain of GATA-4 is bifunctional, modulating both DNA-binding and nuclear localization activities, The N terminus of the protein encodes two independent transcriptional Activation Domains (amino acids 1-74 and amino acids 130-177). Amino acid residues were identified within each domain that are required for transcriptional activation, Finally, we have shown that regions of Xenopus GATA-5 and -6 corresponding to Activation Domains I and II, respectively, function as potent transcriptional activators. The identification and functional characterization of two evolutionarily conserved transcriptional Activation Domains within the GATA-4/5/6 subfamily suggests that each of these domains modulates critical functions in the transcriptional regulatory program(s) encoded by GATA-4, -5, and -6 during vertebrate development. As such these data provide novel insights into the molecular mechanisms that control development of the heart.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago				Ip, Hon/0000-0003-4844-7533	NHLBI NIH HHS [1R01HL51145] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051145] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Bielinska M, 1996, BLOOD, V88, P3720, DOI 10.1182/blood.V88.10.3720.bloodjournal88103720; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KELLEY C, 1993, DEVELOPMENT, V118, P817; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE ME, 1991, J BIOL CHEM, V266, P16188; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LIU SH, 1993, J BIOL CHEM, V268, P21147; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; MORRISEY EE, 1997, IN PRESS DEV BIOL; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Ross RS, 1996, DEVELOPMENT, V122, P1799; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201; ZON LI, 1991, J BIOL CHEM, V266, P22948	56	110	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8515	8524		10.1074/jbc.272.13.8515	http://dx.doi.org/10.1074/jbc.272.13.8515			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079680	hybrid			2022-12-27	WOS:A1997WQ63500063
J	Salinas, M; deWeille, J; Guillemare, E; Lazdunski, M; Hugnot, JP				Salinas, M; deWeille, J; Guillemare, E; Lazdunski, M; Hugnot, JP			Modes of regulation of Shab K+ channel activity by the Kv8.1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; POTASSIUM CHANNEL; MESSENGER-RNA; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; INACTIVATION; SHAKER; GENE; MECHANISMS; PATTERNS	The Rv8.1 subunit is unable to generate K+ channel activity in Xenopus oocytes or in COSm6 cells. The Kv8.1 subunit expressed at high levels acts as a specific suppressor of the activity of Kv2 and Kv3 channels in Xenopus oocytes (Hugnot, J. P., Salinas, M., Lesage, F., Guillemare, E., Weille, J., Heurteaux, C., Mattei, M. G., and Lazdunski, M. (1996) EMBO J. 15, 3322-3331). At lower levels, Kv8.1 associates with Kv2.1 and Kv2.2 to form hybrid Kv8.1/Kv2 channels, which have new biophysical properties and more particularly modified properties of the inactivation process as compared with homopolymers of Kv2.1 or Kv2.2 channels. The same effects have been seen by coexpressing the Kv8.1 subunit and the Kv2.2 subunit in COSm6 cells. In these cells, Kv8.1 expressed alone remains in intracellular compartments, but it can reach the plasma membrane when it associates with Kv2.2, and it then also forms new types of Kv8.1/Kv2.2 channels. Present results indicate that Kv8.1 when expressed at low concentrations acts as a modifier of Kv2.1 and Kv2.2 activity, while when expressed at high concentrations in oocytes it completely abolishes Kv2.1, Kv2.2, or Kv3.4 K+ channel activity. The S6 segment of Kv8.1 is atypical and contains the structural elements that modify inactivation of Kv2 channels.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			de Weille, Jan R/F-8103-2014; SALINAS, Miguel/N-6380-2016	de Weille, Jan R/0000-0002-0505-3166; SALINAS, Miguel/0000-0002-7445-123X				ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; ALBRECHT B, 1993, RECEPTOR CHANNEL, V1, P99; ATTALI B, 1993, J BIOL CHEM, V268, P24283; CHANDY KG, 1995, VOLTAGE GATED K PLUS; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CHRISTIE MJ, 1990, NEURON, V2, P405; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DREWE JA, 1992, J NEUROSCI, V12, P538; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1989, BIOPHYS J, V55, P203, DOI 10.1016/S0006-3495(89)82793-6; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P473, DOI 10.1113/jphysiol.1952.sp004718; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; HWANG PM, 1993, NEUROSCIENCE, V55, P613, DOI 10.1016/0306-4522(93)90427-H; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Luthi A, 1996, J NEUROSCI, V16, P586; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PONGS O, 1993, TRENDS PHARMACOL SCI, V14, P435, DOI 10.1016/0165-6147(93)90182-J; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	41	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8774	8780		10.1074/jbc.272.13.8774	http://dx.doi.org/10.1074/jbc.272.13.8774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079713	hybrid			2022-12-27	WOS:A1997WQ63500096
J	Seeger, M; Ferrell, K; Frank, R; Dubiel, W				Seeger, M; Ferrell, K; Frank, R; Dubiel, W			HIV-1 Tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; MULTICATALYTIC PROTEASE; MOLECULAR-CLONING; DEGRADATION; UBIQUITIN; EXPRESSION; INTERACTS; SUBUNITS; COMPLEX	The proteasomal system consists of a proteolytic core, the 20 S proteasome, which associates in an ATP-dependent reaction with the 19 S regulatory complex to form the functional 26 S proteasome. In the absence of ATP, the 20 S proteasome forms a complex with the gamma-interferon-inducible 11 S regulator. Both the 20 S proteasome and the 11 S regulator have been implied in the generation of antigenic peptides. The human immunodeficiency virus (HIV)-1 Tat protein causes a number of different effects during acquired immunodeficiency syndrome (AIDS). Here we show that HIV-1 Tat protein strongly inhibits the peptidase activity of the 20 S proteasome and that it interferes with formation of the 20 S proteasome-11 S regulator complex. In addition, it slightly increases the activity of purified 26 S proteasome. These results may explain the mechanism by which HIV-1-infected cells escape cytotoxic T lymphocyte response and at least in part immunodeficiency in AIDS patients.	HUMBOLDT UNIV BERLIN,FAC MED,INST BIOCHEM,D-10117 BERLIN,GERMANY; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY	Humboldt University of Berlin; Ruprecht Karls University Heidelberg				Dubiel, Wolfgang/0000-0002-3393-0701				CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; KOSTER AJ, 1995, MOL BIOL REP, V21, P11, DOI 10.1007/BF00990965; KRAFT M, 1995, PEPTIDES 1994, P349; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	27	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8145	8148		10.1074/jbc.272.13.8145	http://dx.doi.org/10.1074/jbc.272.13.8145			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079628	hybrid			2022-12-27	WOS:A1997WQ63500011
J	Zhou, ZF; Corden, JL; Brown, TR				Zhou, ZF; Corden, JL; Brown, TR			Identification and characterization of a novel androgen response element composed of a direct repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; STEROID-HORMONE RECEPTORS; TARGET GENE SPECIFICITY; MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; ESTROGEN-RECEPTOR; STRUCTURAL DETERMINANTS; DEOXYRIBONUCLEIC-ACID; COOPERATIVE BINDING	Transcriptional regulation by the androgen receptor (AR) requires its binding to hormone response element nucleotide sequences in DNA. A consensus glucocorticoid response element (GRE) can mediate transactivation by AR and other members of the AR/glucocorticoid (GR)/progesterone (PR)/mineralocorticoid (MR) receptor subfamily. We identified putative androgen response element (ARE) sequences by binding of a human AR DNA-binding domain fusion protein to DNA in a random sequence selection assay. A 17-base pair consensus nucleotide sequence, termed IDR17, containing three potential GRE-like core binding sites organized as both inverted and direct repeats, was determined from a pool of degenerate oligonucleotides. IDR17 was active in mediating androgen-dependent induction of reporter gene expression in transient transfection assays. Dissection of the IDR17 sequence revealed an 11-base pair sequence (DR-1), consisting of two potential core binding sites oriented as an overlapping direct repeat, as the most potent ARE. DR-1 demonstrated a strong preference for AR binding and transactivation when compared with GR. To our knowledge, this is the first observation that a direct repeat of GRE-like core motifs functions as a preferred hormone response element within the AR/GR/PR/MR subfamily of nuclear receptors.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT POPULAT DYNAM,DIV REPROD BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; CLDUTJENS KBJ, 1996, J BIOL CHEM, V271, P6379; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARBRE P, 1983, NATURE, V303, P413; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; HO KC, 1993, J BIOL CHEM, V268, P27226; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NASLUND MJ, 1986, J UROLOGY, V136, P1136, DOI 10.1016/S0022-5347(17)45239-6; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TAN JA, 1992, J BIOL CHEM, V267, P4456; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONG CI, 1993, J BIOL CHEM, V268, P19004; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOUNG CYF, 1990, MOL ENDOCRINOL, V4, P1841, DOI 10.1210/mend-4-12-1841; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	59	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8227	8235		10.1074/jbc.272.13.8227	http://dx.doi.org/10.1074/jbc.272.13.8227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079641	hybrid			2022-12-27	WOS:A1997WQ63500024
J	Hayashi, N; Matsubara, M; Titani, K; Taniguchi, H				Hayashi, N; Matsubara, M; Titani, K; Taniguchi, H			Circular dichroism and H-1 nuclear magnetic resonance studies on the solution and membrane structures of GAP-43 calmodulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PROTEIN SECONDARY STRUCTURE; GROWTH CONE PROTEIN; NEUROMODULIN GAP-43; AQUEOUS-SOLUTIONS; CHEMICAL-SHIFT; ALPHA-HELICES; B-50 GAP-43; RAT-BRAIN; MARCKS	Growth associated protein-43 (GAP 43) is believed to be palmitoylated near the N terminus and the modification is assumed to be involved in the membrane anchoring of the protein, However, GAP-43 isolated from bovine brain is not palmitoylated as shown by mass spectrometric analysis, but still retains the ability to bind phospholipids, suggesting that other parts of the molecule are involved in the interaction, Upon addition of acidic phospholipids, purified GAP-43 showed a conformational change from random coil to alpha-helix as indicated by a change in CD spectra. A synthetic peptide corresponding to the calmodulin-binding domain showed a similar conformational change from random coil to alpha-helix in the presence of various acidic phospholipids, These results suggest that the calmodulin-binding domain of GAP 43 is directly involved in the GAP-43-membrane interaction and undergoes a conformational change upon binding to phospholipid membranes. After phosphorylation by protein kinase C, the phospholipid-induced conformational changes were no longer observed. Structural characteristics of the calmodulin-binding domain peptide in aqueous and hydrophobic solvents were further studied in detail by two-dimensional H-1 nuclear magnetic resonance, The results obtained suggest that the domain assumes a nascent alpha-helical structure in aqueous solution, which is stabilized under hydrophobic environments.	FUJITA HLTH UNIV,SCH MED,DIV BIOMED POLYMER SCI,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University			Taniguchi, Hisaaki/I-9171-2012; Hayashi, Nobuhiro/F-6088-2011; Matsubara, Mamoru/AAP-4016-2021	Hayashi, Nobuhiro/0000-0002-9950-094X; Matsubara, Mamoru/0000-0002-8893-0485				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1991, J BIOL CHEM, V266, P10544; BAKER P, 1985, J MAGN RESON, V64, P334; BAX A, 1985, J MAGN RESON, V65, P393; BESCHIASCHVILI G, 1992, BIOCHEMISTRY-US, V31, P10044, DOI 10.1021/bi00156a026; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3147; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MEIRI KF, 1990, J NEUROSCI, V10, P256; MUNIER H, 1993, J BIOL CHEM, V268, P1695; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PASTORE A, 1990, J MAGN RESON, V90, P165, DOI 10.1016/0022-2364(90)90375-J; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SPENCER SA, 1992, J BIOL CHEM, V267, P9059; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0; [No title captured]	50	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7639	7645		10.1074/jbc.272.12.7639	http://dx.doi.org/10.1074/jbc.272.12.7639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065419	hybrid			2022-12-27	WOS:A1997WP59200013
J	Pentikainen, MO; Oorni, K; Lassila, R; Kovanen, PT				Pentikainen, MO; Oorni, K; Lassila, R; Kovanen, PT			The proteoglycan decorin links low density lipoproteins with collagen type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; HEPARIN COFACTOR-II; CORE PROTEIN; EXTRACELLULAR-MATRIX; PLASMA-LIPOPROTEINS; DERMATAN SULFATE; BLOOD-VESSELS; HUMAN AORTA; BINDING; BIGLYCAN	Decorin is a small dermatan sulfate-rich proteoglycan which binds to collagen type I in vitro and in vivo. In atherosclerotic lesions the contents of low density lipoprotein (LDL), decorin, and collagen type I are increased, and ultrastructural studies have suggested an association between LDL and collagen in the lesions, To study interactions between LDL, decorin, and collagen type I, we used solid phase systems in which LDL was coupled to a Sepharose column, or in which LDL, decorin, or collagen type I was attached 60 microtiter wells, The interaction between LDL and decorin in the fluid phase was evaluated using a gel mobility shift as say, We found that LDL binds to decorin by ionic interactions. After treatment with chondroitinase ABC, decorin did not bind to LDL, showing that the glycosaminoglycan side chain of decorin is essential for LDL binding, Acetylated and cyclohexanedione-treated LDL did not bind to decorin, demonstrating that both lysine and arginine residues of apoB-100 are necessary for the interaction. When collagen type I was attached to the microtiter plates, only insignificant amounts of LDL bound to the collagen. However, if decorin was first allowed to bind to the collagen, binding of LDL to the decorin-collagen complexes was over 10-fold higher than to collagen alone. Thus, decorin can link LDL with collagen type I in vitro, which suggests a novel mechanism for retention of LDL in collagen-rich areas of atherosclerotic lesions.	WIHURI RES INST, SF-00140 HELSINKI, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOFF HF, 1974, BIOCHIM BIOPHYS ACTA, V351, P407, DOI 10.1016/0005-2795(74)90205-0; HOOVER GA, 1988, ARTERIOSCLEROSIS, V8, P525, DOI 10.1161/01.ATV.8.5.525; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JIMI S, 1994, ATHEROSCLEROSIS, V107, P109, DOI 10.1016/0021-9150(94)90146-5; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAWRIE AS, 1989, BRIT J HAEMATOL, V73, P100, DOI 10.1111/j.1365-2141.1989.tb00227.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; MURATA K, 1986, ATHEROSCLEROSIS, V60, P251, DOI 10.1016/0021-9150(86)90172-3; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NIEVELSTEINPOST P, 1994, ARTERIOSCLER THROMB, V14, P1151, DOI 10.1161/01.ATV.14.7.1151; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; OLSSON U, 1991, BIOCHIM BIOPHYS ACTA, V1097, P37, DOI 10.1016/0925-4439(91)90021-Z; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; PODET EJ, 1991, ARTERIOSCLER THROMB, V11, P116, DOI 10.1161/01.ATV.11.1.116; RIESSEN R, 1994, AM J PATHOL, V144, P962; ROBBINS RA, 1992, ARTERIOSCLER THROMB, V12, P83, DOI 10.1161/01.ATV.12.1.83; SAMBANDAM T, 1991, ARTERIOSCLER THROMB, V11, P561, DOI 10.1161/01.ATV.11.3.561; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Smith E B, 1974, Adv Lipid Res, V12, P1; SMITH EB, 1965, J ATHEROSCLER RES, V5, P241, DOI 10.1016/S0368-1319(65)80065-5; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; Vijayagopal P, 1996, BIOCHEM J, V315, P995, DOI 10.1042/bj3150995; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALTON KW, 1968, J ATHEROSCLER RES, V8, P599, DOI 10.1016/S0368-1319(68)80020-1; WEGROWSKI J, 1986, BIOCHEM J, V235, P823, DOI 10.1042/bj2350823; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WIGHT TN, 1996, ATHEROSCLEROSIS CORO; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10	53	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7633	7638		10.1074/jbc.272.12.7633	http://dx.doi.org/10.1074/jbc.272.12.7633			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065418	hybrid			2022-12-27	WOS:A1997WP59200012
J	Pourquier, P; Ueng, LM; Kohlhagen, G; Mazumder, A; Gupta, M; Kohn, KW; Pommier, Y				Pourquier, P; Ueng, LM; Kohlhagen, G; Mazumder, A; Gupta, M; Kohn, KW; Pommier, Y			Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; WHEAT-GERM; CAMPTOTHECIN; BASE; SEQUENCE; RECOMBINATION; REPLICATION; INHIBITORS; BREAKAGE; ABSENCE	Abasic sites and deamination of cytosine to uracil are probably the most common types of endogenous DNA damage, The effects of such lesions on DNA topoisomer ase I (top1) activity were examined in oligonucleotides containing a unique top1 cleavage site, The presence of uracils and abasic sites within the first 4 bases immediately 5' to the cleavage site suppressed normal top1 cleavage and induced new top1 cleavage sites, Uracils immediately 3' to the cleavage site increased cleavage and produced a camptothecin mimicking effect, A mismatch with a bulge or abasic sites immediately 3' to the top1 cleavage site irreversibly trapped top1 cleavable complexes in the absence of camptothecin and produced a suicide cleavage complex, These results demonstrate that top1 activity is sensitive to physiological, environmental, and pharmacological DNA modifications and that top1 can act as a specific mismatch- and abasic site-nicking enzyme.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005				BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; FRIEDBERG EC, 1995, DNA REPAIR; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; TANIZAWA A, 1995, BIOCHEMISTRY-US, V43, P7200; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH YC, 1994, J BIOL CHEM, V269, P15498	31	189	192	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7792	7796		10.1074/jbc.272.12.7792	http://dx.doi.org/10.1074/jbc.272.12.7792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065442	Green Published, hybrid			2022-12-27	WOS:A1997WP59200036
J	Lin, PJ; LubyPhelps, K; Stull, JT				Lin, PJ; LubyPhelps, K; Stull, JT			Binding of myosin light chain kinase to cellular actin-myosin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION; PROTEIN; CELLS; PHOSPHATASE; PURIFICATION; CONTRACTION; ACTIVATION; CALMODULIN; GIZZARD	Myosin light chain kinase binds to the actomyosin-containing filaments in smooth and nonmuscle cells, However, the region of the kinase necessary for this high affinity binding in vivo is not known, although it has been proposed that the N and C termini bind to actin and myosin in vitro, respectively, Truncated myosin light chain kinases containing the catalytic core and calmodulin-binding domain but lacking N (amino acids 1-655) and/or C (amino acids 1004-1147) termini were expressed in the baculovirus system and purified, All enzymes were catalytically active and Ca2+/calmodulin-dependent, The C-terminal truncated myosin light chain kinase bound to detergent-washed smooth muscle contractile proteins similar to recombinant full-length myosin light chain kinase or enzyme purified from smooth muscle, The apparent affinity of the full-length kinase was greater for the actomyosin-containing filaments with associated proteins than for purified smooth muscle F-actin or actomyosin filaments from skeletal muscle, In contrast, truncations at the N terminus alone or at both N and C termini resulted in no significant binding, Similar effects were observed by two other assays: binding of fluorescently labeled myosin light chain kinases to actin-containing stress fibers in detergent-treated fibroblasts and localization of fluorescently labeled kinases after microinjection into primary smooth muscle cells in culture. The full-length and the C-terminal truncated myosin light chain kinases, but not myosin light chain kinases truncated at the N terminus or both N and C termini, associated with filaments in cells, Thus, the N terminus and not the C terminus of myosin light chain kinase is necessary for high affinity binding to actomyosin-containing filaments in smooth and non-muscle cells.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Luby-Phelps, Katherine/0000-0002-8378-1409	NHLBI NIH HHS [HL26043] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; CHOI OH, 1994, J BIOL CHEM, V269, P536; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HAYAKAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P786, DOI 10.1006/bbrc.1994.1298; HERRING BP, 1992, J BIOL CHEM, V267, P25945; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; ITO M, 1989, J BIOL CHEM, V264, P13971; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NUNNALLY MH, 1984, J BIOL CHEM, V259, P1776; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; STRAUSS JD, 1992, AM J PHYSIOL, V262, pC1437, DOI 10.1152/ajpcell.1992.262.6.C1437; STRZELECKAGOLASZEWSKA H, 1980, EUR J BIOCHEM, V104, P41, DOI 10.1111/j.1432-1033.1980.tb04397.x; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; ZHI G, 1994, J BIOL CHEM, V269, P24723	42	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7412	7420		10.1074/jbc.272.11.7412	http://dx.doi.org/10.1074/jbc.272.11.7412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054442	hybrid			2022-12-27	WOS:A1997WN14700081
J	Greene, NM; Williams, DS; Newton, AC				Greene, NM; Williams, DS; Newton, AC			Identification of protein kinase C phosphorylation sites on bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; PHOTORECEPTORS; MECHANISM	The protein kinase C phosphorylation sites on bovine rhodopsin were identified using proteolytic, phosphoamino acid, mass spectrometric, and peptide sequencing analyses, Tryptic removal of the 9 carboxyl-terminal residues of rhodopsin revealed that a major fraction of the phosphates incorporated by protein kinase C are in a region containing Ser(334), Thr(335), and Thr(336). Phosphoamino acid analysis of the tryptic product established that Ser(334) accounts for approximately 65% of the phosphorylation in this region, Analysis of the endoproteinase Asp-N-generated carboxyl terminus of rhodopsin by mass spectrometry and peptide sequencing revealed that Ser(338) is also a primary phosphorylation site, with minor phosphorylation of Ser(343). Quantitation of high pressure liquid chromatography-separated phosphopeptides, taken together with phosphoamino acid analysis of the tryptic product, revealed that Ser(334) and Ser(338) were phosphorylated equally and each accounted for approximately 35% of the total phosphorylation; Thr(335/336) accounted for just under 20% of the phosphorylation, and Ser(343) accounted for 10%. Thus, the primary protein kinase C sites are Ser(334), and Ser(338), with minor phosphorylation of Thr(335/336), and Ser(343). Ser(334) and Ser(338) have recently been identified as the primary sites of phosphorylation of rhodopsin in vivo (Ohguro, H., Van Hooser, J. P. Milam, A, H., and Palczewski, K. (1995) J. Biol; Chem 270, 14259-14262), Of these sites, only Ser(338) is a significant substrate for rhodopsin kinase in vitro. Identification of Ser(334) as a primary protein kinase C target in vitro is consistent with protein kinase C modulating the phosphorylation of this site in vivo.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NEI NIH HHS [EY08820] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MOLDAY RS, 1985, BIOCHEMISTRY-US, V24, P776, DOI 10.1021/bi00324a036; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Ohguro H, 1996, J BIOL CHEM, V271, P5215; ORR JW, 1992, J BIOL CHEM, V267, P15263; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; STRYER L, 1991, J BIOL CHEM, V266, P10711; UDOVICHENKO IP, 1997, IN PRESS J BIOL CHEM; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Yeagle P L, 1996, Mol Vis, V2, P12	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10341	10344						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099669				2022-12-27	WOS:A1997WV26200003
J	GonzalezGarcia, A; Merida, I; Martinez, C; Carrera, AC				GonzalezGarcia, A; Merida, I; Martinez, C; Carrera, AC			Intermediate affinity interleukin-2 receptor mediates survival via a phosphatidylinositol 3-kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; T-CELL PROLIFERATION; JAK-3 JANUS KINASE; IL-2 RECEPTOR; GAMMA-CHAIN; C-MYC; BETA-CHAIN; FUNCTIONAL COMPONENT; CYTOPLASMIC DOMAINS; SIGNALING PATHWAYS	Peripheral blood T lymphocytes require two signals to enter and progress along the cell cycle from their natural quiescent state, The first activation signal is provided by the stimulation through the T cell receptor, which induces the synthesis of cyclins and the expression of the high affinity interleukin-2 receptor. The second signal, required to enter the S phase, is generated upon binding of interleukin-2 to the high affinity alpha beta gamma interleukin-2 receptor. However, resting T cells already express intermediate affinity beta gamma interleukin-2 receptors, As shown here, T cell stimulation through intermediate affinity receptors is capable of inducing cell rescue from the apoptosis suffered in the absence of stimulation. Characterization of the signaling pathways utilized by beta gamma interleukin-2 receptors in resting T cells, indicated that pp56(lck), but not Jak1 or Jak3, is activated upon receptor triggering. Compelling evidence is presented indicating that phosphatidylinositol 3-kinase associates with the intermediate affinity interleukin-2 receptor and is activated upon interleukin 2 addition. Bcl-x(L) gene was also found to be induced upon beta gamma interleukin-2 receptor stimulation, Finally, pharmacological inhibition of phosphatidylinositol 3-kinase blocked both interleukin-2-mediated bcl-x(L) induction and cell survival. We conclude that beta gamma interleukin-2 receptor mediates T cell survival via a phosphatidylinositol 3-kinase-dependent pathway, possibly involving pp56(lck) and bcl-x(L) as upstream and downstream effectors, respectively.			GonzalezGarcia, A (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,CAMPUS CANTOBLANCO,MADRID 28029,SPAIN.		Merida, Isabel/A-9713-2014; Gonzalez-Garcia, Ana/D-9736-2014	Merida, Isabel/0000-0003-2762-6241; Carrera, Ana/0000-0002-3999-5434; Gonzalez-Garcia, Ana/0000-0002-6669-1735				AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1995, P NATL ACAD SCI USA, V92, P5491, DOI 10.1073/pnas.92.12.5491; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROOME HE, 1995, J IMMUNOL, V155, P2311; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CARRERA AC, 1991, INT IMMUNOL, V3, P673, DOI 10.1093/intimm/3.7.673; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; Minshall C, 1996, J IMMUNOL, V156, P939; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Mor F, 1996, J IMMUNOL, V156, P515; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SATOH T, 1992, J BIOL CHEM, V267, P25423; SEKI H, 1995, CELL IMMUNOL, V163, P30, DOI 10.1006/cimm.1995.1095; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	55	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10220	10226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092570				2022-12-27	WOS:A1997WU03900089
J	Guaiquil, VH; Farber, CM; Golde, DW; Vera, JC				Guaiquil, VH; Farber, CM; Golde, DW; Vera, JC			Efficient transport and accumulation of vitamin C in HL-60 cells depleted of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEHYDROASCORBATE REDUCTASE; ASCORBIC-ACID TRANSPORT; BUTHIONINE SULFOXIMINE; RAT-LIVER; GLUCOSE; INHIBITION; THIOLTRANSFERASE; GLUTAREDOXIN; PURIFICATION; NEUTROPHILS	Human myeloid leukemia cells (HL-60) transport only the oxidized form of vitamin C (dehydroascorbic acid) and accumulate the vitamin in the reduced form, ascorbic acid. We performed a detailed study of the role of glutathione in the intracellular trapping/accumulation of ascorbic acid in HL-60 cells. Uptake studies using HL-60 cells depleted of glutathione by treatment with L-buthionine-(S,R) sulfoximine and diethyl maleate, revealed no changes in the cells' ability to transport dehydroascorbic acid and accumulate ascorbic acid. Similar transport and accumulation rates were obtained using HL-60 cells containing intracellular glutathione concentrations from 6 mM to 1 mu M. HL-60 cells, containing as little as 5 mu M glutathione, were able to accumulate up to 150 mM ascorbic acid intracellularly when incubated with dehydroascorbic acid. Glutathione was capable of reducing dehydroascorbic acid by a direct chemical reaction, but only when present in a greater than 10-fold stoichiometric excess over dehydroascorbic acid. The accumulation of ascorbic acid by HL-60 cells was strongly temperature-dependent and was very inefficient at 16 degrees C. On the other hand, the direct chemical reduction of dehydroascorbic acid by excess glutathione proceeded efficiently at temperatures of 16 degrees C. Our data indicate that glutathione-dependent reductases in HL-60 cells are not responsible for the ability of these cells to accumulate millimolar concentrations of ascorbic acid. These findings indicate that alternative enzymatic mechanisms are involved in the cellular reduction of dehydroascorbic acid.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [P30 CA08748, R01 CA30388] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030388, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ANDERSON R, 1983, CANCER RES, V43, P4696; BIGLEY R, 1981, BIOCHIM BIOPHYS ACTA, V659, P15, DOI 10.1016/0005-2744(81)90266-7; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BODE AM, 1990, CLIN CHEM, V36, P1807; BODE AM, 1993, CURR EYE RES, V12, P593, DOI 10.3109/02713689309001838; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; DYER DL, 1994, AM J PHYSIOL, V267, pC301, DOI 10.1152/ajpcell.1994.267.1.C301; FAY MJ, 1990, LIFE SCI, V46, P619, DOI 10.1016/0024-3205(90)90130-J; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; KAPEGHIAN JC, 1984, LIFE SCI, V34, P577, DOI 10.1016/0024-3205(84)90491-0; KHATAMI M, 1986, INVEST OPHTH VIS SCI, V27, P1665; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MITCHELL JB, 1983, RADIAT RES, V96, P422, DOI 10.2307/3576226; MOORADIAN AD, 1987, DIABETES, V36, P1001, DOI 10.2337/diabetes.36.9.1001; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; PADH H, 1985, CELL BIOL INT REP, V9, P531, DOI 10.1016/0309-1651(85)90017-7; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; STAHL RL, 1985, CANCER RES, V45, P6507; STAHL RL, 1985, BIOCHIM BIOPHYS ACTA, V839, P119, DOI 10.1016/0304-4165(85)90189-8; STANKOVA L, 1975, ANN NY ACAD SCI, V258, P238, DOI 10.1111/j.1749-6632.1975.tb29284.x; VERA JC, 1994, BLOOD, V84, P1628; Vera JC, 1996, J BIOL CHEM, V271, P8719, DOI 10.1074/jbc.271.15.8719; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q	40	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9915	9921						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092530				2022-12-27	WOS:A1997WU03900049
J	Rao, NV; Rao, GV; Hoidal, JR				Rao, NV; Rao, GV; Hoidal, JR			Human dipeptidyl-peptidase I - Gene characterization, localization, and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL ELASTASE GENE; DNA-BINDING PROPERTIES; CHROMOSOMAL LOCALIZATION; TRANSCRIPTION FACTOR; TISSUE DISTRIBUTION; MOLECULAR-CLONING; CATHEPSIN-C; PROTEIN; CELLS; ACTIVATION	Dipeptidyl-peptidase I, a lysosomal cysteine proteinase, is important in intracellular degradation of proteins and appears to be a central coordinator for activation of many serine proteinases in immune/inflammatory cells, Little is known about the molecular genetics of the enzyme, In the present investigation the gene for dipeptidyl-peptidase I was cloned and characterized, The gene spans approximately 3.5 kilobases and consists of two exons and one intron, The genomic organization is distinct from the complex structures of the other members of the papain-type cysteine proteinase family, By fluorescence in situ hybridization, the gene was mapped to chromosomal region 11q14.1-q14.3. Analysis of the sequenced 5'-flanking region revealed no classical TATA or CCAAT box in the GC-rich region upstream of cap site, A number of possible regulatory elements that could account for tissue-specific expression were identified, Northern analyses demonstrated that the dipeptidyl-peptidase I message is expressed at high levels in lung, kidney, and placenta, at moderate to low levels in many organs, and at barely detectable levels in the brain, suggesting tissue-specific regulation, Among immune/inflammatory cells, the message is expressed at high levels in polymorphonuclear leukocytes and alveolar macrophages and their precursor cells, Treatment of lymphocytes with interleukin-2 resulted in a significant increase in dipeptidyl-peptidase I mRNA levels, suggesting that this gene is subjected to transcriptional regulation, The results provide initial insights into the molecular basis for the regulation of human dipeptidyl-peptidase I.	UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV RESP CRIT CARE & OCCUPAT MED, SALT LAKE CITY, UT 84132 USA; VET ADM MED CTR, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37615-09, HL07636] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; FAN YS, 1989, CYTOGENET CELL GENET, V51, P996; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; GUTMANN HR, 1948, J BIOL CHEM, V174, P851; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; ISHIDOH K, 1991, BIOMED BIOCHIM ACTA, V50, P541; JENNE DE, 1994, AM J RESP CRIT CARE, V150, pS147, DOI 10.1164/ajrccm/150.6_Pt_2.S147; KOMINAMI E, 1992, BIOL CHEM H-S, V373, P367, DOI 10.1515/bchm3.1992.373.2.367; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MICHAEL JL, 1989, CELL, V58, P227; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; ORKIN SH, 1992, BLOOD, V80, P575; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Rao NV, 1996, J BIOL CHEM, V271, P2972, DOI 10.1074/jbc.271.6.2972; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SHI GP, 1994, J BIOL CHEM, V269, P11530; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; VANHAPER.T, 1973, CLIN CHIM ACTA, V44, P249, DOI 10.1016/0009-8981(73)90388-4; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	52	126	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10260	10265						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092576				2022-12-27	WOS:A1997WU03900095
J	Solari, R; Offord, RE; Remy, S; Aubry, JP; Wells, TNC; Whitehorn, E; Oung, T; Proudfoot, AEI				Solari, R; Offord, RE; Remy, S; Aubry, JP; Wells, TNC; Whitehorn, E; Oung, T; Proudfoot, AEI			Receptor-mediated endocytosis of CC-chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; INTERNALIZATION; MIP-1-ALPHA; RANTES	Chemokines are chemotactic proteins which play a central role in immune and inflammatory responses, Chemokine receptors are members of the seven transmembrane G-protein coupled family and have recently been shown to be involved in the entry of human immunodeficiency virus (HIV) into target cells, To study chemokine endocytosis in detail we have used novel site-specific chemistry to make a fluorescently labeled CC-chemokine agonist (rhodamine-MIP-1 alpha) and antagonist (NBD-RANTES), We have also generated a CHO cell line stably expressing a hemagglutinin-tagged version of the CC-chemokine receptor 1 (CCR1), and using these reagents we have examined the receptor-mediated endo cytosis of CC-chemokines by confocal microscopy, Our studies reveal that the agonist was internalized and accumulated in transferrin receptor-positive endosomes whereas the antagonist failed to internalize, However, receptor-bound antagonist could be induced to internalize by co-administration of agonist, Analysis of receptor redistribution following chemokine addition confirmed that sequestration was induced by agonists but not by antagonists.	GLAXO WELLCOME RES & DEV LTD,MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1224 GENEVA,SWITZERLAND; GLAXO WELLCOME RES & DEV LTD,CH-1228 GENEVA,SWITZERLAND; AFFYMAX RES INST,PALO ALTO,CA 94304	GlaxoSmithKline; University of Geneva; GlaxoSmithKline				Wells, Timothy/0000-0001-9796-847X				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berry SA, 1996, MOL PHARMACOL, V50, P306; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSOUZA PM, 1996, NAT MED, V2, P1293; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OFFORD RE, 1997, IN PRESS METHODS ENZ; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	29	77	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9617	9620						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092487				2022-12-27	WOS:A1997WU03900006
J	Bouchard, BA; Catcher, CS; Thrash, BR; Adida, C; Tracy, PB				Bouchard, BA; Catcher, CS; Thrash, BR; Adida, C; Tracy, PB			Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	37th Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer Soc Hematol			COAGULATION FACTOR-X; FACTOR-VA; BLOOD-COAGULATION; AMINOPHOSPHOLIPID TRANSLOCASE; PLASMA-MEMBRANE; MESSENGER-RNA; FACTOR-IXA; BINDING; SURFACE; SITE	At sites of vascular injury thrombin is generated via prothrombinase, a stoichiometric (1:1), Ca2+-dependent, and membrane-bound complex consisting of the nonenzymatic cofactor factor Va and the serine protease factor Xa. While the importance of anionic platelet membrane phospholipids in regulating thrombin generation is well recognized, the identification of regulatory protein receptors has eluded investigators. This study reports the first description of a human platelet membrane protein that regulates prothrombinase complex assembly and function, Direct platelet-protein binding studies indicated that, although required, platelet-bound factor Va alone is insufficient to mediate factor Xa binding, and that factor Va and factor Xa bind to discrete sites on activated platelets for which expression is independently regulated as a function of the agonist concentration. When specific monoclonal antibodies against effector cell protease receptor-1 (EPR-1, a 65-kDa membrane receptor for factor Xa) were used in Western blotting, immunohistochemical staining, and/or flow cytometric analyses, activated platelets and their precursors, megakaryocytes, were shown to express EPR-1. These results were confirmed by reverse transcription-polymerase chain reaction of mRNA extracted from megakaryocyte-like cell lines. Additional flow cytometric studies demonstrated that a platelet-bound factor Va/factor Xa complex precluded binding of the anti-EPR-1 antibody, B6, to activated platelets by similar to 50%, Likewise, the anti-EPR-1 antibody was shown to inhibit prothrombinase-catalyzed thrombin generation on activated platelets in a dose- and platelet donor-dependent manner, indicating that platelet-expressed EPR-1 mediates factor Xa assembly into the prothrombinase complex. These collective data indicate that both EPR 1 and membrane-bound factor Va are required to mediate factor Xa binding to the activated platelet to form a functional prothrombinase complex.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DEPT MOL & CELL BIOL,BURLINGTON,VT 05405; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06536	University of Vermont; University of Vermont; Yale University				Bouchard, Beth/0000-0002-0399-566X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 1996, BLOOD, V88, P1457, DOI 10.1182/blood.V88.4.1457.bloodjournal8841457; AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; Ambrosini G, 1996, J BIOL CHEM, V271, P1243, DOI 10.1074/jbc.271.2.1243; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; Bouchard BA, 1997, ARTERIOSCL THROM VAS, V17, P1, DOI 10.1161/01.ATV.17.1.1; CAMIRE RM, 1995, J BIOL CHEM, V270, P20794, DOI 10.1074/jbc.270.35.20794; Charo I.F., 1994, HEMOSTASIS THROMBOSI, P489; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; Duchosal MA, 1996, NATURE, V380, P352, DOI 10.1038/380352a0; FUGMAN DA, 1990, BLOOD, V75, P1252; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1992, NEW ENGL J MED, V326, P800; HAYES KL, 1994, J BIOL CHEM, V269, P28606; Jenny N. S., 1995, Blood, V86, p75A; KANE WH, 1980, J BIOL CHEM, V255, P1170; KANE WH, 1982, J BIOL CHEM, V257, P3963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; London F, 1996, BIOCHEMISTRY-US, V35, P16886, DOI 10.1021/bi960712v; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MILETICH JP, 1978, P NATL ACAD SCI USA, V74, P4033; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1993, THROMB HAEMOSTASIS, V70, P80; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SLONOSKY D, 1988, FASEB J, V2, P5038; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1993, METHOD ENZYMOL, V222, P281; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VILLARREAL XC, 1991, BLOOD, V78, P1216	49	67	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9244	9251						8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083058				2022-12-27	WOS:A1997WU03700063
J	Ishihara, H; Sasaoka, T; Ishiki, M; Takata, Y; Imamura, T; Usui, I; Langlois, WJ; Sawa, T; Kobayashi, M				Ishihara, H; Sasaoka, T; Ishiki, M; Takata, Y; Imamura, T; Usui, I; Langlois, WJ; Sawa, T; Kobayashi, M			Functional importance of Shc tyrosine 317 on insulin signaling in Rat1 fibroblasts expressing insulin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-RELEASING-FACTOR; PROTEIN-KINASE; FACTOR-I; DOMAIN; GRB2; PHOSPHATASE; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Shc is phosphorylated on Tyr-317, which serves as a docking site for Grb2. To investigate the specific role of Shc phosphorylation and Shc.Grb2 coupling on insulin signaling, we generated expression vectors for wild-type (WT-Shc) and a mutant Shc with a Tyr-317 --> Phe substitution (317Y/F-Shc) and stably transfected them into Rat1 fibroblasts expressing insulin receptors (HIRc). From different clonal cell lines, cells expressing 10 times greater amounts of WT-Shc or 317Y/F-Shc compared with endogenous Shc were chosen for analysis of insulin signaling. Insulin-induced Shc phosphorylation and subsequent association with Grb2 was enhanced in WT-Shc cells, Because of competition between Shc and IRS-1 for interaction with the insulin receptor, insulin-stimulated tyrosine phosphorylation of IRS-1 was decreased in WT-Shc cells compared with that in HIRc cells, Likewise, reduction of endogenous Shc expression by antisense Shc mRNA resulted in increased insulin stimulation of IRS-1 phosphorylation, Although 317Y/F-Shc was also able to interact with insulin receptor, decreased amounts of Shc phosphorylation and Shc association with Grb2 were observed in 317Y/F-Shc cells, indicating that 317Y/F-Shc functions as a dominant-negative mutant. The kinetics of mitogen-activated protein (MAP) kinase activation closely paralleled the kinetics of Shc phosphorylation. Thus, insulin stimulation of MAP kinase activation occurred more rapidly and was prolonged in WT-Shc cells, while the activation was delayed and transient in 317Y/F-Shc cells compared with that in HIRc cells, Importantly, WT-Shc cells displayed enhanced sensitivity to insulin stimulation of thymidine and bromodeoxyuridine incorporation, whereas the sensitivity was decreased in 317Y/F-Shc cells. These results indicate that Shc Tyr-317 phosphorylation plays an important role, via coupling with Grb2 and competition with IRS-1, in signal transduction to MAP kinase by insulin, ultimately leading to mitogenesis in Rat1 fibroblasts.	TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Toyama; University of Toronto								BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9581	9586						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083103				2022-12-27	WOS:A1997WU03700108
J	Tong, Q; Xing, SH; Jhiang, SM				Tong, Q; Xing, SH; Jhiang, SM			Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTO-ONCOGENE; THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE DOMAIN; MOLECULAR CHARACTERIZATION; TRANSFORMING GENE; H4 D10S170; IN-VIVO; PROTOONCOGENE; MUTATIONS; CLONING	The PTC1 chimeric oncogene is generated by the fusion of the tyrosine kinase domain of the RET protooncogene to the 5'-terminal region of another gene named H4 (D10S170), This oncogene has been detected only in human papillary thyroid carcinomas. We have previously demonstrated that the putative leucine zipper in the N-terminal region of H4 can mediate oligomerization of the PTC1 oncoprotein in vitro. In this study, we further demonstrated that the PTC1 oncoprotein forms a dimer in vivo, and the leucine zipper is responsible for this dimerization. The H4 leucine zipper-mediated dimerization is essential for tyrosine hyperphosphorylation and the transforming activity of the PTC1 oncoprotein. Introducing a loss-of-function PTC1 mutant into PTC1-transformed NIH3T3 cells suppressed the transforming activity of PTC1 and reversed the transformed phenotype of these cells, presumably by forming inactive heterodimers between the two forms of PTC1. Taken together, these data indicate that constitutive dimerization of the PTC1 oncoprotein is essential for PTC1 transforming activity and suggest that constitutive oligomerization acquired by rearrangement or by point mutations may be a general mechanism for the activation of receptor tyrosine kinase oncogenes.	OHIO STATE UNIV,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210	Ohio State University; Ohio State University					NCI NIH HHS [R29 CA6074] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CAO T, 1995, J CELL BIOL S, V19, P48; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LANZI C, 1992, ONCOGENE, V7, P2189; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TONG Q, 1995, ONCOGENE, V10, P1781; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512	35	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9043	9047						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083029				2022-12-27	WOS:A1997WU03700034
J	Uchiumi, T; Longo, DL; Ferris, DK				Uchiumi, T; Longo, DL; Ferris, DK			Cell cycle regulation of the human polo-like kinase (PLK) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; PROTEIN-KINASE; TRANSCRIPTIONAL REPRESSION; CDC25C TRANSCRIPTION; DROSOPHILA POLO; NF-Y; GENE; EXPRESSION; SPINDLE; IDENTIFICATION	Plk (polo-like kinase) is a serine-threonine kinase that appears to function in mitotic control in mammalian cells. We demonstrated previously that PLK mRNA expression is low at the G(1)-S transition, increases during S phase, and is maximally expressed during G(2)-M. In the present study, we have cloned the human PLK gene and analyzed the structure and function of 2 kilobases of its 5'-flanking region. Using synchronized cultures of HeLa cells transfected with PLK promoter/luciferase constructs, we show that the promoter of PLK is activated at S phase and is maximal at G(2)-M phase. Using various PLK promoter/luciferase constructs, we show that three activating regions are located between 35 and 93 base pairs upstream of the transcription initiation site. We identified a repressor element (CDE/CHR) in the region of the transcription start site, and mutations within this element diminished cell cycle regulation of transcription.	NCI,INTRAMURAL RES SUPPORT PROGRAM,SCI APPLICAT INT CORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,LAB LEUKOCYTE BIOL,DIV CANC TREATMENT,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NIA,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Longo, Dan L./F-6022-2011					BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRAUNINGER A, 1995, ONCOGENE, V11, P1793; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HWANG A, 1995, J BIOL CHEM, V270, P28419; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P10; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Sinha S, 1996, MOL CELL BIOL, V16, P328; SUNKEL CE, 1988, J CELL SCI, V89, P25; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	28	114	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9166	9174						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083047				2022-12-27	WOS:A1997WU03700052
J	Weinander, R; Ekstrom, L; Andersson, C; Raza, H; Bergman, T; Morgenstern, R				Weinander, R; Ekstrom, L; Andersson, C; Raza, H; Bergman, T; Morgenstern, R			Structural and functional aspects of rat microsomal glutathione transferase - The roles of cysteine 49, arginine 107, lysine 67, histidine, and tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; LIVER; ACTIVATION; EXPRESSION; SUBSTRATE; COMPLEX; THETA; PURIFICATION	Rat liver microsomal glutathione transferase is rapidly inactivated upon treatment with the arginine-selective reagent phenylglyoxal or the lysine-selective 1,3,5-trinitrobenzenesulfonate. Glutathione sulfonate, an inhibitor of the enzyme, gives nearly complete protection against inactivation and prevents modification, indicating that these residues form part of or reside close to the active site. Sequence analysis of peptides from peptic and tryptic digests of [7-C-14]phenylglyoxal- and 1,3,5-trinitrobenzenesulfonate-treated microsomal glutathione transferase indicated arginine 107 and lysine 67 as the sites of modification. A set of mutant forms of microsomal glutathione transferase was constructed by site-directed mutagenesis and heterologously expressed in Escherichia coli BL21(DE3). Arginine 107 was exchanged for alanine and lysine residues. The alanine mutant (R107A) exhibited an activity and inhibition profile similar to that of the wild type enzyme but displayed a decreased thermostability. Thus, arginine 107 does not appear to participate in catalysis or substrate binding; instead, an important structural role is suggested for this residue. Lysine 67 was mutated to alanine and arginine with no effect on activity. All three histidines were replaced by glutamine, and the resulting mutant proteins had activities comparable with that of the wild type. It can thus be concluded that the chemical modification experiments indicating that arginine 107, lysine 67, and one of the histidines partake in catalysis can be disproved. However, protection from modification by a competitive inhibitor indicates that these residues could be close to the glutathione binding site. All tyrosine to phenylalanine substitutions resulted in mutants with activities similar to that of the wild type. Interestingly, the exchange of tyrosine 137 appears to result in activation of the enzyme. Thus, the microsomal glutathione transferase must display an alternate stabilization of the thiolate anion of glutathione other than through interaction with the phenolic hydroxyl group of a tyrosine residue. Substitution of cysteine 49 with alanine resulted in a semiactivated mutant enzyme with enzymatic properties partly resembling the activated form of microsomal glutathione transferase. The function of this mutant was not altered upon reaction with N-ethylmaleimide, and cysteine 49 is thus demonstrated as the site of modification that results in activation of microsomal glutathione transferase.	KAROLINSKA INST,INST ENVIRONM MED,DIV BIOCHEM TOXICOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Morgenstern, Ralf/GZH-0158-2022	Raza, Haider/0000-0001-9680-5388				ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; ANDERSSON C, 1990, BIOCHEM J, V272, P479, DOI 10.1042/bj2720479; ANDERSSON C, 1988, BIOCHEM J, V249, P819, DOI 10.1042/bj2490819; ANDERSSON C, 1991, J BIOL CHEM, V266, P2076; ANDERSSON C, 1993, STRUCTURE FUNCTION G, P109; ANIYA Y, 1989, J BIOL CHEM, V264, P1998; ANIYA Y, 1989, J PHARMACOBIO-DYNAM, V12, P235, DOI 10.1248/bpb1978.12.235; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYNES R, 1967, BIOCHEMISTRY-US, V6, P541, DOI 10.1021/bi00854a023; HEBERT H, 1995, EMBO J, V14, P3864, DOI 10.1002/j.1460-2075.1995.tb00058.x; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KAISER R, 1988, BIOCHEMISTRY-US, V27, P1132, DOI 10.1021/bi00404a009; KEEN JH, 1976, J BIOL CHEM, V251, P6183; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MORGENSTERN R, 1989, BIOCHEM J, V260, P577, DOI 10.1042/bj2600577; MORGENSTERN R, 1985, J BIOL CHEM, V260, P3976; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; MORGENSTERN R, 1988, GLUTATHIONE CONJUGAT, P157; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TOMAREV SI, 1993, J BIOL CHEM, V268, P4534; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINANDER R, 1995, BIOCHEM J, V311, P861, DOI 10.1042/bj3110861; WEINANDER R, 1994, J BIOL CHEM, V269, P71; WEINANDER R, 1996, GLUTATHIONE S TRANSF, P49; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	46	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8871	8877						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083005				2022-12-27	WOS:A1997WU03700010
J	Ascherman, DP; Migone, TS; Friedmann, MC; Leonard, WJ				Ascherman, DP; Migone, TS; Friedmann, MC; Leonard, WJ			Interleukin-2 (IL-2)-mediated induction of the IL-2 receptor alpha chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; COMMON GAMMA-CHAIN; BETA-CHAIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; GROWTH-FACTOR; EXPRESSION; ASSOCIATION; PROTEINS	The interleukin-2 receptor alpha chain (IL-2R alpha) is potently induced by antigens, mitogens, and certain cytokines that include IL-2 itself, This induction leads to the formation of high affinity IL-2 receptors when IL-2R alpha is co-expressed with the beta (IL-2R beta) and gamma (gamma(c)) chains of this receptor. We investigated the signaling pathways mediating IL-2-induced IL-2R alpha mRNA expression using 32D myeloid progenitor cells stably transfected with either wild type IL-2R beta or mutants of IL-2R beta containing tyrosine to phenylalanine substitutions, Of the six cytoplasmic tyrosines in IL-2R beta, we have found that only the two tyrosines that mediate Stat5 activation (Tyr-392 and Tyr-510) contribute to IL-2-induced IL-2R alpha gene expression and that either tyrosine alone is sufficient for this process, Interestingly, the IL-7 receptor contains a tyrosine (Tyr-429)-based sequence resembling the motifs encompassing Tyr-392 and Tyr-510 of IL-2R beta. Further paralleling the IL-2 system, IL-7 could activate Stat5 and drive expression of IL-2R alpha mRNA in 32D cells transfected with the human IL-7R. However, IL-3 could not induce IL-2R alpha mRNA in 32D cells, despite its ability to activate Stat5 via the endogenous IL-3 receptor, Moreover, the combination of IL-3 and IL-2 could not ''rescue'' IL-2R alpha mRNA expression in cells containing an IL-2R beta mutant with phenylalanine substitutions at Tyr-392 and Tyr-510, These data suggest that Tyr-392 and Tyr-510 couple to an additional signaling pathway beyond STAT protein activation in IL-2-mediated induction of the IL-2R alpha gene.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Leonard, Warren/AAA-1397-2022					ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; Leonard WJ, 1996, ANNU REV MED, V47, P229; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU KD, 1995, J BIOL CHEM, V270, P22176, DOI 10.1074/jbc.270.38.22176; MILLER J, 1985, J IMMUNOL, V134, P4212; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; OTANI H, 1993, J BIOL CHEM, V268, P22733; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHARON M, 1989, J IMMUNOL, V143, P2530; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	39	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8704	8709		10.1074/jbc.272.13.8704	http://dx.doi.org/10.1074/jbc.272.13.8704			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079703	hybrid			2022-12-27	WOS:A1997WQ63500086
J	Pahan, K; Namboodiri, AMS; Sheikh, FG; Smith, BT; Singh, I				Pahan, K; Namboodiri, AMS; Sheikh, FG; Smith, BT; Singh, I			Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SMOOTH-MUSCLE CELLS; PROTEIN KINASE-A; RENAL MESANGIAL CELLS; C6 GLIOMA-CELLS; TRANSCRIPTION FACTOR; GLIAL-CELLS; MURINE MACROPHAGES; INTERFERON-GAMMA; EXPRESSION	Nitric oxide produced by inducible nitric-oxide synthase (iNOS) in different brain cells in response to various cytokines plays an important role in the pathophysiology of stroke and other neurodegenerative diseases, This study underlines the importance of cAMP in inhibiting the induction of NO production by lipopolysaccharide (LPS) and cytokines in rat primary astrocytes, Compounds (forskolin, 8-bromo-cAMP, and (S-p)-cAMP) that increase cAMP and activate protein kinase A (PKA) were found to inhibit LPS- and cytokine-mediated production of NO as well as the expression of iNOS, whereas compounds (H-89 and (R(p))-cAMP) that decrease cAMP and PKA activity stimulated the production of NO and the expression of iNOS in rat primary astrocytes. Forskolin, but not the inactive analogue 1,9-dideoxyforskolin, inhibited NO production and iNOS expression in a dose-dependent manner in astrocytes, The inhibition of LPS- and/or cytokine-induced NO production in rat C-6 glial cells by forskolin suggest that similar to astrocytes, iNOS expression in C-6 cells is also regulated by similar mechanisms, In contrast, in rat peritoneal macrophages the cAMP analogues stimulated the LPS- and cytokine-induced production of NO. In vitro, the PKA had no effect on iNOS activity in LPS-treated astrocytes or macrophages, suggesting that PKA modulates the intracellular signaling events associated with the induction of iNOS biogenesis rather than the post-translational modification of iNOS. The compounds which activate PKA activity, blocked the activation of NF-kappa beta in astrocytes but stimulated the activation of NF-kappa beta in macrophages, This differential regulation of NF-kappa beta activation in two different cell types (astrocytes and macrophages) by the same second messenger (cAMP) indicates that intracellular events or pathways in the activation of NF-kappa beta may be different, Moreover, this inhibition of iNOS expression in LPS- and cytokine-treated astrocytes by cAMP may be of therapeutic potential in NO-mediated cytotoxicity in neurodegenerative diseases.	MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425	Medical University of South Carolina					NINDS NIH HHS [NS-22576, NS-34741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034741, R37NS022576, R01NS022576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; EBERHARDT W, 1994, BIOCHEM BIOPH RES CO, V200, P163, DOI 10.1006/bbrc.1994.1429; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENG Y, 1995, J CELL PHYSIOL, V163, P545, DOI 10.1002/jcp.1041630315; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRETEN TF, 1995, INT J IMMUNOPHARMACO, V17, P605, DOI 10.1016/0192-0561(95)00058-A; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Ikeda U, 1996, J MOL CELL CARDIOL, V28, P789, DOI 10.1006/jmcc.1996.0073; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LEE SC, 1992, J IMMUNOL, V148, P3391; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MUHL H, 1994, BRIT J PHARMACOL, V112, P1; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; PARK SK, 1994, J NEUROSCI RES, V39, P405, DOI 10.1002/jnr.490390407; RADI R, 1991, J BIOL CHEM, V266, P4244; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; SOWA G, 1994, EUR J PHARM-MOLEC PH, V266, P125, DOI 10.1016/0922-4106(94)90101-5; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WALTON KM, 1992, MOL NEUROBIOL, V4, P197; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZANG X, 1993, J EXP MED, V177, P511	51	128	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7786	7791		10.1074/jbc.272.12.7786	http://dx.doi.org/10.1074/jbc.272.12.7786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065441	hybrid			2022-12-27	WOS:A1997WP59200035
J	Brohmann, H; Pinnecke, S; HoyerFender, S				Brohmann, H; Pinnecke, S; HoyerFender, S			Identification and characterization of new cDNAs encoding outer dense fiber proteins of rat sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ASSIGNMENT; FIBROUS SHEATH; MESSENGER-RNA; DNA; FRAGMENTS; SEQUENCES; GENE; POLYACRYLAMIDE; NITROCELLULOSE; HYBRIDIZATION	A main structure of the mammalian sperm tail is a structure known as the outer dense fibers whose molecular composition as well as their function are still mostly unknown, We report here the isolation and characterization of new cDNAs (odf2) that identifies a highly variable gene locus encoding outer dense fiber proteins, Transcription of odf2 is restricted to testis and more specifically to round spermatids. Transcription starts in step 6 spermatids, which coincides with transcription of the major outer dense fiber protein gene odf1 (Burmester, S., and Hoyer-Fender, S. (1996) Mol. Reprod. Dev. 45, 10-20) and with the formation of the sperm tail, Affinity-purified anti-Odf2 antibodies identified isolated outer dense fibers immunocytochemically and detected at least three protein bands in the molecular mass range of 65,000 to 70,000 Da in total Odf protein preparations, Presence of several protein bands corre lates with the presence of several transcripts and the isolation of slightly different cDNA clones, whereas Southern blot hybridization does not indicate the presence of multiple genes, Computer analyses of the structure of the encoded Odf2 protein revealed an overall alpha-helical structure with two regions identical to the dimerization region of the leucine zipper motif.	UNIV GOTTINGEN,DEPT ZOOL DEV BIOL 3,D-37073 GOTTINGEN,GERMANY	University of Gottingen			Hoyer-Fender, Sigrid/AAV-9181-2020					BACCETTI B, 1973, J SUBMICR CYTOL PATH, V5, P237; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BURFEIND P, 1993, EUR J BIOCHEM, V216, P497, DOI 10.1111/j.1432-1033.1993.tb18168.x; BURFEIND P, 1991, DEV BIOL, V148, P195, DOI 10.1016/0012-1606(91)90329-2; Burmester S, 1996, MOL REPROD DEV, V45, P10, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;10::AID-MRD2&gt;3.0.CO;2-V; CALVIN HI, 1979, BIOL REPROD, V21, P873, DOI 10.1095/biolreprod21.4.873; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASTMANN O, 1993, MOL REPROD DEV, V36, P407, DOI 10.1002/mrd.1080360402; HENKEL R, 1992, BIOL CHEM H-S, V373, P685, DOI 10.1515/bchm3.1992.373.2.685; HOYERFENDER S, 1995, CYTOGENET CELL GENET, V70, P200, DOI 10.1159/000134033; KNORR DW, 1970, ENDOCRINOLOGY, V86, P1298, DOI 10.1210/endo-86-6-1298; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; OKO R, 1989, ANAT REC, V225, P46, DOI 10.1002/ar.1092250108; OLSON GE, 1980, BIOL REPROD, V22, P319, DOI 10.1095/biolreprod22.2.319; PRICE M, 1973, J CELL BIOL S, V59, pA272; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERA JC, 1984, J BIOL CHEM, V259, P5970; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	34	86	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10327	10332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092585	hybrid			2022-12-27	WOS:A1997WU03900104
J	Krupenko, SA; Wagner, C; Cook, RJ				Krupenko, SA; Wagner, C; Cook, RJ			Domain structure of rat 10-formyltetrahydrofolate dehydrogenase - Resolution of the amino-terminal domain as 10-formyltetrahydrofolate hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; ESCHERICHIA-COLI; LIVER CYTOSOL; ACTIVE-SITE; PURIFICATION; IDENTIFICATION; ROLES	We expressed the NH2 terminal domain of! the multidomain, multifunctional enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH), using a baculovirus expression system in insect cells, Expression of the 203-amino acid NH2-terminal domain (residues 1-203), which is 24-30% identical to a group of glycinamide ribonucleotide transformylases (EC 2.1.2.2), resulted in the appearance of insoluble recombinant protein apparently due to incorrect folding, The longer NH2-terminal recombinant protein (residues 1-310), which shares 32% identity with Escherichia coli L-methionyl-t-RNA formyltransferase (EC 2.1.2.9), was expressed as a soluble protein, During expression, this protein was released from cells to the culture medium and was purified from the culture medium by 5-formyltetrahydrofolate-Sepharose affinity chromatography followed by chromatography on a Mono-Q column, We found that the purified NH2-terminal domain bears a folate binding site, possesses 10-formyltetrahydrofolate hydrolase activity, and exists as a monomer, Titration of tryptophan fluorescence showed that native FDH bound both the substrate of the reaction, 10-formyl-5,8-dideazafolate, and the product of the reaction, 5,8-dideazafolate, with the same affinities as its NH2-terminal domain did and that both proteins bound the substrate with a 50 fold higher affinity than the product, Neither the NH2-terminal domain nor its mixture with the previously purified COOH-terminal domain had 10-formyltetrahydrofolate dehydrogenase activity, Formation of complexes between the COOH- and NH2-terminal domains also was not observed, We conclude that the 10-formyltetrahydrofolate dehydrogenase activity of FDH is a result of the action of the aldehyde dehydrogenase catalytic center residing in the COOH terminal domain on the substrate bound in the NH2-terminal domain and that the intermediate domain is necessary to bring the two functional domains together in the correct orientation.	DEPT VET AFFAIRS MED CTR,RES SERV,NASHVILLE,TN 37212	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, SA (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,612 LH,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.				NIDDK NIH HHS [DK49563, DK46788, DK15289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046788, R01DK015289, R37DK015289, R01DK049563] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; CHOW SF, 1985, J BIOL CHEM, V260, P5516; COOK RJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P336, DOI 10.1006/abbi.1995.1403; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GULLION JM, 1992, J BACTERIOL, V174, P4294; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; NEEDLEMAN S, 1979, J MOL BIOL, V48, P444; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; WAGNER C, 1995, ARCH BIOCHEM BIOPHYS, V316, P141, DOI 10.1006/abbi.1995.1021; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715	25	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10273	10278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092578				2022-12-27	WOS:A1997WU03900097
J	Rein, T; Natale, DA; Gartner, U; Niggemann, M; DePamphilis, ML; Zorbas, H				Rein, T; Natale, DA; Gartner, U; Niggemann, M; DePamphilis, ML; Zorbas, H			Absence of an unusual ''densely methylated island'' at the hamster dhfr ori-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE; 5-METHYLCYTOSINE RESIDUES; REPLICATION; GENE; PROTEIN; 5-METHYLDEOXYCYTIDINE; DEMETHYLATION; POLYMERASE; INITIATION; FRAGMENTS	An unusual ''densely methylated island'' (DMI), in which all cytosine residues are methylated on both strands for 127-516 base pairs, has been reported at mammalian origins of DNA replication. This report had far-reaching implications in understanding of DNA methylation and DNA replication. For example, since this DMI appeared in about 90% of proliferating cells, but not in stationary cells, it may regulate origin activation. In an effort to confirm and extend these observations, the DMI at the well characterized ori-beta locus 17 kilobases downstream of the dhfr gene in chromosomes of Chinese hamster ovary cells was checked for methylated cytosines in genomic DNA. The methylation status of this region was examined in randomly proliferating and stationary cells and in cell populations enriched in the G(1), S, or G(2) + M phases of their cell division cycle. DNA was subjected to 1) cleavage by methylation-sensitive restriction endonucleases, 2) hydrazine modification of cytosines followed by piperidine cleavage, and 3) permanganate modification of 5-methylcytosines (C-m) followed by piperidine cleavage. The permanganate reaction is a novel method for direct detection of C-m residues that complements the more commonly used hydrazine method. These methods were capable of detecting C-m in 2% of the cells. At the region of the proposed DMI, only one mC at a CpG site was detected. However, the ori-beta DMI was not detected in any of these cell populations using any of these methods.	UNIV MUNICH,INST BIOCHEM,D-81377 MUNICH,GERMANY; NICHHD,NIH,BETHESDA,MD 20892	University of Munich; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Natale, Darren A/AAE-9303-2019	Natale, Darren A/0000-0001-5809-9523; Rein, Theo/0000-0003-2850-4289				ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ADAMS RLP, 1983, FEBS LETT, V163, P194, DOI 10.1016/0014-5793(83)80817-5; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; FRITZSCHE E, 1987, NUCLEIC ACIDS RES, V15, P5517, DOI 10.1093/nar/15.14.5517; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GILBERT DM, 1994, COLD SPRING HARB SYM, V58, P475; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HUBRICHKUHNER K, 1989, BIOCHEM BIOPH RES CO, V160, P1175, DOI 10.1016/S0006-291X(89)80127-5; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN MS, 1995, HUM GENET, V96, P572; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Rein T, 1995, J INFLAMM, V45, P269; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SHAPIRO R, 1974, J AM CHEM SOC, V96, P906, DOI 10.1021/ja00810a043; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SZYF M, 1991, J BIOL CHEM, V266, P10027; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; TASHEVA ES, 1995, SOMAT CELL MOLEC GEN, V19, P369; VOGEL MC, 1988, FEBS LETT, V236, P9, DOI 10.1016/0014-5793(88)80275-8; WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270	44	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10021	10029						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092544				2022-12-27	WOS:A1997WU03900063
J	Yamano, A; Heo, NH; Teeter, MM				Yamano, A; Heo, NH; Teeter, MM			Crystal structure of Ser-22/Ile-25 form crambin confirms solvent, side chain substate correlations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CRAMBIN; HYDROPHOBIC PROTEIN; ATOMIC RESOLUTION; MOVEMENTS; MACROMOLECULES; 0.83-ANGSTROM; MYOGLOBIN; 130-K	It is not agreed that correlated positions of disordered protein side chains (substate correlations) can be deduced from diffraction data, The pure Ser-22/Ile-25 (SI form) crambin crystal structure confirms correlations deduced for the natural, mixed sequence form of crambin crystals, Physical separation of the mixed form into pure SI form and Pro-22/Leu-25 (PL form) crambin and the PL form crystal structure determination (Yamano, A., and Teeter, M. M. (1994) J. Biol, Chem, 269, 13956-13965) support the proposed (Teeter, M. M., Poe, S. IM., and Heo, N. H. (1993) J. Mol. Biol, 230, 292-311) correlation model, Electron density of mixed form crambin crystals shows four possible pairs of side chain conformations for heterogeneous residue 22 and nearby Tyr-29 (2(2) = 4, two conformations for each of two side chains), One combination can be eliminated because of short van der Waals' contacts, However, only two alternates have been postulated to exist in mixed form crambin: Pro22/Try-29A and Ser-22Try-29B. In crystals of the PL form, Pro-22 and Tyr-29A are found to be in direct van der Waals' contact (Yamano, A., and Teeter, M. M. (1994) J. Biol, Chem, 269, 13956-13965), Comparison of the SI form structure with the mixed form electron density confirms that the fourth combination of side chains does not occur and that side chain correlations are mediated by water networks.	BOSTON COLL,DEPT CHEM,MERKERT CHEM CTR,CHESTNUT HILL,MA 02167; KYUNGPOOK NATL UNIV,DEPT IND CHEM,TAEGU 702701,SOUTH KOREA; RIGAKU CORP,XRAY RES LAB,AKISHIMA,TOKYO 196,JAPAN	Boston College; Kyungpook National University; Rigaku Corporation								Bonvin AMJJ, 1996, J BIOMOL NMR, V7, P72; CASPAR DLD, 1995, STRUCTURE, V3, P327, DOI 10.1016/S0969-2126(01)00163-0; CASPAR DLD, 1988, NATURE, V332, P659, DOI 10.1038/332659a0; CLARAGE JB, 1995, P NATL ACAD SCI USA, V92, P3288, DOI 10.1073/pnas.92.8.3288; CLARAGE JB, 1992, PROTEINS, V12, P145, DOI 10.1002/prot.340120208; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; HENDRICKSON WA, 1980, ACTA CRYSTALLOGR A, V36, P344; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HENDRICKSON WA, 1981, NATURE, V290, P109; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCPHERSON A, 1982, PREPARATION ANAL PRO, P94; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; SMITH JL, 1986, BIOCHEMISTRY-US, V25, P5018, DOI 10.1021/bi00366a008; STEC B, 1995, ACTA CRYSTALLOGR D, V51, P663, DOI 10.1107/S0907444994014484; STURA EA, 1992, CRYSTALLIZATION NUCL, P112; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.bb.20.060191.003045; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0; YAMANO A, 1994, J BIOL CHEM, V269, P13956	24	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9597	9600						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092482				2022-12-27	WOS:A1997WU03900001
J	Arner, EC; Decicco, CP; Cherney, R; Tortorella, MD				Arner, EC; Decicco, CP; Cherney, R; Tortorella, MD			Cleavage of native cartilage aggrecan by neutrophil collagenase (MMP-8) is distinct from endogenous cleavage by aggrecanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; SYNOVIAL-FLUID; CATABOLISM; PROTEOGLYCANS; PROTEIN; SITE; IDENTIFICATION; STROMELYSIN; PROTEOLYSIS	Cleavage of aggrecan core protein at the Glu(373)-Ala(374) site by the unidentified enzyme, ''aggrecanase,'' is thought to play an important role in cartilage degradation. To examine aggrecan cleavage by MMP-8 at this aggrecanase site, we evaluated the release of fragments with the N terminus ARGSVIL from freeze-thawed bovine nasal cartilage using the monoclonal antibody BC-3. Recombinant human MMP-8 catalytic domain cleaved native aggrecan in a concentration related manner between 0.2 and 2 mu g/ml, with complete release of glycosaminoglycan at 2 mu g/ml or greater, Cleavage at the aggrecanase site was observed only at MMP-8 concentrations resulting in complete release of glycosaminoglycan from the cartilage, suggesting that preferential cleavage occurs at a different site, Time course studies indicated that only following depletion of substrate containing the preferred clip site did MMP-8 rapidly cleave at the aggrecanase site, Finally, MMP-8 resulted in a different pattern of BC-3-reactive fragments from that produced by endogenous aggrecanase in live cartilage, and SA751 (N-(1(R)-carboxyethyl)-alpha-(S)-(4-phenyl-3-butynyl)glycyl-L-O-methyltyrosine, N-methylamide), a potent inhibitor of MMP-8 (K-i = 2 nM) which was effective in blocking cleavage by MMP-8 at the aggrecanase site with an IC50 in the nanomolar range, did not prevent aggrecan degradation or specific cleavage at this site by endogenously generated aggrecanase at concentrations up to 100 mu M. Taken together these data suggest that MMP-8 does not represent cartilage aggrecanase.			Arner, EC (corresponding author), DUPONT MERCK PHARMACEUT CO,EXPT STN E4004239,POB 400,WILMINGTON,DE 19880, USA.							Arner EC, 1996, BIOCHEM J, V318, P417, DOI 10.1042/bj3180417; ARNER EC, 1991, ARTHRITIS RHEUM, V34, P1006, DOI 10.1002/art.1780340810; Chubinskaya S, 1996, LAB INVEST, V74, P232; COLE AA, 1995, ACTA ORTHOP SCA S266, V66, P1; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HUANG JJ, 1987, MOL BIOL MED, V4, P169; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; LOEHMANDER SL, 1993, ARTHRITIS RHEUM, V36, P181; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106	27	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9294	9299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083065				2022-12-27	WOS:A1997WU03700070
J	Torii, S; Naito, M; Tsuruo, T				Torii, S; Naito, M; Tsuruo, T			Apoxin I, a novel apoptosis-inducing factor with L-amino acid oxidase activity purified from western diamondback rattlesnake venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AGENT-INDUCED APOPTOSIS; LEUKEMIA U937 CELLS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; FAS-LIGAND; PURIFICATION; ACTIVATION; RESISTANCE; PROTEASES; RECEPTOR	Venom of the western diamondback rattlesnake (Crotalus atrox) induces apoptosis in human umbilical vein endothelial cells, which could result in hemorrhage in tissues bitten by the snake. To identify the hemorrhagic factor, we purified a novel protein, apoxin I, from rattlesnake venom. Apoxin I induced apoptosis in human umbilical vein endothelial, human promyelocytic leukemia HL-60, human ovarian carcinoma A2780, and mouse endothelial KN-3 cells. Amino acid sequence analysis of the apoxin I showed close similarity to L-amino acid oxidase from the Malayan pit viper (Calloselasma rhodostoma). The purified apoxin I oxidized L-leucine but not D-leucine to produce H2O2. The apoxin I-induced apoptosis was inhibited by catalase, a H2O2 scavanger. These results indicate that the H2O2 produced by L-amino acid oxidation by apoxin I is involved in the apoxin I-induced apoptosis and in hemorrhage caused by rattlesnake venom.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; JANSSEN KYOWA CO LTD,SHINAGAWA KU,TOKYO 141,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								ARAKI S, 1993, BIOCHEM BIOPH RES CO, V190, P148, DOI 10.1006/bbrc.1993.1023; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIST M, 1995, J IMMUNOL, V154, P1307; LI ZY, 1994, TOXICON, V32, P1349, DOI 10.1016/0041-0101(94)90407-3; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCCLAIN DE, 1995, FASEB J, V9, P1345, DOI 10.1096/fasebj.9.13.7557025; Noguchi K, 1996, ONCOGENE, V13, P39; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; PONNUDURAI G, 1994, ARCH BIOCHEM BIOPHYS, V313, P373, DOI 10.1006/abbi.1994.1401; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TZENG CM, 1992, BIOCHEM J, V285, P737, DOI 10.1042/bj2850737; VALLON O, 1993, EUR J BIOCHEM, V215, P351, DOI 10.1111/j.1432-1033.1993.tb18041.x; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	24	136	148	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9539	9542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083096	hybrid			2022-12-27	WOS:A1997WU03700101
J	Yule, DI; Ernst, SA; Ohnishi, H; Wojcikiewicz, RJH				Yule, DI; Ernst, SA; Ohnishi, H; Wojcikiewicz, RJH			Evidence that zymogen granules are not a physiologically relevant calcium pool - Defining the distribution of inositol 1,4,5-trisphosphate receptors in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCRINE PANCREAS; CA2+ OSCILLATIONS; PROTEIN-KINASE; SECRETION; TRISPHOSPHATE; LOCALIZATION; MEMBRANE; GP-3	A key event leading to exocytosis of pancreatic acinar cell zymogen granules is the inositol 1,4,5-trisphosphate (InsP(3))-mediated release of Ca2+ from intracellular stores. Studies using digital imaging microscopy and laser-scanning confocal microscopy have indicated that the initial release of Ca2+ is localized to the apical region of the acinar cell, an area of the cell dominated by secretory granules. Moreover, a recent study has shown that InsP(3) is capable of releasing Ca2+ from a preparation enriched in secretory granules (Gerasimenko, O., Gerasimenko, J., Belan, P., and Petersen, O. H., (1996) Cell 84, 473-480). In the present study, we have investigated the possibility that zymogen granules express InsP(3) receptors and are thus Ca2+ release sites. Immunofluorescence staining, obtained with antisera specific to types I, II, or III InsP(3) receptors and analyzed by confocal fluorescence microscopy revealed that all InsP(3) receptor types were present in acinar cells. The type II receptor localized exclusively to an area close to or at the luminal plasma membrane. While types I and III InsP(3) receptors displayed a similar luminal distribution, these receptors were also present at low levels in nuclei. The localization of InsP(3) receptor was in marked contrast to the distribution of amylase, a zymogen granule content protein. In a zymogen granule fraction prepared in an identical manner to the aforementioned report demonstrating InsP(3)-induced Ca2+ release, immunoblotting demonstrated the presence of types I, II, and III InsP(3) receptors, Ca2+ release from this preparation in response to InsP(3), but not thapsigargin, could also be demonstrated. In contrast, when the zymogen granules were further purified on a Percoll gradient, InsP(3) receptors were undetectable, and InsP(3) failed to release Ca2+. Transmission electron microscopy performed on both preparations showed that the Percoll-purified granule preparation consisted of essentially pure zymogen granules, whereas the granules prepared without this step were enriched in granules but also contained significant contamination by mitochondria, endoplasmic reticulum, and nuclei, It is concluded that zymogen granules do not express InsP(3) receptors and thus are not a site of Ca2+ release relevant to the secretory process in the pancreatic acinar cell.	UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; SUNY HLTH SCI CTR, DEPT PHARMACOL, SYRACUSE, NY 13210 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Yule, DI (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, 7744 MED SCI 2, 1150 W MED CTR, ANN ARBOR, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049194, P30DK034933, R01DK041122] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 41122, DK 34933, R29 DK49194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BROCKBANK KJ, 1980, FEBS LETT, V122, P67, DOI 10.1016/0014-5793(80)80403-0; BUITRAGO A, 1977, BIOCHEM BIOPH RES CO, V79, P823, DOI 10.1016/0006-291X(77)91185-8; BURNHAM DB, 1985, BIOCHEM J, V227, P743, DOI 10.1042/bj2270743; DELISLE RC, 1986, AM J PHYSIOL, V250, pG489, DOI 10.1152/ajpgi.1986.250.4.G489; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; DEUTSCH DE, 1995, AM J PHYSIOL-GASTR L, V269, pG779, DOI 10.1152/ajpgi.1995.269.5.G779; DORMER RL, 1981, AM J PHYSIOL, V240, pG130, DOI 10.1152/ajpgi.1981.240.2.G130; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; SCHEELE G, 1980, J BIOL CHEM, V255, P4918; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THREVENOD F, 1992, J MEMBRANE BIOL, V129, P253; WAGNER ACC, 1994, J BIOL CHEM, V269, P9099; Williams John A., 1993, P167; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; YULE DI, 1993, J BIOL CHEM, V268, P12353; Yule DI, 1996, MOL BIOL CELL, V7, P3834	29	160	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9093	9098						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083036				2022-12-27	WOS:A1997WU03700041
J	Basile, A; Sica, A; dAniello, E; Breviario, F; Garrido, G; Castellano, M; Mantovani, A; Introna, M				Basile, A; Sica, A; dAniello, E; Breviario, F; Garrido, G; Castellano, M; Mantovani, A; Introna, M			Characterization of the promoter for the human long pentraxin PTX3 - Role of NF-kappa B in tumor necrosis factor-alpha and interleukin-1 beta regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; AMYLOID-P-COMPONENT; RAT ALPHA-2-MACROGLOBULIN GENE; TRANSCRIPTIONAL ACTIVATION; NEURONAL PENTRAXIN; PENTAXIN FAMILY; C/EBP FAMILY; DNA-BINDING; A-PROTEIN	The ''long pentraxins'' are an emerging family of genes that have conserved in their carboxy-terminal halves a pentraxin domain homologous to the prototypical acute phase protein pentraxins (C-reactive protein and serum amyloid P component) and acquired novel amino-terminal domains. In this report, a genomic fragment of 1371 nucleotides from the human ''long pentraxin'' gene PTX3 is characterized as a promoter on tumor necrosis factor-alpha (TNF alpha) and interleukin (IL)-1 beta exposure in transfected 8387 human fibroblasts by chloramphenicol acetyltransferase and RNase protection assays. In the same cells, the PTX3 promoter does not respond to IL-6 stimulation. Furthermore, IL-1 beta and TNF alpha responsiveness is not seen in the Hep 3B hepatoma cell line, The minimal promoter contains one NF-kappa B element which is shown to be necessary for induction and able to bind p50 homodimers and p65 heterodimers but not c-Rel. Mutants in this site lose the ability to bind NF-kappa B proteins and to respond to TNF alpha and IL-1 beta in functional assays. Sp1- and AP-1 binding sites lying in proximity to the NF-kappa B site do not seem to play a major role for cytokine responsiveness. Finally, cotransfection experiments with expression vectors validate that the natural promoter contains a functional NF-kappa B site.	MARIO NEGRI INST PHARMACOL RES,DEPT IMMUNOL & CELL BIOL,LAB MOL IMMUNOHEMATOL,I-20157 MILAN,ITALY; UNIV BRESCIA,SECT GEN PATHOL & IMMUNOL,I-25123 BRESCIA,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia			Garrido, Gabino/G-2248-2012; Introna, Martino/AAA-5823-2019; Mantovani, Alberto/HCI-7449-2022; Sica, Antonio/AAB-9546-2020	Garrido, Gabino/0000-0002-4547-4109; Introna, Martino/0000-0001-6216-0892; Mantovani, Alberto/0000-0001-5578-236X; BASILE, ANDREA/0000-0001-6739-8613				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALLES VV, 1994, BLOOD, V84, P3483; ALTMEYER A, 1995, J BIOL CHEM, V270, P25584, DOI 10.1074/jbc.270.43.25584; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; CILIBERTO G, 1993, GEN CELL TYPE SPECIF, P200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GOLAY J, 1991, BLOOD, V77, P149; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; Introna M, 1996, BLOOD, V87, P1862; ITOH Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P261, DOI 10.1016/0167-4781(92)90024-T; JAHAVERY R, 1994, MOL CELL BIOL, V14, P116; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KU NO, 1993, BIOCHEM J, V295, P379, DOI 10.1042/bj2950379; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE GW, 1994, J IMMUNOL, V153, P3700; LEE GW, 1993, J IMMUNOL, V150, P1804; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI SP, 1990, J BIOL CHEM, V265, P4136; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANN EA, 1991, J BIOL CHEM, V266, P16931; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MURPHY C, 1995, J BIOL CHEM, V270, P704, DOI 10.1074/jbc.270.2.704; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REID MS, 1994, J BIOL CHEM, V269, P32615; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; WANG JM, 1986, J IMMUNOL, V137, P2726	48	137	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8172	8178		10.1074/jbc.272.13.8172	http://dx.doi.org/10.1074/jbc.272.13.8172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079634	hybrid			2022-12-27	WOS:A1997WQ63500017
J	Cichy, J; Potempa, J; Travis, J				Cichy, J; Potempa, J; Travis, J			Biosynthesis of alpha(1)-proteinase inhibitor by human lung-derived epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; ONCOSTATIN-M; AFFINITY ELECTROPHORESIS; PROTEINS; ALPHA-1-ANTITRYPSIN; GLYCOSYLATION; EMPHYSEMA; RECEPTOR; CDNA	Destruction of components of the extracellular matrix of the lung by neutrophil elastase is believed to be a critical event in the development of obstructive lung disease. The local synthesis of alpha(1)-proteinase inhibitor, the controlling inhibitor of this enzyme, may provide a partial mechanism for neutrophil elastase regulation, especially during inflammation, when proteolytic enzymes are released from phagocytes. In this study, we show that lung-derived epithelial cells not only have the capacity to synthesize functional alpha(1)-PI but also to increase the rate of its production when stimulated by specific inflammatory mediators, including oncostatin M, interleukin-1, and the glucocorticoid analogue, dexamethasone.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; JAGIELLONIAN UNIV, INST MOL BIOL, DEPT MICROBIOL & IMMUNOL, PL-31120 KRAKOW, POLAND	University System of Georgia; University of Georgia; Jagiellonian University				Cichy, Joanna/0000-0002-0552-8344	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL137090, R01HL037090, R01HL026148, R37HL037090] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37090, HL 26148] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; CICHY J, 1995, FEBS LETT, V359, P262, DOI 10.1016/0014-5793(95)00064-G; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MACKIEWICZ A, 1986, ANAL BIOCHEM, V156, P481, DOI 10.1016/0003-2697(86)90282-4; MACKIEWICZ A, 1989, ELECTROPHORESIS, V10, P830, DOI 10.1002/elps.1150101206; MACKIEWICZ A, 1993, EUR J CELL BIOL, V60, P331; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILNE EM, 1994, ELECTROPHORESIS, V15, P1193, DOI 10.1002/elps.11501501180; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; OHLSSON K, 1975, EUR J CLIN INVEST, V5, P221, DOI 10.1111/j.1365-2362.1975.tb02288.x; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SALIER JP, 1980, ELECTROPHORESIS, V1, P193; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHERRER K, 1962, BIOCHEM BIOPH RES CO, V7, P486, DOI 10.1016/0006-291X(62)90341-8; THOMA B, 1994, J BIOL CHEM, V269, P6215; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660	23	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8250	8255		10.1074/jbc.272.13.8250	http://dx.doi.org/10.1074/jbc.272.13.8250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079644	hybrid			2022-12-27	WOS:A1997WQ63500027
J	Leger, J; Kempf, M; Lee, G; Brandt, R				Leger, J; Kempf, M; Lee, G; Brandt, R			Conversion of serine to aspartate imitates phosphorylation-induced changes in the structure and function of microtubule-associated protein tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; DYNAMIC INSTABILITY; ALZHEIMERS-DISEASE; NONNEURONAL CELLS; DEPENDENT KINASE; IDENTIFICATION; SITES; NUCLEATION; BINDING; TANGLES	Microtubule-associated protein tau is a neuronal phosphoprotein that promotes microtubule assembly in vitro and has been shown to play a role in the development of axonal morphology. Tau can be phosphorylated in vitro by several kinases, some of which cause a change in the conformation and activities of tau. Here we report the consequences of converting two of the protein kinase A phosphorylation sites (positions 156 and 327), first to alanine to eliminate phosphorylation, and second to aspartate, to mimic phosphorylation. We show that a serine to aspartate mutation at position 327 results in a conformational change similar to that caused by phosphorylation of this residue. This mutation does not affect the activities of tau in microtubule assembly as compared with wild-type tau. However, an additional mutation at position 156 to aspartate drastically decreases the microtubule nucleation activity of tau but does not affect the activity of tau to promote microtubule growth. All constructs are similarly bound to microtubules and promote process formation when expressed in cytochalasin-treated PC12 cells. We conclude that serine to aspartate mutations provide a useful system for analyzing the effect of individual phosphorylation sites on the conformation and function of tau in vitro and in cells. The results provide evidence that microtubule growth and nucleation can be differentially affected by phosphorylation of individual residues in a region amino-terminally flanking the microtubule binding domain of tau.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Ruprecht Karls University Heidelberg; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Lee, Gloria/F-5965-2011	Brandt, Roland/0000-0003-0101-1257; Lee, Gloria/0000-0002-8633-1534				BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRANDT R, 1994, CELL MOTIL CYTOSKEL, V28, P143, DOI 10.1002/cm.970280206; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BRANDT R, 1993, J NEUROCHEM, V61, P997, DOI 10.1111/j.1471-4159.1993.tb03613.x; BRANDT R, 1996, FRONT BIOSCI, V1, P118; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; EDSON K, 1993, DEVELOPMENT, V117, P689; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE G, 1992, J CELL SCI, V102, P227; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEGER JG, 1994, J CELL SCI, V107, P3403; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; LU Q, 1993, J NEUROSCI, V13, P508; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437	42	100	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8441	8446		10.1074/jbc.272.13.8441	http://dx.doi.org/10.1074/jbc.272.13.8441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079670	hybrid			2022-12-27	WOS:A1997WQ63500053
J	McGary, EC; Rondon, IJ; Beckman, BS				McGary, EC; Rondon, IJ; Beckman, BS			Post-transcriptional regulation of erythropoietin mRNA stability by erythropoietin mRNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYDROXYLASE MESSENGER-RNA; GENE-TRANSCRIPTION; HYPOXIA; EXPRESSION; CELLS; RADIOIMMUNOASSAY; POLYMERASE; HOMOLOGY; ELEMENTS	We have previously identified a sequence in the 3'-untranslated region (3'-UTR) of erythropoietin (Epo) mRNA which binds a protein(s), erythropoietin mRNA-binding protein (ERBP). A mutant lacking the ERBP binding site (Epo(M)) was generated. Hep3B cells were stably transfected with a wild-type Epo (Epo(WT)) cDNA or Epo(M) cDNA construct located downstream of a promoter of cytomegalovirus. Following inhibition of transcription, the half-lives of Epo(WT) and Epo(M) mRNAs were 7 h and 2.5 h in normoxia, respectively. The Epo(M) mRNA half-life remained unchanged in hypoxia, Epo(WT) mRNA half-life increased similar to 40% in response to a 6-h hypoxic pre-exposure and an additional similar to 50% when preexposed to 12 h hypoxia, The steady-state level of Epo(WT) mRNA was 4-fold that of Epo(M) mRNA reflecting the difference in mRNA decay rates in normoxia, The Epo protein level expressed from exogenous Epo(M) was unchanged in both normoxia and hypoxia, In contrast, the Epo protein level expressed from exogenous Epo(WT) increased 50% in hypoxia when compared with normoxia. These observations were further supported by chimeric chloramphenicol acetyltransferase and Epo-3'-UTR constructs. We have demonstrated that Epo mRNA stability was modulated in normoxia and further by hypoxia, therefore, providing evidence that Epo is regulated at the post-transcriptional level through ERBP complex formation.	TULANE UNIV,SCH MED,DEPT PHARMACOL,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,TULANE CANC CTR,NEW ORLEANS,LA 70112	Tulane University; Tulane University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040501] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHARD KL, 1993, STEM CELLS, V11, P1, DOI 10.1002/stem.5530110604; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; ERSLEV AJ, 1975, AM J MED, V58, P25, DOI 10.1016/0002-9343(75)90529-X; FANDREY J, 1993, BLOOD, V81, P617; GALSON DL, 1993, BLOOD, V82, P3321; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; HO V, 1995, J BIOL CHEM, V270, P10084, DOI 10.1074/jbc.270.17.10084; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KURATOWSKA Z, 1961, BLOOD, V18, P527, DOI 10.1182/blood.V18.5.527.527; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MASONGARCIA M, 1990, KIDNEY INT, V38, P969, DOI 10.1038/ki.1990.299; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; REGE AB, 1982, J LAB CLIN MED, V100, P829; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; UENO M, 1989, AM J PHYSIOL, V257, pC743, DOI 10.1152/ajpcell.1989.257.4.C743; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	30	66	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8628	8634		10.1074/jbc.272.13.8628	http://dx.doi.org/10.1074/jbc.272.13.8628			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079694	hybrid			2022-12-27	WOS:A1997WQ63500077
J	Patterson, C; Wu, YX; Lee, ME; DeVault, JD; Runge, MS; Haber, E				Patterson, C; Wu, YX; Lee, ME; DeVault, JD; Runge, MS; Haber, E			Nuclear protein interactions with the human KDR/flk-1 promoter in vivo - Regulation of Sp1 binding is associated with cell type-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; LIGATION-MEDIATED PCR; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR; IN-VIVO; DEVELOPMENTAL EXPRESSION; VASCULAR ENDOTHELIUM; DNA; FLK-1; ENHANCER	The endothelial cell type-specific tyrosine kinase KDR/flk-1 is a receptor for vascular endothelial growth factor and a critical regulator of endothelial cell growth and development. To study mechanisms of endothelial cell differentiation and gene regulation, we have analyzed the topology of the proximal promoter of human KDR/flk-1. A protected sequence between base pairs -110 and -25 was defined by in vitro DNase I footprinting analysis in human umbilical vein endothelial cells (HUVECs), Purified Sp1 alone produced similar protection, and electrophoretic mobility shift assays demonstrated that Sp1 was indeed the major nuclear protein binding to this region, Despite the cell type specificity of KDR/flk-1 expression, no cell type differences were observed in DNA-protein interactions in vitro, In contrast, in vivo footprinting assays demonstrated marked differences in core promoter interactions between cell types, Protection of Sp1 binding sites was observed in HUVECs by in vivo DNase I footprinting, whereas in human fibroblasts and HeLa cells a pattern consistent with nucleosomal positioning was observed. In vivo dimethylsulfate footprinting confirmed that DNA-protein interactions occurred within Sp1 elements in HUVECs but not in nonendothelial cells. It is possible that distant elements coordinate Sp1 binding and chromatin structure to regulate cell type-specific expression of KDR/flk-1.	HARVARD UNIV, SCH PUBL HLTH, CARDIOVASC BIOL LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Patterson, C (corresponding author), UNIV TEXAS, MED BRANCH, DIV CARDIOL, 301 UNIV BLVD, 9-138 MED RES BLDG, GALVESTON, TX 77555 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016771] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57664-01] Funding Source: Medline; NIGMS NIH HHS [GM16771-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CONTRERAS R, 1981, NUCLEIC ACIDS RES, V9, P215, DOI 10.1093/nar/9.2.215; Dang Q, 1996, J BIOL CHEM, V271, P28667, DOI 10.1074/jbc.271.45.28667; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINIE ME, 1992, DEVELOPMENT, V115, P1149; Moore DD, 1995, GLOB MOB SURV; MUELLER P, 1995, CURRENT PROTOCOLS MO; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OI B, 1994, J BIOL CHEM, V269, P7756; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PLATE KH, 1993, CANCER RES, V53, P5822; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SUN D, 1994, BIOCHEMISTRY-US, V33, P9578, DOI 10.1021/bi00198a025; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	46	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8410	8416		10.1074/jbc.272.13.8410	http://dx.doi.org/10.1074/jbc.272.13.8410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079666	hybrid			2022-12-27	WOS:A1997WQ63500049
J	Qiu, ZH; Goodman, MF				Qiu, ZH; Goodman, MF			The Escherichia coli polB locus is identical to dinA, the structural gene for DNA polymerase II - Characterization of Pol II purified from a polB mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTIVE MUTATION; VIRAL-DNA; DAMAGE; PURIFICATION; DEFICIENT	Escherichia coli DNA polymerase II (Pol II) is a member of the group B, ''alpha-like'' family of DNA polymerases. Pol II is encoded by the damage-inducible dinA gene and exhibits SOS induction under the control of Lex A repressor. The polB gene was originally designated as the structural gene for Pol II based on the absence of detectable Pol II activity in cell lysates prepared from a strain containing the mutant polB100 allele. Because polB and dinA mapped at different chromosomal locations, it remained an open question whether polB, in addition to lexA, might be involved in regulating the expression of Pol II. We have cloned and sequenced the polB100 mutant allele, including adjacent surrounding sequences, and have expressed the mutant dinA gene from Pol B100 on a high copy number plasmid. Our sequence data reveal that polB and dinA represent the same gene and that the original transduction mapping of polB was inaccurate. We purified the mutant pol B100 polymerase and show that it retains 5 to 10% of the wild-type level of polymerase activity. The Pol B100 mutation, Gly401 --> Asp(401), is not located within any of the five conserved domains that define group B polymerases. Pol B100 retains a wild-type level of 3' --> 5' exonuclease activity. We suggest that the normal level of exonucleolytic proofreading associated with the mutant Pol B100 enzyme may explain the repeated failures, over the past two decades, to detect phenotypes in polB mutant strains.	UNIV SO CALIF, DEPT BIOL SCI, HEDCO MOL BIOL LABS, LOS ANGELES, CA 90089 USA	University of Southern California					NIA NIH HHS [T32 AG00093] Funding Source: Medline; NIGMS NIH HHS [GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000093] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON WF, 1994, J MOL BIOL, V238, P120, DOI 10.1006/jmbi.1994.1765; BONNER CA, 1988, J BIOL CHEM, V263, P18946; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; Cai H, 1995, METHOD ENZYMOL, V262, P13; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CAMPBELL JL, 1974, J BACTERIOL, V119, P494, DOI 10.1128/JB.119.2.494-499.1974; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; FOSTER PL, 1995, P NATL ACAD SCI USA, V92, P7951, DOI 10.1073/pnas.92.17.7951; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; HIROTA Y, 1972, P NATL ACAD SCI USA, V69, P3238, DOI 10.1073/pnas.69.11.3238; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JUNG G, 1987, P NATL ACAD SCI USA, V84, P8287, DOI 10.1073/pnas.84.23.8287; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; KNIPPERS R, 1970, NATURE, V228, P1050, DOI 10.1038/2281050a0; KORNBERG A, 1992, DNA REPLICATION, P167; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Rangarajan S, 1997, P NATL ACAD SCI USA, V94, P946, DOI 10.1073/pnas.94.3.946; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120	28	56	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8611	8617		10.1074/jbc.272.13.8611	http://dx.doi.org/10.1074/jbc.272.13.8611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079692	hybrid			2022-12-27	WOS:A1997WQ63500075
J	Zhong, HL; Vershon, AK				Zhong, HL; Vershon, AK			The yeast homeodomain protein MAT alpha 2 shows extended DNA binding specificity in complex with Mcm1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATING TYPE LOCUS; HOMEO DOMAIN PROTEIN; CRYSTAL-STRUCTURE; CELL-TYPE; SEQUENCE RECOGNITION; SACCHAROMYCES-CEREVISIAE; REPRESSOR ALPHA-2; COOPERATIVE INTERACTIONS; OPERATOR; TRANSCRIPTION	The MAT alpha 2 (alpha 2) repressor interacts with the Mcm1 protein to turn off a-cell type-specific genes in the yeast Saccharomyces cerevisiae. We compared five natural alpha 2-Mcm1 sites with an alpha 2-Mcm1 symmetric consensus site (AMSC) for their relative strength of repression and found that the AMSC functions slightly better than any of the natural sites. To further investigate the DNA binding specificity of alpha 2 in complex with Mcm1, symmetric substitutions at each position in the alpha 2 half-sites of AMSC were constructed and assayed for their effect on repression in vivo and DNA binding affinity in vitro. As expected, substitutions at positions in which there are base-specific contacts decrease the level of repression. interestingly, substitutions at other positions, in which there are no apparent base-specific contacts made by the protein in the alpha 2-DNA co-crystal structure, also significantly decrease repression. As an alternative method to examining the DNA binding specificity of alpha 2, we performed in vitro alpha 2 binding site selection experiments in the presence and absence of Mcm1. In the presence of Mcm1, the consensus sequences obtained were extended and more closely related to the natural alpha 2 sites than the consensus sequence obtained in the absence of Mcm1. These results demonstrate that in the presence of Mcm1 the sequence specificity of alpha 2 is extended to these positions.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick					NIGMS NIH HHS [GM49265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON TB, 1997, IN PRESS MOL CELL BI, V17; AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAKE A, 1985, TRANSPORT SECRETION, P103; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1996, MOL CELL BIOL, V16, P1764; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MACKAY VL, 1974, GENETICS, V76, P272; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; Mead J, 1996, MOL CELL BIOL, V16, P2135; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SPRAGUE GF, 1983, ANNU REV MICROBIOL, V37, P623, DOI 10.1146/annurev.mi.37.100183.003203; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON KL, 1986, P NATL ACAD SCI USA, V83, P2536, DOI 10.1073/pnas.83.8.2536; WILSON KL, 1984, MOL CELL BIOL, V4, P2420, DOI 10.1128/MCB.4.11.2420; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1992, TRANSCRIPTIONAL REGU, P535; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	55	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8402	8409		10.1074/jbc.272.13.8402	http://dx.doi.org/10.1074/jbc.272.13.8402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079665	hybrid			2022-12-27	WOS:A1997WQ63500048
J	Narayan, VA; Kriwacki, RW; Caradonna, JP				Narayan, VA; Kriwacki, RW; Caradonna, JP			Structures of zinc finger domains from transcription factor Sp1 - Insights into sequence-specific protein-DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ENHANCER BINDING-PROTEIN; RNA POLYMERASE-II; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; GENE-32 PROTEIN; METAL-IONS; YEAST ADR1; ACTIVATION; SPECTROSCOPY	The carboxyl terminus of transcription factor Spl contains three contiguous Cys(2)-His(2) zinc finger domains with the consensus sequence Cys-X(2-4)Cys-X(12)-His=X(12)-His-X(3)-His. We have used standard homonuclear two-dimensional MMR techniques to solve the solution structures of synthetic peptides corresponding to the last two zinc finger domains (Sp1f2 and Sp1f3, respectively) of Spl, Our studies indicate a classical Cys(2)-His(2) type fold for both the domains differing from each other primarily in the conformation of Cys-X(4)-Cys (beta-type I turn) and Cys-X(4)-Cys (beta-type II turn) elements. There are, however, no significant differences in the metal binding properties between the Cys-X(4)-Cys (Sp1f2) and Cys-X(2)-Cys (Sp1f3) subclasses of zinc fingers. The free solution structures of Sp1f2 and Sp1f3 are very similar to those of the analogous fingers of Zif268 bound to DNA. There is NMR spectral evidence suggesting that the Arg-Asp buttressing interaction observed in the Zif-268-DNA complex is also preserved in unbound Sp1f2 and Sp1f3. Modeling Sp1-DNA complex by overlaying the Sp1f2 and Sp1f3 structures on Zif268 fingers I and 2, respectively, predicts the role of key amino acid residues, the interference/protection data, and supports the model of Sp1-DNA interaction proposed earlier.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA	Yale University			Kriwacki, Richard/N-8154-2018; Wilson, Matthew H/K-3193-2013	Kriwacki, Richard/0000-0002-9798-6018; 	NIGMS NIH HHS [GM 48346, 5 T32 GM08293-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; Bagshaw C. R., 1987, SPECTROPHOTOMETRY SP, P91; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERNSTEIN BE, 1994, BIOCHEMISTRY-US, V33, P4460, DOI 10.1021/bi00181a005; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BODENHAUSEN G, 1980, J MAGN RESON, V37, P93, DOI 10.1016/0022-2364(80)90096-7; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHLEBOWSKI JF, 1976, MET IONS BIOL SYST, V6, P1; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GRAY HB, 1980, METHODS DETERMINING, V2, P1; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KUWAHARA J, 1993, BIOCHEMISTRY-US, V32, P5994, DOI 10.1021/bi00074a010; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS MK, 1982, ENZYMES, V15, P109; LIONS F, 1967, J CHEM SOC A, P565, DOI 10.1039/j19670000565; MARET W, 1993, METHOD ENZYMOL, V226, P52; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIU HW, 1994, BIOCHEMISTRY-US, V33, P8139, DOI 10.1021/bi00192a019; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P21, DOI 10.1021/ja00834a006; SCHOLER HJ, 1988, ARCHITECTURE EUKARYO, P89; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SHINNAR M, 1989, MAGNET RESON MED, V12, P74, DOI 10.1002/mrm.1910120109; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUZUKI M, 1991, P ROY SOC B-BIOL SCI, V246, P231, DOI 10.1098/rspb.1991.0149; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771; Wuthrich K, 1986, NMR PROTEINS NUCL AC	71	127	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7801	7809		10.1074/jbc.272.12.7801	http://dx.doi.org/10.1074/jbc.272.12.7801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065444	hybrid			2022-12-27	WOS:A1997WP59200038
J	Peng, SS; Kumar, TKS; Jayaraman, G; Chang, CC; Yu, C				Peng, SS; Kumar, TKS; Jayaraman, G; Chang, CC; Yu, C			Solution structure of toxin b, a long neurotoxin from the venom of the king cobra (Ophiophagus hannah)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NAJA-NAJA-ATRA; ALPHA-BUNGAROTOXIN; SNAKE-VENOMS; CHEMICAL MODIFICATION; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; ACETYLCHOLINE-RECEPTOR; SOLUTION CONFORMATION; BINDING REGIONS	The solution structure of toxin b, a long neurotoxin (73 amino acids and 5 disulfides) from the venom of Ophiophagus hannah (king cobra), has been determined using H-1 NMR and dynamical simulated annealing techniques. The structures were calculated using 485 distance constraints and 52 dihedral angle restraints. The 21 structures that were obtained satisfy the experimental restraints and possess good nonbonded contacts. Analysis of the converged structures revealed that the protein consists of a core region from which three finger-like loops extend outwards, The regular secondary structure in toxin b includes a double and a triple stranded antiparallel beta sheet. Comparison with the solution structures of other long neurotoxins reveals that although the structure of toxin b is similar to those of previously reported long neurotoxins, clear local structural differences are observed in regions proposed to be involved in binding to the acetylcholine receptor. A positively charged cluster is found in the C-terminal tail, in Loop III, and in the tip of Loop II. This cationic cluster could be crucial for the binding of the long neurotoxins to the acetylcholine receptor.	NATL TSING HUA UNIV,DEPT CHEM,HSINCHU,TAIWAN; KAOHSIUNG MED COLL,DEPT BIOCHEM,KAOHSIUNG,TAIWAN	National Tsing Hua University; Kaohsiung Medical University			Jayaraman, G./AAA-6219-2019; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016	Jayaraman, G./0000-0001-5729-2719; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373				BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BAX A, 1985, J MAGN RESON, V65, P335; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BHASKARAN R, 1994, J BIOL CHEM, V269, P23500; BROWN LR, 1992, J MOL BIOL, V227, P118; Brunger A.T., 1992, X PLOR SOFTWARE MANU; CHANG CC, 1993, BIOCHEM BIOPH RES CO, V191, P214, DOI 10.1006/bbrc.1993.1205; CHANG CC, 1995, J PROTEIN CHEM, V14, P89, DOI 10.1007/BF01888366; Chang Chun-Chang, 1994, Journal of the Chinese Biochemical Society, V23, P83; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CHAZIN WJ, 1988, J MOL BIOL, V202, P603, DOI 10.1016/0022-2836(88)90290-2; CHICHEPORTICHE R, 1975, BIOCHEMISTRY-US, V14, P2081, DOI 10.1021/bi00681a007; CLORE GM, 1985, J MOL BIOL, V186, P435, DOI 10.1016/0022-2836(85)90116-0; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; DUFTON MJ, 1983, CRC CR REV BIOCH MOL, V14, P113, DOI 10.3109/10409238309102792; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; ENDO T, 1987, BIOCHEMISTRY-US, V26, P4592, DOI 10.1021/bi00388a063; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; GOAS RL, 1992, BIOCHEMISTRY-US, V31, P4867; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; LIN SR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P255, DOI 10.1016/0167-4838(92)90053-G; LIN SR, 1991, TOXICON, V29, P937, DOI 10.1016/0041-0101(91)90077-5; LIN SR, 1995, J BIOCHEM-TOKYO, V118, P297, DOI 10.1093/oxfordjournals.jbchem.a124906; Lin SR, 1996, J PROTEIN CHEM, V15, P95, DOI 10.1007/BF01886815; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MULACJERICEVIC B, 1987, BIOCHEM J, V248, P847, DOI 10.1042/bj2480847; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PILLET L, 1993, J BIOL CHEM, V268, P909; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V113, P967; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG CC, 1974, TOXICON, V12, P1, DOI 10.1016/0041-0101(74)90096-8; YU C, 1994, J TOXICOL-TOXIN REV, V13, P291, DOI 10.3109/15569549409089966; YU C, 1993, BIOCHEMISTRY-US, V32, P21312	45	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7817	7823		10.1074/jbc.272.12.7817	http://dx.doi.org/10.1074/jbc.272.12.7817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065446	hybrid			2022-12-27	WOS:A1997WP59200040
J	Oster, U; Bauer, CE; Rudiger, W				Oster, U; Bauer, CE; Rudiger, W			Characterization of chlorophyll a and bacteriochlorophyll a synthases by heterologous expression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-CAPSULATUS; TERMINAL STEPS; BIOSYNTHESIS; SYNTHETASE; GENES; GERANYLGERANIOL; ACCUMULATION	Genes coding for putative chlorophyll a synthase (chlG) from Synechocystis sp, PCC 6803 and bacteriochlorophyll a synthase (bchG) from Rhodobacter capsulatus were amplified by the polymerase chain reaction and cloned into T7 RNA polymerase-based expression plasmids, In vitro enzymatic assays indicated that heterologous expression of the chlG and bchG gene products in Escherichia coli conferred chlorophyll a and bacteriochlorophyll a synthase activity, respectively, Chlorophyll a synthase utilized chlorophyllide a, but not bacteriochlorophyllide a, as a substrate, whereas bacteriochlorophyll a synthase utilized bacteriochlorophyllide a, but not chlorophyllide a. Both enzymes were also observed to exhibit a marked preference for phytyl diphosphate over geranylgeranyl diphosphate.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; UNIV MUNICH, INST BOT, D-86038 MUNICH, GERMANY	Indiana University System; Indiana University Bloomington; University of Munich					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000618, R01GM053940] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053940, GM00618, GM53940, R01 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI M, 1995, ANOXYGENIC PHOTOSYNT, P1082; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAUER CE, 1993, J BACTERIOL, V175, P3919, DOI 10.1128/JB.175.13.3919-3925.1993; BENZ J, 1981, Z NATURFORSCH C, V36, P51; BOLLIVAR DW, 1994, BIOCHEMISTRY-US, V33, P12763, DOI 10.1021/bi00209a006; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BOLLIVAR DW, 1994, J BACTERIOL, V176, P5290, DOI 10.1128/JB.176.17.5290-5296.1994; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; FIEDOR L, 1992, J BIOL CHEM, V267, P22043; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; HELFRICH M, 1994, EUR J BIOCHEM, V219, P267, DOI 10.1111/j.1432-1033.1994.tb19938.x; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; Lopez JC, 1996, J BACTERIOL, V178, P3369, DOI 10.1128/jb.178.11.3369-3373.1996; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; RUDIGER W, 1980, EUR J BIOCHEM, V109, P193, DOI 10.1111/j.1432-1033.1980.tb04784.x; Rudiger W, 1993, PIGMENT PROTEIN COMP, P219; RUDIGER W, 1991, CHLOROPHYLLS, P451; SHIOI Y, 1984, J BACTERIOL, V158, P340, DOI 10.1128/JB.158.1.340-343.1984; SOLL J, 1983, PLANT PHYSIOL, V71, P849, DOI 10.1104/pp.71.4.849; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; White R. W., 1996, ESCHERICHIA COLI SAL, P637; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YANG ZM, 1990, J BACTERIOL, V172, P5001, DOI 10.1128/jb.172.9.5001-5010.1990	26	78	88	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9671	9676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092496				2022-12-27	WOS:A1997WU03900015
J	Yang, XD; Yu, L; Yu, CA				Yang, XD; Yu, L; Yu, CA			Resolution and reconstitution of succinate-ubiquinone reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; OXIDOREDUCTASE; IDENTIFICATION; DEHYDROGENASE; PURIFICATION; COMPLEX; PROTEIN; HEART; CYTOCHROME-B556; SUBUNITS	A modified procedure is developed for isolation of highly purified succinate-ubiquinone reductase from Escherichia coli NM256 containing a cloned sdh operon in a multicopy plasmid, Succinate-ubiquinone reductase is solubilized from the membrane by polyoxyethylene-9-lauryl ether and purified by DEAE-Sepharose CL-6B column chromatography, The isolated reductase is resolved into a reconstitutively active, two-subunit succinate dehydrogenase and a two-subunit membrane anchoring protein fraction (the SdhC-SdhD fraction) by alkaline (pH 10.2) treatment of the reductase in the presence of 1 M urea, followed by DEAE-Sepharose CL-6B column chromatography under anaerobic conditions, Isolated succinate dehydrogenase and the SdhC-SdhD fraction alone show no succinate-ubiquinone reductase activity, However, when a given amount of the SdhC-SdhD fraction is mixed with varying amounts of succinate dehydrogenase or vice versa succinate-ubiquinone reductase activity increases as the amount of succinate dehydrogenase or the SdhC-SdhD fraction added increases, Maximum reconstitution is obtained when the weight ratio of succinate dehydrogenase to the SdhC-SdhD fraction reaches 5.26. This ratio is slightly higher than the calculated value of 3.37, obtained by assuming 1 mol of succinate dehydrogenase reacts with 1 mol of SdhC and SdhD. The isolated SdhC-SdhD fraction contains 35 nmol cytochrome b(556)/mg protein, Unlike mitochondrial cytochrome b(560), the cytochrome b(556) is reducible by succinate in the isolated and complex forms, Furthermore, cytochrome b(556) in the isolated SdhC-SdhD fraction has absorption properties, carbon mon oxide reactivity, and EPR characteristics similar to those of cytochrome b(556) in intact succinate-ubiquinone reductase, indicating that its heme environments are not affected by the presence of succinate dehydrogenase, However, the redox potential of cytochrome b(556) in the SdhC-SdhD fraction (22 mV) increases slightly when complexed with succinate dehydrogenase (34 mV). No hybrid succinate-ubiquinone reductase is formed from mitochondrial QPs (the membrane-anchoring protein fraction of bovine heart mitochondrial succinate-ubiquinone reductase) and E. coli succinate dehydrogenase or vice versa, However, the cytochrome b(556) in E. coli SdhC-SdhD fraction is reducible by succinate in the presence of mitochondrial succinate dehydrogenase, and the rate of cytochrome b(556) reduction correlates with the reconstitutive activity of the mitochondrial succinate dehydrogenase.			Yang, XD (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOL BIOL,STILLWATER,OK 74078, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; JENNER ER, 1973, Patent No. 3737516; KITA K, 1989, J BIOL CHEM, V264, P2672; KITA K, 1978, J BIOL CHEM, V253, P8910; KITA K, 1984, J BIOL CHEM, V259, P3368; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Shenoy SK, 1996, FASEB J, V10, P2837; SPENCER ME, 1974, J BACTERIOL, V117, P947, DOI 10.1128/JB.117.3.947-953.1974; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU CA, 1993, J BIOENERG BIOMEMBR, V23, P259; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508	23	12	12	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9683	9689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092498				2022-12-27	WOS:A1997WU03900017
J	Koritschoner, NP; Bocco, JL; PanzettaDutari, GM; Dumur, CI; Flury, A; Patrito, LC				Koritschoner, NP; Bocco, JL; PanzettaDutari, GM; Dumur, CI; Flury, A; Patrito, LC			A novel human zinc finger protein that interacts with the core promoter element of a TATA box-loss gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GLYCOPROTEIN GENE; BINDING-PROTEIN; MAMMALIAN-CELLS; BASAL TRANSCRIPTION; MOLECULAR-CLONING; FAMILY MEMBER; DNA; SEQUENCE; INITIATION	We describe a novel human cDNA isolated by target site screening of a placental expression library, using as a probe; an essential element of a TATA box-less promoter corresponding to a pregnancy-specific glycoprotein gene. The cDNA encoded a predicted protein of 290 amino acids, designated core promoter-binding protein (CPBP), which has three zinc fingers (type Cys(2)-His(2)) at the end of its C-terminal domain, a serine/threonine-rich central region and an acidic domain lying within the N-terminal region. Additional sequence analysis and data base searches revealed that only the zinc finger domains are conserved (60-80% identity) in other transcription factors. In cotransfection assays, CPBP increased the transcription from a minimal promoter containing its natural DNA-binding site. Moreover, a chimeric protein between CPBP and Gal4 DNA binding domain also increased the activity of an heterologous reporter gene containing Gal4 DNA binding sites. The tissue distribution analysis of CPBP mRNA revealed that it is differentially expressed with an apparent enrichment in placental cells. The DNA binding and transcriptional activity of CPBP, in conjunction with its expression pattern, strongly suggests that this protein may participate in the regulation and/or maintenance of the basal expression of PSG and possibly other TATA box-less genes.	UNIV NACL CORDOBA,DEPT BIOQUIM CLIN,FAC CIENCIAS QUIM,RA-5000 CORDOBA,ARGENTINA	National University of Cordoba			Dumur, Catherine/AAH-9489-2020	Bocco, Jose Luis/0000-0002-9682-1270				BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHAMBERLIN ME, 1994, J BIOL CHEM, V269, P17152; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLOVER DM, 1985, DNA CLONING PRACTICA, V1, P76; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KECK U, 1995, EUR J BIOCHEM, V229, P455, DOI 10.1111/j.1432-1033.1995.0455k.x; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; Koritschoner NP, 1996, EUR J BIOCHEM, V236, P365, DOI 10.1111/j.1432-1033.1996.00365.x; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; PANZETTADUTARI GM, 1992, MOL BIOL REP, V16, P255, DOI 10.1007/BF00419665; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	35	122	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9573	9580						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083102				2022-12-27	WOS:A1997WU03700107
J	Neault, JF; TajmirRiahi, HA				Neault, JF; TajmirRiahi, HA			RNA-Diethylstilbestrol interaction studied by Fourier transform infrared difference spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF-THYMUS DNA; METHYLENE-BLUE; RAMAN; POLYNUCLEOTIDES; ACID; SPECIFICITY; PORPHYRINS; MECHANISM; COMPLEXES; BINDING	Diethylstilbestrol: (DES), a synthetic estrogen, is known to be a carcinogen in human and in animals. This study was designed to examine the interaction of DES with yeast RNA in aqueous solution at physiological pH with drug/RNA-phosphate (P) molar ratios of 1/80, 1/40, 1/20, 1/10, 1/4, and 1/2. Fourier transform infrared (FTIR) difference spectroscopy was used to determine the drug binding mode, the binding constant, the sequence selectivity, and RNA secondary structure in the RNA.DES complexes. Spectroscopic evidence showed that at low drug concentration (1/80 and 1/40), DES is intercalating through both Gua-Cyt and Ade-Urd base pairs with minor interaction with the backbone PO2 group (external binding). The calculated binding constant of K similar to 8.5 x 10(4) M(-1) at a drug concentration of 3.12 x 10(-4) M shows that DES is a weaker intercalator than those of the methylene blue, acridine orange, and ethidium bromide. At high drug content (r > 1/40, where r represents the DES/RNA-phosphate molar ratio), a partial helix destabilization occurs with no alteration of RNA conformation upon drug complexation. However, a comparison with DNA.DES complexes showed that drug intercalation causes major reduction of the B-DNA structure in favor of A-DNA with no participation of the backbone PO2 group in the DES.DNA complexation.	UNIV QUEBEC, DEPT BIOL CHEM, TROIS RIVIERES, PQ G9A 5H7, CANADA	University of Quebec; University of Quebec Trois Rivieres								AHMED A, 1995, FEBS LETT, V363, P65, DOI 10.1016/0014-5793(95)00282-E; ALEX S, 1989, INORG CHIM ACTA, V157, P271, DOI 10.1016/S0020-1693(00)80552-6; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BHAT HK, 1994, CARCINOGENESIS, V15, P2137, DOI 10.1093/carcin/15.10.2137; BLACKBURN GM, 1976, BIOCHEM J, V158, P643, DOI 10.1042/bj1580643; BRAHMS S, 1974, ISRAEL J CHEM, V12, P153; BROMLEY SD, 1986, NUCLEIC ACIDS RES, V14, P9133, DOI 10.1093/nar/14.22.9133; BRUN AM, 1994, J AM CHEM SOC, V116, P10383, DOI 10.1021/ja00102a004; CHEN MC, 1974, BIOPOLYMERS, V13, P615, DOI 10.1002/bip.1974.360130313; GLADEK A, 1989, J BIOL CHEM, V264, P16847; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; KIRKMAN HADLEY, 1959, NAIL CANCER INST MONOGR, V1, P1; KRUGLIK SG, 1995, J PHYS CHEM-US, V99, P5732, DOI 10.1021/j100015a066; LIEHR JG, 1985, CARCINOGENESIS, V6, P829, DOI 10.1093/carcin/6.6.829; LOPRETE DM, 1993, BIOCHEMISTRY-US, V32, P4077, DOI 10.1021/bi00066a032; LUTZ WK, 1982, CHEM-BIOL INTERACT, V42, P251, DOI 10.1016/0009-2797(82)90136-3; METZLER M, 1978, BIOCHEM BIOPH RES CO, V85, P874, DOI 10.1016/0006-291X(78)90625-3; METZLER M, 1984, REV BIOCHEM TOXICOL, V6, P191; MULLER W, 1975, EUR J BIOCHEM, V54, P267, DOI 10.1111/j.1432-1033.1975.tb04137.x; NEAULT JF, 1995, J BIOMOL STRUCT DYN, V13, P387, DOI 10.1080/07391102.1995.10508847; Neault JF, 1996, FEBS LETT, V382, P26, DOI 10.1016/0014-5793(96)00093-2; Neault JF, 1996, J BIOL CHEM, V271, P8140, DOI 10.1074/jbc.271.14.8140; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SIDEN RR, 1994, DNA STRUCTURE FUNCTI; SPIRO TG, 1987, BIOL APPL RAMAN SPEC, P81; STARIKOV EB, 1991, BIOPOLYMERS, V31, P255, DOI 10.1002/bip.360310302; TAJMIRRIAHI HA, 1995, FEBS LETT, V370, P105, DOI 10.1016/0014-5793(95)00802-G; TAJMIRRIAHI HA, 1995, BIOPOLYMERS, V35, P493, DOI 10.1002/bip.360350508; TAJMIRRIAHI HA, 1988, BIOCHIM BIOPHYS ACTA, V956, P211, DOI 10.1016/0167-4838(88)90137-9; TAJMIRRIAHI HA, 1994, J BIOMOL STRUCT DYN, V12, P217, DOI 10.1080/07391102.1994.10508098; THOMAS A, 1993, J BIOMOL STRUCT DYN, V11, P67; THOMAS A, 1995, CHEM-BIOL INTERACT, V97, P199; THOMAS GJ, 1973, BIOCHIM BIOPHYS ACTA, V324, P37, DOI 10.1016/0005-2787(73)90248-7; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; TSUBOI M, 1969, APPL SPECTROSC REV, V3, P45; TUITE E, 1994, J AM CHEM SOC, V116, P7548, DOI 10.1021/ja00096a011; TUITE E, 1995, BIOPOLYMERS, V35, P419, DOI 10.1002/bip.360350502; WARD B, 1986, BIOCHEMISTRY-US, V25, P7827, DOI 10.1021/bi00372a007; WARD B, 1986, BIOCHEMISTRY-US, V25, P6875, DOI 10.1021/bi00370a021; WEINER PK, 1982, P NATL ACAD SCI-BIOL, V79, P3754, DOI 10.1073/pnas.79.12.3754; WHEELER GV, 1995, J BIOMOL STRUCT DYN, V13, P399, DOI 10.1080/07391102.1995.10508848; WIESBURGER JH, 1984, ACS MONOGR SER, V182, P1323	43	23	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8901	8904						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083009				2022-12-27	WOS:A1997WU03700014
J	Pepin, MC; Yue, SY; Roberts, E; Wahlestedt, C; Walker, P				Pepin, MC; Yue, SY; Roberts, E; Wahlestedt, C; Walker, P			Novel ''restoration of function'' mutagenesis strategy to identify amino acids of the delta-opioid receptor involved in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; BETA-2-ADRENERGIC RECEPTORS; SUBTYPE SPECIFICITY; INDUCED ANALGESIA; STRUCTURAL BASIS; MOLECULAR-BASIS; CLONING; EXPRESSION; RAT	A novel ''restoration of function'' mutagenesis strategy was developed to identify amino acid sequence combinations necessary to restore the ability to bind delta-selective ligands to an inactive delta/mu receptor chimera in which 10 amino acids of the third extracellular loop of the delta receptor were replaced by the corresponding amino acids from the mu receptor (delta/mu 291-300). This chimera binds a nonselective opioid ligand but is devoid of affinity for delta-selective ligands. A library of mutants was generated in which some of the 10 amino acids of the mu sequence of delta/mu 291-300 were randomly reverted to the corresponding delta amino acid, Using a ligand binding assay, we screened this library to select mutants with high affinity for delta-selective ligands, Sequence analysis of these revertants revealed that a leucine at position 300, a hydrophobic region (amino acids 295-300), and an arginine at position 291 of the human delta-opioid receptor were present in all revertants. Single and double point mutations were then introduced in delta/mu 291-300 to evaluate the contribution of the leucine 300 and arginine 291 residues for the binding of delta-selective ligands, An increased affinity for delta-selective ligands was observed when the tryptophan 300 (mu residue) of delta/mu 291-300 was reverted to a leucine (delta residue). Further site-directed mutagenesis experiments suggested that the presence of a tryptophan at position 300 may block the access of delta-selective ligands to their docking site.	ASTRA RES CTR MONTREAL,ST LAURENT,PQ H4S 1Z9,CANADA				Wahlestedt, Claes/A-7039-2009					ADACHI M, 1994, EUR J PHARM-MOLEC PH, V269, P225; AUDIGIER Y, 1980, EUR J PHARMACOL, V63, P35, DOI 10.1016/0014-2999(80)90114-4; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BILSKY EJ, 1994, LIFE SCI, V55, P37; CHAILLET P, 1984, EUR J PHARMACOL, V101, P83, DOI 10.1016/0014-2999(84)90033-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FREDERICKSON RCA, 1981, SCIENCE, V211, P603, DOI 10.1126/science.6256856; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; GALLIGAN JJ, 1984, J PHARMACOL EXP THER, V229, P641; GETHER U, 1993, J BIOL CHEM, V268, P7893; GOODMAN RR, 1980, P NATL ACAD SCI-BIOL, V77, P6239, DOI 10.1073/pnas.77.10.6239; HAHN EF, 1982, J NEUROSCI, V2, P572; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; Jaffe JH, 1990, PHARMACOL BASIS THER, P485; JENSEN TS, 1986, BRAIN RES, V372, P301, DOI 10.1016/0006-8993(86)91138-8; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KNAPP RJ, 1994, LIFE SCI, V54, P463; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MATHIASEN JR, 1987, EUR J PHARMACOL, V136, P405, DOI 10.1016/0014-2999(87)90314-1; MCLEAN S, 1986, BRAIN RES, V378, P6; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; Meng F, 1996, EUR J PHARMACOL, V311, P285, DOI 10.1016/0014-2999(96)00431-1; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; Ni Q, 1995, ANALGESIA, V1, P185; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PORRECA F, 1987, J PHARMACOL EXP THER, V241, P393; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; ROMER D, 1980, LIFE SCI, V27, P971, DOI 10.1016/0024-3205(80)90107-1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SIMON EJ, 1986, ANN NY ACAD SCI, V463, P31, DOI 10.1111/j.1749-6632.1986.tb21501.x; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; STANDIFER KM, 1994, NEURON, V12, P805, DOI 10.1016/0896-6273(94)90333-6; TAKEMORI AE, 1987, J PHARMACOL EXP THER, V243, P91; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; WAMSLEY JK, 1983, PHARMACOL REV, V35, P69; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WESS J, 1992, MOL PHARMACOL, V41, P369; XUE JC, 1995, J BIOL CHEM, V270, P12977; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	51	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9260	9267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083060				2022-12-27	WOS:A1997WU03700065
J	Zhu, XG; McPhie, P; Lin, KH; Cheng, SY				Zhu, XG; McPhie, P; Lin, KH; Cheng, SY			The differential hormone-dependent transcriptional activation of thyroid hormone receptor isoforms is mediated by interplay of their domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; NUCLEAR RECEPTOR; BINDING-CAPACITY; CO-REPRESSOR; DNA; PROTEIN; CELLS; GENE; DIMERIZATION; SEQUENCE	Human thyroid hormone nuclear receptor isoforms (TR alpha 1 and TR beta 1) express differentially in a tissue-specific and development-dependent manner. It is unclear whether these two isoforms have differential functions. We analyzed their interaction with a thyroid hormone response element with half-site binding motifs arranged in an everted repeat separated by six nucleotides (F2). Despite extensive sequence homologies, the two isoforms bound to F2 with different affinities and ratios of homodimer/monomer. Using F2-containing reporter gene, we found that the transcriptional activity of TR beta 1 was similar to 6-fold higher than that of TR alpha 1. The lower activity of TR alpha 1 was not due to differences in expression of the two isoforms because similar nuclear localization patterns were observed. To understand the structural determinants responsible for these differences, we constructed chimeric receptors in which hinge regions (domain D), hormone binding domains (domain E), and domains (D + E) were sequentially interchanged and their activities were compared. Chimeric TRs containing the domains D, E or (D + E) of TR beta 1 showed increased propensities to form homodimers and mediated higher transactivation activities than TR alpha 1. Thus, differential transactivation activities of TR isoforms are mediated by interplay of their domains and could serve as an important regulatory mechanism to achieve diversity and specificity of pleiotropic T-3 effect.	NIDDKD,MOL BIOL LAB,DIV BASIC SCI,NATL INST HLTH,BETHESDA,MD 20892; NIDDKD,BIOCHEM PHARMACOL LAB,NATL INST HLTH,BETHESDA,MD 20892; CHANG GUANG MED COLL,DEPT BIOCHEM,TAYUAN,TAIWAN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; DARLING DS, 1993, J BIOL CHEM, V268, P10221; FUKUDA T, 1988, ENDOCRINOLOGY, V123, P2646, DOI 10.1210/endo-123-6-2646; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON ML, 1994, METHOD ENZYMOL, V232, P240; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; LIN KH, 1990, J BIOL CHEM, V265, P5161; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LIN KH, 1991, ENDOCRINOLOGY, V128, P2601, DOI 10.1210/endo-128-5-2601; LIN KH, 1994, CANCER LETT, V85, P189, DOI 10.1016/0304-3835(94)90274-7; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LIN KH, 1992, P NATL ACAD SCI USA, V89, P9277; LUNDBACK T, 1993, BIOCHEMISTRY-US, V32, P5074, DOI 10.1021/bi00070a015; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; ONATE SA, 1995, SCIENCE, V270, P1354; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SAROFF HA, 1995, BIOPOLYMERS, V36, P121, DOI 10.1002/bip.360360203; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YEN PM, 1992, J BIOL CHEM, V267, P23248; Zhu XG, 1996, ENDOCRINOLOGY, V137, P712, DOI 10.1210/en.137.2.712	35	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9048	9054						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083030				2022-12-27	WOS:A1997WU03700035
J	Zhao, Y; Boguslawski, G; Zitomer, RS; DePaoliRoach, AA				Zhao, Y; Boguslawski, G; Zitomer, RS; DePaoliRoach, AA			Saccharomyces cerevisiae homologs of mammalian B and B' subunits of protein phosphatase 2A direct the enzyme to distinct cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; YEAST; IDENTIFICATION; EXPRESSION; TYPE-2A; FORMS; GENE	Protein phosphatase 2A (PP2A) is a major cellular serine/threonine protein phosphatase, present in the cell in a variety of heterotrimeric forms that differ in their associated regulatory B-subunit. Cloning of the mammalian B' subunit has allowed the identification of a highly homologous Saccharomyces cerevisiae gene, RTS1. Disruption of the gene results in a temperature-sensitive growth defect that can be suppressed by expression of rabbit B'alpha or B'gamma isoforms. The B'alpha subunit is much more effective in restoring normal growth at 37 degrees C than B'gamma. Immunoprecipitated Rts1p was found associated with type 2A-specific protein phosphatase activity that is sensitive to 2 nM okadaic acid, but not to 100 nM phosphatase inhibitor-2, and to be phosphorylated in vivo. However, overexpression of RTS1 was unable to suppress the cold sensitivity, defective cytokinesis, and abnormal cell morphology resulting from defects in the CDC55 gene, which encodes the yeast homolog of a different B subunit of another form of 2A phosphatase, PP2A(1). These results indicate that Rts1p is a yeast homolog of the mammalian B' subunit and that the various regulatory B-subunits of PP2A are not functionally redundant but direct the enzyme to distinct cellular functions.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA	Indiana University System; Indiana University-Purdue University Indianapolis; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NHLBI NIH HHS [P01 HL6308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLOTET J, 1995, EUR J BIOCHEM, V229, P207, DOI 10.1111/j.1432-1033.1995.tb20457.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EBLE R, 1992, BIOTECHNIQUES, V13, P18; Evangelista CC, 1996, GENETICS, V142, P1083; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMANN R, 1994, YEAST, V10, P567, DOI 10.1002/yea.320100502; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEE J, 1993, J BIOL CHEM, V268, P19192; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Moore DD, 1995, GLOB MOB SURV; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Rose M, 1990, LAB COURSE MANUAL ME; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHU YM, 1995, MOL CELL BIOL, V15, P5618; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; TANG PM, 1991, J BIOL CHEM, V266, P15782; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIE HY, 1994, J BIOL CHEM, V269, P1981; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	57	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8256	8262		10.1074/jbc.272.13.8256	http://dx.doi.org/10.1074/jbc.272.13.8256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079645	hybrid			2022-12-27	WOS:A1997WQ63500028
J	Mu, D; Sancar, A				Mu, D; Sancar, A			Model for XPC-independent transcription-coupled repair of pyrimidine dimers in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-SPECIFIC REPAIR; GROUP-C FIBROBLASTS; ACTIVE GENES; DNA-REPAIR; DHFR GENE; COMPLEMENTATION; PURIFICATION; COMPLEXES; REMOVAL; INVITRO	In humans, DNA lesions such as pyrimidine dimers in the template strand of genes transcribed by RNA polymerase II are repaired faster than those in the coding strand and nontranscribed regions of the genome. This phenomenon, referred to as transcription-coupled repair (i) requires active transcription, (ii) does not require the XPC gene product which is essential for general/basal repair reactions, and (iii) requires the CSA and CSB proteins. We have developed an in vitro model system that consists of purified human excision repair factors and a DNA substrate analogous to a transcription bubble terminating at a cyclobutane thymine dimer. In this system the thymine dimer was excised independent of XPC, Furthermore, the thymine dimer in the bubble-containing substrate was removed approximately 3-fold faster by the excision repair nuclease reconstituted with or without XPC, compared with the removal of thymine dimer from a base paired duplex by the entire set of excision nuclease factors, These results provide important insight into the mechanism of transcription-coupled repair in humans.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,SCH MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NIGMS NIH HHS [GM32388] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRIEDBERG EC, 1995, DNA REPAIR; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GAMPER HB, 1983, COLD SPRING HARB SYM, V47, P455; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SMITH CA, 1993, J BIOL CHEM, V268, P11143; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	35	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7570	7573		10.1074/jbc.272.12.7570	http://dx.doi.org/10.1074/jbc.272.12.7570			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065408	Green Published, hybrid			2022-12-27	WOS:A1997WP59200002
J	Woodcock, DM; Lawler, CB; Linsenmeyer, ME; Doherty, JP; Warren, WD				Woodcock, DM; Lawler, CB; Linsenmeyer, ME; Doherty, JP; Warren, WD			Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSPOSABLE ELEMENT; TRANSCRIPTION FACTOR YY1; DNA METHYLATION; MAMMALIAN-CELLS; EMBRYONIC-DEVELOPMENT; HOST STRAINS; GENE; INSERTION; LINE-1; MOUSE	We have investigated the function and sequence specificity of DNA methylation in the hypermethylated CPG island promoter region of the endogenous human LINE-1 (L1) retrotransposon family, In nontransformed human embryonic fibroblasts, inhibition of DNA methylation with 5-azadeoxycytidine induced a greater than 4-fold increase in transcription from potentially functional L1 elements without increasing the transcription level of the majority of degenerate elements, implicating hypermethylation in the repression of L1 activity, Using bisulfite genomic sequencing to assess the pattern of methylation in a subset of nondegenerate L1 elements, we found 29 sites within a 460-base pair region of the noncoding (top) DNA strand of the L1 promoter in which cytosine methylation was maintained with high efficiency, Of these, 25 were at CG dinucleotides and four were in non-CG sites, When the methylation sites were analyzed for the complementary (bottom) strand, the only highly conserved sites of methylation were in CG dinucleotides. Several of these sites of CG methylation in the bottom (coding) strand were at positions where top (noncoding) strand-derived sequences were unmethylated, suggesting that these sites might be maintained in a hemimethylated state, Hence, there is a subset of human L1 elements in which methylation is efficiently maintained in asymmetric non-CG sites and further that this non-CG; methylation may be part of a wider phenomenon involving hemi-methylation at CG dinucleotides, Maintenance of asymmetric methylation at non CG sites (and possibly at hemi-methylated CG dinucleotides) could be through a novel DNA methyltransferase activity, Alternatively, the promoter region of L1 elements may be induced by factor binding to form some type of secondary structure that presents as a highly efficient substrate for de novo methylation.			Woodcock, DM (corresponding author), PETER MACCALLUM CANC INST,SIR DONALD & LADY TRESCOWTHICK RES LABS,LOCKED BAG 1,A BECKETT ST,MELBOURNE,VIC 3000,AUSTRALIA.		Warren, William/D-4419-2009	Warren, William/0000-0002-3753-1871				BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; BECKER KG, 1993, HUM MOL GENET, V2, P1697, DOI 10.1093/hmg/2.10.1697; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; CIHAK A, 1980, BIOCHEM PHARMACOL, V29, P2929, DOI 10.1016/0006-2952(80)90039-8; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CROWTHER PJ, 1991, NUCLEIC ACIDS RES, V19, P2395, DOI 10.1093/nar/19.9.2395; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; JOST JP, 1995, GENE, V157, P265, DOI 10.1016/0378-1119(95)00036-6; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KLIMASAUSKAS S, 1995, GENE, V157, P163, DOI 10.1016/0378-1119(94)00624-2; Lei H, 1996, DEVELOPMENT, V122, P3195; LINSENMEYER ME, 1992, BRIT J CANCER, V65, P471, DOI 10.1038/bjc.1992.95; MIKI Y, 1992, CANCER RES, V52, P643; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NYCE J, 1986, NUCLEIC ACIDS RES, V14, P4353, DOI 10.1093/nar/14.10.4353; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; SINGER MF, 1995, J BIOL CHEM, V270, P24623, DOI 10.1074/jbc.270.42.24623; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; Smith S.S., 1985, Progress in Clinical and Biological Research, V198, P11; SMITH SS, 1994, PROG NUCLEIC ACID RE, V49, P65; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SNIBSON KJ, 1995, TRANSGENIC RES, V4, P114, DOI 10.1007/BF01969413; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; WOODCOCK DM, 1988, NUCLEIC ACIDS RES, V16, P4465, DOI 10.1093/nar/16.10.4465; Woodcock DM, 1996, BIOCHEM BIOPH RES CO, V222, P460, DOI 10.1006/bbrc.1996.0766; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; WOODCOCK DM, 1986, EXP CELL RES, V166, P103, DOI 10.1016/0014-4827(86)90511-2; [No title captured]	48	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7810	7816		10.1074/jbc.272.12.7810	http://dx.doi.org/10.1074/jbc.272.12.7810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065445	hybrid			2022-12-27	WOS:A1997WP59200039
J	Yu, ZB; Ahmad, S; Schwartz, JL; Banville, D; Shen, SH				Yu, ZB; Ahmad, S; Schwartz, JL; Banville, D; Shen, SH			Protein-tyrosine phosphatase SHP2 is positively linked to proteinase-activated receptor 2-mediated mitogenic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-2 DOMAINS; THROMBIN RECEPTOR; MOLECULAR-CLONING; SH2 DOMAIN; FUNCTIONAL EXPRESSION; SEQUENCE SIMILARITY; INSULIN; SH-PTP2	Proteinase-activated receptor-2 (PAR2), a new member of family of the G protein-coupled receptors, is activated by proteolytic cleavage of its extracellular amino terminus, a mechanism similar to that used by the thrombin receptor. It has been suggested that PAR2 has a potential role in the late phases of the acute inflammatory response and in tissue repair and/or skin-related disorders, Here we demonstrate that the agonist peptide (SLIGRL) stimulated c-fos-mediated mitogenic activation and tyrosine phosphorylation of cellular proteins. One of the tyrosine-phosphorylated proteins was identified as an Src homology-2 domain-containing protein-tyrosine phosphatase, SHP2. The stimulatory effect of the agonist peptide on early gene transcription was markedly blocked by pertussis toxin treatment whereas the induced tyrosine phosphorylation of SHP2 was completely abolished by the drug, More importantly, while expression of wild-type SHP2 enhanced the agonist-stimulatory mitogenic activity, overexpression of a catalytically inactive mutant of SHP2 strongly suppressed the stimulatory effect of the agonist peptide on both early gene transcription and DNA synthesis. These results suggest that SHP2 acts as a positive regulator linked to the PAR2-mediated mitogenic pathway coupled to a pertussis toxin-sensitive heterotrimeric G protein, Demonstration of SHP2 as a positive mediator in a G protein-coupled, receptor-mediated signaling adds to our understanding of the function of both SHP2 and PAR2 in the signaling pathway.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT SECTOR,MONTREAL,PQ H4P 2R2,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,ENVIRONM SECTOR,MONTREAL,PQ H4P 2R2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA	National Research Council Canada; National Research Council Canada; McGill University								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7519	7524		10.1074/jbc.272.11.7519	http://dx.doi.org/10.1074/jbc.272.11.7519			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054456	hybrid			2022-12-27	WOS:A1997WN14700095
J	Keshvara, LM; Isaacson, C; Harrison, ML; Geahlen, RL				Keshvara, LM; Isaacson, C; Harrison, ML; Geahlen, RL			Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE; BINDING; ZAP-70; AUTOPHOSPHORYLATION; PATHWAYS; DOMAIN; BAND-3; MICE; LYN	Syk (p72(syk)) is a 72-kDa cytoplasmic protein-tyrosine kinase that serves as an essential component of the signal transduction machinery coupled to the B-cell antigen receptor. Syk is recruited to the receptor when it is cross-linked and, in response, becomes tyrosine-phosphorylated and activated before it dissociates from the receptor and appears in the cytoplasm. To begin to explore how tyrosine phosphorylation affects Syk activation and receptor binding, Tyr-130, which is localized within the Syk inter-Src homology 2 domain region, was substituted with Phe or Glu, Substitution of Tyr-130 with Phe enhanced the binding of Syk to the receptor and increased receptor-mediated protein tyrosine phosphorylation, while substitution with Glu greatly reduced this interaction, Replacement of Tyr-130 with Glu also increased the basal activity of the kinase, while replacement with Phe decreased its activity and uncoupled kinase activation from receptor engagement, These data suggest that the phosphorylation of Tyr-130 normally plays an important role in mediating both the activation of Syk and its release from the antigen receptor.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA37372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURG DL, 1994, J BIOL CHEM, V269, P28136; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; KUROSAKI T, 1995, J EXP MED, V182, P115; Law CL, 1996, MOL CELL BIOL, V16, P1305; LOW PS, 1987, J BIOL CHEM, V262, P4592; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Peters JD, 1996, J BIOL CHEM, V271, P4755; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Schneider ML, 1995, BIOCHEMISTRY-US, V34, P16574, DOI 10.1021/bi00051a005; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	27	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10377	10381						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099676				2022-12-27	WOS:A1997WV26200010
J	Butterfield, L; Storey, B; Maas, L; Heasley, LE				Butterfield, L; Storey, B; Maas, L; Heasley, LE			c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; IONIZING-RADIATION; TYROSINE KINASE; UV RESPONSE; LINES; PHOSPHORYLATION; GENE; EXPRESSION	Exposure of cultured small cell lung cancer (SCLC) cells to UV radiation induces apoptosis. We observed that the UV sensitivity of a panel of SCLC lines and the activation of c-Jun NH2-terminal kinases (JNKs) by UV in the individual SCLC lines, assessed by binding and phosphorylation of glutathione S-transferase (GST)-c-Jun fusion proteins, ranged widely. In fact, increased JNK activity in this assay was closely correlated with decreased sensitivity to apoptosis following UV irradiation. Increased JNK activity was also detected in anti-JNK1 immune complexes collected from UV-irradiated SCLC cells, although the level of activity was similar among the various SCLC lines and correlated poorly with UV sensitivity. Immunoblot analysis of JNK polypeptides that bound to GST c-Jun revealed at least two JNK polypeptides, one of which appeared only in extracts from UV-irradiated SCLC. To test the role of JNKs in UV-induced apoptosis, nonphosphorylatable mutants of JNK1 or JNK2 in which the phosphorylation site Thr-Pro-Tyr is changed to Ala-Pro-Phe (JNK-APF) and are predicted to behave as competitive inhibitors were stably expressed in SCLC. Expression of JNK1-APF or JNK2-APF significantly reduced UV-stimulated JNK activity. However, JNK1-APF markedly increased the resistance of the cells to UV-induced apoptosis, while JNK2-APF did not influence SCLC sensitivity to UV. The findings suggest that UV-stimulated JNK1 activation promotes UV-induced SCLC apoptosis, while a JNK isoform that is variably activated among the SCLC lines may signal a UV-protective response. We hypothesize that integration of distinct JNK activities dictates the relative responsiveness of SCLC to UV and ionizing radiation.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Butterfield, Lisa H./W-1564-2019	Butterfield, Lisa H./0000-0002-3439-9844	NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline; NIGMS NIH HHS [GM 48826] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BRENNAN J, 1991, CANCER RES, V51, P1708; BUSCHER M, 1988, ONCOGENE, V3, P301; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARMICHAEL J, 1989, EUR J CANCER CLIN ON, V25, P527, DOI 10.1016/0277-5379(89)90266-6; CARMICHAEL J, 1988, BRIT J CANCER, V58, P437, DOI 10.1038/bjc.1988.236; Carmichael J., 1985, BRIT J CANCER, V57, P540, DOI DOI 10.1038/bjc.1988.125; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAI TN, 1995, ONCOGENE, V10, P849; DAMICO D, 1992, ONCOGENE, V7, P339; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GAZDAR AF, 1985, CANCER RES, V45, P2924; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JENSEN GL, 1983, P NATL ACAD SCI-BIOL, V80, P4714, DOI 10.1073/pnas.80.15.4714; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIM CY, 1992, BRIT J CANCER, V66, P844, DOI 10.1038/bjc.1992.371; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUZUKI K, 1992, RADIAT RES, V129, P157, DOI 10.2307/3578152; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	55	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10110	10116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092556				2022-12-27	WOS:A1997WU03900075
J	Bernstein, J; Sella, O; Le, SY; ElroyStein, O				Bernstein, J; Sella, O; Le, SY; ElroyStein, O			PDGF2/c-sis mRNA leader contains a differentiation-linked internal ribosomal entry site (D-IRES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONTRANSLATED REGION; MESSENGER-RNA; NONCODING REGION; TRANSLATION; INITIATION; ELEMENTS; EFFICIENCY; SEQUENCES	It has become clear that a given cell type can qualitatively and quantitatively affect the expression of the platelet-derived growth factor B (PDGF2/c-sis) gene at multiple levels. In a previous report, we showed that PDGF2/c-sis 5'-untranslated region has a translational modulating activity during megakaryocytic differentiation of K562 cells. This study points to the mechanism used for this translational modulation. The unusual mRNA leader, which imposes a major barrier to conventional ribosomal scanning, was found to contain an internal ribosomal entry site that becomes more potent in differentiating cells and was termed differentiation-linked internal ribosomal entry site (D-IRES), The D-IRES element defines a functional role for the cumbersome 1022-nucleotide-long mRNA leader and accounts for its uncommon, evolutionary conserved architecture. The differentiation-linked enhancement of internal translation, which provides an additional step to the fine tuning of PDGF2/c-sis gene expression, might be employed by numerous critical regulatory genes with unusual mRNA leaders and might have widespread implications for cellular growth and development.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; NCI, MATH BIOL LAB, DCBDC, NIH, FREDERICK, MD 21702 USA	Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Elroy-Stein, Orna/0000-0002-3716-1540; Sella Tavor, Osnat/0000-0001-5748-2045				BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JH, 1990, STRUCTURE METHODS, P127; COHEN JI, 1987, J VIROL, V61, P3035, DOI 10.1128/JVI.61.10.3035-3039.1987; Dirks RPH, 1996, MOL BIOL REP, V22, P1, DOI 10.1007/BF00996300; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HORVATH P, 1995, CELL GROWTH DIFFER, V6, P1103; Jackson RJ, 1995, RNA, V1, P985; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LE SY, 1989, J THEOR BIOL, V138, P495, DOI 10.1016/S0022-5193(89)80047-5; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2173, DOI 10.1093/nar/21.9.2173; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2445, DOI 10.1093/nar/21.10.2445; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Merrick WC., 1996, TRANSLATION CONTROL, P31; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEPER GC, 1994, FEBS LETT, V352, P271, DOI 10.1016/0014-5793(94)00975-9; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VANDERVELDEN A, 1995, VIROLOGY, V214, P82, DOI 10.1006/viro.1995.9952; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994; Witherell GW, 1995, VIROLOGY, V214, P660, DOI 10.1006/viro.1995.0081	32	151	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9356	9362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083072				2022-12-27	WOS:A1997WU03700077
J	DePillis, GD; Ozaki, S; Kuo, JM; Maltby, DA; deMontellano, PRO				DePillis, GD; Ozaki, S; Kuo, JM; Maltby, DA; deMontellano, PRO			Autocatalytic processing of heme by lactoperoxidase produces the native protein-bound prosthetic group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOPEROXIDASE; PEROXIDASE; BOVINE; LUPUS	The covalently bound prosthetic group of lactoperoxidase (LPO) has been obtained by hydrolysis of the protein and identified as a dihydroxylated heme. A baculovirus expression system has been developed for LPO and used to obtain protein in which the heme is only partially covalently bound. Reaction of the purified heme apoLPO complex with H2O2 results in both autocatalytic modification of the heme and covalent attachment to the protein. Hydrolytic experiments establish that the autocatalytically incorporated heme is bound normally. Two monohydroxylated heme intermediates have been detected. The peroxidative activity of LPO increases in proportion to the extent of covalently bound heme. The LPO results provide a paradigm for autocatalytic incorporation of heme groups into the mammalian peroxidases, including myeloperoxidase and eosinophil peroxidase, all of which exhibit strong sequence similarity with LPO and have covalently-bound heme groups.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM 32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BASILE G, 1980, J BIOL CHEM, V255, P7181; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; HENDERSON WR, 1991, PEROXIDASES CHEM BIO, V1, P105; JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636; Klebanoff SJ, 1991, PEROXIDASES CHEM BIO, V1, P1; MAGNUSSEN RP, 1991, PEROXIDASES CHEM BIO, V1, P199; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; NICHOL AW, 1987, BIOCHEM J, V247, P147, DOI 10.1042/bj2470147; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; THOMAS EL, 1991, PEROXIDASES CHEM BIO, V1, P123; THONYMEYER L, 1994, BBA-BIOENERGETICS, V1187, P260, DOI 10.1016/0005-2728(94)90123-6; UETRECHT JP, 1988, CHEM RES TOXICOL, V1, P133, DOI 10.1021/tx00003a001; VILJA P, 1991, J IMMUNOL METHODS, V141, P277, DOI 10.1016/0022-1759(91)90154-8; VISCO C, 1985, J BIOL CHEM, V260, P6133; Xie ZY, 1996, J BIOL CHEM, V271, P4632; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	22	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8857	8860						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083001				2022-12-27	WOS:A1997WU03700006
J	Hsu, TA; Takahashi, N; Tsukamoto, Y; Kato, K; Shimada, I; Masuda, K; Whiteley, EM; Fan, JQ; Lee, YC; Betenbaugh, MJ				Hsu, TA; Takahashi, N; Tsukamoto, Y; Kato, K; Shimada, I; Masuda, K; Whiteley, EM; Fan, JQ; Lee, YC; Betenbaugh, MJ			Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPODOPTERA-FRUGIPERDA CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; INSECT CELLS; MEMBRANE-GLYCOPROTEINS; CARBOHYDRATE MOIETY; IMMUNOGLOBULIN-G; GLYCOSYLATION; PROTEIN; CHAINS; ACETYLGLUCOSAMINE	Structures of the N-linked oligosaccharide attached to the heavy chain of a heterologous murine IgG(2a) produced from Trichoplusia ni (TN-5B1-4, High Five) insect cells were characterized. Coexpression of the chaperone immunoglobulin heavy chain-binding protein (BiP) in the baculovirus-infected insect cells increased the soluble intracellular and secreted IgG level. This facilitated the detailed analysis of N-glycans from both intracellular and secreted IgG. Following purification of the immunoglobulins using Protein A-Sepharose, glycopeptides, prepared by trypsin-chymotrypsin digestion, were further digested with glycoamidase from sweet almond emulsin to obtain the oligosaccharide moieties. The resulting oligosaccharides were then reductively aminated with a-aminopyridine and the structures identified by two-dimensional high performance liquid chromatography mapping (Tomiya, N., Awaya, J., Kurono, M., Endo, S., Arata, Y., and Takahashi, N. (1988) Anal. Biochem. 171, 73-90). The N-glycans obtained from the secreted IgG contain 35% complex type, some with terminal galactose residues at either alpha 1,3-Man or alpha 1,6-Man branches of the Man(3)GlcNAc(2) core. The remaining oligosaccharides detected in the secreted IgG were principally hybrid (30%) and paucimannosidic (35%) type N-glycans. Most (84%) of these secreted glycoforms contained fucose alpha 1,6-linked to the innermost GlcNAc residue and the presence of a potentially allergenic fucose alpha 1,3-linked to the innermost GlcNAc residue was also detected. In contrast, the intracellular immunoglobulins included 50% high mannose-type N glycans with lower levels of complex, hybrid, and paucimannosidic-type structures. Reverse phase one-dimensional high performance liquid chromatography analysis of the IgG N-glycans in the absence of heterologous BiP exhibited a similar distribution of intracellular and secreted glycoforms. These studies indicate that Trichoplusia ni TN-5B1-4 cells are capable of terminal galactosylation. However, the processing pathways in these cell lines appear to diverge from mammalian cells in the formation of paucimannosidic structures, in the presence of alpha 1,3-fucose linkages, and in the absence of sialylation.	JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BALTIMORE, MD 21218 USA; NAKANO VINEGAR CO LTD, CENT RES INST, GLYCOLAB, HANDA 475, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, TOKYO 113, JAPAN; MEIJO UNIV, FAC PHARMACEUT SCI, TENPAKU KU, NAGOYA, AICHI 468, JAPAN; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University; University of Tokyo; Meijo University; Johns Hopkins University			Hsu, John Tsu-An/C-1199-2010; Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659; Kato, Koichi/0000-0001-7187-9612				ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 1996, TRENDS GLYCOSCI GLYC, V8, P101, DOI 10.4052/tigg.8.101; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P655, DOI 10.1016/0005-2736(81)90096-1; BUTTERS TD, 1978, CARBOHYD RES, V61, P159, DOI 10.1016/S0008-6215(00)84476-6; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P672, DOI 10.1016/0005-2736(81)90097-3; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P9811, DOI 10.1021/bi00105a001; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P842, DOI 10.1007/BF02631361; DAVIS TR, 1995, IN VITRO CELL DEV-AN, V31, P659; FRANCOIS C, 1962, BIOCHEM J, V83, P335, DOI 10.1042/bj0830335; HARADA H, 1987, ANAL BIOCHEM, V164, P374, DOI 10.1016/0003-2697(87)90507-0; HARD K, 1993, BIOCHEMISTRY-US, V32, P766, DOI 10.1021/bi00054a005; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; Jarvis DL, 1996, NAT BIOTECHNOL, V14, P1288, DOI 10.1038/nbt1096-1288; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; KOYAMA S, 1987, NMR PROTEIN, P117; KUBATA A, 1990, GLYCOBIOLOGY, V1, P5; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LEE YC, 1990, ANAL BIOCHEM, V188, P259, DOI 10.1016/0003-2697(90)90603-7; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUCKOW VA, 1995, PROTEIN PRODUCTION P, P51; Lund J, 1996, J IMMUNOL, V157, P4963; MARZ L, 1995, PROTEIN GLYCOSYLATIO, P543; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NAKAGAWA H, 1995, ANAL BIOCHEM, V226, P130, DOI 10.1006/abio.1995.1200; Ogonah OW, 1996, BIO-TECHNOL, V14, P197, DOI 10.1038/nbt0296-197; Ohsuga H, 1996, J BIOL CHEM, V271, P26653, DOI 10.1074/jbc.271.43.26653; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; RADEMACHER TW, 1986, BIOCHEM SOC SYMP, P131; REN JX, 1995, BIOCHEMISTRY-US, V34, P2489, DOI 10.1021/bi00008a012; SUMMERS MD, 1987, A M U B, V1555; TAKAHASHI N, 1987, BIOCHEMISTRY-US, V26, P1137, DOI 10.1021/bi00378a023; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TANDAI M, 1991, ARCH BIOCHEM BIOPHYS, V291, P339, DOI 10.1016/0003-9861(91)90144-8; TEZUKA K, 1992, EUR J BIOCHEM, V203, P401, DOI 10.1111/j.1432-1033.1992.tb16564.x; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004; YU IP, 1994, ARCH BIOCHEM BIOPHYS, V308, P387	52	92	127	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9062	9070						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083032				2022-12-27	WOS:A1997WU03700037
J	Klomp, LWJ; Lin, SJ; Yuan, DS; Klausner, RD; Culotta, VC; Gitlin, JD				Klomp, LWJ; Lin, SJ; Yuan, DS; Klausner, RD; Culotta, VC; Gitlin, JD			Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; SACCHAROMYCES-CEREVISIAE ENCODES; CANDIDATE GENE; MENKES DISEASE; MOLECULAR CHARACTERIZATION; TRANSPORTING ATPASE; CERULOPLASMIN GENE; RAT CERULOPLASMIN; METALLOTHIONEIN-I; IRON UPTAKE	To search for a mammalian homologue of ATX1, a human liver cDNA library was screened and a cDNA clone was isolated, which encodes a protein with 47% amino acid identity to Atx1p including conservation of the MTCXGC copper-binding domain. RNA blot analysis using this cDNA identified an abundant 0.5-kilobase mRNA in all human tissues and cell lines examined. Southern blot analysis using this same clone indicated that the corresponding gene exists as a single copy in the haploid genome, and chromosomal localization by fluorescence in situ hybridization detected this locus at the interface between bands 5q32 and 5q33. Yeast strains lacking copper/zinc superoxide dismutase (SOD1) are sensitive to redox cycling agents and dioxygen and are auxotrophic for lysine when grown in air, and expression of this human ATX1 homologue (HAH1) in these strains restored growth on lysine-deficient media, Yeast strains lacking ATX1 are deficient in high affinity iron uptake and expression of HAH1 in these strains permits growth on iron-depleted media and results in restoration of copper incorporation into newly synthesized Fet3p. These results identify HAH1 as a novel ubiquitously expressed protein, which may play an essential role in antioxidant defense and copper homeostasis in humans.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,DIV TOXICOL SCI,BALTIMORE,MD 21205; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Washington University (WUSTL)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44464] Funding Source: Medline; NIGMS NIH HHS [GM50016] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Connett JM, 1996, P NATL ACAD SCI USA, V93, P6814, DOI 10.1073/pnas.93.13.6814; CULOTTA VC, 1995, J BIOL CHEM, V270, P2991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; FLEMING RE, 1992, J BIOL CHEM, V267, P479; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Harris Z. Leah, 1996, American Journal of Clinical Nutrition, V63, p836S; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MHLLER T, 1996, LANCET, V347, P877; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MUTTHAUP G, 1996, SCIENCE, V271, P1406; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; Sherman F., 1978, METHODS YEAST GENETI; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; TANNER MS, 1983, ADV PAEDIAT, V8, P103; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	40	300	304	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9221	9226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083055	hybrid			2022-12-27	WOS:A1997WU03700060
J	Lu, HG; Zhong, L; Chang, KP; Docampo, R				Lu, HG; Zhong, L; Chang, KP; Docampo, R			Intracellular Ca2+ pool content and signaling and expression of a calcium pump are linked to virulence in Leishmania mexicana amazonesis amastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; CELL-GROWTH; PLASMODIUM-FALCIPARUM; AXENIC CULTIVATION; CA-2+ TRANSPORT; DONOVANI; CA2+-ATPASE	Virulent and avirulent clones of Leishmania mexicana amazonensis promastigotes or amastigotes were loaded with the fluorescent reagent fura 2/AM to measure intracellular free calcium ([Ca2+](i)), When the cells were treated with the calcium ionophore ionomycin in the nominal absence of extracellular Ca2+, there was an increase of [Ca2+](i) that was further elevated by addition of either NH4Cl, nigericin, or the vacuolar H+-ATPase inhibitor bafilomycin A(1), Similar results were obtained when the order of additions was reversed, Taking into account the relative importance of the ionomycin-releasable and the ionomycin plus NH4Cl-releasable Ca2+ pools, it is apparent that a significant amount of the Ca2+ stored in L. mexicana amazonensis promastigotes and amastigotes is present in an acidic compartment rich in Ca2+ (acidocalcisome), Results indicated that more releasable Ca2+ is stored intracellularly in virulent amastigotes than in virulent promastigotes or avirulent cells of both stages, This higher amount of releasable Ca2+ was correlated with the presence of Ca2+ signals in the virulent amastigotes during invasion of macrophages. Ca2+ signals and invasion were reduced by preloading the parasites with intracellular Ca2+ chelators (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/AM) and quin 2/AM) but not by a non-Ca2+-chelating analog (N-(2-methoxyphenyl)imidoacetic acid/AM), The gene encoding an organelle-type Ca2+-ATPase was cloned and sequenced and found overexpressed in virulent amastigotes as compared with all other forms. Together, these results demonstrate a significant link between expression of a Ca2+-ATPase, intracellular Ca2+ pool content and signaling, and virulence.	UNIV ILLINOIS, COLL VET MED, DEPT PATHOBIOL, MOL PARASITOL LAB, URBANA, IL 61802 USA; FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT MICROBIOL & IMMUNOL, N CHICAGO, IL 60064 USA	University of Illinois System; University of Illinois Urbana-Champaign; Chicago Medical School					FIC NIH HHS [TW-00476] Funding Source: Medline; NIAID NIH HHS [AI-20486] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020486] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBASHIR NT, 1992, ANN TROP MED PARASIT, V86, P487, DOI 10.1080/00034983.1992.11812698; ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BENAIM G, 1990, MOL BIOCHEM PARASIT, V39, P61, DOI 10.1016/0166-6851(90)90008-A; BENAIM G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P79, DOI 10.1016/0005-2736(90)90051-O; Benaim Gustavo, 1993, Biological Research, V26, P141; BLACKFORD S, 1990, J BIOL CHEM, V265, P9617; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRUN R, 1979, ACTA TROP, V36, P289; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Chang K. P., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P213; CHANG KP, 1978, J EXP MED, V147, P515, DOI 10.1084/jem.147.2.515; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COPPENS I, 1993, MOL BIOCHEM PARASIT, V58, P223, DOI 10.1016/0166-6851(93)90044-X; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1996, PARASITOL TODAY, V12, P61, DOI 10.1016/0169-4758(96)80656-9; DOYLE PS, 1991, EXP PARASITOL, V73, P326, DOI 10.1016/0014-4894(91)90104-5; DWYER DM, 1977, EXP PARASITOL, V41, P341, DOI 10.1016/0014-4894(77)90107-2; Dyer M, 1996, MOL BIOCHEM PARASIT, V78, P1, DOI 10.1016/S0166-6851(96)02593-5; EPERON S, 1989, J PROTOZOOL, V36, P502, DOI 10.1111/j.1550-7408.1989.tb01086.x; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hodgkinson VH, 1996, EXP PARASITOL, V83, P94, DOI 10.1006/expr.1996.0053; JUNKER CE, 1967, SCIENCE, V155, P1565; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KILLICKKENDRICK R, 1974, PROC R SOC SER B-BIO, V187, P409, DOI 10.1098/rspb.1974.0085; KIMURA M, 1993, J CELL SCI, V104, P1129; KINK JA, 1988, MOL BIOCHEM PARASIT, V27, P181, DOI 10.1016/0166-6851(88)90037-0; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LIU CM, 1978, J BIOL CHEM, V253, P5892; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MARKIN VS, 1975, J MEMBRANE BIOL, V25, P23, DOI 10.1007/BF01868566; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; MORIYAMA Y, 1994, J BIOCHEM, V115, P213, DOI 10.1093/oxfordjournals.jbchem.a124320; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; PAN AA, 1984, J PARASITOL, V70, P834, DOI 10.2307/3281780; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Rabinovitch M, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P378, DOI 10.1590/S0074-02761988000500029; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SHORTE SL, 1991, CELL CALCIUM, V12, P301, DOI 10.1016/0143-4160(91)90004-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; TROTTEIN F, 1995, EUR J BIOCHEM, V227, P214, DOI 10.1111/j.1432-1033.1995.tb20379.x; VERCESI AE, 1990, MOL BIOCHEM PARASIT, V42, P119, DOI 10.1016/0166-6851(90)90119-7; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WILLIAMSON J, 1981, NATURE, V292, P466, DOI 10.1038/292466a0; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	67	89	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9464	9473						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083086	hybrid			2022-12-27	WOS:A1997WU03700091
J	Nakashima, A; Hosaka, K; Nikawa, J				Nakashima, A; Hosaka, K; Nikawa, J			Cloning of a human cDNA for CTP-phosphoethanolamine cytidylyltransferase by complementation in vivo of a yeast mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; ENCODING CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; CHOLINE-TRANSPORT; ESCHERICHIA-COLI; EXPRESSION; GENE; IDENTIFICATION; BIOSYNTHESIS	CTP-phosphoethanolamine cytidylyltransferase (ET) is the enzyme that catalyzes the formation of CDP-ethanolamine in the phosphatidylethanolamine biosynthetic pathway from ethanolamine. We constructed a Saccharomyces cerevisiae mutant of which the ECT1 gene, putatively encoding ET, was disrupted. This mutant showed a growth defect on ethanolamine-containing medium and a decrease of ET activity. A cDNA clone was isolated from a human glioblastoma cDNA expression library by complementation of the yeast mutant, Introduction of this cDNA into the yeast mutant clearly restored the formation of CDP-ethanolamine and phosphatidylethanolamine in cells. ET activity in transformants was higher than that in wild-type cells. The deduced protein sequence exhibited homology with the yeast, rat, and human CTP-phosphocholine cytidylyl-transferases, as well as yeast ET. The cDNA gene product was expressed as a fusion with glutathione S-transferase in Escherichia coli and shown to have ET activity. These results clearly indicate that the cDNA obtained here encodes human ET.	KYUSHU INST TECHNOL,FAC COMP SCI & SYST ENGN,DEPT BIOCHEM ENGN & SCI,IIZUKA,FUKUOKA 820,JAPAN; GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUMMA 371,JAPAN	Kyushu Institute of Technology; Gunma University								COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; CRAIG L, 1994, J BIOL CHEM, V269, P3311; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MATSUSHITA M, 1995, J BIOCHEM-TOKYO, V117, P447, DOI 10.1093/jb/117.2.447; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MinSeok R, 1996, J BIOCHEM, V120, P1040; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SUNDLER R, 1973, BIOCHIM BIOPHYS ACTA, V306, P218, DOI 10.1016/0005-2760(73)90227-0; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; VERMEULEN PS, 1993, J BIOL CHEM, V268, P7458; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	31	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9567	9572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083101				2022-12-27	WOS:A1997WU03700106
J	Orth, R; Dixit, VM				Orth, R; Dixit, VM			Bik and bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SPINAL MUSCULAR-ATROPHY; BCL-2 HOMOLOG BAK; MAMMALIAN HOMOLOG; SEQUENCE MOTIF; PROTEIN; GENE; FAS; INTERACTS; SURVIVAL	Recent studies have identified a number of cell death pathway components. In this study, we describe the role that two such components, Bik and Bak, play in initiating the apoptotic program. These Bcl-2 family members engage the death pathway downstream of the block imposed by the serpin CrmA, but upstream of the block initiated by cellular inhibitors of apoptosis, which are a family of molecules characterized by a conserved baculovirus inhibitor of apoptosis repeat motif. Distal death pathway components activated by Bik and Bak are similar to those activated by the CD-95 (Fas/Apo1) and tumor necrosis factor death receptors.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Orth, Kim/AAV-4421-2021; dixit, vishva m/A-4496-2012	Orth, Kim/0000-0002-0678-7620; dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA64803, CA68769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068769, R01CA064803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, CANCER RES, V52, P491; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1995, ONCOGENE, V11, P1921; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; ITOH N, 1993, J BIOL CHEM, V268, P10932; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTAVI ZN, 1993, CELL, V74, P609; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	51	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8841	8844						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9082997				2022-12-27	WOS:A1997WU03700002
J	Sakata, H; Stahl, SJ; Taylor, WG; Rosenberg, JM; Sakaguchi, R; Wingfield, PT; Rubin, JS				Sakata, H; Stahl, SJ; Taylor, WG; Rosenberg, JM; Sakaguchi, R; Wingfield, PT; Rubin, JS			Heparin binding and oligomerization of hepatocyte growth factor scatter factor isoforms - Heparan sulfate glycosaminoglycan requirement for Met binding and signalling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; PROTOONCOGENE PRODUCT; BIOLOGICAL-ACTIVITY; MITOGENIC ACTIVITY; RAT HEPATOCYTES; MESSENGER-RNA; IDENTIFICATION; EXPRESSION; PROTEIN	Hepatocyte growth factor/scatter factor (HGF/SF) is a heparin-binding polypeptide that stimulates cell proliferation, motility, and morphogenesis by activation of its receptor, the c-Met tyrosine kinase. HGF/SF consists of a series of structural units, including an amino-terminal segment with a hairpin loop, four kringle domains, and a serine protease-like region. In this study, we demonstrate that the amino-terminal (N) domain retains the heparin-binding properties of full-length HGF/SF. In contrast to a previous hypothesis, selected basic amino acid residues in the hairpin loop are not critical for heparin binding, although alanine substitution at a subset of these sites markedly reduced the biological activity of the HGF/SF isoform, HGF/NK1. Covalent cross-linking experiments performed with wild-type and heparan sulfate glycosaminoglycan (HSGAG)-deficient Chinese hamster ovary (CHO) cells revealed that Met-HGF/NK1 binding was strongly dependent on HSGAG. Addition of heparin to HSGAG-deficient CHO cells not only restored ligand binding, but also increased ligand-dependent Met tyrosine phosphorylation and c-fos expression, Moreover, our results showed that heparin stimulated ligand oligomerization through an interaction with the N domain, These findings establish the importance of the N domain for heparin-ligand and ligand-ligand interactions, and demonstrate a crucial role for HSGAG in receptor binding and signal transduction.	NCI,CELLULAR & MOL BIOL LAB,DBS,BETHESDA,MD 20892; NIAMSD,PROT EXPRESS LAB,BETHESDA,MD 20892; NIDR,GLYCOBIOL PROGRAM,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Wingfield, Paul/0000-0002-9515-4752				ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; CURRAN T, 1987, ONCOGENE, V2, P79; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FALCO JP, 1988, ONCOGENE, V2, P573; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAYE M, 1987, J BIOL CHEM, V262, P16612; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOJI T, 1994, J CELL BIOL, V125, P393, DOI 10.1083/jcb.125.2.393; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MARK MR, 1992, J BIOL CHEM, V267, P26166; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STOKER M, 1985, J CELL SCI, V77, P209; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16872	57	122	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9457	9463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083085				2022-12-27	WOS:A1997WU03700090
J	Tumova, S; Bame, KJ				Tumova, S; Bame, KJ			The interaction between basic fibroblast growth factor and heparan sulfate can prevent the in vitro degradation of the glycosaminoglycan by Chinese hamster ovary cell heparanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC DEGRADATION; RECEPTOR DIMERIZATION; EXTRACELLULAR-MATRIX; LIPOPROTEIN-LIPASE; LYMPHOMA-CELLS; FACTOR BINDING; PROTEOGLYCANS; SURFACE; MOLECULES; PROTEIN	Heparan sulfate proteoglycans on Chinese hamster ovary (CHO) cell surfaces can bind and internalize basic fibroblast growth factor (bFGF), mie have investigated whether this interaction affects heparan sulfate catabolism in vitro by measuring the ability of partially purified CHO heparanase activities to degrade S-35-labeled heparan sulfate glycosaminoglycans in the absence or presence of bFGF. Our studies show that the presence of the growth factor prevents partially purified heparanases from degrading the nascent 81-kDa chains to short 6-kDa products, whether the glycosaminoglycan is free in solution or covalently bound to core proteins. A 30-60 molar excess of the growth factor is required to inhibit completely chain degradation by heparanases, implying that multiple bFGF molecules must be bound to the glycosaminoglycan to prevent heparanase-catalyzed catabolism. This hypothesis is supported by protection studies indicating that nascent CHO heparan sulfate glycosaminoglycans have at least four to eight bFGF binding sites/chain. It does not appear, however, that the growth factor inhibits heparanase-catalyzed degradation of the glycosaminoglycan by binding to the sequence cleaved by the enzyme. Both the nascent and short chains bind bFGF with similar affinity (K-d values of 27.0 +/- 3.5 and 38.9 +/- 5.1 nM, respectively), indicating that heparanase activities do not destroy the bFGF binding sites. Rather, our results suggest that the growth factor interferes sterically with heparanase action by binding the heparan sulfate chain at a sequence next to the cleavage site or at a secondary site recognized by the enzyme.	UNIV MISSOURI, SCH BIOL SCI, DIV MOL BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City			Tumova, Sarka/AAD-6353-2019	Tumova, Sarka/0000-0003-2044-4998				AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAUKER JH, 1987, J BIOL CHEM, V262, P13093; BUEE L, 1991, ANAL BIOCHEM, V195, P238, DOI 10.1016/0003-2697(91)90323-L; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FERRO DR, 1990, CARBOHYD RES, V195, P157, DOI 10.1016/0008-6215(90)84164-P; FOX GM, 1988, J BIOL CHEM, V263, P18452; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P386, DOI 10.1016/S0006-291X(05)81305-1; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GRAYSON LS, 1993, BURNS, V19, P401, DOI 10.1016/0305-4179(93)90061-C; HENNES R, 1988, BRIT J CANCER, V58, P186, DOI 10.1038/bjc.1988.189; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2678; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LORIES V, 1992, J BIOL CHEM, V267, P1116; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SNOW AD, 1990, AM J PATHOL, V137, P1253; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	56	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9078	9085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083034				2022-12-27	WOS:A1997WU03700039
J	Li, K; Williams, RS				Li, K; Williams, RS			Tetramerization and single-stranded DNA binding properties of native and mutated forms of murine mitochondrial single-stranded DNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI SSB; OVERLAP EXTENSION; XENOPUS-LAEVIS; REPLICATION; POLYNUCLEOTIDES; DELETIONS; COMPLEXES; GENE; TRYPTOPHAN-54	We examined previously unexplored aspects of the tetramerization and single-stranded DNA (ssDNA) binding properties of native, precursor, and mutated forms of mitochondrial ssDNA-binding protein (mtSSB) from a mammalian organism (mouse). Tetramic forms of mtSSB reassemble spontaneously after thermal denaturation and undergo subunit exchange. Binding of mtSSB to ssDNA as a function of protein concentration is nonlinear, suggesting a concentration-dependent transition in intrinsic binding affinity and in the topology of the DNA-protein complex. The cleavable presequence at the amino terminus of the precursor form of mtSSB does not disrupt tetramer formation but has a specific inhibitory effect on DNA binding that is not seen in a fusion protein that substitutes a bulkier peptide moiety in this position. Mutated forms of mtSSB bearing amino acid substitutions at highly conserved amino acid positions exhibit subtle or severe defects in ssDNA binding activity and/or tetramerization, even when assembled into heterotetramers in combination with wild-type mtSSB monomers. These experiments provide new insights into structural and functional properties of mammalian mtSSB and have implications for the pathogenesis of human diseases resulting from defects in mtDNA replication.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL BIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, R01HL054794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL54794] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHASE JW, 1985, J BIOL CHEM, V260, P7214; CHASE JW, 1984, J BIOL CHEM, V259, P805; CURTH U, 1991, EUR J BIOCHEM, V196, P87, DOI 10.1111/j.1432-1033.1991.tb15789.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; GALLAGHER S, 1994, CURRENT PROTOCOLS MO; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GLICK B, 1991, ANNU REV GENET, V25, P21; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KHAMIS MI, 1987, FEBS LETT, V211, P155, DOI 10.1016/0014-5793(87)81427-8; LASSON NG, 1990, PEDIATR RES, V28, P131; LOHMAN TM, 1988, BIOCHEMISTRY-US, V27, P2260, DOI 10.1021/bi00407a002; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAHOUNGOU C, 1988, FEBS LETT, V235, P267, DOI 10.1016/0014-5793(88)81276-6; MEYER RR, 1982, J BACTERIOL, V150, P433, DOI 10.1128/JB.150.1.433-435.1982; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MEYER RR, 1979, P NATL ACAD SCI USA, V76, P1702, DOI 10.1073/pnas.76.4.1702; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Price N. C., 1994, MECH PROTEIN FOLDING, P160; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; SANCAR A, 1981, P NATL ACAD SCI USA, V78, P4272; SCHMELLIKSANDAGE CS, 1990, J BACTERIOL, V172, P4378, DOI 10.1128/jb.172.8.4378-4385.1990; SCHNEIDER RJ, 1982, BIOCHEMISTRY-US, V21, P608, DOI 10.1021/bi00533a002; SMITH DB, 1994, CURRENT PROTOCOLS MO; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; ZEVIANI M, 1990, AM J HUM GENET, V47, P904; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	42	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8686	8694		10.1074/jbc.272.13.8686	http://dx.doi.org/10.1074/jbc.272.13.8686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079701	hybrid			2022-12-27	WOS:A1997WQ63500084
J	Sugiyama, T; Zaitseva, EM; Kowalczykowski, SC				Sugiyama, T; Zaitseva, EM; Kowalczykowski, SC			A single-stranded DNA-binding protein is needed for efficient presynaptic complex formation by the Saccharomyces cerevisiae Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-A; COLI RECA PROTEIN; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; SSB PROTEIN; EXCHANGE; REPAIR; GENE; BIOCHEMISTRY; SEQUENCE	Protein-promoted DNA strand exchange requires formation of an active presynaptic complex between the DNA-pairing protein and single-stranded DNA (ssDNA), Formation of such a contiguous filament is stimulated by a ssDNA-binding protein, Here, the effects of replication protein A (RPA) on presynaptic complex formation and DNA strand exchange activities of Rad51 protein were examined, Presynaptic complex formation was assessed by measuring ATP hydrolysis, With phi X174 ssDNA, the ATPase activity of Rad51 protein is stimulated similar to 1.4-fold by RPA, provided that Rad51 protein is in excess of the ssDNA concentration; otherwise, RPA inhibits ATPase activity, In contrast, with ssDNA devoid of secondary structure (poly(dT), poly(dA), poly(dI), and etheno-M13 DNA), RPA does not stimulate the already elevated ATPase activity of Rad51 protein, but inhibits activity at low Rad51 protein concentrations, These results suggest that Rad51 protein and RPA exclude one another from ssDNA by competing for the same binding sites and that RPA exerts its effect on presynaptic complex formation by eliminating secondary structure to which Rad51 protein is bound nonproductively. DNA strand exchange catalyzed by Rad51 protein is also greatly stimulated by RPA, The optimal stoichiometry for stimulation is similar to 20-30 nucleotides of ssDNA/RPA heterotrimer, The ssDNA-binding protein of Escherichia coli can substitute for RPA, showing that the role of RPA is not specific, We conclude that RPA affects both presynaptic complex formation and DNA strand exchange via changes in DNA structure, employing the same mechanism used by the ssDNA-binding protein to effect change in E, coli RecA protein activity.	UNIV CALIF DAVIS, MICROBIOL SECT, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis				Sugiyama, Tomohiko/0000-0003-2942-3667	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CHOW SA, 1988, J BIOL CHEM, V263, P200; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	251	256	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7940	7945		10.1074/jbc.272.12.7940	http://dx.doi.org/10.1074/jbc.272.12.7940			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065463	hybrid			2022-12-27	WOS:A1997WP59200057
J	Wesche, H; Korherr, C; Kracht, M; Falk, W; Resch, K; Martin, MU				Wesche, H; Korherr, C; Kracht, M; Falk, W; Resch, K; Martin, MU			The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN EXPRESSION; T-CELLS; CLONING	Interleukin-1 (IL-1) is a central mediator of the immune system involved in acute and chronic inflammatory responses, Although the sequences of two types of IL-1 receptors are known, the exact molecular events resulting in signal transduction and coupling to downstream signaling elements remain unclear, The recently cloned IL-1 receptor accessory protein (IL-1RAcP) has been suggested as a co-receptor molecule for IL-1RI, supported by the observation that its expression correlates to IL-1 responsiveness, We transfected the EL-4 subline D6/76 with IL-1RAcP cDNA, This cell line is an IL-1 non-responder expressing IL-1RI but lacking constitutive IL-1RAcP expression. The expression of IL-1RAcP in EL-4 D6/76 was sufficient to restore IL-l-induced activation of interleukin-l receptor-associated kinase and of stress-activated protein kinases, translocation of the transcription factors NF kappa B and IL-1 NF to the nucleus, and induction of IL-2 mRNA synthesis, These results proved that IL-1RAcP is an indispensible molecule in the IL-1 receptor signal transduction complex, necessary to link events on the plasma membrane level to downstream signaling pathways, allowing IL-1-dependent activation of transcription factors and gene expression.	HANNOVER MED SCH,DEPT MOL PHARMACOL,D-30623 HANNOVER,GERMANY; UNIV REGENSBURG,DEPT INTERNAL MED,D-93042 REGENSBURG,GERMANY	Hannover Medical School; University of Regensburg				Kracht, Michael/0000-0002-8501-043X				Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DOWER S, 1995, CYTOKINE, V7, P597; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HEGUY A, 1993, J BIOL CHEM, V268, P10490; IWASAKI T, 1993, CYTOKINE, V5, P416, DOI 10.1016/1043-4666(93)90031-Y; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; LOWENTHAL JW, 1989, J IMMUNOL, V137, P1226; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sambrook J., 2002, MOL CLONING LAB MANU; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; Wesche H, 1996, FEBS LETT, V391, P104, DOI 10.1016/0014-5793(96)00713-2	23	260	267	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7727	7731		10.1074/jbc.272.12.7727	http://dx.doi.org/10.1074/jbc.272.12.7727			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065432	hybrid			2022-12-27	WOS:A1997WP59200026
J	Kedishvili, NY; Gough, WH; Chernoff, EAG; Hurley, TD; Stone, CL; Bowman, KD; Popov, KM; Bosron, WF; Li, TK				Kedishvili, NY; Gough, WH; Chernoff, EAG; Hurley, TD; Stone, CL; Bowman, KD; Popov, KM; Bosron, WF; Li, TK			cDNA sequence and catalytic properties of a chick embryo alcohol dehydrogenase that oxidizes retinol and 3 beta,5 alpha-hydroxysteroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; KINETIC CHARACTERIZATION; CLASS-I; EXPRESSION; HORSE; RAT; SPECIFICITY; RESOLUTION; ISOENZYMES; OXIDATION	This study was undertaken to identify the cytosolic 40-kDa zinc-containing alcohol dehydrogenases that oxidize all-trans-retinol and steroid alcohols in fetal tissues, Degenerate oligonucleotide primers were used to amplify by polymerase chain reaction 500-base pair fragments of alcohol dehydrogenase cDNAs from chick embryo limb buds and heart. cDNA fragments that encode an unknown putative alcohol dehydrogenase as well as the class III alcohol dehydrogenase were identified, The new cDNA hybridized with two messages of similar to 2 and 3 kilobase pairs in the adult chicken liver but not in the adult heart, muscle, testis, or brain, The corresponding complete cDNA clones with a total length of 1390 base pairs were isolated from a chicken liver lambda gt11 cDNA library, The open reading frame encoded a 375-amino acid polypeptide that exhibited 67 and 68% sequence identity with chicken class I and III alcohol dehydrogenases, respectively, and had lower identity with mammalian class II (55-58%) and IV (62%) isozymes. Expression of the new cDNA in Escherichia coli yielded an active alcohol dehydrogenase (ADH-F) with subunit molecular mass of similar to 40 kDa. The specific activity of the recombinant enzyme, calculated from active site titration of NADH binding, was 3.4 min(-1) for ethanol at pH 7.4 and 25 degrees C. ADH-F was stereospecific for the 3 beta,5 alpha-versus 3 beta,5 beta-hydroxysteroids. The K-m value for ethanol at pH 7.4 was 17 mM compared with 56 mu M for all-trans-retinol and 31 mu M for epiandrosterone. Antiserum against ADH-F recognized corresponding protein in the chicken liver homogenate. We suggest that ADH-F represents a new class of alcohol dehydrogenase, class VII, based on its primary structure and catalytic properties.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; PURDUE UNIV, SCH SCI, DEPT BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University	Kedishvili, NY (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, 635 BARNHILL DR, MS 405, INDIANAPOLIS, IN 46202 USA.			Kedishvili, Natalia/0000-0001-6917-4891; HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA002342, R37AA007117] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37-AA07117, R37-AA02342, K08 AA00221-01] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Cleland W W, 1979, Methods Enzymol, V63, P103; CRONHOLM T, 1975, ACTA CHEM SCAND B, V29, P571, DOI 10.3891/acta.chem.scand.29b-0571; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; EDENBERG HJ, 1997, IN PRESS COMPREHENSI; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; ESTONIUS M, 1994, BIOCHEMISTRY-US, V33, P15080, DOI 10.1021/bi00254a017; ESTONIUS M, 1990, EUR J BIOCHEM, V194, P593, DOI 10.1111/j.1432-1033.1990.tb15657.x; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMPEL J, 1984, EUR J BIOCHEM, V145, P437, DOI 10.1111/j.1432-1033.1984.tb08573.x; HOOG JO, 1987, BIOSCIENCE REP, V7, P969, DOI 10.1007/BF01122131; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JULIA P, 1986, EXP EYE RES, V42, P305, DOI 10.1016/0014-4835(86)90023-0; KAISER R, 1988, BIOCHEMISTRY-US, V27, P1132, DOI 10.1021/bi00404a009; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; KEDISHVILI NY, 1997, ENZYMOLOGY MOL BIOL, V6, P321; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; PARK DH, 1991, J BIOL CHEM, V266, P13296; Ramaswamy S, 1996, PROTEIN SCI, V5, P663; STONE CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; TIETJEN TG, 1994, J HISTOCHEM CYTOCHEM, V42, P745, DOI 10.1177/42.6.8189036; WALLER G, 1965, ARCH BIOCHEM BIOPHYS, V111, P671, DOI 10.1016/0003-9861(65)90249-3; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; YONETANI T, 1962, ARCH BIOCHEM BIOPHYS, V99, P433, DOI 10.1016/0003-9861(62)90291-6	30	34	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7494	7500		10.1074/jbc.272.11.7494	http://dx.doi.org/10.1074/jbc.272.11.7494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054452	hybrid			2022-12-27	WOS:A1997WN14700091
J	FernandezGonzalez, B; Sandmann, G; Vioque, A				FernandezGonzalez, B; Sandmann, G; Vioque, A			A new type of asymmetrically acting beta-carotene ketolase is required for the synthesis of echinenone in the cyanobacterium Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS GENE-CLUSTER; ESCHERICHIA-COLI; PHYTOENE DESATURASE; HAEMATOCOCCUS-PLUVIALIS; FUNCTIONAL EXPRESSION; HERBICIDE NORFLURAZON; NUCLEOTIDE-SEQUENCE; CLONING; ASTAXANTHIN; COMPLEMENTATION	We have isolated, based on the knowledge of the complete genomic sequence of the cyanobacterium Synechocystis sp. PCC 6803, an open reading frame (slr0088) similar to known bacterial carotene desaturases and have analyzed the function of the encoded protein, Surprisingly, this protein has no detectable desaturase activity with phytoene, hydroxyneurosporene, or zeta-carotene as substrates, but is rather a beta-carotene ketolase that acts asymmetrically introducing a keto group on only one of the two beta-ionone rings of beta-carotene to generate echinenone. This is in contrast to the so far characterized beta-carotene ketolases that act symmetrically, producing the di-keto carotenoid canthaxanthin from beta-carotene without significant accumulation of echinenone. We have designated this new gene crtO. The function of the crtO gene product has been demonstrated by 1) the biosynthesis of echinenone when the crtO gene is expressed in an Escherichia coli strain able to accumulate beta-carotene, 2) the in vitro biosynthesis of echinenone from beta-carotene with cell free extracts from E. coli cells that express the crtO gene, and 3) the absence of echinenone in a Synechocystis strain in which the crtO gene has been insertionally inactivated, The primary structure of the Synechocystis asymmetric ketolase bears no similarity with the known beta-carotene ketolases, crtO is not required for normal growth under standard or high light conditions, neither is the photosynthetic activity of the crtO-deficient strain affected.	CTR INVEST ISLA CARTUJA, INST BIOQUIM VEGETAL & FOTOSINTESIS, SEVILLE 41092, SPAIN; INST BOT, BIOSYNTH GRP, D-60054 FRANKFURT, GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)			Vioque, Agustín/K-1809-2014	Vioque, Agustín/0000-0002-3975-7348				ALBRECHT M, 1995, FEBS LETT, V372, P199, DOI 10.1016/0014-5793(95)00978-I; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1994, J BACTERIOL, V176, P4795, DOI 10.1128/jb.176.16.4795-4802.1994; Bodansky M, 1941, J BIOL CHEM, V140, P365; BRAMLEY PM, 1985, PHYTOCHEMISTRY, V24, P2919, DOI 10.1016/0031-9422(85)80027-3; Breitenbach J, 1996, FEMS MICROBIOL LETT, V140, P241, DOI 10.1016/0378-1097(96)00187-5; Britton G., 1988, Plant pigments., P133; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Hirschberg J., 1994, MOL BIOL CYANOBACTER, DOI [10.1007/978-94-011-0227-8_18, DOI 10.1007/978-94-011-0227-8_18]; KAJIWARA S, 1995, PLANT MOL BIOL, V29, P343, DOI 10.1007/BF00043657; Kaneko T, 1996, DNA Res, V3, P109; Kotani H, 1995, DNA Res, V2, P133, DOI 10.1093/dnares/2.3.133; LINDEN H, 1994, PLANT MOL BIOL, V24, P369, DOI 10.1007/BF00020174; LINDEN H, 1991, Z NATURFORSCH C, V46, P1045; LINDEN H, 1993, FEMS MICROBIOL LETT, V106, P99, DOI 10.1016/0378-1097(93)90062-7; LOTAN T, 1995, FEBS LETT, V364, P125, DOI 10.1016/0014-5793(95)00368-J; MARTINEZFEREZ I, 1994, BBA-GENE STRUCT EXPR, V1218, P145, DOI 10.1016/0167-4781(94)90003-5; MARTINEZFEREZ I, 1994, PESTIC BIOCHEM PHYS, V48, P185, DOI 10.1006/pest.1994.1019; MARTINEZFEREZ IM, 1992, PLANT MOL BIOL, V18, P981, DOI 10.1007/BF00019213; MISAWA N, 1995, BIOCHEM BIOPH RES CO, V209, P867, DOI 10.1006/bbrc.1995.1579; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; NELIS HJ, 1991, J APPL BACTERIOL, V70, P181, DOI 10.1111/j.1365-2672.1991.tb02922.x; Nonnengiesser K, 1996, BOT ACTA, V109, P115, DOI 10.1111/j.1438-8677.1996.tb00551.x; Raisig A, 1996, J BIOCHEM-TOKYO, V119, P559; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDMANN G, 1994, J PLANT PHYSIOL, V143, P444, DOI 10.1016/S0176-1617(11)81805-5; SANDMANN G, 1994, EUR J BIOCHEM, V223, P7, DOI 10.1111/j.1432-1033.1994.tb18961.x; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; YOKOYAMA A, 1994, BIOSCI BIOTECH BIOCH, V58, P1842, DOI 10.1271/bbb.58.1842	33	96	106	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9728	9733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092504				2022-12-27	WOS:A1997WU03900023
J	Franzoni, L; Nicastro, G; Pertinhez, TA; Tato, M; Nakaie, CR; Paiva, ACM; Schreier, S; Spisni, A				Franzoni, L; Nicastro, G; Pertinhez, TA; Tato, M; Nakaie, CR; Paiva, ACM; Schreier, S; Spisni, A			Structure of the C-terminal fragment 300-320 of the rat angiotensin II AT(1A) receptor and its relevance with respect to G-protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; SECONDARY STRUCTURE; NMR-SPECTROSCOPY; TYPE-1 RECEPTOR; H-1-NMR SPECTRA; WASP VENOM; IDENTIFICATION; HELIX; MACROMOLECULES; REQUIREMENTS	Angiotensin II AT(1A) receptor is coupled to G-protein, and the molecular mechanism of signal transduction is still unclear, The solution conformation of a synthetic peptide corresponding to residues 300-320 of the rat AT(1A) receptor, located in the C-terminal cytoplasmic tail and indicated by mutagenesis work to be critical for the G-protein coupling, has been investigated by circular dichroism (CD), nuclear magnetic resonance (NMR) and restrained molecular dynamics calculations, The CD data indicate that, in acidic water, at concentration below 0.8 mM, the peptide exists in a predominantly coil structure while at higher concentration it call form helical aggregates; addition of small amounts of trifluoroethanol induces a secondary structure, mostly due to the presence of helical elements, Using MMR-derived constraints, an ensemble of conformers for the peptide has been determined by restrained molecular dynamics calculations, Analysis of the converged three-dimensional structures indicates that a significant population of them adopts an amphipathic alpha-helical conformation that, depending upon experimental conditions, presents a variable extension in the stretch Leu(6)-Tyr(20). An equilibrium with nonhelical structured conformers is also observed, We suggest that the capability of the peptide to modulate its secondary structure as a function of the medium dielectric constant, as well as its ability to form helical aggregates by means of intermolecular hydrophobic interactions, can play a significant role for G-protein activation.	UNIV PARMA,INST BIOL CHEM,I-43100 PARMA,ITALY; UNIV SAO PAULO,INST CHEM,DEPT BIOCHEM,BR-05599970 SAO PAULO,BRAZIL; UNIV FED SAO PAULO,DEPT BIOPHYS,BR-04044020 SAO PAULO,BRAZIL	University of Parma; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)			Schreier, Shirley/F-7001-2014; Nakaie, Clovis R./B-3444-2014; Spisni, Alberto/AAY-7778-2020					*BYOS TECHN, 1995, INSIGHTII US GUID VE; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1986, J MAGN RESON, V66, P372, DOI 10.1016/0022-2364(86)90043-0; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; WILDE A, 1994, J BIOL CHEM, V269, P7131; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	37	53	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9734	9741						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092505				2022-12-27	WOS:A1997WU03900024
J	Nagiec, MM; Nagiec, EE; Baltisberger, JA; Wells, GB; Lester, RL; Dickson, RC				Nagiec, MM; Nagiec, EE; Baltisberger, JA; Wells, GB; Lester, RL; Dickson, RC			Sphingolipid synthesis as a target for antifungal drugs - Complementation of the inositol phosphorylceramide synthase defect in strain of Saccharomyces cerevisiae by the AUR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PALMITOYLTRANSFERASE; MUTANT STRAINS; HO-GENE; CERAMIDE; YEAST; APOPTOSIS; MEMBRANE; PROTEIN; PHOSPHOLIPIDS; BIOSYNTHESIS	We have identified a Saccharomyces cerevisiae gene necessary for the step in sphingolipid synthesis in which inositol phosphate is added to ceramide to form inositol-P-ceramide a reaction catalyzed by phosphatidylinositol:ceramide phosphoinositol transferase (IPC synthase). This step should be an effective target for antifungal drugs. A key element in our experiments was the development of a procedure for isolating mutants defective in steps in sphingolipid synthesis downstream from the first step including a mutant defective in IPC synthase. An IPC synthase defect is supported by data showing a failure of the mutant strain to incorporate radioactive inositol or N-acetylsphinganine into sphingolipids and, by using an improved assay, a demonstration that the mutant strain lacks enzyme activity. Furthermore, the mutant accumulates ceramide when fed exogenous phytosphingosine as expected for a strain lacking IPC synthase activity. Ceramide accumulation is accompanied by cell death, suggesting the presence of a ceramide-activated death response in yeast. A gene, AUR1 (YKL004w), that complements the IPC synthase defect and restores enzyme activity and sphingolipid synthesis was isolated. Mutations in AUR1 had been shown previously to give resistance to the antifungal drug aureobasidin A, leading us to predict that the drug should inhibit IPC synthase activity. Our data show that the drug is a potent inhibitor of IPC synthase with an IC50 of about 0.2 nM. Fungal pathogens are an increasing threat to human health. Now that IPC synthase has been shown to be the target for aureobasidin A, it should be possible to develop high throughput screens to identify new inhibitors of IPC synthase to combat fungal diseases.	UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER GW, 1980, J BACTERIOL, V142, P474; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GIETZ RD, 1992, NUCLEIC ACIDS RES, V8, P1425; HANSON BA, 1980, J LIPID RES, V21, P309; HANSON BA, 1980, J BACTERIOL, V142, P79, DOI 10.1128/JB.142.1.79-89.1980; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; HEIDLER SA, 1995, ANTIMICROB AGENTS CH, V39, P2765, DOI 10.1128/AAC.39.12.2765; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; TAKESAKO K, 1991, J ANTIBIOT, V44, P919, DOI 10.7164/antibiotics.44.919; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; WELLS GB, 1983, J BIOL CHEM, V258, P200; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	40	302	314	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9809	9817						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092515	hybrid			2022-12-27	WOS:A1997WU03900034
J	Orozco, BM; Miller, AB; Settlage, SB; HanleyBowdoin, L				Orozco, BM; Miller, AB; Settlage, SB; HanleyBowdoin, L			Functional domains of a geminivirus replication protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN MOSAIC-VIRUS; CIRCLE DNA-REPLICATION; CONSERVED NONANUCLEOTIDE MOTIF; SENSE GENE-EXPRESSION; WHEAT DWARF VIRUS; VIRAL-DNA; INITIATOR PROTEINS; REP PROTEIN; BINDING; SEQUENCE	Tomato golden mosaic virus, a member of the gemini-virus family, has a single-stranded DNA genome that is replicated and transcribed in infected giant cells through the concerted action of viral and host factors. One viral protein, AL1, contributes to both processes by binding to a directly repeated, double stranded DNA sequence located in tile overlapping (+) strand origin of replication and AL1 promoter. The AL1 protein, which occurs as a multimeric complex in solution, also catalyzes DNA cleavage during initiation of rolling circle replication. To identify the tomato golden mosaic virus AL1 domains that mediate protein oligomerization, DNA binding, and DNA cleavage, a series of truncated AL1 proteins were produced in a baculovirus expression system and assayed for each activity. These experiments localized the AL1 oligomerization domain between amino acids 121 and 181, the DNA binding domain between amino acids 1 and 181, and the DNA cleavage domain between amino acids 1 and 120. Deletion of the first 29 amino acids of AL1 abolished DNA binding and DNA cleavage, demonstrating that an intact N terminus is required fur both activities. The observation that the DNA binding domain includes the oligomerization domain suggested that AL1-AL1 protein interaction may be a prerequisite for DNA binding but not for DNA cleavage. The significance of these results for AL1 function during geminivirus replication and transcription is discussed.			Orozco, BM (corresponding author), N CAROLINA STATE UNIV,DEPT BIOCHEM,BOX 7622,RALEIGH,NC 27695, USA.			Hanley-Bowdoin, Linda/0000-0001-7999-8595				ARGUELLOASTORGA GR, 1994, VIROLOGY, V203, P90, DOI 10.1006/viro.1994.1458; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CHOI IR, 1995, VIROLOGY, V206, P904, DOI 10.1006/viro.1995.1013; Collin S, 1996, VIROLOGY, V219, P324, DOI 10.1006/viro.1996.0256; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; EAGLE PA, 1994, PLANT CELL, V6, P1157, DOI 10.1105/tpc.6.8.1157; ELMER JS, 1988, PLANT MOL BIOL, V10, P225, DOI 10.1007/BF00027399; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FONTES EPB, 1992, PLANT CELL, V4, P597, DOI 10.1105/tpc.4.5.597; FONTES EPB, 1994, J BIOL CHEM, V269, P8459; FONTES EPB, 1994, PLANT CELL, V6, P405, DOI 10.1105/tpc.6.3.405; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; HAMILTON WDO, 1984, EMBO J, V3, P2197, DOI 10.1002/j.1460-2075.1984.tb02114.x; HanleyBowdoin L, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P287; HANLEYBOWDOIN L, 1990, P NATL ACAD SCI USA, V87, P1446, DOI 10.1073/pnas.87.4.1446; HANSON SF, 1995, VIROLOGY, V211, P1, DOI 10.1006/viro.1995.1373; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HEYRAUD F, 1993, BIOCHIMIE, V75, P605, DOI 10.1016/0300-9084(93)90067-3; HEYRAUDNITSCHKE F, 1995, NUCLEIC ACIDS RES, V23, P910, DOI 10.1093/nar/23.6.910; HOFER JMI, 1992, PLANT CELL, V4, P213, DOI 10.1105/tpc.4.2.213; HONG YG, 1995, J GEN VIROL, V76, P2415, DOI 10.1099/0022-1317-76-10-2415; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUPIN I, 1995, FEBS LETT, V362, P116, DOI 10.1016/0014-5793(95)00221-T; KOONIN EV, 1992, J GEN VIROL, V73, P2763, DOI 10.1099/0022-1317-73-10-2763; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Laufs J, 1995, BIOCHIMIE, V77, P765, DOI 10.1016/0300-9084(96)88194-6; LAUFS J, 1995, P NATL ACAD SCI USA, V92, P3879, DOI 10.1073/pnas.92.9.3879; Laufs J, 1995, FEBS LETT, V377, P258, DOI 10.1016/0014-5793(95)01355-5; LAZAROWITZ SG, 1992, CRIT REV PLANT SCI, V11, P327, DOI [10.1080/07352689209382350, 10.1080/713608038]; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGAR S, 1995, PLANT CELL, V7, P705, DOI 10.1105/tpc.7.6.705; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; Orozco BM, 1996, J VIROL, V70, P148, DOI 10.1128/JVI.70.1.148-158.1996; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; ROST B, 1993, J MOL BIOL, V232, P585; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STANLEY J, 1995, VIROLOGY, V206, P707, DOI 10.1016/S0042-6822(95)80093-X; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUNTER G, 1990, VIROLOGY, V179, P69, DOI 10.1016/0042-6822(90)90275-V; THOMMES P, 1993, FEBS LETT, V319, P95, DOI 10.1016/0014-5793(93)80044-U; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; XIE Q, 1995, EMBO J, V14, P4073, DOI 10.1002/j.1460-2075.1995.tb00079.x; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851	53	91	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9840	9846						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092519				2022-12-27	WOS:A1997WU03900038
J	Zhao, YM; Loyer, P; Lin, HM; Valentine, V; Kidd, V; Kraft, AS				Zhao, YM; Loyer, P; Lin, HM; Valentine, V; Kidd, V; Kraft, AS			Cloning and chromosomal location of a novel member of the myotonic dystrophy family of protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; CYTOPLASMIC DOMAIN; CATALYTIC SUBUNIT; CELL-GROWTH; CTG REPEAT; GENE; EXPRESSION; BINDING; IDENTIFICATION; LOCALIZATION	We have cloned a novel serine/threonine protein kinase (PK428) which is highly related (65%) within the kinase domain to the myotonic dystrophy protein kinase (DM-PK), as well as the cyclic AMP-dependent protein kinase (33%). Northern blots demonstrate that PK428 mRNA is distributed widely among tissues and is expressed at the highest levels in pancreas, heart, and skeletal muscle, with lower levels in liver and lung. Two PK428 mRNAs 10 and 3.8 kilobase pairs in size are seen in a number of cell lines, including hematopoietic and breast cancer cells. An antibody generated to a glutathione S-transferase-PK428 fusion protein detects a 65-kDa protein in these cell lines, and a similarly sized protein when the cloned cDNA is transiently expressed in Cos 7 cells. Immunoprecipitation of the transiently expressed PK428 protein and incubation with [gamma-P-32]ATP demonstrate that it is capable of autophosphorylation. In addition, immunoprecipitates of the PK428 protein kinase also phosphorylated histone H1 and a peptide encoding a cyclic AMP-dependent protein kinase substrate. The gene corresponding to the 3.8-kb PK428 mRNA, and its corresponding 65 kDa protein, was isolated by polymerase chain reaction screening of a P1 phage human genomic library. Using this P1 phage clone as a probe, the PK428 gene was located on 1q41-42, a possible location for a human senescence gene, a gene associated with Rippling muscle disease, as well as a region associated with genetically acquired mental retardation.	UNIV COLORADO, HLTH SCI CTR, DIV MED ONCOL, DENVER, CO 80262 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; St Jude Children's Research Hospital; St Jude Children's Research Hospital			LOYER, Pascal/K-1838-2019	LOYER, PASCAL/0000-0002-5656-2673	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bush EW, 1996, J BIOL CHEM, V271, P548, DOI 10.1074/jbc.271.1.548; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Engel AG, 1994, MYOLOGY, P1192; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER PS, 1989, MYOTONIC DYSTROPHY, P1192; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIMBERLING WJ, 1995, AM J HUM GENET, V56, P216; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MAEDA M, 1995, J BIOL CHEM, V270, P20246, DOI 10.1074/jbc.270.35.20246; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; RAMPAZZO A, 1995, HUM MOL GENET, V4, P2151, DOI 10.1093/hmg/4.11.2151; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAMBOURI L, 1993, NAT GENET, V4, P233; STEPHAN DA, 1994, NEUROLOGY, V44, P1915, DOI 10.1212/WNL.44.10.1915; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TIMCHENKO L, 1995, P NATL ACAD SCI USA, V92, P5366, DOI 10.1073/pnas.92.12.5366; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; VERSCHUURENBEMELMANS CC, 1995, AM J MED GENET, V58, P83, DOI 10.1002/ajmg.1320580116; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063; WIEMANN S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P93, DOI 10.1016/0167-4781(92)90144-O; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	32	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10013	10020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092543				2022-12-27	WOS:A1997WU03900062
J	Ma, Q; Whitlock, JP				Ma, Q; Whitlock, JP			A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DIOXIN RECEPTOR; AROMATIC-HYDROCARBONS; BINDING ACTIVITIES; SNAP HELIX; CLONING; IMMUNOPHILIN; COMPONENT; DOMAINS; LIGAND	To identify new proteins involved in dioxin-dependent signal transduction and transcriptional regulation, we used a yeast two-hybrid system to identify proteins that interact with the Ah receptor (AhR). We cloned a mouse cDNA, which encodes a novel similar to 37-kDa protein that binds to AhR; we have designated the protein as Ah receptor-interacting protein (AIP). The amino acid sequence of mouse AIP exhibits homology with members of the FK506-binding protein family. AIP also contains three tetratricopeptide repeat (TPR) motifs; the TPR sequence is present in proteins required for cell cycle control and RNA synthesis and in steroid receptor-binding immunophilins. Coimmunoprecipitation experiments in mouse hepatoma cells reveal that AIP is cytoplasmic and associates with unliganded Ah receptor and with hsp90; 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment disrupts the AhR-AIP-hsp90 interaction. Overexpression of AIP augments the response of the CYP1A1 gene to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Our data suggest that AIP influences ligand receptivity and/or nuclear targeting of AhR.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719, F32ES005679] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03719, ES 05679] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bartel Paul L., 1993, V131, P153; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CONNEY AH, 1982, CANCER RES, V42, P4875; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1994, J BIOL CHEM, V269, P27337; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAIN S, 1994, J BIOL CHEM, V269, P31518; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MILLER AG, 1983, J BIOL CHEM, V258, P3523; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1993, MOL PHARMACOL, V45, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wiederrecht Greg, 1994, Perspectives in Drug Discovery and Design, V2, P57, DOI 10.1007/BF02171737; YEM AW, 1992, J BIOL CHEM, V267, P2868	46	338	353	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8878	8884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083006				2022-12-27	WOS:A1997WU03700011
J	Rammes, A; Roth, J; Goebeler, M; Klempt, M; Hartmann, M; Sorg, C				Rammes, A; Roth, J; Goebeler, M; Klempt, M; Hartmann, M; Sorg, C			Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; MONOCLONAL-ANTIBODY; NEURITE EXTENSION; PERIPHERAL-BLOOD; PLASMA-MEMBRANE; COMPLEX; DIFFERENTIATION; CELLS; CALPROTECTIN; EXPRESSION	Myeloid-related protein (MRP) 8 and MRP14, two members of the S100 family expressed in myelomonocytic cells, have been ascribed some extracellular functions, e.g. antimicrobial, cytostatic, and chemotactic activities. Since S100 proteins lack structural requirements for secretion via the classical endoplasmic reticulum/Golgi route, the process of secretion is unclear. We now demonstrate the specific, energy-dependent release of MRP8 and MRP14 by human monocytes after activation of protein kinase C. This secretory process is not blocked by inhibitors of vesicular traffic through the endoplasmic reticulum and Golgi, and comparative studies on tumor necrosis factor-alpha and interleukin-1 beta indicate that MRP8 and MRP14 follow neither the classical nor the interleukin-1-like alternative route of secretion. Inhibition by microtubule-depolymerizing agents revealed that MRP8/MRP14 secretion requires an intact tubulin network. Accordingly, upon initiation of MRP8/RIRP14 secretion, immunofluorescence microscopy showed a co-localization of both proteins with tubulin filaments. Release of MRP8 and MRP14 is associated with down-regulation of their de novo synthesis, suggesting that extracellular signaling via MRP8/MRP14 is restricted to distinct differentiation stages of monocytes. Our data provide evidence that the S100 proteins MRP8 and MRP14 are secreted after activation of protein kinase C via a novel pathway requiring an intact microtubule network.	UNIV MUNSTER,INST EXPT DERMATOL,D-48129 MUNSTER,GERMANY; UNIV MUNSTER,DEPT PEDIAT,D-48129 MUNSTER,GERMANY; UNIV WURZBURG,DEPT DERMATOL,D-97080 WURZBURG,GERMANY	University of Munster; University of Munster; University of Wurzburg			Goebeler, Matthias/P-3612-2019; Goebeler, Matthias/F-7118-2013					ALLEN JN, 1991, AM J PHYSIOL, V261, pL315, DOI 10.1152/ajplung.1991.261.4.L315; BALDARI CT, 1989, J IMMUNOL, V142, P785; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BRUN JG, 1994, J RHEUMATOL, V21, P733; BRUN JG, 1995, APMIS, V103, P233, DOI 10.1111/j.1699-0463.1995.tb01100.x; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; DONATO R, 1990, ADV EXP MED BIOL, V269, P103; DORIN JR, 1990, GENOMICS, V8, P420, DOI 10.1016/0888-7543(90)90027-R; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GOEBELER M, 1993, J LEUKOCYTE BIOL, V53, P11, DOI 10.1002/jlb.53.1.11; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; MURTHY ARK, 1993, J IMMUNOL, V151, P6291; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; ROTH J, 1992, IMMUNOBIOLOGY, V186, P304, DOI 10.1016/S0171-2985(11)80259-7; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; ROTH J, 1993, BLOOD, V82, P1875; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; vandenBos C, 1996, J IMMUNOL, V156, P1247; VANDUUREN BL, 1979, CANCER RES, V39, P2644; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; YUI S, 1995, J LEUKOCYTE BIOL, V58, P307, DOI 10.1002/jlb.58.3.307; ZWADLO G, 1986, J IMMUNOL, V137, P512	46	455	491	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9496	9502						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083090				2022-12-27	WOS:A1997WU03700095
J	Sasaki, T; Gohring, W; Mann, K; Maurer, P; Hohenester, E; Knauper, V; Murphy, G; Timpl, R				Sasaki, T; Gohring, W; Mann, K; Maurer, P; Hohenester, E; Knauper, V; Murphy, G; Timpl, R			Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; BINDING-SITE; IV COLLAGEN; V COLLAGEN; OSTEONECTIN; SPARC; CALCIUM; BONE; GLYCOSYLATION; SPECIFICITY	The 33-kDa matrix protein BM-40 (SPARC, osteonectin) consists of an acidic N-terminal domain I, a central cysteine-rich follistatin-like module, and a C-terminal extracellular calcium-binding (EC) module. Previous studies attributed collagen IV and high affinity calcium binding of EM-40 to its EC module, which was shown by x-ray crystallography to consist of an EF-hand pair surrounded by several alpha-helical and loop segments. This module was now shown by surface plasmon resonance assay to bind with similar affinities to collagens I, III, and V. Cleavage of recombinant BM-40 and its EC module by collagenase-3, gelatinases A and B, matrilysin, and stromelysin-1 showed similar fragment patterns, whereas collagenase-1 was inactive, Some differences were, however, observed in cleavage rates and the preference of certain cleavage sites. Edman degradation of fragments demonstrated only three to four major cleavage sites in the central region of domain I and a single uniform cleavage in helix C of the EC module, Cleavage is accompanied by a 7-20-fold increase in binding activity for collagens I, IV, and V but revealed only small effects on calcium-dependent alpha-helical changes in the EC module. The data were interpreted to indicate that helix C cleavage is mainly responsible for enhancing collagen affinity by exposing the underlying helix A of the EC module. A similar activation may also occur in situ as indicated previously for tissue-derived BM-40.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; UNIV COLOGNE,FAC MED,INST BIOCHEM 2,D-50931 COLOGNE,GERMANY; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND	Max Planck Society; University of Cologne; University of London; Birkbeck University London			Mann, Karlheinz/C-4254-2008	Knauper, Vera/0000-0002-3965-9924				Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; KELM RJ, 1991, J BIOL CHEM, V266, P9632; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; MANN K, 1987, FEBS LETT, V218, P167, DOI 10.1016/0014-5793(87)81040-2; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MAYER U, 1993, EUR J BIOCHEM, V217, P877, DOI 10.1111/j.1432-1033.1993.tb18316.x; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55, DOI 10.3109/17453679509157648; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NUOVILA AP, 1996, CURR OPIN CELL BIOL, V8, P692; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OTSUKA K, 1984, J BIOL CHEM, V259, P9805; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; TYREE B, 1989, J BONE MINER RES, V4, P877; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Xie RL, 1996, J BIOL CHEM, V271, P8121, DOI 10.1074/jbc.271.14.8121; XIE RL, 1995, J BIOL CHEM, V270, P23212, DOI 10.1074/jbc.270.39.23212	39	133	139	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9237	9243						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083057				2022-12-27	WOS:A1997WU03700062
J	Urbani, A; Bianchi, E; Narjes, F; Tramontano, A; DeFrancesco, R; Steinkuhler, C; Pessi, A				Urbani, A; Bianchi, E; Narjes, F; Tramontano, A; DeFrancesco, R; Steinkuhler, C; Pessi, A			Substrate specificity of the hepatitis C virus serine protease NS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE NONSTRUCTURAL PROTEINS; IN-VITRO; VIRAL POLYPROTEIN; COMPLEX-FORMATION; CLEAVAGE ACTIVITY; ESCHERICHIA-COLI; NS4A; RECOMBINANT; TRANS; REQUIREMENTS	The substrate specificity of a purified protein encompassing the hepatitis C virus NS3 serine protease domain was investigated by introducing systematic modifications, including non-natural amino acids, into substrate peptides derived from the NS4A/NS4B cleavage site, Kinetic parameters were determined in the absence and presence of a peptide mimicking the protease co-factor NS4A (Pep4A), Based on this study we draw the following conclusions: (i) the NS3 protease domain has an absolute requirement for a small. residue in the P1 position of substrates, thereby confirming previous modelling predictions. (ii) Optimization of the P1 binding site occupancy primarily influences transition state binding, whereas the occupancy of distal binding sites is a determinant for both ground state and transition state binding, (iii) Optimized contacts at distal binding sites may contribute synergistically to cleavage efficiency.	IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ROME,ITALY	Merck & Company			De Francesco, Raffaele/J-6003-2012; Urbani, Andrea/B-2953-2012; Tramontano, anna/D-5378-2009	De Francesco, Raffaele/0000-0001-8754-5123; Tramontano, anna/0000-0002-5610-3338; Bianchi, Elisabetta/0000-0002-5302-6912; Narjes, Frank/0000-0002-3104-7771				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P198, DOI 10.1128/JVI.69.1.198-205.1995; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DSOUZA EDA, 1995, J GEN VIROL, V76, P1729, DOI 10.1099/0022-1317-76-7-1729; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Failla CM, 1996, FOLD DES, V1, P35, DOI 10.1016/S1359-0278(96)00010-7; Fersht A., 1985, ENZYME STRUCTURE MEC; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hong Z, 1996, J VIROL, V70, P4261, DOI 10.1128/JVI.70.7.4261-4268.1996; KAKIUCHI N, 1995, BIOCHEM BIOPH RES CO, V210, P1059, DOI 10.1006/bbrc.1995.1764; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; KOLYKHALOV AA, 1994, J VIROL, V68, P7525, DOI 10.1128/JVI.68.11.7525-7533.1994; KOMODA Y, 1994, J VIROL, V68, P7351, DOI 10.1128/JVI.68.11.7351-7357.1994; KOMODA Y, 1994, GENE, V145, P221; LEINBACH SS, 1994, VIROLOGY, V204, P163, DOI 10.1006/viro.1994.1520; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Mori A, 1996, FEBS LETT, V378, P37, DOI 10.1016/0014-5793(95)01423-3; OVERTON H, 1995, J GEN VIROL, V76, P3009, DOI 10.1099/0022-1317-76-12-3009; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; SATOH S, 1995, J VIROL, V69, P4255, DOI 10.1128/JVI.69.7.4255-4260.1995; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; Shoji I, 1995, HEPATOLOGY, V22, P1648, DOI 10.1016/0270-9139(95)90186-8; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; Steinkuhler C, 1996, J VIROL, V70, P6694; SUZUKI T, 1995, J GEN VIROL, V76, P3021, DOI 10.1099/0022-1317-76-12-3021; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TAMJI Y, 1995, J VIROL, V69, P1575; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; WANG W, 1994, BIOCHEMISTRY-US, V33, P14636, DOI 10.1021/bi00252a032; YAMANAKA G, 1995, J BIOL CHEM, V270, P30168	39	100	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9204	9209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083052				2022-12-27	WOS:A1997WU03700057
J	Wong, E; Bayly, C; Waterman, HL; Riendeau, D; Mancini, JA				Wong, E; Bayly, C; Waterman, HL; Riendeau, D; Mancini, JA			Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His(513)->Arg and Ile(523)->Val mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; CYCLOOXYGENASE; INFLAMMATION; EXPRESSION; MECHANISM; PROTEIN; ASPIRIN; CDNA	Modeling of the active site of prostaglandin G/H synthase-2 (PGHS-2) onto PGHS-1 utilizing the known crystal structure of PGHS-1 shows that the only residues impinging directly on the active site that were not conserved in the two enzymes are His(513) and Ile(523) of PGHS-1 (Arg(499) and Val(509) of PGHS-2). These residues of human PGHS-1 were each mutated to the corresponding PGHS-2 residues (His(513) --> Arg and Ile(523) --> Val) and a double mutant (His(513) --> Arg,Ile(523) --> Val) containing both residues was also constructed. The mutant enzyme forms were expressed in COS-7 cells, and their properties were compared with those of the normal isoforms using microsomal membranes. The mutated enzyme forms all had apparent K-m values within 1.4-fold that of the wild type enzyme, and the specific activity of the mutants were within 2-fold of that of PGHS-1. DuP697, NS-398, DFU, and SC-58125 are selective PGHS-2 inhibitors that act as time-dependent inhibitors of PGHS-2 and rapidly reversible competitive inhibitors of PGHS-1. The single Ile(523) --> Val mutation increased the sensitivity to each of these selective inhibitors with most of the effect detected using instantaneous inhibition assays, except for DuP697, whose potency was further increased by preincubation with the enzyme. The double PGHS-1 His(513) --> Arg,Ile(523) --> Val mutant became more sensitive to inhibition by NS-398 and DFU than the single IV mutant, and time-dependent inhibition was observed. In contrast, the single HR mutation did not increase the sensitivity to inhibition by the selective PGHS-2 inhibitors. The potency of a selective PGHS-1 inhibitor, L-745,296, was decreased 5- and 13-fold in the HR and HR-IV mutants, respectively. All the results indicate that mutations of His(513) and Ile(523) residues of PGHS-1 can strongly increase sensitivity to selective PGHS-2 inhibition and restore time-dependent inhibition. They also suggest that the corresponding Arg(499) and Val(509) residues of PGHS-2 are essential determinants in differentiating between the interaction of nonselective NSAIDs and selective PGHS-2 inhibitors and their mechanism of action.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOL BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company; Merck & Company								Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KARGMAN SL, 1995, CANCER RES, V55, P2556; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEBLANC Y, 1995, BIOORG MED CHEM LETT, V5, P2123, DOI 10.1016/0960-894X(95)00359-2; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; PEARLMAN DA, 1995, AMBER 4 1; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1990, BIOCHIM BIOPHYS ACTA, V1083, P1; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928	31	116	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9280	9286						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083063				2022-12-27	WOS:A1997WU03700068
J	Asakura, S; Niwa, K; Tomozawa, T; Jin, YM; Madoiwa, S; Sakata, Y; Sakai, T; Funayama, H; Soe, G; Forgerty, F; Hirata, H; Matsuda, M				Asakura, S; Niwa, K; Tomozawa, T; Jin, YM; Madoiwa, S; Sakata, Y; Sakai, T; Funayama, H; Soe, G; Forgerty, F; Hirata, H; Matsuda, M			Fibroblasts spread on immobilized fibrin monomer by mobilizing a beta(1)-class integrin, together with a vitronectin receptor alpha(v)beta(3) on their surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-INSOLUBLE GLOBULIN; IIB-IIIA COMPLEX; HUMAN S-PROTEIN; CELL-ADHESION; GAMMA-CHAIN; ENDOTHELIAL-CELLS; ALPHA-CHAIN; ELECTRON-MICROSCOPY; BETA CHAIN; GPIIB-IIIA	Human and murine fibroblasts were found to spread far more avidly on fibrin monomer monolayers than on immobilized fibrinogen, indicating that removal of fibrinopeptides by thrombin is a prerequisite for the fibrin-mediated augmentation of cell spreading. In fact, cell spreading was not efficiently augmented on monolayers of a thrombin-treated dysfibrinogen lacking the release of fibrinopeptide A due to an A alpha Arg-16 --> Cys substitution. Since a synthetic Arg-Gly-Asp (RGD)-containing peptide inhibited the fibrin-mediated cell spreading, subsequent dissociation of the carboxyl-terminal globular domain of the A alpha-chains appears to render the RGD segments accessible to the cell-surface integrins. In support of this, fibrin-augmented cell spreading was inhibited by an antibody recognizing a 12-kDa peptide segment with gamma Met-89 at its amino terminus, which is located in close association with the RGD segment at A alpha 95-97 in the helical coiled-coil interdomainal connector. The fibrin-mediated augmentation of cell spreading was inhibited not only by an antibody against human vitronectin receptor (LM 609) but also by an antibody against the beta(1) subunit of integrin (mAb13), suggesting that the beta(1)-class integrin together with a vitronectin receptor, alpha(v) beta(3), is mobilized onto the surface of fibroblasts upon contact with the fibrin monomer monolayer.	JICHI MED SCH,INST HEMATOL,DIV HAMATOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DEPT CARDIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; IATRON LABS INC,CENT RES LABS,MITO,CHIBA 28922,JAPAN; UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,LAB BIOSIGNALING,HARIMA,HYOGO 0205,JAPAN	Jichi Medical University; Jichi Medical University; University of Wisconsin System; University of Wisconsin Madison; University of Hyogo	Asakura, S (corresponding author), JICHI MED SCH,INST HEMATOL,DIV HEMOSTASIS & THROMBOSIS RES,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BASSON CT, 1990, J CELL BIOL, V110, P789, DOI 10.1083/jcb.110.3.789; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CIERNIEWSKI C, 1977, J BIOL CHEM, V252, P8917; CIERNIEWSKI CS, 1987, J BIOL CHEM, V262, P13896; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DEJANA E, 1987, J CELL BIOL, V104, P1403, DOI 10.1083/jcb.104.5.1403; DEJANA E, 1990, BLOOD, V75, P1509; DOOLITTLE RF, 1973, ADV PROTEIN CHEM, V27, P27; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FRANCIS CW, 1980, BLOOD, V56, P456; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; GRINNELL F, 1976, EXP CELL RES, V102, P51, DOI 10.1016/0014-4827(76)90298-6; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HANTGAN RR, 1995, BLOOD, V86, P1001, DOI 10.1182/blood.V86.3.1001.bloodjournal8631001; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LANGUINO LR, 1989, BLOOD, V73, P734; MATSUDA M, 1990, FIBRINOGEN, V4, P43; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSESSON MW, 1995, J CLIN INVEST, V96, P1053, DOI 10.1172/JCI118091; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; NEUGEBAUER KM, 1992, J CELL BIOL, V116, P809, DOI 10.1083/jcb.116.3.809; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TERUKINA S, 1988, J BIOL CHEM, V263, P13579; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEYAMA M, 1978, JPN J EXP MED, V48, P135; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	42	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8824	8829		10.1074/jbc.272.13.8824	http://dx.doi.org/10.1074/jbc.272.13.8824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079719	hybrid			2022-12-27	WOS:A1997WQ63500102
J	Berk, PD; Zhou, SL; Kiang, CL; Stump, D; Bradbury, M; Isola, LM				Berk, PD; Zhou, SL; Kiang, CL; Stump, D; Bradbury, M; Isola, LM			Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; LIVER PLASMA-MEMBRANES; PANCREATIC BETA-CELLS; BINDING-PROTEIN; OLEATE UPTAKE; PHOSPHOLIPID-BILAYERS; HEPATOCELLULAR UPTAKE; UNILAMELLAR VESICLES; ISOLATED HEPATOCYTES; GLUCOSE-TRANSPORT	To examine whether fatty acid transport is abnormal in obesity, the kinetics of [H-3]oleate uptake by hepatocytes, cardiac myocytes, and adipocytes from adult male Wistar (+/+), Zucker lean (fa/+) and fatty (fa/fa), and Zucker diabetic fatty (ZDF) rats were studied. A tissue-specific increase in oleate uptake was found in fa/fa and ZDF adipocytes, in which the V-max was increased 9-fold (p < 0.005) and 13-fold (p < 0.001), respectively. This increase greatly exceeded the 2-fold increase in the surface area of adipocytes from obese animals, and did not result from trans-stimulation secondary to increased lipolysis. Adipocyte tumor necrosis factor-alpha mRNA levels, assayed by Northern hybridization, increased in the order +/+ < fa/fa < ZDF. Oleate uptake was also studied in adipocytes from 20-24-day-old male +/+, fa/+, and fa/fa weanlings. These animals were not obese, and had equivalent plasma fatty acid and glucose levels. Tumor necrosis factor-cy mRNA levels in +/+ and fa/fa cells also were similar. Nevertheless, V-max was increased 2.9-fold (p < 0.005) in fa/fa compared +/+ cells. These studies indicate 1) that regulation of fatty acid uptake is tissue-specific and 2) that up-regulation of adipocyte fatty acid uptake is an early event in Zucker fa/fa rats. These findings are independent of the role of any particular fatty acid transporter. Adipocyte mRNA levels of three putative transporters, mitochondrial aspartate aminotransferase, fatty acid translocase, and fatty acid transporting protein (FATP) were also determined; mitochondrial aspartate aminotransferase and FATP mRNAs correlated strongly with fatty acid uptake.	CUNY MT SINAI SCH MED,DEPT MED,DIV HEMATOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,DIV BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Berk, PD (corresponding author), CUNY MT SINAI SCH MED,DIV LIVER DIS,DEPT MED,1 GUSTAVE L LEVY PL,BOX 1633,NEW YORK,NY 10029, USA.		Bradbury, Michael W/G-5002-2013	Bradbury, Michael W/0000-0002-6384-2681	NIDDK NIH HHS [DK26687, DK-26438] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687, R01DK026438] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1988, J BIOL CHEM, V263, P14678; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1985, J BIOL CHEM, V260, P9969; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; BARTHOLOMEW DJ, 1959, BIOMETRIKA, V46, P36; Berk PD, 1996, SEMIN LIVER DIS, V16, P107, DOI 10.1055/s-2007-1007224; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BERMAN M, 1967, US PHS PUBLICATION, V1703; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BESSESEN DH, 1995, OBES RES, V3, P179, DOI 10.1002/j.1550-8528.1995.tb00134.x; Bjorntorp Per, 1994, Current Opinion in Lipidology, V5, P166, DOI 10.1097/00041433-199405030-00003; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BRAY GA, 1970, J LIPID RES, V11, P517; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Civelek VN, 1996, P NATL ACAD SCI USA, V93, P10139, DOI 10.1073/pnas.93.19.10139; CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DANIS RP, 1993, INVEST OPHTH VIS SCI, V34, P2367; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; EZZOUBIR A, 1994, J LIPID RES, V35, P930; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FUJII S, 1987, LIPIDS, V22, P544, DOI 10.1007/BF02540374; GROOP LC, 1991, J CLIN ENDOCR METAB, V72, P96, DOI 10.1210/jcem-72-1-96; GRUEN R, 1978, METABOLISM, V27, P1955, DOI 10.1016/S0026-0495(78)80012-2; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; HENNES MMI, 1990, INT J OBESITY, V14, P831; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HEWETT K, 1983, AM J PHYSIOL, V245, pH830, DOI 10.1152/ajpheart.1983.245.5.H830; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; Johnson, 1990, ILAR NEWS, V32, P4, DOI [DOI 10.1093/ILAR.32.3.4, 10.1093/ilar.32.3.4]; JOHNSON PR, 1971, J LIPID RES, V12, P706; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KAPLAN ML, 1980, METABOLISM, V29, P333, DOI 10.1016/0026-0495(80)90006-2; KLEINFELD AM, 1993, BIOCHEMISTRY-US, V32, P2053, DOI 10.1021/bi00059a024; LASH JM, 1989, DIABETES, V38, P854, DOI 10.2337/diabetes.38.7.854; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; Noy Noa, 1993, P313; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; PETERSON RG, 1990, FRONT DIABETES RES, V9, P456; RICHIERI GV, 1995, J LIPID RES, V36, P229; ROSE H, 1994, BBA-LIPID LIPID MET, V1215, P321, DOI 10.1016/0005-2760(94)90060-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SORRENTINO D, 1992, AM J PHYSIOL, V263, pG380, DOI 10.1152/ajpgi.1992.263.3.G380; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SORRENTINO D, 1994, AM J PHYSIOL, V266, pG425, DOI 10.1152/ajpgi.1994.266.3.G425; SORRENTINO D, 1994, J HEPATOL, V21, P551, DOI 10.1016/S0168-8278(94)80100-2; SORRENTINO D, 1994, GASTROENTEROLOGY, V107, P1415, DOI 10.1016/0016-5085(94)90544-4; Sorrentino Dario, 1993, P197; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUMP DD, 1992, J HEPATOL, V16, P304, DOI 10.1016/S0168-8278(05)80661-0; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TRIMBLE ME, 1989, AM J PHYSIOL, V257, pF539, DOI 10.1152/ajprenal.1989.257.4.F539; TRUETT GE, 1995, AM J PHYSIOL-ENDOC M, V268, pE15, DOI 10.1152/ajpendo.1995.268.1.E15; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; Weisiger Richard A., 1993, P171; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WOSILAIT WD, 1976, COMPUT PROG BIOMED, V6, P142, DOI 10.1016/0010-468X(76)90020-9; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; ZAKIM D, 1990, HEPATOLOGY, V1, P65; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHOU SL, 1992, J BIOL CHEM, V267, P14456; ZHOU SL, 1994, BIOCHEM J, V297, P315, DOI 10.1042/bj2970315; ZUCKER LM, 1972, ENDOCRINOLOGY, V90, P1320, DOI 10.1210/endo-90-5-1320; ZUCKER LM, 1972, J LIPID RES, V13, P234	93	114	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8830	8835		10.1074/jbc.272.13.8830	http://dx.doi.org/10.1074/jbc.272.13.8830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079720	hybrid			2022-12-27	WOS:A1997WQ63500103
J	Kerper, LE; Hinkle, PM				Kerper, LE; Hinkle, PM			Cellular uptake of lead is activated by depletion of intracellular calcium stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; CHROMAFFIN CELLS; DIVALENT-CATIONS; PLASMA-MEMBRANE; CHANNELS; ENTRY; THAPSIGARGIN; INHIBITION; CURRENTS; INFLUX	The mechanisms of cellular lead uptake were characterized using a fluorescence method in cells loaded with indo-1. Pb2+ bound to intracellular indo-1 with much higher affinity than Ca2+ and quenched fluorescence at all wavelengths. Pb2+ uptake into pituitary GH(3) cells, glial C-6 cells, and a subclone of HEK293 cells was assessed by fluorescence quench at a Ca2+-insensitive emission wavelength. Pb2+ uptake was concentration and time-dependent. Pb2+ uptake in all three cell types occurred at a much faster rate when intracellular Ca2+ stores were depleted by two different methods: addition of drugs that inhibit the endoplasmic reticulum Ca2+ pump (thapsigargin, cyclopiazonic acid, and tert-butyl-hydroquinone), and prolonged incubation of cells in Ca2+-free media, Application of receptor agonists, which deplete intracellular Ca2+ stores via inositol trisphosphate-sensitive channels, did not activate Pb2+ uptake. Agonists were just as effective as thapsigargin in stimulating uptake of Ca2+ but less so in stimulating uptake of Mn2+. Basal and stimulated Pb2+ uptake were partially reduced by 1 mM extracellular Ca2+ and strongly inhibited by 10 mM Ca2+.Pb2+ entry in GH(3) cells was inhibited by two drugs that block capacitative Ca2+ entry, La3+ and SK&F 96365. Depolarization of electrically excitable GH(3) cells increased the initial rate of Pb2+ uptake 1.6-fold, whereas thapsigargin increased uptake 12-fold. In conclusion, Pb2+ crosses the plasma membrane of GH(3), C-6, and HEK293 cells via channels that are activated by profound depletion of intracellular Ca2+ stores.	UNIV ROCHESTER, SCH MED & DENT, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NCI NIH HHS [CA11098] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline; NIEHS NIH HHS [ES05855] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDEREGG G, 1977, HELV CHIM ACTA, V60, P123, DOI 10.1002/hlca.19770600115; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DEANE R, 1990, J NEUROCHEM, V54, P905, DOI 10.1111/j.1471-4159.1990.tb02337.x; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HUGHES AD, 1994, CELL CALCIUM, V15, P317, DOI 10.1016/0143-4160(94)90071-X; INAZU M, 1993, LIFE SCI, V53, pPL315, DOI 10.1016/0024-3205(93)90626-E; KWAN CY, 1990, J BIOL CHEM, V265, P678; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; Martell A. E., 1974, CRITICAL STABILITY C; MENDELOWITZ D, 1992, AM J PHYSIOL, V262, pH942, DOI 10.1152/ajpheart.1992.262.4.H942; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; NELSON EJ, 1994, BIOCHEM J, V302, P147, DOI 10.1042/bj3020147; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; SCHWARZ G, 1994, CELL CALCIUM, V15, P45, DOI 10.1016/0143-4160(94)90103-1; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; SIMONS TJB, 1986, J PHYSIOL-LONDON, V378, P287, DOI 10.1113/jphysiol.1986.sp016220; SIMONS TJB, 1987, J NEUROCHEM, V48, P383, DOI 10.1111/j.1471-4159.1987.tb04105.x; SUN LR, 1995, J NEUROPHYSIOL, V74, P574, DOI 10.1152/jn.1995.74.2.574; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOMSIG JL, 1991, BIOCHIM BIOPHYS ACTA, V1069, P197, DOI 10.1016/0005-2736(91)90124-Q; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	34	105	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8346	8352		10.1074/jbc.272.13.8346	http://dx.doi.org/10.1074/jbc.272.13.8346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079658	hybrid			2022-12-27	WOS:A1997WQ63500041
J	Yano, M; Kanazawa, M; Terada, K; Namchai, C; Yamaizumi, M; Hanson, B; Hoogenraad, N; Mori, M				Yano, M; Kanazawa, M; Terada, K; Namchai, C; Yamaizumi, M; Hanson, B; Hoogenraad, N; Mori, M			Visualization of mitochondrial protein import in cultured mammalian cells with green fluorescent protein and effects of overexpression of the human import receptor Tom20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE TRANSCARBAMYLASE; EXPRESSION; PRECURSORS; TRANSPORT; YEAST; GENE; DNA	The presequence of the ornithine transcarbamylase precursor (pOTC) was fused to green fluorescent protein (GFP), yielding pOTC-GFP and pOTCN-GFP containing the presequence plus 4 and 58 residues of mature ornithine transcarbamylase, respectively, When GFP cDNA was transfected into COS-7 cells, the cytosol and nucleus were fluorescent, On the other hand, pOTC-GFP cDNA gave strong fluorescence of a unique mitochondrial pattern, After fractionation of cells expressing pOTC-GFP with digitonin, fluorescence was recovered mostly in the particulate fraction, Immunoblot analysis showed that processed GFP was present in the particulate fraction, whereas pOTC-GFP was recovered in both the soluble and particulate fractions. pOTC-GFP and pOTCN-GFP synthesized in vitro were imported efficiently into the isolated mitochondria, Single and triple amino acid mutations in the presequence resulted in impaired mitochondrial import and in a loss of mitochondrial fluorescence. Perinuclear aggregation of fluorescent mitochondria was observed when the human mitochondrial import receptor Tom20 (hTom20) was coexpressed with pOTC-GFP. Overexpression of hTom20 (not Delta hTom20, which lacks the anchor sequence) resulted in stimulated mitochondrial import of pOTC-GFP in COS-7 cells, When pOTC-GFP cDNA was microinjected into nuclei of human fibroblast cells, mitochondrial fluorescence was detected as early as 2-3 h after injection. These results show that GFP fusion protein can be used to visualize mitochondrial structures and to monitor mitochondrial protein import in a single cell in real time.	KUMAMOTO UNIV,SCH MED,DEPT MOL GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA	Kumamoto University; Kumamoto University; La Trobe University			Hoogenraad, Nicholas J/C-7505-2011					CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; GOPING IS, 1995, FEBS LETT, V373, P45; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORWICH AL, 1985, J CELL BIOL, V100, P1515, DOI 10.1083/jcb.100.5.1515; HORWICH AL, 1987, J CELL BIOL, V105, P669, DOI 10.1083/jcb.105.2.669; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; ISAYA G, 1988, MOL CELL BIOL, V8, P5150, DOI 10.1128/MCB.8.12.5150; JAUSSI R, 1982, J BIOL CHEM, V257, P13334; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LII R, 1996, TRENDS CELL BIOL, V6, P56; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MORI M, 1989, CELL STRUCT FUNCT, V14, P653, DOI 10.1247/csf.14.653; MORI M, 1981, P NATL ACAD SCI-BIOL, V78, P6056, DOI 10.1073/pnas.78.10.6056; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; TERADA K, 1995, MOL CELL BIOL, V15, P3708; Venerando R, 1996, FEBS LETT, V382, P256, DOI 10.1016/0014-5793(96)00182-2; YAMAIZUMI M, 1983, MOL CELL BIOL, V3, P511, DOI 10.1128/MCB.3.4.511	26	69	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8459	8465		10.1074/jbc.272.13.8459	http://dx.doi.org/10.1074/jbc.272.13.8459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079673	hybrid			2022-12-27	WOS:A1997WQ63500056
J	Dickeson, SK; Walsh, JJ; Santoro, SA				Dickeson, SK; Walsh, JJ; Santoro, SA			Contributions of the I and EF hand domains to the divalent cation-dependent collagen binding activity of the alpha(2)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIA VLA-2 COMPLEX; LIGAND-BINDING; ALPHA-2-BETA-1 VLA-2; LAMININ RECEPTOR; A-DOMAIN; ADHESION; SITE; PLATELETS; SEQUENCE; PROTEINS	The alpha(2) beta(1) integrin binds collagen in a Mg2+-dependent manner that is inhibited by Ca2+, Like the intact integrin, purified recombinant proteins containing the or, integrin I domain, either alone or with variable numbers of cu, integrin EF hand metal binding sites, bound collagen in a Mg2+-dependent manner, and Ca2+ did not support binding, However, unlike the intact integrin, Ca2+ did not inhibit the Mg2+-dependent binding of any of the fusion proteins to collagen. Binding to collagen was saturable and blocked by the alpha(2) beta(1) function blocking antibody 6F1. Deletional analysis demonstrated that residues present within the amino-terminal 35 amino acids contribute to the 6F1 epitope and are required for Mg2+-dependent collagen binding, The results indicate that the I domain contains a Mg2+ binding site that is essential for collagen binding and that the I domain alone is sufficient for collagen binding. Binding is markedly enhanced in a divalent cation dependent manner by the addition of the first EF hand motif, Mutation of the EF hand to an inactive form completely abrogated the effect, The sites necessary for Ca2+ inhibition are not present within the I domain or the adjacent region containing the three EF hand sites.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040506, R01HL049082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49082, HL-40506] Funding Source: Medline; NIDDK NIH HHS [DK-45181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; COLLER BS, 1989, BLOOD, V74, P182; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KERN A, 1994, J BIOL CHEM, V269, P22811; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Marston F. A. O., 1987, DNA CLONING, P59; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; RANDI AM, 1994, J BIOL CHEM, V269, P12395; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAATZ WD, 1990, BIOCHEM BIOPH RES CO, V168, P107, DOI 10.1016/0006-291X(90)91681-H; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	32	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7661	7668		10.1074/jbc.272.12.7661	http://dx.doi.org/10.1074/jbc.272.12.7661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065422	hybrid			2022-12-27	WOS:A1997WP59200016
J	Huang, LJS; Durick, K; Weiner, JA; Chun, J; Taylor, SS				Huang, LJS; Durick, K; Weiner, JA; Chun, J; Taylor, SS			Identification of a novel protein kinase A anchoring protein that binds both type I and type II regulatory subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-KINASE; SUBCELLULAR-LOCALIZATION; ESCHERICHIA-COLI; OLFACTORY CILIA; BOVINE BRAIN; RII-BETA; PHOSPHORYLATION; EXPRESSION; CLONING; ASSOCIATION	Compartmentalization of cAMP-dependent protein kinase is achieved in part by interaction with A-kinase anchoring proteins (AKAPs), All of the anchoring proteins identified previously target the kinase by tethering the type II regulatory subunit, Here we report the cloning and characterization of a novel anchoring protein, D-AKAP1, that interacts with the N terminus of both type I and type II regulatory subunits, A novel cDNA encoding a 125-amino acid fragment of D-AKAP1 was isolated from a two-hybrid screen and shown to interact specifically with the type I regulatory subunit, Although a single message of 3.8 kilobase pairs was detected for D-AKAP1 in all embryonic stages and in most adult tissues, cDNA cloning revealed the possibility of at least four splice variants, All four isoforms contain a core of 526 amino acids, which includes the R binding fragment, and may be expressed in a tissue-specific manner, This core sequence was homologous to S-AKAP84, including a mitochondrial signal sequence near the amino terminus (Lin, R, Y., Moss, S, B,, and Rubin, C, S, (1995) J, Biol, Chem. 270, 27804-27811), D-AKAP1 and the type I regulatory subunit appeared to have overlapping expression patterns in muscle and olfactory epithelium by in situ hybridization, These results raise a novel possibility that the type I regulatory subunit may be anchored via anchoring proteins.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,PROGRAM NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Weiner, Joshua/AAA-6532-2021	Weiner, Joshua/0000-0002-3352-2847	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH051699] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIGMS NIH HHS [2T32GM07240-21A1] Funding Source: Medline; NIMH NIH HHS [R29MH51699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DEVILLER P, 1984, MOL CELL ENDOCRINOL, V38, P21, DOI 10.1016/0303-7207(84)90141-2; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HELDMAN J, 1986, J NEUROCHEM, V47, P1527, DOI 10.1111/j.1471-4159.1986.tb00790.x; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KLANCK TM, 1996, SCIENCE, V271, P1589; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SCHWOCH G, 1990, BIOCHEM J, V270, P181, DOI 10.1042/bj2700181; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEN W, 1994, J BIOL CHEM, V269, P32214	37	258	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8057	8064		10.1074/jbc.272.12.8057	http://dx.doi.org/10.1074/jbc.272.12.8057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065479	hybrid			2022-12-27	WOS:A1997WP59200073
J	Imani, F; Rager, KJ; Catipovic, B; Marsh, DG				Imani, F; Rager, KJ; Catipovic, B; Marsh, DG			Interleukin-4 (IL-4) induces phosphatidylinositol 3-kinase (p85) dephosphorylation - Implications for the role of SHP-1 in the IL-4-induced signals in human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR; STIMULATING FACTOR; MYELOID CELLS; PROLIFERATION; TRANSDUCTION; PHOSPHORYLATION; EXPRESSION; SUBUNIT	Interleukin 4 (IL-4) is a potent cytokine produced by T cells and to a lesser extent by tumor-associated natural killer cells, basophils, and mast cells, IL-4 treatment of T cells and macrophages leads to augmentation of their cytotoxic activity, In human B cells, IL-4 is a potent stimulator of Ig class switching from IgM to IgE, The diverse biological responses induced by IL-4 are mediated through a high affinity receptor complex (IL-4R). Although a wealth of information has accumulated regarding IL-4R, the exact mechanisms of IL-4R-mediated signaling pathways in human B cells are not well defined, In an attempt to characterize the IL-4-induced signals in human B cells, we have found that IL-4 treatment induced rapid dephosphorylation of the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase. To identify the protein-tyrosine phosphatase involved in the IL-4-mediated dephosphorylation, we performed Western blot analysis using monoclonal antibodies specific to protein-tyrosine phosphatases, Upon IL-4 treatment, SHP-1 was specifically translocated to the cellular membrane fraction. Furthermore, immunoprecipitation studies revealed that SHP-1 could be specifically coimmunoprecipitated with the IL-4R as well as with phosphatidylinositol 3-kinase (p85). Collectively, our observations suggest that in addition to protein phosphorylation, protein tyrosine dephosphorylation may play a role in the IL-4-induced signaling pathways.			Imani, F (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224, USA.				NIAID NIH HHS [AI00059] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HE YW, 1995, J IMMUNOL, V155, P9; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KAVANAUGH WM, 1994, BIOCHEMISTRY-US, V33, P11046, DOI 10.1021/bi00202a026; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MIRESLUIS AR, 1994, CYTOKINE, V6, P389, DOI 10.1016/1043-4666(94)90063-9; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; PANDRAU D, 1992, J CLIN INVEST, V90, P1697, DOI 10.1172/JCI116042; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	32	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7927	7931		10.1074/jbc.272.12.7927	http://dx.doi.org/10.1074/jbc.272.12.7927			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065461	hybrid			2022-12-27	WOS:A1997WP59200055
J	Miyamoto, T; Kaneko, A; Kakizawa, T; Yajima, H; Kamijo, K; Sekine, R; Hiramatsu, K; Nishii, Y; Hashimoto, T; Hashizume, K				Miyamoto, T; Kaneko, A; Kakizawa, T; Yajima, H; Kamijo, K; Sekine, R; Hiramatsu, K; Nishii, Y; Hashimoto, T; Hashizume, K			Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor - Competitive binding to the response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; TISSUE-SPECIFIC REGULATION; COA OXIDASE GENE; ACTIVATED RECEPTOR; FATTY-ACIDS; BIFUNCTIONAL ENZYME; LIPID-METABOLISM; CLOFIBRIC ACID; HIGH-AFFINITY; PPAR-GAMMA	Peroxisome proliferators (e.g. clofibric acid) and thyroid hormone play an important role in the metabolism of lipids, These effecters display their action through their own nuclear receptors, peroxisome proliferator-activated receptor (PPAR) and thyroid hormone receptor (TR), PPAR and TR are ligand dependent, DNA binding, trans-acting transcriptional factors belonging to the erbA-related nuclear receptor superfamily, The present study focused on the convergence of the effectors on the peroxisome proliferator response element (PPRE), Transcriptional activation induced by PPAR through a PPRE was significantly suppressed by co-transfection of TR in transient transfection assays, The inhibition, however, was not affected by adding 3,5,3'-triiodo-L-thyronine (T3). Furthermore, the inhibition was not observed in cells cotransfected with retinoic acid receptor or vitamin D3 receptor, The inhibitory action by TR was lost by introducing a mutation in the DNA binding domain of TR, indicating that competition for DNA binding is involved in the molecular basis of this functional interaction, Gel shift assays revealed that TRs, expressed in insect cells, specifically bound to the P-32-labeled PPRE as heterodimers with the retinoid X receptor (RXR), Both PPAR and TR bind to PPRE, although only PPAR mediates transcriptional activation via PPRE, TR RXR heterodimers are potential competitors with PPAR RXR for binding to PPREs, It is concluded that PPAR-mediated gene expression is negatively controlled by TR at the level of PPAR binding to PPRE, We report here the novel action of thyroid hormone receptor in controlling gene expression through PPREs.	SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University	Miyamoto, T (corresponding author), SHINSHU UNIV,SCH MED,DEPT GERIATR ENDOCRINOL & METAB,3-1-1 ASAHI,MATSUMOTO,NAGANO 390,JAPAN.							BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BERGE RK, 1984, TOXICOL APPL PHARM, V73, P35, DOI 10.1016/0041-008X(84)90050-4; BLENNEMANN B, 1992, ENDOCRINOLOGY, V130, P637, DOI 10.1210/en.130.2.637; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CATTLEY RC, 1989, CANCER RES, V49, P3246; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FALCONE M, 1994, EUR J ENDOCRINOL, V130, P97, DOI 10.1530/eje.0.1300097; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HEIMBERG M, 1985, ENDOCR REV, V6, P590, DOI 10.1210/edrv-6-4-590; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; ICHIKAWA K, 1987, ENDOCRINOL JAPON, V34, P245; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KURAKAWA R, 1994, NATURE, V371, P528; LANE JT, 1991, ENDOCRINOLOGY, V129, P2881, DOI 10.1210/endo-129-6-2881; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSMAN DS, 1988, CANCER RES, V48, P6739; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P3027, DOI 10.1210/endo-129-6-3027; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MIYAMOTO T, 1994, MOL CELL ENDOCRINOL, V102, P111, DOI 10.1016/0303-7207(94)90104-X; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; NORTH D, 1992, PEDIATR RES, V31, P330, DOI 10.1203/00006450-199204000-00005; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RODRIGUEZ M, 1992, ENDOCRINOLOGY, V131, P1612, DOI 10.1210/en.131.4.1612; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; TAKEDA T, 1992, BIOCHEM BIOPH RES CO, V185, P211, DOI 10.1016/S0006-291X(05)80977-5; THRALL CL, 1983, BRAIN RES, V279, P177, DOI 10.1016/0006-8993(83)90176-2; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUCA A, 1993, ENDOCRINOLOGY, V132, P1913, DOI 10.1210/en.132.5.1913; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7752	7758		10.1074/jbc.272.12.7752	http://dx.doi.org/10.1074/jbc.272.12.7752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065436	hybrid			2022-12-27	WOS:A1997WP59200030
J	Mukherjee, R; Jow, L; Croston, GE; Paterniti, JR				Mukherjee, R; Jow, L; Croston, GE; Paterniti, JR			Identification characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR gamma 2 versus PPAR gamma 1 and activation with retinoid X receptor agonists and antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; CDNA CLONING; FATTY-ACIDS; GAMMA; EXPRESSION; CELLS; GENE; ENHANCER; MEMBER	We describe the cloning, characterization, and tissue distribution of the two human peroxisome proliferator activated receptor isoforms hPPAR gamma 2 and hPPAR gamma 1. In cotransfection assays the two isoforms were activated to approximately the same extent by known PPAR gamma activators, Human PPAR gamma binds to DNA as a heterodimer with the retinoid X receptor (RXR). This heterodimer was activated by both RXR agonists and antagonists and the addition of PPAR gamma ligands with retinoids resulted in greater than additive activation, Such heterodimer-selective modulators may have a role in the treatment of PPAR gamma/RXR-modulated diseases like diabetes. Northern blot analysis indicated the presence of PPAR gamma in skeletal muscle, and a sensitive RNase protection assay confirmed the presence of only PPAR gamma 1 in muscle that was not solely due to fat contamination. However, both PPAR gamma 1 and PPAR gamma 2 RNA were detected in fat, and the ratio of PPAR gamma 1 to PPAR gamma B RNA varied in different individuals. The presence of tissue-specific distribution of isoforms and the variable ratio of PPAR gamma 1 to PPAR gamma 2 raised the possibility that isoform expression may be modulated in disease states like non insulin-dependent diabetes mellitus. Interestingly, a third protected band was detected with fat RNA indicating the possible existence of a third human PPAR gamma isoform.	LIGAND PHARMACEUT INC,DEPT NEW LEADS DISCOVERY,SAN DIEGO,CA 92121	Ligand Pharmaceuticals	Mukherjee, R (corresponding author), LIGAND PHARMACEUT INC,DEPT CARDIOVASC RES,9393 TOWNE CTR DR,SAN DIEGO,CA 92121, USA.							ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; ELDERSHAW TPD, 1995, HORM METAB RES, V27, P169, DOI 10.1055/s-2007-979932; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; Greene M. E., 1995, Gene Expression, V4, P281; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koch SSC, 1996, J MED CHEM, V39, P3229, DOI 10.1021/jm960311d; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; OLEFSKY JM, 1995, CURR OPIN ENDOCRINOL, V2, P290; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	40	377	397	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8071	8076		10.1074/jbc.272.12.8071	http://dx.doi.org/10.1074/jbc.272.12.8071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065481	hybrid			2022-12-27	WOS:A1997WP59200075
J	Tahiliani, PD; Singh, L; Auer, KL; LaFlamme, SE				Tahiliani, PD; Singh, L; Auer, KL; LaFlamme, SE			The role of conserved amino acid motifs within the integrin beta(3) cytoplasmic domain in triggering focal adhesion kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; OUT SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; NPXY MOTIF; IN-VIVO; SUBUNIT; PROTEIN; CYTOSKELETAL; PP125(FAK)	Integrin-mediated adhesion of cells to extracellular matrix proteins triggers a variety of intracellular signaling pathways including a cascade of tyrosine phosphorylations, In many cell types, the cytoplasmic focal adhesion tyrosine kinase, FAK, appears to be the initial protein that becomes tyrosine-phosphorylated in response to adhesion; however, the molecular mechanisms regulating integrin-triggered FAK phosphorylation are not understood, Previous studies have shown that the integrin beta(1), beta(3), and beta(5) subunit cytoplasmic domains all contain sufficient information to trigger FAK phosphorylation when expressed in single-subunit chimeric receptors connected to an extracellular reporter, In the present study, beta(3) cytoplasmic domain deletion and substitution mutants were constructed to identify amino acids within the integrin beta(3) cytoplasmic domain that regulate its ability to trigger FAK phosphorylation, Cells transiently expressing chimeric receptors containing these mutant cytoplasmic domains were magnetically sorted and assayed for the tyrosine phosphorylation of FAK, Analysis of these mutants indicated that structural information in both the membrane proximal and C-terminal segments of the beta(3) cytoplasmic domain is important for triggering FAK phosphorylation. In the C-terminal segment of the beta(3) cytoplasmic domain, the highly conserved NPXY motif was found to be required for the beta(3) cytoplasmic domain to trigger FAK phosphorylation. However, the putative FAK binding domain within the N-terminal segment of the beta(3) cytoplasmic domain was found to be neither required nor sufficient for this signaling event. We also demonstrate that the serine 752 to proline mutation, known to cause a variant of Glanzmann's thrombasthenia, inhibits the ability of the beta(2) cytoplasmic domain to signal FAK phosphorylation, suggesting that a single mutation in the beta(3) cytoplasmic domain can inhibit both ''inside-out'' and ''outside-in'' integrin signaling.	ALBANY MED COLL UNION UNIV, DEPT PHYSIOL & CELL BIOL, ALBANY MED COLL, ALBANY, NY 12208 USA	Albany Medical College					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051540] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07529] Funding Source: Medline; NIGMS NIH HHS [GM51540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEONG L, 1995, J CELL SCI, V108, P3817; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PATCH LA, 1995, J CELL SCI, V108, P1371; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215; TAPLEY P, 1989, ONCOGENE, V4, P325; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	57	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7892	7898		10.1074/jbc.272.12.7892	http://dx.doi.org/10.1074/jbc.272.12.7892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065456	hybrid			2022-12-27	WOS:A1997WP59200050
J	Yan, WQ; Pan, HO; Ishida, H; Nakashima, K; Suzuki, F; Nishimura, M; Jikko, A; Oda, R; Kato, Y				Yan, WQ; Pan, HO; Ishida, H; Nakashima, K; Suzuki, F; Nishimura, M; Jikko, A; Oda, R; Kato, Y			Effects of concanavalin A on chondrocyte hypertrophy and matrix calcification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CHICK CHONDROCYTES; ALKALINE-PHOSPHATASE; PARATHYROID-HORMONE; X COLLAGEN; TERMINAL DIFFERENTIATION; CARTILAGE; INSULIN; INDUCTION; RECEPTOR; BINDING	Resting chondrocytes do not usually undergo differentiation to the hypertrophic stage and calcification, However, incubating these cells with concanavalin A resulted in 10-100-fold increases in alkaline phosphatase activity, binding of 1,25(OH)(2)-vitamin D-3, type X collagen synthesis, Ca-45 incorporation into insoluble material, and calcium content. On the other hand, other lectins tested (including wheat germ agglutinin, lentil lectin, pea lectin, phytohemagglutinin-l, and phytohemagglutinin-E) marginally affected alkaline phosphatase activity, although they activate lymphocytes. Methylmannoside reversed the effect of concanavalin A on alkaline phosphatase within 48 h, Concanavalin A did not increase alkaline phosphatase activity in articular chondrocyte cultures. In resting chondrocyte cultures, succinyl concanavalin A was as potent as concanavalin A in increasing alkaline phosphatase activity, the incorporation of [S-35]sulfate, D-[H-3]glucosamine, and [H-3]serine into proteoglycans, and the incorporation of [H-3]serine into protein, although concanavalin A, but not succinyl concanavalin A, induced a rapid change in the shape of the cells from flat to spherical. These findings suggest that concanavalin A induces a switch from the resting, to the growth-plate stage, and that this action of concanavalin A is not secondary to changes in the cytoskeleton. Chondrocytes exposed to concanavalin A may be useful as a novel model of endochondral bone formation.	HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH DENT,DEPT OPERAT DENT,MINAMI KU,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH DENT,DEPT PROSTHODONT,MINAMI KU,HIROSHIMA 734,JAPAN; NIPPON HOECHST MARION ROUSSEL,LAB BONE RES,KAWAGOE,SAITAMA 350,JAPAN; OSAKA UNIV,FAC DENT,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC DENT,DEPT RADIOL,SUITA,OSAKA 565,JAPAN	Hiroshima University; Hiroshima University; Hiroshima University; Osaka University; Osaka University				Nakashima, Kazuhisa/0000-0003-0491-2149				BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BESSEY OA, 1946, J BIOL CHEM, V164, P321; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOHME K, 1992, J CELL BIOL, V116, P1035, DOI 10.1083/jcb.116.4.1035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CZECH MP, 1974, J BIOL CHEM, V249, P7499; DAHL LK, 1952, J EXP MED, V95, P341, DOI 10.1084/jem.95.4.341; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EINSPAHR H, 1986, J BIOL CHEM, V261, P1618; GUNTHER GR, 1973, P NATL ACAD SCI USA, V70, P1012, DOI 10.1073/pnas.70.4.1012; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; IWAMOTO M, 1989, DEV BIOL, V136, P500, DOI 10.1016/0012-1606(89)90275-3; JOHNSONWINT B, 1982, ANAL BIOCHEM, V122, P338, DOI 10.1016/0003-2697(82)90292-5; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KATO Y, 1990, ENDOCRINOLOGY, V127, P114, DOI 10.1210/endo-127-1-114; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; KATO Y, 1981, J BIOCHEM-TOKYO, V90, P1377, DOI 10.1093/oxfordjournals.jbchem.a133603; KATZEN HM, 1981, BIOCHEMISTRY-US, V20, P5800, DOI 10.1021/bi00523a024; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; MAKHAILOV AT, 1988, CELL DIFFER, V22, P145; MAOR G, 1987, COLLAGEN REL RES, V7, P351; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; QUARTO R, 1992, J CELL BIOL, V119, P989, DOI 10.1083/jcb.119.4.989; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; SAITO M, 1983, J BIOL CHEM, V258, P7499; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; TACCHETTI C, 1989, DEV BIOL, V132, P442, DOI 10.1016/0012-1606(89)90240-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WU LNY, 1989, J BIOL CHEM, V264, P21346; YAN WQ, 1990, J BIOL CHEM, V265, P10125	39	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7833	7840		10.1074/jbc.272.12.7833	http://dx.doi.org/10.1074/jbc.272.12.7833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065448	hybrid			2022-12-27	WOS:A1997WP59200042
J	Houssa, B; Schaap, D; vanderWal, J; Goto, K; Kondo, H; Yamakawa, A; Shibata, M; Takenawa, T; vanBlitterswijk, WJ				Houssa, B; Schaap, D; vanderWal, J; Goto, K; Kondo, H; Yamakawa, A; Shibata, M; Takenawa, T; vanBlitterswijk, WJ			Cloning of a novel human diacylglycerol kinase (DGK theta) containing three cysteine-rich domains, a proline-rich region, and a pleckstrin homology domain with an overlapping Ras-associating domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID 2ND MESSENGERS; PROTEIN-KINASE; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; ZINC-FINGER; BINDING; EXPRESSION; SEQUENCE; GENE	Diacylglycerol kinase (DGK) attenuates levels of second messenger diacylglycerol in cells and produces another (putative) messenger, phosphatidic acid, We have previously purified a 110-kDa DGK from rat brain (Kato, M., and Takenawa, T. (1990) J. Biol. Chem. 265, 794-800). Here we report the cDNA cloning from human brain and retina cDNA libraries. The cDNA encodes a novel DGK isotype, termed DGK theta, of 941 amino acids with an apparent molecular mass of 110 kDa. DGK theta contains a C-terminal putative catalytic domain, which is present in all eukaryotic DGKs. In contrast to other DGK isotypes, DGK theta contains three cysteine rich domains instead of two, The third cysteine-rich domain is most homologous to the second one in other DGK isotypes. This particular sequence homology extends C-terminally beyond the typical cysteine/histidine core structure and is DGK-specific. DGK theta furthermore contains various domains for protein-protein interaction, such as a proline- and glycine-rich domain with a putative SH3 domain-binding site and a pleckstrin homology domain with an overlapping Ras-associating domain. DGK theta is expressed in the brain and, to a lesser extent, in the small intestine, duodenum, and liver, In situ hybridization of DGK theta mRNA in adult rat brain reveals high expression in the cerebellar cortex and hippocampus. DGK theta activity in COS cell lysates is optimal toward diacylglycerols containing an unsaturated fatty acid at the sn-2 position.	NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM, NL-1066 CX AMSTERDAM, NETHERLANDS; TOHOKU UNIV, SCH MED, DEPT ANAT, SENDAI, MIYAGI 980, JAPAN; UNIV TOKYO, INST MED SCI, DEPT BIOCHEM, TOKYO 108, JAPAN	Netherlands Cancer Institute; Tohoku University; University of Tokyo								BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KATO M, 1990, J BIOL CHEM, V265, P794; KHAN WA, 1994, J BIOL CHEM, V269, P9729; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHAAP D, 1994, BIOCHEM J, V304, P661, DOI 10.1042/bj3040661; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; VANBLITTERSWIJK WJ, 1994, CURR TOP MEMBR, V40, P413, DOI 10.1016/S0070-2161(08)60990-9; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	58	96	101	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10422	10428						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099683				2022-12-27	WOS:A1997WV26200017
J	Suzuki, H; Kamakura, M; Morii, M; Takeguchi, N				Suzuki, H; Kamakura, M; Morii, M; Takeguchi, N			The phospholipid flippase activity of gastric vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOSAL BARRIER; PARIETAL-CELLS; ACID-SECRETION; P-GLYCOPROTEIN; MEMBRANE; STIMULATION; ATPASE; ASYMMETRY; RETICULUM; INHIBITOR	We found that isolated gastric vesicles contain a novel Mg2+-ATP-dependent phospholipid translocation (flippase) activity, Fluorescence analogue of phosphatidylcholine, 2-(12-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino) dodecanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine, was ATP-dependently translocated from the outer (cytosolic) to inner (luminal) leaflet of the Lipid membrane bilayer of hog gastric vesicles, The translocation was saturable and depended on time and the ATP concentration (K-m = 3.1 mu M). The basal Mg2+-ATPase activity of gastric vesicles in the absence of K+ showed high (K-m = 1.6 mu m) and low (K-m = 80 mu M) affinities for ATP, indicating that the present flippase activity is driven mostly by the high affinity Mg2+-ATPase activity. It required Mg2+ but not K+. Verapamil, which is an inhibitor of mouse mdr2 phosphatidylcholine flippase, did not inhibit the present flippase activity, Isolated sarcoplasmic reticulum vesicles that contain Ca2+-ATPase did not show any flippase activity. Fluorescence analogues of phosphatidylserine and phosphatidylethanolamine were similarly translocated by the gastric flippase, These phospholipid flippase activities were inhibited by 2-methyl-8-(phenylmethoxy)imidazo[1,2-a]-pyridine-3-acetonitrile (SCH 28080) (IC50 = 0.14-0.25 mu M), a specific K+-ATPase inhibitor of gastric H+,K+-ATPase rich in gastric vesicles. IC50 value for the SCH 28080-inhibitable Mg2+-ATPase activity was about 0.13 mu m, indicating that the phospholipid translocation was driven mostly by the SCH 28080-sensitive Mg2+-ATPase activity, Possible physiological roles of flippases were discussed in relation with the gastric acid secretory and cytoprotective mechanisms.	TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,TOYAMA 93001,JAPAN	University of Toyama								ASANO S, 1987, J BIOL CHEM, V262, P13263; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; FADOK VA, 1992, J IMMUNOL, V148, P2207; HASHIMOTO A, 1992, PFLUG ARCH EUR J PHY, V422, P84, DOI 10.1007/BF00381517; HELANDER HF, 1986, ANAT REC, V216, P373, DOI 10.1002/ar.1092160306; HILLS BA, 1992, AUST NZ J MED, V22, P441, DOI 10.1111/j.1445-5994.1992.tb02167.x; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; MORII M, 1986, J BIOL CHEM, V261, P2343; Morii M, 1996, J BIOL CHEM, V271, P4068; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; OGATA T, 1993, ANAT REC, V237, P208, DOI 10.1002/ar.1092370208; OLAISSON H, 1985, J BIOL CHEM, V260, P1262; RABON E, 1982, BIOCHIM BIOPHYS ACTA, V688, P515, DOI 10.1016/0005-2736(82)90363-7; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Shin JM, 1996, J BIOL CHEM, V271, P1904, DOI 10.1074/jbc.271.4.1904; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; TAKEGUCHI N, 1983, J BIOL CHEM, V358, P3094; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TOMINAGA M, 1995, J BIOL CHEM, V270, P27887, DOI 10.1074/jbc.270.46.27887; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WOLOSIN JM, 1981, J BIOL CHEM, V256, P3149; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0	36	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10429	10434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099684				2022-12-27	WOS:A1997WV26200018
J	Fadden, P; Haystead, TAJ; Lawrence, JC				Fadden, P; Haystead, TAJ; Lawrence, JC			Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; INDEPENDENT PATHWAYS; SECONDARY STRUCTURE; 3T3-L1 ADIPOCYTES; FAT-CELLS; INITIATION; GROWTH; DEPHOSPHORYLATION; FACTOR-EIF-4E	Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase in vitro decreased PHAS-I binding to eukaryotic initiation factor (eIF)-4E. The decrease in binding lagged behind the phosphorylation of PHAS-I in Ser(64), the preferred site of MAP kinase, Binding of the Ala(64) mutant of PHAS-I to eIF-4E was abolished by MAP kinase, indicating that phosphorylation of sites other than Ser(64) control binding. To identify such sites, PHAS-I was phosphorylated with MAP kinase and [gamma-P-32]ATP and then cleaved proteolytically before the resulting phosphopeptides were isolated by reverse phase chromatography and directly identified by amino acid sequencing, Phosphorylated residues were located by determining the cycles in which P-32 was released when phosphopeptides were subjected to sequential Edman degradation. With an extended incubation in vitro, MAP kinase phosphorylated Thr(36), Thr(45), Ser(64), Thr(69), and Ser(82). In rat adipocytes, the phosphorylation of all five sites was increased by insulin and decreased by rapamycin although there were differences in the magnitude of the effects, A form of PHAS-I phosphorylated exclusively in Thr(36) remained bound to eIF-4E, indicating that phosphorylation of Thr(36) is insufficient for dissociation of the PHASI.eIF-4E complex. In summary, our results indicate that multiple phosphorylation sites are involved in the control of PHAS-I. All five sites identified fit a (Ser/Thr) Pro motif, suggesting that the phosphorylation of PHAS-I in cells is mediated by a proline-directed protein kinase.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CTR HLTH SCI,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ALLEN G, 1989, SEQUENCING PROTEINS, P256; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DENTON RM, 1981, DIABETOLOGIA, V21, P347; DIGGLE TA, 1991, BIOCHEM J, V279, P545, DOI 10.1042/bj2790545; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; DIGGLE TA, 1992, BIOCHEM J, V282, P729, DOI 10.1042/bj2820729; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; GEER P, 1994, PROTIEN PHOSPHORYLAT, P31; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAWRENCE JC, 1997, ADV ENZYME REGULATIO; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245	49	156	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10240	10247						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092573				2022-12-27	WOS:A1997WU03900092
J	Guan, GM; Dai, PH; Osborne, TF; Kim, JB; Shechter, I				Guan, GM; Dai, PH; Osborne, TF; Kim, JB; Shechter, I			Multiple sequence elements are involved in the transcriptional regulation of the human squalene synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; BINDING PROTEIN-1; STEROL REGULATION; NF-Y; PROMOTER; SREBP-1; IDENTIFICATION; EXPRESSION	The expression of human squalene synthase (HSS) gene is transcriptionally regulated in HepG-2 cells, up to 10-fold, by variations in cellular cholesterol homeostasis, An earlier deletion analysis of the 5'-flanking region of the HSS gene demonstrated that most of the HSS promoter activity is detected within a 69-base pair sequence located between nucleotides -131 and -200, ADD1/SREBP-1c, a rat homologue of sterol regulatory element binding protein (SREBP)-1c binds to sterol regulatory element (SRE)-1-like sequence (HSS-SRE-1) present in this region (Guan, G., Jiang, G., Koch, R. L. and Shechter, I. (1995) J. Biol. Chem. 270, 21958-21965), In our present study, we demonstrate that mutation of this HSS-SRE-1 element significantly reduced, but did not abolish, the response of HSS promoter to change in sterol concentration, Mutation scanning indicates that two additional DNA promoter sequences are involved in sterol-mediated regulation, The first sequence contains an inverted SRE-3 element (Inv-SRE-3) and the second contains an inverted Y-box (Inv-Y-box) sequence, A single mutation in any of these sequences reduced, but did not completely remove, the response to sterols, Combination mutation studies showed that the HSS promoter activity was abolished only when all three elements were mutated simultaneously, Go-expression of SRE-1- or SRE-2-binding proteins (SREBP-1 or SREBP-2) with HSS promoter-luciferase reporter resulted in a dramatic increase of HSS promoter activity, Gel mobility shift studies indicate differential binding of the SREBPs to regulatory sequences in the HSS promoter. These results indicate that the transcription of the HSS gene is regulated by multiple regulatory elements in the promoter.	UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT BIOCHEM,BETHESDA,MD 20814; UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92717; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Uniformed Services University of the Health Sciences - USA; University of California System; University of California Irvine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				KIM, Jae Bum/0000-0003-2337-6935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050628, R01HL048540] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50628, HL48540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUAN G, 1995, J BIOL CHEM, V270, P21968; HUA X, 1995, GENOMICS, V2535, P667; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	32	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10295	10302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092581				2022-12-27	WOS:A1997WU03900100
J	Ingram, MF; Shelness, GS				Ingram, MF; Shelness, GS			Folding of the amino-terminal domain of apolipoprotein B initiates microsomal triglyceride transfer protein-dependent lipid transfer a to nascent very low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; DITHIOTHREITOL TREATMENT; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; DISULFIDE BONDS; EXPRESSION; SEQUENCE	The initial assembly of apolipoprotein B100 (apoB) into lipoprotein particles occurs cotranslationally. To examine steps required to initiate this process, the intracellular folding and assembly of the amino-terminal 28% of apoB (apoB28) was examined using several criteria including nonreducing gel electrophoresis, sensitivity to dithiothreitol (DTT)-mediated reduction, and buoyant density gradient centrifugation, In hepatoma cells, after a 1-min pulse with radiolabeled amino acids, labeled apoB28 migrated during gel electrophoresis in the folded position and was resistant to reduction in vivo with 2 mM DTT. A similar rate and extent of folding was observed in Chinese hamster ovary cells, a microsomal triglyceride transfer protein (MTP)-negative cell line that can neither lipidate nor efficiently secrete apoB28, Amino terminal folding of apoB28 was essential for its subsequent intracellular lipidation as apoB28 synthesized in hepatoma cells under reducing conditions remained lipid poor (d > 1.25 g/ml) and was retained intracellularly. Upon DTT removal, reduced apoB28 underwent a process of rapid (t(1/2) approximate to 2 min) posttranslational folding followed by a slower process of MTP-dependent lipidation. As with the cotranslational assembly pathway, post-translational lipidation of apoB28 displayed a strict dependence upon amino-terminal folding. We conclude that: 1) folding of the aminoterminal disulfide bonded domain of apoB is achieved prior to the completion of translation and is independent of MTP and events associated with buoyant lipoprotein formation and 2) domain specific folding of apoBs amino-terminal region is required to initiate MTP-dependent lipid transfer to nascent apoB in the hepatic endoplasmic reticulum.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL49373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHAN L, 1992, J BIOL CHEM, V267, P25621; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DIXON JL, 1993, J LIPID RES, V34, P167; ESSER V, 1988, J BIOL CHEM, V263, P13282; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Ingram MF, 1996, J LIPID RES, V37, P2202; KAJI EH, 1993, J BIOL CHEM, V268, P22195; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; OPSTELTEN DJE, 1993, J VIROL, V67, P7394, DOI 10.1128/JVI.67.12.7394-7401.1993; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; PETERS T, 1982, J BIOL CHEM, V257, P8847; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	54	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10279	10286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092579				2022-12-27	WOS:A1997WU03900098
J	MacrezLepretre, N; Kalkbrenner, F; Morel, JL; Schultz, G; Mironneau, J				MacrezLepretre, N; Kalkbrenner, F; Morel, JL; Schultz, G; Mironneau, J			G protein heterotrimer G alpha(13)beta(1)gamma(3) couples the angiotensin AT(1A) receptor to increases in cytoplasmic Ca2+ in rat portal vein myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GTP-BINDING PROTEIN; II TYPE-1 RECEPTOR; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; GAMMA-SUBUNIT; BETA-SUBUNIT; SYNTHETIC PEPTIDES; MOLECULAR-CLONING; CALCIUM CHANNELS	The subunit composition of angiotensin AT(1) receptor-activated G protein was identified by using antisense oligonucleotide injection into the nucleus of rat portal vein myocytes. In these cells, we have previously shown that increases in the cytoplasmic calcium concentration ([Ca2+](i)) induced by activation of angiotensin AT(1) receptors were dependent on extracellular Ca2+ entry by L-type Ca2+ channels and subsequent Ca2+-induced Ca2+ release from the intracellular stores. The angiotensin AT(1) receptor-activated increases in [Ca2+](i) were selectively inhibited by injection of antisense oligonucleotides directed against the mRNAs coding for the alpha(13), beta(1), and gamma(3) subunits. A correlating reduction in G alpha(13), G beta(1), and G gamma(3) protein expression was confirmed by immunocytochemistry. In addition, anti-alpha(13) antibody and synthetic peptide corresponding to the carboxyl terminus of the G alpha(13) subunit inhibited, in a concentration-dependent manner, the angiotensin AT(1) receptor-mediated Ca2+ response. Reverse transcription-polymerase chain reaction analysis skewed that only the angiotensin AT(1) receptor was expressed in rat portal vein smooth muscle. Furthermore, injection of anti-AT(1A) oligonucleotides selectively inhibited the angiotensin II-induced increase in [Ca2+](i). We conclude that the receptor-activated signal leading to increases in [Ca2+](i) is transduced by the heterotrimeric G(13) protein composed of alpha(13)/beta(1)/gamma(3) subunits and that the carboxyl terminus of the G alpha(13) subunit interacts with the ansotensin AT(1A) receptor.	UNIV BORDEAUX 2,LAB PHYSIOL CELLULAIRE & PHARMACOL MOL,CNRS,ESA 5017,F-33076 BORDEAUX,FRANCE; FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin			Morel, Jean-Luc/AAY-9235-2020	MACREZ, Nathalie/0000-0002-3844-4403; morel, jean-luc/0000-0001-8079-6851				ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; BKAILY G, 1988, PFLUG ARCH EUR J PHY, V412, P448, DOI 10.1007/BF01907567; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FREEMAN EJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P84, DOI 10.1006/abbi.1995.1269; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KALKBRENNER F, 1995, EMBO J, V14, P101; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; Kitamura K, 1996, J BIOL CHEM, V271, P7412, DOI 10.1074/jbc.271.13.7412; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; LEPRETRE N, 1994, J PHARMACOL EXP THER, V268, P167; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; MACREZLEPRETRE N, 1996, J PHARMACOL EXP THER, V270, P468; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MAUXION F, 1987, NUCLEIC ACIDS RES, V15, P7638, DOI 10.1093/nar/15.18.7638; MIRONNEAU J, 1980, EUR J PHARMACOL, V68, P275; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OHYA Y, 1991, CIRC RES, V68, P763, DOI 10.1161/01.RES.68.3.763; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PERALDI S, 1989, J NEUROSCI, V9, P806; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169	62	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10095	10102						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092554				2022-12-27	WOS:A1997WU03900073
J	Uhlmann, F; Cai, JS; Gibbs, E; ODonnell, M; Hurwitz, J				Uhlmann, F; Cai, JS; Gibbs, E; ODonnell, M; Hurwitz, J			Deletion analysis of the large subunit p140 in human replication factor C reveals regions required for complex formation and replication activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; PRIMER-TEMPLATE JUNCTION; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; MULTIPLE FUNCTIONS; BINDING-PROTEIN; 37-KDA SUBUNIT; HELA-CELLS	Replication factor C (RFC) and proliferating cell nuclear antigen (PCNA) are processivity factors for eukaryotic DNA polymerases delta and epsilon. RFC contains multiple activities, including its ability to recognize and bind to a DNA printer end and load the ring-shaped PCNA onto DNA in an ATP-dependent reaction. PCNA then tethers the polymerase to the template allowing processive DNA chain elongation. Human RFC consists of five distinct subunits (P140, p40, p38, p37, and p36), and RFC activity can be reconstituted from the five cloned gene products. To characterize the role of the large subunit p140 in the function of the RFC complex, deletion mutants were created that defined a region within the p140 C terminus required for complex formation with the four small subunits. Deletion of the p140 N-terminal half, including the DNA ligase homology domain, resulted in the formation of all RFC complex with enhanced activity in replication and PCNA loading. Deletion of additional N-terminal amino acids, including those constituting the RFC homology box II that is conserved among all five RFC subunits, disrupted RFC replication function. DNA primer end recognition and PCNA binding activities, located in the p140 C-terminal half, were unaffected in this mutant, but PCNA loading was abolished.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Cornell University				Uhlmann, Frank/0000-0002-3527-6619	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38839, GM 38559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GARY M, 1995, NUCLEIC ACIDS RES, V23, P4986; HALLIGAN BD, 1995, GENE AMST, V11, P217; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; McAlear MA, 1996, GENETICS, V142, P65; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689	39	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10058	10064						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092549				2022-12-27	WOS:A1997WU03900068
J	Zwollo, P; Arrieta, H; Ede, K; Molinder, K; Desiderio, S; Pollock, R				Zwollo, P; Arrieta, H; Ede, K; Molinder, K; Desiderio, S; Pollock, R			The Pax-5 gene is alternatively spliced during B-cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; DNA-BINDING PROTEIN; PAIRED DOMAIN; IKAROS GENE; PROMOTER; DIFFERENTIATION; RECOGNITION; EXPRESSION; ISOFORMS; ENCODES	The transcription factor Pax-5 is expressed during the early stages of B-cell differentiation and influences the expression of several B-cell-specific genes, In addition to the existing isoform (Pax-5, which we have named Pax-5a), we have isolated three new isoforms, Pax-5b, Pax-5d, and Pax-5e, from murine spleen and B-lymphoid cell lines using library screenings and polymerase chain reaction amplification. Isoforms Pax-5b and Pax-5e have spliced out their second exon, resulting in proteins with only a partial DNA binding domain, Isoforms Pax-5d and Pax-5e have deleted the 3'-region, which encodes the transactivating domain, and replaced it with a novel sequence. The existence of alternative Pax-5 transcripts was confirmed using RNase protection assays, Furthermore, Pax-5a and Pax-5b proteins were detected using Western blot analysis, Pax-5a was detectable in pro-, pre-, and mature B cell lines, but not in two plasmacytomas; Pax-5b was shown to be present at low levels in mature B-cell lines and, unexpectedly, in one plasma cell line, but not in pro-B cell or T-cell lines. Mobility shift assays showed that in vitro translated Pax-5a and Pax-5d, but not Pax-5b or Pax-5e, could interact with a B-cell-specific activator protein-binding site on the blk promoter, Using this assay, we also showed that Pax-5d was present in nuclear extracts of some (but not all) B-lymphoid lines and interacts with the B-cell-specific activator protein-binding site. The pattern of differential expression of alternatively spliced Pax-5 isoforms suggests that they may be important regulators of transcription during B-cell maturation.	OCCIDENTAL COLL,DEPT BIOL,LOS ANGELES,CA 90041; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Occidental College; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Zwollo, P (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.							ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Harlow E., 1988, ANTIBODIES LAB MANUA; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIAO F, 1992, J IMMUNOL, V148, P2909; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAPLETON P, 1993, NAT GENET, V3, P424; STUART ET, 1995, HUM MOL GENET, V4, P1717, DOI 10.1093/hmg/4.suppl_1.1717; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TAKEDA H, 1994, GENE DEV, V8, P45, DOI 10.1101/gad.8.1.45; THEVENIN C, 1994, FASEB J, V8, P221; TSUKAMOTO K, 1994, HUM GENET, V93, P270, DOI 10.1007/BF00212021; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	31	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10160	10168						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092562	hybrid			2022-12-27	WOS:A1997WU03900081
J	Kullander, K; Kaplan, D; Ebendal, T				Kullander, K; Kaplan, D; Ebendal, T			Two restricted sites on the surface of the nerve growth factor molecule independently determine specific TrkA receptor binding and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH MOTIF; NEUROTROPHIC FACTOR; BIOLOGICAL-ACTIVITY; AFFINITY RECEPTOR; RECOMBINANT HUMAN; NGF; BRAIN; GENE; DISRUPTION; RESIDUES	Nerve growth factor (NGF) and neurotrophin-3 (NT-3) mediate activities such as survival, differentiation, and proliferation in various subsets of neurons, In this report, we define precisely the residues in human NGF responsible for NGF biological activity and binding specificity to the neurotrophin receptor TrkA. In earlier studies we defined five amino acid residues of NGF which confer NGF-like activity to NT-3 when replacing corresponding residues in the 120-amino acid long NT-3 molecule. Using this gain-of-function strategy we report the further dissection of this functional epitope. We also define another motif separated topographically in the NGF dimer and determined to be independently responsible for NGF specificity. The first of the two motifs determined to elicit NGF specificity is defined by the residues Val-48, Pro-49, and Gln-96, which are situated in the two top beta-loops of NGF. The second motif is represented by residues Pro-5 and Phe-7 situated in the proximal part of the NH2 terminus. Both motifs contain structurally important residues revealing a novel principle, where specificity for neurotrophin ligand-receptor interactions could be determined by variable residues modifying the conformation of the neurotrophin backbone. These findings will enhance further the possibility of mimicking NGF with low molecular weight compounds.	MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA	McGill University	Kullander, K (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT DEV NEUROSCI,BOX 587,S-75123 UPPSALA,SWEDEN.			Kullander, Klas/0000-0001-6418-5460				ALT FW, 1978, J BIOL CHEM, V253, P1357; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; Backstrom A, 1996, J NEUROSCI RES, V46, P67; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; EBENDAL T, 1984, CELLULAR MOL BIOL NE, P231; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; EstenneBouhtou G, 1996, INT J PEPT PROT RES, V48, P337; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Hallbook F, 1995, INT J DEV BIOL, V39, P855; HEFTI F, 1987, J NEURAL TRANSM-SUPP, V24, P309; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERRUP K, 1973, P NATL ACAD SCI USA, V70, P3884, DOI 10.1073/pnas.70.12.3884; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; ILAG LL, 1994, J BIOL CHEM, V269, P19941; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; PRICE DL, 1982, SCIENCE, V215, P1237; ROBINSON RC, 1995, BIOCHEMISTRY-US, V34, P4139, DOI 10.1021/bi00013a001; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; Shamovsky IL, 1996, J AM CHEM SOC, V118, P9743, DOI 10.1021/ja9611194; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SODERSTROM S, 1990, J NEUROSCI RES, V27, P665, DOI 10.1002/jnr.490270427; SUTER U, 1992, J NEUROSCI, V12, P306; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WILLIAMS R, 1993, DEV BRAIN RES, V75, P235, DOI 10.1016/0165-3806(93)90028-9; WINDISCH JM, 1995, FEBS LETT, V374, P125, DOI 10.1016/0014-5793(95)01047-I; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YAN H, 1991, J BIOL CHEM, V266, P12099	57	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9300	9307						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083066				2022-12-27	WOS:A1997WU03700071
J	Marians, KJ; Hiasa, H				Marians, KJ; Hiasa, H			Mechanism of quinolone action - A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICKING-CLOSING ENZYME; ESCHERICHIA-COLI; NALIDIXIC-ACID; GYRASE; PURIFICATION; INHIBITION; TARGET; TYROSINE; SUBUNIT; CLONING	Quinolones are potent broad spectrum antibacterial drugs that target the bacterial type II DNA topoisomerases, Their cytotoxicity derives from their ability to shift the cleavage-religation equilibrium required for topoisomerase action toward cleavage, thereby effectively trapping the enzyme on the DNA. It has been proposed that these drugs act by binding to the enzyme-DNA complex. Using catalytically inactive and quinolone-resistant mutant topoisomerase IV proteins, nitrocellulose filter DNA binding assays, and KMnO4 probing of drug-DNA and drug-DNA-enzyme complexes, we show: (i) that norfloxacin binding to DNA induces a structural alteration, which probably corresponds to an unwinding of the helix, that is exacerbated by binding of the topoisomerase and by binding of the drug to the enzyme and (ii) that formation of this structural perturbation in the DNA precedes DNA cleavage by the topoisomerase in the ternary complex. We conclude that cleavage of the DNA and the resultant opening of the DNA gate during topoisomerization requires the induction of strain in the DNA that is bound to the enzyme. We suggest that quinolones may act to accelerate the rate of DNA cleavage by stimulating acquisition of this structural perturbation in the ternary complex.			Marians, KJ (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLAND RJ, 1994, MOL MICROBIOL, V14, P371, DOI 10.1111/j.1365-2958.1994.tb01297.x; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; KATO J, 1992, J BIOL CHEM, V267, P25676; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KREUZER KN, 1979, J BACTERIOL, V140, P425; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; PENG H, 1993, J BIOL CHEM, V268, P24481; PENG H, 1995, J BIOL CHEM, V270, P52286; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SWANBERG SL, 1987, J MOL BIOL, V197, P729, DOI 10.1016/0022-2836(87)90479-7; TSE YC, 1980, J BIOL CHEM, V255, P5560; YAMAGISHI JI, 1981, J BACTERIOL, V148, P450, DOI 10.1128/JB.148.2.450-458.1981	29	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9401	9409						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083078				2022-12-27	WOS:A1997WU03700083
J	SkorkoGlonek, J; Lipinska, B; Krzewski, K; Zolese, G; Bertoli, E; Tanfani, F				SkorkoGlonek, J; Lipinska, B; Krzewski, K; Zolese, G; Bertoli, E; Tanfani, F			HtrA heat shock protease interacts with phospholipid membranes and undergoes conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; ESCHERICHIA-COLI SURVIVAL; STRESS-RESPONSE PROTEIN; GENERALIZED POLARIZATION; ELEVATED-TEMPERATURES; PERIPLASMIC PROTEINS; LAURDAN FLUORESCENCE; ACIDIC PHOSPHOLIPIDS; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE	The HtrA (DegP) protein of Escherichia coli is a heat shock serine protease, essential for cell survival only at temperatures above 42 degrees C. It has been shown by genetic experiments that HtrA is an envelope protease, functioning in the periplasmic space. To clarify the cellular localization of HtrA, E. coli cells were fractionated, and HtrA was not detected by the immunoblotting technique in the periplasm or in the fraction of soluble proteins but was found in the inner membrane. The protein could be partially eluted from the total membrane fraction by a high ionic strength solution, whereas solutions affecting protein conformation released HtrA almost com pletely. These results, taken together with the evidence showing that HtrA functions in the periplasm, indicate that HtrA is a peripheral membrane protein, localized on the periplasmic side of the inner membrane. As the first step toward solving the problem of HtrA-membrane interactions, the structure of HtrA in the presence of phosphatidylglycerol (PG), phosphatidylethanolamine (PE), or cardiolipin (CL) was analyzed by fluorescence and Fourier-transform infrared spectroscopy. The infrared and fluorescence data indicated an interaction of HtrA with PG and CL but not with PE suspensions. Fluorescence spectroscopy revealed that this interaction was at the level of the polar head group of the phospholipid. In the PG/HtrA system, small changes were observed in the HtrA secondary structure and a remarkable decrease of the thermal stability of the protein, which suggested changes in HtrA tertiary structure. This suggestion was supported by fluorescence data that showed a shift of the fluorescence emission spectrum of HtrA tyrosine residues in the presence of PG and a reduced fluorescence intensity, phenomena not observed in the presence of PE or CL suspensions. Infrared data revealed also that the interaction of HtrA with PG leads to a protection of unfolded protein against aggregation at relatively low temperatures. The conformational changes of HtrA in the presence of PG influenced the proteolytic activity of HtrA by increasing it at the temperatures 37-45 degrees C and inhibiting it at 50-55 degrees C. CL inhibited HtrA activity at all of the temperatures tested.	UNIV GDANSK, DEPT BIOCHEM, PL-80822 GDANSK, POLAND; UNIV ANCONA, SCH MED, INST BIOCHEM, I-60131 ANCONA, ITALY	Fahrenheit Universities; University of Gdansk; Marche Polytechnic University			Tanfani, Fabio/F-1441-2010; Skorko-Glonek, Joanna/AAF-5516-2020	Skorko-Glonek, Joanna/0000-0002-8084-5251; Tanfani, Fabio/0000-0001-7685-4692; Lipinska, Barbara/0000-0001-9510-4811				AMBROSINI A, 1994, CHEM PHYS LIPIDS, V72, P127, DOI 10.1016/0009-3084(94)90096-5; AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; BANECKI B, 1992, J BIOL CHEM, V267, P25051; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; BIRDSELL DC, 1967, J BACTERIOL, V93, P427, DOI 10.1128/JB.93.1.427-437.1967; BLUME A, 1988, BIOCHEMISTRY-US, V27, P8239, DOI 10.1021/bi00421a038; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAVARD D, 1989, J BACTERIOL, V171, P6316, DOI 10.1128/jb.171.11.6316-6322.1989; Cronan Jr. J.E., 1987, ESCHERICHIA COLI SAL, P474; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; DESORMEAUX A, 1992, BIOCHEMISTRY-US, V31, P12173, DOI 10.1021/bi00163a029; ENDO T, 1989, J BIOL CHEM, V264, P2951; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; FERNANDEZBALLESTER G, 1992, BIOCHEM J, V288, P421, DOI 10.1042/bj2880421; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Garner J, 1996, EMBO J, V15, P2313, DOI 10.1002/j.1460-2075.1996.tb00585.x; Glazebrook J, 1996, J BACTERIOL, V178, P745, DOI 10.1128/jb.178.3.745-752.1996; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; JOHNSON K, 1991, MOL MICROBIOL, V5, P401, DOI 10.1111/j.1365-2958.1991.tb02122.x; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KINNUNEN PKJ, 1994, CHEM PHYS LIPIDS, V73, P181, DOI 10.1016/0009-3084(94)90181-3; KUSTERS R, 1994, J BIOL CHEM, V269, P1560; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; MENZEL DB, 1964, BIOCHIM BIOPHYS ACTA, V84, P133, DOI 10.1016/0926-6542(64)90069-1; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; NEU HC, 1965, J BIOL CHEM, V240, P3685; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Osborn M J, 1974, Methods Enzymol, V31, P642; OVERVOORDE PJ, 1994, J BIOL CHEM, V269, P15154; OWEN P, 1982, TECHNIQUES LIPID MEM, P1; PARASASSI T, 1986, CELL MOL BIOL, V32, P103; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; Phillips RW, 1995, MICROB PATHOGENESIS, V19, P277, DOI 10.1016/S0882-4010(96)80001-5; POLITINO M, 1987, J BIOL CHEM, V262, P10109; ROOP RM, 1994, INFECT IMMUN, V62, P1000, DOI 10.1128/IAI.62.3.1000-1007.1994; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SEKIMIZU K, 1994, CHEM PHYS LIPIDS, V73, P223, DOI 10.1016/0009-3084(94)90183-X; SEOL JH, 1991, BIOCHEM BIOPH RES CO, V176, P730; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YOO SJ, 1993, FEBS LETT, V327, P17, DOI 10.1016/0014-5793(93)81029-Y; [No title captured]	60	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8974	8982						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083020				2022-12-27	WOS:A1997WU03700025
J	Bennett, JS; Chan, C; Vilaire, G; Mousa, SA; DeGrado, WF				Bennett, JS; Chan, C; Vilaire, G; Mousa, SA; DeGrado, WF			Agonist-activated alpha nu beta 3 on platelets and lymphocytes binds to the matrix protein osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; MURINE MONOCLONAL-ANTIBODY; VITRONECTIN RECEPTOR; INTEGRIN RECEPTOR; GLYCOPROTEIN-IIB; LIGAND-BINDING; SMOOTH-MUSCLE; FIBRINOGEN; EXPRESSION; ALPHA(V)BETA(3)	The phosphorylated acidic glycoprotein osteopontin is present in the extracellular matrix of atherosclerotic plaques and the wall of injured but not normal arteries. To determine if osteopontin could serve as a substrate for platelet adhesion, we measured the adherence of resting and agonist-stimulated human platelets to immobilized recombinant human osteopontin. Agonist-stimulated but not resting platelets bound to osteopontin by a process that was mediated primarily by alpha v beta 3. alpha v beta 3-mediated adherence occurred at physiologic concentrations of calcium and was inhibited by an alpha v beta 3-selective cyclic peptide. Assays using phorbol myristate acetate-stimulated transfected B lymphocytes expressing both alpha v beta 3 and alpha IIb beta 3 confirmed that activated alpha v beta 3 not activated alpha IIb beta 3 was responsible for the cellular adherence we measured. These studies indicate that alpha v beta 3 can reside on the cell surface in an inactive state and can be converted to a ligand binding conformation by cellular agonists. Moreover, they suggest that platelet adherence to osteopontin mediated by activated alpha v beta 3 could play a role in anchoring platelets to disrupted atherosclerotic plaques and the walls of injured arteries. By inhibiting alpha v beta 3 function, it may be possible to inhibit platelet-mediated vascular occlusion with a minimal effect on primary hemostasis.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19880	University of Pennsylvania; DuPont	Bennett, JS (corresponding author), UNIV PENN,DIV HEMATOL ONCOL,STELLAR CHANCE LABS,SCH MED,DEPT MED,RM 1005,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.		Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL051258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51258, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach AC, 1996, J AM CHEM SOC, V118, P293, DOI 10.1021/ja953163+; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BENNETT JS, 1996, TRENDS CARDIOVAS MED, V16, P31; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; *EPIC INV, 1994, NEW ENGL J MED, V330, P956; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FITZPATRICK LA, 1994, J CLIN INVEST, V94, P1597, DOI 10.1172/JCI117501; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HIROTA S, 1993, AM J PATHOL, V143, P1003; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; LAWLER J, 1989, BLOOD, V74, P2022; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; MURRY CE, 1994, AM J PATHOL, V145, P1450; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SMITH JW, 1990, J BIOL CHEM, V265, P2168; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8	33	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8137	8140		10.1074/jbc.272.13.8137	http://dx.doi.org/10.1074/jbc.272.13.8137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079626	hybrid			2022-12-27	WOS:A1997WQ63500009
J	Hogenesch, JB; Chan, WK; Jackiw, VH; Brown, RC; Gu, YZ; PrayGrant, M; Perdew, GH; Bradfield, CA				Hogenesch, JB; Chan, WK; Jackiw, VH; Brown, RC; Gu, YZ; PrayGrant, M; Perdew, GH; Bradfield, CA			Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; HEAT-SHOCK PROTEIN; ARYL-HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR NETWORK; DNA-BINDING ACTIVITY; AH-RECEPTOR; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; 2-HYBRID SYSTEM; NERVOUS-SYSTEM	In an effort to better understand the mechanism of toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin, we employed an iterative search of human expressed sequence tags to identify novel basic-helix-loop-helix-PAS (bHLH-PAS) proteins that interact with either the Ah receptor (AHR) or the Ah receptor nuclear translocator (ARNT). We characterized five new ''members of the PAS superfamily,'' or MOPs 1-5, that are similar in size and structural organization to the AHR and ARNT. MOPs 1-4 have N-terminal bHLH and PAS domains and C-terminal variable regions. MOP5 contained the characteristic PAS domain and a variable C terminus; it is possible that the cDNA contains a bHLH domain, but the entire open reading frame has yet to be completed. Coimmunoprecipitation studies, yeast two-hybrid analysis, and transient transfection experiments demonstrated that MOP1 and MOP2 dimerize with ARNT and that these complexes are transcriptionally active at defined DNA enhancer sequences in vivo. MOP3 was found to associate with the AHR in vitro but not in vivo. This observation, coupled with the fact that MOP3 formed tighter associations with the 90-kDa heat shock protein than the human AHR, suggests that MOP3 may be a conditionally active bHLH-PAS protein that requires activation by an unknown ligand. The expression profiles of the AHR, MOP1, and MOP2 mRNAs, coupled with the observation that they all share ARNT as a common dimeric partner, suggests that the cellular pathways mediated by MOP1 and MOP2 may influence or respond to the dioxin signaling pathway.	UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; NORTHWESTERN UNIV, SCH MED, DEPT MOL PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA; PENN STATE UNIV, DEPT VET SCI, STATE COLL, PA 16802 USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University					NCI NIH HHS [P30-CA07175] Funding Source: Medline; NIEHS NIH HHS [ES05703, ES05660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005703, R37ES005703, R01ES005703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHEN H, 1995, NAT GENET, V10, P9, DOI 10.1038/ng0595-9; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Ema M, 1996, MOL CELL BIOL, V16, P5865; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKS RG, 1994, MECH DEVELOP, V45, P269, DOI 10.1016/0925-4773(94)90013-2; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; HWANG DM, 1994, J MOL CELL CARDIOL, V26, P1329, DOI 10.1006/jmcc.1994.1151; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; MURALIDHAR MG, 1993, MECH DEVELOP, V41, P129, DOI 10.1016/0925-4773(93)90043-W; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	70	388	409	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8581	8593		10.1074/jbc.272.13.8581	http://dx.doi.org/10.1074/jbc.272.13.8581			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079689	hybrid			2022-12-27	WOS:A1997WQ63500072
J	Ueno, H; Sasaki, K; Miyagawa, K; Honda, H; Mitani, K; Yazaki, Y; Hirai, H				Ueno, H; Sasaki, K; Miyagawa, K; Honda, H; Mitani, K; Yazaki, Y; Hirai, H			Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the Ras pathway in epidermal growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; CAENORHABDITIS-ELEGANS; EGF STIMULATION; JURKAT CELLS; V-CBL; PROTOONCOGENE; PRODUCT; GRB2; INSULIN	Many growth factors including epidermal growth factor (EGF) induce tyrosine phosphorylation of the c-Cbl proto-oncogene product, whose function, however, remains unclear. Recently, Sli-1, a Caenorhabditis elegans homologue of c-Cbl, was found to be a negative regulator of let-23-mediated vulval induction pathway, suggesting that c-Cbl may negatively regulate EGF receptor (EGFR)-mediated signaling. In this study, by an antisense RNA approach, we examined the effects of expression level of c-Cbl on EGFR signaling and showed that overexpression of c-Cbl reduces and antisense repression of c-Cbl enhances autophosphorylation of EGF receptors and activation of the JAR-STAT pathway. However, in contrast to the Sli-1 protein, the expressed amount of c-Cbl does not affect activation of the Ras pathway, suggesting that the EGFR-mediated signaling pathways are differently regulated by c-Cbl among nematodes and mammals.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLAKE TJ, 1991, ONCOGENE, V6, P53; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JONGEWARD GD, 1995, GENETICS, V139, P1553; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1996, ONCOGENE, V12, P1117; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIYAZAKI J, 1989, GENE, V79, P269; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Odai H, 1995, JPN J CANCER RES, V86, P1119, DOI 10.1111/j.1349-7006.1995.tb03303.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKIS AM, 1993, NATURE, V363, P83; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TOBE K, 1991, J BIOL CHEM, V266, P24793; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	35	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8739	8743		10.1074/jbc.272.13.8739	http://dx.doi.org/10.1074/jbc.272.13.8739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079708	hybrid			2022-12-27	WOS:A1997WQ63500091
J	Chen, JM; Dando, PM; Rawlings, ND; Brown, MA; Young, NE; Stevens, RA; Hewitt, E; Watts, C; Barrett, AJ				Chen, JM; Dando, PM; Rawlings, ND; Brown, MA; Young, NE; Stevens, RA; Hewitt, E; Watts, C; Barrett, AJ			Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASES; SCHISTOSOMA-MANSONI; EGG-WHITE; PURIFICATION; INHIBITORS; EXPRESSION; PRECURSORS; CYSTATIN; SEQUENCE; SEEDS	Legumain is a cysteine endopeptidase that shows strict specificity for hydrolysis of asparaginyl bonds, The enzyme belongs to peptidase family C13, and is thus unrelated to the better known cysteine peptidases of the papain family, C1 (Rawlings, N, D., and Barrett, A. J, (1994) Methods Enzymol, 244, 461-486), To date, legumain has been described only from plants and a blood fluke, Schistosoma mansoni, We now show that legumain is present in mammals, We have cloned and sequenced human legumain and part of pig legumain, We have also purified legumain to homogeneity (2200 fold, 8% yield) from pig kidney, The mammalian sequences are clearly homologous with legumains from non mammalian species, Pig legumain is a glycoprotein of about 34 kDa, decreasing to 31 kDa on deglycosylation, It is an asparaginyl endopeptidase, hydrolyzing Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide and benzoyl-Asn-p-nitroanilide. Maximal activity is seen at pH 5.8 under normal assay conditions, and the enzyme is irreversibly denatured at pH 7 and above, Mammalian legumain is a cysteine endopeptidase, inhibited by iodoacetamide and maleimides, but unaffected by compound E64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane). It is inhibited by ovocystatin (cystatin from chicken egg white) and human cystatin C with K-i values < 5 nM. We discuss the significance of the discovery of a cysteine endopeptidase of a new family and distinctive specificity in man and other mammals.	BABRAHAM INST, MRC, PEPTIDASE LAB, BABRAHAM CB2 4AT, CAMBS, ENGLAND; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Dundee			Rawlings, Neil D./I-4867-2012; Barrett, Alan J/G-8970-2013; Rawlings, Neil/M-5566-2013	Barrett, Alan J/0000-0002-6082-4437; Rawlings, Neil/0000-0001-5557-7665; Hewitt, Eric/0000-0002-6238-6303; Watts, Colin/0000-0001-6183-2087				ABE Y, 1993, J BIOL CHEM, V268, P3525; ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; ALONSO JM, 1995, PLANT PHYSIOL, V109, P541, DOI 10.1104/pp.109.2.541; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; Barrett AJ, 1996, PERSPECT DRUG DISCOV, V6, P1, DOI 10.1007/BF02174042; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Bottari A, 1996, PHYSIOL PLANTARUM, V97, P475, DOI [10.1111/j.1399-3054.1996.tb00506.x, 10.1034/j.1399-3054.1996.970309.x]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; BUTTLE DJ, 1990, FEBS LETT, V262, P58, DOI 10.1016/0014-5793(90)80153-A; CSOMA C, 1984, BIOCHEM J, V222, P769, DOI 10.1042/bj2220769; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; DAWSON EMC, 1987, DATA BIOCH RES, P427; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELMEANAWY MA, 1990, AM J TROP MED HYG, V43, P67, DOI 10.4269/ajtmh.1990.43.67; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HALASZ P, 1977, EUR J BIOCHEM, V79, P491, DOI 10.1111/j.1432-1033.1977.tb11832.x; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1995, J PLANT PHYSIOL, V145, P632, DOI 10.1016/S0176-1617(11)81275-7; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; ISHII S, 1994, METHOD ENZYMOL, V244, P605; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MAKOFF AJ, 1989, BIO-TECHNOL, V7, P1043; Maunsbach A B, 1974, Methods Enzymol, V31, P330; MIN W, 1994, NAT STRUCT BIOL, V1, P502, DOI 10.1038/nsb0894-502; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; RICE P, 1995, PROGRAM MANUAL EGCG; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharma KK, 1996, BIOCHEM BIOPH RES CO, V218, P365, DOI 10.1006/bbrc.1996.0064; *U WISC, 1994, PROGR MAN WISC PACK; YAMAUCHI D, 1992, PLANT CELL PHYSIOL, V33, P789; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	44	289	303	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8090	8098		10.1074/jbc.272.12.8090	http://dx.doi.org/10.1074/jbc.272.12.8090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065484	hybrid			2022-12-27	WOS:A1997WP59200078
J	Froehlich, JE; Keegstra, K				Froehlich, JE; Keegstra, K			Identification of a translocation intermediate occupying functional protein import sites in the chloroplastic envelope membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; TRANSIT PEPTIDE; FUSION PROTEIN; CONTACT SITES; BINDING; MITOCHONDRIA; TRANSPORT	We used complexes of avidin and biotinylated precursors to generate translocation intermediates that occupy functional transport sites and thereby block the transport of other precursor proteins into pea chloroplasts. Cysteine residues of purified precursor to the small subunit of rubisco (prSS) were modified with the biotinylation reagent biotin-1-biotinamido-4-[-4'-(maleimidomethyl)-cyclohexane-carboxamido]but Chemically biotinylated prSS was readily imported into chloroplasts. The addition of avidin, however, resulted in the formation of an avidin-biotinylated precursor complex that could not be imported into chloroplasts even when precursors had already engaged the transport apparatus before avidin was added. On fractionation, the avidin-biotinylated precursor complex associated with envelope membranes. Titration of transport sites with avidin-biotinylated precursor complexes revealed that saturation was reached at 2,000 molecules/chloroplast. Even with less than saturating levels of complexes, a sufficient number of translocation sites could be occupied with avidin precursor complexes so that the import rate of freshly added radiolabeled prSS was reduced by 35%. From these observations we conclude that the trapped intermediates were blocking functional translocation sites. These biotinylated translocation intermediates should be useful in future efforts to purify and characterize the chloroplastic protein import machinery.			Froehlich, JE (corresponding author), MICHIGAN STATE UNIV,US DOE,PLANT RES LAB,E LANSING,MI 48823, USA.							AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; Bruce BD, 1994, PLANT MOL BIOL MAN J, VJ1, P1; CASHMORE AR, 1984, GENETIC ENG PLANTS, P29; CLINE K, 1985, J BIOL CHEM, V260, P3691; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ENDO T, 1995, J BIOCHEM, V118, P753, DOI 10.1093/oxfordjournals.jbchem.a124976; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; KO K, 1992, J BIOL CHEM, V267, P13910; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; Maniatis T., 1982, MOL CLONING; NIELSEN E, 1997, IN PRESS EMBO J; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REISS B, 1989, P NATL ACAD SCI USA, V86, P886, DOI 10.1073/pnas.86.3.886; ROBINSON C, 1985, EUR J BIOCHEM, V152, P67, DOI 10.1111/j.1432-1033.1985.tb09164.x; ROSENBERG AH, 1987, GENE, V56, P25; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; WASMANN CC, 1988, J BIOL CHEM, V263, P617; WU CB, 1994, J BIOL CHEM, V269, P32264	40	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8077	8082		10.1074/jbc.272.12.8077	http://dx.doi.org/10.1074/jbc.272.12.8077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065482	hybrid			2022-12-27	WOS:A1997WP59200076
J	Ishii, I; Izumi, T; Tsukamoto, H; Umeyama, H; Ui, M; Shimizu, T				Ishii, I; Izumi, T; Tsukamoto, H; Umeyama, H; Ui, M; Shimizu, T			Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ELECTRON CRYOMICROSCOPY; MOLECULAR-CLONING; HORMONE RECEPTOR; G-PROTEINS; EXPRESSION; RHODOPSIN; CDNA; INHIBITION; MUTATIONS	To determine ligand-binding sites of a platelet-activating factor (PAF) receptor, alanine-scanning mutagenesis was carried out. All 23 polar amino acids in the putative 7-transmembrane (TM) domains of a guinea pig PAF receptor were individually replaced with alanine. The ligand-binding properties of mutant receptors were determined after transient expression in COS-7 cells, Mutants in TM II (N58A, D63A), TM III (N100A, T101A, S104A) and TM VII (D289A) displayed higher PAF-binding affinities than seen with the wild-type receptor. In contrast, mutants in TM V (H188A), TM VI (H248A, H249A, Q252A), and TM VII (Q276A, T278A) showed lower affinities. Representative mutants were then stably expressed in Chinese hamster ovary cells to observe PAF-induced cellular signals (arachidonate release, phosphatidylinositol hydrolysis, adenylyl cyclase inhibition). An N100A mutant with the highest affinity was constitutively active and was responsive to lyso-PAF, an inactive derivative of PAF. One nanomolar PAF induced no signals in low affinity mutants, an EC(50) value for the wild-type receptor. Three histidines (His-188, His 248, His 249) might form a binding pocket for the phosphate group of PAF, since zinc effectively inhibited ligand binding. Based on these results, a three-dimensional molecular model of PAF and its receptor was generated using bacteriorhodopsin as a reference protein.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,UI LAB,RIKEN,WAKO,SAITAMA 35101,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,DEPT CHEM PHYS,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; RIKEN; Kitasato University				Ishii, Isao/0000-0002-5367-205X				ALI H, 1994, J BIOL CHEM, V269, P24557; BAZAN NG, 1993, J LIPID MEDIATOR, V6, P421; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CHAO W, 1989, J BIOL CHEM, V264, P13591; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; GERARD NP, 1994, J IMMUNOL, V152, P793; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUO Y, 1988, ARCH BIOCHEM BIOPHYS, V260, P841, DOI 10.1016/0003-9861(88)90515-2; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; IZUMI T, 1995, BIOCHEM J, V305, P829, DOI 10.1042/bj3050829; KAJIHARA A, 1993, PROTEIN ENG, V6, P615, DOI 10.1093/protein/6.6.615; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NUNEZ D, 1989, ARCH BIOCHEM BIOPHYS, V272, P466, DOI 10.1016/0003-9861(89)90241-5; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SNYDER F, 1987, PLATELET ACTIVATING; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	50	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7846	7854		10.1074/jbc.272.12.7846	http://dx.doi.org/10.1074/jbc.272.12.7846			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065450	hybrid			2022-12-27	WOS:A1997WP59200044
J	Katada, J; Hayashi, Y; Sato, Y; Muramatsu, M; Takiguchi, Y; Harada, T; Fujiyoshi, T; Uno, I				Katada, J; Hayashi, Y; Sato, Y; Muramatsu, M; Takiguchi, Y; Harada, T; Fujiyoshi, T; Uno, I			A novel peptide motif for platelet fibrinogen receptor recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING SITE; GPIIB-IIIA; VITRONECTIN RECEPTOR; INTEGRIN; RGD; ANTAGONIST; ADHESION; MUTATION; DOMAIN	To develop a specific antagonist of platelet alpha IIb beta 3 using small linear peptides, we synthesized a series of hexapeptides that did not have an Arg-Gly-Asp (RGD) sequence and examined their anti-platelet activity and their specificity for alpha IIb beta 3, We found a novel motif sequence, Pro-X1-X2-X3-Asp-X4, where X1 to X4 were all L-form alpha-amino acids, which specifically inhibited aggregation of human platelets at submicromolar concentrations, The Pro residue at the N terminus was essential to the anti-platelet activity, and the acetylation of the imino group of this residue also resulted in the complete loss of the activity, The results of the binding assay using purified human platelet alpha IIb beta 3 and placental, PQ and those of the cell adhesion assay suggest that this motif peptide is highly specific for platelet alpha IIb beta 3 among other integrins. Flow cytometric studies using an fluorescein isothiocyanate-labeled RGD peptide showed that this motif peptide inhibited the binding of an RGD peptide to activated platelets, suggesting that it has the same inhibitory mode as RGD peptides, Conformational analysis of this motif peptide and an RGD-containing peptide suggests that the imino group of the Pro residue may substitute for the role of the guanidino group of the Arg residue of the RGD sequence.			Katada, J (corresponding author), NIPPON STEEL CORP LTD,LIFE SCI RES CTR,ADV TECHNOL RES LABS,NAKAHARA KU,1618 IDA,KAWASAKI,KANAGAWA 211,JAPAN.			Katada, Jun/0000-0003-3588-3686				BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BARRETT JS, 1994, CLIN PHARMACOL THER, V56, P377, DOI 10.1038/clpt.1994.152; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; CHENG S, 1994, J MED CHEM, V37, P1, DOI 10.1021/jm00027a001; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FROJMOVIC M, 1991, BIOPHYS J, V59, P815, DOI 10.1016/S0006-3495(91)82294-9; Hayashi Y, 1996, BIOORG MED CHEM LETT, V6, P1351, DOI 10.1016/0960-894X(96)00224-7; HORTON MA, 1985, CANCER RES, V45, P5663; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIYAMA M, 1993, CHEM PHARM BULL, V41, P1118; KARCZEWSKI J, 1994, J BIOL CHEM, V269, P6702; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MULLER G, 1992, ANGEW CHEM INT EDIT, V31, P326, DOI 10.1002/anie.199203261; PEISHOFF CE, 1992, J MED CHEM, V35, P3962, DOI 10.1021/jm00099a026; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; VANHOOF G, 1992, BIOCHEM PHARMACOL, V44, P479, DOI 10.1016/0006-2952(92)90439-P; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	38	8	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7720	7726		10.1074/jbc.272.12.7720	http://dx.doi.org/10.1074/jbc.272.12.7720			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065431	hybrid			2022-12-27	WOS:A1997WP59200025
J	Velcich, A; Palumbo, L; Selleri, L; Evans, G; Augenlicht, L				Velcich, A; Palumbo, L; Selleri, L; Evans, G; Augenlicht, L			Organization and regulatory aspects of the human intestinal mucin gene (MUC2) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; HUMAN GASTRIC MUCIN; CARCINOEMBRYONIC ANTIGEN; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GUT EPITHELIUM; BINDING-SITE; DNA-BINDING; EXPRESSION; CLONING	The human MUC2 gene maps to chromosome 11p15, where three additional mucin genes have been located, and encodes the most abundant gastrointestinal mucin normally expressed in the intestinal goblet cell lineage, However, in pathological conditions, including colorectal cancer, MUC2 can be abnormally expressed. Therefore, it is of considerable interest to understand the regulation of the MUC2 gene and how the mechanism is altered in colon cancer, Toward this goal, we have isolated a group of overlapping clones (contig) spanning 85 kilobases harboring the entire MUC2 locus, including sequences located upstream of the gene, Detection of two DNase I-hypersensitive sites in the 5' region of the MUC2 gene suggests the presence of DNA regulatory elements. To better characterize this region, we have sequenced 12 kilobases of the upstream region and analyzed it for functional activity by cloning portions of it into a luciferase reporter vector and assaying for promoter/enhancer activity using a transient transfection assay, A fragment from the AUG translational initiation codon +1 to -848 confers maximal transcriptional activity in several intestinal cell lines, Elements located further upstream exert a negative effect on the expression of the reporter gene when tested in conjunction with homologous or heterologous promoters, The same pattern of expression is observed when the MUC2/luciferase constructs are transfected into HeLa cells, which do not express the endogenous MUC2 gene, However, the level of activity in HeLa cells is at least an order of magnitude higher, suggesting that additional sequences singularly or in combination are responsible for the tissue- and cell lineage-specific expression of MUC2. Finally, we have identified an additional mucin-like gene (MUCX), located upstream of MUC2. We show that this MUCX gene, that is transcribed in opposite orientation to that of MUC2, is expressed with a pattern distinct from that of MUC2, yet similar to that of MUC5B and MUC6, two additional mucin genes located at chromosome 11p15. Recent information on the order of the mucin genes at chromosome 11p15 suggests that MUCX may be MUC6, one of the already identified mucin genes, or a novel one, yet to be fully characterized.	STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; UNIV TEXAS, SW MED CTR, MCDERMOTT CTR HUMAN GROWTH & DEV, DALLAS, TX 75235 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Velcich, A (corresponding author), MONTEFIORE MED CTR, DEPT ONCOL, ALBERT EINSTEIN CANC CTR, 111 E 210TH ST, BRONX, NY 10467 USA.				NCI NIH HHS [CA-68965, P30CA-13330, CA-55913] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068965, P30CA013330, R29CA055913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOLAND CR, 1982, P NATL ACAD SCI-BIOL, V79, P2051, DOI 10.1073/pnas.79.6.2051; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHEN CJ, 1995, CANCER RES, V55, P3873; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CONG NV, 1990, HUM GENET, V86, P167; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; ENVER T, 1985, NATURE, V318, P680, DOI 10.1038/318680a0; FERL RJ, 1987, J BIOL CHEM, V262, P7947; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUM JR, 1995, GASTROENTEROLOGY, V108, pA476; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HEERDT BG, 1991, ONCOGENE, V6, P125; HO SB, 1993, CANCER RES, V53, P641; HO SB, 1995, CANCER RES, V55, P2681; Hong D, 1996, GASTROENTEROLOGY, V110, pA806; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIM YS, 1995, GASTROENTEROLOGY, V109, P999, DOI 10.1016/0016-5085(95)90412-3; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; Pigny P, 1996, BIOCHEM BIOPH RES CO, V220, P186, DOI 10.1006/bbrc.1996.0378; PIGNY P, 1996, 4 INT WORKSH CARC AS, P16; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SELLERI L, 1995, GENOMICS, V26, P489, DOI 10.1016/0888-7543(95)80167-K; TIBBETTS LM, 1993, CANCER, V71, P315, DOI 10.1002/1097-0142(19930115)71:2<315::AID-CNCR2820710208>3.0.CO;2-B; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TYTGAT KMAJ, 1994, GASTROENTEROLOGY, V107, P1352, DOI 10.1016/0016-5085(94)90537-1; VELCICH A, 1993, J BIOL CHEM, V268, P13956; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; YAN PS, 1990, LAB INVEST, V63, P698	48	48	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7968	7976		10.1074/jbc.272.12.7968	http://dx.doi.org/10.1074/jbc.272.12.7968			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065467	hybrid			2022-12-27	WOS:A1997WP59200061
J	Wemmie, JA; Steggerda, SM; MoyeRowley, WS				Wemmie, JA; Steggerda, SM; MoyeRowley, WS			The Saccharomyces cerevisiae AP-1 protein discriminates between oxidative stress elicited by the oxidants H2O2 and diamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; MUTATIONAL ANALYSIS; PLEIOTROPIC DRUG; YEAST-CELLS; JUN FAMILY; IN-VITRO; GENE; RESISTANCE; YAP1	The Saccharomyces cerevisiae AP-1 protein (yAP-1) is a key mediator of oxidative stress tolerance. Transcriptional activation by yAP-1 has been shown to be inducible by exposure of cells to H2O2 and diamide, among other oxidative stress eliciting compounds. Here we define the segments of the yAP-1 protein that are required to respond to this environmental challenge. Western blotting analyses indicated that levels of yAP-1 do not change during oxidative stress. Deletion mutagenesis and gene fusion experiments indicate that two different segments of yAP-1 are required for oxidative stress inducibility. These two domains function differentially depending on the type of oxidant used to generate oxidative stress. Three repeated cysteine-serine glutamate sequences located in the carboxyl terminus are required for normal regulation of yAP-1 function during oxidative stress. Replacement of these cysteine-serine-glutamate repeats by alanine residues does not similarly affect H2O2 and diamide regulation of yAP-1 function. While yAP-1 transactivation is enhanced by exposure to either H2O2 or diamide, the protein responds to the oxidative stress produced by these compounds in nonidentical ways.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harlow E., 1988, ANTIBODIES LAB MANUA; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Melville SB, 1996, P NATL ACAD SCI USA, V93, P1226, DOI 10.1073/pnas.93.3.1226; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NUNOSHIBA T, 1994, NUCLEIC ACIDS RES, V22, P2958, DOI 10.1093/nar/22.15.2958; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WERTMAN KF, 1992, GENETICS, V132, P337; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323	44	84	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7908	7914		10.1074/jbc.272.12.7908	http://dx.doi.org/10.1074/jbc.272.12.7908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065458	hybrid			2022-12-27	WOS:A1997WP59200052
J	Dillon, DA; Chen, XM; Zeimetz, GM; Wu, WI; Waggoner, DW; Dewald, J; Brindley, DN; Carman, GM				Dillon, DA; Chen, XM; Zeimetz, GM; Wu, WI; Waggoner, DW; Dewald, J; Brindley, DN; Carman, GM			Mammalian Mg2+-independent phosphatidate phosphatase (PAP2) displays diacylglycerol pyrophosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MIXED MICELLES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RAT-LIVER; PHOSPHATIDYLINOSITOL SYNTHASE; SUBCELLULAR-LOCALIZATION; INOSITOL LIPIDS; DNA-SYNTHESIS; ACID; PURIFICATION	Recent studies indicate that the metabolism of diacylglycerol pyrophosphate (DGPP) is involved in a novel lipid signaling pathway. DGPP phosphatases (DGPP phosphohydrolase) from Saccharomyces cerevisiae and Escherichia coli catalyze the dephosphorylation of DGPP to yield phosphatidate (PA) and then catalyze the dephosphorylation of PA to yield diacylglycerol. We demonstrated that the Mg2+-independent form of PA phosphatase (PA phosphohydrolase, PAPS) purified from rat liver catalyzed the dephosphorylation of DGPP. This reaction was Mg2+-independent, insensitive to inhibition by N-ethylmaleimide and bromoenol lactone, and inhibited by Mn2+ ions. PAP2 exhibited a high affinity for DGPP (K-m = 0.04 mol %). The specificity constant (V-max/K-m) for DGPP was 1.3-fold higher than that of Pk DGPP inhibited the ability of PAPS to dephosphorylate PA, and PA inhibited the dephosphorylation of DGPP. Like rat liver PAP2, the Mg2+-independent PA phosphatase activity of DGPP phosphatase purified hom S. cerevisiae was inhibited by lyse-PA, sphingosine l-phosphate, and ceramide l-phosphate. Mouse PAP2 showed homology to DGPP phosphatases from S. cerevisiae and E. coli, especially in localized regions that constitute a novel phosphatase sequence motif. Collectively, our work indicated that rat liver PAP2 is a member of a phosphatase family that includes DGPP phosphatases from S. cerevisiae and E. coli. We propose a model in which the phosphatase activities of rat liver PAP2 and the DGPP phosphatase of S. cerevisiae regulate the cellular levels of DGPP, PA, and diacylglycerol.	RUTGERS STATE UNIV, NEW JERSEY AGR EXPT STN, COOK COLL, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, SIGNAL TRASDUCT LABS, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, HERITAGE MED RES CTR 357, EDMONTON, AB T6G 2S2, CANADA	Rutgers State University New Brunswick; University of Alberta; University of Alberta					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAID A, 1983, METHOD ENZYMOL, V96, P192; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KANOH H, 1992, J BIOL CHEM, V267, P25309; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; Kocsis MG, 1996, LIPIDS, V31, P785, DOI 10.1007/BF02522974; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; RIEDEL B, 1997, IN PRESS PLANT SCI; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Siess EA, 1996, FEBS LETT, V381, P169, DOI 10.1016/0014-5793(96)00111-1; SMITH SW, 1957, J BIOL CHEM, V228, P915; Stukey J, 1997, PROTEIN SCI, V6, P469; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	50	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10361	10366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099673				2022-12-27	WOS:A1997WV26200007
J	Koopmann, W; Krangel, MS				Koopmann, W; Krangel, MS			Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MAST-CELL LEUKEMIA; PLATELET FACTOR-IV; HEPARIN-BINDING; 3-DIMENSIONAL STRUCTURE; CHEMOTACTIC CYTOKINES; FUNCTIONAL EXPRESSION; DIRECTED MUTAGENESIS; POLYACRYLAMIDE GELS; CRYSTAL-STRUCTURE	Chemokines bind to receptors of the seven-transmembrane type on target cells and also bind to glycosaminoglycans (GAGs), including heparin. In this study, we have sought to identify structural motifs mediating binding of the beta-chemokine macrophage inflammatory protein-1 alpha (MIP-1 alpha) to GAGs. Alignment of beta-chemokine amino acid sequences revealed the presence of several highly conserved basic amino acids, and molecular modeling predicted that the side chains of three of the basic amino acids fold closely together in MIP-1 alpha. Site-directed mutagenesis was used to change the conserved basic residues in MIP-1 alpha to alanines, and both wild-type and mutant proteins were produced in a transient COS cell expression system. Wild type MIP-1 alpha bound to heparin-Sepharose, while three of the mutants, R18A R46A, and R48A, failed to bind. Mutant K45A eluted from heparin-Sepharose at lower NaCl concentrations than wild type, while the binding of K61A, with a mutation in the C-terminal alpha-helix, was indistinguishable from that of the wild-type protein. To determine whether GAG-binding capacity is required for receptor binding and cell activation, we performed competition radioligand binding and calcium mobilization experiments using one of the non-heparin-binding mutants, R46A. R46A bound as efficiently as wild-type MIP-1 alpha to CCR1 and was equally active in eliciting increases in intracellular free calcium concentrations. Our data define a GAG binding site in MIP-1 alpha consisting of three noncontiguous basic amino acids and show that the capacity to bind to GAGs is not a prerequisite for receptor binding or signaling in vitro.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27701 USA	Duke University					NIAID NIH HHS [AI37548] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037548] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GILAT D, 1994, J IMMUNOL, V153, P4899; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IRVING SG, 1990, NUCLEIC ACIDS RES, V18, P3261, DOI 10.1093/nar/18.11.3261; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MAIONE TE, 1991, CANCER RES, V51, P2077; MANN DM, 1994, J BIOL CHEM, V269, P23661; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SELVAN RS, 1994, J BIOL CHEM, V269, P13893; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; YOSHIMURA T, 1993, J IMMUNOL, V150, P5025	47	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10103	10109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092555				2022-12-27	WOS:A1997WU03900074
J	Vyas, AA; Pan, JJ; Patel, HV; Vyas, KA; Chiang, CM; Sheu, YC; Hwang, JK; Wu, WG				Vyas, AA; Pan, JJ; Patel, HV; Vyas, KA; Chiang, CM; Sheu, YC; Hwang, JK; Wu, WG			Analysis of binding of cobra cardiotoxins to heparin reveals a new beta-sheet heparin-binding structural motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NAJA-NAJA-ATRA; PROTEIN INTERACTIONS; SNAKE-VENOM; IDENTIFICATION; PROTEOGLYCANS; ANALOGS	Heparin and heparan sulfate have recently been shown to bind to snake cardiotoxin (CTX) and to potentiate its penetration into phospholipid monolayer under physiological ionic conditions. Herein we analyze the heparin-binding domain of CTX using 10 CTXs from Taiwan and African cobra venom, We also performed computer modeling to obtain more information of the binding at molecular level, The results provide a molecular model for interaction of CTX-heparin complex where the cationic belt of the conserved residues on the concave surface of three finger beta-sheet polypeptides initiates ionic interaction with heparin-like molecules followed by specific binding of Lys residues near the tip of loop 2 of CTX. The dissociation constants of CTXs differ by as much as 4 orders of magnitude, ranging from similar to 140 mu M for toxin gamma to similar to 20 nM for CTX M3, depending on the presence of Lys residues near the tip of loop 2. High affinity heparin binding becomes possible due to the presence of Arg-28, Lys-33, or the so-called consensus heparin binding sequence of XKKXXXKRX near the tip of the loop, The well defined three-finger loop structure of CTX provides an interesting template for the design of high affinity heparin-binding polypeptides with beta-sheet structure. The finding that several cobra CTXs and phospholipase A2 bind to heparin with different affinity may provide information on the synergistic action of the two venom proteins.	NATL TSING HUA UNIV, DEPT LIFE SCI, HSINCHU 30043, TAIWAN	National Tsing Hua University			Vyas, Kavita/GRJ-4578-2022					ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chiang CM, 1996, BIOCHEMISTRY-US, V35, P9177, DOI 10.1021/bi960077t; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; DUFTON MJ, 1991, SNAKE TOXINS, P359; Endo T., 1991, P165; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLETCHER JE, 1993, TOXICON, V31, P669, DOI 10.1016/0041-0101(93)90375-S; FRYKLUND L, 1975, BIOCHEMISTRY-US, V14, P2865, DOI 10.1021/bi00684a012; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; LIN SR, 1995, J PROTEIN CHEM, V297, P297; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1991, CHEM IND-LONDON, P45; LOMONTE B, 1994, J BIOL CHEM, V269, P29867; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; OLSON ST, 1991, J BIOL CHEM, V266, P6342; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; ROSENFELD L, 1987, BIOCHEMISTRY-US, V12, P639; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; SINGHAL AK, 1993, BIOCHEMISTRY-US, V32, P8036, DOI 10.1021/bi00082a026; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Sun YJ, 1997, BIOCHEMISTRY-US, V36, P2403, DOI 10.1021/bi962594h; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Wuster W, 1996, TOXICON, V34, P399, DOI 10.1016/0041-0101(95)00139-5; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	34	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9661	9670						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092495	hybrid			2022-12-27	WOS:A1997WU03900014
J	Woscholski, R; Finan, PM; Radley, E; Totty, NF; Sterling, AE; Hsuan, JJ; Waterfield, MD; Parker, PJ				Woscholski, R; Finan, PM; Radley, E; Totty, NF; Sterling, AE; Hsuan, JJ; Waterfield, MD; Parker, PJ			Synaptojanin is the major constitutively active phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase in rodent brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; 3,4,5-TRISPHOSPHATE; WORTMANNIN; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; TRANSLOCATION; ACTIVATION; INHIBITOR; VPS34	The major constitutive phosphatidylinositol-3,4,5-P-3 (PtdIns) 5-phosphatase activity was purified and subjected to peptide sequence analysis providing extensive amino acid sequence which was subsequently used for cloning the cDNA. Peptide and cDNA sequences revealed that the purified PtdIns(3,4,5)P-3 5-phosphatase was identical to a splice variant of a recently cloned inositol polyphosphate 5-phosphatase termed synaptojanin. Since synaptojanin is not known to possess PtdIns(3,4,5)P-3 5-phosphatase activity, we verified that the purified PtdIns(3,4,5)P-3 5-phosphatase activity and synaptojanin are identical by Western blot using specific antibodies raised against synaptojanin sequences, Immunoprecipitation from crude lysates of rat brain tissue showed that synaptojanin accounts for the major part of the active PtdIns(3,4,5)P-3 5-phosphatase activity, It is also shown that the protein is localized to the soluble fraction, Expression of a truncated recombinant protein demonstrates that the conserved 5-phosphatase region of the synaptojanin gene expresses PtdIns(3,4,5)P-3 5-phosphatase activity, However, immunological analysis demonstrates that the PtdIns(3,4,5)P-3 5-phosphatase activity expressed from the synaptojanin gene in brain is due to a particular splice variant which contains a 16-amino acid insert as shown by immunoprecipitation using a specific antibody raised against this particular splice variant.	IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND; YAMANOUCHI RES INST,OXFORD OX4 4SX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOL BIOL,LONDON WC1E 6BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Hsuan, Justin/C-8825-2009; Parker, Peter j/D-5192-2013	Hsuan, Justin/0000-0001-6083-7564; parker, peter/0000-0002-6218-2933				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001	33	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9625	9628						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092489				2022-12-27	WOS:A1997WU03900008
J	Deak, F; Piecha, D; Bachrati, C; Paulsson, M; Kiss, I				Deak, F; Piecha, D; Bachrati, C; Paulsson, M; Kiss, I			Primary structure and expression of matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor type A-like module superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; FACTOR-B; GENE; THROMBOSPONDIN; SITES; COMPLEMENT; INTEGRINS; ALIGNMENT; SUBUNITS	A mouse cDNA encoding a novel member of the von Willebrand factor type A-like module superfamily was cloned, The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites, A sequence similarity search indicated the closest relation to the trimeric cartilage matrix protein (CMP), Since they constitute a novel protein family, we introduce the term matrilin-2 for the new protein, reserving matrilin-1 as an alternative name for CMP. A 3.9-kilobase matrilin-2 mRNA was detected in a variety of mouse organs, including calvaria, uterus, heart, and brain, as well as fibroblast and osteoblast cell lines, Expressed human and rat cDNA sequence tags indicate a high degree of interspecies conservation, A group of 120-150-kDa bands was, after reduction, recognized specifically with an antiserum against the matrilin-2-glutathione S-transferase fusion protein in media of the matrilin-2-expressing cell lines, Assuming glycosylation, this agrees well with the predicted minimum M(r) of the mature protein (104,300). Immunolocalization of matrilin-2 in developing skeletal elements showed reactivity in the perichondrium and the osteoblast layer of trabecular bone. CMP binds both collagen fibrils and aggrecan, and because of the similar structure and complementary expression pattern, matrilin-2 is likely to perform similar functions in the extracellular matrix assembly of other tissues.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY; UNIV COLOGNE,FAC MED,INST BIOCHEM,D-50931 COLOGNE,GERMANY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Cologne			Bachrati, Csanad/ABF-2020-2021	Bachrati, Csanad/0000-0003-1703-5894				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; ASZODI A, 1994, MATRIX BIOL, V14, P181, DOI 10.1016/0945-053X(94)90007-8; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Bourdon M. A., 1990, EXTRACELLULAR MATRIX, P166; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLOMBATTI A, 1991, BLOOD, V77, P2305; ENGEL J, 1994, DEVELOPMENT, P35; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HANFORD PA, 1991, NATURE, V351, P164; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MUNDLOS S, 1994, DEV DYNAM, V199, P241, DOI 10.1002/aja.1001990308; Muratoglu S, 1995, EUR J CELL BIOL, V68, P411; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STIRPE NS, 1989, DEVELOPMENT, V107, P23; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	39	68	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9268	9274						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083061				2022-12-27	WOS:A1997WU03700066
J	Hu, YH; Metzler, B; Xu, QB				Hu, YH; Metzler, B; Xu, QB			Discordant activation of stress-activated protein kinases or c-jun NH2-terminal protein kinases in tissues of heat-stressed mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; HA-RAS; PHOSPHORYLATION; RAF-1; EXPRESSION; RECEPTOR; BINDING; DOMAIN	Stress-activated protein kinases (SAPK) or c-Jun NH2-terminal protein kinases (JNK) are believed to be crucial signal transducers between stress stimuli and genetic responses in mammalian cells. These kinases are activated in various types of in vitro cultured cells by heat shock, but a similar activation of SAPK/JNK in tissues in vivo has yet to be shown. In the present study, C57BL/6 mice were exposed to elevated ambient temperature for various time periods, and SAPR/JNK activities determined in protein extracts of brain, heart, liver, spleen, lung, and kidney using protein kinase assay and Western blot analyses. The time course and relative magnitude of the heat-induced SAPK/JNK activity differed among tissues of the same animal. Significant activation of SAPK/JNK was achieved in heart, liver, and kidney at 60 or 90 min of heat stress. This increased activity of SAPK/JNK kinases was demonstrated to result from activation or phosphorylation of existing proteins in tissues. The maximal activation of these kinases showed no direct relationship with the elevation in body temperature (38-40.5 degrees C). Interestingly, SAPK/JNK activation did not occur in lung, brain, or spleen of the same heat-stressed mouse. Although elevated body temperature (40.5 degrees C) did not result in SAPK/JNK activation in spleen and lung tissues, heat stress induced SAPK/JNK activation in cultured organs or fibroblasts derived from spleen or lung of C57BL/6 mice. Furthermore, activity and amount of SAPK/JNK proteins were the most abundant in brain among tissues examined. Thus, our findings demonstrated that heat shock-induced SAPK/JNK activation in vivo lacks much of the characteristic coordinate control of activation of cultured cell lines, and suggests that the mechanisms controlling SAPK/JNK activation are influenced by physiologic factors that cannot be studied in vitro.	AUSTRIAN ACAD SCI,INST BIOMED AGING RES,A-6020 INNSBRUCK,AUSTRIA	Austrian Academy of Sciences								ABDELHAFIZ HAM, 1992, MOL ENDOCRINOL, V61, P2079; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRESHNEY RI, 1994, ANIMAL CELL CULTURE, P57; GIBBS DM, 1985, BRAIN RES, V335, P360, DOI 10.1016/0006-8993(85)90494-9; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARRIS HW, 1994, J BIOL CHEM, V269, P11993; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; POMO CP, 1994, J BIOL CHEM, V269, P26546; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Xu QB, 1996, LAB INVEST, V74, P178	40	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9113	9119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083039				2022-12-27	WOS:A1997WU03700044
J	Khanna, KK; Yan, J; Watters, D; Hobson, K; Beamish, H; Spring, K; Shiloh, Y; Gatti, RA; Lavin, MF				Khanna, KK; Yan, J; Watters, D; Hobson, K; Beamish, H; Spring, K; Shiloh, Y; Gatti, RA; Lavin, MF			Defective signaling through the B cell antigen receptor in Epstein-Barr virus-transformed ataxia-telangiectasia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; LYMPHOCYTES-B; SACCHAROMYCES-CEREVISIAE; MAMMALIAN PROTEIN; CROSS-LINKING; T-CELLS; GENE	A characteristic series of immunological abnormalities are observed in the human genetic disorder ataxiatelangiectasia (A-T). The recent cloning of a gene mutated in this syndrome provides additional evidence for a defect in intracellular signaling in A-T. We have investigated the possibility that signaling through the B cell antigen receptor is one manifestation of the A-T defect. In response to cross-linking of the B cell receptor, several A-T cell lines were defective in their mitogenic response; in addition Ca2+ mobilization from internal stores was either absent or considerably reduced in these cell lines in response to cross-linking. The defect in signaling was not due to difference in expression of surface immunoglobulin. The defective response in A-T cells was also evident in several arms of the intracellular cascade activated by B cell cross-linking. Tyrosine phosphorylation of phospholipase C gamma 1, a key step in activation of the enzyme, was reduced or negligible in some A-T cell lines. This defect in signaling was also seen at the level of Lyn tyrosine kinase activation and its association with and activation of phosphatidylinositol 3-kinase. Our results provide evidence for a role for the ATM gene product in intracellular signaling which may account at least in part for the abnormalities in B cell function in A-T.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV QUEENSLAND,DEPT SURG,BRISBANE,QLD 4072,AUSTRALIA	Tel Aviv University; Sackler Faculty of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Queensland	Khanna, KK (corresponding author), QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,PO ROYAL BRISBANE HOSP,BRISBANE,QLD 4029,AUSTRALIA.		Watters, Dianne J/E-6007-2010; Hobson, Keith/Q-9306-2019; Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Yan, Jun/F-1224-2010	Watters, Dianne J/0000-0002-2555-5825; Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381; Yan, Jun/0000-0001-9617-0335; Spring, Kevin/0000-0003-0601-924X				AMMANN AJ, 1969, NEW ENGL J MED, V281, P469, DOI 10.1056/NEJM196908282810904; Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHAUDHRI G, 1988, CELL IMMUNOL, V115, P204, DOI 10.1016/0008-8749(88)90174-8; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELMORE E, 1976, J CELL PHYSIOL, V89, P429, DOI 10.1002/jcp.1040890308; EPSTEIN WL, 1966, INT ARCH ALLER A IMM, V30, P15, DOI 10.1159/000229789; FAHEY KA, 1987, J IMMUNOL, V138, P3935; FIDELUS RK, 1988, CELL IMMUNOL, V113, P175, DOI 10.1016/0008-8749(88)90015-9; FISCHER A, 1995, IMMUNOLOGIST, V3, P237; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JEITNER TM, 1994, BBA-MOL CELL RES, V1223, P15, DOI 10.1016/0167-4889(94)90068-X; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONDO N, 1993, EXP CLIN IMMUNOGENET, V10, P16; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER CL, 1993, J VIROL, V67, P3087, DOI 10.1128/JVI.67.6.3087-3094.1993; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NELSON DL, 1980, INSERM S, V16, P141; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; PARTAIN K, 1986, BIOCHEM BIOPH RES CO, V140, P1079, DOI 10.1016/0006-291X(86)90745-X; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PETERSON RD, 1964, LANCET, V1, P1189; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PUCK JM, 1994, HUM MOL GENET, V3, P1457, DOI 10.1093/hmg/3.suppl_1.1457; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHEUERMANN RH, 1995, J EXP MED, V182, P903, DOI 10.1084/jem.182.4.903; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; STROBER W, 1968, J CLIN INVEST, V47, P1905, DOI 10.1172/JCI105881; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Waldmann T., 1982, ATAXIA TELANGIECTASI, P37; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464	59	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9489	9495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083089				2022-12-27	WOS:A1997WU03700094
J	Lacerda, HM; Pullinger, GD; Lax, AJ; Rozengurt, E				Lacerda, HM; Pullinger, GD; Lax, AJ; Rozengurt, E			Cytotoxic necrotizing factor 1 from Escherichia coli and dermonecrotic toxin from Bordetella bronchiseptica induce p21(rho)-dependent tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; PASTEURELLA-MULTOCIDA TOXIN; BINDING PROTEIN-RHO; LYSOPHOSPHATIDIC ACID; GROWTH-FACTOR; MAP-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ADP-RIBOSYLTRANSFERASE; BOMBESIN STIMULATION; MOLECULAR-CLONING	Treatment of Swiss 3T3 cells with cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli and dermonecrotic toxin (DNT) from Bordetella bronchiseptica, which directly target and activate p21(rho), stimulated tyrosine phosphorylation of focal adhesion kinase (p125(fak)) and paxillin. Tyrosine phosphorylation induced by CNF1 and DNT occurred after a pronounced lag period (2 h), and was blocked by either lysosomotrophic agents or incubation at 22 degrees C. CNF1 and DNT stimulated tyrosine phosphorylation of p125(fak) and paxillin, actin stress fiber formation, and focal adhesion assembly with similar kinetics. Cytochalasin D and high concentrations of platelet-derived growth factor disrupted the actin cytoskeleton and completely inhibited CNF1 and DNT induced tyrosine phosphorylation. Microinjection of Clostridium botulinum C3 exoenzyme which ADP-ribosylates and inactivates p21(rho) function, prevented tyrosine phosphorylation of focal adhesion proteins in response to either CNF1 or DNT. In addition, our results demonstrated that CNF1 and DNT do not induce protein kinase C activation, inositol phosphate formation, and Ca2+ mobilization. Moreover, CNF1 and DNT stimulated DNA synthesis without activation of p42(mapk) and p44(mapk) providing additional evidence for a novel p21(rho)-dependent signaling pathway that leads to entry into the S phase of the cell cycle in Swiss 3T3.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT CHEM ENDOCRINOL,LONDON EC1A 7BE,ENGLAND; UMDS,GUYS HOSP,LONDON SE1 9RT,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1990, ADP RIBOSYLATING TOX, P97; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAPRIOLI A, 1984, BIOCHEM BIOPH RES CO, V118, P587, DOI 10.1016/0006-291X(84)91343-3; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHONG LD, 1994, CELL, V79; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HORIGUCHI Y, 1993, INFECT IMMUN, V61, P3611, DOI 10.1128/IAI.61.9.3611-3615.1993; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; HORIGUCHI Y, 1989, MICROB PATHOGENESIS, V6, P361, DOI 10.1016/0882-4010(89)90078-8; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1992, MOL BIOL CELL, V3, P383; Pullinger GD, 1996, INFECT IMMUN, V64, P4163, DOI 10.1128/IAI.64.10.4163-4171.1996; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1995, CANCER SURV, V24, P81; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETH A, 1991, J BIOL CHEM, V266, P23521; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P1; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	72	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9587	9596						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083104				2022-12-27	WOS:A1997WU03700109
J	Lubas, WA; Frank, DW; Krause, M; Hanover, JA				Lubas, WA; Frank, DW; Krause, M; Hanover, JA			O-linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; TERMINAL N-ACETYLGLUCOSAMINE; GLYCOGEN-SYNTHASE; HEXOSAMINE BIOSYNTHESIS; INSULIN-RESISTANCE; GLYCOSYLATION; PHOSPHORYLATION; GLYCOPROTEINS; GLUCOSAMINE; TRANSCRIPTION	O-Linked GlcNAc addition and phosphorylation may compete for sites on nuclear pore proteins and transcription factors. We sequenced O-linked GlcNAc transferase from rabbit blood and identified the homologous Caenorhabditis elegans transferase gene on chromosome III. We then isolated C. elegans and human cDNAs encoding the transferase. The enzymes from the two species appear to be highly conserved; both contain multiple tetratricopeptide repeats and nuclear localization sequences, The C. elegans transferase accumulated in the nucleus and in perinuclear aggregates in overexpressing transgenic lines, O-Linked GlcNAc transferase activity was also elevated in HeLa cells transfected with the human cDNA. At least four human transcripts were observed in the tissues examined ranging in size from 4.4 to 9.3 kilobase pairs, The two largest transcripts (7.9 and 9.3 kilobase pairs) were enriched at least 12-fold in the pancreas, Based on its substrate specificity and molecular features, we propose that O-linked GlcNAc transferase is part of a glucose-responsive pathway previously implicated in the pathogenesis of diabetes mellitus.	NIDDK,LAB CELL BIOCHEM & BIOL,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Krause, Michael/0000-0001-6127-3940				BALKAN B, 1994, DIABETES, V43, P1173, DOI 10.2337/diabetes.43.10.1173; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; DONG DLY, 1996, J BIOL CHEM, V271, P20846; Favello A, 1995, METHOD CELL BIOL, V48, P551; Fisher E.H., 1955, J BIOL CHEM, V216, P121; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOMA FL, 1993, J BIOL CHEM, V268, P12609; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; MACAULAY C, 1995, J BIOL CHEM, V270, P254, DOI 10.1074/jbc.270.1.254; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mello C, 1995, METHOD CELL BIOL, V48, P451; NYAME K, 1987, J BIOL CHEM, V262, P7990; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STARR CM, 1990, J BIOL CHEM, V265, P6868; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	34	397	421	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9316	9324						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083068				2022-12-27	WOS:A1997WU03700073
J	Gerwins, P; Blank, JL; Johnson, GL				Gerwins, P; Blank, JL; Johnson, GL			Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; CDC42 GTPASES; PHOSPHORYLATION; BINDING; STRESS; CASCADE; FAMILY; DOMAIN; RAC	Mitogen-activated protein kinases (MAPKs) are components of sequential kinase cascades that are activated in response to a variety of extracellular signals, Members of the MAPK family include the extracellular response kinases (ERKs or p42/44(MAPK)), the c-Jun aminoterminal kinases (JNKs), and the p38/Hog 1 protein kinases. MAPKs are phosphorylated and activated by MAPK kinases (MKKs or MEKs), which in turn are phosphorylated and activated by MKK/MEK kinases (Raf and MKKK/MEKKs). We have isolated two cDNAs encoding splice variants of a novel MEK kinase, MEKK4. The MEKK4 mRNA is widely expressed in mouse tissues and encodes for a protein of approximately 180 kDa. The MEKK4 carboxyl-terminal catalytic domain is approximately 55% homologous to the catalytic domains of MEKKs 1, 2, and 3. The amino-terminal region of MEKK4 has little sequence homology to the previously cloned MEKK proteins. MEKK4 specifically activates the JNK pathway but not ERKs or p38, distinguishing it from MEKKs 1, 2 and 3, which are capable of activating the ERK pathway. MEKK4 is localized in a perinuclear, vesicular compartment similar to the Gels. MEKK4 binds to Cdc42 and Rac; kinase-inactive mutants of MEKK4 block Cdc42/Rac stimulation of the JNK pathway. MEKK4 has a putative pleckstrin homology domain and a proline-rich motif, suggesting specific regulatory functions different from those of the previously characterized MEKKs.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, PROGRAM MOL SIGNAL TRANSDUCT, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIDDK NIH HHS [DK 38871, DK 48845] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KINGSTON RE, 1992, SHORT PROTOCOLS MOL; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	60	210	216	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8288	8295		10.1074/jbc.272.13.8288	http://dx.doi.org/10.1074/jbc.272.13.8288			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079650	hybrid			2022-12-27	WOS:A1997WQ63500033
J	Yamazawa, T; Takeshima, H; Shimuta, M; Iino, M				Yamazawa, T; Takeshima, H; Shimuta, M; Iino, M			A region of the ryanodine receptor critical for excitation-contraction coupling in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE CHANNEL; SARCOPLASMIC-RETICULUM VESICLES; FUNCTIONAL EXPRESSION; CA-2+ RELEASE; MICE LACKING; CA2+ RELEASE; CDNA	Ca2+ release mediated by the ryanodine receptor (RyR) regulates many important cell functions including excitation-contraction (E-C) coupling in skeletal muscle, by which membrane depolarization controls the opening of RyR via the dihydropyridine receptor. Among the three RyR subtypes, RyR-1 mediates skeletal muscle E-C coupling, whereas RyR-2 and RyR-3 cannot substitute for RyR-1. We carried out expression experiments using cultured mutant skeletal myocytes not having intrinsic intracellular Ca2+ release channels to study the structure-function relationship of amino acid residues 1303-1406 in RyR-1 (D2 region). In this region the amino acid sequences are highly divergent between RyR-1 and RyR-2, and the corresponding sequence is lacking in RyR-3, Expression of RyR-1 but not of RyR-2 rescued E-C coupling in the mutant cells. Deletion of either the entire D2 region or its N-terminal half from RyR-1 preserved the function of RyR-1 as a Ca2+ release channel but resulted in the loss of E-C coupling. Substitution of the D2 region for the corresponding sequence of RyR-2 had no effect on the function of RyR-1. These results indicate that the presence of the D2 region is critical for E-C coupling in skeletal muscle, although the D2 region alone cannot determine the functional difference between RyR-1 and RyR-2.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; JAPAN SCI & TECHNOL CORP,CREST,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Japan Science & Technology Agency (JST)				Takeshima, Hiroshi/0000-0003-4525-3725				ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; ARMSTRONG C, 1972, BIOCHIM BIOPHYS ACTA, V468, P31; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GOEGER DE, 1988, BIOCHEM PHARMACOL, V37, P978, DOI 10.1016/0006-2952(88)90195-5; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; IINO M, 1992, BIOCHEM BIOPH RES CO, V185, P713, DOI 10.1016/0006-291X(92)91684-I; ISHII M, 1994, ENDOCR J, V41, pS9, DOI 10.1507/endocrj.41.Supplement_S9; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SHOSHANBARMATZ V, 1994, J MEMBRANE BIOL, V142, P281; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x	26	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8161	8164		10.1074/jbc.272.13.8161	http://dx.doi.org/10.1074/jbc.272.13.8161			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079632	hybrid			2022-12-27	WOS:A1997WQ63500015
J	Garnovskaya, MN; Gettys, TW; vanBiesen, T; Prpic, V; Chuprun, JK; Raymond, JR				Garnovskaya, MN; Gettys, TW; vanBiesen, T; Prpic, V; Chuprun, JK; Raymond, JR			5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through G(i alpha 2) and G(i alpha 3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA-H EXCHANGE; HAMSTER OVARY CELLS; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; EXTRACELLULAR ACIDIFICATION; IMMORTALIZED LYMPHOBLASTS; FUNCTIONAL EXPRESSION; PARATHYROID-HORMONE; SIGNALING PATHWAY	5-HT1A receptors couple to many signaling pathwaysin CHO-K1 cells through pertussis toxin-sensitive G proteins, The purpose of this study was to determine which members of the G(i/o/z) family mediate 5-HT1A receptor-activated Na+/H+ exchange as measured by microphysiometry of cell monolayers. The method was extensively validated, showing that proton efflux was sodium-dependent, inhibited by amiloride analogs, and activated by growth factors, phorbol ester, calcium ionophore, and hypertonic stress. 5-HT and the specific agonist (+/-)-8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide rapidly stimulated proton efflux that was blocked by a specific receptor antagonist, amiloride analogs or pertussis toxin, The activation by 5-HT depended upon extracellular sodium and could be demonstrated under conditions of imposed intracellular acid load, as well as in the presence and absence of glycolytic substrate, Acceleration of proton efflux was not inhibited by sequestration of G protein beta gamma-subunits, a maneuver that blocked 5-HT1A receptor activation of mitogen-activated protein kinase, Transfection of G(z alpha) and pertussis toxin-resistant mutants of G(o alpha) and G(i alpha 1) did not reverse the blockade induced by pertussis toxin, In contrast, pertussis toxin-resistant mutants of G(i alpha 2) and G(i alpha 3) ''rescued'' the ability of 5-HT to increase proton efflux after pertussis toxin treatment, These experiments demonstrate clearly that G(i alpha 2) and G(i alpha 3) can specifically mediate rapid agonist-induced acceleration of Na+/H+ exchange.	MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT BIOCHEM & MOL BIOL,CHARLESTON,SC 29425; VET AFFAIRS MED CTR,CHARLESTON,SC 29425; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; HOWARD HUGHES MED INST,DURHAM,NC 27710	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Howard Hughes Medical Institute			Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Garnovskaya, Maria/0000-0002-6216-038X	NIDDK NIH HHS [DK42486, DK52448] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486, R56DK052448, R01DK052448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BUSCH S, 1995, J BIOL CHEM, V270, P17898, DOI 10.1074/jbc.270.30.17898; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CANO A, 1994, AM J PHYSIOL, V266, pC1603, DOI 10.1152/ajpcell.1994.266.6.C1603; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHIO CL, 1993, MOL PHARMACOL, V45, P25748; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; GUNTUPALLI J, 1994, AM J PHYSIOL, V266, pF658, DOI 10.1152/ajprenal.1994.266.4.F658; HOU CF, 1994, J BIOL CHEM, V269, P10357; HUNT TW, 1994, J BIOL CHEM, V269, P29565; ISOM LL, 1987, J BIOL CHEM, V262, P17504; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LOWE JHN, 1990, J BIOL CHEM, V265, P7188; MA YH, 1994, J BIOL CHEM, V269, P30734; MANGEL AW, 1993, AM J PHYSIOL, V264, pF490, DOI 10.1152/ajprenal.1993.264.3.F490; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MORRIS SJ, 1994, TRENDS PHARMACOL SCI, V15, P250; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; NEVE KA, 1992, J BIOL CHEM, V267, P25748; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; RAYMOND JR, 1995, AM J PHYSIOL-RENAL, V269, pF141, DOI 10.1152/ajprenal.1995.269.2.F141; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; ROSSKOPF D, 1993, J CLIN INVEST, V92, P2553, DOI 10.1172/JCI116865; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIFFERT W, 1995, J CLIN INVEST, V96, P759, DOI 10.1172/JCI118120; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WANG N, 1990, J BIOL CHEM, V265, P1239	50	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7770	7776		10.1074/jbc.272.12.7770	http://dx.doi.org/10.1074/jbc.272.12.7770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065439	hybrid			2022-12-27	WOS:A1997WP59200033
J	Randazzo, PA				Randazzo, PA			Functional interaction of ADP-ribosylation factor 1 with phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; GOLGI MEMBRANES; PHOSPHATIDIC-ACID; BINDING-PROTEIN; PHOSPHOLIPASE-D; CA2+-ACTIVATED SECRETION; RNA-POLYMERASE; AMINO-TERMINUS; CHOLERA-TOXIN	The relationship between ADP-ribosylation factor (Arf) 1 and phosphoinositides, which have been independently implicated as regulators of membrane traffic, was examined. Because both Arf-dependent phospholipase D and Arf1 GTPase-activating protein (GAP) require phosphatidylinositol 4,5-bisphosphate (PIP2), Arf1 complexed with PIP2 has been proposed to interact with target proteins. This hypothesis was tested using Arf1 GAP as a model system. Arf1 was shown to bind 60 PIP2 in Triton X-100 micelles with a K-d of 45 +/- 13 mu M. Arf1 also bound phosphatidic acid but with 10-fold lower affinity. PIP2 binding was specifically disrupted by mutating lysines 15, 16, and 181 and arginine 178 to leucines, Decreased PIP2 binding resulted in an increased EC(50) of PIP2 for activation of Arf GAP. None of the mutations that decreased PIP2 binding affected binding to or activation of GAP by phosphatidic acid, which acts at a functionally distinct site. These data support the hypothesis that PIP2 binding to Arf1 promotes interaction with Arf GAP. The implications of lipid directed protein protein interactions for membrane traffic are discussed.			Randazzo, PA (corresponding author), NCI,BIOL CHEM LAB,DIV BASIC SCI,NIH,BLDG 37,RM 5D-02,BETHESDA,MD 20892, USA.							AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEKMAN R, 1996, SCIENCE, V271, P1526; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TERUI T, 1994, J BIOL CHEM, V269, P28130; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139	43	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7688	7692						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065426				2022-12-27	WOS:A1997WP59200020
J	Siow, YL; Kalmar, GB; Sanghera, JS; Tai, G; Oh, SS; Pelech, SL				Siow, YL; Kalmar, GB; Sanghera, JS; Tai, G; Oh, SS; Pelech, SL			Identification of two essential phosphorylated threonine residues in the catalytic domain of Mekk1 - Indirect activation by Pak3 and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; TYROSINE KINASE; SKELETAL-MUSCLE; CYCLIC-AMP; MITOGEN; YEAST; JUN; PATHWAYS	The 78-kDa protein kinase Mekk1 plays an important role in the stress response pathway that involves the activation of downstream kinases Sek1 and stress-activated protein kinase/c-Jun NH2-terminal kinase. Conserved serine and threonine residues located between the kinase subdomains VII and VIII of many protein kinases are phosphorylated for maximal kinase activation. Two threonine residues within this region in Mekk1 at positions 560 and 572, but not the serine at 557, were shown to be essential for catalytic activity in this study. When these threonine residues were replaced with alanine, there was a significant loss in phosphotransferase activity toward the primary substrate, Sek1, and a large decrease in autophosphorylation activity. Site-directed mutagenesis demonstrated that these threonine residues cannot be replaced with either serine or glutamic acid for preservation of phosphotransferase activity. Further examination of the Mekk1 mutants isolated from P-32-labeled transfected COS cells showed that Thr-560 and Thr-572 were indeed phosphorylated after two-dimensional tryptic-chymotryptic phosphopeptide analysis. Additional determinants in the NH2-terminal domain of Mekk1 also play a role in the regulation of Mekk1 activity. Although Pak3 and PKC can activate Mekk1 in vivo, this interaction is indirect and independent, since there was no direct phosphorylation of Mekk1 by Pak3 or PKC or of Pak3 by PKC, respectively.	KINETEK PHARMACEUT INC, VANCOUVER, BC V5Z 1A1, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC, CANADA; SIMON FRASER UNIV, INST MOL BIOL & BIOCHEM, BURNABY, BC V5A 1S6, CANADA	University of British Columbia; Simon Fraser University				Siow, Yaw/0000-0001-6623-2881				ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1995, NEUROBIOL AGING, V16, P247, DOI 10.1016/0197-4580(94)00187-6; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	63	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7586	7594		10.1074/jbc.272.12.7586	http://dx.doi.org/10.1074/jbc.272.12.7586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065412	hybrid			2022-12-27	WOS:A1997WP59200006
J	Kingma, PS; Osheroff, N				Kingma, PS; Osheroff, N			Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTINEOPLASTIC DRUGS; ABASIC SITES; DROSOPHILA-MELANOGASTER; BASE-PAIRS; RELIGATION; SEQUENCE; AGENTS; NMR; ENZYMES; MUTAGENICITY	Apurinic sites are position-specific poisons of topoisomerase II and stimulate DNA scission similar to 10-18-fold when they are located within the 4-base overhang generated by enzyme-mediated cleavage (Kingma, P. S., and Osheroff, N. (1997) J. Biol. Chem. 272, 1148-1155). To determine whether other major forms of spontaneous DNA damage also act as topoisomerase II poisons, the effects of position-specific apyrimidinic sites and deaminated cytosines (i.e. uracil:guanine mismatches) on the type II enzyme were determined, Both of these lesions stimulated topoisomerase II-mediated DNA scission with the same positional specificity as apurinic sites but were less efficacious, Moreover, apurinic sites dominated the effects of apyrimidinic sites in substrates that contained multiple lesions, The differential ability of spontaneous lesions to enhance DNA cleavage did not correlate with either a decreased stability of the double helix or the size of the gap formed by base loss, Rather, it appears to be due (at least in part) to increased rates of religation for substrates containing apyrimidinic sites or deaminated cytosines. These results suggest that several forms of spontaneous DNA damage are capable of acting as endogenous poisons of topoisomerase II.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED ONCOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NIGMS NIH HHS [GM33944, GM53960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; Capranico G, 1996, Cancer Chemother Biol Response Modif, V16, P68; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CARBONNAUX C, 1990, NUCLEIC ACIDS RES, V18, P4075, DOI 10.1093/nar/18.14.4075; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHRISTIANS FC, 1995, PREV MED, V24, P329, DOI 10.1006/pmed.1995.1054; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FELIX CA, 1995, CANCER RES, V55, P4287; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FRIEDBERG EC, 1995, DNA REPAIR; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P28018; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GAFFNEY BL, 1989, BIOCHEMISTRY-US, V28, P5881, DOI 10.1021/bi00440a026; Gelfand CA, 1996, BIOPOLYMERS, V38, P439; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; HICKMAN JA, 1992, CANC METASTASIS REV, V11, P12; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LIU L, 1994, DNA TOPOISOMERASES T; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; NETO JBC, 1992, J BIOL CHEM, V267, P19718; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; PURMAL AA, 1994, J BIOL CHEM, V269, P22046; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021/bi00200a007; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SUPER HJG, 1993, BLOOD, V82, P3705; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	57	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7488	7493		10.1074/jbc.272.11.7488	http://dx.doi.org/10.1074/jbc.272.11.7488			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054451	hybrid			2022-12-27	WOS:A1997WN14700090
J	Martins, LM; Kottke, T; Mesner, PW; Basi, GS; Sinha, S; Frigon, N; Tatar, E; Tung, JS; Bryant, K; Takahashi, A; Svingen, PA; Madden, BJ; McCormick, DJ; Earnshaw, WC; Kaufmann, SH				Martins, LM; Kottke, T; Mesner, PW; Basi, GS; Sinha, S; Frigon, N; Tatar, E; Tung, JS; Bryant, K; Takahashi, A; Svingen, PA; Madden, BJ; McCormick, DJ; Earnshaw, WC; Kaufmann, SH			Activation of multiple interleukin-1 beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; (ACYLOXY)METHYL KETONES; CYSTEINE PROTEASES; CANCER-THERAPY; IN-VIVO; DEATH; LEUKEMIA; CLEAVAGE; DNA	Recent genetic and biochemical studies have implicated cysteine-dependent aspartate-directed proteases (caspases) in the active phase of apoptosis. In the present study, three complementary techniques were utilized to follow caspase activation during the course of etoposide-induced apoptosis in HL-60 human leukemia cells. Immunoblotting revealed that levels of procaspase-2 did not change during etoposide-induced apoptosis, whereas levels of procaspase-3 diminished markedly 2-3 h after etoposide addition. At the same time, cytosolic peptidase activities that cleaved DEVD-aminotrifluoromethylcoumarin and VEID-aminomethylcoumarin increased 100- and 20-fold, respectively; but there was only a 1.5-fold increase in YVAD-aminotrifluoromethylcoumarin cleavage activity. Affinity labeling with N-(N-alpha-benzyloxycarbonylglutamyl-N-epsilon-biotinyllysyl)- aspartic acid [(2,6-dimethylbenzoyl)oxy] methyl ketone indicated that multiple active caspase species sequentially appeared in the cytosol during the first 6 h after the addition of etoposide. Analysis on one- and two-dimensional gels revealed that two species comigrated with caspase-6 and three comigrated with active caspase-3 species, suggesting that several splice or modification variants of these enzymes are active during apoptosis. Polypeptides that comigrate with the cytosolic caspases were also labeled in nuclei of apoptotic HL-60 cells. These results not only indicate that etoposide-induced apoptosis in HL-60 cells is accompanied by the selective activation of multiple caspases in cytosol and nuclei, but also suggest that other caspase precursors such as procaspase-2 are present but not activated during apoptosis.	MAYO CLIN & MAYO FDN, DIV ONCOL RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, PROT CORE FACIL, ROCHESTER, MN 55905 USA; ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; UNIV EDINBURGH, INST CELL & MOL BIOL, EDINBURGH EH9 3JR, MIDLOTHIAN, SCOTLAND	Mayo Clinic; Mayo Clinic; University of Edinburgh			Earnshaw, William/AAY-7438-2020	Kaufmann, Scott/0000-0002-4900-7145; Earnshaw, William/0000-0002-7191-0621	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008, CA69008] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1994, J BIOL CHEM, V269, P30828; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CREAVEN PJ, 1984, ETOPOSIDE VP 16 CURR, P103; DELBINO G, 1991, CANCER RES, V51, P1165; Dive C, 1992, Semin Cancer Biol, V3, P417; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELDS AP, 1986, EXP CELL RES, V164, P139, DOI 10.1016/0014-4827(86)90461-1; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kaufmann SH, 1996, MOL MED TODAY, V2, P298, DOI 10.1016/1357-4310(96)10023-X; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; KYPRIANOU N, 1991, CANCER RES, V51, P162; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MARTIN DS, 1994, CANCER INVEST, V12, P296, DOI 10.3109/07357909409023028; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIYASHITA T, 1993, BLOOD, V81, P151; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; ROBINSON VJ, 1992, BIOORG CHEM, V20, P42, DOI 10.1016/0045-2068(92)90024-W; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH GK, 1992, CANCER RES, V52, P4895; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	72	208	213	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7421	7430		10.1074/jbc.272.11.7421	http://dx.doi.org/10.1074/jbc.272.11.7421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054443	hybrid			2022-12-27	WOS:A1997WN14700082
J	Thuerauf, DJ; Glembotski, CC				Thuerauf, DJ; Glembotski, CC			Differential effects of protein kinase C, Ras, and Raf-1 kinase on the induction of the cardiac B-type natriuretic peptide gene through a critical promoter-proximal M-CAT element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADRENERGIC STIMULATION; MYOCARDIAL-CELL HYPERTROPHY; MYOSIN LIGHT CHAIN-2; ENHANCER FACTOR-I; TROPONIN-T-GENE; VENTRICULAR MYOCYTES; TRANSCRIPTION FACTORS; INDUCIBLE EXPRESSION; DEPENDENT PATHWAYS; RESPONSE ELEMENTS	The cardiac genes for the A- and B-type natriuretic peptides (ANP and BNP) are coordinately induced by growth promoters, such as alpha(1)-adrenergie receptor agonists (e.g. phenylephrine (PE)). Although inducible elements in the ANP gene have been identified, responsible elements in the BNP gene are unknown. In this study, reporter constructs transfected into neonatal rat ventricular myocytes showed that in the context of 2.5 kilobase pairs of native BNP 5'-flanking sequences, a a-base pair mutation in a promoter-proximal M-CAT site (CAT-TCT) disrupted basal and PE-inducible transcription by more than 98%. Expression of constitutively active forms of Ras, Raf-1 kinase, and protein kinase C, all of which are activated by PE in cardiac myocytes, strongly stimulated BNP reporter expression. Isolated M-CAT elements conferred EE, protein kinase C, and Ras inducibility to a minimal BNP promoter, however, they did not confer Raf-1 inducibility. These results show that M-CAT elements can serve as targets for Ras-dependent, Raf-1-independent pathways, implying the involvement of c-Jun N-terminal kinase and/or p38 mitogen-activated protein kinases, but not extracellular signal-regulated protein kinase/mitogen-activated protein kinase. Moreover, the essential M-CAT element distinguishes the BNP gene from the ANP gene, which utilizes serum response elements and an Sp1-like sequence.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOL BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; ARECI RJ, 1993, MOL CELL BIOL, V13, P2235; ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; BRUDER JT, 1992, GENE DEV, V6, P5454; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CLERK A, 1994, J BIOL CHEM, V269, P32848; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNMON PM, 1990, J MOL CELL CARDIOL, V22, P901; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Hanford DS, 1996, MOL ENDOCRINOL, V10, P1719, DOI 10.1210/me.10.12.1719; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LAPOINTE MC, 1993, MOL ENDOCRINOL, V7, P1284, DOI 10.1210/me.7.10.1284; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; PARKER TG, P NATL ACAD SWCI US; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; ROSENZWEIG A, 1991, ANN REV BIOCH, V60, P220; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SADOSHIMA J, 1995, CIRC RES, V76, P1; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STEWART AF, 1994, J BIOL CHEM, V2698, P3147; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUZUKI E, 1992, CIRC RES, V71, P1039, DOI 10.1161/01.RES.71.5.1039; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WU DQ, 1992, J BIOL CHEM, V267, P25798; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	72	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7464	7472		10.1074/jbc.272.11.7464	http://dx.doi.org/10.1074/jbc.272.11.7464			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054448	hybrid			2022-12-27	WOS:A1997WN14700087
J	Wallon, UM; Overall, CM				Wallon, UM; Overall, CM			The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding - Binding properties of recombinant gelatinase a C domain to extracellular matrix and basement membrane components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; HUMAN 72-KDA GELATINASE; HUMAN NEUTROPHIL COLLAGENASE; CELL-SURFACE BINDING; MR-ACTIVE FORMS; IV COLLAGENASE; TERMINAL DOMAIN; TISSUE INHIBITOR; SUBSTRATE-SPECIFICITY; CATALYTIC DOMAIN	The binding properties of the COOH-terminal hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2, 72-kDa gelatinase) were investigated to determine whether the C domain has binding affinity for extracellular matrix and basement membrane components. Recombinant C domain (rC domain) (Gly(417)-Cys(631)) was expressed in Escherichia coli, and the purified protein, identified using two antipeptide antibodies, was determined by electrospray mass spectrometry to have a mass of 25,925 Da, within 0.1 Da of that predicted. As assessed by microwell substrate binding assays and by column affinity chromatography, the matrix proteins laminin, denatured type I collagen, elastin, SPARC (secreted protein that is acidic and rich in cysteine), tenascin, and MatrigelTM were not bound by the rC domain. Unlike the hemopexin-like domains of collagenase and stromelysin, the rC domain also did not bind native type I collagen. Nor were native or denatured types II, IV, V, and X collagen, or the NC1 domain of type VII collagen bound. However, binding to heparin and fibronectin (K-d, 1.1 x 10(-6) M) could be disrupted by 0.58-0.76 and 0.3 M NaCl, respectively. Using nonoverlapping chymotrypsin-generated fragments of fibronectin, binding sites for the rC domain were found on both the 40-kDa heparin binding and the 120-kDa cell binding fibronectin domains (K-d values, similar to 4-6 x 10(-7) M). The Ca2+ ion, but not the potential structural Zn2+ ion, were found to be essential for maintaining the binding properties of the protein. The ape-form of the rC domain did not bind heparin, and both ethylenediaminetetraacetic acid and the specific Ca2+ ion chelator 1,2-bis(2-amino-phenoxy) ethane=N,N,N',N'-tetraacetic acid, but not the Zn2+ ion chelator 1,10-phenanthroline, eluted the hole form of the rC domain from both heparin-Sepharose and fibronectin. Inductive coupled plasma mass spectrometry also did not detect a Zn2+ ion in the rC domain. In contrast, reduction with 65 mhn dithiothreitol did not interfere with heparin binding, further emphasizing the crucial structural role played by the Ca2+ ion. Together, these data demonstrate for the first time that the hemopexin-like domain of gelatinase A has a binding site for fibronectin and heparin, and that Ca2+ ions are important in maintaining the structure and function of the domain.	UNIV BRITISH COLUMBIA, FAC DENT, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia; University of British Columbia								ALLAN JA, 1991, J CELL SCI, V99, P789; ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; AZZAM HS, 1992, CANCER RES, V52, P4540; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BIGG HF, 1994, BBA-PROTEIN STRUCT M, V1208, P157, DOI 10.1016/0167-4838(94)90173-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; EMONARD HP, 1992, CANCER RES, V52, P5845; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HASTY KA, 1987, J BIOL CHEM, V262, P10048; Hewitt RE, 1996, TRENDS GLYCOSCI GLYC, V8, P23, DOI 10.4052/tigg.8.23; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; LUCK DN, 1992, PROTEIN ENG, V5, P559, DOI 10.1093/protein/5.6.559; MANALAN AS, 1984, J BIOL CHEM, V259, P2047; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OVERALL CM, 1994, ANN NY ACAD SCI, V732, P51, DOI 10.1111/j.1749-6632.1994.tb24724.x; OVERALL CM, 1988, BIOCHEM J, V256, P965, DOI 10.1042/bj2560965; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; OVERALL CM, 1991, TRENDS GLYCOSCI GLYC, V3, P384; OVERALL CM, 1997, IN PRESS TISSUE INHI; Piez KA, 1967, TREATISE COLLAGEN, P207; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU M, 1995, CANCER RES, V55, P3272; ZILTENER HJ, 1987, J IMMUNOL, V138, P1099	65	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7473	7481		10.1074/jbc.272.11.7473	http://dx.doi.org/10.1074/jbc.272.11.7473			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054449	hybrid			2022-12-27	WOS:A1997WN14700088
J	Palaty, CK; Kalmar, G; Tai, G; Oh, S; Amankawa, L; Affolter, M; Aebersold, R; Pelech, SL				Palaty, CK; Kalmar, G; Tai, G; Oh, S; Amankawa, L; Affolter, M; Aebersold, R; Pelech, SL			Identification of the autophosphorylation sites of the Xenopus laevis pim-1 proto-oncogene-encoded protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; COLONY-STIMULATING FACTOR; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; BONE-MARROW; EXPRESSION; LEUKEMIA; RECEPTOR	Pim-1 is an oncogene-encoded serine/threonine kinase expressed primarily in cells of the hematopoietic and germ line lineages. Previously identified only in mammals, pim-1 cDNA was cloned and sequenced from the African clawed frog Xenopus laevis. The coding region of Xenopus pim-1 encoded a protein of 324 residues, which exhibited 64% amino acid identity with the full-length human cognate, Xenopus Pim-1 was expressed in bacteria as a glutathione S-transferase (GST) fusion protein and in COS cells. Phosphoamino acid analysis revealed that recombinant Pim-1 autophosphorylated on serine and threonine and to a more limited extent on tyrosine. Electrospray ionization mass spectroscopy was undertaken to locate these phosphorylation sites, and the primary autophosphorylation site of GST-Pim-1 was identified as Ser-190 with Thr-205 and Ser-4 being minor sites. Ser-190, which immediately follows the high conserved Asp-Phe-Gly motif in catalytic subdomain VII, is also featured in more than 20 other protein kinases. To evaluate the importance of the Ser-190 site on the phosphotransferase activity of Pim-1, Ser-190 was mutated to either alanine or glutamic acid, and the constructs were expressed in bacteria as GST fusion proteins and in COS cells, These mutants confirmed that Ser-190 is a major autophosphorylation site of Pim-1 and indicated that phosphorylation of Pim-1 on the Ser-190 residue may serve to activate this kinase.	KINETEK PHARMACEUT INC,VANCOUVER,BC V5Z 1A1,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA; SIMON FRASER UNIV,INST MOL BIOL & BIOCHEM,BURNABY,BC V5A 1S6,CANADA; UNIV WASHINGTON,DEPT BIOTECHNOL,SEATTLE,WA 98105	University of British Columbia; Simon Fraser University; University of Washington; University of Washington Seattle				Affolter, Michael/0000-0003-1568-4516				AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BAYLIS SA, 1993, J VIROL, V67, P4549, DOI 10.1128/JVI.67.8.4549-4556.1993; BELLE R, 1986, CELL DIFFER DEV, V19, P253, DOI 10.1016/0045-6039(86)90102-8; BERNS A, 1988, ONCOGENE HDB, P121; BIANCHI MW, 1994, MOL GEN GENET, V242, P337, DOI 10.1007/BF00280424; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CUYPERS HT, 1984, CELL, V37, P141; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DOMEN J, 1987, ONCOGENE RES, V1, P103; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KINOSHITA T, 1995, EMBO J, V14, P2266; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LILLY M, 1992, ONCOGENE, V7, P727; Maniatis T., 1982, MOL CLONING; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MEEKER TC, 1987, J CELL BIOCHEM, V35, P105, DOI 10.1002/jcb.240350204; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PADMA R, 1991, CANCER RES, V51, P2486; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; Pelech S L, 1995, Prog Cell Cycle Res, V1, P33; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Saito Y, 1992, GROWTH FACTORS, V7, P297, DOI 10.3109/08977199209046412; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; VERON M, 1994, CELL MOL BIOL, V40, P587; VONLINDERN M, 1989, ONCOGENE, V4, P75; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; WINGETT D, 1991, J IMMUNOL, V147, P3653; WINGETT D, 1995, J CELL BIOCH S, V19, P1; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YIPSCHNEIDER MT, 1995, BLOOD, V12, P3494; YUSHERMAN M, 1992, EMBO J, V11, P71; ZAKUTHOURI R, 1987, GENE, V54, P105, DOI 10.1016/0378-1119(87)90352-0; ZHANG SC, 1992, J EXP ZOOL, V262, P317, DOI 10.1002/jez.1402620312	59	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10514	10521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099695				2022-12-27	WOS:A1997WV26200029
J	Baltensperger, H; Porzig, H				Baltensperger, H; Porzig, H			The P-2U purinoceptor obligatorily engages the heterotrimeric G protein G(16) to mobilize intracellular Ca2+ in human erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C BETA; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; GAMMA-SUBUNITS; NUCLEOTIDE RECEPTOR; FUNCTIONAL-ANALYSIS; BINDING PROTEINS; EXPRESSION; DIFFERENTIATION	To assess the role of G(16), a trimeric G protein exclusively expressed in hematopoietic cells, G(alpha 16) antisense RNA was stably expressed in human erythroleukemia (HEL) cells, Western blot analysis showed that in transfected cell lines, the expression of endogenous G(alpha 16) protein was suppressed, but the expression of G(alpha q/11), G(alpha i2), and G(alpha i3) remained unaffected, Suppression of G(alpha 16) in transfected HEL cells did not interfere with transient elevations of intracellular free Ca2+ concentrations induced by prostaglandin E(1) (PGE(1)), platelet-activating factor, or thrombin, In parental HEL cells, UTP and ATP mobilized Ca2+ from intracellular stores with half-maximum effective concentrations of 3.6 +/- 0.7 and 4.7 +/- 1.6 mu M, respectively, apparently by stimulating P-2U purinoceptors. By contrast, Ca2+ mobilization by UTP or ATP was completely abrogated in G(alpha 16)-suppressed cells, indicating specific coupling of G(16) to P-2U purinoceptors. Pertussis toxin inhibited the effect of UTP in parental HEL cells by 57.6 +/- 4.9%. These data indicate that signaling by the P-2U purinoceptor obligatorily requires G(16) but may be modulated further by activation of G(i). Priming of HEL cells with UTP or ATP prior to stimulation with PGE(1) markedly enhanced the PGE(1)-induced intracellular Ca2+ release. This indirect, potentiating effect of UTP and ATP was not impaired in G(alpha 16)-suppressed cells but was inhibited by pertussis toxin, indicating that functional P-2U purinoceptors are present on these cells and that the potentiating effect primarily depends on G(i). The data demonstrate (i) that G(alpha 16) antisense RNA selectively inhibits endogenous G(alpha 16) protein expression in HEL cells; (ii) that stimulation of endogenous P-2U (P2Y(2)) purinoceptors leads to the mobilization of intracellular Ca2+ by a mechanism that strictly depends on G(alpha 16); and (iii) that P-2U purinoceptors in HEL cells can communicate with two distinct signaling pathways diverging at the G protein level.			Baltensperger, H (corresponding author), UNIV BERN,INST PHARMAKOL,FRIEDBUHLSTR 49,CH-3010 BERN,SWITZERLAND.							Ali H, 1996, J BIOL CHEM, V271, P3200, DOI 10.1074/jbc.271.6.3200; AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Burg M, 1995, FEBS LETT, V377, P426, DOI 10.1016/0014-5793(95)01379-2; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN J, 1995, BIOCHEM SOC T, V23, P129, DOI 10.1042/bst0230129; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DEMAZANCOURT P, 1994, BIOCHEM J, V303, P369, DOI 10.1042/bj3030369; DenisHenriot D, 1996, BIOCHEM BIOPH RES CO, V220, P443, DOI 10.1006/bbrc.1996.0392; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; ERLINGE D, 1995, EUR J PHARM-MOLEC PH, V289, P135, DOI 10.1016/0922-4106(95)90178-7; FEOKTISTOV I, 1994, MOL PHARMACOL, V45, P1160; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HANSEN CA, 1990, METHOD ENZYMOL, V191, P691; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERMOUET S, 1993, FEBS LETT, V327, P183, DOI 10.1016/0014-5793(93)80166-R; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KESSELRING F, 1994, BLOOD, V84, P4088, DOI 10.1182/blood.V84.12.4088.bloodjournal84124088; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; LEE CH, 1992, J BIOL CHEM, V267, P16044; MalamSouley R, 1996, J CELL PHYSIOL, V166, P57, DOI 10.1002/(SICI)1097-4652(199601)166:1<57::AID-JCP7>3.0.CO;2-F; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; NAGATA K, 1995, LIFE SCI, V57, P1675, DOI 10.1016/0024-3205(95)02147-B; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Porzig H, 1995, N-S ARCH PHARMACOL, V353, P21; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PURKISS JR, 1994, BRIT J PHARMACOL, V111, P723, DOI 10.1111/j.1476-5381.1994.tb14797.x; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIPMA H, 1994, EUR J PHARM-MOLEC PH, V268, P431, DOI 10.1016/0922-4106(94)90069-8; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Voisin T, 1996, J BIOL CHEM, V271, P574, DOI 10.1074/jbc.271.1.574; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATSON S, 1996, RECEPTOR ION CHANNEL, P58; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	60	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10151	10159						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092561				2022-12-27	WOS:A1997WU03900080
J	Beggah, AT; Jaunin, P; Geering, K				Beggah, AT; Jaunin, P; Geering, K			Role of glycosylation and disulfide bond formation in the beta subunit in the folding and functional expression of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; ALPHA-SUBUNIT; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; AMINO-ACIDS; K+; MATURATION; REDUCTION	Initial folding is a prerequisite for subunit assembly in oligomeric proteins, In this study, we have compared the role of co-translational modifications in the acquisition of an assembly competent conformation of the beta subunit, the assembly of which is required for the structural and functional maturation of the catalytic Na,K-ATPase alpha subunit. Cysteine or asparagine residues implicated in disulfide bond formation or N-glycosylation, respectively, in the Xenopus beta 1 subunit were eliminated by site-directed mutagenesis, and the assembly efficiency of the mutants and the functional expression of Na+,K+ pumps were studied after expression in Xenopus oocytes, Our results show that lack of each one of the two most C-terminal disulfide bonds indeed permits short term but completely abolishes long term assembly of the beta subunit, On the other hand, lack of the most N-terminal disulfide bonds allows the expression of a small number of functional Na+,K+ pumps at the cell surface, Elimination of all three but not of one or two glycosylation sites produces beta subunits that remain stably expressed in the endoplasmic reticulum, in association with binding protein but not as irreversible aggregates, The assembly efficiency of nonglycosylated beta subunits is decreased but a reduced number of functional Na+,K+ pumps is expressed at the cell surface, The lack of sugars does nob influence the apparent K+ or ouabain affinity of the Na+,K+ pumps. Thus, these data show that disulfide bond formation and N-glycosylation may play important but qualitatively distinct roles in the initial folding of oligomeric protein subunits, Moreover, the results suggest that an endoplasmic reticulum degradation pathway exists, which is glycosylation-dependent.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne								ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; CHOW DC, 1992, AM J PHYSIOL, V263, pC39; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FERRY F, 1989, AM J PHYSIOL, V256, pF1034; Gahmberg CG, 1996, TRENDS BIOCHEM SCI, V21, P308, DOI 10.1016/0968-0004(96)10034-7; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1996, MEMBRANE ASSEMBLY MO, P173; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JAENICKE R, 1995, PHILOS T ROY SOC B, V348, P97, DOI 10.1098/rstb.1995.0050; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMALZING G, 1989, BIOCHEM J, V260, P395, DOI 10.1042/bj2600395; SUN Y, 1994, BBA-PROTEIN STRUCT M, V1207, P236, DOI 10.1016/0167-4838(94)00074-3; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; ZAMOFING D, 1989, AM J PHYSIOL, V256, pC958, DOI 10.1152/ajpcell.1989.256.5.C958; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	42	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10318	10326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092584				2022-12-27	WOS:A1997WU03900103
J	Chen, HW; Ruan, B; Yu, M; Wang, JD; Julin, DA				Chen, HW; Ruan, B; Yu, M; Wang, JD; Julin, DA			The RecD subunit of the RecBCD enzyme from Escherichia coli is a single-stranded DNA-dependent ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CONSENSUS SEQUENCE; RECOMBINATION HOTSPOT-CHI; SITE-DIRECTED MUTAGENESIS; CONSERVED LYSINE RESIDUE; HOMOLOGOUS RECOMBINATION; HELICASE ACTIVITY; NUCLEASE ACTIVITY; EXONUCLEASE-V; HYDROLYSIS; DEOXYRIBONUCLEASE	We have expressed the RecD subunit of the RecBCD enzyme from Escherichia coli as a fusion protein with a 31-amino acid NH2-terminal extension including 6 consecutive histidine residues (HisRecD). The overexpressed fusion protein can be purified in urea-denatured form by metal chelate affinity chromatography. The mixture of renatured HisRecD protein and the RecB and RecC proteins has a high level of ATP-dependent nuclease activity with either single- or double-stranded DNA, enhanced DNA unwinding activity, enhanced ATP hydrolysis activity in the presence of a small DNA oligomer cosubstrate, and chi-cutting activity. These are all characteristics of the RecBCD holoenzyme. The HisRecD protein by itself hydrolyzes ATP in the presence of high concentrations of single-stranded DNA (polydeoxythymidine). The activity is unstable at 37 degrees C, but is measurable at room temperature (about 23 degrees C). The HisRecD has very little ATPase activity in the presence of a much shorter single-stranded DNA (oligodeoxy(thymidine)(12)). HisRecD hydrolyzes ATP more efficiently than GTP and UTP, and has very little activity with GTP. We also purified a fusion protein containing a Lys to Gln mutation in the putative ATP-binding site of RecD. This mutant protein has no ATPase activity, indicating that the observed ATP hydrolysis activity is intrinsic to the RecD protein itself.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742; UNIV MARYLAND,PROGRAM MOL & CELL BIOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park			Chen, Hua-Wei/A-8018-2011		NIGMS NIH HHS [GM39777] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039777, R01GM039777] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BARBOUR SD, 1970, P NATL ACAD SCI USA, V65, P955, DOI 10.1073/pnas.65.4.955; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; Chamberlin M, 1996, BIOCHEMISTRY-US, V35, P15949, DOI 10.1021/bi961643n; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; GOLDMARK PJ, 1970, P NATL ACAD SCI USA, V67, P434, DOI 10.1073/pnas.67.1.434; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; KOPPEN A, 1995, P NATL ACAD SCI USA, V92, P6249, DOI 10.1073/pnas.92.14.6249; KORANGY F, 1992, J BIOL CHEM, V267, P3088; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; KORANGY F, 1992, J BIOL CHEM, V267, P1733; KORANGY F, 1992, J BIOL CHEM, V267, P1727; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MACKAY V, 1974, J BIOL CHEM, V249, P4286; Maniatis T., 1982, MOL CLONING; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MUSKAVITCH KMT, 1982, J BIOL CHEM, V257, P2641; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; MYERS RS, 1994, ANNU REV GENET, V28, P49, DOI 10.1146/annurev.ge.28.120194.000405; OISHI M, 1969, P NATL ACAD SCI USA, V64, P1292, DOI 10.1073/pnas.64.4.1292; PALAS KM, 1990, J BIOL CHEM, V265, P3447; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; SMITH GR, 1995, PHILOS T ROY SOC B, V347, P13, DOI 10.1098/rstb.1995.0003; SMITH GR, 1994, EXPERIENTIA, V50, P234, DOI 10.1007/BF01924006; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TAYLOR AF, 1995, J BIOL CHEM, V270, P24459, DOI 10.1074/jbc.270.41.24459; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; WRIGHT M, 1971, J BIOL CHEM, V246, P6543; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099	47	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10072	10079						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092551				2022-12-27	WOS:A1997WU03900070
J	Peterson, SR; Stackhouse, M; Waltman, MJ; Chen, FQ; Sato, K; Chen, DJ				Peterson, SR; Stackhouse, M; Waltman, MJ; Chen, FQ; Sato, K; Chen, DJ			Characterization of two DNA double-stranded break repair-deficient cell lines that express inactive DNA-dependent protein kinase catalytic subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-SENSITIVE MUTANT; RNA POLYMERASE-II; V(D)J RECOMBINATION; IONIZING-RADIATION; KU-AUTOANTIGEN; SCID MUTATION; END-BINDING; CHO CELLS; MOUSE; GENE	The DNA-dependent protein kinase (DNA PK) is a trimeric enzyme consisting of a 460-kDa catalytic subunit (DNA-PKcs) and a heterodimeric regulatory complex called Ku, which is comprised of 70 (Ku70) and 86 (Ku80) kDa subunits. Mutations that affect the expression of the catalytic or Ku80 subunits of DNA-PK disrupt both V(D)J recombination and DNA double-stranded break repair pathways. In this report, we show that two previously uncharacterized rodent cell lines that are defective in DNA double-stranded break repair express catalytically inactive DNA-PK. The DNA-PKcs from the DNA double-stranded break repair mutant cell limes IRS-20 and SX-9 assembles on double stranded DNA but fails to function as a protein kinase. In addition to the kinase defect, the abundance of the DNA-PKcs from both of these cell lines is reduced relative to wild-type controls. These results suggest that the DNA-PKcs gene from each of these cell lines contains mutations that inactivate the enzymatic activity and the expression or stability of the gene product. These data further strengthen the hypothesis that DNA-PK-mediated protein phosphorylation is a necessary component of the DNA double-stranded break repair pathway.	UNIV ALABAMA,DIV RADIAT BIOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35233; NATL INST RADIOL SCI,DIV RADIOBIOL & BIODOSIMETRY,CHIBA 263,JAPAN	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes for Quantum Science & Technology	Peterson, SR (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,MS M-888,LOS ALAMOS,NM 87545, USA.				NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA50519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CHEN F, 1995, MUTAT RES, V362, P9; DAHMDAPHI J, 1993, INT J RADIAT BIOL, V64, P19, DOI 10.1080/09553009314551071; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SATO K, 1995, J RADIAT RES, V36, P38, DOI 10.1269/jrr.36.38; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; STACKHOUSE MA, 1993, RADIAT RES, V136, P250, DOI 10.2307/3578618; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WARTERS RL, 1995, MUTAT RES-DNA REPAIR, V336, P1, DOI 10.1016/0921-8777(94)00036-6; WARTERS RL, 1993, MUTAT RES, V293, P91, DOI 10.1016/0921-8777(93)90061-K	36	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10227	10231						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092571				2022-12-27	WOS:A1997WU03900090
J	Thornton, DJ; Howard, M; Khan, N; Sheehan, JK				Thornton, DJ; Howard, M; Khan, N; Sheehan, JK			Identification of two glycoforms of the MUC5B mucin in human respiratory mucus - Evidence for a cysteine-rich sequence repeated within the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEOBRONCHIAL MUCINS; ELECTRON-MICROSCOPY; HUMAN BRONCHUS; GLYCOPROTEINS; CDNA; CLONING; PROTEIN; ANTIBODIES; FRAGMENTS; DOMAINS	It has been demonstrated previously that respiratory secretions contain three oligomeric, gel-forming mucins; one of these was identified as the product of the MUC5AC gene (1), Here we demonstrate that the other two mucins are glycoforms of the MUC5B gene product. This was accomplished by trypsin treatment of the purified reduced mucin subunit populations and N-terminal sequencing of the liberated peptides, The products of trypsin digestion were separated by gel filtration into high molecular weight mucin glycopeptides and low molecular weight tryptic peptides. The latter were fractionated by reverse phase chromatography, and four of the major peptides were sequenced. Three of these peptides were identical to and contiguous within a 51-amino acid sequence deduced from a cDNA clone (JER57) encoding a portion of the MUC5B mucin. The other peptide is also present within this sequence but showed identity in only 9 of its 10 residues. A polyclonal antiserum raised against one of these peptides was reactive with the two putative MUC5B glycoforms. Analysis of the high molecular weight glycopeptides indicated that the MUC5B subunit contained different types and lengths of glycosylated domains; one domain of M(r)7.3 x 10(5), two domains of M(r) 5.2 x 10(5), and a third domain of M(r) 2.0 x 10(5). The amino acid composition of the larger two glycopeptides was similar in serine, threonine, and proline content but distinct from that of the smallest glycopeptide, Each of these domains in the mucin subunit is separated by a trypsin-sensitive region, and the relative abundance of the major peptides derived by proteolysis of these regions and their occurrence in a contiguous sequence suggest that they contain a common cysteine-rich motif.			Thornton, DJ (corresponding author), UNIV MANCHESTER,WELLCOME TRUST CTR CELL MATRIX RES,2205 STOPFORD BLDG,MANCHESTER M13 9PT,LANCS,ENGLAND.			Thornton, David/0000-0001-7148-1970	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BIESBROCK AR, 1995, GLYCOCONJ J, V12, P599; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; DOHRMAN A, 1994, EXP LUNG RES, V20, P367, DOI 10.3109/01902149409064393; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUPTA R, 1992, J BIOL CHEM, V267, P3160; GUPTA R, 1990, BIOPOLYMERS, V29, P347, DOI 10.1002/bip.360290207; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; HOVENBERG HW, 1996, GLYCOCONJUGATE J, V13, P1; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; ROSE MC, 1989, J BIOL CHEM, V264, P8193; ROSE MC, 1984, BIOCHEM J, V222, P209; SHANKAR V, 1994, BIOCHEM J, V300, P295, DOI 10.1042/bj3000295; Sheehan JK, 1996, BIOCHEM J, V315, P1055, DOI 10.1042/bj3151055; SHEEHAN JK, 1991, BIOCHEM J, V274, P293, DOI 10.1042/bj2740293; SHEEHAN JK, 1995, AM J RESP CELL MOL, V13, P748, DOI 10.1165/ajrcmb.13.6.7576713; SHEEHAN JK, 1990, BIOCHEM J, V265, P169, DOI 10.1042/bj2650169; THORNTON DJ, 1994, AM J RESP CRIT CARE, V150, P823, DOI 10.1164/ajrccm.150.3.8087358; Thornton DJ, 1996, BIOCHEM J, V316, P967, DOI 10.1042/bj3160967; THORNTON DJ, 1991, BIOCHEM J, V276, P667, DOI 10.1042/bj2760667; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; TYTGAT KMAJ, 1994, GASTROENTEROLOGY, V107, P1352, DOI 10.1016/0016-5085(94)90537-1; ZIMM BH, 1948, J CHEM PHYS, V16, P1009	29	145	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9561	9566						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083100				2022-12-27	WOS:A1997WU03700105
J	Tien, M; Ma, D				Tien, M; Ma, D			Oxidation of 4-methoxymandelic acid by lignin peroxidase - Mediation by veratryl alcohol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; 3,4-DIMETHOXYBENZYL ALCOHOL; HYDROGEN-PEROXIDE; DEGRADING ENZYME; BIODEGRADATION; DEGRADATION; DECOMPOSITION; INVOLVEMENT; MECHANISM; CATALYSIS	The mechanism of veratryl alcohol-mediated oxidation of 4-methoxymandelic acid by lignin peroxidase was studied by kinetic methods. For monomethoxylated substrates not directly oxidized by lignin peroxidase, veratryl alcohol has been proposed to act as a redox mediator. Our previous study showed that stimulation of anisyl alcohol oxidation by veratryl alcohol was not due to mediation but rather due to the requirement of veratryl alcohol to complete the catalytic cycle. Anisyl alcohol can react with compound I but not with compound II. In contrast, veratryl alcohol readily reduces compound II. We demonstrate in the present report that the oxidation of 4-methoxy mandelic acid is mediated by veratryl alcohol. Increasing veratryl alcohol concentration in the presence of 2 mM 4-methoxymandelic acid resulted in increased oxidation of 4-methoxymandelic acid yielding anisaldehyde. This is in contrast to results obtained with anisyl alcohol where increased concentrations of veratryl alcohol caused a decrease in product formation. ESR spectroscopy demonstrated that 4-methhoxymandelic acid caused a decrease in the enzyme-bound veratryl alcohol cation radical signal, which is consistent with its reaction at the active site of the enzyme.	PENN STATE UNIV,CTR BIOMOL STRUCT & FUNCT,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Tien, M (corresponding author), PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802, USA.							BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CANDEIAS LP, 1995, J BIOL CHEM, V270, P16745, DOI 10.1074/jbc.270.28.16745; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; FORNEY LJ, 1982, J BIOL CHEM, V257, P1455; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; GOODWIN DC, 1995, BIOCHEMISTRY-US, V34, P5060, DOI 10.1021/bi00015a017; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1985, J BIOL CHEM, V260, P8348; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; Khindaria A, 1996, BIOCHEMISTRY-US, V35, P6418, DOI 10.1021/bi9601666; KHINDARIA A, 1995, BIOCHEMISTRY-US, V34, P6020, DOI 10.1021/bi00018a003; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KODURI RS, 1995, J BIOL CHEM, V270, P22254, DOI 10.1074/jbc.270.38.22254; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, P NATL ACAD SCI USA, V90, P1242, DOI 10.1073/pnas.90.4.1242; KUAN IC, 1993, J BIOL CHEM, V268, P1; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; Morrisett J.D., 1976, SPIN LABELLING THEOR, P274; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SCHMIDT HWH, 1989, BIOCHEMISTRY-US, V28, P1776, DOI 10.1021/bi00430a053; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1990, APPL ENVIRON MICROB, V56, P2540, DOI 10.1128/AEM.56.8.2540-2544.1990; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; TONON F, 1988, APPL ENVIRON MICROB, V54, P466, DOI 10.1128/AEM.54.2.466-472.1988; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X	29	41	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8912	8917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083011				2022-12-27	WOS:A1997WU03700016
J	Brand, SR; Kobayashi, R; Mathews, MB				Brand, SR; Kobayashi, R; Mathews, MB			The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; RESPONSIVE REGION RNA; LONG TERMINAL REPEAT; ADENOVIRUS VA RNAI; NF-KAPPA-B; BINDING PROTEIN; CELLULAR PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL ELONGATION; MEDIATED TRANSACTIVATION	We demonstrate that the interferon-induced, double-stranded (ds) RNA-activated kinase, PKR, is able to bind to and phosphorylate the human immunodeficiency virus type 1 (HIV-1) trans-activating protein, Tat. Furthermore, Tat can inhibit the activation and activity of the kinase, Phosphorylation of Tat by PKR is dependent on the prior activation of PKR by dsRNA and occurs on serine and threonine residues adjacent to the basic region important for TAR RNA binding and Tat function, Activated PKR efficiently phosphorylates both the two-exon form of Tat (Tat-86) and the single exon form (Tat-72). Mutagenesis indicates that the interaction between PKR and Tat requires the RNA-binding region of Tat, Tat competes with eukaryotic initiation factor 2, a well-characterized substrate of PKR, for phosphorylation by activated PKR. Tat also inhibits the autophosphorylation of PKR by dsRNA, This biochemical evidence of an intimate relationship between Tat, an important regulator of HIV transcription, and PKR, a pleiotropic cellular regulator, may provide insights into HIV-1 pathogenesis and, more generally, virus/host interactions.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11742	Cold Spring Harbor Laboratory					NCI NIH HHS [CA-13106] Funding Source: Medline; NIAID NIH HHS [AI-31802, AI-34552] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031802, R01AI034552] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; COOPER JA, 1983, METHOD ENZYMOL, V99, P368; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; CRANFIELD RE, 1963, J BIOL CHEM, V238, P269; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; DOPPLER C, 1992, AIDS RES HUM RETROV, V8, P245, DOI 10.1089/aid.1992.8.245; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUNNERY S, 1992, P NATL ACAD SCI USA, V89, P11557, DOI 10.1073/pnas.89.23.11557; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAN XM, 1992, J VIROL, V66, P4065, DOI 10.1128/JVI.66.7.4065-4072.1992; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1993, J INTERFERON RES, V13, P153, DOI 10.1089/jir.1993.13.153; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIM YS, 1993, J VIROL, V67, P3739, DOI 10.1128/JVI.67.7.3739-3747.1993; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCCORMACK SJ, 1995, VIROLOGY, V206, P511, DOI 10.1016/S0042-6822(95)80067-0; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; PROUD CG, 1986, TRENDS BIOCHEM SCI, V11, P73, DOI 10.1016/0968-0004(86)90269-0; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; RUBEN S, 1989, J VIROL, V63, P1; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; SHIRAZI Y, 1994, J INTERFERON RES, V14, P259, DOI 10.1089/jir.1994.14.259; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848	75	130	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8388	8395		10.1074/jbc.272.13.8388	http://dx.doi.org/10.1074/jbc.272.13.8388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079663	hybrid			2022-12-27	WOS:A1997WQ63500046
J	Gleissner, M; Kaiser, U; Antonopoulos, E; Schafer, G				Gleissner, M; Kaiser, U; Antonopoulos, E; Schafer, G			The archaeal SoxABCD complex is a proton pump in Sulfolobus acidocaldarius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ARCHAEBACTERIAL TERMINAL OXIDASE; ELECTRON-PARAMAGNETIC RESONANCE; MAGNETIC CIRCULAR-DICHROISM; BO UBIQUINOL OXIDASE; ESCHERICHIA-COLI; QUINOL OXIDASE; REDOX PROTEINS; SUBUNIT-I; BINUCLEAR CENTER	The thermoacidophilic archaeon Sulfolobus acidocaldarius expresses a very unusual quinol oxidase, which contains four heme a redox centers and one copper atom. The enzyme was solubilized with dodecyl maltoside and purified to. homogeneity by a combination of hydrophobic interaction and anion exchange chromatography. The oxidase complex consists of four polypeptide subunits with apparent molecular masses of 64, 39, 27, and 14 kDa that are encoded by the soxABCD operon (Lubben, M., Kolmerer, B., and Saraste, M. (1992) EMBO J. 11, 805-812). The optical spectra and redox potentials of the SoxABCD complex have been characterized, and the absorption coefficients of the contributing cytochromes a(587) and aa(3) were determined. The EPR spectra indicate the presence of three low spin and one high spin heme species, the latter associated with the binuclear heme Cu-B site. Standard midpoint potentials of the cytochrome a(587) heme centers were determined as +210 and +270 mV, respectively. The maximum turnover of the complex (1300 s(-1) at 65 degrees C) was found to be about three times greater than that of the previously studied isolated cytochrome aa(3) subunit alone (Gleissner, M., Elferink, M. G., Driessen, A J., Konings, W. N., Anemuller, S., and Schafer, G. (1994) Eur. J. Biochem 224, 983-990). With N,N,N',N'-tetramethyl-1,4-phenylenediamine as a reductant, the SoxABCD complex reconstituted into liposomes generates a proton motive force. A new method is described by co-reconstitution of SoxABCD with a Sulfolobus Rieske FeS-protein (Sort), allowing energization by cytochrome c. It is based on the finding that this Rieske protein can equilibrate electrons between cytochrome c and quinones reversibly (Schmidt, C. L., Anemuller, S., Teixeira, M., and Schafer, G. (1995) FEBS Lett. 359, 239-243). With this system, generating no scalar protons, the stoichiometry of proton translocation could be determined. A net H+/e(-) ratio >1 was determined, identifying the SoxABCD complex as a proton-pumping quinol oxidase. According to structural analysis, the cytochrome aa, moiety of the complex does not contain the signature of a H+ pumping channel as identified in Rhodobacter sphaeroides or Paracoccus denitrificans. Therefore, for H+ translocation, a mechanism different from that in typical heme-copper oxidases of the aa(3) or bo(3) type is discussed.	UNIV LUBECK, INST BIOCHEM, D-23538 LUBECK, GERMANY; UNIV ERLANGEN NURNBERG, INST THEORET & PHYS CHEM, D-91058 ERLANGEN, GERMANY; UNIV FRANKFURT KLINIKUM, GUSTAV EMBDEN ZENTRUM BIOL CHEM, LAB MIKROBIOL CHEM, D-60590 FRANKFURT, GERMANY	University of Lubeck; University of Erlangen Nuremberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital								AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; Anemueller S., 1994, Journal of Inorganic Biochemistry, V56, P4, DOI 10.1016/0162-0134(94)85045-3; ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANEMULLER S, 1994, FEMS MICROBIOL LETT, V117, P275, DOI 10.1016/0378-1097(94)90571-1; ANEMULLER S, 1989, FEBS LETT, V244, P451, DOI 10.1016/0014-5793(89)80581-2; ANEMULLER S, 1992, EUR J BIOCHEM, V210, P133, DOI 10.1111/j.1432-1033.1992.tb17400.x; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CASEY RP, 1982, EUR J BIOCHEM, V122, P313, DOI 10.1111/j.1432-1033.1982.tb05882.x; CASEY RP, 1986, METHOD ENZYMOL, V126, P13; CASTRESANA J, 1995, J MOL BIOL, V250, P202, DOI 10.1006/jmbi.1995.0371; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; ELFERINK MGL, 1994, BBA-BIOMEMBRANES, V1193, P247, DOI 10.1016/0005-2736(94)90160-0; ELFERINK MGL, 1992, J BIOL CHEM, V267, P1375; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; Freisleben HJ, 1995, CHEM PHYS LIPIDS, V78, P137, DOI 10.1016/0009-3084(95)02491-Z; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; Gennis RB, 1996, CURR BIOL, V6, P36, DOI 10.1016/S0960-9822(02)00416-5; Gerscher S, 1996, BIOCHEMISTRY-US, V35, P12796, DOI 10.1021/bi960896d; GIUFFRE A, 1994, J BIOL CHEM, V269, P31006; GLEISSNER M, 1994, EUR J BIOCHEM, V224, P983, DOI 10.1111/j.1432-1033.1994.00983.x; HALTIA T, 1993, FEBS LETT, V335, P294, DOI 10.1016/0014-5793(93)80750-O; HEIBEL GE, 1993, BIOCHEMISTRY-US, V32, P10878, DOI 10.1021/bi00091a043; HILDEBRANDT P, 1991, FEBS LETT, V283, P131, DOI 10.1016/0014-5793(91)80570-S; HILL HAO, 1985, J ELECTROANAL CHEM, V187, P315; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kroger A, 1978, Methods Enzymol, V53, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, MOL MICROBIOL, V13, P327, DOI 10.1111/j.1365-2958.1994.tb00426.x; LUBBEN M, 1995, BBA-BIOENERGETICS, V1229, P1, DOI 10.1016/0005-2728(94)00174-4; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; LUBBEN M, 1994, SYST APPL MICROBIOL, V16, P556; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P13089, DOI 10.1021/bi961416l; MOLL R, 1988, FEBS LETT, V232, P359, DOI 10.1016/0014-5793(88)80769-5; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V25, P165; MUSSER SM, 1993, FEBS LETT, V327, P131, DOI 10.1016/0014-5793(93)80156-O; MUSSER SM, 1995, BIOPHYS J, V68, P2543, DOI 10.1016/S0006-3495(95)80437-6; MUSSER SM, 1993, FEBS LETT, V335, P296, DOI 10.1016/0014-5793(93)80751-F; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PEISACH J, 1973, ANN NY ACAD SCI, V206, P310, DOI 10.1111/j.1749-6632.1973.tb43219.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; Schafer G, 1996, FEMS MICROBIOL REV, V18, P173, DOI 10.1016/0168-6445(96)00010-1; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; SCHAFER G, 1994, SYST APPL MICROBIOL, V16, P544; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; Schafer G, 1996, BBA-BIOENERGETICS, V1275, P16, DOI 10.1016/0005-2728(96)00043-6; Schmidt CL, 1996, FEBS LETT, V388, P43, DOI 10.1016/0014-5793(96)00511-X; SCHMIDT CL, 1995, FEBS LETT, V359, P239, DOI 10.1016/0014-5793(94)00052-W; SMITH L, 1955, METHOD ENZYMOL, V2, P732, DOI 10.1016/S0076-6879(55)02294-5; SPINNER F, 1994, EBEC SHORT REP, V8, P45; SVENSSON M, 1995, BIOCHEMISTRY-US, V34, P5252, DOI 10.1021/bi00015a040; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P11173, DOI 10.1021/bi00092a029; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; WALKER FA, 1984, J AM CHEM SOC, V106, P6888, DOI 10.1021/ja00335a003; WELTER R, 1994, J BIOL CHEM, V269, P28834; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V230, P466, DOI 10.1016/0003-9861(84)90427-2; Zickermann I, 1996, BBA-BIOENERGETICS, V1277, P93, DOI 10.1016/S0005-2728(96)00086-2	75	46	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8417	8426		10.1074/jbc.272.13.8417	http://dx.doi.org/10.1074/jbc.272.13.8417			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079667	hybrid			2022-12-27	WOS:A1997WQ63500050
J	Gramolini, AO; Dennis, CL; Tinsley, JM; Robertson, GS; Cartaud, J; Davies, KE; Jasmin, BJ				Gramolini, AO; Dennis, CL; Tinsley, JM; Robertson, GS; Cartaud, J; Davies, KE; Jasmin, BJ			Local transcriptional control of utrophin expression at the neuromuscular synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; SKELETAL-MUSCLE FIBERS; EPSILON-SUBUNIT GENE; MDX MOUSE MUSCLE; MESSENGER-RNAS; ACETYLCHOLINE; COMPARTMENTALIZATION; JUNCTIONS; RAT; COMPLEX	Recently, the use of a transgenic mouse model system for Duchenne muscular dystrophy has demonstrated the ability of utrophin to functionally replace dystrophin and alleviate the muscle pathology (see Tinsley, J. M., Potter, A. C., Phelps, S. R., Fisher, R., Trickett, J. I., and Davies, K. E. (1996) Nature 384, 349-353). However, there is currently a clear lack of information concerning the regulatory mechanisms presiding over utrophin expression during normal myogenesis and synaptogenesis. Using in situ hybridization, we show that utrophin mRNAs selectively accumulate within the postsynaptic sarcoplasm of adult muscle fibers. In addition, we demonstrate that a 1.3-kilobase fragment of the human utrophin promoter is sufficient to confer synapse-specific expression to a reporter gene. Deletion of 800 base pairs from this promoter fragment reduces the overall expression of the reporter gene and abolishes its synapse-specific expression. Finally, we also show that utrophin is present at the postsynaptic membrane of ectopic synapses induced to form at sites distant from the original neuromuscular junctions. Taken together, these results indicate that nerve-derived factors regulate locally the transcriptional activation of the utrophin gene in skeletal muscle fibers and that myonuclei located in extrasynaptic regions are capable of expressing utrophin upon receiving appropriate neuronal cues.	UNIV OTTAWA,FAC MED,DEPT PHYSIOL,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,FAC MED,DEPT PHARMACOL,OTTAWA,ON K1H 8M5,CANADA; UNIV OXFORD,DEPT BIOCHEM,GENET UNIT,OXFORD OX1 3QU,ENGLAND; UNIV DENIS DIDEROT,CNRS,INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	University of Ottawa; University of Ottawa; University of Oxford; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite				Robertson, George/0000-0001-8411-7721				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; DUCLERT A, 1993, P NATL ACAD SCI USA, V90, P3043, DOI 10.1073/pnas.90.7.3043; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; GERFEN CR, 1988, BRAIN RES, V460, P161, DOI 10.1016/0006-8993(88)91217-6; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; JASMIN BJ, 1995, FEBS LETT, V374, P393, DOI 10.1016/0014-5793(95)01131-W; JASMIN BJ, 1990, NATURE, V344, P673, DOI 10.1038/344673a0; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JASMIN BJ, 1995, EUR J NEUROSCI, V7, P470, DOI 10.1111/j.1460-9568.1995.tb00343.x; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; Jones G, 1996, P NATL ACAD SCI USA, V93, P5985, DOI 10.1073/pnas.93.12.5985; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KOIKE S, 1995, P NATL ACAD SCI USA, V92, P10624, DOI 10.1073/pnas.92.23.10624; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MIZUNO Y, 1993, J BIOCHEM-TOKYO, V114, P936, DOI 10.1093/oxfordjournals.jbchem.a124281; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; RANVIER L, 1988, TRAITE TECHNIQUE HIS; ROBERTSON GS, 1995, NEUROSCIENCE, V67, P325, DOI 10.1016/0306-4522(95)00049-O; SCHALLING M, 1988, P NATL ACAD SCI USA, V85, P8306, DOI 10.1073/pnas.85.21.8306; SUGITA H, 1993, ACTA CARDIOMYOLOGICA, V1, P11; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VANKEMPEN GTH, 1994, J PHYSIOL-LONDON, V478, P229, DOI 10.1113/jphysiol.1994.sp020245; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125	36	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8117	8120		10.1074/jbc.272.13.8117	http://dx.doi.org/10.1074/jbc.272.13.8117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079621	hybrid			2022-12-27	WOS:A1997WQ63500004
J	Eigenthaler, R; Hofferer, L; Shattil, SJ; Ginsberg, MH				Eigenthaler, R; Hofferer, L; Shattil, SJ; Ginsberg, MH			A conserved sequence motif in the integrin beta(3) cytoplasmic domain is required for its specific interaction with beta(3)-endonexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUT SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; CELL-ADHESION; SUBUNIT; EXPRESSION; PROTEIN; ALPHA; ATTACHMENT	Integrin signaling is mediated by interaction of integrin cytoplasmic domains with intracellular signaling molecules, Recently, we identified a novel Ill-amino acid polypeptide, termed beta(3)-endonexin, which interacts selectively with the integrin beta(3) cytoplasmic domain. In the present study we conducted a systematic mutational analysis of both the integrin beta(3) cytoplasmic domain and beta(3)-endonexin to map sites required for interaction. The interaction of the full-length beta(3) integrin subunit with beta(3)-endonexin in vitro required the beta(3) cytoplasmic domain, In a yeast two-hybrid system, both membrane-proximal and membrane-distal residues of the beta(3) cytoplasmic domain were necessary for interaction with beta(3) endonexin, In particular, the membrane-distal NITY motif at beta(3) 756-759 was critical for the interaction. Exchange of beta(3) residues 756-759 (NITY) for the corresponding residues in beta(1) (NPKY) endowed the beta(1) cytoplasmic domain with the ability to interact with beta(3)-endonexin, Conversely, exchange of the NPKY motif at beta(1) 772-775 for the NITY motif in beta(3) abolished interaction of this chimeric cytoplasmic domain with beta(3)-endonexin, Because the NITY motif is present in the beta(3) but not the beta(1) cytoplasmic domain, these results explain the selective interaction of this cytoplasmic domain with beta(3)-endonexin, In addition, deletional analysis suggested that a core 91-residue sequence of beta(3)-endonexin is sufficient for specific binding to the beta(3) cytoplasmic domain. These studies have identified a cytoplasmic domain sequence motif that specifies an integrin-specific protein-protein interaction.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R01HL056595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56595, HL 48728] Funding Source: Medline; NIAMS NIH HHS [AR 27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARTEL PL, 1993, CELL INTERACTIONS DE; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KASHIWAGI H, 1996, BLOOD S1, V88, P1; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEONG L, 1995, J CELL SCI, V108, P3817; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PRINTEN JA, 1994, GENETICS, V138, P609; RABINOWICH H, 1995, J IMMUNOL, V154, P1124; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; YLANNE J, 1995, J BIOL CHEM, V270, P9550	39	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7693	7698		10.1074/jbc.272.12.7693	http://dx.doi.org/10.1074/jbc.272.12.7693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065427	hybrid			2022-12-27	WOS:A1997WP59200021
J	Hazzard, JT; Govindaraj, S; Poulos, TL; Tollin, G				Hazzard, JT; Govindaraj, S; Poulos, TL; Tollin, G			Electron transfer between the FMN and heme domains of cytochrome P450BM-3 - Effects of substrate and CO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; BACILLUS-MEGATERIUM; REDUCTASE; KINETICS; NADPH	Cytochrome P450BM-3 has the P450 heme domain and FAD/FMN reductase domain linked together in a single polypeptide chain arranged as heme-FMN-FAD. In the accompanying article (Govindaraj, S,, and Poulos, T, L. (1997) J, Biol, Chem, 272, 7915-7921, we have described the preparation and characterization of the various domains of cytochrome P450BM-3, One reason for undertaking this study was to provide simpler systems for studying intramolecular electron transfer reactions, In particular, the heme-FMN version of P450BM-3 that is missing the FAD domain should prove useful in studying the FMN-to-heme electron transfer reaction, This version of P450BM-3 has been designated truncated P450BM-3 or BM3(t). In this study we have used laser flash photolysis techniques to generate the reduced semiquinone of 5-deazariboflavin which in turn reduces the FMN of BM3, to the semiquinone, FMN(radical anion), at a rate constant of 6600 s(-1), whereas the heme is not reduced by the 5-deazariboflavin radical, The reduction of the heme by FMN(radical anion) does not proceed in the absence of carbon monoxide (GO), whereas in the presence of CO the FMN(radical anion) to heme electron transfer rate constant is 18 s(-1). If a fatty acid substrate is present, this rate constant increases to 250 s(-1). Somewhat surprisingly, the rate of heme reduction also is dependent on [GO] which indicates that CO causes some change within the heme pocket and/or interaction between the heme and FMN domains that is required for intramolecular electron transfer.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM & PHYSIOL & BIOPHYS,IRVINE,CA 92697	University of California System; University of California Irvine	Hazzard, JT (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721, USA.				NIDDK NIH HHS [DK15057] Funding Source: Medline; NIGMS NIH HHS [GM42614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARYYA AK, 1991, BIOCHEMISTRY-US, V30, P759, DOI 10.1021/bi00217a027; BHATTACHARYYA AK, 1994, ARCH BIOCHEM BIOPHYS, V310, P318, DOI 10.1006/abbi.1994.1173; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; EDMONDSON DE, 1983, TOP CURR CHEM, V108, P109; GOVINDARAJ S, 1995, BIOCHEMISTRY-US, V34, P11221, DOI 10.1021/bi00035a031; Govindaraj S., 1994, BIOCHEM BIOPH RES CO, V203, P1745; GOVINDARAJ S, 1997, J BIOL CHEM, V271, P7915; LI HY, 1996, NAT STRUCT BIOL, V4, P140; MODI S, 1995, BIOCHEMISTRY-US, V34, P8982, DOI 10.1021/bi00028a006; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; SERVIOUKOVA IF, 1995, ARCH BIOCHEM BIOPHYS, V317, P397; SERVIOUKOVA IF, 1995, BIOCHIMIE PARIS, V77, P562; SERVIOUKOVA IF, 1996, BIOCHEMISTRY-US, V35, P7528; SERVIOUKOVA IF, 1996, BIOCHEMISTRY-US, V35, P7058; TOLLIN G, 1991, ARCH BIOCHEM BIOPHYS, V287, P1, DOI 10.1016/0003-9861(91)90380-2; TOLLIN G, 1993, BIOPHYS CHEM, V48, P259, DOI 10.1016/0301-4622(93)85014-9	18	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7922	7926		10.1074/jbc.272.12.7922	http://dx.doi.org/10.1074/jbc.272.12.7922			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065460	hybrid			2022-12-27	WOS:A1997WP59200054
J	McKee, CM; Lowenstein, CJ; Horton, MR; Wu, J; Bao, C; Chin, BY; Choi, AMK; Noble, PW				McKee, CM; Lowenstein, CJ; Horton, MR; Wu, J; Bao, C; Chin, BY; Choi, AMK; Noble, PW			Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappa B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC PULMONARY FIBROSIS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NECROSIS-FACTOR-ALPHA; ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR; INFLAMMATORY PROTEIN-1-ALPHA; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS; INHIBITS INDUCTION; INTERFERON-GAMMA	Activated macrophages play a critical role in controlling chronic tissue inflammation through the release of a variety of mediators including cytokines, chemokines, growth factors, active lipids, reactive oxygen, and nitrogen species, The mechanisms that regulate macrophage activation in chronic inflammation are poorly understood, A hallmark of chronic inflammation is the turnover of extracellular matrix components, and recent work has suggested that interactions with the extracellular matrix can exert important influences on macrophage effector functions, We have examined the effect of low molecular weight fragments of the extracellular matrix glycosaminoglycan hyaluronan (HA) on the induction of nitric-oxide synthase (iNOS) in macrophages. We found that HA fragments induce iNOS mRNA, protein and activity alone, and markedly synergize with interferon-gamma to induce iNOS gene expression in murine macrophages. In addition, we found that resident tissue alveolar macrophages respond minimally, but inflammatory alveolar macrophages exhibit a marked induction in iNOS expression in response to HA fragments, Finally, we demonstrate that the mechanism of HA fragment-induced expression of iNOS requires activation of the transcriptional regulator nuclear factor kappa B, These data support the hypothesis that HA may be an important regulator of macrophage activation at sites of chronic tissue inflammation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,BALTIMORE,MD 21205	Johns Hopkins University				Lowenstein, Charles/0000-0003-0485-7514	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002880] Funding Source: NIH RePORTER; NHLBI NIH HHS [K11HL02880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; AMOAHAPRAKU B, 1995, KIDNEY INT, V48, P674, DOI 10.1038/ki.1995.337; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; BJERMER L, 1989, THORAX, V44, P126, DOI 10.1136/thx.44.2.126; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CARRE PC, 1991, J CLIN INVEST, V88, P1802, DOI 10.1172/JCI115501; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; DUFFY JM, 1993, CLIN SCI, V85, P343, DOI 10.1042/cs0850343; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GREEN SJ, 1990, J IMMUNOL, V145, P4290; HUOT AE, 1990, CANCER RES, V50, P7863; JAMES SL, 1989, J IMMUNOL, V143, P4208; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771; KIM HK, 1995, J IMMUNOL, V154, P4741; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; LASKIN DL, 1994, AM J RESP CELL MOL, V10, P58, DOI 10.1165/ajrcmb.10.1.8292381; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAZO JS, 1990, PHARMACOL THERAPEUT, V47, P347, DOI 10.1016/0163-7258(90)90061-6; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYNCH JP, 1992, AM REV RESPIR DIS, V145, P1433, DOI 10.1164/ajrccm/145.6.1433; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MASON RM, 1982, J BIOL CHEM, V257, P2236; MBAWUIKE IN, 1989, J LEUKOCYTE BIOL, V46, P119, DOI 10.1002/jlb.46.2.119; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NETTELBLADT O, 1991, EUR RESPIR J, V4, P407; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SAARI H, 1991, ANN RHEUM DIS, V50, P389, DOI 10.1136/ard.50.6.389; SCHALL TJ, 1994, CYTOKINE HDB, P419; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; SMITH RE, 1994, J IMMUNOL, V153, P4704; STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZHANG K, 1994, J IMMUNOL, V153, P4733	61	249	252	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8013	8018		10.1074/jbc.272.12.8013	http://dx.doi.org/10.1074/jbc.272.12.8013			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065473	hybrid			2022-12-27	WOS:A1997WP59200067
J	Nussberger, S; Steel, A; Trotti, D; Romero, MF; Boron, WF; Hediger, MA				Nussberger, S; Steel, A; Trotti, D; Romero, MF; Boron, WF; Hediger, MA			Symmetry of H+ binding to the intra- and extracellular side of the H+-coupled oligopeptide cotransporter PepT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; CHARGE MOVEMENTS; NA+/GLUCOSE COTRANSPORTER; GLUCOSE COTRANSPORTER; XENOPUS OOCYTES; VOLTAGE-CLAMP; NA/K PUMP; KINETICS; PH	Ion-coupled solute transporters exhibit pre-steady-tate currents that resemble those of voltage-dependent ion channels. These currents were assumed to be mostly due to binding and dissociation of the coupling ion near the extracellular transporter surface, Little attention was given to analogous events that may occur at the intracellular surface, To address this issue, we performed voltage clamp studies of Xenopus oocytes expressing the intestinal H+-coupled peptide cotransporter PepT1 and recorded the dependence of transient charge movements in the absence of peptide substrate on changing intra- (pH(i)) and extracellular pH (pH(o)). Rapid steps in membrane potential induced transient charge movements that showed a marked dependence on pH(i) and pH(o). At a pH(o) of 7.0 and a holding potential (V-h) of -50 mV, the charge movements were mostly inwardly directed, whereas reduction of pH(o) to below 7.0 resulted in outwardly directed charge movements, When pH(i) was reduced, inwardly directed charge movements were observed, The data on the voltage dependence of the transient charge movements were fitted by the Boltzmann equation, yielding an apparent valence of 0.65 +/- 0.03 (n = 7), The midpoint voltage (V-0.5) of the charge distribution shifted linearly as a function of pH(i) and pH(o). Our results indicate that, as a first approximation, the magnitude and polarity of the transient charge movements depend upon the prevailing H+ electro-chemical gradient, We propose that PepT1 has a single proton binding site that is symmetrically accessible from both sides of the membrane and that decreasing the H+ chemical potential (Delta mu(H)) or increasing the membrane potential (V-m) shifts this binding site from an outwardly to an inwardly facing occluded state, This concept constitutes an important extension of previous kinetic models of ion-coupled solute transporters by including a more detailed description of intracellular events.	BRIGHAM & WOMENS HOSP,DIV RENAL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University			Boron, Walter/ABI-1564-2020	Nussberger, Stephan/0000-0003-3619-4452; Romero, Michael F/0000-0002-1555-7835; Hediger, Matthias/0000-0003-1946-027X; Boron, Walter/0000-0003-4741-7287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171, F32DK009342] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009342-02, DK43171, F32 DK009342-01, F32 DK009342-03, F32 DK009342] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boron WF, 1992, KIDNEY PHYSL PATHOPH, P219; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LU CC, 1995, P NATL ACAD SCI USA, V92, P11220, DOI 10.1073/pnas.92.24.11220; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MCEWAN GTA, 1990, J MED ENG TECHNOL, V14, P16, DOI 10.3109/03091909009028758; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Nussberger S, 1996, BIOPHYS J, V70, P998, DOI 10.1016/S0006-3495(96)79643-1; NUSSBERGER S, 1995, EXP NEPHROL, V3, P211; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; STEEL A, 1997, J PHYSIOL-LONDON, P563; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2	23	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7777	7785		10.1074/jbc.272.12.7777	http://dx.doi.org/10.1074/jbc.272.12.7777			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065440	hybrid			2022-12-27	WOS:A1997WP59200034
J	Dohlman, HG; Thorner, J				Dohlman, HG; Thorner, J			RGS proteins and signaling by heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHEROMONE RESPONSE PATHWAY; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; GTP HYDROLYSIS; A-FACTOR; BETA-2-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; GENE; BINDING		UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06520	University of California System; University of California Berkeley; Yale University			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1983, J BACTERIOL, V155, P903, DOI 10.1128/JB.155.2.903-906.1983; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1991, GENE DEV, V5, P475, DOI 10.1101/gad.5.3.475; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PEROUTKA SJ, 1994, HDB RECEPTORS CHANNE; PERRY WL, 1995, GENETICS, V141, P321; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKIE TM, 1994, SOC GEN PHY, V49, P249; WU HK, 1995, LEUKEMIA, V9, P1291; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	63	445	448	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	1997	272	7					3871	3874		10.1074/jbc.272.7.3871	http://dx.doi.org/10.1074/jbc.272.7.3871			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WH019	9064301	hybrid			2022-12-27	WOS:A1997WH01900001
J	CarleUrioste, JC; EscobarVera, J; ElGogary, S; HenriqueSilva, F; Torigoi, E; Crivellaro, O; HerreraEstrella, A; ElDorry, H				CarleUrioste, JC; EscobarVera, J; ElGogary, S; HenriqueSilva, F; Torigoi, E; Crivellaro, O; HerreraEstrella, A; ElDorry, H			Cellulase induction in Trichoderma reesei by cellulose requires its own basal expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ENDOGLUCANASE-I; GENE-EXPRESSION; HYGROMYCIN-B; SEQUENCE; TRANSFORMATION; DEGRADATION; INVOLVEMENT	The induction of cellulases by cellulose, an insoluble polymer, in the filamentous fungus Trichoderma reesei is puzzling, We previously proposed a mechanism that is based on the presence of low levels of cellulase in the uninduced fungus; this basal cellulase activity would digest cellulose-releasing oligosaccharides that could enter the cell and trigger expression of cellulases. We now present experiments that lend further support to this model, We show here that transcripts of two mem bers of the cellulase system, cbh1 and egl1, are present in uninduced T. reesei cells, These transcripts are induced at least 1100-fold in the presence of cellulose, We also show that a construct containing the hygromycin B resistance-encoding gene driven by the cbh1 promoter confers hygromycin B resistance to T. reesei cells grown in the absence of cellulose. Moreover, cellulose induced production of the cbh1 transcript was suppressed when antisense RNA against three members of the cellulase system was expressed in vivo. Experiments are presented indicating that extracellular cellulase activity is the rate-limiting event in induction of synthesis of the cellulase transcripts by cellulose, The results reveal a critical requirement for basal expression of the cellulase system for induction of synthesis of its own transcripts by cellulose.	UNIV SAO PAULO,INST CHEM,DEPT BIOCHEM,BR-05508900 SAO PAULO,BRAZIL	Universidade de Sao Paulo			Henrique-Silva, Flavio/A-1937-2013; Herrera-Estrella, Alfredo/J-8210-2019; Herrera-Estrella, Alfredo/F-3185-2011	Herrera-Estrella, Alfredo/0000-0002-4589-6870; Herrera-Estrella, Alfredo/0000-0002-4589-6870				ABRAHAONETO J, 1995, BIOCHEMISTRY-US, V34, P10456, DOI 10.1021/bi00033a018; Barr BK, 1996, BIOCHEMISTRY-US, V35, P586, DOI 10.1021/bi9520388; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHEN C M, 1987, Bio-Technology (New York), V5, P274; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; ELGOGARY S, 1989, P NATL ACAD SCI USA, V86, P6138, DOI 10.1073/pnas.86.16.6138; FAGERSTAM LG, 1980, FEBS LETT, V119, P97, DOI 10.1016/0014-5793(80)81006-4; GOTTLIEB G, 1985, MEASUREMENT AUDITION, P3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; KUBICEK CP, 1993, J BIOL CHEM, V268, P19364; KUBICEK CP, 1987, J GEN MICROBIOL, V133, P1481; LEBOUL J, 1982, J ANTIBIOT, V35, P527, DOI 10.7164/antibiotics.35.527; LJUNGDAHL LG, 1985, ADV MICROB ECOL, V8, P237; MANDELS M, 1960, J BACTERIOL, V79, P816, DOI 10.1128/JB.79.6.816-826.1960; MANDELS M, 1962, J BACTERIOL, V83, P400, DOI 10.1128/JB.83.2.400-408.1962; MATHEUCCI E, 1995, GENE, V161, P103, DOI 10.1016/0378-1119(95)00283-C; Montenecourt BS, 1983, TRENDS BIOTECHNOL, V1, P156; MULLANEY EJ, 1985, MOL GEN GENET, V199, P37, DOI 10.1007/BF00327506; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; Sambrook J., 2002, MOL CLONING LAB MANU; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; STAHLBERG J, 1993, BIOCHIM BIOPHYS ACTA, V1157, P107, DOI 10.1016/0304-4165(93)90085-M; STERNBERG D, 1979, J BACTERIOL, V139, P761, DOI 10.1128/JB.139.3.761-769.1979; TEERI T, 1983, BIO-TECHNOL, V1, P696, DOI 10.1038/nbt1083-696; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; VAHERI M, 1979, BIOTECHNOL LETT, V1, P41, DOI 10.1007/BF01395789; VANARSDELL JN, 1987, BIO-TECHNOL, V5, P60, DOI 10.1038/nbt0187-60	33	71	80	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10169	10174						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092563	hybrid			2022-12-27	WOS:A1997WU03900082
J	Lin, BC; Wong, CW; Chen, HW; Privalsky, ML				Lin, BC; Wong, CW; Chen, HW; Privalsky, ML			Plasticity of tetramer formation by retinoid X receptors - An alternative paradigm for DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; RESPONSE ELEMENTS; THYROID-HORMONE; NUCLEAR RECEPTOR; ACID RECEPTORS; BINDING DOMAIN; DIRECT REPEATS; GENE; RXR; HETERODIMERS	Retinoid X receptors (RXRs) are transcription factors that traditionally have been thought to bind DNA as protein dimers. Recently, however, it has been recognized that RXRs call also kind to DNA as protein tetramers, Receptor tetramers form cooperatively on response elements containing suitably reiterated half-sites, and play an important role in determining the specificity of DNA recognition by different nuclear receptors. We report here that RXR tetramers exhibit significant functional plasticity, and form on response elements possessing diverse half site orientations and spacings. This ability of RXRs to form tetramers and related oligomers appears to contribute to the synergistic transcriptional activation observed when multiple, spatially separated response elements are introduced into a single pro meter. Oligomerization may therefore be a common paradigm for DNA recognition and combinatorial regulation by several different classes of transcription factors.	UNIV CALIF DAVIS,DIV BIOL SCI,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NCI NIH HHS [R37 CA-53394] Funding Source: Medline; NIGMS NIH HHS [GM 08343-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARLSONJURICA MA, 1990, ENDOCR REV, V11, P201; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; KLEINHITPASS L, 1988, J MOL BIOL, V201, P537; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROWE A, 1991, DEVELOPMENT, V111, P771; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	41	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9860	9867						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092522				2022-12-27	WOS:A1997WU03900041
J	Schischmanoff, PO; Yaswen, P; Parra, MK; Lee, G; Chasis, JA; Mohandas, N; Conboy, JG				Schischmanoff, PO; Yaswen, P; Parra, MK; Lee, G; Chasis, JA; Mohandas, N; Conboy, JG			Cell shape-dependent regulation of protein 4.1 alternative pre-mRNA splicing in mammary epthelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRIN-ACTIN-BINDING; MEMBRANE SKELETAL PROTEIN-4.1; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; GLYCOPHORIN-C; MESSENGER-RNA; ERYTHROCYTE-MEMBRANE; 4.1-BINDING SITE; GENE-EXPRESSION; TERNARY COMPLEX	Expression of the complex gene encoding multiple isoforms of structural protein 4.1 is regulated by alternative pre-mRNA splicing During erythropoiesis, developmental stage-specific inclusion of exon 16 generates protein 4.1 isoforms having a fully functional spectrinactin binding domain, Here we show that human mammary epithelial cells (HMEC), coincident with the dramatic morphological changes induced by altered culture conditions, exhibit a novel pre-mRNA splicing switch involving a new exon (exon 17B, 450 nucleotides) in the COOH-terminal coding region, 4.1 RNA expressed in proliferating HMEC adherent to culture dishes mostly excluded exon 17B, whereas 4.1 transcripts processed in nondividing suspension cultures of HMEC strongly included this exon, This pre-mRNA splicing switch was reversible: cells transferred from poly(2-hydroxyethyl methacrylate) back to plastic resumed cell division and down-regulated exon 17B expression, More detailed studies revealed complex tissue-specific alternative splicing of exon 17B and another new exon 17A (51 nucleotides), These results predict the existence of multiple 4.1 protein isoforms with diverse COOH termini, Moreover, they strongly suggest that regulation of gene expression during differentiation of epithelial cells is mediated not only by transcriptional mechanisms, but also by post-transcriptional processes such as alternative pre mRNA splicing.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY NATL LAB,DIV LIFE SCI,BERKELEY,CA 94720; CHU BICETRE,BIOCHIM LAB,F-94275 LE KREMLIN BICETR,FRANCE; UNIV PARIS 05,F-75006 PARIS,FRANCE	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Cite					NHLBI NIH HHS [HL45182] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045182, R56HL045182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOSE MJ, 1994, MOL BIOL CELL S, V5, P66; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FEDDAL S, 1992, BLOOD, V80, P2925; FEHON RG, 1994, DEVELOPMENT, V120, P545; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HORNE WC, 1993, BLOOD, V82, P2558; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HUANG JP, 1993, J BIOL CHEM, V268, P3758; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; JAROLIM P, 1992, BLOOD S, V80, P144; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KRAUSS SW, 1995, BLOOD S1, V86, P415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MARCOTTE P, 1990, ABA J, V76, P12; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; REID ME, 1990, BLOOD, V75, P2229; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TEMPLE GF, 1977, P NATL ACAD SCI USA, V74, P3047, DOI 10.1073/pnas.74.7.3047; WINARDI R, 1995, BLOOD, V86, P4315, DOI 10.1182/blood.V86.11.4315.bloodjournal86114315	42	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10254	10259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092575	hybrid			2022-12-27	WOS:A1997WU03900094
J	Uhlmann, F; Gibbs, E; Cai, JS; ODonnell, M; Hurwitz, J				Uhlmann, F; Gibbs, E; Cai, JS; ODonnell, M; Hurwitz, J			Identification of regions within the four small subunits of human replication factor C required for complex formation and DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; MULTIPLE FUNCTIONS; HELA-CELLS; RF-C; ACTIVATOR-1; ALPHA	Replication factor C (RFC) and proliferating cell nuclear antigen (PCNA) are processivity factors for eukaryotic DNA polymerases delta and epsilon. RFC binds to a DNA primer end and loads PCNA onto DNA in an ATP-dependent reaction. The five RFC subunits p140, p40, p38, p37, and p36, all of which are required to form the active RFC complex, share regions of high homology including the defined RFC boxes II-VIII. RFC boxes III and V constitute a putative ATP binding site, whereas the function of the other conserved boxes is unknown. To study the individual subunits in the RFC complex and the role of the RFC boxes, deletion mutations were created in all subunits. Sequences close to the C terminus of each of the small subunits are required for formation of the five subunit complex. A N-terminal region of the small subunits, containing the RFC homology box II, plays a critical role in the function of these subunits, deletion of which reduces but does not abolish RFC activity in loading PCNA onto DNA and in supporting an RFC-dependent replication reaction. The N termini of p37 and p40, although highly homologous, are not interchangeable, suggesting unique functions for the individual subunits.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Howard Hughes Medical Institute				Uhlmann, Frank/0000-0002-3527-6619	NIGMS NIH HHS [GM 38839, GM 38559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	31	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10065	10071						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092550				2022-12-27	WOS:A1997WU03900069
J	Inoue, M; Minami, M; Matsumoto, M; Kishimoto, T; Akira, S				Inoue, M; Minami, M; Matsumoto, M; Kishimoto, T; Akira, S			The amino acid residues immediately carboxyl-terminal to the tyrosine phosphorylation site contribute to interleukin 6-specific activation of signal transducer and activator of transcription 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; PHASE RESPONSE FACTOR; DNA-BINDING PROTEINS; CYTOKINE RECEPTORS; MOLECULAR-CLONING; STAT PATHWAY; MOUSE-LIVER; GP130; FAMILY	Signal transducers and activators of transcription (Stat) proteins play an important role in signaling through a variety of cytokine and growth factor receptors. Each of the Stat proteins is activated in a ligand-specific manner. Only the Src homology 2 (SH2) domains of Stat1 and Stat2 are critical for the ligand-specific activation of interferon signaling. In this study we determined the domains in Stat3 protein that contribute to interleukin 6 (IL-6)-specific phosphorylation. Based on evidence that Stat3, but not Stat1, is activated in the presence of low levels of IL-6 and soluble IL-6 receptor, we constructed various swap mutants between Stat3 and Stat1 and examined their response to IL-6 after their transient expression into COS7 cells. The region upstream of the SH2 domain was exchangeable between Stat1 and Stat3, whereas the region carboxyl-terminal to the SH2 domain of Stat3 was critical to phosphorylation by IL-6. However, unlike Stat1 and Stat2 in interferon signaling, the swap mutant in which 5 amino acid residues just carboxyl-terminal to the tyrosine phosphorylation site (Tyr(705)) in Stat3 was replaced by the corresponding region derived from Stat1 was not phosphorylated in response to IL-6. Substituting 1 amino acid (Lys(709)) at position +4 relative to Tyr(705) abolished the tyrosine phosporylation of Stat3 in response to IL-6. Co-immunoprecipitation experiments demonstrated that these mutants were associated with gp130 at an extent similar to wild-type Stats3. Taken together, these results show that the amino acid residues immediately carboxyl-terminal to the tyrosine phosphorylation site are involved in IL-6-specific activation of Stat3.	OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,DEPT INTERNAL MED 3,SCH MED,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Akira, Shizuo/C-3134-2009; Kishimoto, Tadamitsu/C-8470-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FELDMAN GM, 1994, J BIOL CHEM, V269, P10747; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KIRSHMAN K, 1996, ONCOGENE, V13, P125; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARRERO MB, 1995, NATURE, V375, P2447; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TIAN SS, 1994, BLOOD, V84, P1760; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	53	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9550	9555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083098				2022-12-27	WOS:A1997WU03700103
J	Magliozzo, RS; Marcinkeviciene, JA				Magliozzo, RS; Marcinkeviciene, JA			The role of Mn(II)-peroxidase activity of mycobacterial catalase-peroxidase in activation of the antibiotic isoniazid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; PROTEIN SECONDARY STRUCTURE; MANGANESE PEROXIDASE; TUBERCULOSIS; PURIFICATION; OXIDATION; GENE; RESISTANCE; MECHANISM; BACILLUS	The catalase-peroxidase of Mycobacteria smegmatis exhibits Mn(II)-peroxidase activity characterized by a low K-m for Mn(II) (5 mu M) and a high K-m for t-butyl hydroperoxide (100 mM). This activity, monitored by the formation of Mn(III)-malate or -malonate, is inhibited by co(II) but not by superoxide dismutase. Optical evidence for binding of Mn(II) to the resting (ferric) enzyme is found in a change in intensity of the Soret peak upon titration with Mn(II). A potential role for Mn(III) in the antimycobacterial action of the antibiotic isoniazid is suggested by the rapid reduction of Mn(III)-malonate by this drug. The stoichiometry of the reaction is consistent with two single electron transfer steps per mole of isoniazid.	YESHIVA UNIV,ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Magliozzo, RS (corresponding author), YESHIVA UNIV,ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NCRR NIH HHS [RR02583] Funding Source: Medline; NIAID NIH HHS [AI33696] Funding Source: Medline; NIGMS NIH HHS [GM40168] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040168, R01GM040168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cleland W W, 1979, Methods Enzymol, V63, P103; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HICKS DB, 1995, BBA-BIOENERGETICS, V1229, P347, DOI 10.1016/0005-2728(95)00016-C; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; KHINDARIA A, 1995, BIOCHEMISTRY-US, V34, P7773, DOI 10.1021/bi00023a025; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; MAYFIELD MB, 1994, GENE, V142, P231, DOI 10.1016/0378-1119(94)90266-6; MORRIS SL, 1992, J GEN MICROBIOL, V138, P2363, DOI 10.1099/00221287-138-11-2363; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SRIPRAKASH KS, 1970, J GEN MICROBIOL, V60, P125, DOI 10.1099/00221287-60-1-125; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; YOUN HD, 1995, J BIOL CHEM, V270, P13740, DOI 10.1074/jbc.270.23.13740; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	27	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8867	8870						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083004				2022-12-27	WOS:A1997WU03700009
J	Sultana, S; Nirodi, CS; Ram, N; Prabhu, L; Padmanaban, G				Sultana, S; Nirodi, CS; Ram, N; Prabhu, L; Padmanaban, G			A 65-kDa protein mediates the positive role of heme in regulating the transcription of CYP2B1/B2 gene in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITONE; EXPRESSION; IDENTIFICATION; INDUCTION; BINDING; ACID	Heme deficiency precipitated by CoCl2 administration to rats leads to a striking decrease in the inducibility of CYP2B1/B2 mRNA levels and its transcription by phenobarbitone (PB), besides decreasing the basal levels. Exogenous hemin administration counteracts the effects of CoCl2 administration. The binding of nuclear proteins to labeled positive cis-acting element (-69 to -98 nucleotides) in the near 5'-upstream region of the gene is inhibited by CoCl2 administration to saline or PR-treated rats, as assessed in gel shift assays. Administration of exogenous hemin to the animal or addition in vitro to the extracts is able to overcome the effects of CoCl2 treatment. The protein mediating this effect has been purified from CoCl2 administered nuclear extracts by heparin-agarose, positive element oligonucleotide affinity, and heme affinity column chromatography. This 65-kDa protein manifests very little binding to the positive element, but in the presence of certain other nuclear proteins, shows a strong heme-responsive binding. The purified protein binds heme. It is also able to stimulate transcription of a minigene construct of the CYP2B1/B2 gene containing -179 nucleotides of the 5'-upstream region and the I exon in a cell-free system, manifesting heme response. It is concluded that the 65-kDa protein mediates the constitutive requirement of heme for the transcription of CYP2B1/B2 gene.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore								DWARKI VJ, 1987, J BIOL CHEM, V262, P16958; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HE JS, 1991, J BIOL CHEM, V266, P7864; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; PALMITER RD, 1973, J BIOL CHEM, V248, P2095; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9629; RAM N, 1995, ARCH BIOCHEM BIOPHYS, V317, P39, DOI 10.1006/abbi.1995.1133; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RAVISHANKAR H, 1983, ARCH BIOCHEM BIOPHYS, V225, P16, DOI 10.1016/0003-9861(83)90002-4; RAVISHANKAR H, 1985, J BIOL CHEM, V260, P1588; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; TAYLOR CW, 1973, EXP CELL RES, V82, P215, DOI 10.1016/0014-4827(73)90264-4; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; VENKATESWAR V, 1991, ARCH BIOCHEM BIOPHYS, V290, P167, DOI 10.1016/0003-9861(91)90603-G	19	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8895	8900						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083008				2022-12-27	WOS:A1997WU03700013
J	Benaroudj, N; Fouchaq, B; Ladjimi, MM				Benaroudj, N; Fouchaq, B; Ladjimi, MM			The COOH-terminal peptide binding domain is essential for self-association of the molecular chaperone HSC70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; UNCOATING ATPASE; ESCHERICHIA-COLI; UNFOLDED PROTEINS; SUBSTRATE-BINDING; COGNATE PROTEIN; CLATHRIN COATS; HSP70; PURIFICATION; IDENTIFICATION	We have previously shown that the molecular chaperone HSC70 self-associates in solution into dimers, trimers, and probably high order oligomers, according to a slow temperature- and concentration-dependent equilibrium that is shifted toward the monomer upon binding of ATP peptides or unfolded proteins. To determine the structural basis of HSC70 self-association, the oligomerization properties of the isolated amino- and carboxyl-terminal domains of this protein have been analyzed by gel electrophoresis, size exclusion chromatography, and analytical ultracentrifugation. Whereas the amino-terminal ATPase domain (residues 1-384) was found to be monomeric in solution even at high concentrations, the carboxyl-terminal peptide binding domain (residues 385-646) exists as a slow temperature- and concentration-dependent equilibrium involving monomers, dimers, and trimers. The association equilibrium constant obtained for this domain alone is on the order of 10(5) M(-1), very close to that determined previously for the entire protein, suggesting that self-association of HSC70 is determined solely by its carboxyl-terminal domain. Furthermore, oligomerization of the isolated carboxyl-terminal peptide binding domain is, like that of the entire protein, reversed by peptide binding, indicating that self-association of the protein may be mediated by the peptide binding site and, as such, should play a role in the regulation of HSC70 chaperone function. A general model for self-association of HSP70 is proposed in which the protein is in equilibrium between two states differing by the conformation of their carboxyl-terminal domain and their self-association properties.	CNRS,LAB ENZYMOL & BIOCHIM STRUCT,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Benaroudj, Nadia/0000-0002-6475-0041				ADAMS ET, 1968, BIOCHEMISTRY-US, V7, P1044, DOI 10.1021/bi00843a025; ADAMS ET, 1978, PHYSICAL ASPECTS PRO, P1; ANDERSON JV, 1994, PLANT PHYSIOL, V104, P1371, DOI 10.1104/pp.104.4.1371; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HOHFELD J, 1995, CELL, V83, P589; KIM DH, 1992, J CELL PHYSIOL, V153, P353, DOI 10.1002/jcp.1041530215; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KWON OS, 1994, J BIOL CHEM, V269, P266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TH, 1991, J BIOL CHEM, V266, P1635; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MILTHORPE BK, 1975, BIOPHYS CHEM, V3, P169, DOI 10.1016/0301-4622(75)80007-X; MORRIS M, 1985, BIOPHYS CHEM, V23, P49, DOI 10.1016/0301-4622(85)80063-6; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RALSTON GB, 1992, ANAL ULTRACENTRIFUGA, P253; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; WINZOR DJ, 1994, MODERN ANAL ULTRACEN, P67; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	55	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8744	8751		10.1074/jbc.272.13.8744	http://dx.doi.org/10.1074/jbc.272.13.8744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079709	hybrid			2022-12-27	WOS:A1997WQ63500092
J	Janes, PW; Lackmann, M; Church, WB; Sanderson, GM; Sutherland, RL; Daly, RJ				Janes, PW; Lackmann, M; Church, WB; Sanderson, GM; Sutherland, RL; Daly, RJ			Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; SH2 DOMAIN; CRYSTAL-STRUCTURES; POINT MUTATION; BINDING-SITE; PROTEIN; KINASE; SPECIFICITY	The Src homology 2 (SH2) domain-containing protein Grb7 and the erbB2 receptor tyrosine kinase are over expressed in a subset of human breast cancers. They also co-immunoprecipitate from cell lysates and associate directly in vitro. Whereas the Grb7 SH2 domain binds strongly to erbB2, the SH2 domain of Grb14, a protein closely related to Grb7, does not. We have investigated the preferred binding site of Grb7 within the erbB2 intracellular domain and the SH2 domain residues that determine the high affinity of Grb7 compared with Grb14 for this site, Phosphopeptide competition and site-directed mutagenesis revealed that Tyr-1139 of erbB2 is the major binding site for the Grb7 SH2 domain, indicating an overlap in binding specificity between the Grb7 and Grb2 SH2 domains. Substituting individual amino acids in the Grb14 SH2 domain with the corresponding residues from Grb7 demonstrated that a Gin to Leu change at the beta D6 position imparted high affinity erbB2 interaction, paralleled by a marked increase in affinity for the Tyr-1139 phosphopeptide. The reverse switch at the beta D6 position abrogated Grb7 binding to erbB2. This residue therefore represents an important determinant of SH2 domain specificity within the Grb7 family.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, GARVAN INST MED RES, NEUROBIOL RES PROGRAM, DARLINGHURST, NSW 2010, AUSTRALIA; LUDWIG INST CANC RES, GROWTH REGULAT LAB, MELBOURNE, VIC 3050, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Ludwig Institute for Cancer Research			Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008; Church, William/H-6040-2013	Church, William/0000-0002-8033-5518; Daly, Roger/0000-0002-5739-8027				COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GULLICK WJ, 1990, INT J CANCER, P55; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JANES PW, 1994, ONCOGENE, V9, P3601; Keegan K, 1996, ONCOGENE, V12, P1537; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OOI J, 1995, ONCOGENE, V10, P1621; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; RICCI A, 1995, ONCOGENE, V11, P1519; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEGATTO O, 1990, New Biologist, V2, P187; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	71	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8490	8497		10.1074/jbc.272.13.8490	http://dx.doi.org/10.1074/jbc.272.13.8490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079677	hybrid			2022-12-27	WOS:A1997WQ63500060
J	Khan, KMF; Falcone, DJ				Khan, KMF; Falcone, DJ			Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; EXTRACELLULAR-MATRIX; HUMAN-MONOCYTES; IV COLLAGENASE; GROWTH-FACTOR; PROSTAGLANDIN E(2); TISSUE INHIBITOR; CELL-ADHESION; GELATINASE-B; CATHEPSIN-B	Urokinase-type plasminogen activator (uPA) and 92-kDa matrix metalloproteinase (MMP-9) expression by RAW264.7 macrophages were up-regulated when plated on extracellular matrices, Collagen IV, fibronectin, and tenascin stimulated macrophages' MMP-9 expression, in contrast, laminin stimulated both uPA and MMP-9 expression in a dose- and time-dependent manner. The increase in macrophage uPA activity was preceded by an increase in their steady state levels of uPA mRNA. Laminin-induced uPA expression was most pronounced in RAW264.7 macrophages followed by THP-1 monocytes, J774A.1 macrophages, and bone marrow-derived macrophages. Neither laminin nor matrix induced alterations in THP-1 monocyte expression of plasminogen activator inhibitor, tissue inhibitor of metalloprotein ase (TIMP)-1 or TIMP-2. Synthetic laminin peptides were utilized to identify the laminin domain(s) responsible for induction of uPA expression, Peptides derived from the beta 1 chain of laminin had no effect on macrophage uPA expression, whereas SIKVAV, derived from alpha 1 chain, stimulated uPA expression 20-fold. Preincubation of THP-1 monocytes with a monoclonal antibody directed against the alpha 6 subunit of the alpha 6 beta 1 laminin receptor blocked matrix induction of uPA without affecting the induction of MMP-9. These results demonstrate that macrophage binding to laminin plays an important role in the regulation of their degradative phenotype via the up-regulation of uPA and MMP-9.	CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT ANAT & CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,CTR VASC BIOL,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University					NHLBI NIH HHS [R01 HL40819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; Aumailley M, 1996, J INVEST DERMATOL, V106, P209, DOI 10.1111/1523-1747.ep12340471; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BU CH, 1995, J BIOL CHEM, V270, P18563, DOI 10.1074/jbc.270.31.18563; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CHEUNG HT, 1996, FASEB J, V9, P3826; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GOWN AM, 1986, AM J PATHOL, V125, P191; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Grant G A, 1992, Matrix Suppl, V1, P217; GYETKO MR, 1993, J LEUKOCYTE BIOL, V53, P598, DOI 10.1002/jlb.53.5.598; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HAMILTON JA, 1993, CELL IMMUNOL, V152, P7, DOI 10.1006/cimm.1993.1263; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; KIRCHHEIMER JC, 1990, J IMMUNOL, V145, P1518; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOOLWIJK P, 1995, J RHEUMATOL, V22, P385; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LAMARRE J, 1994, BIOCHEM J, V302, P199, DOI 10.1042/bj3020199; LUND LR, 1991, J BIOL CHEM, V266, P5177; MARTINEZ J, 1994, EUR J CELL BIOL, V64, P257; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MIGNATTI P, 1995, KIDNEY INT, V47, pS12; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; PENTLAND AP, 1995, J INVEST DERMATOL, V104, P52, DOI 10.1111/1523-1747.ep12613488; PLOW EF, 1990, CELL DIFFER DEV, V32, P293, DOI 10.1016/0922-3371(90)90042-U; PLUZNIK DH, 1992, EXP HEMATOL, V20, P57; PULFORD KAF, 1989, J CLIN PATHOL, V42, P414, DOI 10.1136/jcp.42.4.414; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; RICHARDSON M, 1988, CLIN INVEST MED, V11, P139; SAKAMOTO N, 1991, CANCER RES, V51, P903; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WAHL LM, 1993, J PERIODONTOL, V64, P467; WANTANABE G, 1993, J CELL SCI, V104, P991; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; YE RD, 1989, J BIOL CHEM, V264, P5495	70	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8270	8275		10.1074/jbc.272.13.8270	http://dx.doi.org/10.1074/jbc.272.13.8270			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079647	hybrid			2022-12-27	WOS:A1997WQ63500030
J	Servant, G; Laporte, SA; Leduc, R; Escher, E; Guillemette, G				Servant, G; Laporte, SA; Leduc, R; Escher, E; Guillemette, G			Identification of angiotensin II-binding domains in the rat AT(2) receptor with photolabile angiotensin analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; TYPE-2 RECEPTOR; SUBSTANCE-P; CLONING; MUTAGENESIS; INHIBITION; EXPRESSION; AGONIST; PEPTIDE; PROTEIN	To identify binding domains between angiotensin II (AngII) and its type 2 receptor (AT(2)), two different radiolabeled photoreactive analogs were prepared by replacing either the first or the last amino acid in the peptide with p-benzoyl-L-phenylalanine (Bpa). Digestion of photolabeled receptors with kallikrein revealed that the two photoreactive analogs label the amino-terminal part of the receptor within the first 182 amino acids. Digestion of I-125-[Bpa(1)]AngII . AT(2) receptor complex with endoproteinase Lys-C produced a glycoprotein of 80 kDa. Deglycosylation of this 80-kDa product decreased its apparent molecular mass to 4.6 kDa and further cleavage of this 4.6-kDa product with V8 protease decreased its molecular mass to 3.6 kDa, circumscribing the labeling site of I-125-[Bpa(1)]AngII within amino acids 330 of AT(2) receptor. Treatment of I-125-[Bpa(8)]AngII . AT(2) receptor complex with cyanogen bromide produced two major receptor fragments of 3.6 and 2.6 kDa. Cyanogen bromide hydrolysis of a mutant AT(2) receptor produced two major fragments of 12.6 kDa and 2.6 kDa defining the labeling site of I-125-[Bpa(8)]AngII within residues 129-138 of AT(2) receptor. Our results indicate that the aminoterminal tail of the AT(2) receptor interacts with the amino-terminal end of AngII, whereas the inner half of the third transmembrane domain of AT(2) receptor interacts with the carboxyl-terminal end of AngII.	UNIV SHERBROOKE,FAC MED,DEPT PHARMACOL,SHERBROOKE,PQ J1H 5N4,CANADA	University of Sherbrooke			Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X; Escher, Emanuel/0000-0001-6601-987X				BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; BOSSE R, 1993, REGUL PEPTIDES, V44, P215, DOI 10.1016/0167-0115(93)90245-4; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FONG TM, 1992, J BIOL CHEM, V267, P25664; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GROBLEWSKI T, 1995, BIOCHEM BIOPH RES CO, V209, P153, DOI 10.1006/bbrc.1995.1483; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; Hunyady L, 1996, TRENDS PHARMACOL SCI, V17, P135, DOI 10.1016/0165-6147(96)81588-4; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PARISH CR, 1969, BIOCHEM J, V113, P489, DOI 10.1042/bj1130489; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; REGOLI D, 1974, PHARMACOL REV, V26, P69; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SERVANT G, 1993, MOL PHARMACOL, V43, P677; Servant G, 1996, BIOCHEM J, V313, P297, DOI 10.1042/bj3130297; SERVANT G, 1994, MOL PHARMACOL, V45, P1112; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024	31	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8653	8659		10.1074/jbc.272.13.8653	http://dx.doi.org/10.1074/jbc.272.13.8653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079697	hybrid			2022-12-27	WOS:A1997WQ63500080
J	Yanagisawa, J; Takahashi, M; Kanki, H; YanoYanagisawa, H; Tazunoki, T; Sawa, E; Nishitoba, T; Kamishohara, M; Kobayashi, E; Kataoka, S; Sato, T				Yanagisawa, J; Takahashi, M; Kanki, H; YanoYanagisawa, H; Tazunoki, T; Sawa, E; Nishitoba, T; Kamishohara, M; Kobayashi, E; Kataoka, S; Sato, T			The molecular interaction of Fas and FAP-1 - A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; CYTOSKELETAL-ASSOCIATED PROTEINS; DEATH DOMAIN; GUANYLATE KINASES; BAND-4.1 FAMILY; CLONING; EXPRESSION; HOMOLOGY; ANTIGEN	Fas (APO-1/CD95), which isa member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that induces apoptosis. A protein tyrosine phosphatase, Fas-associated phosphatase-l (FAP-1), that was previously identified as a Fas binding protein interacts with the C-terminal 15 amino acids of the regulatory domain of the Fas receptor. To identify the minimal region of the Fas C-terminal necessary for binding to FAP-1, we employed an in vitro inhibition assay of Fas/FAP-1 binding using a series of synthetic peptides as well as a screen of random peptide libraries by the yeast two-hybrid system. The results showed that the C-terminal three amino acids (SLV) of human Fas were necessary and sufficient for its interaction with the third PDZ (GLGF) domain of FAP-1. Furthermore, the direct cytoplasmic microinjection of this tripeptide (Ac-SLV) resulted in the induction of Fas-mediated apoptosis in a colon cancer cell line that expresses both Fas and FAP-1. Since t(S/T)X(V/L/I) motifs in the C termini of several other receptors have been shown to interact with PDZ domain in signal transducing molecules, this may represent a general motif for protein-protein interactions with important biological functions.	COLUMBIA UNIV COLL PHYS & SURG,DEPT OTOLARYNGOL HEAD & NECK SURG & PATHOL,DIV MOL ONCOL,NEW YORK,NY 10032; KIRIN BREWERY CO LTD,PHARMACEUT RES LAB,TAKASAKI,GUMMA 37012,JAPAN; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University; Kirin Brewery Company Limited; Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055147] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM55147-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HILL DE, 1987, METHOD ENZYMOL, V155, P558; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KITAMURA K, 1994, FEBS LETT, V351, P35, DOI 10.1016/0014-5793(94)00810-8; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mori S, 1996, CANCER RES, V56, P1874; NEITHAMMER M, 1996, J NEUROSCI, V16, P2157; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHNORRENBERG G, 1989, TETRAHEDRON, V45, P7759, DOI 10.1016/S0040-4020(01)85791-4; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG XW, 1995, CANCER RES, V55, P6012; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	44	129	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8539	8545		10.1074/jbc.272.13.8539	http://dx.doi.org/10.1074/jbc.272.13.8539			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079683	hybrid			2022-12-27	WOS:A1997WQ63500066
J	Yamauchi, J; Kaziro, Y; Itoh, H				Yamauchi, J; Kaziro, Y; Itoh, H			C-terminal mutation of G protein beta subunit affects differentially extracellular signal-regulated kinase and c-Jun N-terminal kinase pathways in human embryonal kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ADRENERGIC-RECEPTOR KINASE; GAMMA-SUBUNITS; MAP KINASE; SACCHAROMYCES-CEREVISIAE; POTASSIUM CHANNEL; MESSENGER-RNAS; ACTIVATION; CLONING; BINDING	G protein beta and gamma subunits (G beta and G gamma) form a complex that is involved in various signaling pathways. We reported that the C-terminal 10 amino acids of G beta are required for association with G gamma (Yamauchi, J., Kaziro, Y., and Itoh, H. (1995) Biochem. Biophys. Res. Commun., 214, 694-700). To evaluate further the significance of the G-terminal region of G beta in the formation of a G beta gamma complex and its signal transduction, we constructed several C-terminal mutants and expressed them in human embryonal kidney 293 cells, The mutant lacking the C-terminal 2 amino acids (Delta C2) failed to associate with G gamma, whereas deletion of the C-terminal amino acid (Delta C1), replacement of Trp at -2 position by Ala (W339A), and addition of six histidines ((His)(6)) at the G terminus did not affect the association with G gamma. We also studied the effect of these mutations on the activation of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK). Go-expression of the Delta C2 or (His), mutant with Gy did not activate MAPK/ERK at all, whereas the Delta C1 or W339A mutant showed the MAPK/ERK activation. The JNK/SAPK activity was stimulated by the W339A, Delta C2, or (His), mutant, but not by the Delta C1 mutant, These results suggest that the C-terminal region of GP participates differentially in the signaling for MAPK/ERK and JNW/SAPK activations in mammalian cells.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Coria R, 1996, YEAST, V12, P41; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOTOH Y, 1994, ONCOGENE, V9, P1891; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	47	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7602	7607		10.1074/jbc.272.12.7602	http://dx.doi.org/10.1074/jbc.272.12.7602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065414	hybrid			2022-12-27	WOS:A1997WP59200008
J	Murai, H; Ikeda, M; Kishida, S; Ishida, O; OkazakiKishida, M; Matsuura, Y; Kikuchi, A				Murai, H; Ikeda, M; Kishida, S; Ishida, O; OkazakiKishida, M; Matsuura, Y; Kikuchi, A			Characterization of Ral GDP dissociation stimulator-like (RGL) activities to regulate c-fos promoter and the GDP/GTP exchange of Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; CELL-TRANSFORMATION; PLASMA-MEMBRANE; PROTEINS; ACTIVATION; P21; BINDING; KINASE; DOMAIN; RHO	Ral GDP dissociation stimulator-like (RGL) has been identified to be a possible effector protein of has. RGL shares 50% amino acid identity with Ral GDP dissociation stimulator and contains the CDC25-like domain in the central region and the Has-interacting domain in the C-terminal region. Since the modes of activation and action of RGL have not yet been clarified, in this paper we have analyzed the functions of RGL. In COS cells, RGL interacted with Ras(G12V/E37G) (a pus mutant in which Gly-12 and Glu-37 were changed to Val and Gly, respectively) which failed to bind to Raf, but not with Ras(G12V/T35S) which bound to Raf. Raf did not inhibit the binding of RGL to Ras(G12V/E37G) under the condition that Raf inhibited that of RGL to Ras(G12V). Expression of either RGL or Raf into NIH3T3 cells slightly activated c-fos promoter, while coexpression of both proteins greatly stimulated the c-fos promoter activity. RGL stimulated the GDP/GTP exchange of Ral and this action was enhanced by the post-translational modification of Ral. However, RGL was not active on Has, Rac, CDC42, Rap, or Rho. Furthermore, this action of RGL to stimulate the GDP/GTP exchange of Ral was dependent on Has in COS cells. These results suggest that RGL constitutes another Ras-signaling pathway which is distinct from the Raf pathway and indicate that the RGL pathway regulates the c-fos promoter activity and the GDP/GTP exchange of Ral.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST HLTH,DEPT VIROL 2,SHINJYUKU KU,TOKYO 162,JAPAN	Hiroshima University				kishida, shosei/0000-0003-0405-851X				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GORMAN C, 1985, DNA CLONING PRACTICA, V2; GORMAN C, 1985, DNA CLONING PRACTICA, V3; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee T, 1996, DEVELOPMENT, V122, P409; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Okazaki M, 1996, CANCER RES, V56, P2387; ORITA S, 1993, J BIOL CHEM, V268, P25542; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Wolthuis RMF, 1996, ONCOGENE, V13, P353	56	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10483	10490						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099691				2022-12-27	WOS:A1997WV26200025
J	Cadene, M; Duranton, J; North, A; Si-Tahar, M; Chignard, M; Bieth, JG				Cadene, M; Duranton, J; North, A; Si-Tahar, M; Chignard, M; Bieth, JG			Inhibition of neutrophil serine proteinases by suramin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ELASTASE; CATHEPSIN-G; ALPHA-1-PROTEINASE INHIBITOR; POLYMORPHONUCLEAR LEUKOCYTES; POTENT INHIBITOR; HEPARIN; MECHANISM; EMPHYSEMA; BINDING; DRUG	Suramin, a hexasulfonated naphtylurea recently used as an anti-tumor drug, is a potent inhibitor of human neutrophil elastase, cathepsin G, and proteinase 3. The complexes it forms with these enzymes are partially active on synthetic substrates, but full inhibition takes place when elastase activity is measured with fibrous elastin or when cathepsin G activity is measured using platelet aggregation. One molecule of elastase binds four molecules of suramin with a K-i of 2 X 10(-7) M as determined by enzyme inhibition or intrinsic fluorescence enhancement of suramin. The binding curves show no sign of cooperativity or anticooperativity. The K-i for the complexes with cathepsin G and proteinase 3 are 8 x 10(-8) and 5 x 10(-7) M, respectively. Ionic strength increases the K-i of the elastase suramin complex in a way that suggests that four of the six sulfonate groups of suramin form ionic interactions with basic residues of the enzyme and that at saturation almost all arginines of elastase form salt bridges with suramin. The neutrophil proteinase-inhibitory activity of suramin might be used to prevent tissue destruction and thrombus formation in diseases where massive infiltration and activation of neutrophils take place.	UNIV STRASBOURG 1, ENZYMOL LAB, INSERM, U392, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE; INST PASTEUR, UNITE PHARMACOL CELLULAIRE, INSERM, UA IP, U285, F-75015 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SI-TAHAR, Mustapha/L-4149-2014; Chignard, Michel/B-4351-2008; Si-Tahar, Mustapha/W-8034-2019	SI-TAHAR, Mustapha/0000-0002-5792-7742; Chignard, Michel/0000-0003-3810-6575; Si-Tahar, Mustapha/0000-0002-5792-7742; Cadene, Martine/0000-0003-4936-2662				BAICI A, 1980, BIOCHEM PHARMACOL, V29, P1723, DOI 10.1016/0006-2952(80)90131-8; BAICI A, 1981, BIOCHEM PHARMACOL, V30, P703, DOI 10.1016/0006-2952(81)90154-4; BELORGEY D, 1995, FEBS LETT, V361, P265, DOI 10.1016/0014-5793(95)00173-7; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; BOOTS J, 1953, T FARADAY SOC, V49, P696; BOUDIER C, 1992, J BIOL CHEM, V267, P4370; BRUCH M, 1986, BIOCHEM J, V238, P269, DOI 10.1042/bj2380269; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; DANESI R, 1993, BRIT J CANCER, V68, P932, DOI 10.1038/bjc.1993.457; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; FERRERLOPEZ P, 1990, AM J PHYSIOL, V258, pC1100, DOI 10.1152/ajpcell.1990.258.6.C1100; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; HART D, 1989, PARASITOL TODAY, V5, P117, DOI 10.1016/0169-4758(89)90054-9; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; LAFUMA C, 1991, EUR RESPIR J, V4, P1004; LAROCCA RV, 1991, CANCER, V67, P1509, DOI 10.1002/1097-0142(19910315)67:6<1509::AID-CNCR2820670608>3.0.CO;2-F; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; LIN Y, 1995, P NATL ACAD SCI USA, V92, P11044, DOI 10.1073/pnas.92.24.11044; MILLS GB, 1990, CANCER RES, V50, P3036; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; VANOOSTEROM AT, 1990, EUR J CANCER, V26, P422, DOI 10.1016/0277-5379(90)90008-H; VOOGD TE, 1993, PHARMACOL REV, V45, P177	35	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9950	9955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092534				2022-12-27	WOS:A1997WU03900053
J	DeLisle, S; Marksberry, EW; Bonnett, C; Jenkins, DJ; Potter, BVL; Takahashi, M; Tanzawa, K				DeLisle, S; Marksberry, EW; Bonnett, C; Jenkins, DJ; Potter, BVL; Takahashi, M; Tanzawa, K			Adenophostin A can stimulate Ca2+ influx without depleting the inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in the Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM INFLUX; INTRACELLULAR CALCIUM; PENICILLIUM-BREVICOMPACTUM; POTENT AGONISTS; LAEVIS OOCYTES; TRISPHOSPHATE; RECEPTOR; MEMBRANE; ACTIVATION; CHANNELS	Adenophostin A possesses the highest known affinity or the inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) receptor (InsP(3)R). The compound shares with Ins(1,4,5)P-3 those structural elements essential far binding to the InsP(3)R. However, its adenosine 2'-phosphate moiety has no counterpart in the Ins(1,4,5)P-3 molecule. To determine whether its unique structure conferred a distinctive biological activity, we characterized the adenophostin-induced Ca2+ signal in Xenopus oocytes using the Ca2+-gated Cl- current assay. In high concentrations, adenophostin A released Ca2+ from Ins(1,4,5)P-3-sensitive stores and stimulated a Cl- current that depended upon the presence of extracellular Ca2+. We used this Cl- current as a marker of Ca2+ influx. In low concentrations, however, adenophostin A stimulated Ca2+ influx exclusively. In contrast, Ins(1,4,5)P-3 and (2-hydroxyethyl)-alpha-D-glucopyranoside 2',3,4-trisphosphate, an adenophostin A mimic lacking most of the adenosine moiety, always released intracellular Ca2+ before causing Ca2+ influx. Ins(1,4,5)P-3 could still release Ca2+ during adenophostin A-induced Ca2+ influx, confirming that the Ins(1,4,5)P-3-sensitive intracellular Ca2+ stores had not been emptied. Adenophostin- and Ins(1,4,5)P-3-induced Ca2+ influx were not additive, suggesting that both agonists stimulated a common Ca2+ entry pathway. Heparin, which blocks binding to the InsP(3)R, prevented adenophostin-induced Ca2+ influx. These data indicate that adenophostin A can stimulate the influx of Ca2+ across the plasma membrane without inevitably emptying the Ins(1,4,5)P-3-sensitive intracellular Ca2+ stores.	VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52240; UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND; SANKYO CO LTD,BIOL RES LABS,TOKYO 108,JAPAN; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201	US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Iowa; University of Bath; Daiichi Sankyo Company Limited; University System of Maryland; University of Maryland Baltimore			Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; DELISLE S, 1994, AM J PHYSIOL, V266, pC429, DOI 10.1152/ajpcell.1994.266.2.C429; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; DELISLE S, 1995, AM J PHYSIOL, V268, pC1484; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; Jenkins DJ, 1996, CARBOHYD RES, V287, P169, DOI 10.1016/0008-6215(96)00078-X; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KUSANO K, 1982, J PHYSIOL-LONDON, V328, P143, DOI 10.1113/jphysiol.1982.sp014257; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MOREAU M, 1980, DEV BIOL, V78, P201, DOI 10.1016/0012-1606(80)90329-2; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1989, J NEUROSCI, V9, P4068; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON KR, 1985, DEV BIOL, V109, P504, DOI 10.1016/0012-1606(85)90475-0; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; TAKAHASHI M, 1993, J ANTIBIOT, V46, P1643, DOI 10.7164/antibiotics.46.1643; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; Thomas D, 1996, BIOCHEM J, V318, P649, DOI 10.1042/bj3180649; WILCOX RA, 1995, MOL PHARMACOL, V47, P1204	35	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9956	9961						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092535				2022-12-27	WOS:A1997WU03900054
J	Kelm, M; Dahmann, R; Wink, D; Feelisch, M				Kelm, M; Dahmann, R; Wink, D; Feelisch, M			The nitric oxide superoxide assay - Insights into the biological chemistry of the NO/O-2(-center dot) interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY VASCULAR TONE; RESONANCE SPECTROSCOPY; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; ANION PRODUCTION; PEROXYNITRITE; KINETICS; NO; HYPERTENSION; MECHANISMS	Nitric oxide (NO) is a widespread signaling molecule involved in the regulation of an impressive spectrum of diverse cellular functions. Superoxide anions (O-2(radical anion)) not only contribute to the localization of NO action by rapid inactivation, but also give rise to the formation of the potentially toxic species peroxynitrite (ONOO-) and other reactive nitrogen oxide species. The chemistry and biological effect of ONOO- depend on the relative rates of formation of NO and O-2(radical anion). However, the simultaneous quantification of NO and O-2(radical anion) has not been achieved yet due to their high rate of interaction, which is almost diffusion-controlled. A sensitive spectrophoto metric assay was developed for the simultaneous quantification of NO and O-2(radical anion) in aqueous solution that is based on the NO-induced oxidation of oxyhemoglobin (oxyHb) to methemoglobin and the O-2(radical anion)-mediated reduction of ferricytochrome c. Using a photodiode array photometer, spectral changes of either reaction were analyzed, and appropriate wavelengths were identified for the simultaneous monitoring of absorbance changes of the individual reactions, oxyHb oxidation was followed at 541.2 nm (isosbestic wavelength for the conversion of ferri- to ferrocytochrome c), and ferricytochrome c reduction was followed at 465 nm (wavelength at which absorbance changes during oxyHb to methemoglobin conversion were negligible), using 525 nm as the isosbestic point for both reactions, At final concentrations of 20 mu M ferricytochrome c and 5 mu M oxyHb, the molar extinction coefficients were determined to be epsilon(465-525) = 7.3 mM(-1) cm(-1) and epsilon(541.2-525) = 6.6 mM(-1) cm(-1), respectively. The rates of formation of either NO or O-2(radical anion) determined with the combined assay were virtually identical to those measured with the classical oxyhemoglobin and cytochrome c assays, respectively. The assay was successfully adapted to either kinetic or end point determination in a cuvette or continuous on-line measurement of both radicals in a flow-through system. Maximal assay sensitivity was -25 nM for NO and O-2(radical anion). Cross-reactivity with ONOO- was controlled for by the presence (if L-methionine. Generation of NO from the NO donor spermine diazeniumdiolate could be reliably quantified in the presence and absence of low, equimolar, and high flux rates of O-2(radical anion). Likewise, O-2(radical anion) enzymatically generated from hypoxanthine/xanthine oxidase could be specifically quantified with no difference in absolute rates in the presence or absence of concomitant NO generation at different flux rates. Nonenzymatic decomposition of 3-morpholinosydnonimine hydrochloride (100 mu M) in phosphate buffer, pH 7.4 (37 degrees C), was found to be associated with almost stoichiometric production of NO and O-2(radical anion) (1.24 mu M NO/min and 1.12 mu M O-2(radical anion)/min). Assay selectivity and applicability to biological systems were demonstrated in cultured endothelial cells and isolated aortic tissue using calcium ionophore and NADH for stimulation of NO and O-2(radical anion) formation, respectively. Based on these data, a computer model was elaborated that successfully predicts the reaction of NO and O-2(radical anion) with hemoprotein and may thus help to further elucidate these reactions. In conclusion, the nitric oxide/superoxide assay allows the specific, sensitive, and simultaneous detection of NO and O-2(radical anion). The simulation model developed also allows the reliable prediction of the reaction between NO and O-2(radical anion) as well as their kinetic interaction with other biomolecules. These new analytical tools will help to gain further insight into the physiological and pathophysiological significance of the formation of these radicals in cell homeostasis.	UNIV DUSSELDORF,DEPT MED,DIV CARDIOL PULM DIS & ANGIOL,D-40225 DUSSELDORF,GERMANY; NCI,TUMOR BIOL SECT,RADIAT BIOL BRANCH,NIH,BETHESDA,MD 20892	Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158; Azad, Mahan/0000-0002-8633-3513; Wink, David/0000-0002-5652-7480; Kelm, Malte/0000-0003-0060-1052				ABELSON JN, 1995, METHODS COMPANION ME; ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; BOHN H, 1989, J CARDIOVASC PHA S11, V14, P6; Bonner F.T., 2010, CHEMINFORM, V28, DOI [10.1002/chin.199715245, DOI 10.1002/CHIN.199715245]; BRAUN M, 1975, DIFF EQUAT, P159; BUTLER J, 1982, J BIOL CHEM, V257, P747; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; FEELISCH M, 1995, EUR J CLIN INVEST, V25, P737, DOI 10.1111/j.1365-2362.1995.tb01952.x; Feelisch M., 1996, METHODS NITRIC OXIDE; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; Fridovich I., 1985, CRC HDB METHODS OXYG, P121; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; Greenwald R.A, 1985, CRC HDB METHODS OXYG; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Hampl V., 1996, METHODS NITRIC OXIDE, P309; HARRISON DG, 1993, CIRCULATION, V87, P1461, DOI 10.1161/01.CIR.87.5.1461; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Katusic ZS, 1996, FREE RADICAL BIO MED, V20, P443, DOI 10.1016/0891-5849(96)02116-8; KELM M, 1995, HYPERTENSION, V25, P186, DOI 10.1161/01.HYP.25.2.186; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; Kelm M., 1996, METHODS NITRIC OXIDE, P47; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEMBERG R., 1956, REV PURE AND APPL CHEM, V6, P1; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVA E, 1995, CIRCULATION, V91, P2310, DOI 10.1161/01.CIR.91.9.2310; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PRYOR WA, 1995, FREE RADICAL BIO MED, V18, P75, DOI 10.1016/0891-5849(94)00105-S; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; Stehouwer CDA, 1996, EUR J CLIN INVEST, V26, P535, DOI 10.1046/j.1365-2362.1996.1780527.x; SUTTON HC, 1976, BIOCHEM J, V155, P503, DOI 10.1042/bj1550503; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; VALENTINE JS, 1975, J AM CHEM SOC, V97, P224, DOI 10.1021/ja00834a058; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HE; VANDEWALLE PL, 1987, FEBS LETT, V210, P195, DOI 10.1016/0014-5793(87)81336-4; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	57	151	167	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9922	9932						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092531				2022-12-27	WOS:A1997WU03900050
J	Dibrov, E; Robinson, KM; Lemire, BD				Dibrov, E; Robinson, KM; Lemire, BD			The COQ5 gene encodes a yeast mitochondrial protein necessary for ubiquinone biosynthesis and the assembly of the respiratory chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE FLAVOPROTEIN SUBUNIT; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUCCINATE-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ELECTRON-TRANSFER; MUTANTS; MEMBRANE; DNA; METHYLTRANSFERASES	Saccharomyces cerevisiae is a facultative anaerobe capable of meeting its energy requirements by fermentation and is thus an ideal system for studying the biogenesis of respiring mitochondria. We have isolated a respiration-deficient mutant exhibiting a pleiotropic loss of the mitochondrial electron transport chain. The corresponding wild-type gene, COQ5, was cloned, sequenced, and able to restore respiratory growth. Deletion of the chromosomal COQ5 gene results in a respiration deficiency and reduced levels of respiratory protein components. Exogenously added decylubiquinone can partially restore electron transport chain function to mitochondrial membranes from the deletion mutant. The COQ5 nucleotide sequence predicts a polypeptide of 307 amino acids containing a mitochondrial targeting signal. COQ5p is 43% identical to the polypeptide predicted by the Escherichia coli open reading frame, o251 (1). The COQ5 gene, when introduced into E. coli, complements the respiratory deficiency of an ubiE mutant that maps near o251, suggesting that it is the yeast homolog of the ubiE gene product. We conclude that the COQ5 gene encodes the mitochondria-localized 2-hexaprenyl-6-methoxy-1,4-benzoquinone methyltransferase of the yeast ubiquinone biosynthetic pathway.	UNIV ALBERTA, DEPT BIOCHEM, MRC, GRP MOL BIOL MEMBRANE, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEATTIE DS, 1992, ARCH BIOCHEM BIOPHYS, V292, P499, DOI 10.1016/0003-9861(92)90022-O; BENTLEY R, 1987, ESCHERICHIA COLI SAL, P512; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Cox G B, 1979, Methods Enzymol, V56, P106; CRANE F. L., 1971, Methods in Enzymology, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V387, P441, DOI 10.1016/0005-2728(75)90084-5; DESANTIS A, 1984, ARCH BIOCHEM BIOPHYS, V232, P354; DIBROV PA, 1993, FEBS LETT, V336, P530, DOI 10.1016/0014-5793(93)80870-Z; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; ERNSTER L, 1993, CLIN INVESTIGATOR, V71, pS60, DOI 10.1007/BF00226842; Gibson F, 1978, Methods Enzymol, V53, P600; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JESNOWSKI R, 1995, CURR GENET, V27, P318, DOI 10.1007/BF00352100; KIM IC, 1973, EUR J BIOCHEM, V36, P509, DOI 10.1111/j.1432-1033.1973.tb02937.x; LILL R, 1996, TRENDS CELL BIOL, V6, P5661; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Mattoon J R, 1979, Methods Enzymol, V56, P117; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WU GH, 1992, J GEN MICROBIOL, V138, P2101, DOI 10.1099/00221287-138-10-2101; WU GH, 1993, J GEN MICROBIOL, V139, P1795, DOI 10.1099/00221287-139-8-1795; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971	40	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9175	9181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083048				2022-12-27	WOS:A1997WU03700053
J	Woolridge, DP; VazquezLaslop, N; Markham, PN; Chevalier, MS; Gerner, EW; Neyfakh, AA				Woolridge, DP; VazquezLaslop, N; Markham, PN; Chevalier, MS; Gerner, EW; Neyfakh, AA			Efflux of the natural polyamine spermidine facilitated by the Bacillus subtilis multidrug transporter Blt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; RESISTANCE; GENE; NORA	Multidrug transporters pump structurally dissimilar toxic molecules out of cells. It is not known, however, if detoxification is the primary physiological function of these transporters. The chromosomal organization of the gene encoding the Bacillus subtilis multidrug transporter Bit suggests a specific function for this protein; it forms a single operon with another gene, bltD, whose protein product is identified here as a spermine/spermidine acetyltransferase, an enzyme catalyzing a key step in spermidine degradation. Overexpression of the Blt transporter in B. subtilis leads not only to the multidrug-resistance phenotype but also to the efflux of large amounts of spermidine into the medium; this efflux is supressed by an inhibitor of Blt, reserpine. Taken together, these results strongly suggest that the natural function of the Blt transporter is the efflux of spermidine, whereas multiple drugs may be recognized by Blt merely opportunistically.	UNIV ILLINOIS,CTR BIOPHARMACEUT BIOTECHNOL,CHICAGO,IL 60607; UNIV ILLINOIS,DEPT MED CHEM & PHARMACOGNOSY,CHICAGO,IL 60607; UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT BIOCHEM,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences					NCI NIH HHS [CA30052, CA23074] Funding Source: Medline; NIGMS NIH HHS [GM49819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074, R01CA030052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BRON S, 1990, MOL BIOL METHODS BAC, P148; CARPER SW, 1991, J BIOL CHEM, V266, P12439; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; FUKUCHI J, 1994, J BIOL CHEM, V269; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROSSMAN AD, 1985, J BACTERIOL, V161, P939, DOI 10.1128/JB.161.3.939-943.1985; ISHII I, 1994, CELL MOL BIOL, V40, P925; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SEILER N, 1980, J CHROMATOGR, V221, P227, DOI 10.1016/S0378-4347(00)84307-8; SICCARDI AG, ANTIMICROB AGENTS CH, V8, P370; TIMMERS K, 1978, BIOINORG CHEM, V9, P145, DOI 10.1016/S0006-3061(00)80286-0; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	20	80	96	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8864	8866						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083003				2022-12-27	WOS:A1997WU03700008
J	Beggs, HE; Baragona, SC; Hemperly, JJ; Maness, PF				Beggs, HE; Baragona, SC; Hemperly, JJ; Maness, PF			NCAM140 interacts with the focal adhesion kinase p125(fak) and the SRC-related tyrosine kinase p59(fyn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE N-CAM; IMMUNOELECTRON-MICROSCOPIC LOCALIZATION; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; 2ND MESSENGER SYSTEMS; NEURITE OUTGROWTH; MUTANT MICE; SIGNAL-TRANSDUCTION; RAT-BRAIN; FYN	Axonal growth cones respond to adhesion molecules and extracellular matrix components by rapid morphological changes and growth rate modification, Neurite outgrowth mediated by the neural cell adhesion molecule (NCAM) requires the src family tyrosine kinase p59(fyn) in nerve growth cones, but the molecular basis for this interaction has not been defined, The NCAM140 isoform, which is found in migrating growth cones, selectively co-immunoprecipitated with p59(fyn) from nonionic detergent (Brij 96) extracts of early postnatal mouse cerebellum and transfected rat B35 neuroblastoma and COS-7 cells. p59(fyn) did not associate significantly with the NCAM180 isoform, which is found at sites of stable neural cell contacts, or with the glycophosphatidylinositol-linked NCAM180 isoform, pp60(c-src), a tyrosine kinase that promotes neurite growth on the neuronal cell adhesion molecule L1, did not interact with any NCAM isoform, Whereas p59(fyn) was constitutively associated with NCAM140, the focal adhesion kinase p125(fak), a nonreceptor tyrosine kinase known to mediate integrin-dependent signaling, became recruited to the NCAM140-p59(fyn) complex when cells were reacted with antibodies against the extracellular region of NCAM. Treatment of cells with a soluble NCAM fusion protein or with NCAM antibodies caused a rapid and transient increase in tyrosine phosphorylation of p125(fak) and p59(fyn). These results suggest that NCAM140 binding interactions at the cell surface induce the assembly of a molecular complex of NCAM140, p125(fak), and p59(fyn) and activate the catalytic function of these tyrosine kinases, initiating a signaling cascade that may modulate growth cone migration.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM, CHAPEL HILL, NC 27599 USA; BECTON DICKINSON RES CTR, DEPT NEUROBIOL, RES TRIANGLE PK, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Becton Dickinson					NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOSCH A, 1993, J NEUROBIOL, V24, P344, DOI 10.1002/neu.480240307; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARE DJ, 1993, ONCOGENE, V8, P1429; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BIXBY JL, 1992, J NEUROBIOL, V23, P468, DOI 10.1002/neu.480230503; BURDENGULLEY SM, 1995, J NEUROSCI, V15, P4370; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOKE M P, 1989, New Biologist, V1, P66; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; FURUTA Y, 1995, ONCOGENE, V11, P1989; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Gomez TM, 1996, J NEUROBIOL, V29, P18, DOI 10.1002/(SICI)1097-4695(199601)29:1<18::AID-NEU2>3.0.CO;2-A; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KLINZ SG, 1995, J NEUROCHEM, V65, P84; KLINZ SG, 1995, ANAL CELL ADHESION M; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU L, 1993, J NEUROSCI RES, V35, P327, DOI 10.1002/jnr.490350313; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MILLER DR, 1993, J NEUROCHEM, V60, P2134, DOI 10.1111/j.1471-4159.1993.tb03498.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Morse W. R., 1996, Society for Neuroscience Abstracts, V22, P1469; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; NOBLE M, 1985, NATURE, V316, P725, DOI 10.1038/316725a0; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; PAYNE HR, 1992, CELL MOTIL CYTOSKEL, V21, P65, DOI 10.1002/cm.970210108; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SAFFELL JL, 1994, J CELL BIOL, V125, P427, DOI 10.1083/jcb.125.2.427; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; Worley T, 1996, J NEUROSCI, V16, P2294; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	79	220	226	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8310	8319		10.1074/jbc.272.13.8310	http://dx.doi.org/10.1074/jbc.272.13.8310			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079653	hybrid			2022-12-27	WOS:A1997WQ63500036
J	Dan, JH; VanDeerlin, VMD; Tollefsen, DM				Dan, JH; VanDeerlin, VMD; Tollefsen, DM			Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; DEPENDENT INHIBITOR; ANTITHROMBIN-III; HUMAN-PLASMA; CHYMOTRYPSIN; COAGULATION; SUBSTRATE	Heparin cofactor II (HCII) inhibits thrombin by forming a stable 1:1 complex, Heparin and dermatan sulfate increase the rate of complex formation greater than or equal to 1000-fold. Mutation of leucine 444 to arginine at the P1 position of recombinant HCII (rHCII) increases the rate of inhibition of thrombin similar to 100-fold in the absence of a glycosaminoglycan (Derechin, V. M., Blinder, M. A., and Tollefsen, D. M. (1990) J. Biol. Chem. 265, 5623-5628). We now report that heparin facilitates dissociation of the thrombin-rHCII(L444R) complex, In the presence of heparin, thrombin is inhibited rapidly and completely by a 35-fold molar excess of rHCII(L444R), but subsequently similar to 50% of the thrombin activity reappears with a t(1/2) of similar to 20 min, At higher ratios of rHCII(L444R) to thrombin, the reappearance of thrombin activity is delayed and the final plateau of activity is decreased. Electrophoretic analysis indicates that proteolysis of excess rHCII(L444R) precedes the reappearance of thrombin activity. Addition of heparin at longer intervals after formation of the thrombin-rHCII(L444R) complex causes a progressive decrease in the thrombin plateau, suggesting that in the absence of heparin the complex is slowly converted to a non-dissociable form, By contrast to heparin, dermatan sulfate does not facilitate dissociation of the thrombin-rHCII(L444R) complex. Our findings indicate that the P1 residue of HCII affects not only the rate of inhibition of thrombin but also the stability of the resulting complex.	WASHINGTON UNIV,SCH MED,DIV HEMATOL,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-14147, HL-55520] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055520, P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DANIELSSON A, 1983, BIOCHEM J, V213, P345, DOI 10.1042/bj2130345; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; JESTY J, 1979, J BIOL CHEM, V254, P44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PARKER KA, 1985, J BIOL CHEM, V260, P3501; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223	23	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8243	8249		10.1074/jbc.272.13.8243	http://dx.doi.org/10.1074/jbc.272.13.8243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079643	hybrid			2022-12-27	WOS:A1997WQ63500026
J	Goodtzova, K; Kanugula, S; Edara, S; Pauly, GT; Moschel, RC; Pegg, AE				Goodtzova, K; Kanugula, S; Edara, S; Pauly, GT; Moschel, RC; Pegg, AE			Repair of O-6-benzylguanine by the Escherichia coli Ada and Ogt and the human O6-alkylguanine-DNA alkyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CRYSTAL-STRUCTURE; DNA-REPAIR; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; TUMOR-CELLS; ACTIVE-SITE; RAT-LIVER; METHYLTRANSFERASE; INACTIVATION	O-6-Methylguanine is removed from DNA via the transfer of the methyl group to a cysteine acceptor site present in the DNA repair protein O-6-alkylguanine-DNA alkyltransferase. The human alkyltransferase is inactivated by the free base O-6-benzylguanine, raising the possibility that substantially larger alkyl groups could also be accepted as substrates, However, the Escherichia coli alkyltransferase, Ada-C, is not inactivated by O-6-benzylguanine, The Ada-C protein was rendered capable of reaction by the incorporation of two site-directed mutations converting Ala(316) to a proline (A316P) and Trp(336) to alanine (W336A) or glycine (W336G), These changes increase the space at the active site of the protein where Cys(321) is buried and thus permit access of the O-6-benzylguanine inhibitor, Reaction of the mutant A316P/FY336A-Ada-C with O-6-benzylguanine was greatly stimulated by the presence of DNA, providing strong support for the concept that binding of DNA to the Ada-C protein activates the protein, The Ada-C protein was able to repair O-6-benzylguanine in a 16-mer oligodeoxyribonucleotide. However, the rate of repair was very slow, whereas the E. coli Ogt, the human alkyltransferase, and the mutant A316P/W336A-Ada-C alkyltransferases reacted very rapidly with this 16-mer substrate and preferentially repaired it when incubated with a mixture of the methylated and benzylated 16-mers. These results show that benzyl groups are better substrates than methyl groups for alkyltransferases provided that steric factors do not prevent binding of the substrate in the correct orientation for alkyl group transfer.	PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOL PHYSIOL,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Pauly, Gary/0000-0002-3481-7129	NCI NIH HHS [CA-57725, CA-18138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057725, R37CA018138, U19CA057725, R01CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAE MY, 1995, J MED CHEM, V38, P359, DOI 10.1021/jm00002a018; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; CIOCCO GM, 1995, CANCER RES, V55, P4085; CRONE TM, 1995, CARCINOGENESIS, V16, P1687, DOI 10.1093/carcin/16.8.1687; CRONE TM, 1994, CANCER RES, V54, P6221; CRONE TM, 1993, CANCER RES, V53, P4750; DEMPLE B, 1995, CURR BIOL, V5, P719, DOI 10.1016/S0960-9822(95)00143-6; DEMPLE B, 1985, P NATL ACAD SCI USA, V82, P2688, DOI 10.1073/pnas.82.9.2688; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DOLAN ME, 1991, CANCER RES, V51, P3367; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; ELDER RH, 1994, BIOCHEM J, V298, P231, DOI 10.1042/bj2980231; Fried MG, 1996, BIOCHEMISTRY-US, V35, P15295, DOI 10.1021/bi960971k; FRIEDMAN HS, 1992, J NATL CANCER I, V84, P1926, DOI 10.1093/jnci/84.24.1926; Gerson Stanton L., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P699; GOODTZOVA K, 1994, BIOCHEMISTRY-US, V33, P8385, DOI 10.1021/bi00194a001; HECHT SS, 1991, EXP LUNG RES, V17, P501, DOI 10.3109/01902149109064435; IYAMA A, 1994, CARCINOGENESIS, V15, P627, DOI 10.1093/carcin/15.4.627; KANUGULA S, 1995, BIOCHEMISTRY-US, V34, P7113, DOI 10.1021/bi00021a024; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LIEM LK, 1994, NUCLEIC ACIDS RES, V22, P1613, DOI 10.1093/nar/22.9.1613; LIN DX, 1990, CARCINOGENESIS, V11, P1653, DOI 10.1093/carcin/11.9.1653; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu XK, 1996, CHEM RES TOXICOL, V9, P949, DOI 10.1021/tx960067t; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOODY PCE, 1995, CONTR ONCOL, V49, P16; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; MORIMOTO K, 1985, CARCINOGENESIS, V6, P1027, DOI 10.1093/carcin/6.7.1027; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAULY GT, 1991, BIOCHEMISTRY-US, V30, P11700, DOI 10.1021/bi00114a014; PAULY GT, 1988, CHEM RES TOXICOL, V1, P391, DOI 10.1021/tx00006a011; PEARL LH, 1995, TRENDS BIOCHEM SCI, V20, P421, DOI 10.1016/S0968-0004(00)89092-1; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, BIOCHEM PHARMACOL, V50, P1141, DOI 10.1016/0006-2952(95)00249-Y; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Pegg Anthony E., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P565; PETERSON LA, 1993, CANCER RES, V53, P2780; POTTER PM, 1987, NUCLEIC ACIDS RES, V15, P9177, DOI 10.1093/nar/15.22.9177; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; Roy S. K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P370; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Samson LD, 1992, ESSAYS BIOCHEM, V27, P69; Siglin JC, 1996, CARCINOGENESIS, V17, P1135, DOI 10.1093/carcin/17.5.1135; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VAUGHAN P, 1991, CARCINOGENESIS, V12, P263, DOI 10.1093/carcin/12.2.263; VERDINE GL, 1994, CELL, V76, P197, DOI 10.1016/0092-8674(94)90326-3; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	59	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8332	8339		10.1074/jbc.272.13.8332	http://dx.doi.org/10.1074/jbc.272.13.8332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079656	hybrid			2022-12-27	WOS:A1997WQ63500039
J	Hosokawa, H; Sawamura, T; Kobayashi, S; Ninomiya, H; Miwa, S; Masaki, T				Hosokawa, H; Sawamura, T; Kobayashi, S; Ninomiya, H; Miwa, S; Masaki, T			Cloning and characterization of a brain-specific cationic amino acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ECOTROPIC RETROVIRUS RECEPTOR; L-ARGININE; RAT-BRAIN; SYSTEM Y(+); IDENTIFICATION; CELLS; GENE; EXPRESSION; L-<H-3>ARGININE	rCAT3 (rat cationic amino acid transporter 3), a cDNA that encodes a novel member of the murine CAT family was isolated, The protein encoded by rCAT3 contained 619 amino acids, 53-58% of which were identical with those of the murine CAT family proteins previously described (mouse CAT1, CAT2a, CAT2b, and rat CAT1), Transient expression of rCAT3 and L-[C-14]arginine incorporation experiments in COS7 cells verified a high affinity system y(+) transporter activity of rCAT3. First, rCAT3-mediated L-[C-14]arginine incorporation was time-dependent and saturable with half-saturation constant (K-m) values of 103 +/- 12 mu M (mean +/- S.E., n = 3). Second, the incorporation was specific for cationic amino acids as evidenced from the inhibition by L-arginine, L-lysine, and L-ornithine. Third, neither sodium nor chloride ions in the extracellular medium were required for the activity. Fourth, the incorporation was inhibited by high potassium-induced membrane depolarization, On Northern blot using RNAs from various rat tissues, the expression of rCAT3 mRNA was restricted to the brain. These results indicated a role of rCAT3 in the system y(+) transporter activity in the nervous tissue.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,GRAD SCH HUMAN & ENVIRONM STUDIES,DEPT NEUROSCI,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Sawamura, Tatsuya/E-7103-2010; Miwa, Soichi/D-8468-2012					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ASANO T, 1992, J BIOL CHEM, V267, P19636; BOGLE RG, 1992, BRIT J PHARMACOL, V105, P768, DOI 10.1111/j.1476-5381.1992.tb09053.x; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSSOLATI O, 1989, AM J PHYSIOL, V256, pC930, DOI 10.1152/ajpcell.1989.256.4.C930; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; CORASANITI MT, 1992, NEUROSCI LETT, V147, P221, DOI 10.1016/0304-3940(92)90600-C; DO KQ, 1994, NEUROSCIENCE, V60, P581, DOI 10.1016/0306-4522(94)90488-X; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOPES MC, 1994, NEUROSCI LETT, V181, P1, DOI 10.1016/0304-3940(94)90546-0; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MITCHELL JA, 1990, NEUROSCIENCE, V57, P890; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDLIN A, 1994, GLIA, V11, P262, DOI 10.1002/glia.440110307; SOUTHAM E, 1991, J NEUROCHEM, V56, P2072, DOI 10.1111/j.1471-4159.1991.tb03468.x; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WESTERGAARD N, 1993, J NEUROCHEM, V61, P364, DOI 10.1111/j.1471-4159.1993.tb03579.x; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994	32	90	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8717	8722		10.1074/jbc.272.13.8717	http://dx.doi.org/10.1074/jbc.272.13.8717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079705	hybrid			2022-12-27	WOS:A1997WQ63500088
J	Shen, WF; Rozenfeld, S; Lawrence, HJ; Largman, C				Shen, WF; Rozenfeld, S; Lawrence, HJ; Largman, C			The Abd-B-like Hox homeodomain proteins can be subdivided by the ability to form complexes with Pbx1a on a novel DNA target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENES; TRANSCRIPTIONAL ACTIVATOR; COOPERATIVE INTERACTIONS; BINDING SPECIFICITY; CRYSTAL-STRUCTURE; EXPRESSION; DROSOPHILA; E2A; EXTRADENTICLE; CLUSTER	Previous studies showed that the Hox homeodomain proteins from paralog groups 1-8 display cooperative DNA binding with the non-Hox homeodomain protein Pbx, mediated by a canonical YPWM. Although the Abd-B-like Hox proteins in paralogs 9-13 lack this sequence, Hoxb-9 and Hoxa-10 were reported to bind with Pbx1a to DNA. We show that these interactions require a tryptophan 6 amino acids N-terminal to the homeodomain, Binding site selection for Hoxb-9 with Pbx1a yielded ATGATTTACGAC, containing a novel TTAC Hox-binding site adjacent to a Pbx site, In the presence of Pbx1a, Hoxb-9 and Hoxa-10 bound to targets containing either TTAC or TTAT. These data extend previous findings that interactions with Pbx define a Hox protein binding code for different DNA sequences across paralog groups 1 through 10. Members of the 11, 12, and 13 paralogs do not cooperatively bind DNA with Pbx1a, despite the presence of tryptophan residues N-terminal to the homeodomain in Hoxd-12 and Hoxd-13. Hoxa-11, Hoxd-12, or Hoxd-13, in the presence of Pbx1a, selected a TTAC Hox site but lacking a Pbx1a site, These data suggest that Abd-B-like Hox proteins bind to a novel TTAC site and can be divided by their cooperative binding to DNA with Pbx1a.	VET ADM MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NIDDK NIH HHS [N44DK-3-2219] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Burglin Thomas R., 1994, P25; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU QA, 1995, MOL CELL BIOL, V15, P3786; MALICKI J, 1993, MECH DEVELOP, V42, P139, DOI 10.1016/0925-4773(93)90003-G; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; PETERSON RL, 1992, MECH DEVELOP, V37, P151, DOI 10.1016/0925-4773(92)90077-W; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; ROGINA B, 1993, NUCLEIC ACIDS RES, V21, P1316, DOI 10.1093/nar/21.5.1316; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; Zeltser L, 1996, DEVELOPMENT, V122, P2475	39	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8198	8206		10.1074/jbc.272.13.8198	http://dx.doi.org/10.1074/jbc.272.13.8198			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079637	hybrid			2022-12-27	WOS:A1997WQ63500020
J	VanDamme, EJM; Barre, A; Rouge, P; VanLeuven, F; Peumans, WJ				VanDamme, EJM; Barre, A; Rouge, P; VanLeuven, F; Peumans, WJ			Isolation and molecular cloning of a novel type 2 ribosome-inactivating protein with an inactive B chain from elderberry (Sambucus nigra) Bark	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; HYDROPHOBIC CLUSTER-ANALYSIS; AMINO-ACID SEQUENCES; LECTINS; 2.5-A; MUTAGENESIS	One of the predominant proteins in the bark of elderberry (Sambucus nigra) has been identified as a novel type 2 ribosome-inactivating protein that exhibits a normal RNA N-glycosidase activity, but is devoid of carbohydrate binding activity, Sequence analysis of the corresponding cDNA clones revealed a striking homology to the previously cloned bark lectins from elderberry, suggesting that the new protein is a lectin-related protein, Molecular modeling of the protein confirmed that its A chain is fully active, whereas its B chain contains two functionally inactive carbohydrate-binding sites. These findings not only demonstrate for the first time the occurrence of a type 2 ribosome-inactivating protein with an inactive B chain, but also offer interesting perspectives for the synthesis of immunotoxins with an improved selectivity.	KATHOLIEKE UNIV LEUVEN, CTR HUMAN GENET, B-3001 LOUVAIN, BELGIUM; UNIV TOULOUSE 3, INST PHARMACOL & BIOL STRUCT, UPR CNRS 9062, F-31062 TOULOUSE, FRANCE	KU Leuven; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	VanDamme, EJM (corresponding author), KATHOLIEKE UNIV LEUVEN, LAB PHYTOPATHOL & PLANT PROTECT, WILLEM DE CROYLAAN 42, B-3001 LOUVAIN, BELGIUM.		Van Damme, Els/U-3904-2019; Rouge, Pierre/T-2059-2019; Van Damme, Els J/B-4410-2015	Van Damme, Els/0000-0001-9848-766X; Barre, annick/0000-0002-1360-8491				BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BROEKAERT WF, 1984, BIOCHEM J, V221, P163, DOI 10.1042/bj2210163; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GIRBES T, 1993, PLANT MOL BIOL, V22, P1181, DOI 10.1007/BF00028990; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; HANKINS CN, 1988, PLANT PHYSIOL, V86, P67, DOI 10.1104/pp.86.1.67; Kaku H, 1996, J BIOL CHEM, V271, P1480, DOI 10.1074/jbc.271.3.1480; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V277, P255, DOI 10.1016/0003-9861(90)90576-K; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; KIM Y, 1992, PROTEIN ENG, V5, P775, DOI 10.1093/protein/5.8.775; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MIRKOV TE, 1994, PLANT MOL BIOL, V26, P1103, DOI 10.1007/BF00040692; NSIMBALUBAKI M, 1986, PLANT PHYSIOL, V80, P747, DOI 10.1104/pp.80.3.747; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; PEUMANS WJ, 1986, MOL BIOL SEED STORAG, P53; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; VANDAMME EJM, 1991, EUR J BIOCHEM, V202, P23, DOI 10.1111/j.1432-1033.1991.tb16339.x; VanDamme EJM, 1996, EUR J BIOCHEM, V237, P505, DOI 10.1111/j.1432-1033.1996.0505k.x; VanDamme EJM, 1996, PLANT MOL BIOL, V31, P657, DOI 10.1007/BF00042237; VanDamme EJM, 1996, EUR J BIOCHEM, V235, P128, DOI 10.1111/j.1432-1033.1996.00128.x; VANDENABEELE J, 1995, WATER RES, V29, P579, DOI 10.1016/0043-1354(94)00173-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WETZEL S, 1989, PLANTA, V178, P275, DOI 10.1007/BF00391854	31	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8353	8360		10.1074/jbc.272.13.8353	http://dx.doi.org/10.1074/jbc.272.13.8353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079659	hybrid			2022-12-27	WOS:A1997WQ63500042
J	Inukai, K; Funaki, M; Ogihara, T; Katagiri, H; Kanda, A; Anai, M; Fukushima, Y; Hosaka, T; Suzuki, M; Shin, BC; Takata, K; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T				Inukai, K; Funaki, M; Ogihara, T; Katagiri, H; Kanda, A; Anai, M; Fukushima, Y; Hosaka, T; Suzuki, M; Shin, BC; Takata, K; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T			p85 alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-kinase), p50 alpha, p55 alpha, and p85 alpha, with different PI 3-kinase activity elevating responses to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; RECEPTOR TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORTER; CELLS; WORTMANNIN; INHIBITOR; ACTIVATION; PROTEINS	Phosphatidylinositol 3-kinase (PI 3-kinase) is stimulated by association with a variety of tyrosine kinase receptors and intracellular tyrosine-phosphorylated substrates. We isolated a cDNA that encodes a 50-kDa regulatory subunit of PI 3-kinase with an expression cloning method using P-32-labeled insulin receptor substrate-1 (IRS-1), This 50-kDa protein contains two SH2 domains and an inter-SH2 domain of p85 alpha, but the SH3 and bcr homology domains of p85 alpha were replaced by a unique 6-amino acid sequence, Thus, this protein appears to be generated by alternative splicing of the p85 alpha gene product, We suggest that this protein be called p50 alpha. Northern blotting using a specific DNA probe corresponding to p50 alpha revealed 6.0- and 2.8-kb bands in hepatic, brain, and renal tissues, The expression of p50 alpha protein and its associated PI 3-kinase were detected in lysates prepared from the liver, brain, and muscle using a specific antibody against p50 alpha. Taken together, these observations indicate that the p85 alpha gene actually generates three protein products of 85, 55, and 50 kDa. The distributions of the three proteins (p85 alpha, p55 alpha, and p50 alpha), in various rat tissues and also in various brain compartments, were found to be different, Interestingly, p50 alpha forms a heterodimer with p110 that can as well as cannot be labeled with wortmannin, whereas p85 alpha and p55 alpha associate only with p110 that can be wortmannin-labeled. Furthermore, p50 alpha exhibits a markedly higher capacity for activation of associated PI 3-kinase via insulin stimulation and has a higher affinity for tyrosine-phosphorylated IRS-1 than the other isoforms. Considering the high level of p50 alpha expression in the liver and its marked responsiveness to insulin, p50 alpha appears to play an important role in the activation of hepatic PI 3-kinase, Each of the three alpha isoforms has a different function and may have specific roles in various tissues.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; ASAHI LIFE FDN, INST ADULT DIS, SHINJUKU KU, TOKYO 160, JAPAN; GUNMA UNIV, INST MOL & CELLULAR REGULAT, LAB MOL & CELLULAR MORPHOL, MAEBASHI, GUMMA 371, JAPAN; YAMAGUCHI UNIV, SCH MED, DEPT INTERNAL MED 3, UBE, YAMAGUCHI 755, JAPAN	University of Tokyo; Asahi Life Foundation; Gunma University; Yamaguchi University				Shin, Bo-Chul/0000-0002-7569-5121				Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; FOLLI F, 1994, J NEUROSCI, V14, P6412; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	140	148	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7873	7882		10.1074/jbc.272.12.7873	http://dx.doi.org/10.1074/jbc.272.12.7873			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065454	hybrid			2022-12-27	WOS:A1997WP59200048
J	Panda, D; Singh, JP; Wilson, L				Panda, D; Singh, JP; Wilson, L			Suppression of microtubule dynamics by LY290181 - A potential mechanism for its antiproliferative action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL MICROTUBULES; KINETIC STABILIZATION; TRANSITION FREQUENCIES; CELL-PROLIFERATION; STEADY-STATE; IN-VITRO; TUBULIN; INSTABILITY; BINDING; VINBLASTINE	LY290181, 2-amino-4-(3-pyridyl)-4H-naphtho(1,2-b)pyran-3-carbonitrile, is a potent antiproliferative compound that blocks cells in the G(2)/M phase of the cell cycle by an apparent action on microtubules. In the present work we found that LY290181 bound to tubulin with high affinity (1 mol of LY290181 per mol of tubulin dimer; K-a, 3.8 x 10(5) M(-1)) and that it did not appear to bind at the colchicine or vinblastine-binding sites, LY290181 strongly stabilized microtubule dynamics as determined by video microscopy. It reduced the rate and extent of growing and shortening, reduced the catastrophe frequency and increased the rescue frequency, and increased the percentage of time the microtubules spent in an attenuated state, At the lowest effective LY290181 concentrations (0.1-0.3 mu M), suppression of dynamics occurred with little reduction in polymer mass, However, at higher concentrations, LY290181 strongly reduced the polymer mass with half-maximal inhibition at a concentration of 0.75 mu M. We suggest that LY290181 may exert its antiproliferative activity by stabilizing spindle microtubule dynamics by binding to tubulin at a novel site.	LILLY RES LABS, INDIANAPOLIS, IN 46285 USA	Eli Lilly	Panda, D (corresponding author), UNIV CALIF SANTA BARBARA, DEPT MOL CELLULAR & DEV BIOL, SANTA BARBARA, CA 93106 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS13560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayley Peter M., 1994, V13, P111; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BOURDEAUXPONTIER M, 1968, J CHIM PHYS PCB, V75, P973; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1989, INT REV CYTOL, V115, P139; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; Dustin P., 1984, MICROTUBULES; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; Hamel E., 2018, MICROTUBULE PROTEINS, P89, DOI [10.1201/9781351074643-4, DOI 10.1201/9781351074643-4]; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOROWITZ P, 1984, J BIOL CHEM, V259, P4647; Hyams J. S., 1994, MICROTUBULES; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Kuriyama R., 1974, J BIOCHEM-TOKYO, V81, P1115; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEE JC, 1975, J BIOL CHEM, V250, P9276; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P739, DOI 10.1021/bi00351a035; SARKAR N, 1995, BIOCHEMISTRY-US, V34, P13367, DOI 10.1021/bi00041a013; SHELDEN E, 1993, J CELL BIOL, V120, P935, DOI 10.1083/jcb.120.4.935; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; VANDECANDELAERE A, 1995, BIOCHEMISTRY-US, V34, P1332, DOI 10.1021/bi00004a028; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WARD LD, 1994, BIOCHEMISTRY-US, V33, P11891, DOI 10.1021/bi00205a027; WILSON L, 1975, BIOCHEMISTRY-US, V14, P5586, DOI 10.1021/bi00697a008; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; Wilson Leslie, 1994, V13, P59; Wordeman Linda, 1994, V13, P287	43	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7681	7687		10.1074/jbc.272.12.7681	http://dx.doi.org/10.1074/jbc.272.12.7681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065425	hybrid			2022-12-27	WOS:A1997WP59200019
J	Yang, LH; Ahmed, SA; Rhee, S; Miles, EW				Yang, LH; Ahmed, SA; Rhee, S; Miles, EW			Importance of conserved and variable C-terminal residues for the activity and thermal stability of the beta subunit of tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BIENZYME COMPLEX; ALPHA-SUBUNIT; ALPHA(2)BETA(2) COMPLEX; MUTUAL ACTIVATION; SITE; SYNTHETASE; INACTIVATION; MUTAGENESIS	To assess the functional roles of helix 13 and of the conserved and variable residues in the C-terminal region (residues 378-397) of the tryptophan synthase beta subunit, we have constructed four C-terminal truncations and 12 point mutations. The effects of these mutations on kinetic and spectroscopic properties and thermal stability are reported here. The mutant beta subunits all form stable alpha(2) beta(2) complexes that have been purified to homogeneity. The mutant alpha(2) beta(2) complexes are divided into two classes on the basis of activity in the reaction of L-serine with indole to form tryptophan. Class I enzymes, which have mutations at Arg-379 or Asp-381 or truncations (384-397 or 385-397), exhibit significant activity (138% of wild type). Class II enzymes, which have mutations at Lys-382 or Asp 383 or truncations (382-397 or 385-397), exhibit very low activity (<1% of wild type), Although Class II enzymes have drastically reduced activity in the reaction of L-serine with indole and an altered distribution of enzyme-substrate intermediates in the reaction of L-serine with beta-mercaptoethanol, they retain activity in the reaction of beta-chloro-L-alanine with indole. Correlation of the results with the three-dimensional structure of the alpha(2) beta(2) complex suggests that Lys-382 and Asp-383 serve important roles in a proposed ''open'' to ''closed'' conformational change that occurs in the reactions of L-serine, Because mutant beta subunits having C-terminal truncations (383-397 or 384-397) undergo much more rapid thermal inactivation at 60 degrees C than the wild type beta subunit, the C-terminal helix 13 stabilizes the beta subunit.	NIDDK, ENZYME STRUCT & FUNCT SECT, BIOCHEM PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA; NIDDK, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; Ahmed SA, 1996, J BIOL CHEM, V271, P29100, DOI 10.1074/jbc.271.46.29100; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; COTTON RGH, 1972, J BIOL CHEM, V247, P1883; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381; NAVON A, 1995, J BIOL CHEM, V270, P4255, DOI 10.1074/jbc.270.9.4255; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang D, 1996, FASEB J, V10, P1231; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1972, ENZYMES, V7, P1; Yee MC, 1996, J BIOL CHEM, V271, P14754, DOI 10.1074/jbc.271.25.14754	35	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7859	7866		10.1074/jbc.272.12.7859	http://dx.doi.org/10.1074/jbc.272.12.7859			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065452	hybrid			2022-12-27	WOS:A1997WP59200046
J	Mulcahy, RT; Wartman, MA; Bailey, HH; Gipp, JJ				Mulcahy, RT; Wartman, MA; Bailey, HH; Gipp, JJ			Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA-CELL-LINES; MESSENGER-RNA; RAT-KIDNEY; DETOXIFY CARCINOGENS; NUCLEOTIDE-SEQUENCE; OXIDATIVE STRESS; LIGHT SUBUNIT; GLUTATHIONE; IDENTIFICATION; ENZYMES	Glutathione (GSH) is an abundant cellular non-protein sulfhydryl that functions as an important protectant against reactive oxygen species and electrophiles, is involved in the detoxification of xenobiotics, and contributes to the maintenance of cellular redox balance, The rate-limiting enzyme in the de novo synthesis of glutathione is gamma-glutamylcysteine synthetase (GCS), a heterodimer consisting of heavy and light subunits expressing catalytic and regulatory functions, respectively, Exposure of HepG2 cells to beta-naphthoflavone (beta-NF) resulted in a time- and dose-dependent increase in the steady-state mRNA levels for both subunits, In order to identify sequences mediating the constitutive and induced expression of the heavy subunit gene, a series of deletion mutants created from the 5'-flanking region (-3802 to +465) were cloned into a luciferase reporter vector (pGL3-Basic) and transfected into HepG2 cells, Constitutive expression was maximally directed by sequences between -202 and +22 as well as by elements between -3802 to -2752, The former sequence contains a consensus TATA box, Increased luciferase expression following exposure to 10 mu M beta-NF was only detected in cells transfected with a reporter vector containing the full-length -3802:+465 fragment, Hence, elements directing constitutive and induced expression of the GCS heavy subunit are present in the distal portion of the 5'-flanking region, between positions -3802 and -2752, Sequence analysis revealed the presence of several putative consensus response elements in this region, including two potential antioxidant response elements (ARE3 and ARE4), separated by 34 base pairs. When cloned into the thymidine kinase-luciferase vector, pT81-luciferase, and transfected into HepG2 cells, both ARE3 and ARE4 increased basal luciferase expression approximately 20-fold. When cloned in tandem in their native arrangement the increase in luciferase activity was in excess of 100-fold, suggesting a strong interaction between the two sequences, Luciferase expression was elevated in beta-NF-treated cells transfected with the AREA-th-luciferase vector and all DNA fragments containing ARE4. In contrast, ARE3 did not direct increased luciferase expression in response to beta-NF nor did it significantly modify the magnitude of induction directed by ARE4. The influence of the ARE4 oligonucleotide on constitutive and induced expression was eliminated by introduction of a single base mutation, converting the core ARE sequence in ARE4 fi om 5'-GTGACTCAGCG-3' to 5'-GGGACTCAGCG-3'. When introduced into the full-length -3802:+465 segment, the same single base mutation also eliminated both functions, Collectively the data indicate that the constitutive and P-NF-induced expression of the human GCS heavy subunit gene is mediated by a distal ARE sequence containing an embedded tetradecanoylphorbol-13-acetate-responsive element.	UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison	Mulcahy, RT (corresponding author), UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,K4-316,600 HIGHLAND AVE,MADISON,WI 53792, USA.				NCI NIH HHS [KO8-CA01749, R01-CA57549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001749, R01CA057549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY HH, 1994, J CLIN ONCOL, V12, P194, DOI 10.1200/JCO.1994.12.1.194; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUMP EA, 1983, CANCER RES, V43, P997; CHUNG AS, 1981, BIOCHEM PHARMACOL, V30, P3217, DOI 10.1016/0006-2952(81)90521-9; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; LI Y, 1992, J BIOL CHEM, V267, P15097; LIU RM, 1994, CARCINOGENESIS, V15, P2347, DOI 10.1093/carcin/15.10.2347; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Liu RM, 1996, AM J RESP CELL MOL, V14, P186, DOI 10.1165/ajrcmb.14.2.8630269; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1989, COENZYMES COFACTOR A, V3, P367; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; NARDI G, 1990, J CHROMATOGR-BIOMED, V530, P122, DOI 10.1016/S0378-4347(00)82310-5; NEAL GE, 1988, GLUTATHIONE CONJUGAT, P281; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Schroder CP, 1996, CANCER INVEST, V14, P158, DOI 10.3109/07357909609018891; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SHI MM, 1994, J BIOL CHEM, V269, P26512; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; SIERRARIVERA E, 1995, CYTOGENET CELL GENET, V70, P278, DOI 10.1159/000134051; SierraRivera E, 1996, CYTOGENET CELL GENET, V72, P252, DOI 10.1159/000134202; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TALALAY P, 1987, CANCER BIOL THERAPEU, P197; TEW KD, 1994, CANCER RES, V54, P4313; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsuchiya K, 1995, GENOMICS, V30, P630, DOI 10.1006/geno.1995.1293; WOODS JS, 1992, ARCH BIOCHEM BIOPHYS, V296, P350, DOI 10.1016/0003-9861(92)90583-I; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	46	408	421	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7445	7454		10.1074/jbc.272.11.7445	http://dx.doi.org/10.1074/jbc.272.11.7445			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054446	hybrid			2022-12-27	WOS:A1997WN14700085
J	Schaller, A; Martin, F; Muller, B				Schaller, A; Martin, F; Muller, B			Characterization of the calf thymus hairpin-binding factor involved in histone pre-mRNA 3' end processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; MESSENGER-RNA; STEM-LOOP; CELL-CYCLE; U7 SNRNA; SEQUENCES; PRECURSOR; INVITRO; PROTEIN; GENERATION	Using ion exchange chromatography we have enriched the RNA hairpin-binding factor involved in histone pre-mRNA processing from calf thymus whole cell extract. We demonstrate that the interaction of the factor with its target RNA sequence, the hairpin structure located at the 3' end of mature histone mRNA, is sequence-specific and highly salt-resistant. We have developed a simple in vitro system which allows detection of activities stimulating histone pre-mRNA 3' end processing, based on mouse cell nuclear extract fractionated by Mono Q column chromatography. Using this system, we show that the bovine hairpin-binding factor participates in histone pre-mRNA 3' end processing in vitro. We have further purified the hairpin-binding factor in form of a RNA protein complex by RNA-mediated elution from phosphocellulose. This led to a fraction highly enriched for 2 proteins of 40 and 43 kDa.	UNIV BERN,ABT ENTWICKLUNGSBIOL,INST ZOOL,CH-3012 BERN,SWITZERLAND	University of Bern			Schaller, André/L-4174-2018; MARTIN, Franck/D-9042-2015	Schaller, André/0000-0001-5174-5764; MARTIN, Franck/0000-0001-9724-4025; Muller, Berndt/0000-0003-1279-5421				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTEN M, 1988, EMBO J, V7, P801, DOI 10.1002/j.1460-2075.1988.tb02878.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dominski Z, 1995, RNA, V1, P915; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ECKNER R, 1992, NUCLEIC ACIDS RES, V20, P1023, DOI 10.1093/nar/20.5.1023; GALLI G, 1983, CELL, V34, P823, DOI 10.1016/0092-8674(83)90539-1; GICK O, 1987, P NATL ACAD SCI USA, V84, P8937, DOI 10.1073/pnas.84.24.8937; GICK O, 1986, EMBO J, V5, P1319, DOI 10.1002/j.1460-2075.1986.tb04362.x; Hanson RJ, 1996, BIOCHEMISTRY-US, V35, P2146, DOI 10.1021/bi9521856; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; PANDEY NB, 1994, MOL CELL BIOL, V14, P1709, DOI 10.1128/MCB.14.3.1709; SCHALLER A, 1995, CHARACTERIZATION PAR; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STAUBER C, 1986, EMBO J, V5, P3297, DOI 10.1002/j.1460-2075.1986.tb04643.x; STREIT A, 1993, NUCLEIC ACIDS RES, V21, P1569, DOI 10.1093/nar/21.7.1569; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345; WANG Z, 1997, GENE DEV, V10, P3028; WILLIAMS AS, 1994, NUCLEIC ACIDS RES, V22, P4660, DOI 10.1093/nar/22.22.4660; WILLIAMS AS, 1995, NUCLEIC ACIDS RES, V23, P654, DOI 10.1093/nar/23.4.654	34	7	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10435	10441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099685				2022-12-27	WOS:A1997WV26200019
J	Kiselyov, VV; Berezin, V; Maar, TE; Soroka, V; Edvardsen, K; Schousboe, A; Bock, E				Kiselyov, VV; Berezin, V; Maar, TE; Soroka, V; Edvardsen, K; Schousboe, A; Bock, E			The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in double-reciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; HOMOPHILIC BINDING; SUBSTRATUM ADHESION; IDENTIFICATION; SEQUENCE; CDNA; DETERMINANTS; POLYPEPTIDE; KINETICS; PROTEINS	To study the function of the first immunoglobulin (Ig)-like domain of the neural cell adhesion molecule (NCAM), it was produced as a recombinant fusion protein in a bacterial expression system and as a recombinant protein in a eukaryotic expression system of the yeast Pichia pastoris. For comparison, other NCAM domains were also produced as fusion proteins. By means of surface plasmon resonance analysis, it was shown that the first Ig-like NCAM domain binds the second Ig like NCAM domain with a dissociation constant 5.5 +/- 1.6 x 10(-5) M. Furthermore, it was found that the first Ig like domain binds heparin. It was also demonstrated that the second Ig-like NCAM domain binds heparin and that both domains bind collagen type I via heparin but not collagen type I directly.	ROYAL DANISH SCH PHARM, DEPT BIOL, DK-2100 COPENHAGEN, DENMARK	Royal Danish School of Pharmacy	Kiselyov, VV (corresponding author), UNIV COPENHAGEN, PANUM INST, PROT LAB, BLEGDAMSVEJ 3C, BLDG 62, DK-2200 COPENHAGEN, DENMARK.		Kiselyov, Vladislav/D-2273-2009					BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V103, P1739, DOI 10.1083/jcb.103.5.1739; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; GEGELASHVILI G, 1996, TREATISE BIOMEMBRANE, V3, P33; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HARBOE N, 1973, SCAND J IMMUNOL, V2, P161; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Kasper C, 1996, J NEUROSCI RES, V46, P173; KROG L, 1992, APMIS, V100, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; Piez K A, 1967, TREATISE COLLAGEN, V1, P207; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; RASMUSSEN S, 1982, SCAND J IMMUNOL, V15, P179, DOI 10.1111/j.1365-3083.1982.tb00636.x; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SANTONI MJ, 1987, NUCLEIC ACIDS RES, V15, P8621, DOI 10.1093/nar/15.21.8621; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915	35	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10125	10134						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092558				2022-12-27	WOS:A1997WU03900077
J	Sallese, M; Mariggio, S; Collodel, G; Moretti, E; Piomboni, P; Baccetti, B; DeBlasi, A				Sallese, M; Mariggio, S; Collodel, G; Moretti, E; Piomboni, P; Baccetti, B; DeBlasi, A			Protein-coupled receptor kinase GRK4 - Molecular analysis of the four isoforms and ultrastructural localization in spermatozoa and germinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACROSOME REACTION; RHODOPSIN KINASE; 2 ISOFORMS; CLONING; RECOVERIN; SPERM	G protein-coupled receptor kinase 4 (GBK4) presents some peculiar characteristics Chat make it a unique member within the GRK multigene family, For example, this is the only GRK for which four splice variants (GRK4 alpha, -beta, -gamma, -delta) have been identified. We developed a simple assay to study kinase activity, and we found that GRK alpha, but not GRK4 beta, -gamma, and -delta, was able to phosphorylate rhodopsin in an agonist-dependent manner, GRK4 alpha kinase activity was inhibited by Ca2+/calmodulin (CaM) (IC50 = 80 nM), and a direct interaction between GRK4 alpha and Ca2+/CaM was revealed using CaM-conjugated Sepharose 4B. The other three GRK4 isoforms did not interact with CaM in parallel experiments, The present investigation also aimed to define cellular and ultrastructural localization of GRK4. A substantial expression of GRK4 mRNA was only found in testis and in the spermatogonia cell line GC-1 spg. Specific GRK4 immunoreactivity was only found on sperm membranes, and immunochemical and ultrastructural analyses showed that it is associated to the acrosomal membranes and to the outer mitochondrial membranes, GRR4 gamma was the only detectable isoform in human sperm. We concluded that: i) only GRK4 alpha can phosphorylate rhodopsin and that this activity is inhibited by CaM; ii) the other three isoforms do not phosphorylate rhodopsin and do not interact with CaM; and iii) the association of GRK4 with highly specialized sperm organelles, which are essential for fertilization, strongly indicates that this kinase is involved in this process.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY; UNIV SIENA,IST BIOL GEN,I-53100 SIENA,ITALY; CNR,CTR STUDIO CELLULE GERMINALI,I-53100 SIENA,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Siena; Consiglio Nazionale delle Ricerche (CNR)			piomboni, paola/AAB-9868-2019; Sallese, Michele/J-5347-2016; Mariggio', Stefania/H-5467-2015; collodel, giulia/AAW-5217-2021	Sallese, Michele/0000-0002-2555-3571; Mariggio', Stefania/0000-0002-6397-3016; collodel, giulia/0000-0003-1587-0159; Moretti, Elena/0000-0002-9467-0501				Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903; BACCETTI B, 1988, J SUBMICR CYTOL PATH, V20, P209; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; FILIPPINI A, 1994, ENDOCRINOLOGY, V134, P1537, DOI 10.1210/en.134.3.1537; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KRAUSZ C, 1994, HUM REPROD, V9, P471, DOI 10.1093/oxfordjournals.humrep.a138529; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y; ZANEVELD LJD, 1993, HUM REPROD, V8, P2006, DOI 10.1093/oxfordjournals.humrep.a137972	21	78	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10188	10195						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092566				2022-12-27	WOS:A1997WU03900085
J	Chillaron, J; Estevez, R; Samarzija, I; Waldegger, S; Testar, X; Lang, F; Zorzano, A; Busch, A; Palacin, M				Chillaron, J; Estevez, R; Samarzija, I; Waldegger, S; Testar, X; Lang, F; Zorzano, A; Busch, A; Palacin, M			An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; XENOPUS-OOCYTES; CYSTIC-FIBROSIS; RAT-KIDNEY; EXPRESSION CLONING; GENETIC-HETEROGENEITY; ENDOPLASMIC-RETICULUM; GLUCOSE-TRANSPORTER; BETA-SUBUNIT	The human rBAT protein elicits sodium-independent, high affinity obligatory exchange of cystine, dibasic amino acids, and some neutral amino acids in Xenopus oocytes (Chillaron, J., Estevez, R., Mora, C., Wagner, C. A., Suessbrich, H., Lang, F., Gelpi, J. L., Testar, X., Busch, A. E., Zorzano, A., and Palacin, M. (1996) J. Biol. Chem. 271, 17761-17770). Mutations in rBAT have been found to cause cystinuria (Calonge, M. J., Gasparini, P., Chillaron, J., Chillon, M., Galluci, M., Rousaud, F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barcelo, P., Estivill, X., Zorzano, A., Nunes, V., and Palacin, M. (1994) Nat. Genet. 6, 420-426). We have performed functional studies with the most common point mutation, M467T, and its relative, M467K, using the oocyte system. The K-m and the voltage dependence for transport of the different substrates were the same in both M467T and wild type-injected oocytes. However, the time course of transport was delayed in the M467T mutant: maximal activity was accomplished 3-4 days later than in the wild type. This delay was cRNA dose-dependent: at cRNA levels below 0.5 ng the M467T failed to achieve the wild type transport level. The M467K: mutant displayed a normal K-m, but the V-max was between 5 and 35% of the wild type. The amount of rBAT protein was similar in normal and mutant-injected oocytes. In contrast to the wild type, the mutant proteins remained endoglycosidase H-sensitive, suggesting a longer residence time in the endoplasmic reticulum. We quantified the amount of rBAT protein in the plasma membrane by surface labeling with biotin 2 and 6 days after injection. Most of the M467T and M467K protein was located in an intracellular compartment. The converse situation was found in the wild type. Despite the low amount of M467T protein reaching the plasma membrane, the transport activity at 6 days was the same as in the wild type-injected oocytes. The increase in plasma membrane rBAT protein between 2 and 6 days was completely dissociated from the rise in transport activity. These data indicate impaired maturation and transport to the plasma membrane of the M467T and M467K mutant, and suggest that rBAT alone is unable to support the transport function.	UNIV BARCELONA,FAC BIOL,DEPT BIOCHEM & MOL BIOL,E-08028 BARCELONA,SPAIN; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY	University of Barcelona; Eberhard Karls University of Tubingen			Chillaron, Josep/ABF-7663-2021; Palacín, Manuel/G-9786-2015; Estevez, Raul/D-8610-2015; Zorzano, Antonio/R-5479-2018	Chillaron, Josep/0000-0003-3068-7598; Estevez, Raul/0000-0003-1579-650X; Palacin, Manuel/0000-0002-8670-293X				BEAR C E, 1992, Biophysical Journal, V61, pA127; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLER AL, 1990, J MEMBRANE BIOL, V115, P169; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CAMPANELLA C, 1977, DEV BIOL, V56, P1, DOI 10.1016/0012-1606(77)90150-6; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; COADY MJ, 1994, FEBS LETT, V356, P164; COPELAND CS, 1986, J CELL BIOL, V103, P1169; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; GAWANTKA V, 1992, DEVELOPMENT, V115, P595; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GROVES JD, 1992, J BIOL CHEM, V267, P22163; HAYES G, 1994, J BIOL CHEM, V269, P24143; HEMLER ME, 1982, J IMMUNOL, V129, P623; KANNER BI, 1994, CELL PHYSIOL BIOCHEM, V4, P164; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; MULLER AHJ, 1993, MECH DEVELOP, V42, P77, DOI 10.1016/0925-4773(93)90100-C; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1995, AM J HUM GENET, V56, P1297; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; SEGAL S, 1995, METABOLIC MOL BASES, V3, P3581; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; THOMAS HM, 1993, BIOCHEM J, V290, P707, DOI 10.1042/bj2900707; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WILCOX DA, 1994, J BIOL CHEM, V269, P4450; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	55	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9543	9549						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083097				2022-12-27	WOS:A1997WU03700102
J	Frey, MR; Saxon, ML; Zhao, XY; Rollins, A; Evans, SS; Black, JD				Frey, MR; Saxon, ML; Zhao, XY; Rollins, A; Evans, SS; Black, JD			Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VILLUS-ASSOCIATED ENTEROCYTES; RAT FIBROBLASTS; DNA-SYNTHESIS; HUMAN-COLON; DEPENDENT KINASES; GROWTH-INHIBITION; GENE-EXPRESSION; TRANSGENIC MICE; DOWN-REGULATION; PHORBOL ESTERS	The molecular mechanisms underlying protein kinase C (PKC) isozyme-mediated control of cell growth and cell cycle progression are poorly understood. Our previous analysis of PKC isozyme regulation in the intestinal epithelium in situ revealed that multiple members of the PKC family undergo changes in expression and subcellular distribution precisely as the cells cease proliferating in the mid-crypt region, suggesting that activation of one or more of these molecules is involved in negative regulation of cell growth in this system (Saxon, M. L., Zhao, X., and Black, J. D. (1994) J. Cell Biol. 126, 747-763). In the present study, the role of PKC isozyme(s) in control of intestinal epithelial cell growth and cell cycle progression was examined directly using the IEC-18 immature crypt cell line as a model system. Treatment of IEC-18 cells with PKC agonists resulted in translocation of PKC alpha, delta, and epsilon from the soluble to the particulate subcellular fraction, cell cycle arrest in G(1) phase, and delayed transit through S and/or G(2)/M phases. PKC-mediated cell cycle arrest in G(1) was accompanied by accumulation of the hypophosphorylated, growth-suppressive form of the retinoblastoma protein and induction of the cyclin-dependent kinase inhibitors p21(waf1/cip1) and p27(kip1). Reversal of these cell cycle regulatory effects was coincident with activator-induced down-regulation of PKC alpha, delta, and epsilon. Differential down-regulation of individual PKC isozymes revealed that PKC alpha in particular is sufficient to mediate cell cyclearrest by PKC agonists in this system. Taken together, the data implicate PKC alpha in negative regulation of intestinal epithelial cell growth both in vitro and in situ via pathways which involve modulation of Cip/Kip family cyclin-dependent kinase inhibitors and the retinoblastoma growth suppressor protein.	ROSWELL PK CANC INST, DEPT EXPT THERAPEUT, BUFFALO, NY 14263 USA; ROSWELL PK CANC INST, DEPT MOL MED, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute			Frey, Mark/G-3691-2015; Frey, Mark/M-1739-2019	Frey, Mark/0000-0002-2561-5402; Frey, Mark/0000-0002-2561-5402	PHS HHS [16056] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ASIEDU C, 1995, CANCER RES, V55, P3716; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; CRAVEN PA, 1992, CANCER RES, V52, P2216; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUILLEM JG, 1987, CANCER RES, V47, P2036; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HIRAMA T, 1995, BLOOD, V86, P841; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG YH, 1995, CELL GROWTH DIFFER, V6, P1381; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOPP R, 1991, CANCER RES, V51, P205; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livneh E, 1996, ONCOGENE, V12, P1545; MICHIELI P, 1994, CANCER RES, V54, P3391; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; QUARONI A, 1981, J NATL CANCER I, V67, P1353; Quaroni A, 1980, Methods Cell Biol, V21B, P403; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SEVERSON DL, 1989, AM J PHYSIOL, V256, pC11, DOI 10.1152/ajpcell.1989.256.1.C11; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; WALI RK, 1991, BIOCHIM BIOPHYS ACTA, V1092, P119, DOI 10.1016/0167-4889(91)90185-Z; WALI RK, 1995, CANCER RES, V55, P5257; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEISER MM, 1973, J BIOL CHEM, V248, P2536; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yeudall WA, 1995, ORAL ONCOL, V31B, P291, DOI 10.1016/0964-1955(95)00028-3; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668; ZHOU W, 1993, J BIOL CHEM, V268, P23041	76	136	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9424	9435						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083081				2022-12-27	WOS:A1997WU03700086
J	Strausak, D; Solioz, M				Strausak, D; Solioz, M			CopY is a copper-inducible repressor of the Enterococcus hirae copper ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; BACILLUS-LICHENIFORMIS; 434 REPRESSOR; GENE; RESISTANCE; PROTEIN; METALLOTHIONEIN; OPERATORS	The cop operon of Enterococcus hirae effects copper homeostasis in this organism. It encodes a repressor, CopY, an activator, CopZ, and two P-type copper ATPases, CopA and CopB. Expression of all four genes is regulated by the ambient copper. In this regulation, CopY apparently acts as a copper-inducible repressor, By DNase I footprinting, it was shown that purified CopY protected two discrete sites in the region encompassing nucleotides -71 to -11 relative to the transla tional start site and containing hyphenated inverted repeats. Transcription is initiated between these repeats at nucleotide -42, in a domain that remained accessible to DNase I in the DNA-repressor complex. Chemical cross-linking revealed that CopY exists as a dimer in solution. In DNA band-shift assays, it was apparent that the CopY-DNA interaction occurred in two discrete steps. Half-maximal binding of repressor to the two operator sites was observed at 2 x 10(-9) M and 5 x 10(-9) M CopY, respectively. Copper ions released CopY from the promoter/operator with an apparent half-binding constant for Cu(I) of 20 mu M. The site-directed mutations A-61T and A-30T essentially abolished the binding of CopY to the respective binding sites, and the double mutation A-61T/A-30T inactivated both binding sites. Thus, CopY is a copper-inducible repressor of the cop operon of E. hirae, exhibiting highly specific DNA-protein interactions with two sites on the cop promoter/operator and playing a key role in copper homeostasis in E. hirae.	UNIV BERN,DEPT CLIN PHARMACOL,CH-3010 BERN,SWITZERLAND	University of Bern			Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721				ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; FISHER RF, 1989, J BACTERIOL, V171, P5492, DOI 10.1128/jb.171.10.5492-5502.1989; HIMENO T, 1986, J BACTERIOL, V168, P1128, DOI 10.1128/jb.168.3.1128-1132.1986; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1995, J BIOL CHEM, V270, P4349, DOI 10.1074/jbc.270.9.4349; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PABO CO, 1984, ANN REV BIOCH, V53, P596; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; SUZUKI E, 1993, ANTIMICROB AGENTS CH, V37, P1219, DOI 10.1128/AAC.37.6.1219; WASER M, 1992, J BIOL CHEM, V267, P5396; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; Wilson K, 1995, CURRENT PROTOCOLS MO; WITTMAN V, 1988, J BACTERIOL, V170, P3206, DOI 10.1128/jb.170.7.3206-3212.1988; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; YOON KP, 1991, J BACTERIOL, V173, P7643, DOI 10.1128/jb.173.23.7643-7649.1991	29	87	90	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8932	8936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083014				2022-12-27	WOS:A1997WU03700019
J	Tsai, AL; Wei, CH; Baek, HK; Kulmacz, RJ; VanWart, HE				Tsai, AL; Wei, CH; Baek, HK; Kulmacz, RJ; VanWart, HE			Comparison of peroxidase reaction mechanisms of prostaglandin H synthase-1 containing heme and mangano protoporphyrin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; VESICULAR GLAND MICROSOMES; ENDOPEROXIDE SYNTHETASE; KINETICS; HYDROPEROXIDES; PHOTOCHEMISTRY; INACTIVATION; ACTIVATION; PORPHYRINS; RESONANCE	Prostaglandin H synthase (PGHS) is a heme protein that catalyzes both the cyclooxygenase and peroxidase reactions needed to produce prostaglandins G(2) and H-2 from arachidonic acid. Replacement of the heme group by mangano protoporphyrin 1X largely preserves the cyclooxygenase activity, but lowers the steady-state peroxidase activity by 25-fold. Thus, mangano protoporphyrin IX serves as a useful tool to evaluate the function of the heme in PGHS. A detailed kinetic analysis of the peroxidase reaction using 15-hydroperoxyeicosatetraenoic acid (15-HPETE), EtOOH, and other peroxides as substrates has been carried out to compare the characteristics of PGHS reconstituted with mangano protoporphyrin IX (Mn-PGHS) to those of the native heme enzyme (Fe-PGHS). The rate constant describing the reaction of Mn-PGHS with 15-HPETE to form the oxidized, Mn(IV) intermediate with absorption at 420 nm, exhibits saturable behavior as the 15-HPETE concentration is raised from 10 to 400 mu M. This is most likely due to the presence of a second, earlier intermediate between the resting enzyme and the Mn(IV) species. Measurements at high substrate concentrations permitted resolution of the absorbance spectra of the two oxidized Mn-PGHS intermediates. The spectrum of the initial intermediate, assigned to a Mn(V) species, had a line shape similar to that of the later intermediate, assigned to a Mn(IV) species, suggesting that a porphyrin pi-cation radical is not generated in the peroxidase reaction of Mn-PGHS. The rate constant estimated for the formation of the earlier intermediate with 15-HPETE is 1.0 x 10(6) M(-1) s(-1) (20 degrees C, pH 7.3). A rate constant of 400 +/- 100 s(-1) was estimated for the second step in the reaction. Thus, Mn-PGHS reacts considerably more slowly than Fe-PGHS with 15-HPETE to form the first high-valent intermediate, but the two enzymes appear to follow a similar overall reaction mechanism for generation of oxidized intermediates. The difference in rate constants explains the observed lower steady-state peroxidase activity of Mn-PGHS compared with Fe-PGHS.	UNIV TEXAS,HLTH SCI CTR,DIV HEMATOL,DEPT INTERNAL MED,HOUSTON,TX 77030; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOL BIOPHYS,TALLAHASSEE,FL 32306	University of Texas System; University of Texas Health Science Center Houston; State University System of Florida; Florida State University; State University System of Florida; Florida State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030509, R01GM027276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27276, GM30509, GM44911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; CARNIERI N, 1982, J CHEM SOC DALTON, P931, DOI 10.1039/dt9820000931; CARNIERI N, 1982, J CHEM SOC DALTON, P1231, DOI 10.1039/dt9820001231; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FUHRHOP JH, 1974, STRUCT BOND, V18, P1; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; GUPTA RK, 1980, ARCH BIOCHEM BIOPHYS, V202, P1, DOI 10.1016/0003-9861(80)90398-7; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HORI H, 1987, BIOCHIM BIOPHYS ACTA, V912, P74, DOI 10.1016/0167-4838(87)90249-4; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Landino LM, 1996, BIOCHEMISTRY-US, V35, P2637, DOI 10.1021/bi952546h; MAEDER M, 1990, ANAL CHEM, V62, P2220, DOI 10.1021/ac00219a013; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; OGINO N, 1978, J BIOL CHEM, V253, P5061; OHKI S, 1979, J BIOL CHEM, V254, P829; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; TSAI AL, 1993, J BIOL CHEM, V268, P8554; VANWART HE, 1985, J BIOL CHEM, V260, P8372; YONETANI T, 1969, J BIOL CHEM, V244, P4580	31	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8885	8894						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083007				2022-12-27	WOS:A1997WU03700012
J	Chen, CH; Zheng, B; Han, JH; Lin, SC				Chen, CH; Zheng, B; Han, JH; Lin, SC			Characterization of a novel mammalian RGS protein that binds to G alpha proteins and inhibits pheromone signaling in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; RECEPTOR; DESENSITIZATION; PHOSPHOPROTEIN; PHENOTYPE; MECHANISM; SUBUNITS; ENCODES	Genetic studies of molecules that negatively regulate G-coupled receptor functions have led to the identification of a large gene family with an evolutionarily conserved domain, termed the RGS domain. It is now understood that RGS proteins serve as GTPase-activating proteins for subfamilies of the heterotrimeric G-proteins. We have isolated from mouse pituitary a full-length cDNA clone encoding a novel member of the RGS protein family, termed RGS16, as well as the full-length cDNA of mRGS5 and mRGS2. Tissue distribution analysis shows that the novel RGS16 is predominantly expressed in liver and pituitary, and that RGS5 is preferentially expressed in heart and skeletal muscle. In contrast, RGS2 is widely expressed. Genetic analysis using the pheromone response halo assay and FUS1 gene induction assay show that overexpression of the RGS16 gene dramatically inhibits yeast response to cy-factor, whereas neither RGS2 nor RGS5 has any discernible effect on pheromone sensitivity, pointing to a possible functional diversity among RGS proteins. In vitro binding assays reveal that RGS5 and RGS16 bind to G alpha(i) and G alpha(o) subunits of heterotrimeric G-proteins, but not to G alpha(s). Based on mutational analysis of the conserved residues in the RGS domain, we suggest that the G-protein binding and GTPase-activating protein activity may involve distinct functional structures of the RGS proteins, indicating that RGS proteins may exert a dual function in the attenuation of signaling via G-coupled receptors.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, REGULATORY BIOL LAB, SINGAPORE 119260, SINGAPORE; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Scripps Research Institute			Han, J/G-4671-2010; Lin, SC/G-4666-2010	Zheng, Bin/0000-0002-0998-7177				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOERTE A, 1995, J BIOL CHEM, V270, P22556, DOI 10.1074/jbc.270.38.22556; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; Sambrook J., 2002, MOL CLONING LAB MANU; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WU HK, 1995, LEUKEMIA, V9, P1291; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	36	147	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8679	8685		10.1074/jbc.272.13.8679	http://dx.doi.org/10.1074/jbc.272.13.8679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079700	hybrid			2022-12-27	WOS:A1997WQ63500083
J	Pan, C; Mason, TL				Pan, C; Mason, TL			Functional analysis of ribosomal protein L2 in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; SACCHAROMYCES-CEREVISIAE; TRANSFER-RNA; NUCLEAR GENE; PEPTIDYLTRANSFERASE ACTIVITY; CROSS-LINKING; SUBUNIT; SITES; BINDING; RECONSTITUTION	The yeast nuclear gene RML2, identified through genomic sequencing of Saccharomyces cerevisiae chromosome V, was shown to encode a mitochondrial homologue of the bacterial ribosomal protein L2. Immunoblot analysis showed that the mature Rml2p is a 37-kDa polypeptide component of the mitochondrial 54 S large ribosomal subunit. Null mutants of RML2 are respiration-deficient and convert to [rho(-)] or [rho degrees] cytoplasmic petites, indicating that Rml2p is essential for mitochondrial translation. RML2 is regulated transcriptionally in response to carbon source and the accumulation of Rml2p is dependent on the presence of the 21 S large rRNA. Site-directed mutagenesis showed that a highly conserved 7-amino acid sequence (Val(336) to Asp(342)) Of Rml2p is essential for function. Substitution of Gin for His-343, the most highly conserved histidine in the L2 protein family, caused cold-sensitive respiratory growth but did not affect the assembly of 54 S ribosomal subunits. Mitochondrial protein synthesis was normal in the His(343) to Gin (H343Q) mutant grown at the permissive temperature (30 degrees C) and was severely impaired after growth at the nonpermissive temperature (18 degrees C). His(343) corresponds to His(229) in Escherichia coli L2, which has been implicated in a direct involvement in peptidyl transferase activity. The conditional phenotype of the H343Q mutant indicates that His(343) is not essential for peptidyl transferase activity in yeast mitochondria.	UNIV MASSACHUSETTS,DEPT BIOCHEM & MOL BIOL,PROGRAM MOL & CELLULAR BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst								ABDURASHIDOVA GG, 1990, FEBS LETT, V269, P398, DOI 10.1016/0014-5793(90)81202-Y; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEAUCLERK AA, 1988, EMBO J, V11, P3589; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHIU MI, 1992, GENETICS, V132, P987; Cooperman BS, 1995, BIOCHEM CELL BIOL, V73, P1087, DOI 10.1139/o95-117; DAIGNANFORNIER B, 1988, NUCLEIC ACIDS RES, V16, P9299, DOI 10.1093/nar/16.19.9299; EGEBJERG J, 1991, J MOL BIOL, V222, P251, DOI 10.1016/0022-2836(91)90210-W; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FAHNESTOCK SR, 1975, BIOCHEMISTRY-US, V14, P5321, DOI 10.1021/bi00695a016; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fourney R.M., 1988, FOCUS, V10, P5; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Garrett R. A., 1996, RIBOSOMAL RNA STRUCT, P327; GARRETT RA, 1974, J MOL BIOL, V88, P553, DOI 10.1016/0022-2836(74)90503-8; GRAACK HR, 1992, EUR J BIOCHEM, V206, P373, DOI 10.1111/j.1432-1033.1992.tb16937.x; GULLE H, 1988, NUCLEIC ACIDS RES, V16, P815, DOI 10.1093/nar/16.3.815; HAMPL H, 1981, J BIOL CHEM, V256, P2284; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PAN C, 1995, NUCLEIC ACIDS RES, V23, P3673, DOI 10.1093/nar/23.18.3673; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; ROMERO DP, 1990, J BIOL CHEM, V265, P18185; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMID G, 1984, FEBS LETT, V177, P189, DOI 10.1016/0014-5793(84)81281-8; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMPTER VG, 1991, EUR J BIOCHEM, V196, P255, DOI 10.1111/j.1432-1033.1991.tb15812.x; WATANABE K, 1985, EUR J BIOCHEM, V153, P299, DOI 10.1111/j.1432-1033.1985.tb09300.x; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOWER J, 1988, BIOCHEMISTRY-US, V27, P8114, DOI 10.1021/bi00421a021; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	38	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8165	8171		10.1074/jbc.272.13.8165	http://dx.doi.org/10.1074/jbc.272.13.8165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079633	hybrid			2022-12-27	WOS:A1997WQ63500016
J	Govindaraj, S; Poulos, TL				Govindaraj, S; Poulos, TL			The domain architecture of cytochrome P450BM-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-MEGATERIUM; FLAVIN MONONUCLEOTIDE; FUNCTIONAL DOMAINS; CODING NUCLEOTIDE; REDUCTASE; OXIDOREDUCTASE; BINDING; IDENTIFICATION; HEMOPROTEIN; P450(BM-3)	Cytochromes P450 utilize redox partners to deliver electrons from NADPH/NADH to the P450 heme center, Microsomal P450s utilize an FAD/FMN reductase, The bacterial fatty acid hydroxylase, P450BM-3, is similar except the P450 heme and FAD/FMN proteins are linked together in a single polypeptide chain arranged as heme-FMN-FAD. Sequence comparisons indicate that the P450BM-3 FMN and FAD domains are similar to flavodoxin and ferredoxin reductase, respectively, Previous work has shown that the heme and FMN/FAD domains can be separately expressed and purified, In this study we have expressed, purified, and characterized the following additional domains: heme-FMN, FMN, and FAD. Each domain retains their prosthetic groups although the FMN domain is more labile, The FAD domain retains a high level of ferricyanide reductase activity but no cytochrome c reductase activity, In addition, we have deleted a 110-residue stretch in the FAD domain that is not present in ferredoxin reductase, This protein retains both FAD and heme but not FMN. We also have investigated the dimerization pattern of the individual domains that lead to the following conclusions, Holo-P450BM-3 appears to dimerize via interactions that do not involve disulfide bond formation, whereas the reductase and FAD domains form intermolecular disulfides. This indicates that the Cys residues not available for dimerization in holo-P450BM-3 are unmasked in the individual domains.	UNIV CALIF IRVINE,DEPT MOL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK SD, 1994, BIOCHEMISTRY-US, V33, P12056, DOI 10.1021/bi00206a007; BLACK SD, 1994, ARCH BIOCHEM BIOPHYS, V310, P126, DOI 10.1006/abbi.1994.1148; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; DJORDJEVIC S, 1995, P NATL ACAD SCI USA, V92, P3214, DOI 10.1073/pnas.92.8.3214; Govindaraj S, 1996, PROTEIN SCI, V5, P1389, DOI 10.1002/pro.5560050717; GOVINDARAJ S, 1995, BIOCHEMISTRY-US, V34, P11221, DOI 10.1021/bi00035a031; Hazzard JT, 1997, J BIOL CHEM, V272, P7922, DOI 10.1074/jbc.272.12.7922; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LI HY, 1991, J BIOL CHEM, V266, P11909; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OSTER T, 1991, J BIOL CHEM, V266, P22718; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7528, DOI 10.1021/bi960330p; SHIN M, 1963, BIOCHEM Z, V338, P84; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	28	38	39	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7915	7921		10.1074/jbc.272.12.7915	http://dx.doi.org/10.1074/jbc.272.12.7915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065459	hybrid			2022-12-27	WOS:A1997WP59200053
J	Ruddon, RW; Bedows, E				Ruddon, RW; Bedows, E			Assisted protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN CHORIONIC-GONADOTROPIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; MOLECULAR CHAPERONES; DISULFIDE-ISOMERASE; INFLUENZA HEMAGGLUTININ; LINKED OLIGOSACCHARIDES; CRYSTAL-STRUCTURE; BIP		UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & CELL BIOL, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ruddon, RW (corresponding author), UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA.				NCI NIH HHS [CA32949, P30 CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032949, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1994, ENDOCRINOLOGY, V135, P911, DOI 10.1210/en.135.3.911; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HUTH JR, 1994, BIOTECHNOL BIOENG, V44, P66, DOI 10.1002/bit.260440110; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Otteken A, 1996, J VIROL, V70, P3407, DOI 10.1128/JVI.70.6.3407-3415.1996; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SACCUZZOBEEBE J, 1990, J BIOL CHEM, V265, P312; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WALL JG, 1995, CURR OPIN BIOTECH, V6, P507, DOI 10.1016/0958-1669(95)80084-0; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	59	131	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	1997	272	6					3125	3128		10.1074/jbc.272.6.3125	http://dx.doi.org/10.1074/jbc.272.6.3125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WG192	9081984	hybrid			2022-12-27	WOS:A1997WG19200001
J	Miller, TM; Tansey, MG; Johnson, EM; Creedon, DJ				Miller, TM; Tansey, MG; Johnson, EM; Creedon, DJ			Inhibition of phosphatidylinositol 3-kinase activity blocks depolarization- and insulin-like growth factor I-mediated survival of cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRICAL-ACTIVITY PROMOTES; RETINAL GANGLION-CELLS; PHOSPHOINOSITIDE 3-KINASE; SYMPATHETIC NEURONS; MEMBRANE DEPOLARIZATION; INTRACELLULAR CALCIUM; SIGNAL TRANSDUCTION; FACTOR DEPENDENCE; MAP KINASE; S6 KINASE	Depolarizing concentrations of potassium promote the survival of many neuronal cell types including cerebellar granule cells. To begin to understand the intracellular mediators of neuronal survival, we have tested whether the survival-promoting effect of potassium depolarization on cerebellar granule cells is dependent on either mitogen-activated protein (MAP) kinase or phosphatidylinositol 3-kinase (PI-3-K) activity. In 7-day cerebellar granule cell cultures, potassium depolarization activated both MAP kinase and PI-3-K. Preventing the activation of MAP kinase with the MEK1 inhibitor PD98059 did not affect potassium saving. In contrast, the survival-promoting effect of 25 mM potassium was negated by the addition of 30 mu M LY 294002 or 1 mu M wortmannin, two distinct inhibitors of PI-3-K. The cell death induced by PI-3-K inhibition was indistinguishable from the cell death caused by potassium deprivation; LY 294002-induced death included nuclear condensation, was blocked by cycloheximide, and had the same time course as potassium deprivation-induced cell death. Cerebellar granule cells can also be maintained in serum free medium containing either 100 ng/ml insulin-like growth factor I (IGF-I) or 800 mu M cAMP. PI-3-K inhibition completely blocked the survival-promoting activity of IGF-I, but had no effect on cAMP-mediated survival. These data indicate that the survival-promoting effects of depolarization and IGF-I, but not cAMP, require PI-3-K activity.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12947] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BOZYCZKOCOYNE D, 1993, J NEUROSCI METH, V50, P205, DOI 10.1016/0165-0270(93)90009-G; BURGOYNE RD, 1993, J NEUROCYTOL, V22, P689, DOI 10.1007/BF01181314; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CATSICAS M, 1992, J NEUROSCI, V12, P4642; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLIRESTA L, 1993, J NEUROSCI, V13, P243; GALLO V, 1987, J NEUROSCI, V7, P2203; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HOPE HMR, 1994, J BIOL CHEM, V269, P23648; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KINGSBURY AE, 1985, DEV BRAIN RES, V17, P17, DOI 10.1016/0165-3806(85)90128-2; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller TM, 1996, J NEUROSCI, V16, P7487; NEWBERRY EP, 1995, BIOCHEM BIOPH RES CO, V208, P253, DOI 10.1006/bbrc.1995.1331; NISHI R, 1981, DEV BIOL, V87, P301, DOI 10.1016/0012-1606(81)90153-6; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUIJTER JM, 1991, INT J DEV NEUROSCI, V9, P331, DOI 10.1016/0736-5748(91)90054-P; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THANGNIPON W, 1983, DEV BRAIN RES, V11, P177, DOI 10.1016/0165-3806(83)90215-8; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Virdee K, 1996, J NEUROCHEM, V67, P1801; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WETTS R, 1983, DEV BRAIN RES, V10, P41, DOI 10.1016/0165-3806(83)90119-0; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG J, 1995, J BIOL CHEM, V270, P22804	66	215	217	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9847	9853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092520				2022-12-27	WOS:A1997WU03900039
J	Nasman, J; Jansson, CC; Akerman, KEO				Nasman, J; Jansson, CC; Akerman, KEO			The second intracellular loop of the alpha(2)-adrenergic receptors determines subtype-specific coupling to cAMP production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MULTIPLE G-PROTEINS; HUMAN ALPHA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; ADENYLATE-CYCLASE; ALPHA(2A)-ADRENERGIC RECEPTOR; ACETYLCHOLINE-RECEPTORS; EXPRESSION; BINDING; STIMULATION	The alpha(2)-adrenergic receptors (alpha(2)-ARs), which primarily couple to inhibition of cAMP production, have been reported to have a stimulating effect on adenylyl cyclase activity in certain cases. When expressed in Spodoptera frugiperda Sf9 cells the alpha(2A) subtype showed only inhibition of forskolin-stimulated cAMP production when activated by norepinephrine (NE), whereas the alpha(2B) subtype displayed a biphasic dose-response curve with inhibition at low concentrations of NE and a potentiation at higher concentrations. To further investigate the subtype-specific coupling, we expressed a set of chimeric alpha(2A)-/alpha(2B)-ARs at similar expression levels in Sf9 cells to determine the structural domain responsible for the difference between the two subtypes. When the third intracellular loops were interchanged between alpha(2A) and alpha(2B) subtypes, the coupling specificity remained un changed, indicating that this loop does not confer selectivity toward a stimulating response. A biphasic dose-response curve, typical for the alpha(2B) subtype, could be seen when the second intracellular loop of the alpha(2B) subtype was inserted into the alpha(2A) subtype, suggesting that this loop is important for determining the subtype-specific coupling of alpha(2)-ARs to cAMP production. Site-directed mutagenesis of non-conserved amino acids in the second intracellular loop of the alpha(2A) subtype indicated that several residues are involved in the coupling specificity.	UNIV TURKU,DEPT PHARMACOL & CLIN PHARMACOL,FIN-20520 TURKU,FINLAND	University of Turku	Nasman, J (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT PHYSIOL & MED BIOPHYS,BOX 572,S-75123 UPPSALA,SWEDEN.							BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CHABRE O, 1994, J BIOL CHEM, V269, P5730; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1994, MOL PHARMACOL, V45, P696; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; Higuchi R., 1989, PCR TECHNOLOGY, P61; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JANSSON CC, 1995, EUR J PHARM-MOLEC PH, V290, P75, DOI 10.1016/0922-4106(95)90019-5; JONES SB, 1991, MOL PHARMACOL, V39, P239; KAGAYA A, 1992, J NEURAL TRANSM-GEN, V88, P25, DOI 10.1007/BF01245034; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MCCLUE SJ, 1994, EUR J PHARM-MOLEC PH, V267, P185, DOI 10.1016/0922-4106(94)90170-8; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKERBLOM C, 1993, BIOCHIM BIOPHYS ACTA, V1176, P269, DOI 10.1016/0167-4889(93)90055-T; PARIS H, 1989, MOL PHARMACOL, V35, P345; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P101; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; WONG SKF, 1990, J BIOL CHEM, V265, P6219	36	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9703	9708						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092501				2022-12-27	WOS:A1997WU03900020
J	Tripet, B; Vale, RD; Hodges, RS				Tripet, B; Vale, RD; Hodges, RS			Demonstration of coiled-coil interactions within the kinesin neck region using synthetic peptides - Implications for motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; PROTEIN SECONDARY STRUCTURE; STIMULATED ATP HYDROLYSIS; CIRCULAR-DICHROISM; HEAVY-CHAIN; ELECTROSTATIC REPULSIONS; QUATERNARY STRUCTURE; LEUCINE RESIDUES; REVERSED-PHASE; MODEL PROTEINS	Kinesin is a dimeric motor protein that can move for several micrometers along a microtubule without dissociating. The two kinesin motor domains are thought to move processively by operating in a hand-over-hand manner, although the mechanism of such cooperativity is unknown. Recently, a similar to 50-amino acid region adjacent to the globular motor domain (termed the neck) has been shown to be sufficient for conferring dimerization and processive movement. Based upon its amino acid sequence, the neck is proposed to dimerize through a coiled-coil interaction. To determine the accuracy of this prediction and to investigate the possible function of the neck region in motor activity, we have prepared a series of synthetic peptides corresponding to different regions of the human kinesin neck (residues 316-383) and analyzed each peptide for its respective secondary structure content and stability. Results of our study show that a peptide containing residues 330-369 displays all of the characteristics of a stable, two-stranded alpha-helical coiled-coil. On the other hand, the NH2-terminal segment of the neck (residues similar to 316-330) has the capacity to adopt a beta-sheet secondary structure. The COOH-terminal residues of the neck region (residues 370-383) are not alpha-helical, nor do they contribute significantly to the overall stability of the coiled-coil, suggesting that these residues mark the beginning of a hinge located between the neck and the extended alpha-helical coiled coil stalk domain. Interestingly, the two central heptads of the coiled-coil segment in the neck contain conserved, ''non-ideal'' residues located within the hydrophobic core, which we show destabilize the coiled-coil interaction. These residues may enable a portion of the coiled-coil to unwind during the mechanochemical cycle, and we present a model in which such a phenomenon plays an important role in kinesin motility.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,MED RES COUNCIL,GRP PROT STRUCT & FUNCT,EDMONTON,AB T6G 2H7,CANADA; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143	University of Alberta; University of Alberta; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [R01 GM038499] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038499] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; KOHN WD, 1995, PROTEIN SCI, V4, P237; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; MORII H, 1997, IN PRESS BIOCHEMISTR; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pace C N, 1986, Methods Enzymol, V131, P266; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale Ronald D., 1993, P175; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHU BY, 1993, PROTEIN SCI, V2, P383; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	58	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8946	8956						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083016				2022-12-27	WOS:A1997WU03700021
J	Yuen, CT; Chai, WG; Loveless, RW; Lawson, AM; Margolis, RU; Feizi, T				Yuen, CT; Chai, WG; Loveless, RW; Lawson, AM; Margolis, RU; Feizi, T			Brain contains HNK-1 immunoreactive O-glycans of the sulfoglucuronyl lactosamine series that terminate in 2-linked or 2,6-linked hexose (mannose)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; ION MASS-SPECTROMETRY; NERVOUS-SYSTEM; LINKED OLIGOSACCHARIDES; ALKALINE BOROHYDRIDE; E-SELECTIN; L2/HNK-1 CARBOHYDRATE; CELL-ADHESION; RAT-BRAIN; GLYCOLIPIDS	The monoclonal antibody HNK-1 originally raised to an antigenic marker of natural killer cells also binds to selected regions in nervous tissue. The antigen is a carbohydrate that has attracted much interest as its expression is developmentally regulated in nervous tissue, and it is found, and proposed to be a ligand, on several of the adhesive glycoproteins of the nervous system. It is also expressed on glycolipids and proteoglycans, and is the target of monoclonal auto-antibodies that give rise to a demyelinating disease. The epitope, as characterized on glycolipids isolated from the nervous system, is expressed on 3-sulfated glucuronic acid joined by beta 1-3-linkage to a neolacto backbone. Here we exploit the neoglycolipid technology, in conjunction with immunodetection and in situ liquid secondary ion mass spectrometry, to characterize HNK-1-positive oligosaccharide chains derived by reductive alkaline release from total brain glycopeptides. The immunoreactive oligosaccharides detected are tetra- to octasaccharides that are very minor components among a heterogeneous population, each representing less than 0.1% of the starting material. Their peripheral and backbone sequences resemble those of the HNK-1-positive glycolipids. An unexpected finding is that they terminate not with N-acetylgalactosaminitol but with hexitol (2-substituted and 2,6-disubstituted). In a tetrasaccharide investigated in the greatest detail, the hexitol is identified as a substituted mannitol.	NORTHWICK PK HOSP & CLIN RES CTR,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,GLYCOSCI LAB,HARROW HA1 3UJ,MIDDX,ENGLAND; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Imperial College London; New York University				Feizi, Ten/0000-0001-6495-0329; Chai, Wengang/0000-0003-2977-5347	NIMH NIH HHS [MH-0012] Funding Source: Medline; NINDS NIH HHS [NS-13876] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABO T, 1981, J IMMUNOL, V127, P1024; ARIGA T, 1987, J BIOL CHEM, V262, P848; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BURGER D, 1990, J NEUROCHEM, V54, P1569, DOI 10.1111/j.1471-4159.1990.tb01206.x; CHAI W, 1991, BIOL MASS SPECTROM, V20, P169, DOI 10.1002/bms.1200200403; CHAI WG, 1993, CARBOHYD RES, V239, P107, DOI 10.1016/0008-6215(93)84207-M; Chiba A, 1997, J BIOL CHEM, V272, P2156; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FINNE J, 1979, J BIOL CHEM, V254, P295; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HAKOMORI S, 1985, CANCER RES, V45, P2405; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HOUNSELL EF, 1984, BIOCHEM SOC T, V12, P607, DOI 10.1042/bst0120607; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; Jaques AJ, 1996, BIOCHEM J, V316, P427, DOI 10.1042/bj3160427; JUNGALWALA FB, 1992, J NEUROCHEM, V58, P1045, DOI 10.1111/j.1471-4159.1992.tb09360.x; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; Lubineau A, 1994, Bioorg Med Chem, V2, P1143, DOI 10.1016/S0968-0896(00)82066-0; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARGOLIS RK, 1970, BIOCHEMISTRY-US, V9, P4389, DOI 10.1021/bi00824a020; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NICOLAOU KC, 1993, J AM CHEM SOC, V115, P8843, DOI 10.1021/ja00072a049; OKA S, 1992, J BIOL CHEM, V267, P22711; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCUDDER P, 1987, EUR J BIOCHEM, V168, P585, DOI 10.1111/j.1432-1033.1987.tb13457.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WING DR, 1992, GLYCOCONJUGATE J, V9, P293, DOI 10.1007/BF00731089; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	46	103	105	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8924	8931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083013				2022-12-27	WOS:A1997WU03700018
J	Anjuere, F; Kuznetsov, D; Romero, P; Cerottini, JC; Jongeneel, CV; Luescher, IF				Anjuere, F; Kuznetsov, D; Romero, P; Cerottini, JC; Jongeneel, CV; Luescher, IF			Differential roles of T cell receptor alpha and beta chains in ligand binding among H-2K(d)-restricted cytolytic T lymphocyte clones specific for a photoreactive Plasmodium berghei circumsporozoite peptide derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; CRYSTAL-STRUCTURE; VIRAL PEPTIDES; RECOGNITION; COMPLEX; IMMUNIZATION; REPERTOIRE; MOLECULES; RESIDUES; H-2K(B)	To study the interaction of T cell receptor with its ligand, a complex of a major histocompatibility complex molecule and a peptide, we derived H-2K(d)-restricted cytolytic T lymphocyte clones from mice immunized with a Plasmodium berghei circumsporozoite peptide (PbCS) 252-260 (SYIPSAEKl) derivative containing photoreactive N-epsilon-[4-azidobenzoyl] lysine in place of Pro-255. This residue and Lys-259 were essential parts of the epitope recognized by these clones, Most of the clones expressed BV1S1A1 encoded beta chains along with specific complementary determining region (CDR) 3 beta regions but diverse cu chain sequences. Surprisingly, all T cell receptors were preferentially photoaffinity labeled on the a chain, For a representative T cell receptor, the photoaffinity labeled site was located in the V alpha C-strand. Computer modeling suggested the presence of a hydrophobic pocket, which is formed by parts of the V alpha/J alpha C-, F-, and G-strands and adjacent CDR3 alpha residues and structured to be able to avidly bind the photoreactive ligand side chain. We previously found that a T cell receptor specific for a PbCS peptide derivative containing this photoreactive side chain in position 259 similarly used a hydrophobic pocket located between the junctional CDR3 loops. We propose that this nonpolar domain in these locations allow T cell receptors to avidly and specifically bind epitopes containing non-peptidic side chains.	UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND	Ludwig Institute for Cancer Research; University of Lausanne			Jongeneel, Cornelis V/B-2135-2012; Anjuere-Casile, Fabienne/O-5779-2016	Anjuere-Casile, Fabienne/0000-0003-3144-8652; Kuznetsov, Dmitry/0000-0002-9972-947X; Jongeneel, Cornelis Victor/0000-0002-3922-1906				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ANJUERE F, 1995, ANAL BIOCHEM, V229, P61, DOI 10.1006/abio.1995.1379; Arden Bernhard, 1995, Immunogenetics, V42, P501; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; CASANOVA JL, 1991, J EXP MED, V174, P1371, DOI 10.1084/jem.174.6.1371; CHEVALLIER S, 1993, J BIOL CHEM, V267, P8192; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GANJU RK, 1992, P NATL ACAD SCI USA, V89, P11552, DOI 10.1073/pnas.89.23.11552; Haurum JS, 1995, EUR J IMMUNOL, V25, P3270, DOI 10.1002/eji.1830251211; JAULIN C, 1992, J IMMUNOL, V149, P3990; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KATAYAMA CD, 1995, EMBO J, V14, P927, DOI 10.1002/j.1460-2075.1995.tb07074.x; KELLY JM, 1993, EUR J IMMUNOL, V23, P3318, DOI 10.1002/eji.1830231239; KOHLER J, 1995, EUR J IMMUNOL, V25, P92, DOI 10.1002/eji.1830250118; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN S, 1992, J IMMUNOL, V149, P2569; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; NALEFSKI EA, 1992, J EXP MED, V175, P1553, DOI 10.1084/jem.175.6.1553; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; ROMERO P, 1992, J IMMUNOL, V148, P1871; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROMERO P, 1993, J EXP MED, V177, P1245; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUN R, 1995, IMMUNITY, V3, P573, DOI 10.1016/1074-7613(95)90128-0	37	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8505	8514		10.1074/jbc.272.13.8505	http://dx.doi.org/10.1074/jbc.272.13.8505			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079679	hybrid			2022-12-27	WOS:A1997WQ63500062
J	Balboa, MA; Balsinde, J; Jones, SS; Dennis, EA				Balboa, MA; Balsinde, J; Jones, SS; Dennis, EA			Identity between the Ca2+-independent phospholipase A(2) enzymes from P388D(1) macrophages and Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; INHIBITION	A novel Ca2+-independent phospholipase A(2) (iPLA(2)) has recently been purified and characterized from P388D(1) macrophages (Ackermann, E. J,, Kempner, E, S,, and Dennis, E, A. (1994) J, Biol. Chem. 269, 9227-9233), This enzyme appears to play a key role in regulating basal phospholipid remodeling reactions, Also an iPLA(2) from Chinese hamster ovary (CHO) cells has been purified, molecularly cloned, and expressed (Tang, J,, Kriz, R,, Wolfman, N,, Shaffer, M,, Seehra, J,, and Jones, S. S, (1997) J. Biol. Chem. 272, 8567-8575), We report herein that the cloned CHO iPLA(2) is equivalent to the mouse enzyme purified from P388D(1) cells, Polymerase chain reaction amplification of cDNA fragments from P388D, cells using primers based on the CHO iPLA(2) sequence, revealed a high degree of homology between the mouse and hamster enzymes at both the nucleotide and amino acid levels (92 and 95%, respectively). Identity between the two proteins was further demonstrated by using immunochemical, pharmacological, and biochemical approaches. Thus, an antiserum generated against the CHO enzyme recognized the P388D(1) cell enzyme and gave similar molecular masses (about 83 kDa) for the two enzymes under the same experimental conditions, Further, the CHO enzyme has exactly the same sensitivity to inhibition by a variety of compounds previously shown to inhibit the P388D(1) enzyme, including bromoenol lactone, palmitoyl trifluoromethyl ketone, and methyl arachidonyl fluorophosphonate, Additionally, covalent modification of the CHO enzyme by [H-3]bromoenol lactone is dependent on active enzyme as is the P588D(1) iPLA(2), Finally, both enzymes have the same specific activities under identical experimental conditions.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; GENET INST INC,CAMBRIDGE,MA 02140	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018	Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26,171] Funding Source: Medline; NIGMS NIH HHS [GM 20,501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567	16	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8576	8580		10.1074/jbc.272.13.8576	http://dx.doi.org/10.1074/jbc.272.13.8576			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079688	hybrid, Green Published			2022-12-27	WOS:A1997WQ63500071
J	Esposito, D; Scocca, JJ				Esposito, D; Scocca, JJ			Purification and characterization of HP1 Cox and definition of its role in controlling the direction of site-specific recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST ATTACHMENT SITE; TRANSFER-RNA GENES; BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; BINDING-SITES; PHAGE LAMBDA; PROTEIN; DNA; INTEGRATION; EXCISION	The protein that activates site-specific excision of the HP1 genome from the Hemophilus influenzae chromosome, HP1 Cox, was purified. Native Cox consists of four 8.9-kDa protomers. Tetrameric Cox self-associates to octamers; the apparent dissociation constant was 8 mu M protomer, suggesting that under reaction conditions Cox is largely tetrameric. Cox binding sites consist of two direct repeats of the consensus motif 5'-GGTMAW-WWWA; one Cox tetramer binds to each motif. Cox binding interfered with the interaction of HP1 integrase with one of its binding sites, IBS5. This competition is central to directional control, as shown by studies on mutated sites. Both Cox binding sites were necessary for Cox to fully inhibit integration and activate excision, although Cox continued to affect recombination when the single binding site proximal to IBS5 remained intact. Eliminating the IBS5 site completely prevented integration but greatly enhanced excision. Excisive recombination continued to require Cox even when IBS5 was inactivated. Cox must therefore play a positive role in assembling the nucleoprotein complexes producing excisive recombination, by inducing the formation of a critical conformation in those complexes.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University				Esposito, Dominic/0000-0002-9987-1687				ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BALL CA, 1991, J BACTERIOL, V173, P4032, DOI 10.1128/jb.173.13.4032-4038.1991; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; BAUER CE, 1986, J MOL BIOL, V192, P513, DOI 10.1016/0022-2836(86)90273-1; BETTER M, 1983, CELL, V32, P161, DOI 10.1016/0092-8674(83)90506-8; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BUSHMAN W, 1984, CELL, V39, P699, DOI 10.1016/0092-8674(84)90477-X; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; ESPOSITO D, 1994, MOL MICROBIOL, V13, P685, DOI 10.1111/j.1365-2958.1994.tb00462.x; Esposito D, 1996, NUCLEIC ACIDS RES, V24, P2360, DOI 10.1093/nar/24.12.2360; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODMAN SD, 1989, J BACTERIOL, V171, P4232, DOI 10.1128/JB.171.8.4232-4240.1989; HAKIMI JM, 1994, J BIOL CHEM, V269, P21340; HAKIMIASTUMIAN J, 1989, J BACTERIOL, V171, P1747; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HAUSER MA, 1990, NUCLEIC ACIDS RES, V18, P5305, DOI 10.1093/nar/18.17.5305; HO YS, 1992, J BIOL CHEM, V267, P14388; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HOWLETT GJ, 1987, METHOD ENZYMOL, V150, P447; HUDSON GS, 1983, J BIOL CHEM, V258, P3114; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PIERSON LS, 1987, J MOL BIOL, V196, P487, DOI 10.1016/0022-2836(87)90026-X; POLLET RJ, 1979, J BIOL CHEM, V254, P30; PRAKASH V, 1985, METHOD ENZYMOL, V117, P53; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1987, DNA REPLICATION RECO, P691; SAHA S, 1989, P NATL ACAD SCI USA, V86, P3973, DOI 10.1073/pnas.86.11.3973; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shearwin KE, 1996, J BIOL CHEM, V271, P11525, DOI 10.1074/jbc.271.19.11525; STERNBERG N, 1981, J MOL BIOL, V150, P487, DOI 10.1016/0022-2836(81)90376-4; THOMPSON J F, 1987, P735; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1989, MOBILE DNA, P1; WEISBERG RA, 1983, LAMBDA, V2, P211; YU A, 1993, J BACTERIOL, V175, P7848, DOI 10.1128/JB.175.24.7848-7855.1993; YU A, 1993, J BACTERIOL, V175, P1239, DOI 10.1128/JB.175.5.1239-1249.1993; ZAGURSKY RJ, 1991, BIOTECHNIQUES, V11, P36	52	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8660	8670		10.1074/jbc.272.13.8660	http://dx.doi.org/10.1074/jbc.272.13.8660			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079698	hybrid			2022-12-27	WOS:A1997WQ63500081
J	Harris, CM; Massey, V				Harris, CM; Massey, V			The reaction of reduced xanthine dehydrogenase with molecular oxygen - Reaction kinetics and measurement of superoxide radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; HALF-REACTION; OXIDASE; MECHANISM; FLAVINS; FLAVOPROTEINS; PURIFICATION; INACTIVATION; POTENTIALS; REDUCTION	Xanthine dehydrogenase (XDH) from bovine milk contains significant activity in xanthine/oxygen turnover assays, The oxidative half-reaction of XDH with molecular oxygen has been studied in detail, at 25 degrees C, pH 7.5, to determine the basis of the preference of XDH for NAD over oxygen as oxidizing substrate. Spectral changes of XDH accompanying oxidation were followed by stopped-flow spectrophotometry, The amount of superoxide radicals formed during oxidation was investigated to assess the ability of XDH to catalyze production of oxygen radicals. Reduced XDH reacts with oxygen in at least 4 bi-molecular steps, with 1.7-1.9 mol of superoxide per mol of XDH formed from the last 2 electrons oxidized. A model is discussed in which the flavin hydroquinone transfers electrons to oxygen to produce hydrogen peroxide at a rate constant of at least 72,000 M(-1) s(-1) whereas flavin semiquinone reduces oxygen to form superoxide as slow as 16 M(-1) s(-1). Steady-state kinetics of xanthine/oxygen and NADH/oxygen turnover of XDH were determined to have h(cat) values of 2.1 +/- 0.1 and 2.5 +/- 0.9 s(-1), respectively, at 25 degrees C, pH 7.5, XDH is therefore capable of catalyzing the formation of reduced oxygen species at one-third the rate of xanthine/NAD turnover, 6.3 s(-1) (Hunt, J., and Massey, V. (1992) J. Biol. Chem. 267, 21479-21485), in the absence of NAD. As XDH contains a significant and intrinsic xanthine oxidase activity, estimates of relative amounts of XO and XDH based solely upon turnover assays must be made with caution, Initial-rate assays containing varying amounts of xanthine, NAD, and oxygen indicate that at 100% oxygen saturation, NADH formation is only inhibited at concentrations of xanthine and NAD below K-m for each substrate.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou D. P., 1971, THESIS U MICHIGAN; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BRAY RC, 1964, J BIOL CHEM, V239, P2667; Harris CM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P723; HILLE R, 1982, J BIOL CHEM, V257, P8898; HILLE R, 1981, J BIOL CHEM, V256, P9090; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Mayhew S.G., 1975, ENZYMES, V12, P57; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; Segel I. H., 1976, BIOCH CALCULATIONS, P414; STANKOVICH MT, 1978, J BIOL CHEM, V253, P4971; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015	30	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8370	8379		10.1074/jbc.272.13.8370	http://dx.doi.org/10.1074/jbc.272.13.8370			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079661	hybrid			2022-12-27	WOS:A1997WQ63500044
J	Nirula, A; Moore, DJ; Gaynor, RB				Nirula, A; Moore, DJ; Gaynor, RB			Constitutive binding of the transcription factor interleukin-2 (IL-2) enhancer binding factor to the IL-2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; GENE FORK-HEAD; NUCLEAR FACTOR; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; ANTIGEN RECEPTOR; CYCLOSPORINE-A; LYMPHOCYTES-T; IN-VIVO; FAMILY	A positive regulatory element in the interleukin-2 (IL-2) promoter, designated the antigen receptor response element-2, is essential for the induction of IL-2 gene expression upon the binding of an inducible multiprotein complex of proteins known as nuclear factor of activated T cells, In the current study, we demonstrated that the winged helix transcription factor IL-2 enhancer binding factor (ILF) is constitutively expressed in both resting and activated Jurkat cells and binds to two adjacent sequence motifs immediately downstream of the binding site for NFAT. One of these elements has a high degree of homology with consensus binding sites for a variety of winged-helix DNA binding proteins, and the second site functions to modulate ILF binding, Mutagenesis of each of the two sequence elements required for ILF binding decreased IL-2 promoter activity when assayed in transfection assays, Although ILF bound constitutively to the IL-2 promoter, it was not detected as a component of the NFAT complex, These results suggest that important regulatory sequences in the IL-2 promoter are bound by ILF and that this binding may be involved in the control of IL-2 gene expression.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOL VIROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BROWN L, 1994, MOL CELL BIOL, V14, P1245, DOI 10.1128/MCB.14.2.1245; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; KAO PN, 1994, J BIOL CHEM, V269, P20691; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI C, 1992, GENOMICS, V13, P665, DOI 10.1016/0888-7543(92)90139-J; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	42	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7736	7745		10.1074/jbc.272.12.7736	http://dx.doi.org/10.1074/jbc.272.12.7736			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065434	hybrid			2022-12-27	WOS:A1997WP59200028
J	Leibrecht, I; Kessler, D				Leibrecht, I; Kessler, D			A novel L-cysteine/cystine C-S-lyase directing [2Fe-2S] cluster formation of Synechocystis ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; CYANOBACTERIA; MECHANISM; CHLOROPLASTS; BINDING; PRODUCT; NIFS; DYE	Iron-sulfur proteins acquire their clusters by posttranslational assembly, To identify components involved in this process an in vitro assay for holoprotein formation was established using the [2Fe-2S] ferredoxin of the cyanobacterium Synechocystis as a model, Conversion of apoferredoxin to the holo- form was observed in an anaerobic reaction medium containing Fe(NH4)(2)(SO4)(2), L-cysteine, glutathione, and catalytic amounts of Synechocystis extract, specifically depleted of endogeneous ferredoxin, An approximate 2500-fold purification of the converter activity yielded a monomeric, 43-kDa, pyridoxal phosphate-containing enzyme, which catalyzed the breakdown of L-cysteine to yield sulfide (assembled in ferredoxin), pyruvate, and ammonia; 1 mol of [2Fe-2S] ferredoxin was formed per 2 mol of cysteine utilized, The purified enzyme also catalyzed the p-elimination reaction with cysteine in the absence of apoferredoxin. An increased reactivity was found with cystine instead of cysteine, which should yield cysteine persulfide as the primary product, These results provide a function-based identification of a cysteine/cystine C-S-lyase as a participant in ferredoxin Fe-S cluster formation. A substrate-derived cysteine persulfide could be involved in this reaction.	UNIV HEIDELBERG, INST BIOL CHEM, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								Akerboom T P, 1981, Methods Enzymol, V77, P373; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V11, P369, DOI 10.1016/0968-0004(86)90206-9; DELAVIER.C, 1965, BIOCHIM BIOPHYS ACTA, V99, P375, DOI 10.1016/S0926-6593(65)80137-0; FISCHER EH, 1958, J AM CHEM SOC, V80, P2906, DOI 10.1021/ja01544a082; FLAVIN M, 1962, J BIOL CHEM, V237, P768; Flint DH, 1996, J BIOL CHEM, V271, P16068; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; HASE T, 1982, J BIOCHEM-TOKYO, V92, P1357, DOI 10.1093/oxfordjournals.jbchem.a134059; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HUTSON KG, 1980, FEMS MICROBIOL LETT, V7, P279, DOI 10.1111/j.1574-6941.1980.tb01604.x; HUTSON KG, 1978, BIOCHEM J, V172, P465, DOI 10.1042/bj1720465; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Kaneko T, 1996, DNA Res, V3, P109; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KREDICH NM, 1973, J BIOL CHEM, V248, P6187; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALKIN R, 1966, BIOCHEM BIOPH RES CO, V23, P822, DOI 10.1016/0006-291X(66)90561-4; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V871, P243, DOI 10.1016/0167-4838(86)90205-0; MUROPASTOR MI, 1992, EUR J BIOCHEM, V203, P99, DOI 10.1111/j.1432-1033.1992.tb19833.x; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PILON M, 1992, J BIOL CHEM, V267, P2548; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHMIDT A, 1988, METHOD ENZYMOL, V167, P572; Shin M, 1971, METHOD ENZYMOL, V23, P440; TAKAHASHI Y, 1991, PLANT PHYSIOL, V95, P104, DOI 10.1104/pp.95.1.104; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; TANIGUCHI T, 1974, BIOCHIM BIOPHYS ACTA, V364, P284, DOI 10.1016/0005-2744(74)90014-X; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; WHITE RH, 1983, BIOCHEM BIOPH RES CO, V112, P66, DOI 10.1016/0006-291X(83)91798-9; WILLIAMS DE, 1964, ANN NY ACAD SCI, V121, P373, DOI 10.1111/j.1749-6632.1964.tb14210.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	38	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10442	10447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099686				2022-12-27	WOS:A1997WV26200020
J	KriegerBrauer, HI; Medda, PK; Kather, H				KriegerBrauer, HI; Medda, PK; Kather, H			Insulin-induced activation of NADPH-dependent H2O2 generation in human adipocyte plasma membranes is mediated by G alpha(12)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CATALYZED ADP-RIBOSYLATION; BC3H-1 MURINE MYOCYTES; PERTUSSIS-TOXIN; ADENYLATE-CYCLASE; TYROSINE KINASE; CHOLERA-TOXIN; HL-60 CELLS; FAT-CELLS; H2O2-GENERATING SYSTEM	Human fat cells possess a multireceptor-linked H2O2-generating system that is activated by insulin. Previous studies revealed that manganese was the sole cofactor required for a hormonal regulation of NADPH-dependent H2O2 generation in vitro. In this report it is shown that the synergistic activation of NADPH-dependent H2O2 generation by Mn2+ and insulin was blocked by GDP beta S (guanosine 5'-O-(2-thiodiphosphate)), pertussis toxin and COOH-terminal anti-G alpha(i1-2) or the corresponding peptide. Consistently, manganese could be replaced by micromolar concentrations of GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)), which increased NADPH-dependent H2O2 generation by 20-40%. Insulin shifted the dose response curve for GTP gamma S to the left (>10-fold) and increased the maximal response. In the presence of 10 mu M GTP gamma S, the hormone was active at picomolar concentrations, indicating that insulin acted via its cognate receptor. The insulin receptor and G(i) were co-adsorbed on anti-Ga-i and anti-insulin receptor beta-subunit (anti-IR beta) affinity columns. Partially purified insulin receptor preparations contained G alpha(s), G alpha(i2), and G beta gamma (but no G alpha(i1), or Ga alpha(i3)). The functional nature of the insulin receptor-G(i2) complex was made evident by insulin's ability to modulate labeling of G(i) by bacterial toxins. Insulin action was mimicked by activated G alpha(i), but not by G alpha(o), or G beta gamma, indicating that insulin's signal was transduced via G alpha(i2). Thus, NADPH oxidase is the first example of an effector system that is coupled to the insulin receptor via a heterotrimeric G protein.			KriegerBrauer, HI (corresponding author), UNIV HEIDELBERG,MED KLIN,KLIN INST HERZINFARKTFORSCH,BERGHEIMERSTR 58,D-69115 HEIDELBERG,GERMANY.							ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; CARO JF, 1994, J CELL BIOCHEM, V54, P309, DOI 10.1002/jcb.240540307; CARR C, 1994, BIOCHEM J, V298, P493, DOI 10.1042/bj2980493; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAVIS HW, 1990, BIOCHEM J, V270, P401, DOI 10.1042/bj2700401; GAWLER D, 1987, NATURE, V327, P229, DOI 10.1038/327229a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; GOREN HJ, 1985, CAN J PHYSIOL PHARM, V63, P1017, DOI 10.1139/y85-167; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HEYWORTH CM, 1986, BIOCHEM J, V235, P145, DOI 10.1042/bj2350145; IIRI T, 1989, J BIOL CHEM, V264, P21394; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JO H, 1992, ENDOCRINOLOGY, V131, P2855, DOI 10.1210/en.131.6.2855; JO HJ, 1993, BIOCHEM J, V294, P19, DOI 10.1042/bj2940019; KAARTINEN JM, 1994, BBA-GEN SUBJECTS, V1201, P69, DOI 10.1016/0304-4165(94)90153-8; KATHER H, 1983, FEBS LETT, V161, P149, DOI 10.1016/0014-5793(83)80749-2; KATHER H, 1985, J CLIN INVEST, V76, P1559, DOI 10.1172/JCI112137; KATOTA S, 1987, J BIOL CHEM, V262, P8252; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; KILGOUR E, 1993, CELL SIGNAL, V5, P97, DOI 10.1016/0898-6568(93)90062-Q; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MATTERA R, 1986, J BIOL CHEM, V261, P1173; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOISES RS, 1990, J CELL PHYSIOL, V144, P538, DOI 10.1002/jcp.1041440323; MORRIS NJ, 1995, BIOCHEM J, V308, P693, DOI 10.1042/bj3080693; MOSS J, 1979, ANNU REV BIOCHEM, V48, P581, DOI 10.1146/annurev.bi.48.070179.003053; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MULLER G, 1994, J CELL BIOL, V126, P1267, DOI 10.1083/jcb.126.5.1267; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; RAVINDRA R, 1993, J CELL BIOCHEM, V53, P181, DOI 10.1002/jcb.240530302; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; RUSS M, 1992, FEBS LETT, V314, P72, DOI 10.1016/0014-5793(92)81464-W; RUSS M, 1994, EUR J BIOCHEM, V219, P325, DOI 10.1111/j.1432-1033.1994.tb19944.x; SAKAI H, 1994, J BIOL CHEM, V269, P23426; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217; SRIVASTAVA SK, 1994, FEBS LETT, V340, P124, DOI 10.1016/0014-5793(94)80186-X; Stanners J, 1995, J BIOL CHEM, V270, P30635, DOI 10.1074/jbc.270.51.30635; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENTE SR, 1990, P NATL ACAD SCI USA, V87, P2805, DOI 10.1073/pnas.87.7.2805; YANG LJ, 1993, J BIOL CHEM, V268, P3739	58	139	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10135	10143						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092559				2022-12-27	WOS:A1997WU03900078
J	McGilvray, ID; Lu, ZY; Bitar, R; Dackiw, APB; Davreux, CJ; Rotstein, OD				McGilvray, ID; Lu, ZY; Bitar, R; Dackiw, APB; Davreux, CJ; Rotstein, OD			VLA-4 integrin cross-linking on human monocytic THP 1 cells induces tissue factor expression by a mechanism involving mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MAP KINASE; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; FACTOR PROMOTER; GENE INDUCTION; LIPOPOLYSACCHARIDE; BINDING	Adhesion molecules such as VLA 4 are important not only for monocyte adhesion to extracellular matrix proteins, but also for subsequent cell activation. Monocyte adherence to fibronectin or engagement of VLA-4 has been demonstrated to stimulate production of potent inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1, and the procoagulant tissue factor protein, However, the intracellular signaling cascades leading to gene expression have not been elucidated, Using the human monocytic THP-1 cell line, VLA-4 cross-linking by monoclonal antibodies directed against its alpha(4) and beta(1) subunits produced a time-dependent increase in tyrosine phosphorylation of a broad range of cellular proteins, Using Western blot analysis directed against the phosphorylated form of the extracellular signal-related kinase (ERK) mitogen-activated protein (MAP) kinase proteins, as well as immunoprecipitation and in vitro kinase assays, we found that VLA-4 crosslinking increased ERK1/ERK2 tyrosine phosphorylation and activity, In conjunction, integrin cross-linking also increased NF-kappa B nuclear translocation and 4-h expression of tissue factor, Inhibition of tyrosine kinase activity with genistein (10 mu g/ml) as well as selective MAP kinase inhibition with the MEK-1 inhibitor PD98059 abolished the VLA-4-dependent ERK tyrosine phosphorylation, inhibited NF kappa B nuclear binding, and abrogated tissue factor expression induced by both VLA-4 cross-linking and adhesion to fibronectin in THP-1 cells and human peripheral blood monocytes, These studies point to the involvement of the MAP kinase pathway in the activation of monocytic cells during transmigration to inflammatory sites.	TORONTO GEN HOSP,GEN DIV,DEPT SURG,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto				McGilvray, Ian/0000-0003-4649-546X				ADUNYAH SE, 1995, BIOCHEM BIOPH RES CO, V206, P103, DOI 10.1006/bbrc.1995.1015; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; BRISSEAU GF, 1993, ROLE PROCOAGULANT AC, P69; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEFRANCO AL, 1995, BACTERIAL ENDOTOXINS, P407; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURDEN DL, 1995, J IMMUNOL, V154, P4039; FAN ST, 1993, J IMMUNOL, V150, P2972; FAN ST, 1995, J IMMUNOL, V154, P3266; GARNOTEL R, 1995, J BIOL CHEM, V270, P27495, DOI 10.1074/jbc.270.46.27495; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; KOONG AC, 1994, CANCER RES, V54, P5273; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LETARTE M, 1993, LEUKEMIA, V7, P93; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIU MK, 1994, J IMMUNOL, V153, P2642; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; LO SK, 1995, J IMMUNOL, V154, P4768; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MCRITCHIE DI, 1991, J LAB CLIN MED, V118, P48; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK JH, 1993, BLOOD, V82, P2470; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; ROTSTEIN OD, 1988, J INFECT DIS, V158, P766, DOI 10.1093/infdis/158.4.766; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SATO T, 1995, J IMMUNOL, V155, P2939; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; SPORN SA, 1990, J IMMUNOL, V144, P4434; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; WHARRAM BL, 1991, J IMMUNOL, V146, P1437; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	53	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10287	10294						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092580				2022-12-27	WOS:A1997WU03900099
J	Paetzel, M; Strynadka, NCJ; Tschantz, WR; Casareno, R; Bullinger, PR; Dalbey, RE				Paetzel, M; Strynadka, NCJ; Tschantz, WR; Casareno, R; Bullinger, PR; Dalbey, RE			Use of site-directed chemical modification to study an essential lysine in Escherichia coli leader peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL ACTIVE-SITE; SIGNAL PEPTIDASE; ASPARTATE-AMINOTRANSFERASE; BACILLUS-SUBTILIS; AMINO-ACIDS; NUCLEASE-A; SEQUENCE; PROTEINS; RESIDUES; SERINE	Escherichia coli leader peptidase, which catalyzes the cleavage of signal peptides from pre-proteins, is an essential, integral membrane serine peptidase that has its active site residing in the periplasmic space. It contains a conserved lysine residue that has been proposed to act as the general base, abstracting the proton from the side chain hydroxyl group of the nucleophilic serine 90. To help elucidate the role of the essential lysine 145 in the activity of E. coli leader peptidase, we have combined site-directed mutagenesis and chemical modification methods to introduce unnatural amino acid side chains at the 145-position. We show that partial activity can be restored to an inactive K145C leader peptidase mutant by reacting it with 2-bromoethylamine . HBr to produce a lysine analog (gamma-thia-lysine) at the 145-position. Modification with the reagents 3-bromopropylamine . HBr and 2-mercaptoethylamine also allowed for partial restoration of activity showing that there is some flexibility in the length requirements of this essential residue. Modification with (2-bromoethyl)trimethylammonium . Br to form a positively charged, nontitratable side chain at the 145-position failed to restore activity to the inactive K145C leader peptidase mutant. This result, along with an inactive K145R mutant result, supports the claim that the lysine side chain at the 145-position is essential due to its ability to form a hydrogen bond(s) or to act as a general base rather than because of an ability to form a critical salt bridge. We find that leader peptidase processes the pre-protein substrate, pro OmpA nuclease A, with maximum efficiency at pH 9.0, and apparent pK(a) values for titratable groups at approximately 8.7 and 9.3 are revealed. We show that the lysine modifier maleic anhydride inhibits leader peptidase by reacting with lysine 145. The results of this study are consistent with the hypothesis that the lysine at the 145-position of leader peptidase functions as the active site general base. A model of the active site region of leader peptidase is presented based an the structure of the E. coli UmuD', and a mechanism for bacterial leader peptidase is proposed.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210; UNIV ALBERTA,MRC,GRP PROT STRUCT & FUNCT,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University System of Ohio; Ohio State University; University of Alberta				Paetzel, Mark/0000-0002-7408-5487	NIGMS NIH HHS [GM48805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM048805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOP AE, 1995, BIOORG MED CHEM LETT, V5, P443, DOI 10.1016/0960-894X(95)00052-U; AMMON HL, 1991, ACTA CRYSTALLOGR C, V47, P1476, DOI 10.1107/S0108270190012835; [Anonymous], 1982, MOL CLONING LAB MANU; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; Cole R.D., 1967, METHOD ENZYMOL, V11, P315; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; DEV IK, 1990, J BIOL CHEM, V265, P20069; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GLOSS LM, 1995, BIOCHEMISTRY-US, V34, P12323, DOI 10.1021/bi00038a028; GLOSS LM, 1995, BIOCHEMISTRY-US, V34, P3990, DOI 10.1021/bi00012a017; HABEEB A, 1970, BIOCHEMISTRY-US, V25, P4939; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; ITANO HA, 1972, J BIOL CHEM, V247, P4819; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KIM YT, 1995, J BIOCHEM-TOKYO, V117, P535, DOI 10.1093/oxfordjournals.jbchem.a124741; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; LINDLEY H, 1956, NATURE, V178, P647, DOI 10.1038/178647a0; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; MEANS GE, 1971, CHEM MODIFICATION PR, P76; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; RAFTERY MA, 1966, J BIOL CHEM, V241, P3457; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; SMITH HB, 1988, J BIOL CHEM, V263, P4921; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUNG M, 1992, J BIOL CHEM, V267, P13154; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; WESTHEIMER FH, 1995, TETRAHEDRON, V51, P3, DOI 10.1016/0040-4020(94)00865-R; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	53	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9994	10003						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092541				2022-12-27	WOS:A1997WU03900060
J	Alejo, A; Yanez, RJ; Rodriguez, JM; Vinuela, E; Salas, ML				Alejo, A; Yanez, RJ; Rodriguez, JM; Vinuela, E; Salas, ML			African swine fever virus trans-prenyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; PYROPHOSPHATE SYNTHASE; CONSERVED ASPARTATE; MOLECULAR-CLONING	The present study describes the characterization of an African swine fever virus gene homologous to prenyltransferases. The gene, designated B318L, is located within the EcoRI B fragment in the central region of the virus genome, and encodes a polypeptide with a predicted molecular weight of 35,904. The protein is characterized by the presence of a putative hydrophobic transmembrane domain at the amino end. The gene is expressed at the late stage of virus infection, and transcription is initiated at positions -118, -119, -120, and -122 relative to the first nucleotide of the translation start codon. Protein B318L presents a colinear arrangement of the four highly conserved regions and the two aspartate-rich motifs characteristic of geranylgeranyl diphosphate synthases, farnesyl diphosphate synthases, and other prenyltransferases. Throughout these regions, the percentages of identity between protein B318L and various prenyltransferases range from 28.6 to 48.7%. The gene was cloned in vector pTrxFus without the amino-terminal hydrophobic region and expressed in Escherichia coli. The recombinant protein, purified essentially to homogeneity by affinity chromatography, catalyzes the sequential condensation of isopentenyl diphosphate with different allylic diphosphates, farnesyl diphosphate being the best allylic substrate of the reaction. All-trans-polyprenyl diphosphates containing 3-13 isoprene units are synthesized, which identifies the B318L protein as a trans-prenyltransferase.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL SERVERO OCHOA, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Alejo, Ali/AAF-1477-2020; Rodriguez Martinez, Javier Maria/A-5478-2017	Alejo, Ali/0000-0002-1613-6063; Yanez-Munoz, Rafael J/0000-0001-7113-1938; Rodriguez Martinez, Javier Maria/0000-0003-0146-9903				ALMAZAN F, 1993, J VIROL, V67, P553; ALMAZAN F, 1992, J VIROL, V66, P6655; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378-1119(93)90326-X; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CARRASCOSA AL, 1993, VIROLOGY, V193, P460, DOI 10.1006/viro.1993.1146; CARRASCOSA JL, 1984, VIROLOGY, V132, P160, DOI 10.1016/0042-6822(84)90100-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; Costa J. V., 1990, Molecular Biology of Iridoviruses., P247; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; EDGINGTON SM, 1994, BIO-TECHNOL, V12, P37, DOI 10.1038/nbt0194-37; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERICSSON J, 1993, J BIOL CHEM, V268, P832; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; ESTEVES A, 1986, VIROLOGY, V152, P192, DOI 10.1016/0042-6822(86)90384-3; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONZALEZ A, 1986, NUCLEIC ACIDS RES, V14, P6835, DOI 10.1093/nar/14.17.6835; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; JOLY A, 1993, J BIOL CHEM, V268, P26983; KALEN A, 1990, J BIOL CHEM, V265, P1158; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KUNTZ M, 1992, PLANT J, V2, P25; KUZNAR J, 1980, VIROLOGY, V101, P169, DOI 10.1016/0042-6822(80)90493-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LUND K, 1986, BIOCHEM CELL BIOL, V64, P1303, DOI 10.1139/o86-171; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MOSS B, 1990, CURR TOP MICROBIOL, V163, P41; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1985, STEROLS BILE ACIDS, P17; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; SALAS ML, 1981, VIROLOGY, V113, P484, DOI 10.1016/0042-6822(81)90176-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOGO JM, 1984, VIROLOGY, V133, P271, DOI 10.1016/0042-6822(84)90394-5; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WITTEK R, 1980, CELL, V21, P277, DOI 10.1016/0092-8674(80)90135-X; YANEZ RJ, 1993, NUCLEIC ACIDS RES, V21, P2423, DOI 10.1093/nar/21.10.2423; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2	74	12	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9417	9423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083080	hybrid, Green Published			2022-12-27	WOS:A1997WU03700085
J	Kreppel, LK; Blomberg, MA; Hart, GW				Kreppel, LK; Blomberg, MA; Hart, GW			Dynamic glycosylation of nuclear and cytosolic proteins - Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE; EIF-2 ALPHA-SUBUNIT; CYTOPLASMIC PROTEINS; TYROSINE PHOSPHORYLATION; LINKED GLCNAC; SNAP HELIX; SEQUENCE; TPR; PURIFICATION	O-Linked N-acetylglucosamine (O-GlcNAc) glycosylation is a dynamic modification of eukaryotic nuclear and cytosolic proteins analogous to protein phosphorylation. We have cloned and characterized a novel gene for an O-GlcNAc transferase (OGT) that shares no sequence homology or structural similarities with other glycosyltransferases. The OGT gene is highly conserved (up to 80% identity) in all eukaryotes examined. Unlike previously described glycosyltransferases, OGT is localized to the cytosol and nucleus. The OGT protein contains multiple tandem repeats of the tetratricopeptide repeat motif. The presence of tetratricopeptide repeats, which can mediate protein-protein interactions, suggests that OGT may be regulated by protein interactions that are independent of the enzyme's catalytic site. The OGT is also modified by tyrosine phosphorylation, indicating that tyrosine kinase signal transduction cascades may play a role in modulating OGT activity.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University				Hart, Gerald/0000-0001-7812-4351	NICHD NIH HHS [HD13563] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P1891; COMER FI, 1996, FASEB J, V10, pA1119; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HART GW, 1997, IN PRESS ANN REV BIO; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOLT GD, 1986, J BIOL CHEM, V261, P8049; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Shaw P, 1996, ONCOGENE, V12, P921; SONGYANG Z, 1995, TRENDS BIOCHEM SCI, V20, P441; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	52	590	616	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9308	9315						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083067				2022-12-27	WOS:A1997WU03700072
J	Zhao, F; GhezzoSchoneich, E; Aced, GI; Hong, JY; Milby, T; Schoneich, C				Zhao, F; GhezzoSchoneich, E; Aced, GI; Hong, JY; Milby, T; Schoneich, C			Metal-catalyzed oxidation of histidine in human growth hormone - Mechanism, isotope effects, and inhibition by a mild denaturing alcohol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE; HYDROGEN-PEROXIDE; AQUEOUS-SOLUTION; SUPEROXIDE-DISMUTASE; PROTEIN OXIDATION; HYDROXYL RADICALS; METHIONINE; COPPER; SITE; RESIDUES	Metal-catalyzed oxidation of proteins represents an important pathway of post-translational modification. We utilized human growth hormone (hGH), a protein with a well defined metal-binding site, to study the detailed mechanism of metal-catalyzed oxidation by ascorbate/Cu(II)/O-2. Particularly His(18) and His(21) within the metal-binding site were oxidized, predominantly to S-oxo-His with the incorporated oxygen originating from molecular oxygen, based on amino acid analysis, tryptic mapping, mass spectrometry, isotopic labeling, and H-1 NMR. The anaerobic reduction of a hGH/Cu(II) mixture by ascorbate generated a hGH-Cu(I) complex with NMR spectral features different from those of native hGH and hGH/Cu(II). The anaerobic reaction of this hGH-Cu(I) complex with hydrogen peroxide resulted in the oxidation of His(18) and His(21), suggesting that a fraction of Cu(I) was bound at the metal-binding site of hGH. Site-specific oxidation of hGH required an intact metal-binding site and could largely (about 80%) be inhibited by the presence of greater than or equal to 28% (v/v) 1-propanol which appears (i) to perturb the metal-binding site and (ii) to interact with a reactive oxygen species formed at the perturbed metal-binding site. The inhibition by 1-propanol-d(7) (CD3CD2CD2OH) was significantly lower than that by 1-propanol-h(7) with [residual hGH](1-propanol-h7)/[residual hGH](1-propanol-d7) = 1.95 at 30% (v/v) 1-propanol, reflecting a kinetic isotope effect close to that for the reaction of a hydroxyl radical with C-alpha-HID bonds of methanol, suggesting the involvement of a hydroxyl radical-like species in the oxidation of His.	UNIV KANSAS, DEPT PHARMACEUT CHEM, LAWRENCE, KS 66047 USA; GENENTECH INC, PHARMACEUT R&D, San Francisco, CA 94080 USA	University of Kansas; Roche Holding; Genentech					NATIONAL INSTITUTE ON AGING [P01AG012993] Funding Source: NIH RePORTER; NIA NIH HHS [P01AG12993] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABILDGAARD F, 1992, BIOCHEMISTRY-US, V31, P8587, DOI 10.1021/bi00151a028; ASMUS KD, 1973, J PHYS CHEM-US, V77, P1218, DOI 10.1021/j100629a007; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; BOBROWSKI K, 1991, J CHEM SOC PERK T 2, P353, DOI 10.1039/p29910000353; BOBROWSKI K, 1989, J PHYS CHEM-US, V93, P6381, DOI 10.1021/j100354a022; BOBROWSKI K, 1987, INT J RADIAT BIOL, V52, P139, DOI 10.1080/09553008714551561; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DAVIES MJ, 1995, BIOCHEM J, V305, P643, DOI 10.1042/bj3050643; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERSHOV BG, 1991, J PHYS CHEM-US, V95, P8996, DOI 10.1021/j100175a104; FARBER JM, 1986, J BIOL CHEM, V261, P4574; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HILLER KO, 1981, J AM CHEM SOC, V103, P2734, DOI 10.1021/ja00400a042; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; LIAW SH, 1993, BIOCHEMISTRY-US, V32, P7999, DOI 10.1021/bi00082a022; *MACK PRINT CO, 1989, US PHARM, P1246; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MULKERRIN MG, 1993, ACS SYM SER, V526, P240; Pearlman R, 1993, Pharm Biotechnol, V5, P1; SAMUNI A, 1973, J PHYS CHEM-US, V77, P1629, DOI 10.1021/j100632a007; SATO K, 1992, J BIOL CHEM, V267, P25371; SCHONEICH C, 1994, J AM CHEM SOC, V116, P4641, DOI 10.1021/ja00090a012; SHAW K, 1968, INORG CHEM, V7, P1619, DOI 10.1021/ic50066a029; SMITH CD, 1992, ANN NY ACAD SCI, V663, P110, DOI 10.1111/j.1749-6632.1992.tb38654.x; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TOMITA M, 1969, BIOCHEMISTRY-US, V8, P5149, DOI 10.1021/bi00840a069; TURNER C, 1983, BIOCHEM J, V213, P107, DOI 10.1042/bj2130107; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; UCHIDA K, 1993, FEBS LETT, V332, P208, DOI 10.1016/0014-5793(93)80632-5; UCHIDA K, 1986, BIOCHEM BIOPH RES CO, V138, P659, DOI 10.1016/S0006-291X(86)80547-2; WICAR S, 1994, ANAL CHEM, V66, P3908, DOI 10.1021/ac00094a011; WILLAM S, 1994, NATURE, V372, P478; YIM MB, 1993, J BIOL CHEM, V268, P4099; Zhao F, 1996, PHARMACEUT RES, V13, P931, DOI 10.1023/A:1016021716274	49	113	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9019	9029						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083026				2022-12-27	WOS:A1997WU03700031
J	Liu, YF; Deth, RC; Devys, D				Liu, YF; Deth, RC; Devys, D			SH3 domain-dependent association of Huntington with epidermal growth factor receptor signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; DISEASE; PROTEIN; APOPTOSIS; GENE; GRB2; PHOSPHORYLATION; EXPRESSION; REPEAT; LENGTH	Based on the presence of multiple proline-rich moths in the huntingtin sequence, we tested its possible association with epidermal growth factor (EGF) receptor signaling complexes through SH3 domain-containing modules. We found that huntingtin is associated with Grb2, RasGAP, and tyrosine-phosphorylated EGF receptor. These associations are regulated by activation of the EGF receptor, suggesting that they may be part of EGF receptor-mediated cellular signaling cascade. In vitro binding studies indicate that SH3 domains of Grb2 or RasGAP are required for their binding to huntingtin. Our results suggest that huntingtin may be a unique adapter protein for EGF receptor-mediated signaling and may be involved in the regulation of Bus-dependent signaling pathways.	BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; UNIV STRASBOURG 1,INST GENET & BIOL MOL & CELLULAIRE,F-67404 STRASBOURG,FRANCE	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Liu, YF (corresponding author), NORTHEASTERN UNIV,DEPT PHARMACEUT SCI,312 MUGAR LIFE SCI BLDG,BOSTON,MA 02115, USA.		Deth, Richard/AFV-2608-2022	Devys, Didier/0000-0001-9655-3512				ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; *HUNT DIS COLL RES, 1993, CELL, V72, P971; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; TANKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	26	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8121	8124		10.1074/jbc.272.13.8121	http://dx.doi.org/10.1074/jbc.272.13.8121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079622	hybrid			2022-12-27	WOS:A1997WQ63500005
J	Cribbs, DH; Pike, CJ; Weinstein, SL; Velazquez, P; Cotman, CW				Cribbs, DH; Pike, CJ; Weinstein, SL; Velazquez, P; Cotman, CW			All-D-enantiomers of beta-amyloid exhibit similar biological properties to all-L-beta-amyloids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; D-AMINO ACIDS; ALZHEIMERS-DISEASE; HIPPOCAMPAL CULTURES; BILAYER-MEMBRANES; TRANSGENIC MICE; FIBRILS INVITRO; THIOFLAVINE-T; PROTEIN; PEPTIDE	The amyloidogenic peptide beta-amyloid has previously been shown to bind to neurons in the form of fibrillar clusters on the cell surface, which induces neurodegeneration and activates a program of cell death characteristic of apoptosis. To further investigate the mechanism of A beta neurotoxicity, we synthesized the all-D- and all-L-stereoisomers of the neurotoxic truncated form of A beta (A beta(25-35)) and the full-length peptide (A beta(1-42)) and compared their physical and biological properties. We report that the purified peptides exhibit nearly identical structural and assembly characteristics as assessed by high performance liquid chromatography, electron microscopy, circular dichroism, and sedimentation analysis, In addition, both enantiomers induce similar levels of toxicity in cultured hippocampal neurons, These data suggest that the neurotoxic actions of A beta result not from stereoisomer-specific ligand-receptor interactions but rather from A beta cellular interactions in which fibril features of the amyloidogenic peptide are a critical feature, The promiscuous nature of these beta-sheet-containing fibrils suggests that the accumulation of amyloidogenic peptides in vivo as extracellular deposits represents a site of bioactive peptides with the ability to provide inappropriate signals to cells leading to cellular degeneration and disease.	UNIV CALIF IRVINE,INST BRAIN AGING & DEMENTIA,DEPT NEUROL,IRVINE,CA 92717	University of California System; University of California Irvine	Cribbs, DH (corresponding author), UNIV CALIF IRVINE,INST BRAIN AGING & DEMENTIA,DEPT PSYCHOBIOL,IRVINE,CA 92717, USA.		Pike, Christian J/D-4013-2018	Pike, Christian/0000-0003-4577-7668	NATIONAL INSTITUTE ON AGING [R35AG007918, R01AG013007] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07918, AG 13007] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BANZON JA, 1992, PROTEIN ENG, V5, P113, DOI 10.1093/protein/5.2.113; BLANC JP, 1984, J BIOL CHEM, V259, P9549; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BURDICK D, 1992, J BIOL CHEM, V267, P546; BURDICK D, 1997, IN RPESS BRAIN RES; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; CARRELL RW, 1994, AM J RESP CRIT CARE, V150, P171; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; COTMAN CW, 1997, MOL MECH DEMENTIA, P73; Cribbs DH, 1996, NEUROSCIENCE, V75, P173, DOI 10.1016/0306-4522(96)80001-P; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; ElKhoury J, 1996, NATURE, V382, P716; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; FLOURET G, 1965, J AM CHEM SOC, V87, P3775, DOI 10.1021/ja01094a045; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giulian D, 1996, J NEUROSCI, V16, P6021; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEVINE H, 1995, NEUROBIOL AGING, V16, P755, DOI 10.1016/0197-4580(95)00052-G; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAY PC, 1993, J NEUROCHEM, V61, P2330, DOI 10.1111/j.1471-4159.1993.tb07480.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1990, LAB INVEST, V62, P768; NAIKI H, 1991, LAB INVEST, V65, P104; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SEATON BA, 1994, NAT STRUCT BIOL, V1, P350, DOI 10.1038/nsb0694-350; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHEMYAKI.MM, 1967, NATURE, V213, P412, DOI 10.1038/213412a0; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P335; STEWART JM, 1965, NATURE, V206, P619, DOI 10.1038/206619b0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VOGLER K, 1966, HELV CHIM ACTA, V49, P390, DOI 10.1002/hlca.660490144; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	61	74	97	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7431	7436		10.1074/jbc.272.11.7431	http://dx.doi.org/10.1074/jbc.272.11.7431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054444	hybrid			2022-12-27	WOS:A1997WN14700083
J	Grundemann, D; BabinEbell, J; Martel, F; Ording, N; Schmidt, A; Schomig, E				Grundemann, D; BabinEbell, J; Martel, F; Ording, N; Schmidt, A; Schomig, E			Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; BASOLATERAL MEMBRANE-VESICLES; EFFICIENT METHOD; LINE LLC-PK1; TETRAETHYLAMMONIUM; INHIBITORS; DNA; TUBULE; RNA; PH	Renal secretion of organic cations involves at least two distinct transporters, located in the basolateral and apical membranes of proximal tubule cells. Whereas the basolateral transporter has recently been cloned, sequence information about the apical type was not yet available. An organic cation transporter, OCT2p, was cloned from LLC-PK1 cells, a porcine cell line with properties of proximal tubular epithelial cells. OCT2p was heterologously expressed and characterized in human embryonic kidney 293 cells, OCT2p-mediated uptake of the prototypical organic cation [C-14]tetraethylammonium ([C-14]TEA) into 293 cells was saturable. There was a highly significant correlation between the K-i values for the inhibition of apical [C-14]TEA uptake into LLC-PK1 cells and 293 cells transfected with OCT2p (r = 0.995; p < 0.001; n = 6). Although OCT2p is structurally related to OCT1r, the basolateral organic cation transporter from rat kidney, the transporters could be clearly discriminated pharmacologically with corticosterone, decynium22, and O-methylisoprenaline. The findings at hand suggest that OCT2 corresponds to the apical type of organic cation transporter. Reverse transcriptase-polymerase chain reaction indicates that mRNA of OCT1r is limited to non-neuronal tissue, whereas OCT2r, the OCT2p homologue from rat, was found in both the kidney and central nervous regions known to be rich in the monoamine transmitter dopamine.			Grundemann, D (corresponding author), UNIV HEIDELBERG, DEPT PHARMACOL, NEUENHEIMER FELD 366, D-69120 HEIDELBERG, GERMANY.		Gründemann, Dirk/AAD-2217-2022	Martel, Fatima/0000-0002-0525-3416				Aperia A, 1994, Curr Opin Nephrol Hypertens, V3, P39, DOI 10.1097/00041552-199401000-00005; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BABINEBELL J, 1991, N-S ARCH PHARMACOL, V343, pR92; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DANTZLER WH, 1989, AM J PHYSIOL, V256, pF290, DOI 10.1152/ajprenal.1989.256.2.F290; DANTZLER WH, 1988, AM J PHYSIOL, V255, pF167, DOI 10.1152/ajprenal.1988.255.1.F167; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; ESPELUND M, 1990, NUCLEIC ACIDS RES, V18, P6157, DOI 10.1093/nar/18.20.6157; FAUTH C, 1988, AM J PHYSIOL, V254, pF351, DOI 10.1152/ajprenal.1988.254.3.F351; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grundemann D, 1996, BIOTECHNIQUES, V21, P898; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; INUI K, 1985, BIOCHEM J, V227, P199, DOI 10.1042/bj2270199; KEPPLER K, 1992, Naunyn-Schmiedeberg's Archives of Pharmacology, V345, pR103; KUWAHARA M, 1994, BBA-MOL CELL RES, V1220, P132, DOI 10.1016/0167-4889(94)90128-7; LIU ZG, 1992, BIOTECHNIQUES, V12, P28; Martel F, 1996, N-S ARCH PHARMACOL, V354, P320; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MCKINNEY TD, 1990, J AM SOC NEPHROL, V1, P902; MCKINNEY TD, 1988, J CELL PHYSIOL, V137, P513, DOI 10.1002/jcp.1041370317; MILLER JH, 1992, BIOCHIM BIOPHYS ACTA, V1110, P209, DOI 10.1016/0005-2736(92)90361-O; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PALKOVITS M, 1989, CATECHOLAMINES, V2, P1; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; RABITO CA, 1984, J BIOL CHEM, V259, P574; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; RUSS H, 1993, J MED CHEM, V36, P4208, DOI 10.1021/jm00078a010; SAITO H, 1992, AM J PHYSIOL, V262, pC59, DOI 10.1152/ajpcell.1992.262.1.C59; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHOMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1988, J BIOL CHEM, V263, P19494; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903; YUAN G, 1991, J BIOL CHEM, V266, P8978	45	171	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10408	10413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099681				2022-12-27	WOS:A1997WV26200015
J	Veenstra, JA; Pattillo, JM; Petzel, DH				Veenstra, JA; Pattillo, JM; Petzel, DH			A single cDNA encodes all three Aedes leucokinins, which stimulate both fluid secretion by the malpighian tubules and hindgut contractions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIURETIC HORMONE; MANDUCA-SEXTA; LEUCOPHAEA-MADERAE; TOBACCO HORNWORM; LOCUSTA-MIGRATORIA; CONSENSUS SEQUENCE; ACHETA-DOMESTICUS; ION-TRANSPORT; PEPTIDE; IDENTIFICATION	A cDNA encoding preproleucokinin was isolated from a cDNA library of the mosquito Aedes aegypti. The deduced amino acid sequence of Aedes preproleucokinin contains a putative signal peptide of 18 amino acid residues and a 210-amino acid residue proleucokinin. Within the proleucokinin are encoded one copy each of the Aedes leucokinins 1, 2, and 3 isolated previously from this species (Veenstra, J. A. (1994) Biochem. Biophys. Res. Commun. 202, 715-719). All three Aedes leucokinins depolarize the transepithelial voltage of the malpighian tubule in concentrations of less than 10(-9) M and increase the frequency of hindgut contractions at concentrations above 10(-8) M. At higher concentrations the Aedes leucokinins 1 and 3 but not Aedes leucokinin 2 are also able to increase the rate of fluid secretion by the malpighian tubules. The differences of the three Aedes leucokinins in their potencies to induce fluid secretion or depolarizations in the malpighian tubules suggest that there may be more than one type of leucokinin receptor in this tissue.	UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721; UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; CREIGHTON UNIV,DEPT BIOMED SCI,OMAHA,NE 68178	University of Arizona; University of Arizona; University System of Georgia; University of Georgia; Creighton University			Veenstra, Jan/B-4610-2008	Veenstra, Jan Adrianus/0000-0002-2783-0018	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033429, R01AI033108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33429, AI 33108] Funding Source: Medline; NIDDK NIH HHS [DK 49610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKBURN MB, 1995, J INSECT PHYSIOL, V41, P723, DOI 10.1016/0022-1910(95)00005-F; BLACKBURN MB, 1991, BIOCHEM BIOPH RES CO, V181, P927, DOI 10.1016/0006-291X(91)92025-F; BOGERD J, 1995, J BIOL CHEM, V270, P23038, DOI 10.1074/jbc.270.39.23038; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRADLEY TJ, 1985, COMPREHENSIVE INSECT, V4, P421; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; CANTERA R, 1992, CELL TISSUE RES, V269, P65, DOI 10.1007/BF00384727; CANTERA R, 1992, CELL TISSUE RES, V269, P459, DOI 10.1007/BF00353901; CHEN YT, 1994, CELL TISSUE RES, V278, P493, DOI 10.1007/BF00331367; CHEN YT, 1994, CELL TISSUE RES, V276, P69, DOI 10.1007/BF00354786; CLOTTENS FL, 1994, PEPTIDES, V15, P971, DOI 10.1016/0196-9781(94)90059-0; COAST GM, 1990, J INSECT PHYSIOL, V36, P481, DOI 10.1016/0022-1910(90)90098-Z; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Delphin F., 1965, Transactions of the Royal Entomological Society of London, V117, P167; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DIGAN ME, 1992, P NATL ACAD SCI USA, V89, P11074, DOI 10.1073/pnas.89.22.11074; FOURNIER B, 1988, J INSECT PHYSIOL, V34, P309, DOI 10.1016/0022-1910(88)90141-2; Furuya K, 1995, P NATL ACAD SCI USA, V92, P12323, DOI 10.1073/pnas.92.26.12323; Gabe M., 1968, TECHNIQUES HISTOLOGI; GAUDE H, 1975, Zoologischer Anzeiger, V194, P151; GILLETT JD, 1983, PROC R SOC SER B-BIO, V217, P237, DOI 10.1098/rspb.1983.0008; GILLETT JD, 1982, PROC R SOC SER B-BIO, V216, P201, DOI 10.1098/rspb.1982.0070; HAYES TK, 1989, LIFE SCI, V44, P1259, DOI 10.1016/0024-3205(89)90362-7; HAYES TK, 1994, REGUL PEPTIDES, V52, P235, DOI 10.1016/0167-0115(94)90058-2; Holman G.M., 1990, P195; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P205, DOI 10.1016/0742-8413(86)90084-8; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P271, DOI 10.1016/0742-8413(86)90093-9; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P31, DOI 10.1016/0742-8413(87)90043-0; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P27, DOI 10.1016/0742-8413(87)90042-9; KATAOKA H, 1989, P NATL ACAD SCI USA, V86, P2976, DOI 10.1073/pnas.86.8.2976; KAY I, 1991, BIOL CHEM H-S, V372, P505, DOI 10.1515/bchm3.1991.372.2.505; KAY I, 1991, REGUL PEPTIDES, V42, P111; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; LEHMBERG E, 1991, BIOCHEM BIOPH RES CO, V179, P1036, DOI 10.1016/0006-291X(91)91923-Z; MESSER AC, 1995, J EXP BIOL, V198, P2325; MOWRY TM, 1987, J INSECT PHYSIOL, V33, P867, DOI 10.1016/0022-1910(87)90035-7; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NASSEL DR, 1992, J COMP NEUROL, V322, P45, DOI 10.1002/cne.903220105; ODonnell MJ, 1996, J EXP BIOL, V199, P1163; PANNABECKER TL, 1993, J MEMBRANE BIOL, V132, P63; PATEL M, 1994, PEPTIDES, V15, P591, DOI 10.1016/0196-9781(94)90081-7; PETZEL DH, 1985, AM J PHYSIOL, V249, pR701; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1992, REGUL PEPTIDES, V37, P49, DOI 10.1016/0167-0115(92)90063-Z; SHAPIRO JP, 1982, GEN COMP ENDOCR, V46, P176, DOI 10.1016/0016-6480(82)90199-X; THOMPSON KSJ, 1995, PEPTIDES, V16, P95, DOI 10.1016/0196-9781(94)00158-3; VEENSTRA JA, 1991, CELL TISSUE RES, V266, P359, DOI 10.1007/BF00318191; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V202, P715, DOI 10.1006/bbrc.1994.1989; VEENSTRA JA, 1988, J INSECT PHYSIOL, V34, P299, DOI 10.1016/0022-1910(88)90139-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS JC, 1983, J COMP PHYSIOL, V153, P257, DOI 10.1007/BF00689629; WILLIAMS JC, 1984, J COMP PHYSIOL, V154, P301, DOI 10.1007/BF02464411	53	83	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10402	10407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099680	hybrid			2022-12-27	WOS:A1997WV26200014
J	Krupenko, SA; Wagner, C; Cook, RJ				Krupenko, SA; Wagner, C; Cook, RJ			Expression, purification, and properties of the aldehyde dehydrogenase homologous carboxyl-terminal domain of rat 10-formyltetrahydrofolate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; ACTIVE-SITE; CYTOSOL-I; LIVER; OXIDATION; ESTERASE; NITROCELLULOSE; FLUORESCENCE; SPECIFICITY; ISOZYMES	The liver cytosolic enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH) (EC 1.5.1.6) catalyzes two reactions: the NADP(+)-dependent oxidation of 10-formyltetrahydrofolate to tetrahydrofolate and CO2 and the NADP(+)-independent hydrolysis of 10-formyltetrahydrofolate to tetrahydrofolate and formate, The COOH-terminal domain of the enzyme (residues 420-902) is about 48% identical to a family of NAD-dependent aldehyde dehydrogenases (EC 1.2.1.3), and FDH possesses aldehyde dehydrogenase activity, We expressed the COOH-terminal domain (residues 420-902) of FDH in insect cells using a baculovirus expression system, The recombinant protein was released from insect cells to the culture medium and was purified from the medium by a two-step procedure: precipitation with 35% saturated ammonium sulfate followed by chromatography on hydroxyapatite, The purified COOH-terminal domain displayed aldehyde dehydrogenase activity similar to that of native FDH but had neither dehydrogenase nor hydrolase activity toward folate substrates. Aldehyde dehydrogenase activity of the COOH-terminal domain and FDH was independent of the presence of 2-mercaptoethanol while 10-FDDF dehydrogenase activity of FDH occurred only in the presence of 2-mercaptoethanol, The COOH-terminal domain existed as a tetramer showing that the Bites for oligomerization of subunits in native FDH resides in this domain, Using titration of tryptophan fluorescence, it was found that the COOH-terminal domain bound NADP(+) to the same extent as FDH (K-d 0.2 and 0.3 mu M, respectively) but did not bind folate, Both FDH and its COOH-terminal domain also bound NAD(+) (K-d 11 and 16 mu M, respectively) as measured by fluorescence titration, Both proteins were able to catalyze the aldehyde dehydrogenase reaction utilizing NADP(+) or NAD(+), but the K-m for NAD(+) was three orders higher than that for NADP(+) (2 mM and 1.5-2.0 mu M, respectively), The concentration of NAD(+) required for the reaction was high compared with the physiological level of NAD(+), suggesting that the reaction does not occur in vivo, NAD(+) at physiological concentrations stimulated the aldehyde dehydrogenase reaction performed by FDH or its COOH-terminal domain using NADP(+).	DEPT VET AFFAIRS MED CTR,RES SERV,NASHVILLE,TN 37212	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, SA (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,612 LH,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.				NIDDK NIH HHS [DK49563, DK46788, DK15289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049563, R01DK046788, R37DK015289, R01DK015289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROZIAK W, 1993, ENZYMOL MOL BIOL CAR, V4, P5; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAVARI S, MERCK INDEX, P37; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASE GL, 1988, J BIOL CHEM, V263, P10204; CHOW SF, 1985, J BIOL CHEM, V260, P5516; COOK RJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P336, DOI 10.1006/abbi.1995.1403; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUNCAN RJS, 1985, BIOCHEM J, V230, P261, DOI 10.1042/bj2300261; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FRIEDRICH W, 1988, VITAMINS, P502; FUKUBA R, 1974, BIOCHIM BIOPHYS ACTA, V341, P48, DOI 10.1016/0005-2744(74)90064-3; GREENBAU.AL, 1965, BIOCHEM J, V95, P161, DOI 10.1042/bj0950161; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, V2, P3; KIM DW, 1995, FASEB J, V9, pA1289; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LINDSTROM RL, 1993, CURR OPIN OPHTHALMOL, V4, P1, DOI 10.1097/00055735-199302000-00001; MARTIN KO, 1978, J STEROID BIOCHEM, V9, P1233, DOI 10.1016/0022-4731(78)90018-3; MONDER C, 1982, J STEROID BIOCHEM, V17, P41, DOI 10.1016/0022-4731(82)90590-8; MUKERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23, DOI 10.1016/0003-9861(92)90239-S; NEEDLEMAN S, 1979, J MOL BIOL, V48, P444; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SENIOR DJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P211, DOI 10.1016/0003-9861(88)90183-X; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Stamler JS, 1996, NUTR REV, V54, P1; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P2720, DOI 10.1021/bi00513a003; WAGNER C, 1994, FOLATE HLTH DISEASE, P23; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WEINER H, 1989, ENZYMOLOGY MOL BIOL, V2, pR19; WESTLUND P, 1994, FEBS LETT, V345, P99, DOI 10.1016/0014-5793(94)00409-9; YIN SJ, 1995, ENZYMOLOGY MOL BIOL, V5, P9; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794	53	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10266	10272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092577				2022-12-27	WOS:A1997WU03900096
J	Olson, DP; Koenig, RJ				Olson, DP; Koenig, RJ			5'-flanking sequences in thyroid hormone response element half-sites determine the requirement of retinoid X receptor for receptor-mediated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; HIGH-AFFINITY; BINDING-SITE; CO-REPRESSOR; PROTEIN GENE; DNA; ACID; TRANSCRIPTION; IDENTIFICATION; SUPERFAMILY	Thyroid hormone receptors are ligand-inducible transcription factors that can potentially interact with thyroid hormone response elements as homodimers or heterodimers with the retinoid X receptor. It has generally been felt, however, that the heterodimer is responsible for induction of gene expression, We have demonstrated previously that the optimal thyroid hormone receptor binding sequence is not the consensus hexamer half-site AGGTCA but is an octamer, TAAGGTCA. Based upon these findings, we hypothesize that thyroid hormone response elements composed of optimal half-sites (TAAGGTCA) will bind thyroid hormone receptors readily and activate gene expression independently of the retinoid X receptor. In contrast, response elements composed of suboptimal half-sites (e.g. GCAGGTCA) will require the retinoid X receptor to facilitate thyroid hormone receptor-mediated gene expression. To test this hypothesis, we have reconstituted thyroid hormone receptor mediated gene expression in yeast. Our studies confirm the hypothesis that the retinoid X receptor is required for gene expression from response elements composed of suboptimal half-sites, whereas thyroid hormone receptors are sufficient to activate gene expression maximally from response elements containing optimal half sites. Furthermore, coexpression of steroid receptor coactivator-1 is required for ligand-dependent gene activation from single response elements. Surprisingly, however, coexpression of the retinoid X receptor decreases the steroid receptor coactivator-1-dependent thyroid hormone induction. Overall these data demonstrate that the architecture of the thyroid hormone response element dictates the nuclear receptor requirements for gene activation. The studies suggest that different coactivators may be required for gene activation depending upon the response element architecture and the nature of the bound thyroid hormone receptor complex (homo- versus heterodimer).	UNIV MICHIGAN, MED CTR, DIV ENDOCRINOL & METAB, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; Ausubel FM, 1988, MOL REPROD DEV; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; FORCE WR, 1994, J BIOL CHEM, V269, P8863; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; ONATE SA, 1995, SCIENCE, V270, P1354; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Salerno AJ, 1996, NUCLEIC ACIDS RES, V24, P566, DOI 10.1093/nar/24.4.566; SIKORSKI RS, 1989, GENETICS, V122, P19; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	47	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9907	9914						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092529				2022-12-27	WOS:A1997WU03900048
J	Schutz, M; Shahak, Y; Padan, E; Hauska, G				Schutz, M; Shahak, Y; Padan, E; Hauska, G			Sulfide-quinone reductase from Rhodobacter capsulatus - Purification, cloning, and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-CAPSULATA; ANOXYGENIC PHOTOSYNTHESIS; OSCILLATORIA-LIMNETICA; GLUTATHIONE-REDUCTASE; SULFUR BACTERIA; RNA-POLYMERASE; PROTEINS; GENES; CHLOROBIUM; OXIDATION	A sulfide-quinone oxidoreductase (SQR, EC 1.8.5.'.) has been purified to homogeneity from chromatophores of the non-sulfur purple bacterium Rhodobacter capsulatus DSM 155. It is composed of a single polypeptide with an apparent molecular mass of about 55 kDa, exhibiting absorption and fluorescence spectra typical for a flavoprotein and similar to the SQR from the cyanobacterium Oscillatoria limnetica. From N-terminal and tryptic peptide sequences of the pure protein a genomic DNA clone was obtained by polymerase chain reaction amplification. Its sequence contains an open reading frame of 1275 base pairs (EMBL nucleotide sequence data base, accession no, X97478) encoding the SQR of R. capsulatus. The deduced polypeptide consists of 425 amino acid residues with a molecular mass of 47 kDa and a net charge of +9. The high similarity (72%)/identity (48%) between the N termini of the cyanobacterial and the bacterial enzyme was confirmed and extended. Both enzymes exhibit the FAD/NAD(P) binding beta alpha beta-fold (Wierenga, R. K., Terpstra, P., and Hol, W. G. S. (1986) J. Mol. Biol. 187, 101-107). The complete sequence of the SQR from R. capsulatus shows further similarity to flavoproteins, in particular glutathione reductase and lipoamide dehydrogenase. The cloned sqr was expressed in Escherichia coli in a functional form.	UNIV REGENSBURG,LEHRSTUHL ZELLBIOL & PFLANZENPHYSIOL,D-93040 REGENSBURG,GERMANY; AGR RES ORG,VOLCANI CTR,INST HORT,IL-50250 BET DAGAN,ISRAEL; HEBREW UNIV JERUSALEM,DIV MICROBIAL & MOL ECOL,IL-91904 JERUSALEM,ISRAEL	University of Regensburg; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem								Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ARIELI B, 1991, J BIOL CHEM, V266, P104; ARIELI B, 1994, J BIOL CHEM, V269, P5705; BRUNE DC, 1986, ARCH MICROBIOL, V145, P295, DOI 10.1007/BF00443662; BRUNE DC, 1989, BIOCHIM BIOPHYS ACTA, V975, P189, DOI 10.1016/S0005-2728(89)80251-8; Brune DC, 1995, ANOXYGENIC PHOTOSYNT, P847, DOI 10.1007/0-306-47954-0_39; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Gray KA, 1995, ANOXYGENIC PHOTOSYNT, P747; HANSEN TA, 1972, ARCH MIKROBIOL, V86, P49, DOI 10.1007/BF00412399; Imhoff J.F., 1995, ANOXYGENIC PHOTOSYNT, P1, DOI DOI 10.1007/0-306-47954-0_1; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KLUG G, 1984, ARCH MICROBIOL, V139, P319, DOI 10.1007/BF00408373; KLUGHAMMER C, 1995, PHOTOSYNTH RES, V43, P27, DOI 10.1007/BF00029459; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; KUSAI K, 1973, BIOCHIM BIOPHYS ACTA, V325, P304, DOI 10.1016/0005-2728(73)90106-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; M?ller, 1991, CHEM BIOCH FLAVOENZY; Maniatis T., 1982, MOL CLONING; MORTON RA, 1965, BIOCH QUINONES, P23; NELSON N, 1980, METHOD ENZYMOL, V69, P301; OKAMURA MY, 1995, ANOXYGENIC PHOTOSYNT, P577; PADAN E, 1979, ANNU REV PLANT PHYS, V30, P27, DOI 10.1146/annurev.pp.30.060179.000331; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHULZ GE, 1975, FEBS LETT, V54, P86, DOI 10.1016/0014-5793(75)81075-1; SCHUTZ M, 1995, PHOTOSYNTHESIS LIGHT, V2, P673; SHAHAK Y, 1994, PHOTOSYNTH RES, V39, P175, DOI 10.1007/BF00029384; SHAHAK Y, 1992, FEBS LETT, V299, P127, DOI 10.1016/0014-5793(92)80230-E; Shahak Y, 1992, RES PHOTOSYNTHESIS, VII, P483; STADLER R, 1992, THESIS U REGENSBURG; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS JC, 1995, ANOXYGENIC PHOTOSYNT, P1029; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	51	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9890	9894						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092526				2022-12-27	WOS:A1997WU03900045
J	Seiffert, D				Seiffert, D			The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; HUMAN-PLASMA; STRUCTURAL REQUIREMENTS; COMPLEX-FORMATION; HEPARIN; PROTEIN; FORMS; UREA	The ligand binding functions of vitronectin (Vn) are regulated by its conformational state/degree of multimerization. In the native plasma form of Vn, the C-terminal glycosaminoglycan (GAG) binding domain is believed to be cryptic. Here, evidence is provided that the addition of fucoidan or dextran sulfate to unfractionated plasma results in the formation of covalently and non-covalently stabilized Vn multimers. These multimers express conformationally sensitive antibody epitopes and ligand binding sites located in the N terminus of the Vn molecule. While heparin forms complexes with monomeric plasma Vn and induces conformational changes, a reduction in ionic strength is required for induction of multimerization. In addition, heparin serves as a template for the assembly of type 1 plasminogen activator inhibitor induced disulfide-linked Vn multimers. These results support a new model for the structure of native Vn. The C-terminal GAG binding domain is predicted to be exposed in the native conformation, whereas the N terminus is cryptic. Ligand binding to the GAG binding site unfolds the N terminus, thereby exposing cryptic ligand binding sites.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL50704] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; BARNES DW, 1985, J BIOL CHEM, V260, P9117; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; GEBB C, 1986, J BIOL CHEM, V261, P6698; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; KOST C, 1992, J BIOL CHEM, V267, P12098; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LANE DA, 1987, J BIOL CHEM, V262, P16343; Marder VJ., 1994, HEMOSTASIS THROMBOSI, P837; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; Sambrook J., 2002, MOL CLONING LAB MANU; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	30	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9971	9978						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092537				2022-12-27	WOS:A1997WU03900056
J	Sorin, A; Rosas, G; Rao, R				Sorin, A; Rosas, G; Rao, R			PMR1, a Ca2+-ATPase in yeast Golgi, has properties distinct from sarco/endoplasmic reticulum and plasma membrane calcium pumps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CA2+ TRANSPORT ATPASE; RAT MAMMARY-GLANDS; P-TYPE ATPASES; SARCOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; H+-ATPASE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; MOLECULAR-CLONING	PMR1, a P-type ATPase cloned from the yeast Saccharomyces cerevisiae, was previously localized to the Golgi, and shown to be required for normal secretory processes (Antebi, A., and Fink, G.R. (1992) Mol. Biol. Cell 3, 633-654). We provide biochemical evidence that PMR1 is a Ca2+-transporting ATPase in the Golgi, a hitherto unusual location for a Ca2+ pump. As a starting point for structure-function analysis using a mutagenic approach, we used the strong and inducible heat shock promoter to direct high level expression of PMR1 from a multicopy plasmid. Yeast lysates were separated on sucrose density gradients, and fractions assayed for organellar markers. PMR1 is found in fractions containing the Golgi marker guanosine diphosphatase, and is associated with an ATP dependent, protonophore-insensitive Ca-45(2+) uptake activity. This activity is virtually abolished in the absence of the expression plasmid. Furthermore, replacement of the active site aspartate within the phosphorylation domain had the expected effect of abolishing Ca2+ transport activity entirely. Interestingly, the mutant enzymes (Asp-371 --> Glu and Asp-371 --> Asn) demonstrated proper targeting to the Golgi, unlike analogous mutations in the related yeast H+-ATPase. Detailed characterization of calcium transport by PMR1 showed that sensitivity to inhibitors (vanadate, thapsigargin, and cyclopiazonic acid) and affinity for substrates (MgATP and Ca2+) were different from the previously characterized sarco/endoplasmic reticulum and plasma membrane Ca2+-ATPases, PMR1 therefore represents a new and distinct P-type Ca2+-ATPase. Because close homologs of PMR1 have been cloned from rat and other organisms, we suggest that Ca2+-ATPases in the Golgi will form a discrete subgroup that are important for functioning of the secretory pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM52414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ARAB N, 1989, PEDIATR RES, V26, P58, DOI 10.1203/00006450-198907000-00017; BARIK S, 1991, BIOTECHNIQUES, V10, P489; BERKELMAN T, 1994, J BACTERIOL, V176, P4430, DOI 10.1128/jb.176.14.4430-4436.1994; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHANDRA S, 1991, J CELL SCI, V100, P747; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DEMENDONCA RL, 1995, MOL BIOCHEM PARASIT, V72, P129, DOI 10.1016/0166-6851(95)00078-F; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; Fiske CH, 1925, J BIOL CHEM, V66, P375; FREEDMAN RA, 1977, P NATL ACAD SCI USA, V74, P3612, DOI 10.1073/pnas.74.8.3612; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GEISLER M, 1993, J MOL BIOL, V234, P1284, DOI 10.1006/jmbi.1993.1684; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HODSON S, 1978, J CELL SCI, V30, P117; INESI G, 1994, BIOPHYS CHEM, V50, P129, DOI 10.1016/0301-4622(94)85025-9; KANAMARU K, 1993, FEBS LETT, V330, P99, DOI 10.1016/0014-5793(93)80928-N; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1992, ANN NY ACAD SCI, V371, P1; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; ODA K, 1992, J BIOL CHEM, V267, P17465; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; OKOROKOV LA, 1993, EUR J BIOCHEM, V216, P573, DOI 10.1111/j.1432-1033.1993.tb18176.x; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RAO R, 1989, ION TRANSPORT, P35; REITH EJ, 1976, AM J ANAT, V147, P267, DOI 10.1002/aja.1001470302; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; WANG T, 1979, BIOCHEM BIOPH RES CO, V91, P356, DOI 10.1016/0006-291X(79)90626-0; Wasserman R H, 1989, Adv Exp Med Biol, V249, P45; WEST DW, 1981, BIOCHIM BIOPHYS ACTA, V673, P374, DOI 10.1016/0304-4165(81)90469-4; Yoo SH, 1996, J BIOL CHEM, V271, P1558; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V268, pC1133, DOI 10.1152/ajpcell.1995.268.5.C1133	64	210	220	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9895	9901						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092527				2022-12-27	WOS:A1997WU03900046
J	Weil, R; LaurentWinter, C; Israel, A				Weil, R; LaurentWinter, C; Israel, A			Regulation of I kappa B beta degradation - Similarities to and differences from I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; SIGNAL-INDUCED PHOSPHORYLATION; ACTIVATION; INHIBITOR; PROTEIN; DISSOCIATION; PROTEOLYSIS; SUFFICIENT; REQUIRES; GENE	The transcription factor NF-kappa B (nuclear factor-kappa B) is neutralized in nonstimulated cells through cytoplasmic retention by I kappa B inhibitors. In mammalian cells, two major forms of I kappa B proteins, I kappa B alpha and I kappa B beta, have been identified. Upon treatment with a large variety of inducers, I kappa B alpha and I kappa B beta are proteolytically degraded, resulting in NF-kappa B translocation into the nucleus. Recent observations suggest that phosphorylation of serines 32 and 36 and subsequent ubiquitination of lysines 21 and 22 of I kappa B alpha control its signal-induced degradation. In this study we provide evidence that critical residues in the NH2-terminal region of I kappa B beta (serines 19 and 23) as well as its COOH-terminal PEST region control I kappa B beta proteolysis. However Lys-9, the unique lysine residue in the NH2-terminal region of I kappa B beta, is not absolutely required for its degradation. We also demonstrate that following stimulation, an underphosphorylated nondegradable form of I kappa B beta accumulates. Surprisingly, our data suggest that unlike I kappa B alpha, I kappa B beta is constitutively phosphorylated on one or two of the critical NH2-terminal serine residues. Thus, phosphorylation of these sites is necessary for degradation but does not necessarily constitute the signal-induced event that targets the molecule for proteolysis.	INST PASTEUR,UNITE BIOL MOL EXPRESS GENIQUE,CNRS,URA 1149,F-75724 PARIS 15,FRANCE; INST PASTEUR,LAB ELECTROPHORESE BIDIMENSIONNELLE,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Weil, Robert/0000-0001-5235-0932				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DECKHUT AM, 1993, J IMMUNOL, V151, P2658; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; LAURENTWINTER C, 1994, DIFFERENTIATION, V55, P225, DOI 10.1046/j.1432-0436.1994.5530225.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LINK E, 1992, J BIOL CHEM, V267, P239; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sun SC, 1996, MOL CELL BIOL, V16, P1058; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	43	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9942	9949						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092533				2022-12-27	WOS:A1997WU03900052
J	Brasaemle, DL; Barber, T; Kimmel, AR; Londos, C				Brasaemle, DL; Barber, T; Kimmel, AR; Londos, C			Post-translational regulation of perilipin expression - Stabilization by stored intracellular neutral lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; LEYDIG TUMOR-CELLS; HEP G2 CELLS; APOLIPOPROTEIN-B; FATTY-ACIDS; ADIPOCYTES; STEROIDOGENESIS; LIPOPROTEINS; DROPLETS; PROTEIN	The perilipins are a family of polyphosphorylated proteins found exclusively surrounding neutral lipid storage droplets in adipocytes and steroidogenic cells, In steroidogenic cells, the cholesterol ester-rich lipid storage droplets are encoated with perilipins A and C. This study describes the dependence of perilipin levels on neutral lipid storage in cultured Y-1 adrenal cortical cells, The addition of fatty acids and cholesterol to the culture medium of Y-1 adrenal cortical cells greatly increased the storage of cholesterol esters and triacylglycerols concomitant with the formation of many new lipid storage droplets, The addition of fatty acids to the culture medium also produced a transient 6-fold increase in levels of perilipin A, but not C, mRNA, while much larger and stable increases in both perilipin A and C proteins were observed, The increases in perilipin protein levels were dependent upon the metabolism of fatty acids to triacylglycerol or cholesterol esters, since the incubation of cells with bromopalmitate, a poorly metabolized fatty acid, failed to yield large increases in lipid content or perilipin levels, Constitutive expression of epitope-tagged perilipins in transfected Y-1 adrenal cortical cells was regulated by lipid similarly to expression of the endogenous perilipins despite an absence of untranslated perilipin mRNA sequences in the expression constructs. Epitope-tagged perilipin A mRNAs were efficiently loaded with polyribosomes whether or not fatty acids were added to the culture medium; therefore, the increase in perilipin levels in the presence of fatty acids is likely due to factors other than increased translational efficiency, We suggest that the large increase in cellular perilipin levels upon lipid loading of cells is the result of post-translational stabilization of newly synthesized perilipins by stored neutral lipids.	NIDDK,MEMBRANE REGULAT SECT,CELLULAR & DEV BIOL LAB,NATL INST HLTH,BETHESDA,MD 20892; NIDDK,LAB CELL BIOCH & BIOL,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Brasaemle, Dawn/0000-0002-8553-8285				AMRI EZ, 1994, J LIPID RES, V35, P930; BISGAIER CL, 1985, J STEROID BIOCHEM, V23, P967, DOI 10.1016/0022-4731(85)90054-8; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BOCOS C, 1995, J STEROID BIOCHEM, V53, P467, DOI 10.1016/0960-0760(95)00093-F; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BUONASSISI V, 1962, P NATL ACAD SCI USA, V48, P1184, DOI 10.1073/pnas.48.7.1184; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; DIXON JL, 1993, J LIPID RES, V34, P167; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Schoonjans K, 1996, J LIPID RES, V37, P907; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; STRALFORS P, 1987, ENZYMES B, V18, P147; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	30	125	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9378	9387						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083075				2022-12-27	WOS:A1997WU03700080
J	Fawcett, JP; Aloyz, R; McLean, JH; Pareek, S; Miller, FD; McPherson, PS; Murphy, RA				Fawcett, JP; Aloyz, R; McLean, JH; Pareek, S; Miller, FD; McPherson, PS; Murphy, RA			Detection of brain-derived neurotrophic factor in a vesicular fraction of brain synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR NGF; PROTEIN; SYNAPTOTAGMIN; PLASTICITY; VESICLES; NEURONS; SEIZURE; RELEASE; SYSTEM	The mRNA encoding brain-derived neurotrophic factor (BDNF) is widely distributed in central nervous system neurons, including in hippocampus and cortex. However, little is known about the physiology of BDNF protein within neurons, including how it is processed or packaged and the mechanisms that control its release. In this study, we have used antibodies to monitor the subcellular distribution of BDNF in cortical extracts from adult rats treated with kainic acid. BDNF immunoreactivity is elevated in rat cortex 12 h after kainic acid treatment. The protein is enriched in a vesicular fraction isolated hom lysed synaptosomes, its distribution being similar to that of synaptotagmin, which is associated with synaptic vesicles and large dense core vesicles at nerve terminals. The vesicular pool of BDNF is digested by proteinase K only in the presence of Triton X-100 suggesting localization of BDNF in membrane fractions. Immunocytochemistry detects diffuse and punctate BDNF staining within cell bodies and processes of cortical neurons from kainic acid-treated rats, as well as in messy fiber terminals of rat hippocampus. Taken together, these data show that BDNF can accumulate axonally within a vesicular compartment of brain neurons. Results support the idea that endogenous BDNF may be transported anterogradely and released by regulated secretory mechanisms.	MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,MONTREAL NEUROL INST,CELL BIOL EXCITABLE TISSUE GRP,MONTREAL,PQ H3A 2B4,CANADA; MEM UNIV NEWFOUNDLAND,DIV BASIC MED SCI,ST JOHNS,NF A1B 3V6,CANADA	McGill University; McGill University; Memorial University Newfoundland				Aloyz, Raquel/0000-0002-6812-497X; Fawcett, Jim/0000-0003-0043-2164				BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; Kobayashi NR, 1996, EUR J NEUROSCI, V8, P1018, DOI 10.1111/j.1460-9568.1996.tb01588.x; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERIN MS, 1991, J BIOL CHEM, V266, P623; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1997, IN PRESS NEUROSCIENC	27	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8837	8840						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9082996				2022-12-27	WOS:A1997WU03700001
J	Linz, B; Koloteva, N; Vasilescu, S; McCarthy, JEG				Linz, B; Koloteva, N; Vasilescu, S; McCarthy, JEG			Disruption of ribosomal scanning on the 5'-untranslated region, and not restriction of translational initiation per se, modulates the stability of nonaberrant mRNAs in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; MAMMALIAN-CELLS; BINDING-PROTEIN; ENDONUCLEOLYTIC CLEAVAGE; SECONDARY STRUCTURE; NONSENSE MUTATIONS; FIREFLY LUCIFERASE; CODING REGION; INHIBITION; DECAY	Translation and mRNA decay constitute key players in the post-transcriptional control of gene expression. We examine the mechanisms by which the 5'-untranslated region (UTR) of nonaberrant mRNAs acts to modulate both these processes in Saccharomyces cerevisiae. Two classes of functional relationship between ribosome-5'-UTR interactions and mRNA decay are identifiable. In the first of these, elements in the main open reading frame (ORF) dictate how the decay process reacts to inhibitory structures in the 5'-UTR. The same types of stability modulation can be elicited by transregulation of translation via inducible binding of the iron-regulatory protein to an iron-responsive element located 9 nucleotides from the 5' cap. A eukaryotic translational repressor can therefore modulate mRNA decay via the 5'-UTR. In contrast, translational regulation mediated via changes in the activity of the cap-binding eukaryotic translation initiation factor eIF-4E bypasses translation-dependent pathways of mRNA degradation. Thus modulation of mRNA stability via the 5'-UTR depends on disruption of the scanning process, rather than changes in translational initiation efficiency per se. In the second class of pathway, an upstream ORF (uORF) functions as a powerful destabilizing element, inducing termination-dependent degradation that is apparently independent of any main ORF determinants but influenced by the efficiencies of ribosomal recognition of the uORF start and stop codons. This latter mechanism provides a regulatable means to modulate the stability of nonaberrant mRNAs via a UPF-dependent pathway.	UMIST, DEPT BIOMOL SCI, MANCHESTER M60 1QD, LANCS, ENGLAND	University of Manchester								BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BROWN AJP, 1989, YEAST, V5, P239, DOI 10.1002/yea.320050405; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHANG J, 1993, MOL CELL BIOL, V13, P1892; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEVELAND D W, 1989, New Biologist, V1, P121; CZAPLINSKI K, 1995, RNA, V1, P610; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONAHUE TF, 1990, METHOD ENZYMOL, V185, P366; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Guthrie C., 1991, METHOD ENZYMOL, V194, P21; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Harford J, 1993, CONTROL MESSENGER ST, P239; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LANG V, 1994, J BIOL CHEM, V269, P6117; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LINDER P, 1992, ANTON LEEUW INT J G, V62, P47, DOI 10.1007/BF00584462; LOSSON R, 1983, EMBO J, V2, P2179, DOI 10.1002/j.1460-2075.1983.tb01720.x; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MAQUAT LE, 1995, RNA, V1, P453; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MEYER BJ, 1992, MOL MICROBIOL, V6, P1095, DOI 10.1111/j.1365-2958.1992.tb01547.x; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; MULLER PP, 1986, CELL, V45, P201; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P89836; PELSY F, 1984, CURR GENET, V8, P277, DOI 10.1007/BF00419725; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; PELTZ SW, 1993, PROTEIN SYNTHESIS TA, P1; Ptushkina M, 1996, BBA-GENE STRUCT EXPR, V1308, P142, DOI 10.1016/0167-4781(96)00096-6; RAUE HA, 1994, TRENDS BIOTECHNOL, V12, P444, DOI 10.1016/0167-7799(94)90019-1; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RuizEchevarria MJ, 1996, EMBO J, V15, P2810, DOI 10.1002/j.1460-2075.1996.tb00641.x; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1994, J BIOL CHEM, V269, P18630; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TATSUMI H, 1988, AGR BIOL CHEM TOKYO, V52, P1123; VANDENHEUVEL JJ, 1990, YEAST, V6, P473, DOI 10.1002/yea.320060604; VANDENHEUVEL JJ, 1989, GENE, V79, P83, DOI 10.1016/0378-1119(89)90094-2; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x; YUN DF, 1995, MOL CELL BIOL, V15, P1021; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	74	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9131	9140						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083042				2022-12-27	WOS:A1997WU03700047
J	Brock, TG; McNish, RW; Bailie, MB; PetersGolden, M				Brock, TG; McNish, RW; Bailie, MB; PetersGolden, M			Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; BASOPHILIC LEUKEMIA-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONATE METABOLISM; ACTIVATING PROTEIN; BLOOD MONOCYTES; EXPRESSION; ACID; DIFFERENTIATION; LEUKOTRIENE-B4	5-Lipoxygenase catalyzes the synthesis of leukotrienes from arachidonic acid, The subcellular distribution of 5-lipoxygenase is known to be cell type dependent and is cytosolic in blood neutrophils. In this study, we asked whether neutrophil recruitment into sites of inflammation can alter the subcellular compartmentation of 5-lipoxygenase. In peripheral blood neutrophils from rats, 5-lipoxygenase was exclusively cytosolic, as expected, However, in glycogen-elicited peritoneal neutrophils, abundant soluble 5-lipoxygenase was in the nucleus, Upon activation with calcium ionophore A23187, intranuclear 5-lipoxygenase translocated to the nuclear envelope, Elicited neutrophils required a greater concentration of A23187 for activation than did blood neutrophils (half-maximal response, 160 versus 52 nM, respectively) but generated greater amounts of leukotriene B-4 upon maximal stimulation (26.6 versus 7.68 ng/10(6) cells, respectively), Intranuclear 5-lipoxygenase was also evident in human blood neutrophils after adherence to a variety of surfaces, suggesting that adherence alone is sufficient to drive 5-lipoxygenase redistribution, These results demonstrate a physiologically relevant circumstance in which the subcellular distribution of 5-lipoxygenase can be rapidly altered in resting cells, independent of 5-lipoxygenase activation, Nuclear import of 5-lipoxygenase may be a universal accompaniment of neutrophil recruitment into sites of inflammation, and this may be associated with alterations in enzymatic function.			Brock, TG (corresponding author), UNIV MICHIGAN, DIV PULM & CRIT CARE MED, DEPT INTERNAL MED, M3317 MED SCI 1, ANN ARBOR, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047391, P50HL046487, T32HL007749] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07749, R01 HL47391, P50 HL46487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALTER MS, 1989, J IMMUNOL, V142, P602; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1996, J IMMUNOL, V156, P2522; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; COFFEY M, 1992, J BIOL CHEM, V267, P570; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Drazen J M, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P251; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; MINAMIKAWA T, 1995, CELL CALCIUM, V17, P165, DOI 10.1016/0143-4160(95)90031-4; MUNZENMAIER DH, 1995, AM J PHYSIOL-HEART C, V269, pH565, DOI 10.1152/ajpheart.1995.269.2.H565; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; PETERSEN MM, 1992, IMMUNOLOGY, V75, P275; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PHAN SH, 1986, AM J PATHOL, V124, P343; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; POWELL WS, 1990, J BIOL CHEM, V265, P9131; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STANKOVA J, 1995, BLOOD, V85, P3719, DOI 10.1182/blood.V85.12.3719.bloodjournal85123719; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; SUZUKI K, 1993, AM J RESP CELL MOL, V8, P500, DOI 10.1165/ajrcmb/8.5.500; Tithof PK, 1996, ENVIRON HEALTH PERSP, V104, P52, DOI 10.2307/3432760; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	35	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8276	8280		10.1074/jbc.272.13.8276	http://dx.doi.org/10.1074/jbc.272.13.8276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079648	hybrid			2022-12-27	WOS:A1997WQ63500031
J	MontesanoRoditis, L; Glitz, DG; Perrault, AR; Cooperman, BS				MontesanoRoditis, L; Glitz, DG; Perrault, AR; Cooperman, BS			Incorporation of dinitrophenyl protein L23 into totally reconstituted Escherichia coli 50 S ribosomal subunits and its localization at two sites by immune electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; ARYL AZIDE ANALOG; BACILLUS-STEAROTHERMOPHILUS; 3-DIMENSIONAL STRUCTURE; PUROMYCIN BINDING; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; CROSS-LINKING; 30-S SUBUNITS; 23S RNA	Escherichia coli ribosomal protein L23 was derivatized with [H-3]2,4-dinitrofluorobenzene both at the N terminus and at internal lysines. Dinitrophenyl-L23 (DNP-L23) was taken up into 50 S subunits from a reconstitution mixture containing rRNA and total 50 S protein depleted in L23. Unmodified L23 competed with DNP-L23 for uptake, indicating that each protein form bound in an identical or similar position within the subunit. Modified L23, incorporated at a level of 0.7 or 0.4 DNP groups per 50 S, was localized by electron microscopy of subunits complexed with antibodies to dinitrophenol. Antibodies were seen at two major sites with almost equal frequency. One site is beside the central protuberance, in a region previously identified as the peptidyltransferase center. The second location is at the base of the subunit, in the area of the exit site from which the growing peptide leaves the ribosome. Models derived from image reconstruction show hollows or canyons in the subunit and a tunnel that Links the transferase and exit sites. Our results indicate that L23 is at the subunit interior, with separate elements of the protein at the subunit surface at or near both ends of this tunnel.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90095 USA; UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032769] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32769, GM 53416, GM 53450] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1994, J MOL BIOL, V235, P1251, DOI 10.1006/jmbi.1994.1078; AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BRIMACOMBE R, 1993, TRANSLATIONAL APPARATUS, P433; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; COOPERMAN BS, 1990, RIBOSOME, P491; EGEBJERG J, 1991, J MOL BIOL, V222, P251, DOI 10.1016/0022-2836(91)90210-W; FEARON K, 1992, J BIOL CHEM, V267, P5162; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GHRIST BFD, 1990, HPLC BIOL MACROMOLEC, P403; GIRI L, 1986, ADV PROTEIN CHEM, V36, P1; GLITZ DG, 1988, METHOD ENZYMOL, V164, P493; GRANT PG, 1979, BIOCHEMISTRY-US, V18, P2149, DOI 10.1021/bi00578a003; HACKL W, 1988, EUR J BIOCHEM, V174, P431, DOI 10.1111/j.1432-1033.1988.tb14116.x; HARAUZ G, 1987, J MOL EVOL, V26, P347, DOI 10.1007/BF02101154; HARDESTY B, 1993, TRANSLATIONAL APPARATUS, P347; HEROLD M, 1987, J BIOL CHEM, V262, P8826; HERWIG S, 1993, J BIOL CHEM, V268, P4643; HOFFMAN DW, 1994, EMBO J, V13, P205, DOI 10.1002/j.1460-2075.1994.tb06250.x; KERLAVAGE AR, 1983, J BIOL CHEM, V258, P6313; KOOI EA, 1994, J MOL BIOL, V240, P243, DOI 10.1006/jmbi.1994.1438; KOOI EA, 1993, P NATL ACAD SCI USA, V90, P213, DOI 10.1073/pnas.90.1.213; LAKE JA, 1982, J MOL BIOL, V161, P89, DOI 10.1016/0022-2836(82)90280-7; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LUHRMANN R, 1981, P NATL ACAD SCI-BIOL, V78, P7276, DOI 10.1073/pnas.78.12.7276; METZENBERG S, 1993, NUCLEIC ACIDS RES, V21, P4936, DOI 10.1093/nar/21.21.4936; MONTESANORODITIS L, 1993, J BIOL CHEM, V268, P18701; Mueller F, 1995, BIOCHEM CELL BIOL, V73, P767, DOI 10.1139/o95-085; NAG B, 1991, J BIOL CHEM, V266, P22129; NAGANO K, 1988, J THEOR BIOL, V134, P199, DOI 10.1016/S0022-5193(88)80202-9; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3797, DOI 10.1021/bi00259a013; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3809, DOI 10.1021/bi00259a014; Nierhaus K H, 1979, Methods Enzymol, V59, P443; NOWOTNY V, 1986, STRUCTURE FUNCTION G, P101; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLAH TV, 1988, J BIOL CHEM, V263, P4795; OLAH TV, 1993, J BIOL CHEM, V268, P18696; OLSON HM, 1985, J BIOL CHEM, V260, P326; OLSON HM, 1988, J BIOL CHEM, V263, P4801; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OLSON HM, 1982, J BIOL CHEM, V257, P2649; PORTER RR, 1948, BIOCHEM J, V42, P287, DOI 10.1042/bj0420287; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; RUTGERS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P74, DOI 10.1016/0167-4781(90)90144-Q; RYABOVA LA, 1988, FEBS LETT, V226, P255, DOI 10.1016/0014-5793(88)81434-0; SANGER F, 1945, BIOCHEM J, V39, P507, DOI 10.1042/bj0390507; STADE K, 1995, NUCLEIC ACIDS RES, V23, P2371, DOI 10.1093/nar/23.13.2371; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STOFFLER G, 1974, RIBOSOMES, P615; STOFFLERMEILICKE M, 1983, P NATL ACAD SCI-BIOL, V80, P6780, DOI 10.1073/pnas.80.22.6780; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; TISCHENDORF GW, 1974, MOL GEN GENET, V134, P187, DOI 10.1007/BF00267715; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Vasiliev V D, 1979, Methods Enzymol, V59, P612; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; WEITZMANN C, 1985, BIOCHEMISTRY-US, V24, P2268, DOI 10.1021/bi00330a022; WEITZMANN CJ, 1990, BIOCHEMISTRY-US, V29, P3458, DOI 10.1021/bi00466a006; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WOWER I, 1981, NUCLEIC ACIDS RES, V9, P4285, DOI 10.1093/nar/9.17.4285; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6	67	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8695	8703		10.1074/jbc.272.13.8695	http://dx.doi.org/10.1074/jbc.272.13.8695			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079702	hybrid			2022-12-27	WOS:A1997WQ63500085
J	Shirakabe, K; Yamaguchi, K; Shibuya, H; Irie, K; Matsuda, S; Moriguchi, T; Gotoh, Y; Matsumoto, K; Nishida, E				Shirakabe, K; Yamaguchi, K; Shibuya, H; Irie, K; Matsuda, S; Moriguchi, T; Gotoh, Y; Matsumoto, K; Nishida, E			TAK1 mediates the ceramide signaling to stress-activated protein kinase c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-FREE SYSTEM; FACTOR-ALPHA; TRANSDUCTION PATHWAY; SPHINGOMYELINASE; RAS; PHOSPHORYLATION; IDENTIFICATION; APOPTOSIS; CASCADE	Ceramide has been proposed as a second messenger molecule implicated in a variety of biological processes. It has recently been reported that ceramide activates stress-activated protein kinase (SAPK, also known as c-Jun NH2-terminal kinase JNK), a subfamily member of mitogen-activated protein kinase superfamily molecules and that the ceramide/SAPK/JNK signaling pathway is required for stress-induced apoptosis. However, the molecular mechanism by which ceramide induces SAPK/JNK activation is unknown. Here we show that TAK1, a member of the mitogen-activated protein kinase kinase kinase family, is activated by treatment of cells with agents and stresses that induce an increase in ceramide. Ceramide itself stimulated the kinase activity of TAK1. Expression of a constitutively active form of TAK1 resulted in activation of SAPK/JNK and SEK1/MKK4, a direct activator of SAPK/JNK, Furthermore, expression of a kinase-negative form of TAK1 interfered with the activation of SAPK/JNK induced by ceramide. These results indicate that TAK1 may function as a mediator of ceramide signaling to SAPK/JNK activation.	KYOTO UNIV,INST VIRUS RES,DEPT MOL BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL MOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Kyoto University; Nagoya University; Hokkaido University			Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	30	294	304	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8141	8144		10.1074/jbc.272.13.8141	http://dx.doi.org/10.1074/jbc.272.13.8141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079627	hybrid			2022-12-27	WOS:A1997WQ63500010
J	Chaudhuri, J; Si, K; Maitra, U				Chaudhuri, J; Si, K; Maitra, U			Function of eukaryotic translation initiation factor 1A (eIF1A) (formerly called eIF-4C) in initiation of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN PROTEIN; RABBIT RETICULOCYTES; SACCHAROMYCES-CEREVISIAE; CALF LIVER; FACTOR-II; IMMUNOCHEMICAL CHARACTERIZATION; COMPLEX-FORMATION; PURIFICATION; EXPRESSION; CLONING	We have used an efficient in vitro translation initiation system to show that the mammalian 17-kDa eukaryotic initiation factor, eIF1A (formerly designated eIF4C), is essential for transfer of the initiator Met-tRNA(f) (as Met-tRNA(f) . eIF2 . GTP ternary complex) to 40 S ribosomal subunits in the absence of mRNA to form the 40 S preinitiation complex (40 S . Met-tRNA(f) . eIF2 . GTP). Furthermore, eIF1A acted catalytically in this reaction to mediate highly efficient transfer of the Met-tRNA(f) . eIF2 . GTP ternary complex to 40 S ribosomal subunits. The 40 S complex formed was free of eIF1A indicating that its role in 40 S preinitiation complex formation is not to stabilize the binding of Met-tRNA(f) to 40 S ribosomes, Additionally, the eIF1A-mediated 40 S initiation complex formed in the presence of AUG codon efficiently joined 60 S ribosomal subunits in an eIF5-dependent reaction to form a functional 80 S initiation complex. In contrast to other reports, we found that eIF1A plays no role either in the subunit joining reaction or in the generation of ribosomal subunits from 80 S ribosomes, Our results indicate that the major function of eIF1A is to mediate the transfer of Met-tRNA(f) to 40 S ribosomal subunits to form the 40 S preinitiation complex.			Chaudhuri, J (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10461, USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1978, J BIOL CHEM, V253, P3078; BENNE R, 1978, J BIOL CHEM, V253, P3070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI A, 1981, J BIOL CHEM, V256, P3988; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; DHOLAKIA JN, 1987, J BIOL CHEM, V262, P10164; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GOUMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39, DOI 10.1016/0005-2787(80)90131-8; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1983, MICROBIOL REV, V47, P1; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MERRICK WC, 1995, TRANSLATIONAL CONTRO, P31; Naranda T, 1996, MOL CELL BIOL, V16, P2307; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1986, J BIOL CHEM, V261, P7723; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SEAL SN, 1982, J BIOL CHEM, V257, P8634; SMITH KE, 1975, J BIOL CHEM, V250, P6880; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TIMMER RT, 1993, J BIOL CHEM, V268, P24863; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TRACHSEL H, 1995, TRANSLATIONAL CONTRO, P113; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	38	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7883	7891		10.1074/jbc.272.12.7883	http://dx.doi.org/10.1074/jbc.272.12.7883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065455	hybrid			2022-12-27	WOS:A1997WP59200049
J	Riitano, D; Werge, TM; Costa, T				Riitano, D; Werge, TM; Costa, T			A mutation changes ligand selectivity and transmembrane signaling preference of the neurokinin-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; COMMON BINDING-SITE; NONPEPTIDE ANTAGONIST; TACHYKININ RECEPTORS; NK1 RECEPTOR; DOMAINS; IDENTIFICATION; HYDROLYSIS; AGONISTS; POTENT	studied the biochemical properties of a genetically engineered neurokinin-1 receptor (NK(1)R) in which two residues lying on the extracellular edge of the fourth transmembrane domain were replaced by equivalently located elements of the neurokinin-2 receptor (G166C, Y167F NK(1)R mutant), The mutation produced two effects, The first is enhancement of the apparent binding affinity for heterologous tachykinins (substance K and neurokinin B) and for N- or C-terminal modified analogues of substance P, but not for substance P itself, its full-length analogues, and several peptide and nonpeptide antagonists, Only two antagonists, as exceptions, were found 60 exhibit a diminished affinity for the mutant receptor. The second effect is a shift in NK(1)R preference for distinct G protein-mediated signaling pathways, NK(1)R mediated phosphoinositide hydrolysis was enhanced both in transiently and permanently transfected cells, while stimulation of cAMP accumulation did not change in transient expression experiments and was reduced in permanently expressing cells. The effect of the mutation on ligand affinity was not related to any obvious structural commonality, nor to the selectivity for different neurokinin receptors or the agonistic/antagonistic nature of the ligand, However, all ligands responding to the mutation appear to share the ability to induce phosphoinositide signaling more efficiently than cAMP responses when binding to NK(1)R. We suggest that the mutation shifts the internal equilibria of different functional forms of NK(1)R. A theoretical analysis according to a multistate allosteric model suggests that the link between binding and biological changes can result from altered stability constants of substates in the conformational space of the receptor.	IST SUPER SANITA,PHARMACOL LAB,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)			costa, tommaso/AAD-3714-2019; Werge, Thomas/G-7263-2012	costa, tommaso/0000-0002-8729-3357; 				AMATI V, 1995, PROTEIN ENG, V8, P403, DOI 10.1093/protein/8.4.403; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; CASCIERI MA, 1995, MOL PHARMACOL, V47, P660; COSTA T, 1992, MOL PHARMACOL, V41, P549; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DRAPER NR, 1966, APPLIED REGRESSION A; EDMONDSALT X, 1993, EUR J PHARMACOL, V250, P403; ERSPAMER V, 1981, TRENDS NEUROSCI, V4, P297; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1994, J BIOL CHEM, V269, P14957; FUJII T, 1992, BRIT J PHARMACOL, V107, P785, DOI 10.1111/j.1476-5381.1992.tb14524.x; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; Huang RRC, 1995, BIOCHEMISTRY-US, V34, P16467, DOI 10.1021/bi00050a030; KRAUSER K, 1994, NEUROPEPTIDES, V26, P37; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; MCLEAN S, 1993, J PHARMACOL EXP THER, V267, P472; MORIMOTO H, 1992, PHARM EXP THER, V262, P393; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKANISHI S, 1987, PHYSIOL REV, V67, P123; NAKJIMA Y, 1992, J BIOL CHEM, V267, P2437; OGINO Y, 1992, J NEUROCHEM, V58, P46, DOI 10.1111/j.1471-4159.1992.tb09275.x; Sagan S, 1996, J PHARMACOL EXP THER, V276, P1039; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHWARTZ TW, 1995, CURR PHARM DES, V1, P222; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SISTO A, 1995, 14 AM PEPT S COL OH, P648; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; WERGE TM, 1994, J BIOL CHEM, V269, P22054; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; Wyman J., 1990, FUNCTIONAL CHEM BIOL; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	37	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7646	7655		10.1074/jbc.272.12.7646	http://dx.doi.org/10.1074/jbc.272.12.7646			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065420	hybrid			2022-12-27	WOS:A1997WP59200014
J	Thomson, MJ; Williams, MG; Frost, SC				Thomson, MJ; Williams, MG; Frost, SC			Development of insulin resistance in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; HEXOSE-TRANSPORT; MESSENGER-RNA; DIFFERENTIAL REGULATION; SKELETAL-MUSCLE; EXPRESSION; GLUT4; MEMBRANE; HEPG2; NIDDM	Insulin resistance is a manifestation of both diabetes mellitus and obesity, However, the mechanism is still not clearly identified, Herein, we describe a procedure that allows us to evaluate the development of insulin resistance in 3T3-L1 adipocytes, Under these conditions, we show that the concentration of insulin required for 50% desensitization of glucose transport activity is 100 pM; maximal desensitization could be achieved with 1 nM. This demonstrates for the first time that 3T3-L1 adipocytes develop insulin resistance in response to physiologically relevant concentrations of insulin, Glucose (or glucosamine), in addition to insulin, was required to establish desensitization. The expression of GLUT4 protein decreased by 50% with exposure to 10 nM insulin, The dose-dependent loss of GLUT4 was similar to the dose dependence for insulin-resistant transport activity, Translocation in the presence of acute insulin was apparent, but the extent of recruitment directly reflected the decrease in GLUT4 protein, GLUT4 mRNA also declined, but the ED(50) was approximately 5 nM. Together, these data suggest that the loss of GLUT4 protein likely underlies the cause of desensitization. However, the loss of GLUT4 protein did not correlate with the loss in GLUT4 mRNA suggesting post-translational control of GLUT4 expression.	UNIV FLORIDA,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK45035] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FRAYN KN, 1989, BIOCHEM SOC T, V17, P1091, DOI 10.1042/bst0171091; FROESCH ER, 1965, MOL PHARMACOL, V1, P280; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1992, DIABETES CARE, V15, P396, DOI 10.2337/diacare.15.3.396; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCMAHON RJ, 1996, AM J PHYSIOL, V1996, pE640; OKA Y, 1988, J BIOL CHEM, V263, P13432; OLEFSKY JM, 1988, AM J MED, V85, P86, DOI 10.1016/0002-9343(88)90401-9; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Reed B C, 1980, Adv Enzyme Regul, V18, P97, DOI 10.1016/0065-2571(80)90011-4; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RICORT JM, 1994, FEBS LETT, V347, P42, DOI 10.1016/0014-5793(94)00510-9; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171	36	133	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7759	7764		10.1074/jbc.272.12.7759	http://dx.doi.org/10.1074/jbc.272.12.7759			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065437	hybrid			2022-12-27	WOS:A1997WP59200031
J	Ku, NO; Omary, MB				Ku, NO; Omary, MB			Phosphorylation of human keratin 8 in vivo at conserved head domain serine 23 and at epidermal growth factor-stimulated tail domain serine 431	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT NETWORKS; SIMPLE EPITHELIAL-CELLS; O-LINKED GLYCOSYLATION; GENETIC SKIN DISEASES; AMINO-ACID SEQUENCE; PROTEIN-KINASE; MESSENGER-RNA; SIGNAL-TRANSDUCTION; PAIRWISE CONTROL; MITOTIC ARREST	Dynamic phosphorylation is one mechanism that regulates the more than 20 keratin type I and II intermediate filament proteins in epithelial cells. The major type II keratin in ''simple type'' glandular epithelia is keratin 8 (K8). We used biochemical and mutational approaches to localize two major in vivo phosphorylation sites of human K8 to the head (Ser-23) and tail (Ser-431) domains. Since Ser-23 of K8 is highly conserved among all type II keratins, we also examined if the corresponding Ser-59 in stratified epithelial keratin 6e is phosphorylated. Mutation of K6e Ser-59 abolished its phosphorylation in (PO4)-P-32-labeled baby hamster kidney cell transfectants. With regard to K8 phosphorylation at Ser-431, it increases dramatically upon stimulation of cells with epidermal growth factor (EGF) or after mitotic arrest and is the major K8 phosphorylated residue after incubating K8 immunoprecipitates with mitogen-activated protein or cdc2 kinases. A monoclonal antibody that specifically recognizes phosphoserine 431-K8 manifests increased reactivity with K8 and recognizes reorganized K8/18 filaments after EGF stimulation. Our results suggest that in viuo serine phosphorylation of K8 and K6e within the conserved head domain motif is likely to reflect a conserved phosphorylation site of most if not all type II keratins. Furthermore, K8 Ser-431 phospho rylation occurs after EGF stimulation and during mitotic arrest and is likely to be mediated by mitogen-activated protein and cdc2 kinases, respectively.	VET ADMIN PALO ALTO HLTH CARE SYST, DEPT MED, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, CTR DIGEST DIS, STANFORD, CA 94305 USA	Stanford University				Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK38707, DK 47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando S, 1996, BIOCHEM BIOPH RES CO, V221, P67, DOI 10.1006/bbrc.1996.0546; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; BARICAULT L, 1994, J CELL SCI, V107, P2909; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1993, J CELL SCI, V105, P433; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU CF, 1994, J CELL SCI, V107, P1833; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; COLLIN C, 1992, DIFFERENTIATION, V51, P137, DOI 10.1111/j.1432-0436.1992.tb00690.x; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEERY WJ, 1993, CELL MOTIL CYTOSKEL, V26, P325, DOI 10.1002/cm.970260407; DONG DLY, 1993, J BIOL CHEM, V268, P16679; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fuchs Elaine, 1994, Trends in Cell Biology, V4, P321, DOI 10.1016/0962-8924(94)90233-X; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; HSIEH JT, 1992, J BIOL CHEM, V267, P2303; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KAWAHARA H, 1990, LIFE SCI, V47, P859, DOI 10.1016/0024-3205(90)90598-L; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; KNAPP B, 1986, NUCLEIC ACIDS RES, V14, P751, DOI 10.1093/nar/14.2.751; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; Liao J, 1996, ELECTROPHORESIS, V17, P1671, DOI 10.1002/elps.1150171104; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; MORITA T, 1988, GENE, V68, P109; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; OSHIMA RG, 1982, J BIOL CHEM, V257, P3414; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YAMAMOTO R, 1990, MOL ENDOCRINOL, V4, P370, DOI 10.1210/mend-4-3-370; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x	68	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7556	7564		10.1074/jbc.272.11.7556	http://dx.doi.org/10.1074/jbc.272.11.7556			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054461	hybrid			2022-12-27	WOS:A1997WN14700100
J	Ray, SK; Yang, XQ; Chiu, IM				Ray, SK; Yang, XQ; Chiu, IM			Transcriptional activation of fibroblast growth factor 1.B promoter is mediated through an 18-base pair cis-acting element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; HEPARIN-BINDING; FACTOR-I; RAT-BRAIN; EXPRESSION; GENE; PROTEIN; CLONING; TISSUES; IDENTIFICATION	Four different transcripts encoding fibroblast growth factor 1 (FGF-1, also known as aFGF) have been previously identified in our laboratory. Among them, FGF-1.B is the major transcript expressed specifically in the neuronal cells in brain tissue. Using the transient transfection experiment in a glioblastoma cell line, U1240MG, that expresses 1.B, we previously identified two regulatory regions (RR1 and RR2) in the brain-specific pro meter, FGF-1.B. In the present study, we showed that the minimal region required for the DNA-protein interaction in RR2 resides in an 18-base pair (-484 to -467) sequence, by using DNase I footprinting and methylation interference studies and electrophoretic mobility. shift assays, This minimal cis-acting element was found to be sufficient in enhancing the reporter activity driven by the heterologous herpes simplex virus thymidine kinase promoter in the 1,B-positive U1240MG: cell line. This enhancing effect, however, was not detected in a glioblastoma cell line, U1242MG, which is negative for 1.B expression, By electrophoretic mobility shift assays, we also identified a specific DNA-protein complex, namely complex I, which is specific for 1,B-positive cell lines and human brain tissue, By in situ UV cross-linking experiment, we further showed that complex I contains two major DNA-binding proteins of apparent molecular masses of 37 and 98 kDa. Our results suggest that the formation of complex I, resulting from the heterodimerization of a 37-kDa protein (1.B-specific) and a 98-kDa protein (ubiquitous) may likely be a prerequisite for the enhanced expression of 1.B transcript in neuronal cells.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			yang, xin/HGU-9981-2022; Chiu, Ing-Ming/B-1534-2008; Yang, Xiaoqi/E-2070-2011		NATIONAL CANCER INSTITUTE [K04CA001369, R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611, K04CA01369] Funding Source: Medline; NIDDK NIH HHS [R01DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; DU XY, 1994, J NEUROSCI, V14, P7688; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSPODAROWICZ D, 1987, NUCL MED BIOL, V14, P421, DOI 10.1016/0883-2897(87)90019-5; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GUILLEMOT F, 1992, DEVELOPMENT, V114, P743; HARA Y, 1994, BRAIN RES, V664, P101, DOI 10.1016/0006-8993(94)91959-3; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STOCK A, 1992, J NEUROSCI, V12, P4688; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; ZULCH KJ, 1986, BRAIN TUMORS, P101	40	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7546	7555		10.1074/jbc.272.11.7546	http://dx.doi.org/10.1074/jbc.272.11.7546			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054460	hybrid			2022-12-27	WOS:A1997WN14700099
J	Sakai, N; Vaisman, BL; Koch, CA; Hoyt, RF; Meyn, SM; Talley, GD; Paiz, JA; Brewer, HB; SantamarinaFojo, S				Sakai, N; Vaisman, BL; Koch, CA; Hoyt, RF; Meyn, SM; Talley, GD; Paiz, JA; Brewer, HB; SantamarinaFojo, S			Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene - Generation of a new animal model for human LCAT deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; A-I; SUBPOPULATIONS; EXPRESSION	We have established a mouse model for human LCAT deficiency by performing targeted disruption of the LCAT gene in mouse embryonic stem cells, Homozygous LCAT-deficient mice were healthy at birth and fertile, Compared with age-matched wild-type littermates, the LCAT activity in heterozygous and homozygous knockout mice was reduced by 30 and 99%, respectively, LCAT deficiency resulted in significant reductions in the plasma concentrations of total cholesterol, HDL cholesterol, and apoA-I in both LCAT -/- mice (25, 7, and 12%; p < 0.001 of normal) and LCAT +/- mice (65 and 59%;p < 0.001 and 81%; not significant, p = 0.17 of normal), In addition, plasma triglycerides were significantly higher (212% of normal; p < 0.01) in male homozygous knockout mice compared with wild-type animals but remained normal in female knockout LCAT mice, Analyses of plasma lipoproteins by fast protein liquid chromatography and two-dimensional gel electrophoresis demonstrated the presence of heterogenous prep-migrating HDL, as well as triglyceride-enriched very low density lipoprotein, After 3 weeks on a high-fat high-cholesterol diet, LCAT -/- mice had significantly lower plasma concentrations of total cholesterol, reflecting reduced levels of both proatherogenic apoB-containing lipoproteins as well as HDL, compared with controls, Thus, we demonstrate for the first time that the absence of LCAT attenuates the rise of apoB-containing lipoproteins in response to dietary cholesterol, No evidence of corneal opacities or renal insufficiency was detected in 4-month-old homozygous knockout mice, The availability of a homozygous animal model for human LCAT deficiency states will permit further evaluation of the role that LCAT plays in atherosclerosis as well as the feasibility of performing gene transfer in human LCAT deficiency states.	NHLBI, LAB ANIM MED & SURG, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sakai, N (corresponding author), NHLBI, MOL DIS BRANCH,NIH,BLDG 10,RM 7N115, 10 CTR DR, MSC 1666, BETHESDA, MD 20892 USA.		Vaisman, Boris L/B-3453-2008	Meyn, Susan/0000-0002-0894-0721				ALBERS JJ, 1981, J LIPID RES, V22, P1206; Assmann G, 1991, CURR OPIN LIPIDOL, V2, P110; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEN CH, 1982, J LIPID RES, V23, P680; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FIELDING CJ, 1995, J LIPID RES, V36, P211; FORTE T, 1974, SCAND J CLIN LAB INV, V33, P137; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FUNKE H, 1993, J CLIN INVEST, V91, P677, DOI 10.1172/JCI116248; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; KLEIN HG, 1995, J BIOL CHEM, V270, P9443, DOI 10.1074/jbc.270.16.9443; MARZETTA CA, 1993, ARTERIOSCLER THROMB, V13, P834, DOI 10.1161/01.ATV.13.6.834; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; NISHINA PM, 1990, J LIPID RES, V31, P859; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; TALL AR, 1993, J LIPID RES, V34, P1255; VAISMAN BL, 1995, J BIOL CHEM, V270, P12269, DOI 10.1074/jbc.270.20.12269; VAISMAN BL, 1996, CIRCULATION S, V94, P633; VRABEC MP, 1988, ARCH OPHTHALMOL-CHIC, V106, P225	27	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7506	7510		10.1074/jbc.272.11.7506	http://dx.doi.org/10.1074/jbc.272.11.7506			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054454	hybrid			2022-12-27	WOS:A1997WN14700093
J	Field, H; Field, MC				Field, H; Field, MC			Tandem duplication of rab genes followed by sequence divergence and acquisition of distinct functions in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; FLAGELLAR POCKET; MESSENGER-RNAS; PROTEIN; EXPRESSION; FAMILY; GENOME; LOCALIZATION; PROCYCLIN; MEMBRANE	The Ras superfamily of small G proteins governs unidirectional cellular processes by virtue of GTP hydrolysis and concomitant conformational changes, which are in turn regulated by a number of accessory factors, Members of the Rab subfamily are important for correct targeting and fusion of intra-organellar vesicles loaded with trafficking proteins and lipids, During evolution from a prototype gene, novel functions may be acquired by duplicated daughter genes; for Rab proteins, this can be tested by location, which is specifically related to the function of each Rab, We have found an example of two rab genes in Trypanosoma brucei (trab genes) that clearly arose by tandem duplication, being highly related to each other and remaining juxtaposed in the genome, whose products have dramatically different subcellular locations, indicative of discrete functions. These two trab genes, isolated on a single genomic clone, are separated by a short intervening sequence and are in a head-to-tail orientation, The nucleotide sequences of the open reading frames and intervening sequence were determined and show that the genes are paralogues, probably arising from an ancient tandem duplication, Both genes are most homologous to ypt1 and sec4 in the Saccharomyces cerevisiae genome, while phylogenetic reconstruction indicates that although they have clearly diverged, the proteins are more closely related to each other than to other Rab protein sequences available in the data base, Immunofluorescence microscopy, using antibodies raised against the recombinant Trab proteins, clearly demonstrates that the native Trab proteins have completely distinct subcellular locations in the trypanosome, Trab1p is present in a widespread reticular location similar to BiP, suggesting an endoplasmic reticulum location, while Trab7p is observed in a discrete structure adjacent to the kinetoplast, Most interestingly, the Trab7p-positive compartment also appears to divide at the same time, or just prior to, the kinetoplast, i.e. early in mitosis, suggestive of association with structures in the flagellar pocket region, An estimate of the divergence time indicates that the trab1/trab7 duplication occurred similar to 100 million years ago, and therefore, the persistence of this pair suggests an essential role in the survival of T. brucei.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,CELL BIOL LAB,LONDON SW7 2AY,ENGLAND	Imperial College London			Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANGS JD, 1993, J CELL SCI, V105, P1101; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BRICKMAN MJ, 1994, J EUKARYOT MICROBIOL, V41, P533, DOI 10.1111/j.1550-7408.1994.tb01512.x; Clayton C, 1996, MOL BIOCHEM PARASIT, V77, P1, DOI 10.1016/0166-6851(96)02587-X; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Duszenko Michael, 1993, V2 (PARTS A AND B), P227; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; FIELD H, 1992, MOL BIOCHEM PARASIT, V50, P47, DOI 10.1016/0166-6851(92)90243-D; FIELD MC, 1995, MOL BIOCHEM PARASIT, V69, P131, DOI 10.1016/0166-6851(94)00209-6; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Field MC, 1996, J MOL EVOL, V42, P500, DOI 10.1007/BF02352280; Foster R, 1996, MOL CELL BIOL, V16, P2689; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KLOCKNER T, 1995, MOL PAR M SEPT 17 21, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; Li FS, 1996, NUCLEIC ACIDS RES, V24, P534, DOI 10.1093/nar/24.3.534; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; Swofford D.L., 1993, PHYLOGENETIC ANAL US; TENASBROEK ALM, 1996, NATURE, V348, P174; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA, P12	47	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10498	10505						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099693	hybrid			2022-12-27	WOS:A1997WV26200027
J	Ma, XJ; Neurath, M; Gri, G; Trinchieri, G				Ma, XJ; Neurath, M; Gri, G; Trinchieri, G			Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; DNA-BINDING; PROTEIN-PROTEIN; FAMILY; EXPRESSION; ELK-1; PU.1; COOPERATE; INTERACT	Interleukin-12 (IL-12) is a proinflammatory cytokine produced by antigen-presenting cells in response to many microbial infections. IL-12 plays an important role in the generation of T helper type-1 cells, which favor cell-mediated immune response. IL-12 is composed of two different subunits, p40 and p35, whose expression can be regulated concomitantly or differentially. Monocytic cells, the major producers of IL-12, can be primed by interferon-gamma (IFN-gamma) to produce optimal amounts of IL-12 in response to LPS stimulation as a consequence of bacterial infection. The priming effect is exerted primarily at the transcriptional level on the p40 promoter in conjunction with the effects of LPS, possibly by inducing specific transcription factors, which individually have no direct effect but which cooperatively can activate the promoter. We examined in detail one of these DNA-protein interactions observed around an Ets-2 element situated at -211/-207 of the p40 promoter, which is known to be a functionally critical site. This region interacts with a nuclear complex termed F1 that appears to be highly inducible by either IFN-gamma treatment for 16 h or lipopolysaccharide stimulation for 8 h, F1 binding to the Ets-2 site requires a considerable amount of spacing around the Ets-2 site, as revealed by gel mobility shift and in vitro methylation assays. Supershift experiments and DNA affinity purification indicated that both Ets-2 and a novel, antigenically related protein with an approximate molecular mass of 109 kDa are part of the F1 complex, together with additional components including IRF-1 and c-Rel. This novel protein is designated GLp109 for its inducibility by IFN-gamma or lipopolysaccharide. Its possible role in the activation of the IL-12 p40 promoter is discussed.	UNIV MAINZ, INTERNAL MED CLIN, IMMUNOL LAB, D-55101 MAINZ, GERMANY	Johannes Gutenberg University of Mainz	Ma, XJ (corresponding author), WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA.		Trinchieri, Giorgio/F-9369-2015	Trinchieri, Giorgio/0000-0001-5892-7464; GRI, Giorgia/0000-0002-2826-0459	NCI NIH HHS [CA10815, CA32898, CA20833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032898, R37CA020833, R01CA020833, P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1988, CURRENT PROTOCOLS S, V3; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HROMAS R, 1993, BLOOD, V82, P2998; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JOHN S, 1995, MOL CELL BIOL, V15, P1786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P2335; RASSUK AG, 1995, IMMUNITY, V3, P223; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	30	127	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10389	10395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099678				2022-12-27	WOS:A1997WV26200012
J	Mineo, C; Anderson, RGW; White, MA				Mineo, C; Anderson, RGW; White, MA			Physical association with Ras enhances activation of membrane-bound Raf (RafCAAX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; NIH 3T3 CELLS; PROTEIN-KINASE; PLASMA-MEMBRANE; TRANSFORMATION; PHOSPHORYLATION; BINDING	The transforming activity of artificially membrane-targeted Raf1 suggests that Pas-mediated recruitment of Raf1 to the plasma membrane is an important step in Raf1 activation, Cellular has is concentrated in the caveolae, a microdomain of the plasma membrane that is highly enriched in caveolin, glycosylphosphatidylinositol-anchored proteins, and signal transduction molecules, Growth factor stimulation recruits Raf1 to this membrane domain, Whether Pas simply promotes Raf1 association with caveolae membranes or also modulates subsequent activation events is presently unclear, We have identified a ras variant, ras12V,37G, that does not interact with Raf1 but does interact with a mutant raf1, raf1(257L), To examine the role of Pas in the activation of membrane-bound Raf1, raf1CAAX, and raf1(257L)CAAX, membrane-targeted variants of Raf1 and raf1(257L), respectively, were expressed in fibroblasts with or without coexpression of ras12V,37G, Cell fractionation localized both raf1CAAX and raf1(257L)CAAX to caveolae membranes independent of ras12V,37G expression; however, coexpression of ras12V,37G enhanced the activation of raf(257L)CAAX, but not raf1CAAX, as monitored by induction of cellular transformation, increased Raf kinase activity, and induction of activated MAP kinase. These results suggest that the Ras/Raf1 interaction plays a role in Raf1 activation that is distinct from membrane recruitment.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [CA71443] Funding Source: Medline; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM43169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Okada T, 1996, J BIOL CHEM, V271, P4671; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	36	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10345	10348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099670				2022-12-27	WOS:A1997WV26200004
J	AliOsman, F; Akande, O; Antoun, G; Mao, JX; Buolamwini, J				AliOsman, F; Akande, O; Antoun, G; Mao, JX; Buolamwini, J			Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants - Evidence for differential catalytic activity of the encoded proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANCE; HUMAN PLACENTA; BREAST-CANCER; MESSENGER-RNA; ENZYMES; DNA	We report the isolation of three full-length cDNAs corresponding to the mRNAs of closely related glutathione S-transferase (GST) Pi genes, designated hGSTP1*A, hGSTP1*B, and hGSTP1*C, expressed in normal cells and malignant gliomas. The variant cDNAs result from A --> G and C --> T transitions at nucleotides +313 and +341, respectively. The transitions changed codon 104 from ATC (Ile) in hGSTP1*A to GTC (Val) in hGSTP1*B and h-GSTP1*C and changed codon 113 from GCG (Ala) to GTG (Val) in hGSTP1*C. Both amino changes are in the electrophile-binding active site of the GST Pi peptide. Computer modeling of the deduced crystal structures of the encoded peptides showed significant deviations in the interatomic distances of critical electrophile-binding active site amino acids as a consequence of the amino acid changes. The encoded proteins expressed in Escherichia coli and purified by GSH affinity chromatography showed a 3-fold lower K-m (CDNB) and a 3-4-fold higher K-cat/K-m for the hGSTP1*A encoded protein than the proteins encoded by hGSTP1*B and hGSTP1*C. Analysis of 75 cases showed the relative frequency of hGSTP1*C to be 4-fold higher in malignant gliomas than in normal tissues. These data provide conclusive molecular evidence of allelopolymorphism of the human GST Pi gene locus, resulting in active, functionally different GST Pi proteins, and should facilitate studies of the role of this gene in xenobiotic metabolism, cancer, and other human diseases.	UNIV MISSISSIPPI, SCH PHARM, PHARMACEUT SCI RES INST, UNIVERSITY, MS 38677 USA; UNIV MISSISSIPPI, SCH PHARM, DEPT MED CHEM, UNIVERSITY, MS 38677 USA	University of Mississippi; University of Mississippi	AliOsman, F (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT EXPT PEDIAT, SECT MOL THERAPEUT, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA127872, R01CA055835, P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [CA55261, R01 CA127872, CA55835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD H, 1990, ARCH BIOCHEM BIOPHYS, V278, P398, DOI 10.1016/0003-9861(90)90277-6; ALIOSMAN F, 1990, CANCER RES, V50, P6976; ALIOSMAN F, 1995, BIOCHIMICA, V4, P28; ALIOSMAN F, 1996, HUMAN CELL CULTURE P, P63; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOYLAND E, 1969, ADV ENZYMOL RAMB, V32, P173; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES S, 1980, CRC CRIT REV BIOCH M, V25, P47; COMMANDEUR JNM, 1995, PHARMACOL REV, V47, P271; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARE A, 1990, CANCER, V66, P2563; KANO T, 1987, CANCER RES, V47, P5626; KETTERER B, 1987, GLUTATHIONE CONJUGAT; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MAURER HR, 1977, J IMMUNOL METHODS, V18, P353, DOI 10.1016/0022-1759(77)90189-2; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MURAMATSU M, 1993, STRUCTURE FUNCTION G, P297; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1993, STRUCTURE FUNCTION G, P15; SAINTRUF C, 1991, ONCOGENE, V6, P403; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1989, ADV CANCER RES, V52, P205; Segel IH, 1976, BIOCH CALCULATIONS, P208; SHE H, 1995, BIOCHEM PHARMACOL, V50, P1233; Simons P C, 1981, Methods Enzymol, V77, P235; STRANGE RC, 1992, BIOCHIM BIOPHYS ACTA, V1139, P222, DOI 10.1016/0925-4439(92)90138-D; TAKUMI T, 1994, BIOTECHNIQUES, V17, P443; TEW KD, 1994, CANCER RES, V54, P4313; TIDEFELT U, 1992, CANCER RES, V52, P3281; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x	49	599	626	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10004	10012						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092542				2022-12-27	WOS:A1997WU03900061
J	Barkovich, RJ; Shtanko, A; Shepherd, JA; Lee, PT; Myles, DC; Tzagoloff, A; Clarke, CF				Barkovich, RJ; Shtanko, A; Shepherd, JA; Lee, PT; Myles, DC; Tzagoloff, A; Clarke, CF			Characterization of the COQ5 gene from Saccharomyces cerevisiae - Evidence for a C-methyltransferase in ubiquinone biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MITOCHONDRIAL-MEMBRANE SYSTEM; RAT-LIVER MITOCHONDRIA; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; VITAMIN-E; DEPENDENT METHYLTRANSFERASES; YEAST; TRANSFORMATION; ANTIOXIDANT	Ubiquinone (coenzyme Q or Q) is a lipophilic metabolite that functions in the electron transport chain in the plasma membrane of prokaryotes and in the inner mitochondrial membrane of eukaryotes. Q-deficient mutants of Saccharomyces cerevisiae fall into eight complementation groups (coq1-coq8), Yeast mutants from the coq5 complementation group lack Q and as a result are respiration-defective and fail to grow on nonfermentable carbon sources, A nuclear gene, designated COQ5 was isolated from a yeast genomic library based on its ability to restore growth of a representative coq5 mutant on media containing glycerol as the sole carbon source, The DNA segment responsible for the complementation contained an open reading frame (GenBank(TM) accession number Z49210) with 44% Sequence identity over 262 amino acids to UbiE, which is required for a C-methyltransferase step in the Q and menaquinone biosynthetic pathways in Escherichia coli, Both the ubiE and COQ5 coding sequences contain sequence motifs common to a wide variety of S-adenosyl-L-methionine-dependent methyltransferases. A gene fusion expressing a biotinylated form of Coq5p retains function, as assayed by the complementation of the coq5 mutant, This Coq5-biotinylated fusion protein is located in mitochondria. The synthesis of two farnesylated analogs of intermediates in the ubiquinone biosynthetic pathway is reported, These reagents have been used to develop in vitro C-methylation assays with isolated yeast mitochondria, These studies show that Coq5p is required for the C-methyltransferase step that converts 2-methoxy-5-polyprenyl-1,4-benzoquinone to 2-methoxy-5-methyl-6-polyprenyl-1,4-benioquinone.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Columbia University					NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline; NIGMS NIH HHS [GM45952, GM08496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL022174, R01HL022174, R37HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008496, R01GM045952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ERNSTER L, 1993, CLIN INVESTIGATOR, V71, pS60, DOI 10.1007/BF00226842; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; HANAKI Y, 1991, NEW ENGL J MED, V325, P814; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOCKING MB, 1973, CAN J CHEM, V51, P2384, DOI 10.1139/v73-357; HOUSER RM, 1977, J BIOL CHEM, V252, P4017; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; Kaiser C., 1994, METHODS YEAST GENETI, P209; KALEN A, 1990, J BIOL CHEM, V265, P1158; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; MARBOIS BN, 1994, GENE, V138, P213; MATSURA T, 1992, BIOCHIM BIOPHYS ACTA, V1127, P277, DOI 10.1016/0005-2760(92)90232-K; Meganathan R., 1996, ESCHERICHIA COLI SAL, P642; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NAVAB M, 1995, AM J CARDIOL, V76, pC18, DOI 10.1016/S0002-9149(99)80466-4; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; POON WW, 1997, IN PRESS MOL ASPECTS; ROTHSTEIN R, 1983, METHOD ENZYMOL, V101, P201; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Shepherd JA, 1996, TETRAHEDRON LETT, V37, P2395, DOI 10.1016/0040-4039(96)00324-3; STILL WC, 1978, J AM CHEM SOC, V100, P1481, DOI 10.1021/ja00473a025; STILLE JK, 1986, ANGEW CHEM INT EDIT, V25, P508, DOI 10.1002/anie.198605081; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; TECLEBRHAN H, 1995, BBA-LIPID LIPID MET, V1256, P157, DOI 10.1016/0005-2760(95)00016-6; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TEUBER HJ, 1959, CHEM BER-RECL, V92, P674, DOI 10.1002/cber.19590920321; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; TRUMPOWER BL, 1974, J BIOL CHEM, V249, P3041; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WISSENBACH U, 1992, ARCH MICROBIOL, V158, P68, DOI 10.1007/BF00249068; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971; ZIMMER H, 1971, CHEM REV, V71, P229, DOI 10.1021/cr60270a005; [No title captured]	58	72	74	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9182	9188						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083049				2022-12-27	WOS:A1997WU03700054
J	Ernsting, BR; Dixon, JE				Ernsting, BR; Dixon, JE			The PPS1 gene of Saccharomyces cerevisiae codes for a dual specificity protein phosphatase with a role in the DNA synthesis phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; TYROSINE-PHOSPHATASE; YEAST; SEQUENCE; TRANSCRIPTION; PHEROMONE; PROMOTER; CLONING; KINASE; DEPHOSPHORYLATION	We report the identification of the PPS1 gene of Saccharomyces cerevisiae, The deduced amino acid sequence of PPS1p shows similarity with protein-tyrosine phosphatases (PTPases) and is most closely related to a subfamily of PTPases that are capable of dephosphorylating phosphoseryl and phosphothreonyl residues as well as phosphotyrosyl residues, Analysis of the predicted amino acid sequence suggests that the protein consists of an active phosphatase domain, an inactive phosphatase-like domain, and an NH2-terminal extension, Mutation of the catalytic cysteinyl residue: in the active phosphatase domain reduced the in vitro activity of the mutant protein to less than 0.5% of wild type activity, while mutation of the corresponding cysteinyl residue of the inactive phosphatase-like domain had no effect on in vitro activity. The PPS1 protein was expressed in Escherichia coli, and the protein was shown to catalyze the hydrolysis of p-nitrophenyl phosphate, dephosphorylate phosphotyrosyl, and phosphothreonyl residues in synthetic diphosphorylated peptides and to inactivate the human ERK1 protein. PPS1 transcript abundance is coregulated with that of the divergently transcribed DPB3 gene, which codes for a subunit of DNA polymerase II, with both transcripts showing peak abundance in S phase, pps1 Delta mutant strains did not differ from PPS1 strains under any of the conditions tested, but overexpression of the PPS1 protein in S. cerevisiae led to synchronous growth arrest and to aberrant DNA synthesis, A screen for suppressors of this growth arrest identified the RAS2 gene as a multicopy suppressor of the PPS1p overexpression arrest, The arrest was not suppressed by the presence of multicopy RAS1, TPK2, or TPK3 genes or by the presence of 5 mM cAMP in the growth medium, suggesting that PPS1 functions in a pathway involving RAS2, but not TPK kinases or adenylate cyclase.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NCI NIH HHS [CA09676] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COE JGS, 1994, MOL GEN GENET, V244, P661, DOI 10.1007/BF00282757; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; GANSTER RW, 1993, MOL CELL BIOL, V13, P3650, DOI 10.1128/MCB.13.6.3650; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1992, J BIOL CHEM, V267, P10024; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HOLMSTROM K, 1994, YEAST, V10, pS47, DOI 10.1002/yea.320100007; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANNEY TR, 1983, J BACTERIOL, V155, P291, DOI 10.1128/JB.155.1.291-301.1983; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MYASNIKOV AN, 1991, GENE, V109, P143, DOI 10.1016/0378-1119(91)90600-G; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; Rose MD., 1990, METHODS YEAST GENETI; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WAN J, 1992, J BIOL CHEM, V267, P11274; WEST RW, 1987, GENE DEV, V1, P1118, DOI 10.1101/gad.1.10.1118; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9332	9343						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083070				2022-12-27	WOS:A1997WU03700075
J	Saito, S; Goto, K; Tonosaki, A; Kondo, H				Saito, S; Goto, K; Tonosaki, A; Kondo, H			Gene cloning and characterization of CDP-diacylglycerol synthase from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-KINASE-C; LIGHT-MEDIATED BREAKDOWN; PHOSPHATIDIC-ACID; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ENDOGENOUS PHOSPHORYLATION; DIGLYCERIDE SYNTHETASE; MOLECULAR-CLONING; VERTEBRATE RETINA; ESCHERICHIA-COLI	A cDNA encoded a 462-amino acid protein, which showed CDP-diacylglycerol synthase (CDS) activity was cloned for the first time as the vertebrate enzyme molecule from rat brain cDNA library. The deduced molecular mass of this rat CDS was 53 kDa, and putative primary structure included several possible membrane-spanning regions. At the amino acid sequence level, rat CDS shared 55.5%, 31.7% and 20.9% identity with already known Drosophila, Saccharomyces cerevisiae, and Escherichia coli CDS, respectively. This rat CDS preferred 1-stearoyl-2-arachidonoyl phosphatidic acid as a substrate, and its activity was strongly inhibited by phosphatidylglycerol 4,5-bisphosphate. By immunoblotting analysis of COS cells overexpressed with the epitope-tagged for rat CDS, a 60-kDa band was detected. By epitope-tag immunocytochemistry, the CDS protein was mainly localized in close association with the membrane of the endoplasmic reticulum of the transfected cells. The intense mRNA expression of CDS was localized in the cerebellar Purkinje cells, the pineal body, and the inner segment of photoreceptor cells. Additionally, very intense expression was detected in postmitotic spermatocytes and spermatids.	TOHOKU UNIV,SCH MED,DEPT ANAT,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; YAMAGATA UNIV,SCH MED,DEPT ANAT,YAMAGATA 99023,JAPAN	Tohoku University; Yamagata University								BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAY NS, 1993, CURR EYE RES, V12, P981, DOI 10.3109/02713689309029224; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; Holub B J, 1978, Adv Lipid Res, V16, P1; ICHO T, 1985, J BIOL CHEM, V260, P2078; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; JUNG HH, 1993, CURR EYE RES, V12, P727, DOI 10.3109/02713689308995768; KAPOOR CL, 1987, EXP EYE RES, V45, P545, DOI 10.1016/S0014-4835(87)80065-9; KAPOOR CL, 1984, BIOCHEM BIOPH RES CO, V122, P1397, DOI 10.1016/0006-291X(84)91246-4; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIN CH, 1991, BIOCHEM INT, V25, P299; LING LE, 1989, J BIOL CHEM, V264, P5080; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLSKEE RF, 1993, BIOESSAYS, V18, P645; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MOK AYP, 1992, FEBS LETT, V312, P236, DOI 10.1016/0014-5793(92)80942-A; MOK AYP, 1992, BIOCH CELL BIOL, V71, P183; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P2; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCHMIDT SY, 1983, J BIOL CHEM, V258, P6863; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TANABE Y, 1988, MOL CELL BIOL, V8, P466; TOKER A, 1994, J BIOL CHEM, V269, P32358; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	55	61	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9503	9509						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083091				2022-12-27	WOS:A1997WU03700096
J	Denver, RJ; Pavgi, S; Shi, YB				Denver, RJ; Pavgi, S; Shi, YB			Thyroid hormone-dependent gene expression program for Xenopus neural development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CENTRAL-NERVOUS-SYSTEM; AMPHIBIAN METAMORPHOSIS; CREATINE-KINASE; BRAIN-DEVELOPMENT; RECEPTOR GENES; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; REGULATED GENE; ELECTRIC ORGAN	Although thyroid hormone (TH) plays a significant role in vertebrate neural development, the molecular basis of TH action on the brain is poorly understood. Using polymerase chain reaction-based subtractive hybridization we isolated 34 cDNAs for TH-regulated genes in the diencephalon of Xenopus tadpoles. Northern blots verified that the mRNAs are regulated by TH and are expressed during metamorphosis. Kinetic analyses showed that most of the genes are up-regulated by TH within 4-8 h and 13 are regulated by TH only in the brain. All cDNA fragments were sequenced and the identities of seven were determined through homology with known genes; an additional five TH-regulated genes were identified by hybridization with known cDNA clones. These include five transcription factors (including two members of the steroid receptor superfamily), a TH-converting deiodinase, two metabolic enzymes, a protein disulfide isomerase-like protein that may bind TH, a neural-specific cytoskeletal protein, and two hypophysiotropic neuropeptides. This is the first successful attempt to isolate a large number of TH-target genes in the developing vertebrate brain. The gene identities allow predictions about the gene regulatory networks underlying TH action on the brain, and the cloned cDNAs provide tools for understanding the basic molecular mechanisms underlying neural cell differentiation.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Denver, RJ (corresponding author), UNIV MICHIGAN,DEPT BIOL,3077 NAT SCI BLDG,ANN ARBOR,MI 48109, USA.		Denver, Robert/AAT-7481-2021	Shi, Yun-Bo/0000-0002-6330-0639				ANIELLO F, 1991, J NEUROCHEM, V57, P1781, DOI 10.1111/j.1471-4159.1991.tb06381.x; [Anonymous], 1989, STORY IODINE DEFICIE; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; ASHIZAWA K, 1992, P NATL ACAD SCI USA, V89, P9277, DOI 10.1073/pnas.89.19.9277; BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; BLUM H, 1991, J BIOL CHEM, V266, P10254; BRADY ST, 1981, CELL, V23, P515, DOI 10.1016/0092-8674(81)90147-1; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; BROWN DD, 1995, RECENT PROG HORM RES, V50, P309; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; BULANT M, 1992, FEBS LETT, V296, P292, DOI 10.1016/0014-5793(92)80307-3; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1987, J CELL BIOL, V104, P381, DOI 10.1083/jcb.104.3.381; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DENVER RJ, 1996, METAMORPHOSIS POSTEM, P433, DOI DOI 10.1016/B978-012283245-1/50014-2; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; DUNANT Y, 1988, J NEUROCHEM, V50, P431, DOI 10.1111/j.1471-4159.1988.tb02930.x; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; ETKIN W, 1965, J MORPHOL, V116, P371, DOI 10.1002/jmor.1051160305; FARWELL AP, 1995, ENDOCRINOLOGY, V136, P3909, DOI 10.1210/en.136.9.3909; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; FORREST D, 1994, SEMIN CANCER BIOL, V5, P167; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GADALETA MN, 1985, NEUROCHEM RES, V10, P163, DOI 10.1007/BF00964565; GAO XM, 1994, BBA-GENE STRUCT EXPR, V1218, P194, DOI 10.1016/0167-4781(94)90010-8; GONA AG, 1987, DEV NEUROBIOLOGY FRO, P255; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; GOOS HJT, 1978, AM ZOOL, V18, P401; HAYANO T, 1995, FEBS LETT, V372, P210, DOI 10.1016/0014-5793(95)00996-M; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLTZMAN D, 1991, DEV BRAIN RES, V58, P181, DOI 10.1016/0165-3806(91)90004-3; HOSKINS SG, 1990, J NEUROBIOL, V21, P970, DOI 10.1002/neu.480210704; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; Iglesias T, 1996, EMBO J, V15, P4307, DOI 10.1002/j.1460-2075.1996.tb00805.x; IGLESIAS T, 1995, BIOCHEM BIOPH RES CO, V210, P995, DOI 10.1006/bbrc.1995.1755; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; ISMAILBEIGI F, 1993, TRENDS ENDOCRIN MET, V4, P152, DOI 10.1016/1043-2760(93)90104-M; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KATYARE SS, 1977, ARCH BIOCHEM BIOPHYS, V182, P155, DOI 10.1016/0003-9861(77)90294-6; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KIKUYAMA S, 1979, CELL TISSUE RES, V198, P27; KIKUYAMA S, 1993, INT REV CYTOL, V145, P105, DOI 10.1016/S0074-7696(08)60426-X; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; Koibuchi N, 1996, ENDOCRINOLOGY, V137, P5096, DOI 10.1210/en.137.11.5096; Kollros J.J., 1981, P445; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP, P52; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEBEL JM, 1993, GLIA, V9, P105, DOI 10.1002/glia.440090203; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; LEZOUALCH F, 1994, NEUROSCI LETT, V180, P197, DOI 10.1016/0304-3940(94)90520-7; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PASQUINI JM, 1994, DEV NEUROSCI-BASEL, V16, P1, DOI 10.1159/000112080; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; ROE BA, 1985, J BIOL CHEM, V260, P9759; RUPP K, 1994, J BIOL CHEM, V269, P2501; SAFRAN M, 1992, ENDOCRINOLOGY, V131, P2413, DOI 10.1210/en.131.5.2413; Sambrook J., 2002, MOL CLONING LAB MANU; SAUTER A, 1993, J BIOL CHEM, V268, P13166; SEPPET EK, 1994, MOL CELL BIOCHEM, V133, P299, DOI 10.1007/BF01267962; Shi Y-B., 1996, METAMORPHOSIS POSTEM, P505; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STENZELPOORE MP, 1992, MOL ENDOCRINOL, V6, P1716, DOI 10.1210/me.6.10.1716; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STRYER L, 1995, BIOCHEMISTRY-US, P539; TATA JR, 1968, DEV BIOL, V18, P415, DOI 10.1016/0012-1606(68)90050-X; TATA JR, 1994, BIOCHEM CELL BIOL, V72, P581, DOI 10.1139/o94-077; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TATA JR, 1996, METAMORPHOSIS POSTEM, P466; Thompson CC, 1996, J NEUROSCI, V16, P7832; VEGANUNEZ E, 1995, J CLIN INVEST, V96, P893, DOI 10.1172/JCI118136; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WANG Z, 1993, J BIOL CHEM, V268, P16270; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090	90	115	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8179	8188		10.1074/jbc.272.13.8179	http://dx.doi.org/10.1074/jbc.272.13.8179			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079635	hybrid			2022-12-27	WOS:A1997WQ63500018
J	Dorner, B; Muller, S; Entschladen, F; Schroder, JM; Frankel, P; Kraft, R; Friedl, P; ClarkLewis, I; Kroczek, RA				Dorner, B; Muller, S; Entschladen, F; Schroder, JM; Frankel, P; Kraft, R; Friedl, P; ClarkLewis, I; Kroczek, RA			Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NH2-TERMINAL RESIDUES; LYMPHOCYTE LOCOMOTION; MOLECULAR-CLONING; CYCLOSPORINE-A; CHEMOKINE; INTERLEUKIN-8; EXPRESSION; ACTIVATION; LYMPHOTACTIN	Recently, we identified a novel putative human cytokine expressed by activated CD8(+) T cells, which was designated ATAC (activation-induced, T cell-derived, and chemokine-related; the same molecule has been identified independently as lymphotactin and single cysteine motif-1). In this report, we provide evidence that ATAC is a secreted 93-amino acid protein that is generated from its precursor by proteolytic cleavage between Gly(21) and Val(22). An estimated 60% of ATAC (Val(22)-Gly(114)) is secreted as an unmodified protein with a molecular mass of 10,271.72 Da (apparent molecular mass of 12 kDa in SDS-polyacrylamide gel electrophoresis) and in which Cys(32) and Cys(69) are linked by a disulfide bridge. Unmodified ATAC is a cationic protein with a pI of 11.35 and is capable of binding to heparin. Some 40% of ATAC is O-glycosylated within 25 min of synthesis, giving rise to the appearance of a homogeneous 15-kDa (minor fraction) and a heterogeneous, terminally sialylated 17-19-kDa (major fraction) protein species in SDS-polyacrylamide gel electrophoresis. The secretion of all ATAC protein variants is completed within 30-40 min of synthesis. In terms of function, various ATAC protein forms were consistently ineffective in chemotaxis assays. In contrast, both purified natural ATAC and a chemically synthesized aglycosyl analog induced locomotion (chemokinesis) in purified CD4(+) and CD8(+) T cell populations at 400 ng/ml.	ROBERT KOCH INST,D-13353 BERLIN,GERMANY; UNIV WITTEN HERDECKE,INST IMMUNOL,D-58448 WITTEN,GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL,DEPT DERMATOL,D-24105 KIEL,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT PROT CHEM,D-13125 BERLIN,GERMANY; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA	Robert Koch Institute; Witten Herdecke University; University of Kiel; Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of British Columbia; University of British Columbia			Friedl, Peter/A-8961-2010; Schroeder, Jens M/B-3994-2009; Steinbach, Sabine/D-8891-2011	Friedl, Peter/0000-0002-0119-4041; Dorner, Brigitte/0000-0002-5100-2546				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; ERNST CA, 1994, J IMMUNOL, V152, P3541; FRIEDL P, 1993, J IMMUNOL METHODS, V165, P157, DOI 10.1016/0022-1759(93)90341-4; FRIEDL P, 1995, J IMMUNOL, V154, P4973; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MULLER S, 1995, EUR J IMMUNOL, V25, P1744, DOI 10.1002/eji.1830250638; OPDENAKKER G, 1995, FASEB J, V9, P453, DOI 10.1096/fasebj.9.5.7896019; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1	23	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8817	8823		10.1074/jbc.272.13.8817	http://dx.doi.org/10.1074/jbc.272.13.8817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079718	hybrid			2022-12-27	WOS:A1997WQ63500101
J	Guse, AH; Berg, I; daSilva, CP; Potter, BVL; Mayr, GW				Guse, AH; Berg, I; daSilva, CP; Potter, BVL; Mayr, GW			Ca2+ entry induced by cyclic ADP-ribose in intact T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; CALCIUM-ENTRY; RELEASE; CELLS; STORES; DEPLETION; MOBILIZATION; MICROSOMES; ACTIVATION; INHIBITOR	Cyclic ADP-ribose (cADPr) is a potent Ca2+-mobilizing natural compound (Lee, H. C., Walseth, T. F., Bratt, G. T., Hayes, R. N., and Clapper, D. L. (1989) J. Biol. Chem. 264, 1608-1615) which has been shown to release Ca2+ from an intracellular stare of permeabilized T-lymphocytes (Guse, A. H., Silva, C. P., Emmrich, F., Ashamu, G., Potter, B. V. L., and Mayr, G. W. (1995) J. Immunol. 155, 3353-3359). Microinjection of cADPr into intact single T lymphocytes dose dependently induced repetitive but irregular Ca2+ spikes which were almost completely dependent on the presence of extracellular Ca2+. The Ca2+ spikes induced by cADPr could be blocked either by co-injection of cADPr with the specific antagonist 8-NH2-cADPr, by omission of Ca2+ from the medium, or by superfusion of the cells with Zn2+ or SK-F 96365. Ratiometric digital Ca2+ imaging revealed that single Ca2+ spikes were initiated at several sites (''hot spots'') close to the plasma membrane. These hot spots then rapidly formed a circular zone of high Ca2+ concentration below the plasma membrane which subsequently propagated like a closing optical diaphragm into the center of the cell. Taken together these data indicate a role for cADPr in Ca2+ entry in T-lymphocytes.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	Guse, AH (corresponding author), UNIV HAMBURG,INST PHYSIOL CHEM,DEPT ENZYME CHEM,ABT ENZYMCHEM,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.		Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012					ALBRITTON NL, 1992, SCIENCE, V258, P1812; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1929; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39950001359; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; FAVRE CJ, 1996, J LAB CLIN MED, V128, P1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1995, J IMMUNOL, V155, P3353; Guse AH, 1996, J BIOL CHEM, V271, P23946, DOI 10.1074/jbc.271.39.23946; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MILLS SJ, 1995, BIOORG MED CHEM LETT, V5, P203, DOI 10.1016/0960-894X(95)00012-I; MORRISSETTE J, 1993, FEBS LETT, V330, P271; PREMACK BA, 1994, J IMMUNOL, V152, P5226; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	31	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8546	8550		10.1074/jbc.272.13.8546	http://dx.doi.org/10.1074/jbc.272.13.8546			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079684	hybrid			2022-12-27	WOS:A1997WQ63500067
J	Isobe, T; Hisaoka, T; Shimizu, A; Okuno, M; Aimoto, S; Takada, Y; Saito, Y; Takagi, J				Isobe, T; Hisaoka, T; Shimizu, A; Okuno, M; Aimoto, S; Takada, Y; Saito, Y; Takagi, J			Propolypeptide of von Willebrand factor is a novel ligand for very late antigen-4 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; ALTERNATIVELY SPLICED DOMAIN; VONWILLEBRAND-FACTOR; COUNTER-RECEPTOR; BINDING-SITES; VLA-4; FIBRONECTIN; VCAM-1; ENDOTHELIUM; MELANOMA	We have previously reported that propolypeptide of von Willebrand factor (pp-vWF) promotes melanoma cell adhesion in a beta 1 integrin-dependent manner. In this report, we identified the alpha subunit of the cell adhesion receptor for pp-vWF as alpha 4. Human leukemia cell lines that express alpha 4 beta 1 integrin (very late antigen-4, VLA-4), but not cell lines which lack VLA-4, attached well to pp-vWF substrate and these adhesions were completely inhibited by anti-alpha 4 integrin monoclonal antibody HP2/1. Adhesion of mouse melanoma expressing alpha 4 integrin was also inhibited by anti-mouse alpha 4 mAb PS/2. Furthermore, transfection of human alpha 4 cDNA into alpha 4(-) Chinese hamster ovary cells resulted in an acquisition of adhesive activity to pp-vWF, indicating that pp-vWF is a ligand for VLA-4 integrin. Using a recombinant fragment of pp-vWF, the cell attachment site was shown to be located within amino acid residues 376-455 of pp-vWF. A series of synthetic peptides covering this region were tested for the ability to promote cell attachment and a 15-residue peptide designated T2-15 (DCQDHSFSIVIETVQ, residues numbered 395-409) promoted VLA-4 dependent cell adhesion. The peptide was also capable of inhibiting cell adhesion to pp-vWF, suggesting that this sequence represents the cell attachment site, By affinity chromatography using peptide T2-15-Sepharose, it was found that alpha 4 beta 1 integrin complex from extracts of surface iodinated B16 cells specifically bound to the peptide. These results strongly suggest that pp-vWF is a novel physiological ligand for VLA-4.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT SCI BIOL, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; SUMITOMO MET IND LTD, PHARMACEUT RES DEPT, KYOTO 61902, JAPAN; OSAKA UNIV, INST PROT CHEM, OSAKA 565, JAPAN; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Tokyo Institute of Technology; Nippon Steel & Sumitomo Metal Corporation; Osaka University; Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589				ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAROFALO A, 1995, CANCER RES, V55, P414; GOTO Y, 1991, J MOL BIOL, V218, P387, DOI 10.1016/0022-2836(91)90720-Q; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HESSION C, 1991, J BIOL CHEM, V266, P6682; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KRAMER RH, 1989, CANCER RES, V49, P393; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MAY MJ, 1993, J CELL SCI, V106, P109; MCCARROLL DR, 1985, J CLIN INVEST, V75, P1089, DOI 10.1172/JCI111802; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OKAHARA H, 1994, CANCER RES, V54, P3233; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; POSTIGO AA, 1993, RES IMMUNOL, V144, P723, DOI 10.1016/S0923-2494(93)80057-6; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONIG LAB MANUA; SCOTT JP, 1981, BLOOD, V58, P1075; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKAGI J, 1994, EUR J BIOCHEM, V222, P861, DOI 10.1111/j.1432-1033.1994.tb18933.x; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; USUI T, 1993, J BIOL CHEM, V268, P12311; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0	45	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8447	8453		10.1074/jbc.272.13.8447	http://dx.doi.org/10.1074/jbc.272.13.8447			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079671	hybrid			2022-12-27	WOS:A1997WQ63500054
J	Williams, DR; Chen, JH; Fisher, MJ; Rees, HH				Williams, DR; Chen, JH; Fisher, MJ; Rees, HH			Induction of enzymes involved in molting hormone (ecdysteroid) inactivation by ecdysteroids and an agonist, 1,2-dibenzoyl-1-tert-butylhydrazine (RH-5849)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECDYSONE 20-MONOOXYGENASE ACTIVITY; STEROID HYDROXYLASE-ACTIVITY; LARVAL-PUPAL DEVELOPMENT; MANDUCA-SEXTA; SPODOPTERA-LITTORALIS; COTTON LEAFWORM; MIDGUT; IDENTIFICATION; LEPIDOPTERA; PROMOTER	Molting in insects is regulated by molting hormones (ecdysteroids). The major active hormone, 20-hydroxyecdysone, is formed by ecdysone 20-monooxygenase-catalyzed hydroxylation of ecdysone. During times of decreasing hormone titers, inactivation occurs by several routes including (i) 26-hydroxylation and further oxidation to the 26-oic acid, (ii) formation of various conjugates (e.g. phosphates), and (iii) in Lepidoptera in particular, ecdysone oxidase-catalyzed formation of 3-dehydroecdysteroid, which is reduced to 3-epiecdysteroid, followed by phosphotransferase-catalyzed formation of phosphate conjugates, Administration of the nonsteroidal ecdysteroid agonist RH-5849 (1,2-dibenzoyl-1-tert-butylhydrazine), but not 20-hydroxyecdysone, to tobacco hornworm (Manduca sexta) resulted in induction of midgut cytosolic ecdysone oxidase and ecdysteroid phosphotransferase activities, In addition, both 20-hydroxyecdysone and RH-5849 caused induction of ecdysteroid 26-hydroxylase activity in midgut mitochondria and microsomes, whereas 20-hydroxylase was induced to a lesser extent by 20-hydroxyecdysone in mitochondria and by either RH-5849 or 20-hydroxyecdysone in microsomes, Commensurate with induction of the enzymes by ecdysteroid and RH-5849 is a requirement for RNA and protein synthesis, without precluding indirect mechanisms, These results indicate that molting hormone stimulates at least one universal route of its own inactivation by inducing ecdysteroid 26-hydroxylase activity and are discussed in relation to an analogous phenomenon observed for vitamin D inactivation in vertebrates.	UNIV LIVERPOOL, DEPT BIOCHEM, LIVERPOOL L69 7ZB, MERSEYSIDE, ENGLAND	University of Liverpool								BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BERGMAN T, 1991, BIOCHEM J, V276, P427, DOI 10.1042/bj2760427; BEYDON P, 1987, ARCH INSECT BIOCHEM, V4, P139, DOI 10.1002/arch.940040207; BOLLENBACHER WE, 1981, GEN COMP ENDOCR, V44, P302, DOI 10.1016/0016-6480(81)90005-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JH, 1996, BIOCHEM SOC T, V24, pS436, DOI 10.1042/bst024436s; CHEN JH, 1994, BIOCHEM J, V301, P89, DOI 10.1042/bj3010089; CHEN JH, 1994, BIOCHEM J, V299, P711, DOI 10.1042/bj2990711; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HOGGARD N, 1989, ARCH INSECT BIOCHEM, V10, P241, DOI 10.1002/arch.940100307; KEOGH DP, 1989, BIOCHEM BIOPH RES CO, V165, P442, DOI 10.1016/0006-291X(89)91090-5; KEOGH DP, 1991, BIOCHEM BIOPH RES CO, V176, P522, DOI 10.1016/0006-291X(91)90956-8; Koolman J, 1989, ECDYSONE; Kramer W., 1986, Sterol biosynthesis, inhibitors and anti-feeding compounds., P25; KUMAR R, 1978, J BIOL CHEM, V253, P3804; Lafont R., 1984, P196; Lafont R., 1989, P167; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OBERLANDER H, 1995, ARCH INSECT BIOCH PH, V7, P145; Rees H.H., 1984, P181; REES HH, 1995, EUR J ENTOMOL, V92, P9; Riddiford L.M., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P975, DOI 10.1007/BF00919715; Smith S.L., 1985, P295; SMITH SL, 1983, MOL CELL ENDOCRINOL, V31, P227, DOI 10.1016/0303-7207(83)90151-X; SRIVATSAN J, 1987, BIOCHEM BIOPH RES CO, V148, P1075, DOI 10.1016/S0006-291X(87)80241-3; WEBB TJ, 1995, BIOCHEM J, V312, P561, DOI 10.1042/bj3120561; Weirich G.F., 1989, P174; WEIRICH GF, 1993, ARCH INSECT BIOCHEM, V23, P199, DOI 10.1002/arch.940230406; WEIRICH GF, 1985, ARCH INSECT BIOCHEM, V2, P385, DOI 10.1002/arch.940020406; WEIRICH GF, 1986, ARCH INSECT BIOCHEM, V3, P109, DOI 10.1002/arch.940030202; WING KD, 1988, SCIENCE, V241, P470, DOI 10.1126/science.241.4864.470; YU SJ, 1995, ARCH INSECT BIOCHEM, V28, P365, DOI 10.1002/arch.940280406	34	37	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8427	8432		10.1074/jbc.272.13.8427	http://dx.doi.org/10.1074/jbc.272.13.8427			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079668	hybrid			2022-12-27	WOS:A1997WQ63500051
J	Genazzani, AA; Mezna, M; Summerhill, RJ; Galione, A; Michelangeli, F				Genazzani, AA; Mezna, M; Summerhill, RJ; Galione, A; Michelangeli, F			Kinetic properties of nicotinic acid adenine dinucleotide phosphate-induced Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; 1,4,5-TRISPHOSPHATE-INDUCED CALCIUM-RELEASE; INOSITOL TRISPHOSPHATE; CEREBELLAR MICROSOMES; STORES; RECEPTOR; AGONIST; NAADP	Three endogenous molecules have now been shown to release Ca2+ in the sea urchin egg: inositol trisphosphate (InsP(3)), cyclic adenosine 5'-diphosphate ribose (cADPR), and nicotinic acid adenine dinucleotide phosphate (NAADP) a derivative of NADP, While the mechanism through which the first two molecules are able to release Ca2+ is established and well characterized with InsP, and cADPR-activating InsP(3) and ryanodine receptors, respectively, the newly described NAADP has been shown to release Ca2+ via an entirely different mechanism, The most striking feature of this novel Ca2+ release mechanism is its inactivation, since subthreshold concentrations of NAADP are able to fully and irreversibly desensitize the channel, In the present study we have investigated the fast kinetics of activation and inactivation of NAADP-induced Ca2+ release, NAADP was found to release Ca2+ in a biphasic manner, and such release was preceded by a pronounced latent period, which was inversely dependent on concentration, Moreover, the kinetic features of NAADP-induced Ca2+ release were not altered by pretreatment with low concentrations of NAADP, although the extent of Ca2+ release was greatly affected, Our data suggest that the inactivation of NAADP-induced Ca2+ release is an all-or-none phenomenon, and while some receptors have been fully inactivated, those that remain sensitive to NAADP do so without any change in kinetic features.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Genazzani, AA (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Genazzani, Armando/AAI-8280-2020	Genazzani, Armando/0000-0003-1923-7430; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAZAR DF, 1993, J NEUROCHEM, V61, P1135, DOI 10.1111/j.1471-4159.1993.tb03630.x; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEZNA M, 1995, J BIOL CHEM, V270, P28097; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; TOVEY S, 1995, BIOCHEM SOC T, V23, pS429, DOI 10.1042/bst023429s; XU YJ, 1995, BIOCHEMISTRY-US, V34, P2815, DOI 10.1021/bi00009a010	23	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7669	7675		10.1074/jbc.272.12.7669	http://dx.doi.org/10.1074/jbc.272.12.7669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065423	hybrid			2022-12-27	WOS:A1997WP59200017
J	Jung, YS; Vassiliev, IR; Yu, JP; McIntosh, L; Golbeck, JH				Jung, YS; Vassiliev, IR; Yu, JP; McIntosh, L; Golbeck, JH			Strains of Synechocystis sp. PCC 6803 with altered PsaC .2. EPR and optical spectroscopic properties of F-A and F-B in aspartate, serine, and alanine replacements of cysteines 14 and 51.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND 4FE-4S CLUSTER; PHOTOSYSTEM-I COMPLEX; IRON-SULFUR PROTEIN; SITE-DIRECTED CONVERSION; ELECTRON-TRANSFER; PYROCOCCUS-FURIOSUS; RECOMBINATION; FERREDOXIN; 3FE-4S; MUTANT	A psaC deletion mutant of the unicellular cyanobacterium Synechocystis sp, PCC 6803 was utilized to incorporate site-specific amino acid substitutions in the cysteine residues that ligate the F-A and F-B iron-sulfur clusters in Photosystem I (PS I). Cysteines 14 and 51 of PsaC were changed to aspartic acid (C14D(PsaC), C51D(PsaC), C14D/C51D(PsaC)), serine (C14S(PsaC), C51S(PsaC)), and alanine (C14A(PsaC), C51A(PsaC)), and the properties of F-A and F-B were characterized by electron paramagnetic resonance spectroscopy and time-reserved optical spectroscopy, The C14D(PsaC)-PS I and C14S(PsaC)-PS I complexes showed high levels of photoreduction of F-A with g values of 2.045, 1.944, and 1.852 after illumination at 15 K, but there was no evidence of reduced F-B in the g = 2 region, The C51D(PsaC)-PS I and C51S(PsaC)-PS I complexes showed low levels of photoreduction of F-B with g values of 2.067, 1.931, and 1.881 after illumination at 15 K, but there was no evidence of reduced F-A in the g = 2 region, The presence of F-B was inferred in C14D(PsaC)-PS I and C14S(PsaC)-PS I, and the presence of F-A was inferred in C51D(PsaC)-PS I and C51S(PsaC)-PS I by magnetic interaction in the photoaccumulated spectra and by the equal spin concentration of the irreversible P700(+) cation generated by illumination at 77 K, Flash-induced optical absorbance changes at 298 K in the presence of a fast electron donor indicate that two electron accepters function after F-X in the four mutant PS I complexes at room temperature, These data suggest that a mixed-ligand [4Fe-4S] cluster is present in the mutant sites of CI LX-PS I and C5LX-PS I (where X = D or S), but that the proposed spin state of S = 3/2 renders the resonances undetectable in the g 2 region, The C14A(PsaC)-PS I, C51A(PsaC)-PS I and C14D/C51D(PsaC)-PS I complexes show only the photoreduction of F-X, consistent with the absence of PsaC. These results show that only those PsaC proteins that contain two [4Fe-4S] clusters are capable of assembling onto PS I cores in vivo.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588; UNIV NEBRASKA,CTR BIOL CHEM,LINCOLN,NE 68588; MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Michigan State University; Michigan State University				Yu, Jianping/0000-0003-0466-3197				ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; Belford R L., 1979, EPR S 21 ROCK MOUNT; BOTTIN H, 1987, BIOCHIM BIOPHYS ACTA, V892, P91, DOI 10.1016/0005-2728(87)90251-9; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; CHAMOROVSKY SK, 1982, BIOCHIM BIOPHYS ACTA, V679, P146, DOI 10.1016/0005-2728(82)90266-3; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; HE WZ, 1994, PHOTOSYNTH RES, V41, P381, DOI 10.1007/BF02183040; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; Mannan RM, 1996, EMBO J, V15, P1826, DOI 10.1002/j.1460-2075.1996.tb00532.x; MANNAN RM, 1994, ARCH BIOCHEM BIOPHYS, V315, P68, DOI 10.1006/abbi.1994.1472; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MCTAVISH H, 1995, J BACTERIOL, V177, P3960, DOI 10.1128/jb.177.14.3960-3964.1995; MEHARI T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P139, DOI 10.1016/S0005-2728(05)80280-4; MEHARI T, 1995, J BIOL CHEM, V270, P28108; MOUESCA JM, 1994, INORG CHEM, V33, P4819, DOI 10.1021/ic00100a004; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; SAKURAI H, 1991, PHOTOSYNTH RES, V27, P65, DOI 10.1007/BF00029977; SAUER K, 1978, BIOCHIM BIOPHYS ACTA, V503, P120, DOI 10.1016/0005-2728(78)90166-4; SETIF P, 1984, BIOCHIM BIOPHYS ACTA, V767, P404, DOI 10.1016/0005-2728(84)90038-0; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TELSER J, 1995, J AM CHEM SOC, V117, P5133, DOI 10.1021/ja00123a016; VASSILIEV I, 1996, BIOPHYS J, V72, P301; VASSILIEV IR, 1995, BIOPHYS J, V69, P1544, DOI 10.1016/S0006-3495(95)80026-3; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; Yu JP, 1997, J BIOL CHEM, V272, P8032, DOI 10.1074/jbc.272.12.8032; YU L, 1993, BIOCHEMISTRY-US, V32, P8251, DOI 10.1021/bi00083a028; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001	34	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8040	8049		10.1074/jbc.272.12.8040	http://dx.doi.org/10.1074/jbc.272.12.8040			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065477	hybrid			2022-12-27	WOS:A1997WP59200071
J	Terry, DR; Spector, I; Higa, T; Bubb, MR				Terry, DR; Spector, I; Higa, T; Bubb, MR			Misakinolide A is a marine macrolide that caps but does not sever filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC DIMERIC MACROLIDE; SPONGE THEONELLA SP; ABSOLUTE STEREOSTRUCTURE; NATURAL-PRODUCTS; CAPPING PROTEIN; SWINHOLIDE-A; F-ACTIN; POLYMERIZATION; BINDING; INHIBITION	We have investigated the biochemical properties of the marine natural product, misakinolide A, a 40-membered dimeric lactone macrolide that differs from swinholide A only in the size of the macrolide ring, Analytical ultracentrifugation and steady-state fluorescence experiments show that misakinolide A binds simultaneously to two actin subunits with virtually the same affinity as swinholide A, suggesting that the modification in the ring size does not change the actin-binding site, Sedimentation equilibrium experiments suggest that binding is independent at each binding site, with a K-d of approximately 50 nM, Remarkably, misakinolide A does not sever actin filaments like swinholide A; rather, it caps the barbed end of F-actin, When capped by misakinolide A, the elongation rate constant at the barbed end is reduced to zero; pointed end growth was affected only to the extent that the compound sequesters unpolymerized actin, Misakinolide A has essentially no effect on the off-rate of actin subunits leaving the barbed end, Energy-minimized models of misakinolide A and swinholide A are consistent with conservation of identical binding sites in both molecules, but a difference in orientation of one binding site relative to the other may explain why swinholide A has severing activity whereas misakinolide A only has capping activity.	UNIV FLORIDA,DEPT MED,COLL MED,HLTH SCI CTR,GAINESVILLE,FL 32610; SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; UNIV RYUKYUS,DEPT MARINE SCI,NISHIHARA,OKINAWA 90301,JAPAN	State University System of Florida; University of Florida; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of the Ryukyus								Braet F, 1996, HEPATOLOGY, V24, P627; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1994, J BIOL CHEM, V269, P14869; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Duncan MD, 1996, J SURG RES, V63, P359, DOI 10.1006/jsre.1996.0276; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; IWIG M, 1996, J CELL BIOL, V67, P145; KARPOVA TS, 1995, J CELL BIOL, V131, P1483, DOI 10.1083/jcb.131.6.1483; KATO Y, 1987, TETRAHEDRON LETT, V28, P6225, DOI 10.1016/S0040-4039(00)61853-1; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KOBAYASHI M, 1990, CHEM PHARM BULL, V38, P2409; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; PATTERSON GML, 1993, CELL MOTIL CYTOSKEL, V24, P39, DOI 10.1002/cm.970240105; Rothkegel M, 1996, J CELL SCI, V109, P83; Saito S, 1996, CLIN EXP PHARMACOL P, V23, P743, DOI 10.1111/j.1440-1681.1996.tb01770.x; SAITO S, 1994, J BIOL CHEM, V269, P29710; SENDEROWICZ AMJ, 1995, J NATL CANCER I, V87, P46, DOI 10.1093/jnci/87.1.46; SOUTHWICK FS, 1995, J BIOL CHEM, V270, P45, DOI 10.1074/jbc.270.1.45; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUN HQ, 1994, J BIOL CHEM, V269, P9473; TANAKA J, 1990, CHEM PHARM BULL, V38, P2967, DOI 10.1248/cpb.38.2967; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Watabe S, 1996, CELL STRUCT FUNCT, V21, P199, DOI 10.1247/csf.21.199	26	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7841	7845		10.1074/jbc.272.12.7841	http://dx.doi.org/10.1074/jbc.272.12.7841			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065449	hybrid			2022-12-27	WOS:A1997WP59200043
J	Jeong, JK; Huang, QH; Lau, SS; Monks, TJ				Jeong, JK; Huang, QH; Lau, SS; Monks, TJ			The response of renal tubular epithelial cells to physiologically and chemically induced growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNA; TRANSCRIPTION FACTOR-IIIA; GENE-EXPRESSION; RIBONUCLEOTIDE REDUCTASE; TRICHOSTATIN-A; POTENT INHIBITOR; PROTEIN-KINASES; DNA-DAMAGE; CYCLE; STAUROSPORINE	Cells respond to a variety of stresses by activating the transcription of a battery of ''acute phase'' or ''stress response'' genes. The nature of this response is tailored to the nature of the stress. The extent to which physiologically and pathophysiologically induced growth arrest share common genomic responses is unclear. We therefore compared the effects of a physiologically induced (serum and nutrient depletion) and a chemically induced (2-Br-bis-(GSyl)HQ and 2-Br-6-(GSyl)HQ) stress in renal tubular epithelial cells (LLC-PK1). The response to physiological stress, induced by serum depletion, involves growth arrest characterized by an inhibition of DNA synthesis that occurs in the absence of a decrease in histone mRNA or an increase in gadd153 mRNA, one of the growth arrest and DNA damage inducible genes. In contrast, the chemical-induced stress involves growth arrest accompanied by a decrease in histone mRNA, particularly core histone H2B and H2A mRNA, and the induction of gadd153. Chemical-induced changes in histone mRNA inversely correlate to changes in the expression of a stress gene, hsg70, whose expression is dependent upon the maintenance of appropriate nucleosomal structure.	UNIV TEXAS, COLL PHARM, DIV PHARMACOL & TOXICOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007359] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07359] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Butterworth M, 1996, CHEM RES TOXICOL, V9, P793, DOI 10.1021/tx9501952; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN EA, 1987, BIOCHEM CELL BIOL, V65, P35, DOI 10.1139/o87-005; COLE LA, 1986, AM J PHYSIOL, V251, pC293, DOI 10.1152/ajpcell.1986.251.2.C293; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DATTA R, 1992, MOL PHARMACOL, V41, P64; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FOX RM, 1985, PHARMACOL THERAPEUT, V30, P31, DOI 10.1016/0163-7258(85)90046-4; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; GUPTA S, 1994, GROWTH FACTORS, V10, P171, DOI 10.3109/08977199409000235; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HILL BA, 1993, CHEM RES TOXICOL, V6, P459, DOI 10.1021/tx00034a012; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Jeong JMK, 1996, MOL PHARMACOL, V50, P592; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANDSBERGER N, 1995, DEV BIOL, V170, P62, DOI 10.1006/dbio.1995.1195; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MARZLUFF WF, 1993, CONTROL MESSENGER RN, P267; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1621; MCLAREN RS, 1993, J BIOL CHEM, V268, P14637; MERTENS JJWM, 1995, ARCH BIOCHEM BIOPHYS, V320, P51, DOI 10.1006/abbi.1995.1341; MIYASHITA T, 1994, FEBS LETT, V353, P225, DOI 10.1016/0014-5793(94)01034-X; MONKS TJ, 1992, CRIT REV TOXICOL, V22, P243, DOI 10.3109/10408449209146309; MONKS TJ, 1988, MOL PHARMACOL, V34, P492; Morimoto RI, 1990, STRESS PROTEINS BIOL; MORRIS TD, 1991, MOL CELL BIOL, V11, P544, DOI 10.1128/MCB.11.1.544; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; Peters MMCG, 1996, CHEM RES TOXICOL, V9, P133, DOI 10.1021/tx950122i; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; RIVERA MI, 1994, TOXICOL APPL PHARM, V128, P239, DOI 10.1006/taap.1994.1203; Stein GS, 1995, INT REV CYTOL, V162A, P251; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TERADA N, 1993, EXP CELL RES, V204, P260, DOI 10.1006/excr.1993.1032; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; THNG JPH, 1994, J BIOL CHEM, V269, P9568; THOMPSON EM, 1995, DEVELOPMENT, V121, P3425; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; VanDolah FM, 1996, J CELL PHYSIOL, V166, P49, DOI 10.1002/(SICI)1097-4652(199601)166:1<49::AID-JCP6>3.0.CO;2-G; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WICE BM, 1981, J BIOL CHEM, V256, P7812; WILLIAMS AS, 1994, NUCLEIC ACIDS RES, V22, P4660, DOI 10.1093/nar/22.22.4660; Wolffe A., 1994, REGULATION CHROMATIN; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHAN QM, 1994, CANCER RES, V54, P2755	62	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7511	7518		10.1074/jbc.272.11.7511	http://dx.doi.org/10.1074/jbc.272.11.7511			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054455	hybrid			2022-12-27	WOS:A1997WN14700094
J	Kim, TK; Roeder, RG				Kim, TK; Roeder, RG			Critical role of the second stirrup region of the TATA-binding protein for transcriptional activation both in yeast and human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; TBP; DOMAIN; GENE; HOLOENZYME; COMPLEX; TFIIB	We previously identified three TATA-binding protein (TBP) point mutations (L114K, L189K, and K211L) that have severe effects on transcriptional activation by acidic activators, but no effect on basal transcription, in a yeast-derived TBP-dependent in vitro transcription system (Kim, T. K., Hashimoto, S., Kelleher, R. J., III, Flanagan, P. M., Kornberg, R. D., Horikoshi, M., and Roeder, R. G. (1994) Nature 369, 252-255). These activation defects were also demonstrated in vivo in yeast cells (Lee, M., and Struhl, K. (1995) Mel. Cell, Biol. 15, 5461-5469), Here, the transcriptional activities of these and other TBP mutations were examined in human by both in vitro and in vivo assays, Mutations L189K and E188K, which lie in the second stirrup region of TBP, show defective activation by acidic activators both in yeast and human, Somewhat surprisingly, mutations L114K and K211L have almost no demonstrable effect on activation by acidic activators in human, in contrast to their severe effects on defective activator responses in yeast. The implications of these results for TBP structure and function are discussed.	ROCKEFELLER UNIV, BIOCHEM & MOL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University								ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HUI G, 1994, CELL, V78, P513; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM TK, 1993, J BIOL CHEM, V268, P20866; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE M, 1995, MOL CELL BIOL, V15, P5461; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MODTADERI Z, 1996, NATURE, V383, P188; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0	44	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7540	7545		10.1074/jbc.272.11.7540	http://dx.doi.org/10.1074/jbc.272.11.7540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054459	hybrid			2022-12-27	WOS:A1997WN14700098
J	Ihara, Y; Sakamoto, Y; Mihara, M; Shimizu, K; Taniguchi, N				Ihara, Y; Sakamoto, Y; Mihara, M; Shimizu, K; Taniguchi, N			Overexpression of N-acetylglucosaminyltransferase III disrupts the tyrosine phosphorylation of Trk with resultant signaling dysfunction in PC12 cells treated with nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; STRUCTURAL DETERMINANTS; PROTOONCOGENE PRODUCT; ADHESION MOLECULES; CDNA CLONING; EXPRESSION; RECEPTOR; GENE; PROTEIN; CAM	beta-1,4-N-Acetylglucosaminyltransferase III (GnT-III: EC 2.4.1.144) is a pivotal glycosyltransferase which participates in branch formation by catalysis of the synthesis of a bisecting GlcNAc structure in N-glycans. These structures are thought to be one of the unique features of the N-glycans of neural tissues, To examine the intra-cellullar role of GnT-III expression and its product in neural cells, its gene was overexpressed in rat pheochromocytoma PC12 cells which normally express a low level of GnT-III. In the GnT-III gene-transfected cells, lectin blot analysis showed that some glycoproteins showed increased levels of bisecting GlcNAc structures, Following treatment with nerve growth factor (NGF) the control cells showed neurite outgrowth for differentiation whereas the transfectants showed no morphological response or change in the rate of cell growth, Transient tyrosine phosphorylation of the Trk/NGF receptor was detected at 5-15 min after NGF treatment in control cells, but not detected in the GnT-III gene-transfected cells despite the intact binding of NGF to the cells. More over the dimerization of Trk with NGF treatment was not induced in the GnT-III transfectant as compared with the dimerization seen in control cells, These results indicate that overexpression of GnT-III gene in PC12 cells affects some functions of glycoprotein receptors such as Trk by alteration of N-glycan structures, and results in changes in the intracellular signaling pathway of tyrosine phosphorylation modified by NGF.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	Osaka University			Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Mihara, Masahito/0000-0001-5103-7784				BALDWIN AN, 1995, J BIOL CHEM, V270, P4594, DOI 10.1074/jbc.270.9.4594; BHAUMIK M, 1995, GENE, V164, P295, DOI 10.1016/0378-1119(95)00260-D; BREEN KC, 1988, DEVELOPMENT, V104, P147; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FRIEDLANDER DR, 1985, J CELL BIOL, V101, P412, DOI 10.1083/jcb.101.2.412; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1980, ADV CELL NEUROBIOL, P373; GUROFF G, 1984, CELL CULTURE NEUROSC, P245; HAHN TJ, 1992, J BIOL CHEM, V267, P23982; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IHARA Y, 1995, GLYCOCONJ J, V12, P784; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LECONTE I, 1992, J BIOL CHEM, V267, P17415; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; MUTOH T, 1993, J NEUROCHEM, V60, P1540, DOI 10.1111/j.1471-4159.1993.tb03319.x; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAKANISHI N, 1985, J BIOL CHEM, V260, P7791; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIURA T, 1990, CANCER RES, V50, P5345; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RICHARDS RI, 1984, CELL, V37, P263, DOI 10.1016/0092-8674(84)90322-2; SHIMIZU H, 1993, J BIOCHEM-TOKYO, V114, P334, DOI 10.1093/oxfordjournals.jbchem.a124177; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; Yoshimura M, 1996, CANCER RES, V56, P412; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	42	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9629	9634						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092490				2022-12-27	WOS:A1997WU03900009
J	ONeill, TJ; Zhu, YY; Gustafson, TA				ONeill, TJ; Zhu, YY; Gustafson, TA			Interaction of MAD2 with the carboxyl terminus of the insulin receptor but not with the IGFIR - Evidence for release from the insulin receptor after activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; FACTOR-I RECEPTOR; YEAST HO GENE; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; KINASE-ACTIVITY; NPEY MOTIF; PROTEIN; SHC; IRS-1	We have utilized the yeast two-hybrid system to identify proteins that interact with the cytoplasmic domain of the insulin receptor (IR). We identified a human cDNA encoding a protein that appears to be the human homolog of the yeast MAD2 protein, which we term hMAD2. The yeast MAD2 protein was first identified in a genetic screen to identify cell cycle checkpoint regulatory proteins, yet the mechanism by which MAD2 functions in cell cycle control is currently unclear. Here we show that hMAD2 requires the COOH-terminal 30 amino acids of the IR for interaction and that hMAD2 does not interact with the related insulin like growth factor I receptor. Interestingly, hMAD2 does not require IR tyrosine autophosphorylation for interaction because it interacts with a kinase-dead IR in the yeast two-hybrid system. In support of this finding, hMAD2-GST fusions were found to interact strongly in vitro with receptors derived from noninsulin-stimulated cells. Furthermore, using two independent in vitro assays, IR activation was found to significantly reduce the interaction of hMAD2 with the IR. Lastly, we show that hRMAD2 can be coimmunoprecipitated with the IR from Chinese hamster ovary IR cell lysates, suggesting that this interaction occurs in vivo in cells of mammalian origin. Our results suggest that hMAD2 represents a novel class of proteins that is specific for interaction with the IR as compared with the insulin-like growth factor I receptor and that interacts best with the inactive IR and is released upon receptor autophosphorylation. The function of hMAD2 and its potential role in insulin signaling remain to be elucidated.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOL & CELLULAR BIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [DK44093, DK50602] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050602, R29DK044093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FARIA TN, 1994, J BIOL CHEM, V269, P13922; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; Miller J.H., 1972, EXPT MOL GENETICS; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1610; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RON D, 1992, BIOTECHNIQUES, V13, P866; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YIN TG, 1994, J BIOL CHEM, V269, P26614; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	55	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10035	10040						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092546				2022-12-27	WOS:A1997WU03900065
J	Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Pisick, E; Prasad, KVS; Griffin, JD				Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Pisick, E; Prasad, KVS; Griffin, JD			Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-Kit, phosphatidylinositol 3-kinase, and p120(CBL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPOTTING W LOCUS; CELL FACTOR; PROTO-ONCOGENE; SH3 DOMAIN; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; CBL PROTOONCOGENE; KINASE RECEPTOR; PI 3-KINASE; PC12 CELLS	Steel factor (SF) is a growth and survival factor for hematopoietic cells, The receptor for SF, c-Kit, contains intrinsic tyrosine kinase activity, and binding of SF induces rapid tyrosine phosphorylation of several cellular proteins, including c-ait itself, Activation of C-Kit is shown here to induce tyrosine phosphorylation of CRKL, and CRKL coprecipitated with c-Kit through an interaction that required the CRKL SH3 domains and not the SH2 domain, CRKL associated with c-Kit indirectly as part of a larger complex of proteins, Two proteins in this complex were identified as the p85 regulatory subunit of phosphatidylinositol 3-kinase (p85(PI3K)) and the proto-oncoprotein p120(CBL). Because p85(PI3K) is known to bind to the activated c-Kit receptor, the possibility that CRKL interacted with c-Kit indirectly through p85(PI3K) was investigated, Far Western blotting with a CRKL-SH3 glutathione S-transferase fusion protein showed that CRKL binds directly to p85(PI3K) in vitro, However, although a small amount of CRKL was preassociated with p85(PI3K), the interaction was increased after SF stimulation, suggesting that the interactions of these three proteins are complex, We conclude that SF induces the formation of a signaling complex potentially containing CRKL and p120(CBL), of which bind to c-Kit through p85PI3K. These data suggest that one function of CRKL in normal cells might be to recruit signaling molecules such as CBL into a complex with PI3K, Such complexes could be important in propagating signals involving PI3K such as gene expression and adhesion.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute					NATIONAL CANCER INSTITUTE [K12CA001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA01730] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andoniou CE, 1996, ONCOGENE, V12, P1981; CERY GO, 1995, J EXP MED, V182, P611; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FREDRICKSON TN, 1984, J NATL CANCER I, V72, P447; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOWRY PA, 1991, EXP HEMATOL, V19, P994; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RYGAARD K, 1993, BRIT J CANCER, V67, P37, DOI 10.1038/bjc.1993.7; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SATTLER M, 1996, ONCOGENE, V12, P893; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SERVE H, 1994, J BIOL CHEM, V269, P6026; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STANULLA M, 1995, ACTA NEUROPATHOL, V89, P158; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WIKTORJEDRZEJCZ.K, 1981, CELL TISSUE KINET, V14, P211; Wisniewski D, 1996, LEUKEMIA, V10, P1436; Wisniewski D, 1996, LEUKEMIA, V10, P229; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	62	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10248	10253						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092574				2022-12-27	WOS:A1997WU03900093
J	Bush, KT; Goldberg, AL; Nigam, SK				Bush, KT; Goldberg, AL; Nigam, SK			Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; TRANSMEMBRANE PROTEIN; ABNORMAL PROTEINS; ESCHERICHIA-COLI; STRESS PROTEINS; CELL; GENES; DEGRADATION; TRANSCRIPTION; ACIDOPHILUM	The accumulation of misfolded proteins in the cytosol leads to increased expression of heat-shock proteins, while accumulation of such proteins in the endoplasmic reticulum (ER) stimulates the expression of many ER resident proteins, most of which function as molecular chaperones. Recently, inhibitors of the proteasome have been identified that can block the rapid degradation of abnormal cytosolic and ER-associated proteins. We therefore tested whether these agents, by causing the accumulation of abnormal proteins, might stimulate the expression of cytosolic heat-shock proteins and/or ER molecular chaperones and thereby induce thermotolerance. Exposure of Madin-Darby canine kidney cells to various proteasome inhibitors, including the peptide aldehydes (MG132, MG115, N-acetyl-leucyl-leucyl-nor-leucinal) and lactacystin, inhibited the degradation of short-lived proteins and increased markedly the levels of mRNAs encoding cytosolic heat-shock proteins (Hsp70, polyubiquitin) and ER chaperones (BiP, Grp94, ERp72), as shown by Northern blot analysis. However, inhibitors of cysteine proteases (E64), serine proteases (leupeptin), or metalloproteases (1,10-phenanthroline) had no effect on the levels of these mRNAs. The relative efficacies of the peptide aldehyde inhibitors in inducing these mRNAs correlated with their potencies against the proteasome. Furthermore, reduction of the aldehyde group of MG132 decreased its inhibitory effect on proteolysis and largely prevented the induction of these mRNAs. Although treatment with the proteasome inhibitors caused rapid increases in mRNA levels (as early as 2 h after treatment with MG132), the inhibitors did not detectably affect total protein synthesis, total protein secretion, ER morphology, or the retention of ER-lumenal proteins, even after 18 h of treatment. Together, the findings suggest that inhibition of proteasome function induces heat-shock proteins and ER chaperones due to the accumulation of sufficient amounts of abnormal proteins and/or the inhibition of degradation of a key regulatory factor (e.g. heat-shock factor). Since expression of heat-shock proteins can protect cells from thermal injury, we tested whether the proteasome inhibitors might also confer thermotolerance. Treatment of cells with MG132 for as little as 2 h, markedly increased the survival of cells subjected to high temperatures (up to 46 degrees C). Thus, these agents may have applications in protecting against cell injury.	HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DIV RENAL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School								ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BAIER R, 1996, CELL STRESS CHAPERON, V1, P33; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BUSH KT, 1994, BIOCHEM J, V303, P705, DOI 10.1042/bj3030705; BUSH KT, 1994, J BIOL CHEM, V269, P23694; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DELCAYRE C, 1988, J CLIN INVEST, V82, P460, DOI 10.1172/JCI113619; DILLMANN WH, 1986, CIRC RES, V59, P110, DOI 10.1161/01.RES.59.1.110; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fra A, 1993, Subcell Biochem, V21, P143; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; INOUE S, 1992, J BIOL CHEM, V267, P9080; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P177; KARMAZYN M, 1990, AM J PHYSIOL, V259, pH424, DOI 10.1152/ajpheart.1990.259.2.H424; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MORI K, 1993, CELL, V74, P743; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J., 2002, MOL CLONING LAB MANU; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WILLIAMS RS, 1993, J CLIN INVEST, V92, P503, DOI 10.1172/JCI116594	50	383	393	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9086	9092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083035				2022-12-27	WOS:A1997WU03700040
J	Johnson, RA; Desaubry, L; Bianchi, G; Shoshani, I; Lyons, E; Taussig, R; Watson, PA; Cali, JJ; Krupinski, J; Pieroni, JP; Iyengar, R				Johnson, RA; Desaubry, L; Bianchi, G; Shoshani, I; Lyons, E; Taussig, R; Watson, PA; Cali, JJ; Krupinski, J; Pieroni, JP; Iyengar, R			Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3'-polyphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CYCLIC-AMP; MOLECULAR-CLONING; RAT-BRAIN; ADENOSINE; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS; KINETICS; CELLS; BASAL	Recombinant adenylyl cyclase isozyme Types I, II, VI, VII, and three splice variants of Type VIII were compared for their sensitivity to P-site-mediated inhibition by several adenine nucleoside derivatives and by the family of recently synthesized adenine nucleoside 3'-polyphosphates (Desaubry, L., Shoshani, I., and Johnson, R. A. (1996) J. Biol. Chem. 271, 14028-14034). Inhibitory potencies were dependent on isozyme type, the mode of activation of the respective isozymes, and on P-site ligand. For the nucleoside derivatives potency typically followed the order 2',5'-dideoxyadenosine (2',5'-ddAdo) > beta-adenosine > 9-(cyclopentyl)-adenine (9-CP-Ade) greater than or equal to 9-(tetrahydrofuryl)-adenine (9-THF-Ade; SQ 22,536), with the exception of Type II adenylyl cyclase, which was essentially insensitive to inhibition by 9-CP-Ade. For the adenine nucleoside 3'-polyphosphates inhibitory potency followed the order Ado < 2'-dAdo < 2',5'-ddAdo and 3'-mono- < 3'-di- < 3'-triphosphate. Differences in potency of these ligands were noted between isozymes. The most potent ligand was 2',5'-dd-3'-ATP with IC50 values of 40-300 nM. The data demonstrate isozyme selectivity for some ligands, suggesting the possibility of isozyme-selective inhibitors to take advantage of differences in P-site domains among adenylyl cyclase isozymes. Differential expression of adenylyl cyclase isozymes may dictate the physiological sensitivity and hence importance of this regulatory mechanism in different cells or tissues.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822; CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029	University of Michigan System; University of Michigan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Johnson, RA (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.		Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NHLBI NIH HHS [HL 42365] Funding Source: Medline; NIDDK NIH HHS [DK 38828] Funding Source: Medline; NIGMS NIH HHS [GM 46395] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; FAIN JN, 1972, J BIOL CHEM, V247, P6866; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MITCHEL REJ, 1967, CAN J BIOCHEM CELL B, V45, P89, DOI 10.1139/o67-010; MONTGOMERIE J, 1961, J AM CHEM SOC, V83, P630, DOI 10.1021/ja01464a031; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; SHERIDAN RC, 1972, INORG SYNTH, V13, P23; SOECHTIG E, 1981, Pharmacology (Basel), V23, P82; STUBNER D, 1989, FEBS LETT, V248, P155, DOI 10.1016/0014-5793(89)80452-1; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; YEAGER RE, 1986, J NEUROCHEM, V47, P139; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745	37	83	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8962	8966						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083018				2022-12-27	WOS:A1997WU03700023
J	Morris, NJ; Ducret, A; Aebersold, R; Ross, SA; Keller, SR; Lienhard, GE				Morris, NJ; Ducret, A; Aebersold, R; Ross, SA; Keller, SR; Lienhard, GE			Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; GLUT4 VESICLES; TRAFFICKING; CELLS	A 97-kDa protein present in the glucose transporter (GLUT4 isotype)-containing vesicles from rat adipocytes has been isolated, the sequences of two tryptic peptides were obtained, and on the basis of these its cDNA partially cloned, The 97-kDa protein is almost certainly identical to a major integral glycoprotein of this size in the rat adipocyte plasma membrane, since its predicted N-terminal sequence is the same as that recently determined for this glycoprotein by amino acid sequencing, Moreover, the predicted partial sequence (322 amino acids) of the 97-kDa protein is highly homologous to the corresponding region of a human placental amine oxidase, which was cloned simultaneously and proposed to be a secreted protein. The amino acid sequence of the 97-kDa rat/human amine oxidase indicates that the protein consists of a very short N-terminal cytoplasmic domain followed by a single transmembrane segment and a large extracellular domain containing the catalytic site, Thus this study establishes the 97-kDa rat/human amine oxidase as the first integral membrane amine oxidase to be cloned, The membrane amine oxidase was more abundant in the plasma membranes than the low density microsomes of the adipocyte, and in contrast to some other proteins found in GLUT4 vesicles, it did not redistribute to the plasma membrane in response to treatment of the cells with insulin.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV WASHINGTON, DEPT MOL BIOTECHNOL, SEATTLE, WA 98195 USA	Dartmouth College; University of Washington; University of Washington Seattle				Morris, Nicholas/0000-0002-8389-7508	NIDDK NIH HHS [DK 25336] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK025336, R01DK025336, R55DK025336] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Buffoni F, 1995, PROG BRAIN RES, V106, P323; Callingham BA, 1995, PROG BRAIN RES, V106, P305; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; Ducret A, 1996, ELECTROPHORESIS, V17, P866, DOI 10.1002/elps.1150170508; HARTMANN C, 1996, IN PRESS METHODS ENZ; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JOCHEN A, 1995, MOL MEMBR BIOL, V12, P277, DOI 10.3109/09687689509072428; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Lyles GA, 1995, PROG BRAIN RES, V106, P293; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MU D, 1994, J BIOL CHEM, V269, P9926; NEUMANN R, 1975, J BIOL CHEM, V250, P6362; NOVOTNY WF, 1994, J BIOL CHEM, V269, P9921; PAZ MA, 1991, J BIOL CHEM, V266, P689; RAIMONDI L, 1992, COMP BIOCHEM PHYS B, V102, P953, DOI 10.1016/0305-0491(92)90108-4; RAIMONDI L, 1991, BIOCHEM PHARMACOL, V41, P469, DOI 10.1016/0006-2952(91)90549-K; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TANNER LI, 1987, J BIOL CHEM, V262, P8975; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhang XP, 1996, GENE, V179, P279, DOI 10.1016/S0378-1119(96)00387-3	26	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9388	9392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083076				2022-12-27	WOS:A1997WU03700081
J	Tarr, K; Watowich, SS; Longmore, GD				Tarr, K; Watowich, SS; Longmore, GD			Cell surface organization of the erythropoietin receptor complex differs depending on its mode of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; ERYTHROID PROGENITOR CELLS; FRIEND-ERYTHROLEUKEMIA VIRUS; MEMBRANE GLYCOPROTEIN; GP55 GLYCOPROTEIN; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; ENVELOPE PROTEIN; POLYCYTHEMIA; DIFFERENTIATION	During erythroid development erythropoietin (EPO) binds specifically to a receptor primarily present on committed erythroid progenitors, stimulating mitogenic, survival, and differentiative growth response pathways, Other modes of erythropoietin receptor (EPO-R) activation, such as interaction with the env gene Friend virus envelope glycoprotein (F-gp55) of spleen focus-forming virus or specific mutations in the extracellular domain of the EPO-R, give rise to pathological consequences, in vivo and EPO-independent proliferation and differentiation of cultured cells, Activating extracellular receptor mutations result in covalently linked receptor homodimers. These observations and others have led to the proposal that EPO activates the EPO-R by inducing dimer formation on the cell surface. It has been assumed that F-gp55 also induces dimer formation of the EPO-R; however, clear evidence of this is lacking, In addition, EPO and F-gp55 stimulation of the EPO-R elicit different biological responses. To probe whether the cell surface EPO-R is structurally different with these activators, we contrasted the cell sw face EPO-R complex formed following receptor activation by EPO, F-gp55, and mutations in the extracellular domain of the receptor, Our results indicate that cell surface forms of activated EPO-R differ, as judged by their differential association with F-gp55 and pattern of associated cell surface proteins. Interestingly, we find that the env gene of an anemic strain of Friend virus, Rauscher virus envelope glycoprotein, does not interact with the EPO-R at the cell surface. Thus, the mode of Rauscher virus envelope glycoprotein-induced erythroblastosis may be distinct from F-gp55-induced erythroblastosis and possibly not involve the EPO-R.	WASHINGTON UNIV, SCH MED, DIV HEMATOL, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DIV HEMATOL, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center				Watowich, Stephanie/0000-0003-1969-659X				AHLERS N, 1994, J VIROL, V68, P7235, DOI 10.1128/JVI.68.11.7235-7243.1994; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FERRO FE, 1993, J BIOL CHEM, V268, P5741; GLINIAK BC, 1991, J BIOL CHEM, V266, P22991; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gotoh A, 1996, BLOOD, V88, P138; HANKINS WD, 1980, CELL, V22, P693; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; LI JP, 1986, J VIROL, V57, P534, DOI 10.1128/JVI.57.2.534-538.1986; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MCARTHUR GA, 1995, EXP HEMATOL, V23, P645; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; PINTER A, 1985, VIROLOGY, V143, P646, DOI 10.1016/0042-6822(85)90406-4; RAUSCHER FJ, 1962, J NATL CANCER I, V29, P515; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUSCETTI SK, 1979, J VIROL, V30, P787, DOI 10.1128/JVI.30.3.787-798.1979; RUSCETTI SK, 1981, NATURE, V294, P663, DOI 10.1038/294663a0; RUTA M, 1980, J VIROL, V35, P844, DOI 10.1128/JVI.35.3.844-853.1980; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; RUTA M, 1982, J BIOL CHEM, V257, P126; SHOWERS MO, 1992, BLOOD, V80, P3070; SHOWERS MO, 1993, MOL CELL BIOL, V13, P739, DOI 10.1128/MCB.13.2.739; TAMBOURIN PE, 1979, LEUKEMIA RES, V3, P117, DOI 10.1016/0145-2126(79)90009-2; TROXLER DH, 1977, J VIROL, V22, P361, DOI 10.1128/JVI.22.2.361-372.1977; TROXLER DH, 1980, VIROLOGY, V102, P28, DOI 10.1016/0042-6822(80)90067-7; VOGT M, 1985, J VIROL, V55, P184, DOI 10.1128/JVI.55.1.184-192.1985; WANG YL, 1993, J VIROL, V67, P1322, DOI 10.1128/JVI.67.3.1322-1327.1993; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WOGNUM AW, 1990, BLOOD, V76, P697; WOLFF L, 1982, J VIROL, V43, P472, DOI 10.1128/JVI.43.2.472-481.1982; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	57	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9099	9107						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083037				2022-12-27	WOS:A1997WU03700042
J	Wieland, T; Chen, CK; Simon, MI				Wieland, T; Chen, CK; Simon, MI			The retinal specific protein RGS-r competes with the gamma subunit of cGMP phosphodiesterase for the alpha subunit of transducin and facilitates signal termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENT MEMBRANES; GTP-BINDING PROTEIN; VISUAL TRANSDUCTION; INHIBITORY SUBUNIT; EFFECTOR; BOVINE; RODS; PHOTORECEPTORS; HYDROLYSIS	In vertebrate photoreceptor cells, transducin mediates signaling between rhodopsin and cGMP phosphodiesterase by transiently binding its gamma subunit (PDE gamma). For the termination of signaling GTP hydrolysis by the transducin a subunit (TD alpha) GTPase is required. This reaction can be accelerated by GTPase-activating proteins (GAPs), e.g. PDE gamma. Recently we identified a second retinal GAP that interacts with TD alpha, RGS-r. Here we compare the GAP function of RGS-r and PDE gamma. Both proteins stimulated single turnover GTPase of TD alpha; however, RGS-r was more effective than PDE gamma. When added together, PDE gamma competitively inhibited the RGS-r-stimulated GTPase. In addition, the interaction of TD alpha in its GTP-bound form (TD alpha(GTP gamma S)), the transition state (TD alpha(GDP*AMF)) and the GDP-bound form (TD alpha(GDP)) with RGS-r and PDE, respectively, was measured by surface plasmon resonance, PDE gamma displayed highest affinity for TD alpha(GTP gamma S), weaker affinity for TD alpha(GDP*AMF), and weakest affinity for TD alpha(GDP). RGS-r exhibited only a comparable high affinity for TD alpha(GDP*AMF). We conclude that the observed competition between RGS-r and PDE gamma for TD alpha occurs when the hydrolysis of GTP is initiated. By competing with PDE gamma and removing it from TD alpha as well as increasing P-i release, RGS-r apparently facilitates signal termination and TD alpha recycling.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology			Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261	NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12288] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; PAGES F, 1992, J BIOL CHEM, V267, P22018; PAGES F, 1993, J BIOL CHEM, V268, P26358; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	30	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8853	8856						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083000				2022-12-27	WOS:A1997WU03700005
J	FitzerAttas, CJ; Schindler, DG; Waks, T; Eshhar, Z				FitzerAttas, CJ; Schindler, DG; Waks, T; Eshhar, Z			Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIBODY-TYPE-SPECIFICITY; C-CBL; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; SH3 DOMAIN; V-CBL; PROTOONCOGENE PRODUCT; EGF STIMULATION	The protein tyrosine kinase Syk is activated upon engagement of immune recognition receptors. We have focused on the identification of signaling elements immediately downstream to Syk in the pathway leading to T cell activation. To circumvent T cell receptor (TCR) CD3 activation of Src family kinases, we constructed a signaling molecule with an extracellular single chain Fv of an anti-TNP antibody, attached via a transmembrane region to Syk (scFv-Syk). In a murine T cell hybridoma, direct aggregation of chimeric Syk with antigen culminates in interleukin-2 production and target cell lysis. Initially, it causes an increase in the association between scFv-Syk and the cytosolic protein Cbl and subsequently promotes tyrosine phosphorylation of Cbl. Interestingly, although both Cbl and phospholipase C-gamma (PLC-gamma) are phosphorylated in this hybridoma upon TCR CD3 cross-linking, these two events are uncoupled in scFv-Syk-transfected cells, in which we were unable to detect antigen-driven PLC-gamma phosphorylation. These results support a model in which Syk can initiate and directly activate the T cell's signaling machinery and position Cbl as a primary tyrosine kinase substrate in this pathway. Furthermore, for efficient PLC-gamma phosphorylation to occur in these cells, the combined actions of different tyrosine kinase families may be required.	WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Fitzer-Attas, Cheryl/0000-0002-8709-1384				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHAN AC, 1994, J IMMUNOL, V152, P4758; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DARBY C, 1994, J IMMUNOL, V152, P5429; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Eshhar Zelig, 1995, Methods (Orlando), V8, P133, DOI 10.1006/meth.1995.9993; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1996, J IMMUNOL, V156, P1369; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GIBSON S, 1993, BLOOD, V82, P1561; GRANJA C, 1991, J BIOL CHEM, V266, P16277; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GROSS G, 1989, TRANSPLANT P, V21, P127; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; LUSTGARTEN J, 1995, EUR J IMMUNOL, V25, P2985, DOI 10.1002/eji.1830251041; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Peters JD, 1996, J BIOL CHEM, V271, P4755; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SMIT L, 1994, J BIOL CHEM, V269, P20209; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110	77	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8551	8557		10.1074/jbc.272.13.8551	http://dx.doi.org/10.1074/jbc.272.13.8551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079685	hybrid			2022-12-27	WOS:A1997WQ63500068
J	Ivanov, VN; NikolicZugic, J				Ivanov, VN; NikolicZugic, J			Transcription factor activation during signal-induced apoptosis of immature CD4(+)CD8(+) thymocytes - A protective role of c-Fos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELL RECEPTOR; LYMPHOCYTES-T; REL FAMILY; DEATH; EXPRESSION; JUN; BCL-2; FRAGMENTATION; HYBRIDOMAS	Many signals that cause apoptotic cell death operate by inducing transcription and translation of other (presumably death effector) mediators, and it is well established that stimulus-induced apoptosis can often be blocked by inhibiting transcription and translation. Transcriptional regulation of apoptosis, however, is incompletely understood, To gain insight into nuclear events associated with signal-induced apoptosis during T cell development, we studied signal-induced apoptosis of ex vivo isolated immature CD8(+)4(+) double-positive (DP) thymocytes. Stimuli utilizing the T cell receptor (TCR) signaling pathway or its parts (an alpha CD3/TCR monoclonal antibody, a Ca2+ ionophore, or a protein kinase C-activating phorbol ester) or a stimulus that antagonizes TCR signaling and apoptosis in T cell hybridoma (forskolin, a cyclic AMP-signaling activator) resulted in massive apoptosis of DP thymocytes, At the same time, these stimuli induced qualitatively similar but quantitatively unique patterns of inducible transcription factors (TFs) NF-kappa B/RelA-p50, AP-1 (Fos-Jun), and NUR-77. We focused our attention on the role of AP-1 (Fos-Jun) complex, which was strongly induced by all of the above stimuli and thus was a candidate for a proapoptotic TF. However, we found that AP-1/c-Fos induction was vital in prolonging DP thymocyte life, as judged by increased spontaneous and induced death of DP cells in Fos(-/-) mice, In direct support of this hypothesis, experiments with antisense oligonucleotides demonstrated that c-Fos plays an essential role in protecting normal DP thymocytes from Ca2+- and cAMP-induced apoptosis but not from TCR-mediated death, Together, these results demonstrate a physiological role for c-Fos in maintaining longevity of DP thymocytes.	MEM SLOAN KETTERING CANC CTR,PROGRAM IMMUNOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center			Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NCI NIH HHS [CA-08253] Funding Source: Medline; NIAID NIH HHS [AI-32064] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032064, R01AI032064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDJELIC S, 1993, J EXP MED, V178, P1745, DOI 10.1084/jem.178.5.1745; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BRIDLE PK, 1992, CURR OPIN GENET DEV, V2, P199; CALNAN B, 1995, IMMUNITY, V3, P272; CHAN Z, 1995, GENE DEV, V9, P1586; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; COHEN JJ, 1984, J IMMUNOL, V132, P38; DIANZANI U, 1992, INT IMMUNOL, V4, P995, DOI 10.1093/intimm/4.9.995; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IVANOV VN, 1993, J IMMUNOL, V151, P4699; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KING LB, 1993, CURR OPIN IMMUNOL, V5, P368, DOI 10.1016/0952-7915(93)90055-W; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEE MR, 1993, J IMMUNOL, V151, P5208; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MCCONKEY DJ, 1990, J IMMUNOL, V145, P227; MCPHEE D, 1979, THYMUS, V1, P151; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; Preston GA, 1996, MOL CELL BIOL, V16, P211; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rincon M, 1996, MOL CELL BIOL, V16, P1074; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1991, J IMMUNOL, V146, P3340; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TADAKUMA T, 1990, EUR J IMMUNOL, V20, P779, DOI 10.1002/eji.1830200411; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TREDE NS, 1995, J IMMUNOL, V155, P902; UCKER DS, 1989, J IMMUNOL, V143, P3461; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WU HY, 1994, J BIOL CHEM, V269, P20067; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	69	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8558	8566						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079686				2022-12-27	WOS:A1997WQ63500069
J	Nuijens, JH; vanBerkel, PHC; Geerts, MEJ; Hartevelt, PP; deBoer, HA; vanVeen, HA; Pieper, FR				Nuijens, JH; vanBerkel, PHC; Geerts, MEJ; Hartevelt, PP; deBoer, HA; vanVeen, HA; Pieper, FR			Characterization of recombinant human lactoferrin secreted in milk of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING PROPERTIES; NUCLEOTIDE-SEQUENCE; PROTEIN LACTOFERRIN; BOVINE COLOSTRUM; CELLS; EXPRESSION; LACTOTRANSFERRIN; TRANSFERRINS; NEUTROPHILS; LIPOPOLYSACCHARIDE	Human lactoferrin (hLF) is an iron-binding protein involved in host defense against infection and severe inflammation. Transgenic mice were produced harboring either hLF cDNA or genomic hLF sequences fused to regulatory elements of the bovine alpha S-1 casein gene. Recombinant hLF expressed in the milk of transgenic mice (transgenic hLF) was compared with natural (human milk-derived) hLF. Immunological identity of the two forms was shown by double antibody immunoassays and the absence of an anti-hLF antibody response in transgenic mice on hyperimmunization with natural hLF. Mono S cation-exchange chromatography and N-terminal protein sequencing of transgenic and natural hLF revealed identical cationicity and N-terminal sequences. SDS-polyacrylamide gel electrophoresis and absorbance measurements of purified transgenic hLF showed this protein was 90% saturated with iron, whereas natural hLF is only 3% saturated. The pH-mediated release of iron from transgenic hLF was not different from that of iron-saturated natural hLF, Unsaturated transgenic hLF could be completely resaturated upon addition of iron. Slight differences in mobility between transgenic and natural hLF on SDS-polyacrylamide gel electrophoresis were abolished by enzymatic deglycosylation, Binding of transgenic and natural hLF to a range of ligands, including bacterial lipopolysaccharide, heparin, single-stranded DNA, Cibacron blue FG 3A, and lectins, was not different. Based on these observations, we anticipate that (unsaturated) rhLF and natural hLF will exert similar, if not identical, antibacterial and anti inflammatory activity in vivo.	LEIDEN UNIV,MED BIOTECHNOL DEPT,LEIDEN INST CHEM,NL-2333 CA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	Nuijens, JH (corresponding author), PHARMING BV,NIELS BOHWEG 11-13,NL-2333 CA LEIDEN,NETHERLANDS.							ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; APPELMELK BJ, 1994, INFECT IMMUN, V62, P2628, DOI 10.1128/IAI.62.6.2628-2632.1994; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BRINES RD, 1983, BIOCHIM BIOPHYS ACTA, V759, P229, DOI 10.1016/0304-4165(83)90317-3; BRITIGAN BE, 1989, BIOCHEM J, V264, P447, DOI 10.1042/bj2640447; COX TM, 1979, BIOCHIM BIOPHYS ACTA, V588, P120, DOI 10.1016/0304-4165(79)90377-5; CROUCH SPM, 1992, BLOOD, V80, P235; ELLISON RT, 1990, J ANTIMICROB CHEMOTH, V25, P479, DOI 10.1093/jac/25.3.479; ELLISON RT, 1991, J CLIN INVEST, V88, P1080, DOI 10.1172/JCI115407; GRUSBY MJ, 1990, P NATL ACAD SCI USA, V87, P6897, DOI 10.1073/pnas.87.17.6897; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; JOHANSON B, 1960, ACTA CHEM SCAND, V14, P510, DOI 10.3891/acta.chem.scand.14-0510; KIJLSTRA A, 1989, CURR EYE RES, V8, P581, DOI 10.3109/02713688908995757; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KRIMPENFORT P, 1991, BIO-TECHNOL, V9, P844, DOI 10.1038/nbt0991-844; LIANG QW, 1993, J AGR FOOD CHEM, V41, P1800, DOI 10.1021/jf00034a053; MANN DM, 1994, J BIOL CHEM, V269, P23661; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MAZURIER J, 1981, EUR J BIOCHEM, V119, P537, DOI 10.1111/j.1432-1033.1981.tb05641.x; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MITRA A, 1994, PLANT PHYSIOL, V106, P977, DOI 10.1104/pp.106.3.977; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; Nuijens JH, 1996, J MAMMARY GLAND BIOL, V1, P285, DOI 10.1007/BF02018081; NUIJENS JH, 1992, J LAB CLIN MED, V119, P159; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; PANELLA TJ, 1991, CANCER RES, V51, P3037; PETSCHOW BW, 1991, PEDIATR RES, V29, P208, DOI 10.1203/00006450-199102000-00021; PLATENBURG GJ, 1994, TRANSGENIC RES, V3, P99, DOI 10.1007/BF01974087; POWELL MJ, 1990, NUCLEIC ACIDS RES, V18, P4013, DOI 10.1093/nar/18.13.4013; REITER B, 1975, IMMUNOLOGY, V28, P83; REY MW, 1990, NUCLEIC ACIDS RES, V18, P5288, DOI 10.1093/nar/18.17.5288; SOUKKA T, 1992, FEMS MICROBIOL LETT, V69, P223; SPIK G, 1994, ADV EXP MED BIOL, V357, P21; STOWELL KM, 1991, BIOCHEM J, V276, P349, DOI 10.1042/bj2760349; vanBerkel PHC, 1996, BIOCHEM J, V319, P117, DOI 10.1042/bj3190117; VANBERKEL PHC, 1995, BIOCHEM J, V312, P107, DOI 10.1042/bj3120107; WANG D, 1995, J LEUKOCYTE BIOL, V57, P865, DOI 10.1002/jlb.57.6.865; WARD PP, 1995, BIO-TECHNOL, V13, P498, DOI 10.1038/nbt0595-498; WU HF, 1995, BLOOD, V85, P421; ZAK B, 1958, AM J CLIN PATHOL, V29, P590; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069	43	52	62	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8802	8807		10.1074/jbc.272.13.8802	http://dx.doi.org/10.1074/jbc.272.13.8802			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079716	hybrid			2022-12-27	WOS:A1997WQ63500099
J	Phelan, ML; Featherstone, MS				Phelan, ML; Featherstone, MS			Distinct HOX N-terminal arm residues are responsible for specificity of DNA recognition by HOX monomers and HOX-PBX heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTOONCOGENE PBX1; CRYSTAL-STRUCTURE; COOPERATIVE INTERACTIONS; SEQUENCE RECOGNITION; HOMEO DOMAIN; TRANSCRIPTIONAL ACTIVATOR; ENGRAILED HOMEODOMAIN; BINDING SPECIFICITY; GENE-PRODUCTS; PROTEIN	Dimerization with extradenticle or PBX homeoproteins dramatically improves DNA binding by HOX transcription factors, indicating that recognition by such complexes is important for HOX specificity. For HOX monomeric binding, a major determinant of specificity is the flexible N-terminal arm. It makes base-specific contacts via the minor groove, including one to the Ist position of a 5'-TNAT-3' core by a conserved arginine (Arg-5). Here we show that Arg-5 also contributes to the stability of HOX PBX complexes, apparently by forming the same DNA contact. We further show that heterodimers of PBX with HOXA1 or HOXD4 proteins have different specificities at another position recognized by the N-terminal arm (the 2nd position in the TNAT core). Importantly, N-terminal arm residues 2 and 3, which distinguish the binding of HOXA1 and HOXD4 monomers, play no role in the specificity of their complexes with PBX In addition, HOXD9 and HOXD10, which are capable of binding both TTAT and TAAT sites as monomers, can cooperate with PBX1A only on a TTAT site. These data suggest that some DNA contacts made by the N-terminal arm are altered by interaction with PBX.	MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,DIV EXPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University			Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KMEMM JD, 1996, GENE DEV, V10, P27; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kuziora M.A., 1991, MECH DEVELOP, V33, P83; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MANAK JR, 1994, DEVELOPMENT, V120, P3605; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; PHELAN ML, 1994, MOL CELL BIOL, V14, P5066, DOI 10.1128/MCB.14.8.5066; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; Sambrook J., 2002, MOL CLONING LAB MANU; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZENG WL, 1993, DEVELOPMENT, V118, P339; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8635	8643		10.1074/jbc.272.13.8635	http://dx.doi.org/10.1074/jbc.272.13.8635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079695	hybrid			2022-12-27	WOS:A1997WQ63500078
J	Rausch, JW; LeGrice, SFJ				Rausch, JW; LeGrice, SFJ			Substituting a conserved residue of the ribonuclease H domain alters substrate hydrolysis by retroviral reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA STRAND TRANSFER; RNASE-H; EXONUCLEASE ACTIVITY; NUCLEOTIDE-SEQUENCE; POINT MUTATIONS; POLYMERASE; SPECIFICITY; TYPE-1; MODULATION	Alterations to the highly conserved Asp(549) Of the retroviral ribonuclease H (RNase H) domain were evaluated in the heterodimeric (p66/p51) reverse transcriptases of human immunodeficiency and equine infectious anemia viruses. In addition to the polymerization-dependent and -independent modes of template hydrolysis, mutants were evaluated via their ability to select and extend the 3' polypurine tract (PPT) primers of these two lentiviruses into (+) strand DNA. Concerted and two-step reactions were designed to evaluate (+) strand priming, the latter of which allows discrimination between selection end extension events. In contrast to enzyme mutated at the highly conserved Glu(478), substitution of Asp(549) With Asn Or Ala reduces, rather than completely eliminates, RNase H activity, When the requirement for RNase H function becomes more stringent, differences in activity are readily evident, most notably in the cleavage events liberating the 5' terminus of the PPT primer. PPT selection thus appears to represent a specialized form of RNase H activity that is more sensitive to minor structural alterations within this domain and may provide a novel therapeutic target.	CASE WESTERN RESERVE UNIV,SCH MED,CTR AIDS RES,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52263] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CIRINO NM, 1993, J BIOL CHEM, V268, P14743; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HUNG SD, 1994, NUCLEIC ACIDS RES, V22, P3426; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6230; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; KAWAKAMI T, 1987, VIROLOGY, V158, P300, DOI 10.1016/0042-6822(87)90202-9; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P293; SMITH JS, 1992, J BIOL CHEM, V267, P15071; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1994, J BIOL CHEM, V269, P8541	38	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8602	8610		10.1074/jbc.272.13.8602	http://dx.doi.org/10.1074/jbc.272.13.8602			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079691	hybrid			2022-12-27	WOS:A1997WQ63500074
J	Wang, R; Wu, LY				Wang, R; Wu, LY			The chemical modification of K-Ca channels by carbon monoxide in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; HISTIDINE-RESIDUES; HEME OXYGENASE; NITRIC-OXIDE; LIVER; IDENTIFICATION; ARTERY; SITE; CHARYBDOTOXIN; INVOLVEMENT	The chemical modification of big conductance calcium-activated potassium (K-Ca) channels in rat tail artery smooth muscle cells by carbon monoxide (CO) was investigated using the cell-free single channel recording technique. Exposure of the internal surface of cell membranes to diethyl pyrocarbonate (DEPC) neither affected the characteristics of K-Ca channels nor modified the stimulatory effect of CO on K-Ca channels. However, when DEPC was applied to the external surface of cell membranes, the open probability of K-Ca channels was reduced. The pH and concentration dependence of the effect of DEPC indicated the specific modification of histidine residues. Kinetic analysis suggested that one externally located histidine residue was modified by DEPC. Treatment of the external surface of cell membranes with DEPC abolished the CO-induced increase in the open probability of K-Ca channels. Likewise, the presence of CO partially protected K-Ca channels from inhibition by DEPC. Moreover, photooxidation of the histidine residue located on the external membrane surface abolished the CO-induced activation of K-Ca channels. Our study demonstrates that the CO-induced increase in the open probability of K-Ca channels may rely specifically on the structure and topological locations of histidine residues.	HOP SACRE COEUR,RES CTR,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal	Wang, R (corresponding author), UNIV MONTREAL,DEPT PHYSIOL,CP 6128,SUCC CTR VILLE,MONTREAL,PQ H3C 3J7,CANADA.		Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620				BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BOSSHARD HR, 1984, J BIOL CHEM, V259, P5683; BOUZAT CB, 1993, PFLUG ARCH EUR J PHY, V423, P365, DOI 10.1007/BF00374929; CHENG KC, 1989, J BIOL CHEM, V264, P19666; CHRISTENSEN BN, 1990, NEURON, V5, P471, DOI 10.1016/0896-6273(90)90086-U; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; DEBIASI M, 1993, BIOPHYS J, V65, P1235, DOI 10.1016/S0006-3495(93)81154-8; EYZAGUIRRE J, 1987, CHEM MODIFICATION EN, P9; FRACE AM, 1992, AM J PHYSIOL, V263, pC1081, DOI 10.1152/ajpcell.1992.263.5.C1081; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; LANGTON PD, 1991, AM J PHYSIOL, V260, pH927, DOI 10.1152/ajpheart.1991.260.3.H927; LEE K, 1994, J MEMBRANE BIOL, V139, P167; LEINDERS T, 1992, PFLUG ARCH EUR J PHY, V422, P223, DOI 10.1007/BF00376206; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, P105; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8087, DOI 10.1021/bi00446a019; MEDINA MA, 1994, BBA-BIOMEMBRANES, V1190, P20, DOI 10.1016/0005-2736(94)90030-2; Miles E W, 1977, Methods Enzymol, V47, P431; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; PISONI RL, 1995, BBA-BIOMEMBRANES, V1236, P23, DOI 10.1016/0005-2736(95)00039-6; RUSCH NJ, 1992, HYPERTENSION, V19, P301, DOI 10.1161/01.HYP.19.4.301; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; VEDERNIKOV YP, 1989, BIOMED BIOCHIM ACTA, V48, P595; WANG R, 1989, AM J PHYSIOL, V256, pH1361, DOI 10.1152/ajpheart.1989.256.5.H1361; WANG R, 1995, CAN J CARDIOL SE, V11, P69; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; ZAKRZEWSKA B, 1992, INT J BIOCHEM, V24, P487, DOI 10.1016/0020-711X(92)90043-Z	32	191	213	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8222	8226		10.1074/jbc.272.13.8222	http://dx.doi.org/10.1074/jbc.272.13.8222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079640	hybrid			2022-12-27	WOS:A1997WQ63500023
J	Browning, DD; Pan, ZK; Prossnitz, ER; Ye, RD				Browning, DD; Pan, ZK; Prossnitz, ER; Ye, RD			Cell type and developmental stage-specific activation of NF-kappa B by fMet-Leu-Phe in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; PROTEIN-KINASES; HL-60 CELLS; PROTEOLYSIS; ALPHA; DIFFERENTIATION; INTERLEUKIN-8	Chemoattractants induce a variety of phagocytic functions including transendothelial migration, degranulation, and the generation of superoxide anions, We report here that the prototypic chemotactic peptide fMet-Leu-Phe (fMLF) stimulates the activation of nuclear factor-kappa B (NF-kappa B), a transcription factor that is central to the regulation of proinflammatory immediate-early gene expression, In freshly prepared peripheral blood mononuclear cells, fMLF (1-100 nM) induced a kappa B binding activity that was receptor-dependent and involved the p50 and p65 subunits of the NF-kappa B/Rel family of proteins, The activation of NF-kappa B by fMLF appeared to be cell-specific and different from the activation of NF-kappa B by tumor necrosis factor alpha (TNF alpha). Neutrophil preparations that responded to fMLF, TNF alpha, and lipopolysaccharides with interleukin-8 secretion did not show NF-kappa B activation, whereas N-formyl peptide receptor (FPR)-transfected HL-60 cells were responsive to TNF alpha but not fMLF for NF-kappa B activation, Differentiation of FPR-transfected HL-60 cells with dimethyl sulfoxide for 3-5 days conferred the capability of the cells to activate NF-kappa B in response to fMLF without a significant increase in the amount of FPR, These results identify NF-kappa B as a transcription factor that can be activated by the prototypic chemotactic peptide and demonstrate that this function is both highly regulated and dependent on signaling components specifically expressed during myeloid differentiation.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016; Prossnitz, Eric R./B-4543-2008	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033503, R29AI036357, R01AI036357, R01AI033503] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36357, AI33503] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; CASSATELLA MA, 1992, J IMMUNOL, V148, P3216; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; IIRI T, 1995, J BIOL CHEM, V270, P5901, DOI 10.1074/jbc.270.11.5901; JACK RM, 1988, J IMMUNOL, V140, P4286; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; MARI B, 1994, J BIOL CHEM, V269, P8517; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STRIETER RM, 1992, AM J PATHOL, V141, P397; TORRES M, 1993, J IMMUNOL, V150, P1563; ULMER AJ, 1979, J IMMUNOL METHODS, V30, P1, DOI 10.1016/0022-1759(79)90268-0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401	37	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7995	8001		10.1074/jbc.272.12.7995	http://dx.doi.org/10.1074/jbc.272.12.7995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065470	hybrid			2022-12-27	WOS:A1997WP59200064
J	Colasanti, M; Cavalieri, E; Persichini, T; Mollace, V; Mariotto, S; Suzuki, H; Lauro, GM				Colasanti, M; Cavalieri, E; Persichini, T; Mollace, V; Mariotto, S; Suzuki, H; Lauro, GM			Bacterial lipopolysacchardie plus interferon-gamma elicit a very fast inhibition of a Ca2+-dependent nitric-oxide synthase activity in human astrocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MESSENGER-RNA EXPRESSION; ENDOTHELIAL-CELLS; NO-SYNTHASE; BINDING; PHOSPHORYLATION; GENERATION; INDUCTION; GENE	Previous results indicate that induction of inducible nitric-oxide synthase (iNOS) expression may be kept suppressed by the endogenous NO level as produced by a constitutive NOS (cNOS) enzyme. In cell types possessing both cNOS and iNOS, this may represent an evident paradox. Here, we report that lipopolysaccharide and interferon-gamma, which are able to strongly induce iNOS in astrocytoma cells, can rapidly inhibit the NO production generated by the constitutive NOS isoform, thus obtaining the best conditions for iNOS induction and resolving the apparent paradox. In fact, a 30-min treatment of T67 cells with the combination of lipopolysaccharide plus interferon-gamma (MM) strongly inhibits the cNOS activity, as determined by measuring [H-3]citrulline production. In addition, the effect of MM is also observed by measuring nitrite, the stable breakdown product of NO: a 30-min pretreatment of T67 cells with MIX is able to reduce significantly the N-methyl-D-aspartate-induced nitrite production. Finally, using reverse transcriptase-polymerase chain reaction, we have observed that a 30-min treatment of T67 cells with MM does not affect expression of mRNA coding for the neuronal NOS-I isoform. These results suggest the novel concept of a possible role of a cNOS isoform in astrocytes as a control function on iNOS induction.	UNIV ROME 3, DEPT BIOL, I-00146 ROME, ITALY; UNIV VERONA, INST BIOL CHEM, I-37134 VERONA, ITALY; UNIV ROMA TOR VERGATA, DEPT BIOL, I-00173 ROME, ITALY	Roma Tre University; University of Verona; University of Rome Tor Vergata			COLASANTI, MARCO/A-5616-2010; mariotto, sofia/AAH-5473-2019	COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; COLASANTI M, 1993, INT J IMMUNOPHARMACO, V15, P763, DOI 10.1016/0192-0561(93)90150-W; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; GRAIER WF, 1994, CIRC RES, V75, P659, DOI 10.1161/01.RES.75.4.659; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kugler P, 1996, GLIA, V16, P165, DOI 10.1002/(SICI)1098-1136(199602)16:2<165::AID-GLIA8>3.3.CO;2-X; LAURO GM, 1986, ACTA NEUROPATHOL, V69, P278, DOI 10.1007/BF00688305; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; MOLLACE V, 1995, BIOCHEM BIOPH RES CO, V215, P793, DOI 10.1006/bbrc.1995.2533; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; PERSICHINI T, 1994, NEUROREPORT, V5, P2477, DOI 10.1097/00001756-199412000-00018; Suzuki H, 1995, ADV NEUROIMMUNOL, V5, P379, DOI 10.1016/0960-5428(95)00024-0; Tracey W.R., 1992, NEUROPROTOCOLS, V1, P125, DOI 10.1016/1058-6741(92)90043-W; WALTER R, 1994, BIOCHEM BIOPH RES CO, V202, P450, DOI 10.1006/bbrc.1994.1949; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	27	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7582	7585		10.1074/jbc.272.12.7582	http://dx.doi.org/10.1074/jbc.272.12.7582			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065411	hybrid			2022-12-27	WOS:A1997WP59200005
J	Lee, SM; Cavallo, L; Griffith, J				Lee, SM; Cavallo, L; Griffith, J			Human p53 binds Holliday junctions strongly and facilitates their cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 ENDONUCLEASE-I; FLUORESCENCE ENERGY-TRANSFER; C-TERMINAL DOMAIN; CELL-CYCLE; DNA-DAMAGE; NUCLEIC-ACIDS; MOUSE CELLS; VISUALIZATION; IRRADIATION; FIBROBLASTS	Holliday junctions in DNA are generated as a product of homologous recombination events, To test the hypothesis that human p53 may bind to Holliday junctions, synthetic junctions with four similar to 75-base pair (Hol(75)) or similar to 565-base pair (Hol(565)) arms were generated, As seen by electron microscopy, under conditions in which 50-61% of the Hol(565) DNAs were bound by p53, 80-96% of the p53 was located specifically at the junction with, in the latter case, only 4% of the p53 visualized at the DNA ends or along the arms. Given the large number of potential binding sites, this represents very high specificity for the junctions. Gel retardation assays using the Hol,, DNA confirm these observations, and indicate that the tight junction complexes have a half-life of greater than 4 h. The binding of p53 to three-way junctions is severalfold less than to four way junctions, Addition of p53 greatly increases the rate of resolution of the Hol,, DNA by T4 endonuclease VII and T7 endonuclease I, two enzymes known to cleave such junctions, This latter finding further confirms the interaction of p53 with Holliday junctions and suggests that p53 binding facilitates their resolution in vivo.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA070343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70343] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALANI E, 1997, IN PRESS J MOL BIOL, V266; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BERTRAND P, 1997, IN PRESS ONCOGENE, V14; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; CLAUS P, 1994, J BIOL CHEM, V269, P33042; COOPER JP, 1990, BIOCHEMISTRY-US, V29, P9261, DOI 10.1021/bi00491a022; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOODSELL DS, 1995, BIOCHEMISTRY-US, V34, P1022, DOI 10.1021/bi00003a037; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HSU MT, 1991, NUCLEIC ACIDS RES, V19, P7193, DOI 10.1093/nar/19.25.7193; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSISCHKY GT, 1996, GENE DEV, V407, P96; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PERRY P, 1975, NATURE, V258, P121, DOI 10.1038/258121a0; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; Pohler JRG, 1996, J MOL BIOL, V260, P678; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wiesmuller L, 1996, J VIROL, V70, P737; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	39	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7532	7539		10.1074/jbc.272.11.7532	http://dx.doi.org/10.1074/jbc.272.11.7532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054458	Green Published, hybrid			2022-12-27	WOS:A1997WN14700097
J	Mazaki, Y; Hashimoto, S; Sabe, H				Mazaki, Y; Hashimoto, S; Sabe, H			Monocyte cells and cancer cells express novel paxillin isoforms with different binding properties to focal adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC VARIANTS; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; KINASE PP125FAK; VINCULIN; FIBRONECTIN; INTEGRINS; GENE	The versatility of integrin functions is mediated by engagement of a number of proteins that assemble with integrins. Among them, paxillin is one of the important molecules interacting with a variety of signaling molecules and cytoskeletal building blocks. We report here that paxillin is not a single molecule with a unique physiological property. We identified two human paxillin isoforms, beta and gamma. These isoforms have distinct amino acid insertions; each consists of a distinct exon, at the same site of previously reported paxillin (paxillin alpha). Several proteins were co-precipitated with paxillin, and we found that beta bound to focal adhesion kinase but weakly to vinculin, and gamma bound to vinculin but only weakly to focal adhesion kinase, although both bound equally to talin. No additional proteins were found to bind to beta and gamma over those binding to alpha. Unlike the alpha isoform, beta and gamma mRNAs were not detected in normal tissues, but several cancer cells expressed both alpha and beta proteins simultaneously. All three isoform proteins were expressed in promonocytic cells with ratios comparable with each other, and the expression patterns were altered during differentiation of floating promonocytic cells into adherent macrophage-like cells. Therefore, each isoform of paxillin exhibits distinct expression and different biochemical as well as physiological properties and thereby appears to act as a distinct module involved in different functions of integrins.	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN; JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYONIE SCI & TECHNOL, KYOTO 61902, JAPAN; OSAKA UNIV, CTR MOL & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	Kyoto University; Japan Science & Technology Agency (JST); Osaka University			Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012	Mazaki, Yuichi/0000-0003-4192-0834				AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; ALBELDA SM, 1990, CANCER RES, V50, P6757; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bauvois B, 1996, EXP CELL RES, V222, P209, DOI 10.1006/excr.1996.0026; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEVRIES JE, 1995, BRIT J CANCER, V71, P271, DOI 10.1038/bjc.1995.55; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FERREIRA OC, 1990, J EXP MED, V171, P351, DOI 10.1084/jem.171.1.351; GIDLUND M, 1981, NATURE, V292, P848, DOI 10.1038/292848a0; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; HARUNA M, 1993, BIOCHEM BIOPH RES CO, V197, P145, DOI 10.1006/bbrc.1993.2453; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABROOK J, 1989, MOL CLONING LAB MANU; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANDEWATER L, 1988, CANCER RES, V48, P5730; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307	57	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7437	7444		10.1074/jbc.272.11.7437	http://dx.doi.org/10.1074/jbc.272.11.7437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054445	hybrid			2022-12-27	WOS:A1997WN14700084
J	PirieShepherd, SR; Stevens, RD; Andon, NL; Enghild, JJ; Pizzo, SV				PirieShepherd, SR; Stevens, RD; Andon, NL; Enghild, JJ; Pizzo, SV			Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN AFFINITY-CHROMATOGRAPHY; HUMAN FACTOR-IX; SIALIC-ACID; JACALIN-AGAROSE; CARBOHYDRATE; OLIGOSACCHARIDES; ACTIVATION; BINDING; VARIANTS; PROTEINS	Human plasminogen, the inactive precursor of plasmin, exists in two major glycoforms. Plasminogen 1 contains an N-linked oligosaccharide at Asn-289 and an O-linked oligosaccharide at Thr-345. Plasminogen 2 is known to contain only an O-linked oligosaccharide at Thr-345. However, plasminogen 2 displays a further well documented microheterogeneity dependent on the N-acetylneuraminic acid content, which has functional consequences with regard to activation of plasminogen. The proposed structure and number of known oligosaccharide linkages in plasminogen 2 is insufficient to account for this microheterogeneity. In the present study, a combination of trypsin digestion, lectin affinity chromatography, Edman degradation amino acid sequence analysis, carbohydrate composition analysis, and mass spectrometry revealed the existence of a novel site for O-linked glycosylation on plasminogen 2 at Ser-248. Direct evidence for the structure of the carbohydrate was obtained from a combination of lectin affinity chromatography, desialylation experiments, and mass spectrometry analysis, These findings provide a structural basis for some of the observed microheterogeneity, and have implications with regard to the known functional consequences of the extent of sialylation of plasminogen.	DUKE UNIV,MED CTR,DEPT PEDIAT,MASS SPECTROMETRY FACIL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHARADWAJ D, 1995, J BIOL CHEM, V270, P6537, DOI 10.1074/jbc.270.12.6537; DAVIDSON DJ, 1993, J CLIN INVEST, V92, P249, DOI 10.1172/JCI116557; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; EDELBERG JM, 1990, J CLIN INVEST, V86, P107, DOI 10.1172/JCI114671; GONZALEZGRONOW M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P269, DOI 10.1016/0167-4838(90)90259-I; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HAYES ML, 1979, J BIOL CHEM, V254, P8768; HAYES ML, 1979, J BIOL CHEM, V254, P8777; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; HORTIN GL, 1994, BLOOD S1, V84, P193; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; MORI K, 1995, J BIOL CHEM, V270, P3261, DOI 10.1074/jbc.270.7.3261; PirieShepherd SR, 1996, FIBRINOLYSIS, V10, P49, DOI 10.1016/S0268-9499(05)80076-1; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; SIEFRING GE, 1974, J BIOL CHEM, V249, P7742	18	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7408	7411		10.1074/jbc.272.11.7408	http://dx.doi.org/10.1074/jbc.272.11.7408			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054441	hybrid			2022-12-27	WOS:A1997WN14700080
J	Katterle, B; Sahlin, M; Schmidt, PP; Potsch, S; Logan, DT; Graslund, A; Sjoberg, BM				Katterle, B; Sahlin, M; Schmidt, PP; Potsch, S; Logan, DT; Graslund, A; Sjoberg, BM			Kinetics of transient radicals in Escherichia coli ribonucleotide reductase - Formation of a new tyrosyl radical in mutant protein R2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PEROXIDASE COMPOUND-ES; RADICAL-DIIRON(III) COFACTOR; MOSSBAUER SPECTROSCOPIES; PHENOTYPIC SELECTION; HYDROGEN-PEROXIDE; SMALL SUBUNIT; FE2+ REACTION; IRON; EPR	Reconstitution of the tyrosyl radical in ribonucleotide reductase protein R2 requires oxidation of a diferrous site by oxygen, The reaction involves one externally supplied electron in addition to the three electrons provided by oxidation of the Tyr-122 side chain and formation of the mu-oxo-bridged diferric site, Reconstitution of R2 protein Y122F, lacking the internal pathway involving Tyr-122, earlier identified two radical intermediates at Trp-107 and Trp-lll in the vicinity of the di-iron site, suggesting a novel internal transfer pathway (Sahlin, Ri,, Lassmann, G., Potsch, S., Sjoberg, B.-M., and Graslund, A. (1995) J. Biol, Chem, 270, 12361-12372), Here, we report the construction of the double mutant W107Y/Y122F and its three dimensional structure and demonstrate that the tyrosine Tyr-107 can harbor a transient, neutral radical (Tyr-107(.)), The Tyr-107(.) signal exhibits the hyperfine structure of a quintet with coupling constants of 1.3 mT for one beta-methylene proton and 0.75 mT for each of the 3 and 5 hydrogens of the phenyl ring, Rapid freeze quench kinetics of EPR-visible intermediates reveal a preferred radical transfer pathway via Trp-lll, Glu-204, and Fe-2, followed by a proton coupled electron transfer through the pi-interaction of the aromatic rings of Trp-(Tyr-)-107 and Trp-lll, The kinetic pattern observed in W107Y/Y122F is considerably changed as compared with Y122F: the Trp-111(.) EPR signal has vanished, and the Tyr-107(.) has the same formation rate as does Trp-111(.) in Y122F, According to the proposed consecutive reaction, Trp-111(.) becomes very short lived and is no longer detectable because of the faster formation of Tyr-107(.). We conclude that the phenyl rings of Trp-lll and Tyr-107 form a better stacking complex so that the proton-coupled electron transfer is facilitated compared with the single mutant, Comparison with the formation kinetics of the stable tyrosyl radical in wild type R2 suggests that these protein-linked radicals are substitutes for the missing Tyr-122, However, in contrast to Tyr-122(.) these radicals lack a direct connection to the radical transfer pathway utilized during catalysis.	UNIV STOCKHOLM,DEPT MOL BIOL,S-10691 STOCKHOLM,SWEDEN; UNIV STOCKHOLM,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN	Stockholm University; Stockholm University			Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V26, P5541; Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; ASCHENBACH H, 1972, CHEM BER, V105, P784; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BERNHARD WA, 1989, J MAGN RESON, V82, P156, DOI 10.1016/0022-2364(89)90176-5; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gray H. B., 1990, ALDRICHIM ACTA, V23, P87; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LINDSTROM B, 1974, J LABELLED COMPD, V10, P187, DOI 10.1002/jlcr.2590100202; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SAHLIN M, 1996, ANNU REV BIOPH BIOM, V25, P259; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P481; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UN S, 1995, J AM CHEM SOC, V117, P10713, DOI 10.1021/ja00148a013; [No title captured]	48	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10414	10421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099682				2022-12-27	WOS:A1997WV26200016
J	Chini, CCS; Grande, JP; Chini, EN; Dousa, TP				Chini, CCS; Grande, JP; Chini, EN; Dousa, TP			Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4 - Regulation of superoxidation and mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PROTEIN-KINASE; SELECTIVE INHIBITORS; AMP; BURST; GENERATION; ISOENZYMES; SUBUNITS; KIDNEY; IV	Some major pathobiologic processes in renal mesangial cells, elicited in response to immunoinflammatory stimuli, are modulated via cAMP-protein kinase A (PKA) signaling pathways; namely, generation of reactive oxygen metabolites (ROM) and accelerated proliferation of mesangial cells. We investigated the role of cAMP phosphodiesterase (PDE) isozymes in these regulatory mechanisms. Generation of ROM in cultured rat mesangial cells was inhibited by selective inhibitors of PDE4, rolipram and denbufylline, whereas PDES inhibitors, cilostamide and lixazinone, had no effect. Conversely, cilostamide or lixazinone suppressed mitogenic synthesis of DNA in mesangial cells, but 1 mu M rolipram or 1 mu M denbufylline showed no inhibitory effect. The efficacy of PDE isozyme inhibitors (IC50) to suppress [H-3]thymidine incorporation or ROM generation paralleled IC50 values for inhibition of cAMP PDE, incubation of mesangial cells with either rolipram alone or with cilostamide alone increased significantly in situ activity of PKA in mesangial cells, assessed by (-cAMP/+cAMP) PKA activity ratio, and the stimulatory effects were additive. Results indicate that in mesangial cells a cAMP pool that is metabolized by PDE4 activates PKA and thereby inhibits ROM generation; another cAMP pool that is metabolized by PDES activates another PKA (isozyme or pool) which suppresses proliferation of mesangial cells, We propose that in mesangial cells, a cAMP-PKA pathway that regulates mitogenesis is determined by activity of PDE3, whereas another cAMP-PKA pathway is directed by activity of PDE4 and controls ROM generation. Therefore, two PDE isozymes within one cell type compartmentalize distinct cAMP signaling pathways.	MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, RENAL PATHOPHYSIOL LAB, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, MAYO MED SCH, DEPT LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic			Grande, Joseph P./AAG-2128-2020	Grande, Joseph P./0000-0001-5674-1682	NIDDK NIH HHS [DK-16105, DK-45280] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016105, R29DK045280] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; ALVAREZ R, 1986, MOL PHARMACOL, V29, P554; ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BAUD L, 1983, J EXP MED, V158, P1836, DOI 10.1084/jem.158.6.1836; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; CHINI CCS, 1994, KIDNEY INT, V46, P28, DOI 10.1038/ki.1994.241; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V215, P868, DOI 10.1006/bbrc.1995.2544; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CORBIN JD, 1983, METHOD ENZYMOL, V99, P227; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; ELKS ML, 1984, ENDOCRINOLOGY, V115, P1262, DOI 10.1210/endo-115-4-1262; GAPSTUR SM, 1988, AM J PHYSIOL, V255, pF292, DOI 10.1152/ajprenal.1988.255.2.F292; GRANDE JP, 1994, J LAB CLIN MED, V124, P112; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; LATTA H, 1992, J AM SOC NEPHROL, V2, pS65; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MANGANIELLO VC, 1986, MECHANISMS INSULIN A, P147; MATOUSOVIC K, 1995, J CLIN INVEST, V96, P401, DOI 10.1172/JCI118049; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; NICHOLSON CD, 1989, BRIT J PHARMACOL, V97, P889, DOI 10.1111/j.1476-5381.1989.tb12029.x; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHMITZPEIFFER C, 1992, CELL SIGNAL, V4, P37, DOI 10.1016/0898-6568(92)90006-T; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SOUNESS JE, 1991, BIOCHEM PHARMACOL, V42, P937, DOI 10.1016/0006-2952(91)90056-B; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsuboi Y, 1996, J CLIN INVEST, V98, P262, DOI 10.1172/JCI118788; Tsuboi Y, 1996, J AM SOC NEPHROL, V7, pA2384; TURNER NC, 1993, BRIT J PHARMACOL, V108, P876, DOI 10.1111/j.1476-5381.1993.tb13481.x; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; WRIGHT CD, 1990, BIOCHEM PHARMACOL, V40, P699, DOI 10.1016/0006-2952(90)90304-4	40	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9854	9859						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092521				2022-12-27	WOS:A1997WU03900040
J	Ferreira, T; Brethes, D; Pinson, B; Napias, C; Chevallier, J				Ferreira, T; Brethes, D; Pinson, B; Napias, C; Chevallier, J			Functional analysis of mutated purine-cytosine permease from Saccharomyces cerevisiae - A possible role of the hydrophilic segment 371-377 in the active carrier conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; MUTANTS; TRANSFORMATION; RECOGNITION; MEMBRANE; MALTOSE; PLASMID; YEAST	The purine-cytosine permease (PCP) is an active transporter located in the plasma membrane of the yeast Saccharomyces cerevisiae, This protein mediates purine (adenine, guanine, and hypoxanthine) and cytosine accumulation in the cell by using an electrochemical potential difference in proton as the energy source. Various mutant strains, with altered K-t(app) (apparent Michaelis constant of transport) of uptake for one or several bases, have already been selected, Their cloning and sequencing revealed that three of them presented substitutions in the same region of the putative sequence of the PCP: this region might correspond to the hydrophilic segment 371-377 (I-A-N-N-I-P-N). Two mutants displayed single mutations, resulting in only one amino acid residue change (N377I and N374I, respectively), and the other displayed three amino acid substitutions (I371V, I375V, and N377G), Therefore, to analyze the contribution of individual amino acid changes to the phenotype of the complex mutant, single (N377G) and double (I371V,I375V) mutants were constructed by site-directed mutagenesis. The influence of single mutations in this region was studied by measuring, for adenine, hypoxanthine, and cytosine, the uptake constants on cells and equilibrium binding parameters on plasma membrane-enriched fractions, Uptake and binding constant determinations showed that all the variations observed for the K-t(app) of uptake were correlated with variations of the binding K-d(app) for the corresponding solutes, Thus, our results emphasize the role of the two asparagine residues, located at positions 374 and 377, respectively, in the binding of the bases, In addition, the sole substitution of the 377 asparagine residue by glycine is responsible for the phenotype of the triple mutant, The effect of pH on the apparent hypoxanthine binding dissociation constant showed that the effects of N377G and N377I changes were, at least partially, due to a shift of the pK(a) of an ionizable amino acid residue of the unliganded permease, These two amino acid residue changes induced a shift of the pK(a) of this group in the unliganded, deprotonated permease about two units toward acidic pH, This result suggests that the 371-377 segment might play a key role in the proper three-dimensional structure of the active purine-cytosine permease.	INST BIOCHIM & GENET CELLULAIRES, CNRS, UPR 9026, F-33077 BORDEAUX, FRANCE	Centre National de la Recherche Scientifique (CNRS)				Pinson, Benoit/0000-0003-2936-9058				BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BLOCH JC, 1992, MOL MICROBIOL, V6, P2989, DOI 10.1111/j.1365-2958.1992.tb01757.x; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRETHES D, 1992, EUR J BIOCHEM, V210, P785, DOI 10.1111/j.1432-1033.1992.tb17481.x; BRETHES D, 1992, EUR J BIOCHEM, V204, P699, DOI 10.1111/j.1432-1033.1992.tb16684.x; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; CHEVALLIER MR, 1975, J BACTERIOL, V122, P629, DOI 10.1128/JB.122.2.629-641.1975; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOSWITZ VC, 1993, MEMBRANE BIOCHEM, V10, P61, DOI 10.3109/09687689309150253; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOPKINS P, 1988, FEMS MICROBIOL LETT, V49, P173; LACROUTE F, 1973, MOL GEN GENET, V125, P319, DOI 10.1007/BF00276587; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; POLAK A, 1973, EUR J BIOCHEM, V32, P276, DOI 10.1111/j.1432-1033.1973.tb02608.x; REICHERT U, 1974, BIOCHIM BIOPHYS ACTA, V356, P108, DOI 10.1016/0005-2736(74)90298-3; REICHERT U, 1975, FEBS LETT, V52, P100, DOI 10.1016/0014-5793(75)80647-8; REICHERT U, 1977, FEBS LETT, V83, P325, DOI 10.1016/0014-5793(77)81033-8; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; RUSSELL ST, 1985, J MOL BIOL, V185, P389, DOI 10.1016/0022-2836(85)90411-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT R, 1984, P NATL ACAD SCI-BIOL, V81, P6276, DOI 10.1073/pnas.81.20.6276; TAN YJ, 1995, J MOL BIOL, V254, P980, DOI 10.1006/jmbi.1995.0670; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x	30	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9697	9702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092500				2022-12-27	WOS:A1997WU03900019
J	Fledelius, C; Johnsen, AH; Cloos, PAC; Bonde, M; Qvist, P				Fledelius, C; Johnsen, AH; Cloos, PAC; Bonde, M; Qvist, P			Characterization of urinary degradation products derived from type I collagen - Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha 1) region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINYL RESIDUES; EHRLICH CHROMOGEN; CROSS-LINKING; ASPARTYL RESIDUES; OSTEOPOROSIS; PROTEINS; PEPTIDES; BONE; ISOASPARTATE; PYRIDINOLINE	The heterogeneity of urinary degradation products of C-terminal telopeptides derived from the alpha 1 chain of human type I collagen was investigated and characterized. The urinary fragments characterized in this study consisted of two cross-linked (X) amino acid sequences derived from the C-terminal telopeptide (alpha 1) of type I collagen. Fragments containing the sequence EXAH-DGGR, with a DG site being either nonisomerized (Asp-Gly) or beta-isomerized (beta Asp-Gly), were identified, Pyr-idinoline was detected among the pyridinium crosslinks, but there was a dominance of deoxypyridinoline and a cross-link containing pyridinoline having a molecular weight identical with that of galactosyl pyridinoline. A nonfluorescent cross-link was also found. The concentration of fragments derived from the C-terminal telopeptide region of type I collagen containing the sequence Asp-Gly (alpha CTX) and/or beta Asp-Gly (beta CTX) was measured by enzyme-linked immunosorbent assays in urine and in collagenase digests of trabecular and cortical bone of young and old origin. It was shown that the urinary ratio between such fragments, alpha CTX/beta CTX, was higher in children compared with adults and that the ratio decreased with increasing age of bone. The results indicated that the C-terminal telopeptide fragments derived from type I collagen excreted into urine originated mainly from bone. In conclusion, it is demonstrated for the first time that the C-terminal telopeptide alpha 1 chain of type I collagen contains an Asp-Gly site prone to undergo beta-isomerization and that the degree of beta-isomerization of this linkage apparently increases with increasing age of bone. These findings indicate that the ratio alpha CTX/beta CTX might be clinically important in diagnosing metabolic bone diseases.	UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	Fledelius, C (corresponding author), OSTEOMETER BIOTECH AS,HERLEV HOVEDGADE 207,DK-2730 HERLEV,DENMARK.			Cloos, Paul/0000-0001-5863-0054				ANTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; BAKHOLDT V, 1989, ANAL BIOCHEM, V177, P318; Bonde M, 1996, CLIN CHEM, V42, P1639; BONDE M, 1995, J CLIN ENDOCR METAB, V80, P864, DOI 10.1210/jc.80.3.864; BONDE M, 1994, CLIN CHEM, V40, P2022; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; COLWELL A, 1990, OSTEOPOROSIS 1990, P590; DELMAS PD, 1993, J BONE MINER RES S2, V8, P549; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; Fledelius C, 1997, SCAND J CLIN LAB INV, V57, P73, DOI 10.1080/00365519709057821; FLEDELIUS C, 1994, CALCIFIED TISSUE INT, V54, P381, DOI 10.1007/BF00305523; GALLETTI P, 1995, BIOCHEM J, V306, P313, DOI 10.1042/bj3060313; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P780, DOI 10.1210/jc.79.3.780; GEIGER T, 1987, J BIOL CHEM, V262, P785; HALEY EE, 1966, BIOCHEMISTRY-US, V5, P3229, DOI 10.1021/bi00874a024; HAYAKAWA Y, 1994, J BIOCHEM-TOKYO, V115, P15, DOI 10.1093/oxfordjournals.jbchem.a124291; HENKEL W, 1987, EUR J BIOCHEM, V165, P427, DOI 10.1111/j.1432-1033.1987.tb11456.x; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; KADLER K, 1994, PROTEIN PROFILES EXT, V1, P512; KIM S, 1980, J BIOL CHEM, V255, P338; Kivirikko K I, 1970, Int Rev Connect Tissue Res, V5, P93; KUHN K, 1982, IMMUNOCHEMISTRY EXTR, P1; KUYPERS R, 1992, BIOCHEM J, V283, P129, DOI 10.1042/bj2830129; LOWENSON J, 1988, BLOOD CELLS, V14, P103; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; OLIYAI C, 1994, PHARMACEUT RES, V11, P751, DOI 10.1023/A:1018944800691; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; REID KBM, 1976, BIOCHEM J, V155, P10; ROBINS SP, 1983, BIOCHEM J, V215, P167, DOI 10.1042/bj2150167; ROBINS SP, 1990, OSTEOPOROSIS 1990, P465; SCOTT JE, 1981, BIOSCIENCE REP, V1, P611, DOI 10.1007/BF01116276; SCOTT JE, 1983, J BIOCHEM-TOKYO, V93, P921, DOI 10.1093/jb/93.3.921; Siris Ethel S., 1993, P375; Termine John D., 1993, P21; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WEISS PH, 1969, J CLIN INVEST, V48, P1, DOI 10.1172/JCI105957	41	166	173	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9755	9763						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092508				2022-12-27	WOS:A1997WU03900027
J	Liu, YC; Liu, YH; Elly, C; Yoshida, H; Lipkowitz, S; Altman, A				Liu, YC; Liu, YH; Elly, C; Yoshida, H; Lipkowitz, S; Altman, A			Serine phosphorylation of Cbl induced by phorbol ester enhances its association with 14-3-3 proteins in T cells via a novel serine-rich 14-3-3-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; V-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; JURKAT CELLS; SH3 DOMAIN; 14-3-3-PROTEINS	Stimulation of the T cell antigen receptor (TCR)-CD3 complex induces rapid tyrosine phosphorylation of Cbl, a protooncogene product which has been implicated in intracellular signaling pathways via its interaction with several signaling molecules. We found recently that Cbl associates directly with a member of the 14-3-3 protein family (14-3-3 tau) in T cells and that the association is increased as a consequence of anti CD3-mediated T cell activation. We report here that phorbol la myristate 13-acetate stimulation of T cells also enhanced the interaction between Cbl and two 14-3-3 isoforms (tau and zeta). Tyrosine phosphorylation of Cbl was not sufficient or required for this increased interaction. Thus, cotransfection of COS cells with Cbl plus Lck and/or Syk family protein-tyrosine kinases caused a marked increase in the phosphotyrosine content of Cbl without a concomitant enhancement of its association with 14-3-3. Phorbol 12-myristate 13-acetate stimulation induced serine phosphorylation of Cbl, and dephosphorylation of immunoprecipitated Cbl by a Ser/Thr phosphatase disrupted its interaction with 14-3-3. By using successive carboxyl-terminal deletion mutants of Cbl, the 14-3-3-binding domain was mapped to a serine-rich 30-amino acid region (residues 615-644) of Cbl. Mutation of serine residues in this region further defined a binding motif distinct from the consensus sequence RSXSXP, which was recently identified as a 14-3-3-binding motif. These results suggest that TCR stimulation induces both tyrosine and serine phosphorylation of Cbl. These phosphorylation events allow Cbl to recruit distinct signaling elements that participate in TCR-mediated signal transduction pathways.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, SAN DIEGO, CA 92121 USA; INST CYTOSIGNAL RES INC, TOKYO 140, JAPAN; NCI, USN, MED ONCOL BRANCH, NATL NAVAL MED CTR, BETHESDA, MD 20889 USA	La Jolla Institute for Immunology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Walter Reed National Military Medical Center				LIU, YUN-CAI/0000-0002-0996-7109	NCI NIH HHS [CA35299] Funding Source: Medline; NIGMS NIH HHS [GM50819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRANJA C, 1991, J BIOL CHEM, V266, P16277; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KEANE MM, 1995, ONCOGENE, V10, P2367; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU YC, 1994, P NATL ACAD SCI USA, V91, P11227, DOI 10.1073/pnas.91.23.11227; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meller N, 1996, MOL CELL BIOL, V16, P5782; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	46	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9979	9985		10.1074/jbc.272.15.9979	http://dx.doi.org/10.1074/jbc.272.15.9979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092538	hybrid			2022-12-27	WOS:A1997WU03900057
J	Bercovich, B; Stancovski, I; Mayer, A; Blumenfeld, N; Laszlo, A; Schwartz, AL; Ciechanover, A				Bercovich, B; Stancovski, I; Mayer, A; Blumenfeld, N; Laszlo, A; Schwartz, AL; Ciechanover, A			Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CONJUGATING ENZYMES; PROTEOLYTIC SYSTEM; RAPID DEGRADATION; ESCHERICHIA-COLI; CARRIER PROTEIN; TRANSFER-RNA; IDENTIFICATION; PURIFICATION; HSP70	Degradation of a protein via the ubiquitin system involves two discrete steps, signaling by covalent conjugation of multiple moieties of ubiquitin and degradation of the tagged substrate. Conjugation is catalyzed via a three-step mechanism that involves three distinct enzymes that act successively: E1, E2, and E3. The first two enzymes catalyze activation of ubiquitin and transfer of the activated moiety to E3, respectively, E3, to which the substrate is specifically bound, catalyzes formation of a polyubiquitin chain that is anchored to the targeted protein. The polyubiquitin-tagged protein is degraded by the 26 S proteasome, and free and reutilizable ubiquitin is released. In addition to the three conjugating enzymes, targeting of certain proteins requires association with ancillary proteins and/or post-translational modification(s). Using a specific antibody to deplete cell extract from the molecular chaperone Hsc70, we demonstrate that this protein is required for the degradation of actin, alpha-crystallin, glyceraldehyde-3-phosphate dehydrogenase, alpha-lactalbumin, and histone H2A. In contrast, the degradation of bovine serum albumin, lysozyme, and oxidized RNase A is Hsc70-independent. Mechanistic analysis revealed that the chaperone is required for the conjugation reaction; however, it does not substitute for E3. Involvement of the chaperone in the proteolytic process requires complex formation with the substrate. Formation of this complex appears to be essential in the proteolytic process. In addition, the proper function of the chaperone in the proteolytic process requires the presence of K+, which allows rapid cycles of dissociation and association of the complex. The chaperone may act by binding to the substrate and unfolding it to expose a ubiquitin ligase-binding site. In addition, it can also act directly on the ubiquitination machinery.	TECHNION ISRAEL INST TECHNOL,FAC MED,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,RAPPAPORT FAMILY INST RES MED SCI,IL-31096 HAIFA,ISRAEL; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,SECT CANC BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,CHILDRENS HOSP,DEPT PEDIAT,ST LOUIS,MO 63110	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)			Ciechanover, Aaron J/C-9166-2017					BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1989, SCIENCE, V246, P282; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DICE JF, 1994, BIOL HEAT SHOCK PROT, P137; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HATTORI H, 1993, J CELL SCI, V104, P629; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Lee DH, 1996, MOL CELL BIOL, V16, P4773; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; OHBA M, 1994, FEBS LETT, V351, P263; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHERMAN MY, 1992, EMBO J, V11, P71; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WORSEN A, 1995, EMBO J, V14, P1867; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679; [No title captured]	47	234	241	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9002	9010						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083024				2022-12-27	WOS:A1997WU03700029
J	Kojima, S; Inui, T; Muramatsu, H; Suzuki, Y; Kadomatsu, K; Yoshizawa, M; Hirose, S; Kimura, T; Sakakibara, S; Muramatsu, T				Kojima, S; Inui, T; Muramatsu, H; Suzuki, Y; Kadomatsu, K; Yoshizawa, M; Hirose, S; Kimura, T; Sakakibara, S; Muramatsu, T			Dimerization of midkine by tissue transglutaminase and its functional implication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ENDOTHELIAL-CELLS; ACID-RESPONSIVE GENE; EPITHELIAL-MESENCHYMAL INTERACTIONS; PLASMINOGEN-ACTIVATOR ACTIVITY; GROWTH-DIFFERENTIATION FACTOR; HEPARIN-BINDING; RETINOIC ACID; CROSS-LINKING; NEURITE OUTGROWTH; TERATOCARCINOMA SYSTEM	Midkine (MK), a retinoic acid-inducible growth/differentiation factor, serves as a substrate for tissue transglutaminase (Kojima, S., Muramatsu, H., Amanuma, H., and Muramatsu, T. 1995. J. Biol. Chem. 270, 9590-9596). Upon incubation with transglutaminase MK forms multimers through cross-linkages. Here, we report the following results. 1) Heparin potentiated the multimer formation by MK. 2) The N- and C-terminal half domains each formed a dimer through the action of transglutaminase. 3) Gln(42) or Gln(44) in the N-terminal half and Gln(95) in the C-terminal half served as amine accepters in the cross-linking reaction, as judged from the incorporation of putrescine into whole MK or each half domain, and the competitive inhibition of the cross-linking by MK-derived peptides containing Gln residue(s). The strongest inhibition was obtained with Ala(41)-Pro(51). 4) This peptide abolished the biological activity of MK to enhance the plasminogen activator activity in bovine aortic endothelial cells. The inhibition was limited against the MK monomer, and not seen against the MK dimer, separated by gel filtration chromatography. These results suggest that dimer formation through transglutaminase-mediated cross-linking is an important step as to the biological activity of MK.	PEPTIDE INST INC,OSAKA 562,JAPAN; NAGOYA UNIV,SCH MED,DEPT BIOCHEM,SHOWA KU,NAGOYA,AICHI 466,JAPAN; TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Nagoya University; Tokyo Institute of Technology	Kojima, S (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,RIKEN,LAB GENE TECHNOL & SAFETY,TSUKUBA,IBARAKI 305,JAPAN.		Kojima, Soichi/N-7104-2015; Kadomatsu, Kenji/G-8083-2012	Kojima, Soichi/0000-0002-5252-1612; 				BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FABRI L, 1992, BIOCHEM INT, V28, P1; FABRI L, 1993, J CHROMATOGR, V646, P213, DOI 10.1016/S0021-9673(99)87023-X; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Gudas Lorraine J., 1994, P443; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Inui T, 1996, J PEPT SCI, V2, P28; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V216, P574, DOI 10.1006/bbrc.1995.2661; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; Mahoney SA, 1996, BIOCHEM BIOPH RES CO, V224, P147, DOI 10.1006/bbrc.1996.0998; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MITSIADIS TA, 1995, J CELL BIOL, V129, P267, DOI 10.1083/jcb.129.1.267; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NARA K, 1989, J BIOL CHEM, V264, P19308; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; SEKIGUCHI K, 1995, J BIOCHEM-TOKYO, V118, P94, DOI 10.1093/oxfordjournals.jbchem.a124898; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1993, CANCER RES, V53, P1281; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YASUHARA O, 1993, BIOCHEM BIOPH RES CO, V192, P246, DOI 10.1006/bbrc.1993.1406; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	51	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9410	9416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083079				2022-12-27	WOS:A1997WU03700084
J	Tucker, C; Goldstein, LSB				Tucker, C; Goldstein, LSB			Probing the kinesin-microtubule interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BETA-TUBULIN; CYTOPLASMIC DYNEIN; ALPHA-TUBULIN; HEAVY-CHAIN; DROSOPHILA KINESIN; ESCHERICHIA-COLI; TERMINAL DOMAIN; ATP HYDROLYSIS; MOTOR DOMAINS	Kinesin is a mechanoenzyme that couples adenosine triphosphate hydrolysis to the generation of force and movement along microtubules. To gain insight into the interactions of kinesin and microtubules, cross-linking, mapping, and proteolysis experiments were executed. The motor domain of kinesin was consistently crosslinked to both alpha- and beta-tubulin subunits. Initial mapping of the cross-linked kinesin suggested that amino acids within the N- and C-terminal cyanogen bromide fragments of the motor domain formed cross-links to both alpha- and beta-tubulin subunits, Mapping of the cross-linked tubulin suggested that cross-linking to kinesin motors occurred within the negatively charged, C-terminal cyanogen bromide fragments of alpha- and beta-tubulin subunits. Treatment of microtubules with subtilisin, a protease that cleaves C-terminal fragments from alpha- and beta-tubulin, reduced their ability to be cross-linked to kinesin motors supporting the idea that C-terminal sequences of alpha- and beta-tubulin may interact with kinesin motors. Finally, of three synthetic peptides, a peptide consisting of the last 12 C-terminal amino acids of beta-tubulin competitively interfered with the microtubule-stimulated adenosine triphosphatase activity of the kinesin motor, further suggesting that C-terminal sequences of beta-tubulin may be involved in kinesin binding.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOL MED,DEPT PHARMACOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35252] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITLING F, 1986, J MOL BIOL, V189, P367, DOI 10.1016/0022-2836(86)90517-6; CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555; COLE DG, 1992, J CELL SCI, V101, P291; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSMITH M, 1991, CELL MOTIL CYTOSKEL, V20, P249, DOI 10.1002/cm.970200308; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GROSS E, 1962, J BIOL CHEM, V237, P1856; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MACCIONI RB, 1986, EUR J BIOCHEM, V156, P375, DOI 10.1111/j.1432-1033.1986.tb09593.x; MARYA PK, 1994, J CELL SCI, V107, P339; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SACKETT DL, 1985, J BIOL CHEM, V260, P10208; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; VONMASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562, DOI 10.1002/cm.970140413; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	47	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9481	9488						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083088				2022-12-27	WOS:A1997WU03700093
J	Cheng, CH; Wang, LK; Sekiguchi, J; Shuman, S				Cheng, CH; Wang, LK; Sekiguchi, J; Shuman, S			Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; DIRECTED MUTAGENESIS; STRAND CLEAVAGE; MUTANT ALLELES; DUPLEX DNA; BINDING; CAMPTOTHECIN; GENE	Vaccinia DNA topoisomerase, a 314-amino acid type I enzyme, catalyzes the cleavage and rejoining of DNA strands through a DNA-(3'-phosphotyrosyl)-enzyme intermediate, To identify amino acids that participate in the transesterification reaction, we introduced alanine substitutions at 39 positions within a conserved 57-amino acid segment upstream of the active-site tyrosine, Purified wild type and mutant proteins were compared with respect to their activities in relaxing supercoiled DNA. The majority of mutant proteins displayed wild type topoisomerase activity, Mutant enzymes that relaxed DNA at reduced rates were subjected to kinetic analysis of the strand cleavage and religation steps under single-turnover and equilibrium conditions, For the wild type topoisomerase, the observed single-turnover cleavage rate constant (k(cl)) was 0.29 s(-1) and the cleavage-religation equilibrium constant (K-cl) was 0.22. The most dramatic mutational effects were seen with R223A; removal of the basic side chain reduced the rates of cleavage and religation by factors of 10(-4.3) and 10(-5.0) respectively, and shifted the cleavage-religation equilibrium in favor of the covalently bound state (K-cl = 1). Introduction of lysine at position 223 restored the rate of cleavage to 1/10 that of the wild type enzyme, We conclude that a basic residue is essential for covalent catalysis and suggest that Arg-223 is a constituent of the active site. Modest mutational effects were observed at two other positions (Lys-220 and Asn-228), at which alanine substitutions slowed the rates of strand cleavage by 1 order of magnitude and shifted the equilibrium toward the noncovalently bound state, Arg-223 and Lys-220 are conserved in all members of the eukaryotic type I topoisomerase family; Asn-228 is conserved among the poxvirus enzymes.	SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Sekiguchi, JoAnn/0000-0002-7178-4258	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caron P R, 1994, Adv Pharmacol, V29B, P271; ENG WK, 1989, J BIOL CHEM, V264, P13373; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; GUPTA M, 1994, J BIOL CHEM, V269, P573; GUPTA M, 1992, J BIOL CHEM, V267, P24177; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; UPTON C, 1990, VIROLOGY, V176, P439, DOI 10.1016/0042-6822(90)90013-H; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Zantinge JL, 1996, J GEN VIROL, V77, P603, DOI 10.1099/0022-1317-77-4-603	30	50	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8263	8269		10.1074/jbc.272.13.8263	http://dx.doi.org/10.1074/jbc.272.13.8263			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079646	hybrid			2022-12-27	WOS:A1997WQ63500029
J	Legan, PK; Rau, A; Keen, JN; Richardson, GP				Legan, PK; Rau, A; Keen, JN; Richardson, GP			The mouse tectorins - Modular matrix proteins of the inner ear homologous to components of the sperm-egg adhesion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TAMM-HORSFALL GLYCOPROTEIN; AMINO-ACID SEQUENCE; EXTRACELLULAR-MATRIX; ELECTRON-MICROSCOPY; MOLECULAR-CLONING; MEMBRANE-PROTEIN; ZONA-PELLUCIDA; DNA; EXPRESSION	The cDNA and derived amino acid sequences for the two major non-collagenous proteins of the mouse tectorial membrane, alpha- and beta-tectorin, are presented. The cDNA for alpha-tectorin predicts a protein of 239,034 Da with 33 potential N-glycosylation sites, and that of beta-tectorin a smaller protein of 36,074 Da with 4 consensus N-glycosylation sites. Southern and Northern blot analysis indicate alpha and beta-tectorin are single copy genes only expressed in the inner ear, and in situ hybridization shows they are expressed by cells both in and surrounding the mechanosensory epithelia. Both sequences terminate with a hydrophobic COOH terminus preceded by a potential endoproteinase cleavage site suggesting the tectorins are synthesized as glycosylphosphatidylinositol-linked, membrane bound precursors, targeted to the apical surface of the inner ear epithelia by the lipid and proteolytically released into the extracellular compartment. The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain. The central, high molecular mass region of alpha-tectorin containing the von Willebrand factor type D repeats has homology with zonadhesin, a sperm membrane protein that binds to the zona pellucida. These results indicate the two major non-collagenous proteins of the tectorial membrane are similar to components of the sperm-egg adhesion system, and, as such may interact in the same manner.	UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Sussex; University of Leeds				Legan, P. Kevin/0000-0002-7403-6415				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGST BD, 1990, J CELL SCI, V97, P247; BAYER ME, 1964, J CELL BIOL, V21, P265, DOI 10.1083/jcb.21.2.265; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; DZIADEK M, 1995, EXPT BASEL, V51, P902; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLETCHER AP, 1970, BIOCHIM BIOPHYS ACTA, V214, P299, DOI 10.1016/0005-2795(70)90007-3; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; Goodyear R, 1996, HEARING RES, V96, P167, DOI 10.1016/0378-5955(96)00045-7; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; GRONDIN G, 1992, EUR J CELL BIOL, V57, P155; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; Killick R, 1997, HEARING RES, V103, P131, DOI 10.1016/S0378-5955(96)00174-8; KILLICK R, 1992, HEARING RES, V64, P21, DOI 10.1016/0378-5955(92)90165-J; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRONESTERFREI A, 1978, CELL TISSUE RES, V193, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; LIM DJ, 1986, HEARING RES, V22, P117, DOI 10.1016/0378-5955(86)90089-4; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCQUEEN EG, 1966, LANCET, V1, P397; OHMORI K, 1982, J CELL BIOL, V95, P632, DOI 10.1083/jcb.95.2.632; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PORTER KR, 1955, J BIOL CHEM, V212, P135; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; SLEPECKY NB, 1992, MATRIX, V11, P80; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENSON FK, 1971, BIOCHIM BIOPHYS ACTA, V236, P59, DOI 10.1016/0005-2795(71)90149-8; TANAKA K, 1975, ANN OTO RHINOL LARYN, V84, P287, DOI 10.1177/000348947508400302; THALMANN I, 1987, LARYNGOSCOPE, V97, P357; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WERSALL J, 1956, Acta Otolaryngol Suppl, V126, P1	57	191	199	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8791	8801		10.1074/jbc.272.13.8791	http://dx.doi.org/10.1074/jbc.272.13.8791			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079715	hybrid			2022-12-27	WOS:A1997WQ63500098
J	Oh, ES; Woods, A; Couchman, JR				Oh, ES; Woods, A; Couchman, JR			Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION FORMATION; BINDING DOMAIN; FIBRONECTIN; FIBROBLASTS; CYTOSKELETAL; ASSOCIATION; ACTIVATION; INTEGRINS; CONTACTS	During cell-matrix adhesion, both tyrosine and serine/threonine kinases are activated. Integrin ligation correlates with tyrosine phosphorylation, whereas the later stages of spreading and focal adhesion and stress fiber formation in primary fibroblasts requires interactions of cell surface proteoglycan with heparin-binding moieties. This correlates with protein kinase C (PKC) activation, and PKC alpha can become localized to focal adhesions in normal, but not transformed, cells. PRC activation has been thought to be downstream of initial receptor-ligand interactions. We now show, however, that syndecan-4 transmembrane heparan sulfate proteoglycan and PKC co-immunoprecipitate and co-patch in vivo. The core protein of syndecan-4 can directly bind the catalytic domain of PKC alpha and potentiate its activation by phospholipid mediators. It can also directly activate PKC alpha in the absence of other mediators. This activity resides in the sequence LGKKPIYKK in the center of the short cytoplasmic domain, and other syndecans lack this sequence and PKC regulatory properties. Syndecan-4 is a focal adhesion component, and this interaction may both localize PKC and amplify its activity at sites of forming adhesions. This represents the first report of direct transmembrane signaling through cell surface proteoglycans.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BEYTH RJ, 1984, EXP CELL RES, V155, P537, DOI 10.1016/0014-4827(84)90213-1; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BURRIDGE K, 1992, J CELL BIOL, V119, P898; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COUCHMAN JR, 1988, J CELL PHYSIOL, V136, P226, DOI 10.1002/jcp.1041360204; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; GALLAGHER JT, 1996, EXTRACELLULAR MATRIX, V2, P230; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LUND KA, 1990, J BIOL CHEM, V265, P20517; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; VUORI K, 1993, J BIOL CHEM, V268, P21456; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277	26	249	255	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8133	8136		10.1074/jbc.272.13.8133	http://dx.doi.org/10.1074/jbc.272.13.8133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079625	hybrid			2022-12-27	WOS:A1997WQ63500008
J	Saito, H; Papaconstantinou, J; Sato, H; Goldstein, S				Saito, H; Papaconstantinou, J; Sato, H; Goldstein, S			Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER SYNDROME; MESSENGER-RNA; COLLAGEN; SEQUENCE; FIBROBLASTS; EXPRESSION; CONTAINS; ASSIGNMENT; INHIBITION; SURFACE	We report here a novel cDNA clone with a predicted protein sequence similar to lysyl oxidase. This full-length cDNA clone of 3432 base pairs (WS9-14) was isolated from human fibroblasts on the basis of its overexpression in senescent cells. It encodes an 87-kDa polypeptide, whose protein is a member of the scavenger receptor cysteine-rich family, because it contains four scavenger receptor cysteine-rich domains that are found in several secreted or cell surface proteins. The WS9-14 protein has a 48% identity with both lysyl oxidase and lysyl oxidase-like protein at a region corresponding to exons 2-6, implying the existence of a lysyl oxidase gene family. The pattern of WS9-14 gene expression by fibroblasts parallels pro-collagen I-alpha 1 expression, Its mRNA level is induced by transforming growth factor beta-1 and indomethacin and inhibited by phorbol ester and retinoic acid. WS9-14 is abundantly expressed in all tumor cell lines examined that attach to culture dishes but not in cell Lines that grow in suspension and is also up-regulated in senescent fibroblasts, These results suggest that WS9-14 gene encodes an extracellular protein that may be specifically involved in cell adhesion and senescence.	UNIV ARKANSAS MED SCI,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET HOSP,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Saito, H (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555, USA.		Papaconstantinou, John/E-3312-2010		NATIONAL INSTITUTE ON AGING [P01AG010514, R01AG008708] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG10514, R01 AG-08708] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HAYFLICK L, 1985, EXP GERONTOL, V20, P145, DOI 10.1016/0531-5565(85)90032-4; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; KAGAN HM, 1994, PATHOL RES PRACT, V190, P910; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREBS CJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P7, DOI 10.1016/0167-4838(93)90056-W; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MAUVIEL A, 1988, FEBS LETT, V231, P125, DOI 10.1016/0014-5793(88)80715-4; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; OIKARINEN H, 1985, J CLIN INVEST, V75, P1545, DOI 10.1172/JCI111859; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; SAITO H, 1991, EXP CELL RES, V192, P373, DOI 10.1016/0014-4827(91)90054-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VAN DE VELDE H, 1991, NATURE, V351, P662; VANGANSEN P, 1988, ARCH GERONTOL GERIAT, V7, P31, DOI 10.1016/0167-4943(88)90021-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; YAMAUCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P898, DOI 10.1016/S0006-291X(88)80124-4	31	96	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8157	8160		10.1074/jbc.272.13.8157	http://dx.doi.org/10.1074/jbc.272.13.8157			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079631	hybrid			2022-12-27	WOS:A1997WQ63500014
J	Tangirala, RK; Murao, K; Quehenberger, O				Tangirala, RK; Murao, K; Quehenberger, O			Regulation of expression of the human monocyte chemotactic protein-1 receptor (hCCR2) by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN ENDOTHELIAL-CELLS; CHEMOATTRACTANT PROTEIN-1; GENE-EXPRESSION; FUNCTIONAL EXPRESSION; INTERFERON-GAMMA; LIGAND-BINDING; CDNA CLONING; THP-1 CELLS; MACROPHAGES	Monocytes enter the subendothelial space in response to a variety of chemotactic agents, notably including monocyte chemotactic protein-1 (MOP-1). To better understand the role of the human MCP-1 receptor (hCCRS) in monocyte recruitment, we have examined the effects of cytokines on expression of the receptor gene by ligand binding and Northern blot analysis. THP-I cells expressed on average about 5000 MCP-I receptors/cell. Differentiation of the cells induced by phorbol myristate acetate resulted in a 75% reduction of receptor gene expression within 2 h. Macrophage colony-stimulating factor had only moderate effect on hCCRS expression. However, interferon gamma inhibited MCP-1 binding by 60% at 48 h. The combination of macrophage colony-stimulating factor and interferon gamma increased the inhibition to 80% at 48 h. This treatment has been shown previously to induce secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin 1 (IL-1) in monocytes. Incubation of THP-1 cells with TNF-alpha and IL-1 induced a rapid downregulation of hCCRS expression and eventual loss of receptor protein. These cytokines exerted their regulatory role at the level of gene transcription. The effect of TNF-alpha alone persisted for 48 h, whereas the cells treated with IL-1 alone regained all of their receptor activity by 48 h. Our results suggest that cytokines can profoundly affect the expression of hCCRS and thus modulate the recruitment of monocytes into sites of acute and chronic inflammation, including the developing atherosclerotic lesion.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007276, P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14197, HL 07276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall CJ, 1996, BIOCHEM J, V313, P633, DOI 10.1042/bj3130633; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; BROWN Z, 1994, AM J PATHOL, V145, P913; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Cohen MC, 1996, AM J CLIN PATHOL, V105, P589; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DATTA R, 1992, BLOOD, V79, P904; DENHOLM EM, 1995, CYTOKINE, V7, P436, DOI 10.1006/cyto.1995.0059; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANCI C, 1995, J IMMUNOL, V154, P6511; GRAVES DT, 1995, CRIT REV ORAL BIOL M, V6, P109, DOI 10.1177/10454411950060020101; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; JIANG YL, 1992, J IMMUNOL, V148, P2423; KIMBALL ES, 1995, J LEUKOCYTE BIOL, V58, P585, DOI 10.1002/jlb.58.5.585; Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603; Maniatis T, 1989, DECONTAMINATION DILU; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OPPENHEIM JJ, 1993, ADV EXP MED BIOL, V351, P183; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SCHEIBENBOGEN C, 1991, J LEUKOCYTE BIOL, V50, P35, DOI 10.1002/jlb.50.1.35; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; SICA A, 1990, J IMMUNOL, V144, P3034; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VOSE JM, 1995, J CLIN ONCOL, V13, P1023, DOI 10.1200/JCO.1995.13.4.1023; YAMAGAMI S, 1994, BIOCHEM BIOPH RES CO, V202, P1156, DOI 10.1006/bbrc.1994.2049; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	48	94	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8050	8056		10.1074/jbc.272.12.8050	http://dx.doi.org/10.1074/jbc.272.12.8050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065478	hybrid			2022-12-27	WOS:A1997WP59200072
J	Bai, WL; Rowan, BG; Allgood, VE; OMalley, BW; Weigel, NL				Bai, WL; Rowan, BG; Allgood, VE; OMalley, BW; Weigel, NL			Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; PROTEIN KINASE-A; GROWTH-FACTOR-I; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; ADENOVIRUS PARTICLES; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; AGONIST ACTIVITY	Many steroid receptors, including chicken progesterone receptor, have been shown to be activated in the absence of their cognate ligands by modulators of kinases and phosphatases. To investigate the molecular mechanism of ligand-independent activation, chicken progesterone receptor mutants in which either one or all four of the previously identified phosphorylation sites have been changed to nonphosphorylatable alanine were analyzed for their ability to be activated by progesterone, 8-bromoadenosine 3':5'-cyclic monophosphate, or a dopamine agonist, SKF82958. Our current study shows that the receptor is differently phosphorylated in ligand-dependent and ligand-independent activation. The transcriptional activity of the receptor in response to 8-bromoadenosine 3':5'-cyclic monophosphate is affected by mutation of either Ser(211) or Ser(260). In addition, our data demonstrated that none of the four sites is absolutely required for the activation of the receptor by either 8-bromoadenosine 3':5'-cyclic monophosphate or the dopamine agonist. Treatment with 8-bromoadenosine 3':5'-cyclic monophosphate did not increase the overall level of receptor phosphorylation or cause phosphorylation of the receptor at alternate sites. These data raise the possibility that ligand-independent activation of the chicken progesterone receptor may be mediated through changes in the phosphorylation of coregulators or other protein factors interacting with the receptors.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NICHD NIH HHS [HD22061, HD07857, HD07495] Funding Source: Medline; NIDDK NIH HHS [F32 DK009151] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022061, P30HD007495, R37HD007857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009151] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRIAN S, 1988, GENE, V67, P271; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; COTTEN M, 1994, VIROLOGY, V205, P254, DOI 10.1006/viro.1994.1641; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANSRA V, 1995, EUR J PHARM-MOLEC PH, V289, P391, DOI 10.1016/0922-4106(95)90119-1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MENDEL DB, 1987, J BIOL CHEM, V262, P5641; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NIZNIK HB, 1992, J PSYCHIATR NEUROSCI, V17, P158; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; ONATE SA, 1995, SCIENCE, V270, P1354; Pedarzani P, 1995, J NEUROPHYSIOL, V74, P2749, DOI 10.1152/jn.1995.74.6.2749; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577	63	51	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10457	10463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099688				2022-12-27	WOS:A1997WV26200022
J	Barleon, B; Totzke, F; Herzog, C; Blanke, S; Kremmer, E; Siemeister, G; Marme, D; MartinyBaron, G				Barleon, B; Totzke, F; Herzog, C; Blanke, S; Kremmer, E; Siemeister, G; Marme, D; MartinyBaron, G			Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; ANGIOGENESIS; PLACENTA; EXPRESSION; SUPERFAMILY; CANCER; KDR	The vascular endothelial growth factor (VEGF) receptor FLT-1 has been shown to be involved in vasculogenesis and angiogenesis. The receptor is characterized by seven Ig-like loops within the extracellular domain, Upon VEGF binding FLT-1 becomes phosphorylated, which has been thought to be preceded by receptor dimerization, To further investigate high affinity binding of VEGF to FLT-1 and ligand-induced receptor dimerization, we expressed in Sf9 cells the entire extracellular domain comprising all seven Ig-like loops: sFLT-1(7) and several truncated mutants consisting of loop one, one and two, one to three, one to four, and one to five, The corresponding proteins, named sFLT-1(1), (2), (3), (4), and (5) were purified, Only mutants sFLT-1(3) to (7) were able to bind I-125-VEGF With high affinity, No binding of VEGF was observed with sFLT-1(1) and sFLT-1(2), indicating that the first three Ig-like loops are involved in high affinity binding of VEGF, The binding of VEGF to sFLT-1(3) could be competed with placenta growth factor (PlGF), a VEGF-related ligand, suggesting that high affinity binding of VEGF and PlGF is mediated by the same or closely related contact sites on sFLT-1. Deglycosylation of the sFLT-1(3), (4), (5), and (7) did not abolish VEGF binding, Furthermore, unglycosylated sFLT-1(3), expressed in Escherichia coli, was able to bind VEGF with similar affinity as sFLT-1(3) or sFLT-1(7), both expressed in Sf9 cells, This indicates that receptor glycosylation is not essential for high affinity binding, Dimerization of the extracellular domains of FLT-1 upon addition of VEGF was detected with all mutants containing the Ig-like loop four, Although sFLT-1(3) was able to bind VEGF, dimerization of this mutant was inefficient, indicating that sites on Ig-Like loop four are essential to stabilize receptor dimers.	TUMOR BIOL CTR, INST MOL MED, D-79106 FREIBURG, GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				, Gerhard/0000-0002-4712-0531				BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERREN B, 1993, J BIOL CHEM, V268, P15088; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PARK JE, 1994, J BIOL CHEM, V269, P25646; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	32	177	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10382	10388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099677				2022-12-27	WOS:A1997WV26200011
J	Breen, GAM; Jordan, EM				Breen, GAM; Jordan, EM			Regulation of the nuclear gene that encodes the alpha-subunit of the mitochondrial F0F1-ATP synthase complex - Activation by upstream stimulatory factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; LOOP-HELIX PROTEIN; DNA-BINDING; MAMMALIAN-CELLS; BETA-SUBUNIT; PROMOTER; EXPRESSION; DOMAIN; FORMS; MYC	We have previously identified several positive cis-acting regulatory regions in the promoters of the bovine and human nuclear-encoded mitochondrial F0F1-ATP synthase oc subunit genes (ATPA). One of these cis-acting regions contains the sequence 5'-CACGTG-3' (an E-box), to which a number of transcription factors containing a basic helix-loop helix motif can bind, This E-box element is required for maximum activity of the ATPA promoter in HeLa cells, The present study identifies the human transcription factor, upstream stimulatory factor 2 (USF2), as a nuclear factor that binds to the ATPA E-box and demonstrates that USF2 plays a critical role in the activation of the ATPA gene in vivo. Evidence includes the following, Antiserum directed against USF2 recognized factors present in HeLa nuclear extracts that interact with the ATPA promoter in mobility shift assays. Wild-type USF2 proteins synthesized from expression vectors trans-activated the ATPA promoter through the E-box, whereas truncated USF2 proteins devoid of the amino-terminal activation domains did not, Importantly, expression of a dominant-negative mutant of USF2 lacking the basic DNA binding domain but able to dimerize with endogenous USF proteins significantly reduced the level of activation of the ATPA promoter caused by ectopically coexpressed USF2, demonstrating the importance of endogenous USF2 in activation of the ATPA gene.			Breen, GAM (corresponding author), UNIV TEXAS,DEPT MOL & CELL BIOL,FO 31,POB 830688,RICHARDSON,TX 75088, USA.							ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AYER DE, 1993, CELL, V72, P221; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Breen GAM, 1996, GENE EXPRESSION, V5, P181; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P9; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIN Q, 1994, J BIOL CHEM, V269, P23894; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Moore DD, 1995, GLOB MOB SURV; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Seelan RS, 1996, J BIOL CHEM, V271, P2112, DOI 10.1074/jbc.271.4.2112; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VANDERZEE CA, 1994, J BIOL CHEM, V269, P6972; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10538	10542						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099698				2022-12-27	WOS:A1997WV26200032
J	Lamkin, TD; Walk, SF; Liu, L; Damen, JE; Krystal, G; Ravichandran, KS				Lamkin, TD; Walk, SF; Liu, L; Damen, JE; Krystal, G; Ravichandran, KS			Shc interaction with Src homology 2 domain containing inositol phosphatase (SHIP) in vivo requires the Shc-phosphotyrosine binding domain and two specific phosphotyrosines on SHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEIN; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; PTB DOMAIN; GRB2; ASSOCIATION; ACTIVATION	The adapter protein She has been implicated in mitogenic signaling via growth factor receptors, cytokine receptors, and antigen receptors on lymphocytes. Besides the well characterized interaction of She with molecules involved in Pas activation, She also associates with a 145-kDa tyrosine-phosphorylated protein upon triggering via antigen receptors and many cytokine receptors. This 145-kDa protein has been recently identified as an SH2 domain containing 5'-inositol phosphatase (SHIP) and has been implicated in the regulation of growth and differentiation in hematopoietic cells. In this report, we have addressed the molecular details of the interaction between She and SHIP in vivo. During T cell receptor signaling, tyrosine phosphorylation of SHIP and its association with She occurred only upon activation. We demonstrate that the phosphotyrosine binding domain of She is necessary and sufficient for its association with tyrosine-phosphorylated SHIP. Through site-directed mutagenesis, we have identified two tyrosines on SHIP, Tyr-917, and Tyr-1020, as the principal contact sites for the Shc-phosphotyrosine binding domain. Our data also suggest a role for the tyrosine kinase Lck in phosphorylation of SHIP. We also show that the SH2 domain of SHIP is dispensable for the She-SHIP interaction in vivo. These data have implications for the localization of the Shc-SHIP complex and regulation of SHIP function during T cell receptor signaling.	UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	University of Virginia; University of Virginia; British Columbia Cancer Agency				Krystal, Gerald/0000-0002-1961-6281	NIAID NIH HHS [AI07496-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Durstin M, 1996, J IMMUNOL, V157, P534; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; ROSS TS, 1991, J BIOL CHEM, V266, P20283; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; ZHOU M, 1995, J BIOL CHEM, V271, P31119; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHUNG X, 1996, P NATL ACAD SCI USA, V92, P5853	51	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10396	10401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099679				2022-12-27	WOS:A1997WV26200013
J	PerezEstevez, A; DiazJullien, C; Covelo, G; Salgueiro, MT; Freire, M				PerezEstevez, A; DiazJullien, C; Covelo, G; Salgueiro, MT; Freire, M			A 180-kDa protein kinase seems to be responsible for the phosphorylation of prothymosin alpha observed in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; CASEIN KINASE-2; RAT THYMUS; GENE; TISSUES; SITE; THYMOSIN-ALPHA-1; PARATHYMOSIN; EXPRESSION; NUCLEI	Prothymosin alpha (ProT alpha) is an acidic protein involved in cell proliferation, Its phosphorylation status is correlated with proliferative activity. Here we report the isolation and characterization of a ProT alpha-phosphorylating kinase (ProT alpha K) from mouse splenocytes that seems to be responsible for the in vivo phosphorylation of ProT alpha and that differs from other protein kinases reported to date, This enzyme, mainly located in the cytosol, has an molecular mass of 180 kDa and appears to be made up of two proteins of 64 and 60 kDa. Its activity was markedly enhanced by mitogenic activation of cells. The ProT alpha residues phosphorylated by the enzyme in vitro are a Thr at position 7 and another Thr at positions 12 or 13, both located within casein kinase 2 (CK-2) consensus motifs; these are the same residues as are phosphorylated in vivo. The new enzyme shows a number of clear structural and catalytic differences from CK-2, It phosphorylates histones H2B and H3, although with weaker activity than ProT alpha. An enzyme with the same characteristics was also found in other murine tissues and cell lines.	UNIV SANTIAGO, FAC BIOL, DEPT BIOQUIM & BIOL MOL, SANTIAGO DE COMPOSTELA 15706, SPAIN	Universidade de Santiago de Compostela			Diaz-Jullien, Cristina/L-4575-2018	Diaz-Jullien, Cristina/0000-0002-4307-8129				BARCIA MG, 1993, J BIOL CHEM, V268, P4704; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; ECONOMOU M, 1988, FEBS LETT, V233, P342, DOI 10.1016/0014-5793(88)80456-3; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FRANCO FJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P43, DOI 10.1016/0167-4838(92)90422-A; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P3853; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; HARITOS AA, 1989, FEBS LETT, V244, P287, DOI 10.1016/0014-5793(89)80547-2; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; INOUE A, 1984, BIOCHEM BIOPH RES CO, V123, P398, DOI 10.1016/0006-291X(84)90427-3; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAELANDSMO GM, 1989, EUR J BIOCHEM, V184, P529, DOI 10.1111/j.1432-1033.1989.tb15046.x; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; MOL PC, 1995, MOL CELL BIOL, V15, P6949; MORI M, 1993, ONCOGENE, V8, P2821; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SMITH MR, 1995, LEUKEMIA LYMPHOMA, V18, P209, DOI 10.3109/10428199509059609; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6	43	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10506	10513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099694				2022-12-27	WOS:A1997WV26200028
J	Rourke, IJ; Johnsen, AH; Din, NN; Petersen, JGL; Rehfeld, JF				Rourke, IJ; Johnsen, AH; Din, NN; Petersen, JGL; Rehfeld, JF			Heterologous expression of human cholecystokinin in Saccharomyces cerevisiae - Evidence for a lysine-specific endopeptidase in the yeast secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PREPRO-ALPHA-FACTOR; MOLECULAR NATURE; HUMAN-PLASMA; MF-ALPHA; GENE; CLEAVAGE; PROCHOLECYSTOKININ; PEPTIDES; PRODUCTS	Precursors of the human regulatory peptide cholecystokinin (CCK) have been expressed in Saccharomyces cerevisiae, and the post-translational processing of secreted CCH-related products analyzed. Recombinant plasmids expressing native human prepro-CCK and a hybrid molecule encompassing the prepro leader of the yeast alpha-mating pheromone fused to pro-CCK were examined. The latter construct resulted in considerably higher levels of pro-CCK secretion and was therefore analyzed in more detail. Two of the protein modifications essential for CCK bioactivity, C-terminal alpha-amidation and tyrosyl sulfation, were not detected in S. cerevisiae. Proteolytic cleavage of pro-CCK occurred C-terminally of three basic sites; (i) Arg(105)-Arg(106) which, upon exposure to carboxypeptidase activity, leads to the production of glycine-extended CCK; (ii) Arg(95) to produce CCK-8 related processing intermediates; and (iii) Lys(81) resulting in CCK-22 related products. To elucidate which protease(s) are involved in these endoproteolytic cleavage events, pro-CCK was expressed in yeast mutants lacking various combinations of the Mkc7, Yap3, and Kex2 proteases, Only in S. cerevisiae strains deficient in Kex2 function was any of the above mentioned pro-CCK cleavages abolished, namely processing at the Arg(105)-Arg(106) and Arg(95) sites. This suggests that mammalian Kex2-like serine proteases may process pro-CCK at single arginine residues. Our data suggests that an as yet uncharacterized endopeptidase(s) in the S. cerevisiae secretory pathway is responsible for the lysine-specific cleavage of pro-CCK.	UNIV COPENHAGEN, RIGSHOSP, DEPT CLIN BIOCHEM, COPENHAGEN O, DENMARK; NOVO NORDISK AS, DK-2880 BAGSVAERD, DENMARK	Rigshospitalet; University of Copenhagen; Novo Nordisk								ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BOURBONNAIS Y, 1994, BIOCHIMIE, V76, P226, DOI 10.1016/0300-9084(94)90150-3; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CANTOR P, 1987, CLIN CHIM ACTA, V168, P153, DOI 10.1016/0009-8981(87)90284-1; Cawley NX, 1996, J BIOL CHEM, V271, P4168; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; DOURISH CT, 1987, TRENDS PHARMACOL SCI, V8, P207, DOI 10.1016/0165-6147(87)90062-9; DRIEDONKS RA, 1995, YEAST, V11, P849, DOI 10.1002/yea.320110907; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; EBERLEIN GA, 1992, J BIOL CHEM, V267, P1517; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GALANOPOULOU AS, 1995, BIOCHEM J, V309, P33, DOI 10.1042/bj3090033; HADFIELD C, 1993, MYCOL RES, V97, P897, DOI 10.1016/S0953-7562(09)80859-9; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; HILSTED L, 1986, ANAL BIOCHEM, V152, P119, DOI 10.1016/0003-2697(86)90129-6; HINES V, 1994, CELL MOL BIOL RES, V40, P273; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10753; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MARTINEZ J, 1986, J MED CHEM, V29, P2201, DOI 10.1021/jm00161a012; MIYAJIMA A, 1986, EMBO J, V5, P1193, DOI 10.1002/j.1460-2075.1986.tb04346.x; MOODY AJ, 1987, FEBS LETT, V212, P302, DOI 10.1016/0014-5793(87)81365-0; PALOHEIMO LI, 1995, CLIN CHIM ACTA, V238, P21, DOI 10.1016/0009-8981(95)06055-I; PALOHEIMO LI, 1994, CLIN CHIM ACTA, V229, P49, DOI 10.1016/0009-8981(94)90228-3; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; REHFELD JF, 1978, J BIOL CHEM, V253, P4016; REHFELD JF, 1994, SCAND J GASTROENTERO, V29, P110, DOI 10.3109/00365529409090448; REHFELD JF, 1988, BIOCHIMIE, V70, P25, DOI 10.1016/0300-9084(88)90155-1; REHFELD JF, 1978, J BIOL CHEM, V253, P4022; RIEHLBELLON N, 1989, BIOCHEMISTRY-US, V28, P2941, DOI 10.1021/bi00433a030; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TAKAHASHI Y, 1986, GENE, V50, P353; TALBO G, 1993, RAPID COMMUN MASS SP, V7, P201, DOI 10.1002/rcm.1290070307; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; VOLLENWEIDER F, 1995, DIABETES, V44, P1075, DOI 10.2337/diabetes.44.9.1075; ZHANG HY, 1994, J BIOL CHEM, V269, P27799; ZHU YS, 1992, MOL MICROBIOL, V6, P511, DOI 10.1111/j.1365-2958.1992.tb01496.x; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9720	9727						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092503				2022-12-27	WOS:A1997WU03900022
J	Shofuda, K; Yasumitsu, H; Nishihashi, A; Miki, K; Miyazaki, K				Shofuda, K; Yasumitsu, H; Nishihashi, A; Miki, K; Miyazaki, K			Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; IV COLLAGENASE; MESSENGER-RNA; STROMAL CELLS; DEGRADING METALLOPROTEINASES; ARTERIAL INJURY; GROWTH-FACTOR; HUMAN COLON; ACTIVATION; GENE	Matrix metalloproteinases (MMPs) produced by rat smooth muscle cells (SMCs) were investigated. SMCs expressed three kinds of membrane type MMP, MT1-MMP, MT2-MMP, and MT3-MMP, and the MT-MMP expression was stimulated by the presence of serum. MT3-MMP was characterized further by cloning its cDNA. A rat MT3-MMP cDNA encoding 607 amino acids and a cDNA for its transmembrane domainless variant MT3-MMP-del were cloned from a rat SMC cDNA library; a human MT3-MMP cDNA was cloned from a fetal brain cDNA library. Human brain MT3-MMP was similar but not identical to the previously reported human placenta MT3-MMP (94.4% homology). When the MT3-MMP cDNA was expressed in COS-7 cells, endogenous progelatinase A was processed to the mature form. The transfection of rat MT3-MMP-del efficiently converted progelatinase A to the intermediate form but not to the mature one, indicating that the transmembrane domain is important for the complete processing of progelatinase A to maturation. Both MT3-MMP-del and MT3-MMP hydrolyzed gelatin and casein, indicating their broad substrate specificity. Results of experiments with a synthetic MMP inhibitor suggested that MT3-MMP-del and MT3-MMP are rapidly degraded immediately after maturation, The present study suggests that multiple forms of MMPs including MT3-MMP are involved in the matrix remodeling of blood vessels.	YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,DIV CELL BIOL,TOTSUKA KU,YOKOHAMA,KANAGAWA 244,JAPAN; TERUMO RES & DEV CTR,INST BIOMED SCI,NAKAI,KANAGAWA 25901,JAPAN	Yokohama City University								Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BENDECK MP, 1994, CIRC RES, V75, P539, DOI 10.1161/01.RES.75.3.539; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1986, J VASC SURG, V3, P877, DOI 10.1067/mva.1986.avs0030877; CLOWES AW, 1986, LAB INVEST, V54, P295; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; Kinoshita T, 1996, CANCER RES, V56, P2535; KISHI J, 1989, CONNECT TISSUE RES, V19, P63, DOI 10.3109/03008208909016815; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MONSKY WL, 1993, CANCER RES, V53, P3159; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; Puente XS, 1996, CANCER RES, V56, P944; PYKE C, 1993, AM J PATHOL, V142, P359; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SOUTHGATE KM, 1992, BIOCHEM J, V288, P93, DOI 10.1042/bj2880093; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YANAGI H, 1991, ATHEROSCLEROSIS, V91, P207, DOI 10.1016/0021-9150(91)90168-3; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; ZEMPO N, 1994, J VASC SURG, V20, P209, DOI 10.1016/0741-5214(94)90008-6	49	107	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9749	9754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092507				2022-12-27	WOS:A1997WU03900026
J	Xiao, WH; Kolla, V; Kalvakolanu, DV				Xiao, WH; Kolla, V; Kalvakolanu, DV			Modulation of interferon action by retinoids - Induction of murine STAT1 gene expression by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAINS; THYROID-HORMONE; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; OXYTOCIN PROMOTER; GENOMIC STRUCTURE; DIRECT REPEATS; RXR-BETA	We have previously demonstrated that up regulation of STAT1 protein by all-trans-retinoic acid (RA) in interferon (IFN)-unresponsive cells permits growth inhibition by IFNs. Here, we show that the promoter of STAT1 directly responds to retinoic acid treatment, Sequence and functional analysis of the murine STAT1 promoter have identified a direct repeat motif that serves as a retinoic acid response: element, Mutagenesis of this element resulted in a loss of response to RA. This element is activated by RA receptors alpha, beta, and gamma. In vivo, RA receptor beta and retinoid X receptor alpha preferentially interacted with this element. Thus, these data define a molecular basis for the synergy between IFNs and retinoids in tumor growth inhibition.	UNIV MARYLAND,CTR CANC,DEPT MICROBIOL & IMMUNOL,PROGRAM ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,MOL & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326				AGUET M, 1981, VIROLOGY, V114, P585, DOI 10.1016/0042-6822(81)90241-5; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KALVAKOLANU DVR, 1993, P NATL ACAD SCI USA, V90, P3167, DOI 10.1073/pnas.90.8.3167; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KATO S, 1995, MOL CELL BIOL, V15, P5858; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RICHARD S, 1991, J BIOL CHEM, V266, P21428; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	39	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9742	9748		10.1074/jbc.272.15.9742	http://dx.doi.org/10.1074/jbc.272.15.9742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092506	hybrid			2022-12-27	WOS:A1997WU03900025
J	Yu, WP; Liu, JJ; Morrice, NA; Wettenhall, REH				Yu, WP; Liu, JJ; Morrice, NA; Wettenhall, REH			Isolation and characterization of a structural homologue of human PRK2 from rat liver - Distinguishing substrate and lipid activator specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FATTY-ACID; PURIFICATION; QUANTITATION; EXPRESSION; DOMAIN	A homologue of human protein kinase C (PKC)-related kinase-2, PRK2, which had previously escaped identification in normal mammalian tissues, was isolated from rat liver as the protease-activated kinase (PAK) originally named PAK-2. The 130-kDa cytosolic enzyme was purified to homogeneity and shown by tryptic peptide and reverse transcriptase- polymerase chain reaction (RT-PCR)-amplified rat cDNA sequence analyses to be structurally related to the 116-kDa rat hepatic PAK-1/protein kinase N (PKN) and, even more closely (95% sequence identity) to the 130-kDa human PKC-related kinase, PRK2. Rat myeloma RNA was used as the RT-PCR template because of its relative abundance in PAR-2/PRK2 mRNA compared with liver and other rat tissues. The catalytic properties of PAK-2/PRK2 in many respects resembled those of hepatic PAK-1/PKN, but were distinguished by more favorable kinetics with several peptide substrates, and greater sensitivity to PKC pseudosubstrate and polybasic amino acid inhibitors. PAK-2/PRK2 was also activated by lipids, particularly cardiolipin and to a lesser extent by other acidic phospholipids and unsaturated fatty acids. Cardiolipin activation was most evident with autophosphorylation and histone H2B phosphorylation, but only marginally evident with the favored ribosomal S6-(229-239) peptide substrate for the protease-activated kinase activity. It was concluded that PAK-2 is the rat homologue of human PRK2, with biochemical properties distinct from although overlapping those of the PAK-1/PKN/PRK1 isoform.	UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne								Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GABRIELLI B, 1984, FEBS LETT, V175, P219, DOI 10.1016/0014-5793(84)80740-1; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1996, P NATL ACAD SCI USA, V93, P10195, DOI 10.1073/pnas.93.19.10195; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ORR JW, 1994, J BIOL CHEM, V269, P8383; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; PALMER RH, 1995, J BIOL CHEM, V270, P22242; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WETTENHALL REH, 1991, PEPTIDE RES, V4, P159; WISE BC, 1982, J BIOL CHEM, V257, P8481	29	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10030	10034						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092545				2022-12-27	WOS:A1997WU03900064
J	Yuan, Y; Crane, DC; Musser, JM; Sreevatsan, S; Barry, CE				Yuan, Y; Crane, DC; Musser, JM; Sreevatsan, S; Barry, CE			MMAS-1, the branch point between cis- and trans-cyclopropane-containing oxygenated mycolates in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; MYCOLIC ACID PATTERNS; CELL-WALL; IDENTIFICATION; CHELONAE; CHROMATOGRAPHY; PERMEABILITY; BIOSYNTHESIS; RESISTANCE; SMEGMATIS	The proportion of mycolic acid containing trans-substituents at the proximal position of the meromycolate chain is an important determinant of fluidity of the mycobacterial cell wall and is directly related to the sensitivity of mycobacterial species to hydrophobic antibiotics. MMAS-1, an enzyme encoded in the gene cluster responsible for the biosynthesis of methoxymycolates, was overexpressed in Mycobacterium tuberculosis and shown to result in the overproduction of trans-cyclopropane and trans-olefin-containing oxygenated mycolic acids. MMAS-1 converted a cis-olefin into a trans-olefin with concomitant introduction of an allylic methyl branch in a precursor to both the methoxy and ketone-containing mycolic acids. In addition to an increase in the amount of trans-mycolate, MMAS-1 expression resulted in a substantial increase in the amount of ketomycolate produced relative to methoxymycolate. Thus MMAS-1 may act at a complex branch point where expression of this enzyme directly affects the cis- to trans-ratio and indirectly affects the keto to methoxy ratio. Overexpression of MMAS-1 resulted in a substantially slower growth rate at moderately elevated temperature, decreased thermal stability of the cell wall as measured by differential scanning calorimetry, and an increased permeability to chenodeoxycholate. These results provide experimental evidence for the intermediacy of trans-olefinic mycolate precursors in trans-cyclopropane formation and suggest that increasing the proportion of the polar ketomycolate subclass may exert a significant fluidizing effect on the cell wall.	NIAID,ROCKY MT LABS,TB RES UNIT,LAB INTRACELLULAR PARASITES,NIH,HAMILTON,MT 59840; BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine			Barry, III, Clifton/H-3839-2012; Sreevatsan, Srinand/V-6808-2019; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Sreevatsan, Srinand/0000-0002-5162-2403; Barry, Clifton E/0000-0002-2927-270X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI-37004] Funding Source: Medline; NIDA NIH HHS [DA-09238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALDOVINI A, 1993, J BACTERIOL, V175, P7282, DOI 10.1128/JB.175.22.7282-7289.1993; ASSELINEAU J, 1950, NATURE, V166, P782, DOI 10.1038/166782a0; Barry CE, 1996, TRENDS MICROBIOL, V4, P275, DOI 10.1016/0966-842X(96)10031-7; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P2620, DOI 10.1128/AAC.39.12.2620; DAVIDSON LA, 1982, J GEN MICROBIOL, V128, P823; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; HAMID ME, 1993, J GEN MICROBIOL, V139, P2203, DOI 10.1099/00221287-139-9-2203; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; JENKINS PA, 1982, BIOL MYCOBACTERIA, V1, P441; KANEDA K, 1986, J CLIN MICROBIOL, V24, P1060, DOI 10.1128/JCM.24.6.1060-1070.1986; LEDERER E, 1969, Q REV CHEM SOC, V23, P453, DOI 10.1039/qr9692300453; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Melian A, 1996, CURR OPIN IMMUNOL, V8, P82, DOI 10.1016/S0952-7915(96)80109-9; MINNIKIN DE, 1980, J CHROMATOGR, V188, P221, DOI 10.1016/S0021-9673(00)88433-2; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; MINNIKIN DE, 1984, J GEN MICROBIOL, V130, P363; MINNIKIN DE, 1967, CHEM COMMUN, V785, P916; MINNIKIN DE, 1967, CHEM COMMUN, V1064, P1172; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SRINAND S, 1996, 96 GEN M AM SOC MICR, P112; STECK PA, 1978, J BIOL CHEM, V253, P5625; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1979, BIOL BIOMEDICAL APPL, V10, P91; TAKAYAMA K, 1984, MYCOBACTERIA SOURCEB, V15, P315; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828	37	76	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10041	10049						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092547				2022-12-27	WOS:A1997WU03900066
J	Zhang, FL; Kirschmeier, P; Carr, D; James, L; Bond, RW; Wang, L; Patton, R; Windsor, WT; Syto, R; Zhang, RM; Bishop, WR				Zhang, FL; Kirschmeier, P; Carr, D; James, L; Bond, RW; Wang, L; Patton, R; Windsor, WT; Syto, R; Zhang, RM; Bishop, WR			Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYLTRANSFERASE INHIBITORS; TRANSFORMING ACTIVITY; SELECTIVE-INHIBITION; KINETIC MECHANISM; CAAX MOTIF; P21RAS; PRENYLATION; SPECIFICITY; EXPRESSION; GROWTH	Ras proteins are small GTP-binding proteins which are critical for cell signaling and proliferation, Four Ras isoforms exist: Ha Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B. The carboxyl termini of all four isoforms are post-translationally modified by farnesyl protein transferase (FPT). Prenylation is required for oncogenic Ras to transform cells, Recently, it was reported that Ki-Ras4B is also an in vitro substrate for the related enzyme geranylgeranyl protein transferase-1 (GGPT-1) (James, G. L., Goldstein, J. L., and Brown, M. S. (1995) J. Biol. Chem. 270, 6221-6226), In the current studies, we compared the four isoforms of Ras as substrates for FPT and GGPT-1, The affinity of FPT for Ki-Ras4B (K-m = 30 nM) is 10-20-fold higher than that for the other Ras isoforms, Consistent with this, when the different Ras isoforms are tested at equimolar concentrations, it requires 10-20-fold higher levels of CAAX-competitive compounds to inhibit Ki-Ras4B farnesylation. Additionally, we found that, as reported for Ki-Ras4B, N-Ras and Ki-Ras4A are also in vitro substrates for GGPT-1. Of the Ras isoforms, N-Ras is the highest affinity substrate for GGPT-1 and is similar in affinity to a standard GGPT-1 substrate terminating in leucine, However, the catalytic efficiencies of these geranylgeranylation reactions are between 15- and 140-fold lower than the corresponding farnesylation reactions, largely reflecting differences in affinity. Carboxyl-terminal peptides account for many of the properties of the Ras proteins, One interesting exception is that, unlike the full-length N-Ras protein, a carboxyl-terminal N-Ras peptide is not a GGPT-1 substrate, raising the possibility that upstream sequences in this protein may play a role in its recognition by GGPT-1. Studies with various carboxyl-terminal peptides from Ki-Ras4B suggest that both the carboxyl-terminal methionine and the upstream polylysine region are important determinants for geranylgeranylation. Furthermore, it was found that full-length Ki-Ras4B, but not other Ras isoforms, can be geranylgeranylated in vitro by FPT. These findings suggest that the different distribution of Ras isoforms and the ability of cells to alternatively process these proteins mag explain in part the resistance of some cell lines to FPT inhibitors.	SCHERING PLOUGH RES INST,DEPT TUMOR BIOL K 15 4700,KENILWORTH,NJ 07033; SCHERING PLOUGH RES INST,DEPT STRUCT CHEM,KENILWORTH,NJ 07033	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute				Zhang, Rumin/0000-0002-6590-6036				ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1993, J BIOL CHEM, V268, P11548; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEON J, 1987, MOL CELL BIOL, V4, P1493; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MANNE V, 1995, ONCOGENE, V10, P1763; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	42	171	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10232	10239						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092572				2022-12-27	WOS:A1997WU03900091
J	BirchenallRoberts, MC; Yoo, YD; Bertolette, DC; Lee, KH; Turley, JM; Bang, OS; Ruscetti, FW; Kim, SJ				BirchenallRoberts, MC; Yoo, YD; Bertolette, DC; Lee, KH; Turley, JM; Bang, OS; Ruscetti, FW; Kim, SJ			The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; RETINOBLASTOMA GENE-PRODUCT; HUMAN MYC PROMOTER; LARGE T-ANTIGEN; S-PHASE ENTRY; V-ABL; CELL-CYCLE; C-ABL; NEOPLASTIC TRANSFORMATION; TRANS-ACTIVATION	The E2F family of transcription factors regulates cell cycle progression, and deregulated expression of E2F-1 can lead to neoplastic transformation. In myeloid cells, introduction and expression of the Abelson leukemia virus causes growth factor independence. Here, the p120 v-Abl protein activates E2F-1-mediated transcription through a physical interaction with the E2F-1 transcription factor. BCR-Abl and c-Abl also stimulate ESF-1-mediated transcription. Our results suggest a new mechanism by which v-Abl leads to factor-independent myeloid cell proliferation: the activation of E2F-1-mediated transcription.	NCI,CHEMOPREVENT LAB,DIV BASIC SCI,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,LAB LEUKOCYTE BIOL,DIV BASIC SCI,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES SUPPORT PROGRAM,SAIC FREDERICK,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ABELSON HT, 1970, CANCER RES, V30, P2213; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BIRCHENALLROBER, 1996, ONCOGENE, V13, P1499; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLER JR, 1990, ONCOGENE, V5, P549; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RISSER R, 1988, P SOC EXP BIOL MED, V188, P235; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	62	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8905	8911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083010				2022-12-27	WOS:A1997WU03700015
J	DeMali, KA; Whiteford, CC; Ulug, ET; Kazlauskas, A				DeMali, KA; Whiteford, CC; Ulug, ET; Kazlauskas, A			Platelet-derived growth factor-dependent cellular transformation requires either phospholipase C gamma or phosphatidylinositol 3 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; FACTOR RECEPTOR-BETA; ALPHA-PDGF RECEPTOR; EXPRESSION; BINDING; SUBUNIT; VECTORS; SIGNAL; VIRUS; CELLS	Although it has been well established that constitutive activation of receptor tyrosine kinases leads to cellular transformation, the signal relay pathways involved have not been systematically investigated. In this study we used a panel of platelet-derived growth factor (PDGF) beta receptor mutants (beta-PDGFR), which selectively activate various signal relay enzymes to define which signaling pathways are required for PDGF-dependent growth of cells in soft agar. The host cell line for these studies was Ph cells, a 3T3-like cell that expresses normal levels of the beta-PDGFR but no PDGF-alpha receptor (alpha-PDGFR). Hence, this cell system can be used to study signaling of mutant alpha PDGFRs or alpha/beta chimeras. We constructed chimeric receptors containing the alpha PDGFR extracellular domain and the beta PDGFR cytoplasmic domain harboring various phosphorylation site mutations. The mutants were expressed in Ph cells, and their ability to drive PDGF-dependent cellular transformation (growth in soft agar) was assayed. Cells infected with an empty expression vector failed to grow in soft agar, whereas introduction of the chimera with a wild-type beta-PDGFR cytoplasmic domain gave rise to a large number of colonies. In contrast, the N(2)F5 chimera, in which the binding sites for phospholipase C gamma (PLC-gamma), Ras-GTPase-activating protein, phosphatidylinositol 3 kinase (PI3K), and SHP-2 were eliminated, failed to trigger proliferation. Restoring the binding sites for Ras-GTPase-activating protein or SHP-2 did not rescue the PDGF-dependent response. In contrast, receptors capable of associating with either PLC-gamma or PI3K relayed a growth signal that was comparable to wild-type receptors in the soft agar growth assay. These findings indicate that the PDGF receptor activates multiple signaling pathways that lead to cellular transformation, and that either PI3K or PLC-gamma are key initiators of such signal relay cascades.	HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; KANSAS STATE UNIV,DIV BIOL,MED VIROL & ONCOL,MANHATTAN,KS 66506	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kansas State University				DeMali, Kris/0000-0003-0906-1371	NCI NIH HHS [CA58291] Funding Source: Medline; NIGMS NIH HHS [GM-48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZENET CE, 1994, ONCOGENE, V9, P517; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOLUB TR, 1994, CELL, V77, P1; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HRC, 1994, J BIOL CHEM, V269, P30604; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VASSBOTN FS, 1993, MOL CELL BIOL, V13, P4066, DOI 10.1128/MCB.13.7.4066; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WHITEFORD CC, 1996, IN PRESS BIOCH J; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	27	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9011	9018						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083025				2022-12-27	WOS:A1997WU03700030
J	Labhart, P				Labhart, P			Transcript cleavage in an RNA polymerase I elongation complex - Evidence for a dissociable activity similar to but distinct from TFIIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL GENE-TRANSCRIPTION; FACTOR-S-II; FACTOR-SII; INITIATION; PURIFICATION; IDENTIFICATION; TERMINATION; SEQUENCE; OOCYTES; CLONING	Stalled Xenopus RNA polymerase I (pol I) elongation complexes bearing a 52-nucleotide RNA were prepared by promoter-initiated transcription in the absence of UTP. When such complexes were isolated and incubated in the presence of Mg2+, the associated RNA was shortened from the 3'-end, and mono- and dinucleotides were released. Shortened transcripts were still associated with the DNA and were quantitatively reelongated upon addition of NTPs. The cleavage activity could be removed from the pol I-ternary complex with buffers containing 0.25% Sarkosyl. These findings indicate that a factor with characteristics similar to elongation factor TFIIS is associated with the pol I elongation complex. However, addition of recombinant Xenopus TFIIS to Sarkosyl-washed pol I elongation complexes had no effect, whereas it showed the expected effects in control reactions with identically prepared pol II elongation complexes. The results thus suggest the existence of a pol I-specific cleavage/elongation factor. I also report the sequence of a novel type of Xenopus TFIIS. The predicted amino acid sequences of the present and previously identified Xenopus TFIIS are less than 65% conserved. Thus, like mammalian species, Xenopus has at least two highly divergent forms of TFIIS.			Labhart, P (corresponding author), Scripps Res Inst, DEPT MOL & EXPT MED, SBR 10, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; Kugawa F, 1996, BIOCHEM BIOPH RES CO, V222, P541, DOI 10.1006/bbrc.1996.0780; Labhart P, 1996, FEBS LETT, V386, P110, DOI 10.1016/0014-5793(96)00420-6; LABHART P, 1995, NUCLEIC ACIDS RES, V23, P2252, DOI 10.1093/nar/23.12.2252; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; Labhart Paul, 1992, Gene Expression, V2, P409; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1973, J BIOCHEM, V73, P879, DOI 10.1093/oxfordjournals.jbchem.a130150; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; REEDER RH, 1992, TRANSCRIPTIONAL REGU, P315; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; SAWADOGO M, 1981, BIOCHEMISTRY-US, V20, P3542, DOI 10.1021/bi00515a037; SCHNAPP G, 1994, EMBO J, V13, P4028, DOI 10.1002/j.1460-2075.1994.tb06719.x; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WIEST DK, 1992, J BIOL CHEM, V267, P7733; XU QH, 1994, J BIOL CHEM, V269, P3100	42	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9055	9061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083031				2022-12-27	WOS:A1997WU03700036
J	Sathyamoorthy, M; deMendez, I; Adams, AG; Leto, TL				Sathyamoorthy, M; deMendez, I; Adams, AG; Leto, TL			p40(phox) down-regulates NADPH oxidase activity through interactions with its SH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CYTOSOLIC COMPONENT; ACTIVATION; COMPLEX; P67(PHOX); P47(PHOX); PROTEINS; P67-PHOX; RECONSTITUTION; P47-PHOX	The NADPH oxidase of phagocytes generates microbicidal oxidants in response to a variety of stimuli. Its activation and assembly involve multiple SH3 domain interactions among several oxidase components. Here we present evidence that the cytosolic oxidase-associated protein, p40(phox), mediates down-regulation of NADPH oxidase through interactions with its SH3 domain, Recombinant p40(phox) was produced in several eukaryotic expression systems (insect, mammalian, and yeast) to explore its role in oxidase function in relation to domains involved in interactions with other factors, p47(phox) and p67(phox). p40(phox) inhibited oxidase activity in vitro when added to neutrophil membranes and recombinant p47(phox), P67(phox) and p21rac. Co-transfection of p40(phox) into R562 cells resulted in significant decreases (similar to 40%) in whole cell oxidase activity. Furthermore, the isolated SH3 domain of p40(phox) was even more effective in inhibiting whole cell oxidase activity, consistent with experiments showing that this domain binds to the same proline-rich target in p47(phox) (residues 358-390) that interacts with p67(phox). In contrast, deletion of the carboxyl-terminal domain of p40(phox) that binds to p67(phox) did not relieve its oxidase inhibitory effects, Thus, p40(phox) appears to down-regulate oxidase function by competing with an SH3 domain interaction between other essential oxidase components.	NIAID,HOST DEF LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DUSI S, 1996, BIOCHEM J, V308, P991; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; Leto T. L., 1995, Molecular Biology of the Cell, V6, p241A; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; WEINTJES FB, 1996, BIOCHEM J, V3217, P919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; XU XM, 1994, J BIOL CHEM, V269, P23569	35	95	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9141	9146						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083043				2022-12-27	WOS:A1997WU03700048
J	Spicer, AP; Olson, JS; McDonald, JA				Spicer, AP; Olson, JS; McDonald, JA			Molecular cloning and characterization of a cDNA encoding the third putative mammalian hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE	We report the isolation of a cDNA encoding the third putative hyaluronan synthase, HAS3. Partial cDNAs and genomic fragments of mouse Has3 were obtained using a degenerate polymerase chain reaction approach. Partial clones facilitated the isolation of genomic and cDNA clones representing the mouse Has3 open reading frame. The open reading frame of 554 amino acids predicted a protein of 63.3 kDa with multiple transmembrane domains and several consensus HA binding motifs. Sequence comparisons indicated that mouse Has3 is most closely related to Has2 (71% amino acid identity) and also related to Has1 (57% identity), Xenopus laevis DG42 (56% identity), and Streptococcus pyogenes HasA (28% identity). Isolation of a genomic fragment of human HAS3 indicated high conservation between mouse and human sequences, similar to those observed for HAS1 and HAS2. Expression of the mouse Has3 open reading frame in transfected COS-1 cells led to high levels of hyaluronan synthesis, as determined through a classical particle exclusion assay, and by in vitro HA synthase assays. These results suggest that there are three putative mammalian hyaluronan synthases encoded by three separate but related genes which comprise a mammalian hyaluronan synthase (HAS) gene family.			Spicer, AP (corresponding author), MAYO CLIN SCOTTSDALE,DEPT BIOCHEM & MOL BIOL,13400 E SHEA BLVD,SCOTTSDALE,AZ 85259, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009311] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 F32 HL09311-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barny MA, 1996, MOL MICROBIOL, V19, P443, DOI 10.1046/j.1365-2958.1996.382911.x; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; HELDERMON C, 1996, GLYCOBIOLOGY, V6, P741; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; SPICER AP, 1997, IN PRESS GENOMICS; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; [No title captured]	26	146	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8957	8961						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083017				2022-12-27	WOS:A1997WU03700022
J	Stockert, RJ; Ren, Q				Stockert, RJ; Ren, Q			Cytoplasmic protein mRNA interaction mediates cGMP-modulated translational control of the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; SUBUNIT MESSENGER-RNAS; CYCLIC-GMP; GENE-EXPRESSION; HEAVY-SUBUNIT; BINDING; CELLS; PHOSPHODIESTERASES; GLUCOKINASE; ADHESION	Expression of the asialoglycoprotein receptor by the human hepatocellular carcinoma cell line HuH-7 in response to intracellular cGMP concentrations was previously shown to be regulated at the translational level. In a cell-free system, initiation of asialoglycoprotein receptor mRNA translation was dependent on the presence of the 7-methylguanylate cap site and was independent of 8-bromo-cGMP levels in which the cells were grown prior to RNA isolation. Stable transfection of COS-7 cells with deletion constructs of the asialoglycoprotein receptor H2b subunit localized the cGMP-responsive cis-acting element to the mRNA 5'-untranslated region (UTR). Addition of biotin (an activator of guanylate cyclase) induced the expression of beta-galactosidase present as a chimeric plasmid containing the H2b 187-nucleotide 5'-UTR An RNA gel retardation assay identified a 37-nucleotide cognate sequence within this 187-nucleotide region. Titration of the 5'-UTR with a cytosolic fraction isolated from HuH-7 grown in the presence or absence of 8-bromo-cGMP or biotin provided direct evidence for an RNA-binding protein responsive to intracellular levels of cGMP. Based on these findings, it seems reasonable to propose that reduction of intracellular levels of cGMP by biotin deprivation results in a negative trans-acting factor associating with the 5'-UTR of asialoglycoprotein receptor mRNAs, thereby inhibiting translation.			Stockert, RJ (corresponding author), ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, DEPT MED, 1300 MORRIS PK AVE, ULLMANN 517, NEW YORK, NY 10461 USA.				NIDDK NIH HHS [DK41296, DK32972] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK032972] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERGER LC, 1992, BIOCHEM CELL BIOL, V70, P770, DOI 10.1139/o92-117; BRASS EP, 1993, PHARMACOL TOXICOL, V72, P369, DOI 10.1111/j.1600-0773.1993.tb01346.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS JC, 1988, HEPATOLOGY, V8, P108, DOI 10.1002/hep.1840080122; COLLINS JC, 1988, J BIOL CHEM, V263, P11280; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DRICKAMER K, 1992, CURR OPIN STRUC BIOL, V2, P653; GUDOSHNIKOV V I, 1991, Byulleten' Eksperimental'noi Biologii i Meditsiny, V111, P478; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JANSEN M, 1995, PEDIATR RES, V37, P681, DOI 10.1203/00006450-199506000-00001; KEAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; PAIETTA E, 1989, J IMMUNOL, V143, P2850; PAIETTA E, 1988, CANCER RES, V48, P280; PITTNER RA, 1986, BIOCHEM J, V240, P253, DOI 10.1042/bj2400253; RASHED HM, 1992, ARCH BIOCHEM BIOPHYS, V298, P640, DOI 10.1016/0003-9861(92)90460-E; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; SPENCE JT, 1981, J BIOL CHEM, V256, P1598; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1993, J BIOL CHEM, V268, P19540; STOCKERT RJ, 1992, J BIOL CHEM, V267, P56; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WEISZ OA, 1991, J CELL BIOL, V115, P495, DOI 10.1083/jcb.115.2.495; WHALIN ME, 1991, MOL PHARMACOL, V39, P711; WU GY, 1983, P NATL ACAD SCI-BIOL, V80, P3078, DOI 10.1073/pnas.80.10.3078; WU GY, 1991, BIOTHERAPY, V3, P87, DOI 10.1007/BF02175102	41	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9161	9165						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083046				2022-12-27	WOS:A1997WU03700051
J	Weitzmann, MN; Woodford, KJ; Usdin, K				Weitzmann, MN; Woodford, KJ; Usdin, K			DNA secondary structures and the evolution of hypervariable tandem arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC REGION ADOPTS; MOUSE MINISATELLITE LOCUS; REPETITIVE NONCODING DNA; TELOMERE-BINDING-PROTEIN; FRAGILE-X SYNDROME; TRINUCLEOTIDE REPEAT; CGG REPEAT; SPONTANEOUS MUTATION; SOMATIC MUTATION; TRIPLET REPEAT	Tandem repeats are ubiquitous in nature and constitute a major source of genetic variability in populations. This variability is associated with a number of genetic disorders in humans including triplet expansion diseases such as Fragile X syndrome and Huntington's disease. The mechanism responsible for the variability/instability of these tandem arrays remains contentious. We show here that formation of secondary structures, in particular intrastrand tetraplexes, is an intrinsic property of some of the more unstable arrays. Tetraplexes block DNA polymerase progression and may promote instability of tandem arrays by increasing the likelihood of reiterative strand slippage. In the course of doing this work we have shown that some of these tetraplexes involve unusual base interactions. These interactions not only generate tetraplexes with novel properties but also lead us to conclude that the number of sequences that can form stable tetraplexes might be much larger than previously thought.	NIDDK, SECT GENOM STRUCT & FUNCT, CELLULAR & MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ARMOUR JAL, 1993, HUM MOL GENET, V2, P1137, DOI 10.1093/hmg/2.8.1137; ARMOUR JAL, 1989, NUCLEIC ACIDS RES, V17, P4925, DOI 10.1093/nar/17.13.4925; ARMOUR JAL, 1995, P ROY SOC B-BIOL SCI, V261, P345, DOI 10.1098/rspb.1995.0157; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; Bell G I, 1982, Prog Clin Biol Res, V103 Pt A, P57; BRERETON HM, 1993, NUCLEIC ACIDS RES, V21, P2563, DOI 10.1093/nar/21.11.2563; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHARETTE MF, 1986, NUCLEIC ACIDS RES, V14, P3343, DOI 10.1093/nar/14.8.3343; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; EICHLER EE, 1995, HUM MOL GENET, V4, P2199, DOI 10.1093/hmg/4.12.2199; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FERRER N, 1995, J MOL BIOL, V245, P8, DOI 10.1016/S0022-2836(95)80034-4; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; HAMMONDKOSACK MCU, 1993, J MOL ENDOCRINOL, V10, P121, DOI 10.1677/jme.0.0100121; HAMMONDKOSACK MCU, 1992, J MOL ENDOCRINOL, V9, P221, DOI 10.1677/jme.0.0090221; HAMMONDKOSACK MCU, 1992, FEBS LETT, V301, P79, DOI 10.1016/0014-5793(92)80214-2; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; HORN GT, 1991, NUCLEIC ACIDS RES, V19, P4772, DOI 10.1093/nar/19.17.4772; Howell R, 1997, MOL BIOL EVOL, V14, P144, DOI 10.1093/oxfordjournals.molbev.a025747; Howell RM, 1996, J BIOL CHEM, V271, P5208; HUANG LS, 1987, J BIOL CHEM, V262, P8952; JARMAN AP, 1989, TRENDS GENET, V5, P367, DOI 10.1016/0168-9525(89)90171-6; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KELLY R, 1991, P ROY SOC B-BIOL SCI, V245, P235, DOI 10.1098/rspb.1991.0115; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Ling GN, 1984, SEARCH PHYSICAL BASI, P227; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; NURNBERG P, 1989, HUM GENET, V84, P75, DOI 10.1007/BF00210676; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; ROSS PD, 1964, BIOPOLYMERS, V2, P79, DOI 10.1002/bip.1964.360020111; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STEPHAN W, 1989, MOL BIOL EVOL, V6, P198, DOI 10.1093/oxfordjournals.molbev.a040542; STEPHAN W, 1994, GENETICS, V136, P333, DOI 10.1093/genetics/136.1.333; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; Weitzmann MN, 1996, J BIOL CHEM, V271, P20958, DOI 10.1074/jbc.271.34.20958; WELLS RD, 1993, GENOME ANAL, V7, P107; WILLARD HF, 1989, GENOME, V31, P737, DOI 10.1139/g89-132; Willard HF, 1991, CURR OPIN GENET DEV, V1, P509, DOI 10.1016/S0959-437X(05)80200-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; WOODFORD K, 1995, NUCLEIC ACIDS RES, V23, P539, DOI 10.1093/nar/23.3.539; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	73	62	63	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9517	9523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083093				2022-12-27	WOS:A1997WU03700098
J	Faergeman, NJ; DiRusso, CC; Elberger, A; Knudsen, J; Black, PN				Faergeman, NJ; DiRusso, CC; Elberger, A; Knudsen, J; Black, PN			Disruption of the Saccharomyces cerevisiae homologue to the murine fatty acid transport protein impairs uptake and growth on long-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ACYL-COA-SYNTHETASES; BINDING-PROTEIN; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; N-MYRISTOYLATION; RAT-LIVER; PREADIPOCYTE DIFFERENTIATION; PHOSPHOLIPID-BILAYERS; CANDIDA-TROPICALIS	The yeast Saccharomyces cerevisiae is able to utilize exogenous fatty acids for a variety of cellular processes including beta-oxidation, phospholipid biosynthesis, and protein modification, The molecular mechanisms that govern the uptake of these compounds in S. cerevisiae have not been described, We report the characterization of FAT1, a gene that encodes a putative membrane-bound long-chain fatty acid transport protein (Fat1p). Fat1p contains 623 amino acid residues that are 33% identical and 54% with similar chemical properties as compared with the fatty acid transport protein FATP described in 3T3-L1 adipocytes (Schaffer and Lodish (1994) Cell 79, 427-436), suggesting a similar function. Disruption of FAT1 results in 1) an impaired growth in YPD medium containing 25 mu M cerulenin and 500 mu M fatty acid (myristate (C-14:0), palmitate (C-16:0), or oleate (C-18:1)); 2) a marked decrease in the uptake of the fluorescent long-chain fatty acid analogue boron dipyrromethene difluoride dodecanoic acid (BODIPY-3823); 3) a reduced rate of exogenous oleate incorporation into phospholipids; and 4) a 2-3-fold decrease in the rates of oleate uptake, These data support the hypothesis that Fat1p is involved in long-chain fatty acid uptake and may represent a long-chain fatty acid transport protein.	ALBANY MED COLL, DEPT BIOCHEM & MOL BIOL, ALBANY, NY 12208 USA; UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ODENSE UNIV, INST BIOCHEM, DK-5230 ODENSE, DENMARK; UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA	Albany Medical College; University of Tennessee System; University of Tennessee Health Science Center; University of Southern Denmark; University of Tennessee System; University of Tennessee Health Science Center			DiRusso, Concetta C/M-1884-2014	Faergeman, Nils/0000-0002-9281-5287; Black, Paul/0000-0002-6272-6881				ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ANDREASEN AA, 1953, J CELL COMPAR PHYSL, V41, P23, DOI 10.1002/jcp.1030410103; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BLACK PN, 1995, BIOCHEM J, V310, P389, DOI 10.1042/bj3100389; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi JY, 1996, J BIOL CHEM, V271, P3581; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaiser C., 1994, METHODS YEAST GENETI; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOHLWEIN SD, 1984, BIOCHIM BIOPHYS ACTA, V792, P310, DOI 10.1016/0005-2760(84)90198-X; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; McHale MW, 1996, YEAST, V12, P319, DOI 10.1002/(SICI)1097-0061(19960330)12:4<319::AID-YEA914>3.3.CO;2-R; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SLOOTS JA, 1991, GENE, V105, P129, DOI 10.1016/0378-1119(91)90524-F; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; TIGRATTI BL, 1996, BIOCHEM J, V313, P487; TRIGATTI BL, 1992, BIOCHEM CELL BIOL, V70, P76, DOI 10.1139/o92-011; Trotter PJ, 1996, J LIPID RES, V37, P336; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; WANG TW, 1994, J BIOL CHEM, V269, P24480; ZHOU SL, 1995, P SOC EXP BIOL MED, V208, P263	49	128	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8531	8538		10.1074/jbc.272.13.8531	http://dx.doi.org/10.1074/jbc.272.13.8531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079682	hybrid			2022-12-27	WOS:A1997WQ63500065
J	Inui, T; Ishibashi, O; Inaoka, T; Origane, Y; Kumegawa, M; Kokubo, T; Yamamura, T				Inui, T; Ishibashi, O; Inaoka, T; Origane, Y; Kumegawa, M; Kokubo, T; Yamamura, T			Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CYSTEINE-PROTEINASES; RAT OSTEOCLAST; LOCALIZATION	Cathepsin K is a recently identified cysteine protease which is abundantly and selectively expressed in osteoclasts, To evaluate the contribution of cathepsin K to bone resorption processes, we investigated the effect of cathepsin K antisense phosphothiorate oligodeoxynucleotide (S-ODN) on the bone-resorbing activity of osteoclasts. Rabbit osteoclasts were cultured on dentine slices for 24 h in the presence or absence of antisense S-ODN in a medium containing 100 nM Tfx(TM)-50, polycationic liposome, as a carrier of the S-ODN, Uptake of the S-ODN by osteoclasts was confirmed microscopically using fluorescein-labeled S-ODN, The treatment with antisense significantly decreased the amount of cathepsin K protein in osteoclasts. The antisense inhibited the osteoclastic pit formation in a concentration-dependent fashion, At 10 mu M the antisense reduced the total pit number and area and average pit depth by 46, 52, and 30%, respectively, The sense and mismatch S-ODNs, which were used as negative controls, had no effect on either the cathepsin K protein level or the pit formation. A nonspecific cysteine protease inhibitor, E-64, also reduced pit formation in a concentration-dependent manner with maximum reductions at 1 mu M of 46, 48, and 35% in the above pit parameters, The inhibitory effect of the antisense almost equal to that of E-64 demonstrates that cathepsin K is a cysteine protease playing a crucial role in osteoclastic bone resorption.	CIBA GEIGY LTD,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN; MEIKAI UNIV,SCH DENT,DEPT ORAL ANAT,SAKADO,SAITAMA 35002,JAPAN	Meikai University			Inui, Takashi/G-1069-2011; Ishibashi, Osamu/J-8413-2019	Ishibashi, Osamu/0000-0003-4698-460X				BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; Delaisse Jean-Marie, 1992, P289; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DELAISSE JM, 1986, CYSTEINE PROTEINASES, P259; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829; GOTO T, 1993, HISTOCHEMISTRY, V99, P411, DOI 10.1007/BF00717054; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; ISHIBASHI O, 1996, J BONE MINER RES  S1, V11, P181; ISHIBASHI O, 1995, J BONE MINER RES  S1, V10, P426; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; LI YP, 1995, J BONE MINER RES, V10, P1197; Ohba Y, 1996, FEBS LETT, V387, P175; OHSAWA Y, 1993, J HISTOCHEM CYTOCHEM, V41, P1075, DOI 10.1177/41.7.8515049; Rojanasakul YY, 1996, ADV DRUG DELIVER REV, V18, P115, DOI 10.1016/0169-409X(95)00020-8; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; SASAKI T, 1993, CELL TISSUE RES, V271, P177, DOI 10.1007/BF00297556; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Woo JT, 1996, EUR J PHARMACOL, V300, P131, DOI 10.1016/0014-2999(95)00858-6	30	144	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8109	8112		10.1074/jbc.272.13.8109	http://dx.doi.org/10.1074/jbc.272.13.8109			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079619	hybrid			2022-12-27	WOS:A1997WQ63500002
J	Wakui, H; Wright, APH; Gustafsson, JA; Zilliacus, J				Wakui, H; Wright, APH; Gustafsson, JA; Zilliacus, J			Interaction of the ligand-activated glucocorticoid receptor with the 14-3-3 eta protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-BINDING DOMAIN; DNA-BINDING; CDNA CLONING; IN-VIVO; GENE; 14-3-3-PROTEIN; COMPLEX; YEAST; TRANSACTIVATION; DETERMINANTS	The glucocorticoid receptor (GR) is a ligand-activated transcription factor. In this study, we used the yeast two-hybrid system to isolate cDNAs encoding proteins that interact with the human GR ligand-binding domain (LBD) in a ligand-dependent manner, One isolated cDNA from a HeLa cell library encoded the COOH-terminal portion of the eta-isoform of the 14-3-3 protein (residues 187-246). Glucocorticoid agonists, triamcinolone acetonide and dexamethasone, induced the GR LBD/14-3-3 eta protein fragment interaction, but an antagonist, RU486, did not. Glutathione S-transferase pull-down experiments in vitro showed that full-length 14-3-3 eta protein also interacted with the activated GR. Transient transfection studies using COS-7 cells revealed a stimulatory effect of 14-3-3 eta protein on transcriptional activation by the Oh. The 14-3-3 family members have recently been found to associate with a number of important signaling proteins, such as protein kinase C and Raf-1, as functional modulators, Our findings suggest a novel regulatory role of 14-3-3 eta protein in GR-mediated signaling pathways and also point to a mechanism whereby GR may cross-talk with other signal transduction systems.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Karolinska Institutet			Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ALAM R, 1994, J BIOCHEM-TOKYO, V116, P416, DOI 10.1093/oxfordjournals.jbchem.a124541; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1989, J BIOL CHEM, V264, P6005; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ICHIMURAOHSHIMA Y, 1992, J NEUROSCI RES, V31, P600, DOI 10.1002/jnr.490310403; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	33	82	84	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8153	8156		10.1074/jbc.272.13.8153	http://dx.doi.org/10.1074/jbc.272.13.8153			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079630	hybrid			2022-12-27	WOS:A1997WQ63500013
J	Chen, H; Wertheimer, SJ; Lin, CH; Katz, SL; Amrein, KE; Burn, P; Quon, MJ				Chen, H; Wertheimer, SJ; Lin, CH; Katz, SL; Amrein, KE; Burn, P; Quon, MJ			Protein-tyrosine phosphatases PTP1B and Syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; HUMAN-PLACENTA; RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; DEPHOSPHORYLATION; SH-PTP2; 1B; PURIFICATION; RESISTANCE; ACTIVATION	The protein-tyrosine phosphatases PTP1B and Syp have both been implicated as modulators of the mitogenic actions of insulin, However, the roles of these protein-tyrosine phosphatases in the metabolic actions of insulin are not well characterized, In this study, we directly assessed the ability of PTP1B and Syp to modulate insulin-stimulated translocation of the insulin-responsive glucose transporter GLUT4 in a physiologically relevant insulin target cell, Primary cultures of rat adipose cells were transiently transfected with either wild-type PTP1B (PTP1B WT), wild-type Syp (Syp-WT), or the catalytically inactive mutants PTP1B-C/S or SypC/S, The effects of overexpression of these constructs on insulin-stimulated translocation of a co-transfected epitope-tagged GLUT4 were studied, Cells overexpressing either PTP1B-C/S or Syp-WT had insulin dose-response curves similar to those obtained with control cells expressing only epitope-tagged GLUT4, In contrast, for cells overexpressing PTP1B-WT the level of GLUT4 on the cell surface at each insulin dose (ranging from 0 to 60 nM) was significantly lower than that observed in the control cells, Interestingly, cells overexpressing the dominant inhibitory mutant Syp-C/S also had a small but statistically significant impairment in insulin responsiveness, At a maximally stimulating concentration of insulin (60 nM), cell surface epitope-tagged GLUT4 was approximately 20% less than that of the control cells, It is possible that effects from high level overexpression of Syp and PTP1B constructs may not reflect what occurs under physiological conditions, Nevertheless, our data raise the possibility that PTP1B may be a negative regulator of insulin-stimulated glucose transport, while Syp may have a small role as a positive mediator of the metabolic actions of insulin.	NHLBI,HYPERTENS ENDOCRINE BRANCH,NIH,BETHESDA,MD 20892; HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Roche Holding			Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707				AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CUSHMAN SW, 1978, J LIPID RES, V19, P269; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; HASEGAWA M, 1996, DIABETES S2, V45, pA50; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; Ing BL, 1996, BIOCHEM BIOPH RES CO, V218, P76, DOI 10.1006/bbrc.1996.0015; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAPPIA PS, 1991, BIOCHEM J, V278, P69, DOI 10.1042/bj2780069; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	36	115	133	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8026	8031		10.1074/jbc.272.12.8026	http://dx.doi.org/10.1074/jbc.272.12.8026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065475	hybrid			2022-12-27	WOS:A1997WP59200069
J	Grouzmann, E; Buclin, T; Martire, M; Cannizzaro, C; Dorner, B; Razaname, A; Mutter, M				Grouzmann, E; Buclin, T; Martire, M; Cannizzaro, C; Dorner, B; Razaname, A; Mutter, M			Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor - Synthesis and pharmacological evaluation of a Y2 antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; FUNCTIONAL EXPRESSION; BRAIN PEPTIDE; Y-2 RECEPTORS; PROTEINS TASP; HIGH-AFFINITY; RELEASE; CLONING; NPY	Neuropeptide Y (NPY) is a potent inhibitor of neurotransmitter release through the Y2 receptor subtype. Specific antagonists for the Y2 receptors have not yet been described, Based on the concept of template-assembled synthetic proteins we have used a cyclic template molecule containing two p-turn mimetics for covalent attachment of four COOH-terminal fragments RQRYNH(2) (NPY 33-36), termed T-4-[NPY(33-36)](4). This structurally defined template-assembled synthetic protein has been tested for binding using SK-N-MC and LN319 cell lines that express the Y1 and Y2 receptor, respectively. T-4-[NPY(33-36)](4) binds to the Y2 receptor with high affinity (IC50 = 67.2 nM) and has poor binding to the Y1 receptor. This peptidomimetic tested on LN319 cells at concentrations up to 10 mu M shows no inhibitory effect on forskolin-stimulated cAMP levels (IC50 for NPY = 2.5 nM). Furthermore, we used confocal microscopy to examine the NPY-induced increase in intracellular calcium in single LN319 cells, Preincubation of the cells with T-4-[NPY(33-36)](4) shifted to the right the dose-response curves for intracellular mobilization of calcium induced by NPY at concentrations ranging from 0.1 nM to 10 mu m. Finally, we assessed the competitive antagonistic properties of T-4-[NPY(33-36)](4) at presynaptic peptidergic Y2 receptors modulating noradrenaline release, the compound T-4 [NPY(33-36)](4) caused a marked shift to the right of the concentration-response curve of NPY 13-36, a Y2-selective fragment, yielding a pA2 value of 8.48. Thus, to our best knowledge, T-4-[NPY(33-36)](4) represents the first potent and selective Y2 antagonist.	CHU VAUDOIS, DIV CLIN PHARMACOL, CH-1011 LAUSANNE, SWITZERLAND; UNIV LAUSANNE, INST CHIM ORGAN, CH-1011 LAUSANNE, SWITZERLAND; UNIV CATTOLICA SACRO CUORE, INST PHARMACOL, I-00168 ROME, ITALY	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Grouzmann, E (corresponding author), CHU VAUDOIS, DIV HYPERTENS, CH-1011 LAUSANNE, SWITZERLAND.		Buclin, Thierry/P-1640-2014	Buclin, Thierry/0000-0003-0639-5536				BARKERGIBB ML, 1995, J ENDOCRINOL, V147, P565, DOI 10.1677/joe.0.1470565; BECKSICKINGER AG, 1992, EUR J BIOCHEM, V206, P957, DOI 10.1111/j.1432-1033.1992.tb17006.x; BECKSICKINGER AG, 1994, EUR J BIOCHEM, V225, P947, DOI 10.1111/j.1432-1033.1994.0947b.x; BLASQUEZ C, 1992, BRAIN RES, V596, P163, DOI 10.1016/0006-8993(92)91544-O; EKBLAD E, 1984, REGUL PEPTIDES, V8, P225, DOI 10.1016/0167-0115(84)90064-8; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; ERNEST I, 1993, HELV CHIM ACTA, V76, P1539; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GAL CS, 1995, FEBS LETT, V362, P192; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GRAY EG, 1962, J ANAT, V96, P79; GREBER S, 1994, BRIT J PHARMACOL, V113, P737, DOI 10.1111/j.1476-5381.1994.tb17055.x; GROUZMANN E, 1995, EUR J BIOCHEM, V234, P44, DOI 10.1111/j.1432-1033.1995.044_c.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HOFFMAN A, 1995, J PHARMACOKINETICS B, V22, P449; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KENAKIN TP, 1993, PHARM ANAL DRUG RECE, P370; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LARSEN PJ, 1994, ENDOCRINOLOGY, V134, P1635, DOI 10.1210/en.134.4.1635; LEBAN JJ, 1995, J MED CHEM, V38, P1150, DOI 10.1021/jm00007a012; Lew MJ, 1996, BRIT J PHARMACOL, V117, P1768, DOI 10.1111/j.1476-5381.1996.tb15352.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; MARTIRE M, 1993, EUR J PHARMACOL, V230, P231, DOI 10.1016/0014-2999(93)90807-T; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; RAITERI M, 1974, EUR J PHARMACOL, V25, P411, DOI 10.1016/0014-2999(74)90272-6; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; SMITH JE, 1975, ANAL BIOCHEM, V64, P149, DOI 10.1016/0003-2697(75)90417-0; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TUCHSCHERER G, 1993, TETRAHEDRON LETT, V34, P8419, DOI 10.1016/S0040-4039(00)61348-5; Tuchscherer G, 1995, J Pept Sci, V1, P3, DOI 10.1002/psc.310010103; VILASECA LA, 1993, BIOCONJUGATE CHEM, V4, P515, DOI 10.1021/bc00024a014; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; WALKER P, 1991, TRENDS PHARMACOL SCI, V12, P111, DOI 10.1016/0165-6147(91)90518-W; Wang J, 1996, ENDOCRINOLOGY, V137, P587, DOI 10.1210/en.137.2.587; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J	45	60	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7699	7706		10.1074/jbc.272.12.7699	http://dx.doi.org/10.1074/jbc.272.12.7699			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065428	hybrid			2022-12-27	WOS:A1997WP59200022
J	Kridel, SJ; Knauer, DJ				Kridel, SJ; Knauer, DJ			Lysine residue 114 in human antithrombin III is required for heparin pentasaccharide-mediated activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; THROMBIN REACTION; BINDING DOMAIN; ANTI-THROMBIN; ACCELERATION; IDENTIFICATION; FLUORESCENCE; SPECTROSCOPY; INACTIVATION; ENHANCEMENT	Recombinant native antithrombin III (ATIII) and two genetic variants with glutamine substitutions at lysine residues 114 and 139 were expressed in insect cells using a baculovirus-driven expression system. The purified proteins were used to evaluate the potential role(s) of these residues in the pentasaccharide-mediated activation of ATIII. The second order rate constants for the inhibition of factor Xa by both of the genetic variants were nearly identical to those of recombinant native ATIII, indicating that the glutamine substitutions did not result in serious protein conformational changes. The glutamine substitution at lysine 139 had no effect on the pentasaccharide-mediated activation of ATIII toward factor Xa. In contrast, lysine 114 was found to be critical in the activation of ATIII toward factor Xa, No activation was observed, even at a pentasaccharide concentration 10 times higher than that required to activate recombinant native ATIII. These data are the first to demonstrate a pivotal role for lysine 114 in the pentasaccharide-mediated activation of ATIII.	UNIV CALIF IRVINE,SCH BIOL SCI,DEPT DEV & CELL BIOL,IRVINE,CA 92697	University of California System; University of California Irvine					NIGMS NIH HHS [W401-GM34001-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNEL F, 1987, AM J HEMATOL, V25, P223, DOI 10.1002/ajh.2830250214; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LIU CS, 1987, EUR J BIOCHEM, V167, P247, DOI 10.1111/j.1432-1033.1987.tb13330.x; NAJJAM S, 1994, BBA-MOL BASIS DIS, V1225, P135, DOI 10.1016/0925-4439(94)90070-1; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; PETERSON CB, 1985, J BIOL CHEM, V260, P6100; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; ROSENFELD L, 1987, BIOCHEMISTRY-US, V12, P639; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054	30	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7656	7660		10.1074/jbc.272.12.7656	http://dx.doi.org/10.1074/jbc.272.12.7656			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065421	hybrid			2022-12-27	WOS:A1997WP59200015
J	PineiroSanchez, ML; Goldstein, LA; Dodt, J; Howard, L; Yeh, Y; Chen, WT				PineiroSanchez, ML; Goldstein, LA; Dodt, J; Howard, L; Yeh, Y; Chen, WT			Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; SEQUENCE-ANALYSIS; PROTEINS; CD26; EXPRESSION; CELLS; INVASIVENESS; INVADOPODIA; CLONING; MEMBER	The 170-kDa membrane-bound gelatinase, seprase, is a cell surface protease, the expression of which correlates with the invasive phenotype of human melanoma and carcinoma cells, We have isolated seprase from cell membranes and shed vesicles of LOX human melanoma cells, The active enzyme is a dimer of N-glycosylated 97-kDa subunits, Sequence analysis of three internal proteolytic fragments of the 97-kDa polypeptide revealed up to 87.5% identity to the 95-kDa fibroblast activation protein alpha (FAP alpha), the function of which is unknown, Thus, we used reverse transcription-polymerase chain reaction to generate a 2.4-kilobase cDNA from LOX mRNA with FAP alpha primers, COS-7 cells transfected with this cDNA expressed a 170 kDa gelatinase that is recognized by monoclonal antibodies directed against seprase, Sequence analysis also showed similarities to the 110-kDa subunit of dipeptidyl peptidase IV (DPPIV), Like DPPIV, the gelatinase activity of seprase was completely blocked by serine-protease inhibitors, including diisopropyl fluorophosphate, Seprase could be affinity-labeled by [H-3]diisopropyl fluorophosphate, but the proteolytically inactive 97-kDa subunit could not, confirming the existence of a serine protease active site on the dimeric form, Proteolytic activity is lost upon dissociation into its 97-kDa subunit following treatment with acid, heat, or cysteine and histidine-modifying agents, We conclude that seprase, FAP alpha, and DPPIV are related serine integral membrane proteases and that seprase is similar to DPPIV, the proteolytic activities of which are dependent upon subunit association.	GEORGETOWN UNIV, LOMBARDI CANC CTR, MED CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, DEPT CELL BIOL, MED CTR, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University			Howard, Linda/B-2463-2009	HOWARD, LINDA/0000-0003-4760-7996	NATIONAL CANCER INSTITUTE [R01CA039077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033711] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-39077] Funding Source: Medline; NHLBI NIH HHS [HL-33711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; CHEN WT, 1994, BREAST CANCER RES TR, V31, P217, DOI 10.1007/BF00666155; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DAVID F, 1993, J BIOL CHEM, V268, P17247; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; FODSTAD O, 1988, INT J CANCER, V41, P442, DOI 10.1002/ijc.2910410322; HOLLENBAUGH D, 1994, CURRENT PROTOCOLS MO; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KJONNIKSEA I, 1994, CANCER RES, V52, P1347; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MONSKY WL, 1994, CANCER RES, V54, P5702; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; POWERS JC, 1988, PROTEINASE INHIBITOR, P55; PUSCHEL G, 1982, EUR J BIOCHEM, V126, P359, DOI 10.1111/j.1432-1033.1982.tb06788.x; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SMITH RE, 1992, HISTOCHEM J, V24, P637, DOI 10.1007/BF01047584; TORIMOTO Y, 1992, MOL IMMUNOL, V29, P183, DOI 10.1016/0161-5890(92)90099-J; WALBORG EF, 1985, EXP CELL RES, V158, P509, DOI 10.1016/0014-4827(85)90474-4; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	22	129	154	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7595	7601		10.1074/jbc.272.12.7595	http://dx.doi.org/10.1074/jbc.272.12.7595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065413	hybrid			2022-12-27	WOS:A1997WP59200007
J	Rusinol, AE; Jamil, H; Vance, JE				Rusinol, AE; Jamil, H; Vance, JE			In vitro reconstitution of assembly of apolipoprotein B48-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN; HEP G2 CELLS; RAT HEPATOMA-CELLS; MICROSOMAL TRIGLYCERIDE; ENDOPLASMIC-RETICULUM; CHOLESTERYL ESTER; DISULFIDE-ISOMERASE; PAUSE TRANSFER	Human apolipoprotein B48 (apoB48) and apoB15 (the NH2-terminal 48 and 15% of apoB100, respectively) were translated in vitro from their respective mRNAs using a rabbit reticulocyte lysate and microsomes derived from rat liver or dog pancreas, Synthesis of phosphatidylcholine and triacylglycerols was reconstituted in freshly isolated microsomes by the addition of precursors of these glycerolipids (acylcoenzyme A, glycerol 3-phosphate, and CDP-choline) before, during, or after translation. Assembly of apoB15 and apoB48 with newly synthesized phospholipids and triacylglycerols was favored by active, co-translational lipid synthesis. Moreover, translocation of apoB48 but not B15 into the microsomal lumen was increased in the presence of co-translational lipid synthesis. When apoB48 was translated in vitro, approximately 50% of apoB48 was buoyant at a density of <1.10 g/ml in the lumen of liver microsomes only when lipid synthesis was reconstituted during translation. Microsomal triacylglycerol transfer protein has been proposed to be essential for lipidation and/or translocation of apoB48. However, apoB48 was translocated into the lumen of dog pancreas microsomes in which the activity of the microsomal triacylglycerol transfer protein was not detectable. These data indicate that (i) apoB15 and apoB48 bind newly synthesized phosphatidylcholine during translocation; (ii) apoB48 but not apoB15 associates co-translationally with triacylglycerols; (iii) translocation of apoB48 but not apoB15 is stimulated by lipid synthesis; (iv) assembly of buoyant apoB48-containing lipoproteins can be reconstituted in. vitro in the presence of active lipid synthesis; and (v) even in microsomes lacking microsomal triacylglycerol transfer protein activity, apoB48 is translocated into the lumen.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB T6G 2S2, CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	University of Alberta; University of Alberta; Bristol-Myers Squibb								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; Davis R.A., 1996, BIOCH LIPIDS LIPOPRO, P473; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; FAST DG, 1995, BBA-LIPID LIPID MET, V1258, P159, DOI 10.1016/0005-2760(95)00116-T; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GIBBONS GF, 1990, BIOCHEM J, V268, P1; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; Ingram MF, 1996, J LIPID RES, V37, P2202; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NOLTE RT, 1994, THESIS BOSTON U BOST; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; WU XJ, 1994, J BIOL CHEM, V269, P12375; Wu XJ, 1996, J LIPID RES, V37, P1198; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; Yang LY, 1996, J LIPID RES, V37, P262; YANG LY, 1995, J LIPID RES, V36, P125; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	64	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8019	8025		10.1074/jbc.272.12.8019	http://dx.doi.org/10.1074/jbc.272.12.8019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065474	hybrid			2022-12-27	WOS:A1997WP59200068
J	Tomasek, JJ; Halliday, NL; Updike, DL; AhernMoore, JS; Vu, TKH; Liu, RW; Howard, EW				Tomasek, JJ; Halliday, NL; Updike, DL; AhernMoore, JS; Vu, TKH; Liu, RW; Howard, EW			Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX; CELL-SURFACE; LATTICE CONTRACTION; HUMAN-FIBROBLASTS; TISSUE INHIBITOR; EXPRESSION; GELS; REORGANIZATION	Gelatinase A (GL-A) is a matrix metalloproteinase (MMP) involved in both connective tissue remodeling and tumor invasion. GL-A activation is mediated by a membrane-type MMP (MT MMP) that cleaves the GL-A propeptide. In this study, we examined the role of the actin cytoskeleton in regulating GL-A activation and MT-MMP-1 expression. Human palmar fascia fibroblasts and human fetal lung fibroblasts were cultured on a planar substratum or within different types of collagen lattices, Fibroblasts that formed stress fibers, either on a planar substratum or within an attached collagen lattice, showed reduced GL-A activation compared with fibroblasts lacking stress fibers, within either floating or stress-released collagen lattices. To determine whether changes in the organization of the actin cy toskeleton could promote GL-A activation, fibroblasts with stress fibers were treated with cytochalasin D. Within 24 h after treatment, GL-A activation was dramatically increased, Associated with this GL-A activation was an increase in MT-MMP-1 mRNA as determined by Northern blot analysis. Treatment with nocodazole, which induced microtubule depolymerization and cell shape changes without affecting stress fibers, did not promote GL-A activation. These results suggest that the extracellular matrix and the actin cytoskeleton transduce signals that modulate GL-A activation and regulate tissue remodeling.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center	Tomasek, JJ (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT ANAT SCI,940 STATON L YOUNG BLVD,BMSB 536,OKLAHOMA CITY,OK 73104, USA.		Halliday, Nancy/L-3942-2019	Halliday, Nancy/0000-0003-4680-0524				Ailenberg M, 1996, BIOCHEM J, V313, P879, DOI 10.1042/bj3130879; AZZAM HS, 1992, CANCER RES, V52, P4540; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURGESS LPA, 1990, ARCH OTOLARYNGOL, V116, P798; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719; GALARDY RE, 1994, CANCER RES, V54, P4715; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HIGGINS PJ, 1995, BIOCHEM J, V306, P497, DOI 10.1042/bj3060497; HIGGINS PJ, 1994, J CELL PHYSIOL, V159, P187, DOI 10.1002/jcp.1041590123; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; LAMBERT CA, 1992, LAB INVEST, V66, P444; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PILCHER BK, 1994, EXP CELL RES, V211, P368, DOI 10.1006/excr.1994.1100; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TOMASEK JJ, 1982, DEV BIOL, V92, P107, DOI 10.1016/0012-1606(82)90155-5; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; TOMASEK JJ, 1984, J CELL BIOL, V99, P536, DOI 10.1083/jcb.99.2.536; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WELCH MP, 1990, J CELL BIOL, V110, P135; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x	34	159	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7482	7487		10.1074/jbc.272.11.7482	http://dx.doi.org/10.1074/jbc.272.11.7482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054450	hybrid			2022-12-27	WOS:A1997WN14700089
J	Clementz, T; Zhou, ZM; Raetz, CRH				Clementz, T; Zhou, ZM; Raetz, CRH			Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A - Acylation by MsbB follows laurate incorporation by HtrB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; NULL MUTATIONS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; BIOSYNTHESIS; LIPOPOLYSACCHARIDE; ENDOTOXINS; SALMONELLA; MEMBRANE; MUTANT; IDENTIFICATION	Overexpression of the Escherichia coli msbB gene on high copy plasmids suppresses the temperature-sensitive growth associated with mutations in the htrB gene, htrB encodes the lauroyl transferase of lipid A biosynthesis that acylates the intermediate (Kdo)(2)-lipid IVA (Brozek, It. A. and Raetz, C. R. H. (1990) J. Biol. Chem, 265, 15410-15417). Since msbB displays 27.5% identity and 42.2% similarity to htrB, me explored the possibility that msbB encodes a related acyltransferase, In contrast to htrB, extracts of strains with insertion mutations in msbB are not defective in transferring laurate from lauroyl acyl carrier protein to (Kdo)(2)-lipid IVA. However, extracts of msbB mutants do not efficiently acylate the product formed by HtrB, designated (IZdo)(2)-(lauroyl)-lipid IVA. Extracts of strains harboring msbB(+) bearing plasmids acylate (Kdo)(2)-(lauroyl)-lipid IVA very rapidly compared with wild type, We solubilized and partially purified MsbB from an overproducing strain, lacking HtrB, MsbB transfers myristate or laurate, activated on ACP, to (Kdo)(2)-(lauroyl)-lipid IVA. Decanoyl, palmitoyl, palmitoleoyl, and (R)-3-hydroxymyristoyl-ACP are poor acyl donors, MsbB acylates (Kdo)(2)-(lauroyl)-lipid IVA about 100 times faster than (Kdo)(2)-lipid IVA. The slow, but measurable, rate whereby MsbB acts on (Kdo)(2)-lipid IVA may explain why overexpression of MsbB suppresses the temperature-sensitive phenotype of htrB mutations, Presumably, the acyloxyacyl group generated by excess MsbB substitutes for the one normally formed by HtrB.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; MYERS KR, 1992, BIOCONJUGATE CHEM, V3, P540, DOI 10.1021/bc00018a013; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; REATZ CRH, 1996, ESCHERICHIA COLI SAL, V1, P1035; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; VANALPHEN L, 1979, EUR J BIOCHEM, V101, P571; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167	34	173	184	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10353	10360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099672				2022-12-27	WOS:A1997WV26200006
J	Jucker, BM; Rennings, AJM; Cline, GW; Shulman, GI				Jucker, BM; Rennings, AJM; Cline, GW; Shulman, GI			C-13 and P-31 NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO REGULATION; SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; CARBOHYDRATE-METABOLISM; DIABETES-MELLITUS; NORMAL MEN; INSULIN; INVIVO; CYCLE; EXERCISE	The effects of increased plasma free fatty acids (FFA) on insulin-dependent whole body glucose disposal, skeletal muscle glycolysis, glycogen synthesis, pyruvate versus FFA/ketone oxidation, and glucose 6-phosphate (Glu-6-P) were investigated in the awake rat, A control group (glycerol-infused) and high plasma FFA group (Liposyn-infused) were clamped at euglycemia (similar to 6 mM). hyperinsulinemia (10 milliunits/kg/min) throughout the experiment (180-240 min), In the initial experiment, C-13 NMR was used to observe [1-C-13]glucose incorporation into [1-C-13]glycogen in the rat hindlimb for glycogen synthesis calculations and into [3-C-13]lactate and [3-C-13]alanine for glycolytic flux calculations, These experiments were followed by P-31 NMR measurements of Glu-6-P changes under identical conditions of the initial experiment, Plasma FFA concentrations were 2.25 +/- 0.36 and 0.20 +/- 0.03 mM in the high plasma FFA and control groups respectively (p < 0.0005), Glucose infusion rates (G(inf)) decreased significantly in the Liposyn-infused rats (29.5 +/- 0.7 and 27.2 +/- 1.2 mg/kg/min for control and high plasma FFA group, respectively, at 15 min to 30.7 +/- 2.3 and 17.7 +/- 1.3 mg/kg/min, respectively, at the end of the experiment, p < 0.002), Glycogen synthesis rates were 163 +/- 32 and 104 +/- 17 nmol/g/min, and glycolytic rates were 57.9 +/- 8.0 and 19.5 +/- 3.6 nmol/g/min (p < 0.002) in the control and high plasma FFA groups, respectively, The relative flux of pyruvate versus free fatty acids and ketones entering the tricarboxylic acid cycle was greater in the control (57 +/- 9%) versus high plasma FFA group (25 +/- 4%) (p < 0.005) as assessed by [4-C-13]glutamate/[3-C-13]lactate steady state isotopic enrichment measurements, Finally, Glu-6-P concentrations increased by 29.8 +/- 7.0 and 52.8 +/- 12.3% (p < 0.05) in the control and high plasma FFA groups, respectively, above their basal concentrations by 180 min. In conclusion, we have demonstrated the ability to use in vivo MMR to elucidate the metabolic fate of glucose within skeletal muscle of an awake rat during a euglycemic-hyperinsulinemic clamp and increased levels of plasma FFA. These data suggest that increased concentrations of plasma FFA inhibit insulin-stimulated muscle glucose metabolism in the rat through inhibition of glycolysis.			Jucker, BM (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,333 CEDAR ST,FITKIN 1, POB 208020, NEW HAVEN, CT 06520 USA.		Rennings, Alexander/H-3541-2015	Shulman, Gerald/0000-0003-1529-5668	NIDDK NIH HHS [R01 DK40936, P30 DK 45735, R01 DK040936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATTY CH, 1971, AM J PHYSIOL, V220, P1928, DOI 10.1152/ajplegacy.1971.220.6.1928; BERGER M, 1976, BIOCHEM J, V158, P191, DOI 10.1042/bj1580191; BEVILACQUA S, 1990, DIABETES, V39, P383, DOI 10.2337/diabetes.39.3.383; BLOCH G, 1993, MAGNET RESON MED, V30, P347, DOI 10.1002/mrm.1910300311; BLOCH G, 1994, AM J PHYSIOL, V266, pE85, DOI 10.1152/ajpendo.1994.266.1.E85; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BODEN G, 1991, DIABETES, V40, P686, DOI 10.2337/diabetes.40.6.686; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; CLINE GW, 1991, J BIOL CHEM, V266, P4094; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; JENKINS AB, 1988, J CLIN INVEST, V82, P293, DOI 10.1172/JCI113586; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; Kim JK, 1996, DIABETES, V45, P446, DOI 10.2337/diabetes.45.4.446; KRUSZYNSKA YT, 1990, DIABETOLOGIA, V33, P396, DOI 10.1007/BF00404087; KRUSZYNSKA YT, 1991, DIABETOLOGIA, V34, P205, DOI 10.1007/BF00405077; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LI J, 1993, METABOLISM, V42, P451, DOI 10.1016/0026-0495(93)90102-T; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASON GF, 1995, J CEREBR BLOOD F MET, V15, P12, DOI 10.1038/jcbfm.1995.2; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; NEWSHOLME EA, 1977, BIOCHEM J, V166, P123, DOI 10.1042/bj1660123; NOLTE LA, 1994, ACTA PHYSIOL SCAND, V151, P51, DOI 10.1111/j.1748-1716.1994.tb09720.x; NUUTILA P, 1992, J CLIN INVEST, V89, P1767, DOI 10.1172/JCI115780; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1994, DIABETOLOGIA, V37, pS155, DOI 10.1007/BF00400839; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1993, AM J PHYSIOL, V265, pE761, DOI 10.1152/ajpendo.1993.265.5.E761; ROTH DA, 1993, J APPL PHYSIOL, V75, P1559, DOI 10.1152/jappl.1993.75.4.1559; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Sidossis LS, 1996, AM J PHYSIOL-ENDOC M, V270, pE733, DOI 10.1152/ajpendo.1996.270.4.E733; SMITH D, 1987, METABOLISM, V36, P1167, DOI 10.1016/0026-0495(87)90244-7; WOLFE BM, 1988, METABOLISM, V37, P323, DOI 10.1016/0026-0495(88)90131-X	42	73	74	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10464	10473						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099689				2022-12-27	WOS:A1997WV26200023
J	Scoggan, KA; Jakobsson, PJ; FordHutchinson, AW				Scoggan, KA; Jakobsson, PJ; FordHutchinson, AW			Production of leukotriene C-4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ENDOTHELIAL-CELLS; HUMAN-PLATELETS; SYNTHASE; PURIFICATION; EXPRESSION; METABOLISM; INHIBITORS; BINDING	Microsomal glutathione S-transferase-II (GST-II) has recently been discovered and characterized as a member of the 5-lipoxggenase-activating protein (FLAP)/5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid (LTC(4)) synthase gene family, which also includes microsomal glutathione S-transferase-I (GST-I) as a distant member of this gene family, This new enzyme is unique as it is the only member of this family capable of efficiently conjugating reduced glutathione to both 5,6-oxido-7,9,11,14-eicosatetraenoic acid (LTA(4)) and 1-chloro-2,4-dinitrobenzene. Although microsomal GST-II has been demonstrated to display both general glutathione S-transferase (GST) and specific LTC(4) synthase activities, its biological function remains unknown, In this study, we investigated the physiological location of microsomal GST-II as well as the relative importance of this enzyme versus LTC(4) synthase for the production of LTC(4) in various human tissues and cells that have been previously demonstrated to possess LTC(4) synthase activity. As determined by Western blot, microsomal GST-II was predominantly expressed in human liver microsomes, human endothelial cell membranes, and sparsely detected in human lung membranes, In contrast, LTC(4) synthase was prevalent in human lung membranes, human platelet homogenates, and human kidney tissue, Concomitant to the formation of LTC(4), microsomal GST-II also produces a new metabolite of LTA(4), a postulated LTC(4) isomer. This isomer was used to distinguish between microsomal GST-II and LTC(4) synthase activities involved in the biosynthesis of LTC(4). Based on the relative production of LTC(4) to the LTC(4) isomer, microsomal GST-IT was demonstrated to be the principal enzyme responsible for LTC(4) production in human liver microsomes and human endothelial cells and played a minor role in the formation of LTC(4) in human lung membranes, In comparison, LTC(4) synthase was the main enzyme capable of catalyzing the conjugation of reduced glutathione to LTA(4) in human lung membranes and human platelet homogenates. Therefore, microsomal GST-II appears to be an integral component in the detoxification of biological systems due to its marked presence in human liver, in accordance with its known GST activity, Microsomal GST-II, however, mag also be pivotal for cysteinyl leukotriene formation in endothelial cells, and this could change our current understanding of the regulation of leukotriene biosynthesis in inflammatory disorders such as asthma.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE,PQ H9R 4P8,CANADA; MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ H3G 1Y6,CANADA	Merck & Company; McGill University			Jakobsson, Per-Johan/ABC-5594-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Andersson C, 1994, Adv Pharmacol, V27, P19, DOI 10.1016/S1054-3589(08)61028-5; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EDENIUS C, 1988, EUR J BIOCHEM, V178, P81, DOI 10.1111/j.1432-1033.1988.tb14431.x; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; Ford-Hutchinson A W, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P13; FORDHUTCHINSON AW, 1994, ANN NY ACAD SCI, V744, P78, DOI 10.1111/j.1749-6632.1994.tb52725.x; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FREY EA, 1992, EUR J PHARMACOL, V244, P239; FUKAI F, 1993, ARCH BIOCHEM BIOPHYS, V305, P378, DOI 10.1006/abbi.1993.1435; HABIB A, 1992, ARCH BIOCHEM BIOPHYS, V298, P544, DOI 10.1016/0003-9861(92)90448-6; HUTCHINSON JH, 1995, J MED CHEM, V38, P4538, DOI 10.1021/jm00022a020; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM BK, 1995, J LIPID MEDIAT CELL, V12, P333, DOI 10.1016/0929-7855(95)00042-O; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LU AYH, 1972, BIOCHEM BIOPH RES CO, V46, P1334, DOI 10.1016/S0006-291X(72)80121-9; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Scoggan KA, 1996, EUR J BIOCHEM, V239, P572, DOI 10.1111/j.1432-1033.1996.0572u.x; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; SODERSTROM M, 1985, BIOCHEM BIOPH RES CO, V128, P265, DOI 10.1016/0006-291X(85)91673-0; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	40	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10182	10187						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092565				2022-12-27	WOS:A1997WU03900084
J	Souaze, F; Rostene, W; Forgez, P				Souaze, F; Rostene, W; Forgez, P			Neurotensin agonist induces differential regulation of neurotensin receptor mRNA - Identification of distinct transcriptional and post-transcriptional mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA; DOWN-REGULATION; CALCIUM MOBILIZATION; GENE-EXPRESSION; HT29 CELLS; RAT; INTERNALIZATION; ACTIVATION	The binding of neurotensin (NT) to specific receptors triggers the multiple functions that NT exerts in both periphery and brain. By studying the effect of the concentration and time of NT agonist exposure, two separate regulatory mechanisms were detected for the neurotensin receptor (NTR) gene in human colonic adenocarcinoma cells (HT-29). The incubation of cells for 6 h with the NT agonist, JMV 449, resulted in an increase of 270% in NTR mRNA levels. These changes were the direct result of new NTR gene transcription, as indicated by run-on and half-life experiments. In addition, the transcriptional activation of the NTR gene was dependent on NT-receptor complex internalization and de novo protein synthesis. A second response was detected with prolonged exposure to JMV 449. In this case, a decrease of 70% was detected in NTR mRNA levels. Unlike the initial phase, this change was mediated by a post-transcriptional event as the half-life of NTR mRNA from treated cells decreased by 50% as compared with control cells. NT agonist appears to regulate the synthesis of NTR mRNA. In HT-29 cells, this feedback is exerted by a biphasic response. These phases are apparently independent and mediated by two separate mechanisms.	HOP ST ANTOINE,INSERM,U339,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Rostene, William/F-2754-2017; souazé, frédérique/AAE-6478-2021; Souazé, Frédérique/K-7937-2015; FORGEZ, Patricia/N-2960-2018	Frederique, Souaze/0000-0003-0476-2603; ROSTENE, WILLIAM/0000-0003-0409-5361				AMAR S, 1987, J NEUROCHEM, V49, P999, DOI 10.1111/j.1471-4159.1987.tb09986.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZZI M, 1994, NEUROSCI LETT, V172, P97, DOI 10.1016/0304-3940(94)90671-8; BOUDIN H, 1995, BIOCHEM J, V305, P277, DOI 10.1042/bj3050277; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CHABRY J, 1993, J BIOL CHEM, V268, P17138; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHECLER F, 1986, PEPTIDES, V7, P1071, DOI 10.1016/0196-9781(86)90136-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DIPAOLA ED, 1993, J PHARMACOL EXP THER, V264, P1; DOULUT S, 1992, PEPTIDE RES, V5, P30; FAURE MP, 1995, J NEUROSCI, V15, P4140; FAURE MP, 1994, J HISTOCHEM CYTOCHEM, V42, P755, DOI 10.1177/42.6.8189037; FERRY RC, 1994, J BIOL CHEM, V269, P31850; GREENBERG ME, 1989, CURRENT PROTOCOLS MO; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Hermans E, 1996, MOL PHARMACOL, V49, P365; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HOSODA K, 1995, MOL PHARMACOL, V48, P206; HU ZW, 1993, J BIOL CHEM, V268, P3610; KASCKOW J, 1991, REGUL PEPTIDES, V36, P153, DOI 10.1016/0167-0115(91)90053-J; KITABGI P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P397; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; NEMEROFF CB, 1980, BRAIN RES, V195, P69, DOI 10.1016/0006-8993(80)90867-7; OHH M, 1995, J CELL BIOCHEM, V59, P202, DOI 10.1002/jcb.240590210; PORT JD, 1992, J BIOL CHEM, V267, P24103; REINECKE M, 1980, CELL TISSUE RES, V205, P383; ROUSELL J, 1995, J BIOL CHEM, V270, P7213, DOI 10.1074/jbc.270.13.7213; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V92, P253, DOI 10.1016/0303-7207(93)90016-D; Sambrook J., 2002, MOL CLONING LAB MANU; Scarceriaux V, 1996, J NEUROENDOCRINOL, V8, P587; Souaze F, 1996, BIOTECHNIQUES, V21, P280; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TURNER JT, 1990, J PHARMACOL EXP THER, V253, P1049; VANISBERG MA, 1991, BIOCHEM PHARMACOL, V42, P2265, DOI 10.1016/0006-2952(91)90229-X; VIJAYAN E, 1994, NEUROENDOCRINOLOGY, V60, P157, DOI 10.1159/000126746; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; YU SS, 1993, J BIOL CHEM, V268, P337	44	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					10087	10094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092553				2022-12-27	WOS:A1997WU03900072
J	Talanian, RV; Quinlan, C; Trautz, S; Hackett, MC; Mankovich, JA; Banach, D; Ghayur, T; Brady, KD; Wong, WW				Talanian, RV; Quinlan, C; Trautz, S; Hackett, MC; Mankovich, JA; Banach, D; Ghayur, T; Brady, KD; Wong, WW			Substrate specificities of caspase family proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; COLI EXPRESSION SYSTEM; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; MOLECULAR-CLONING; MATURE IL-1-BETA; MICE DEFICIENT; INHIBITION	The caspase family represents a new class of intracellular cysteine proteases with known or suspected roles in cytokine maturation and apoptosis. These enzymes display a preference for Asp in the P1 position of substrates, To clarify differences in the biological roles of the interleukin-1 beta converting enzyme (ICE) family proteases, we have examined in detail the specificities beyond the P1 position of caspase 1, -2, -3, -4, -6, and -7 toward minimal length peptide substrates in vitro. We find differences and similarities between the enzymes that suggest a functional subgrouping of the family different from that based on overall sequence alignment. The primary specificities of ICE homologs explain many observed enzyme preferences for macromolecular substrates and can be used to support predictions of their natural function(s). The results also suggest the design of optimal peptidic substrates and inhibitors.			Talanian, RV (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; AYALA JM, 1994, J IMMUNOL, V153, P2592; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; Dang LC, 1996, BIOCHEMISTRY-US, V35, P14910, DOI 10.1021/bi9617771; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELFORD PR, 1995, BRIT J PHARMACOL, V115, P601, DOI 10.1111/j.1476-5381.1995.tb14974.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fersht A., 1985, ENZYME STRUCTURE MEC; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Ku G, 1996, CYTOKINE, V8, P377, DOI 10.1006/cyto.1996.0052; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MALINOWSKI JJ, 1995, PROTEIN SCI, V4, P2149, DOI 10.1002/pro.5560041021; MILLER BE, 1995, J IMMUNOL, V154, P1331; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	61	758	802	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9677	9682						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092497				2022-12-27	WOS:A1997WU03900016
J	Blery, M; Delon, J; Trautmann, A; Cambiaggi, A; Olcese, L; Biassoni, R; Moretta, L; Chavrier, P; Moretta, A; Daeron, M; Vivier, E				Blery, M; Delon, J; Trautmann, A; Cambiaggi, A; Olcese, L; Biassoni, R; Moretta, L; Chavrier, P; Moretta, A; Daeron, M; Vivier, E			Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; T-CELL; ANTIGEN RECEPTOR; MEDIATED CYTOTOXICITY; CYTOPLASMIC DOMAIN; IGG RECEPTORS; GAMMA-CHAIN; HLA-C; LYMPHOCYTES; CALCIUM	Natural killer and T cells express at their surface, members of a multigenic family of killer cell inhibitory receptors (KIR) for major histocompatibility complex Class I molecules. KIR engagement leads to the inhibition of natural killer and T cell activation programs. We investigated here the functional reconstitution of KIR in a non-lymphoid cell type. Using stable transfection in the RBL-2H3 mast cell line, we demonstrated that (i) KIR can inhibit signals induced by Fc epsilon RI gamma or CD3 zeta polypeptides that bear immunoreceptor tyrosine-based activation motifs; (ii) two distinct immunoreceptor tyrosine-based inhibition motifs-bearing receptors, i.e. KIR and Fc gamma RIIB, use distinct inhibitory pathways since KIR engagement inhibits the intracellular Ca2+ release hom endoplasmic reticulum stores, in contrast to Fc gamma RIIB, which only inhibits extracellular Ca2+ entry; (iii) KIR require co-ligation with an immunoreceptor tyrosine-based activation motif-dependent receptor to mediate their inhibitory function. This latter finding is central to the mechanism by which KIR selectively inhibit only the activatory receptors in close vicinity. Taken together our observations also contribute to define and extend the family of immunoreceptor tyrosine-based inhibition motif-bearing receptors involved in the negative control of cell activation.	CNRS MARSEILLE LUMINY,CTR IMMUNOL,INSERM,F-13288 MARSEILLE 09,FRANCE; INST CURIE,INSERM,U255,LAB IMMUNOL CELLULAIRE & CLIN,F-75231 PARIS,FRANCE; GRP HOSP PITIE SALPETRIERE,LAB IMMUNOL CELLULAIRE,CNRS URA 625,CERVI,F-75013 PARIS,FRANCE; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ISTOL & EMBRIOL GEN,I-16132 GENOA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Genoa; IRCCS AOU San Martino IST; University of Genoa			BIASSONI, ROBERTO/J-4677-2018; CHAVRIER, Philippe/B-4707-2010; CHAVRIER, Philippe/AAG-2645-2020; Vivier, Eric/F-8939-2010; Moretta, Lorenzo/AAA-7239-2020	BIASSONI, ROBERTO/0000-0002-4365-8166; CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Vivier, Eric/0000-0001-7022-8287; Moretta, Lorenzo/0000-0003-4658-1747; Delon, Jerome/0000-0003-0222-1192; BLERY, Mathieu/0000-0003-4738-6038				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cambiaggi A, 1996, BLOOD, V87, P2369, DOI 10.1182/blood.V87.6.2369.bloodjournal8762369; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Choi OH, 1996, NATURE, V380, P634; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P1; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DANDREA A, 1995, J IMMUNOL, V155, P2306; Dohring C, 1996, J IMMUNOL, V156, P3098; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; DONNADIEU E, 1994, CURR BIOL, V4, P584, DOI 10.1016/S0960-9822(00)00130-5; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; Lanier L L, 1995, Semin Immunol, V7, P75, DOI 10.1006/smim.1995.0011; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEIBSON PJ, 1995, IMMUNITY, V3, P5, DOI 10.1016/1074-7613(95)90153-1; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; MORETTA L, 1994, ADV IMMUNOL, V55, P341; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; Raulet D H, 1995, Semin Immunol, V7, P103, DOI 10.1006/smim.1995.0014; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Renard V, 1997, IMMUNOL REV, V155, P205, DOI 10.1111/j.1600-065X.1997.tb00953.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VIVIER E, 1991, J IMMUNOL, V147, P4263; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Yokoyama W M, 1995, Semin Immunol, V7, P89, DOI 10.1006/smim.1995.0013	56	99	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8989	8996						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083022				2022-12-27	WOS:A1997WU03700027
J	Yoon, JY; Beinfeld, MC				Yoon, JY; Beinfeld, MC			Prohormone convertase 1 is necessary for the formation of cholecystokinin 8 in Rin5F and STC-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; MESSENGER-RNA; PROPROTEIN CONVERTASES; RAT-BRAIN; ANTISENSE RNA; ATT-20 CELLS; PRO-CCK; PC2; RELEASE; FURIN	Several immortalized cell lines serve as models for procholecystokinin (pro-CCK) processing, Rin5F cells, derived from a rat insulinoma, and STC-1 cells, derived from a murine intestinal tumor, process pro-CCK mainly to amidated CCK 8, Both also make significant quantities of amidated CCK 22, a slightly larger form found in the gut, Many modifications are necessary during pro-CCK processing including cleavages performed by endoproteases, the identities of which are unknown, A candidate endoprotease is prohormone convertase 1 (PC1) also known as PC3, a Ca2+-dependent serine endoprotease of the subtilisin family, Constitutive expression of antisense PC1 message in stably transfected Rin5F cells resulted in a significant reduction of the cellular content of CCK 8 as measured by radioimmunoassay, Several affected cell lines displayed about 80% reduction in CCK content in early passages after transfection. Expression of antisense PC1 message in these cell lines resulted in a selective depletion of CCK 8 and a comparative sparing of CCK 22. The induction of antisense PC1 message within a single subclone of Rin5F cells using the Lac Switch system also resulted in a significant inhibition of CCK content, Expression of antisense PC1 message in a stably transfected STC-1 cell line also resulted in a decrease in CCK content and in PC1 protein expression, and the specific depletion of CCK 8 with comparative sparing of CCK 22, These observations support the hypothesis that PC1 is necessary for pro-CCK processing in Rin5F and STC-1 cells and suggests a role for PC1 endoprotease in the biosynthesis of CCK 8 in vivo.	TUFTS UNIV, SCH MED, DEPT PHARMACOL & EXPT THERAPEUT, BOSTON, MA 02111 USA; ST LOUIS UNIV, SCH MED, DEPT PHARMACOL & PHYSIOL SCI, ST LOUIS, MO 63104 USA	Tufts University; Saint Louis University					NINDS NIH HHS [NS 18667, NS 31602] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031602, R01NS018667] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER G, 1991, GASTROENTEROLOGY, V100, P537, DOI 10.1016/0016-5085(91)90227-C; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARNERIC SP, 1986, PEPTIDES, V7, P97, DOI 10.1016/0196-9781(86)90068-9; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEINFELD MC, 1992, NEUROPEPTIDES, V22, P213, DOI 10.1016/0143-4179(92)90048-2; BEINFELD MC, 1981, BRAIN RES, V212, P51, DOI 10.1016/0006-8993(81)90031-7; BEINFELD MC, 1981, NEUROPEPTIDES, V2, P123, DOI 10.1016/0143-4179(81)90061-5; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BROG JS, 1992, J PHARMACOL EXP THER, V260, P343; CANTOR P, 1989, AM J PHYSIOL, V256, pG53, DOI 10.1152/ajpgi.1989.256.1.G53; Cawley NX, 1996, J BIOL CHEM, V271, P4168; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSI C, 1989, EUR J PHARMACOL, V165, P209, DOI 10.1016/0014-2999(89)90714-0; DOCKRAY GJ, 1978, NATURE, V274, P711, DOI 10.1038/274711a0; EBERLEIN GA, 1992, J BIOL CHEM, V267, P1517; EBERLEIN GA, 1988, PEPTIDES, V9, P993, DOI 10.1016/0196-9781(88)90079-4; Feng B, 1992, Ann N Y Acad Sci, V660, P280, DOI 10.1111/j.1749-6632.1992.tb21085.x; FREEMAN AS, 1991, BRAIN RES, V555, P281, DOI 10.1016/0006-8993(91)90353-W; Friedman TC, 1996, MOL CELL ENDOCRINOL, V116, P89, DOI 10.1016/0303-7207(95)03702-0; FRIEDMAN TC, 1995, ARCH BIOCHEM BIOPHYS, V316, P5, DOI 10.1006/abbi.1995.1002; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; GEOLA FL, 1981, J CLIN ENDOCR METAB, V53, P270, DOI 10.1210/jcem-53-2-270; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HASTIE ND, 1978, P NATL ACAD SCI USA, V75, P1217, DOI 10.1073/pnas.75.3.1217; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INNIS RB, 1979, P NATL ACAD SCI USA, V76, P521, DOI 10.1073/pnas.76.1.521; Johanning K, 1996, J NEUROCHEM, V66, P898; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUTT V, 1968, EUR J BIOCHEM, V6, P156, DOI 10.1111/j.1432-1033.1968.tb00433.x; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PATERSON BM, 1977, P NATL ACAD SCI USA, V74, P4370, DOI 10.1073/pnas.74.10.4370; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; REHFELD JF, 1978, J BIOL CHEM, V253, P4022; RINDI G, 1990, AM J PATHOL, V136, P1349; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SAMBROOKJ, 1989, MOL CLONING LAB MANU; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VERHAGE M, 1991, J NEUROCHEM, V56, P1394, DOI 10.1111/j.1471-4159.1991.tb11437.x; VIERECK JC, 1992, J BIOL CHEM, V267, P19475; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Wang WG, 1997, BIOCHEM BIOPH RES CO, V231, P149, DOI 10.1006/bbrc.1997.6065; YOON JY, 1994, ENDOCRINE, V2, P973	56	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9450	9456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083084				2022-12-27	WOS:A1997WU03700089
J	Gong, JP; Kini, RM; Gwee, MCE; Gopalakrishnakone, P; Chung, MCM				Gong, JP; Kini, RM; Gwee, MCE; Gopalakrishnakone, P; Chung, MCM			Makatoxin I, a novel toxin isolated from the venom of the scorpion Buthus martensi Karsch, exhibits nitrergic actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANOCOCCYGEUS MUSCLE; NITRIC-OXIDE; PURIFICATION	Buthus martensi Karsch venom exhibits nitrergic action in rat anococcygeus muscle (ACM), We have purified a novel toxin, makatoxin I (MkTx I), which exhibits nitrergic action, to homogeneity from this venom by a combination of gel-filtration, cation-exchange chromatography, and reverse-phase chromatography, Its purity was assessed by capillary electrophoresis and mass spectrometry, Its molecular weight was found to be 7031.71 +/- 2.88 as calculated from electrospray mass spectrographic data, The complete amino acid sequence was elucidated by sequencing of reduced and S-pyridylethylated toxin and a carboxyl-terminal peptide, P55-64, generated by the cleavage of toxin with endoproteinase Lys-C, The complete sequence of MkTx I is GRDAYIADSENCTYTCALNPYCNDLCTKNGAKSGYCQWAGRYGNACWCIDLPDKVPIRISGSCR. This toxin is composed of 64 amino acid residues and contains 8 half-cystine residues, Structurally, MkTx I has high similarity to Bot I and Bot II when compared with toxins from other scorpion species, The effects of MkTx I on nitrergic responses were investigated using the rat isolated ACM mounted in Krebs solution (37 degrees C, 5% CO2 in O-2), MkTx I (2 mu g/ml) markedly relaxed the carbachol-precontracted ACM; the relaxation was inhibited by the stereoselective inhibitor of nitric oxide synthase, N omega-nitro-L-arginine methyl ester (50 mu M). Thus, MkTx I is the first alpha-toxin that can mediate nitrergic responses in the rat isolated ACM.	NATL UNIV SINGAPORE,VENOM & TOXIN RES GRP,FAC MED,DEPT ANAT,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,VENOM & TOXIN RES GRP,FAC SCI,BIOSCI CTR,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,VENOM & TOXIN RES GRP,FAC MED,DEPT PHARMACOL,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,VENOM & TOXIN RES GRP,FAC MED,DEPT BIOCHEM,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,VENOM & TOXIN RES GRP,FAC ENGN,BIOPROC TECHNOL CTR,SINGAPORE 119260,SINGAPORE	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore			Chung, Maxey C.M./C-3817-2014; Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251				BAUER CK, 1992, TOXICON, V30, P581, DOI 10.1016/0041-0101(92)90852-V; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; GILLESPI.JS, 1972, BRIT J PHARMACOL, V45, P404, DOI 10.1111/j.1476-5381.1972.tb08097.x; GREGOIRE J, 1983, TOXICON, V21, P153, DOI 10.1016/0041-0101(83)90058-2; KOPEYAN C, 1985, FEBS LETT, V181, P211, DOI 10.1016/0014-5793(85)80262-3; Kopeyan Charles, 1993, Natural Toxins, V1, P308, DOI 10.1002/nt.2620010510; KOWALUK EA, 1992, J PHARMACOL EXP THER, V262, P916; LI CG, 1989, CLIN EXP PHARMACOL P, V16, P933, DOI 10.1111/j.1440-1681.1989.tb02404.x; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MARTIN W, 1991, NOVEL PERIPHERAL NEU, P65; MCINTOSH ME, 1973, TOXINS ANIMAL PLANT, V3, P529; Mebs D., 1990, HDB TOXINOLOGY, P493; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; POSSANI DL, 1980, TOXICON, V18, P175; QI H, 1993, ACTA PHARM SINIC, V14, P361; RAND MJ, 1992, CLIN EXP PHARMACOL P, V19, P147, DOI 10.1111/j.1440-1681.1992.tb00433.x; Rochat H, 1979, Adv Cytopharmacol, V3, P325; SHIH Y, 1982, Acta Physiologica Sinica, V34, P428; Simard J.M., 1990, P414; Song D.X., 1982, B BIOL FR BELG, V1, P22; VAGAS O, 1982, TOXICON, V20, P79; VARGAS O, 1987, EUR J BIOCHEM, V162, P589, DOI 10.1111/j.1432-1033.1987.tb10680.x	23	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8320	8324		10.1074/jbc.272.13.8320	http://dx.doi.org/10.1074/jbc.272.13.8320			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079654	hybrid			2022-12-27	WOS:A1997WQ63500037
J	Johansson, M; Karlsson, A				Johansson, M; Karlsson, A			Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDINE KINASE; EXPRESSION; METABOLISM; HEPATITIS; TOXICITY; LINKAGE	Human thymidine kinase 2 (TK2) is a deoxyribonucleoside kinase that phosphorylates thymidine, deoxycytidine, and deoxyuridine, The enzyme also phosphorylates anti-viral and anti-cancer nucleoside analogs, We have identified an expressed sequence tag cDNA that encoded a 27.5-kDa protein approximate to 30% similar to the human deoxycytidine kinase and deoxyguanosine kinase, The protein was expressed in Escherichia coli and shown to have similar substrate specificity as reported for purified native human TK2, The recombinant TK2 was shown to phosphorylate the anti-cancer nucleoside analog 2',2'-difluorodeoxycytidine. Northern blot analysis showed two mRNA species at 2.4 and 4.0 kilobases predominantly expressed in liver, pancreas, muscle, and brain, We identified a sequence-tagged site designed from the 3' region of the TK2 cDNA, The sequence-tagged site has been mapped to 81-84 centimorgans from the top linkage group of chromosome 16, which corresponds to the 16q22 region, Our data show that deoxycytidine kinase, deoxyguanosine kinase, and TK2 belong to a family of closely related enzymes, At the time of this report all four of the known human deoxyribonucleoside kinases have been cloned, This provides the opportunity to characterize their individual contribution to therapeutic and toxic effects of nucleoside analogs.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; EIBERG H, 1988, CLIN GENET, V34, P272; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; HEINEMANN V, 1988, CANCER RES, V48, P4024; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Johansson M, 1996, GENOMICS, V38, P450, DOI 10.1006/geno.1996.0654; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; MA GT, 1995, J BIOL CHEM, V270, P6595, DOI 10.1074/jbc.270.12.6602; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; Moore M, 1996, CANCER, V78, P633; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; NEUPERT W, 1994, CLIN INVESTIGATOR, V72, P251; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAW T, 1995, LIVER, V15, P169; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; STEGMANN APA, 1993, GENOMICS, V17, P528, DOI 10.1006/geno.1993.1365; Wang JH, 1996, ANTIMICROB AGENTS CH, V40, P1555, DOI 10.1128/AAC.40.6.1555; WILLECKE K, 1977, SOMAT CELL GENET, V3, P237, DOI 10.1007/BF01538743	30	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8454	8458		10.1074/jbc.272.13.8454	http://dx.doi.org/10.1074/jbc.272.13.8454			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079672	hybrid			2022-12-27	WOS:A1997WQ63500055
J	MacNeill, C; Ayres, B; Laverriere, AC; Burch, JBE				MacNeill, C; Ayres, B; Laverriere, AC; Burch, JBE			Transcripts for functionally distinct isoforms of chicken GATA-5 are differentially expressed from alternative first exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; DNA-BINDING PROTEIN; MAMMALIAN-CELLS; DEVELOPING HEART; REGULATORY GENE; MESSENGER-RNAS; ZINC-FINGER; IN-VITRO; TRANSLATION; SEQUENCES	Our analysis of cDNA and genomic clones unexpectedly revealed that the chicken gata-5 gene is differentially expressed from alternative first exons, Moreover, we show that the respective transcripts are differentially processed to yield mrnas for two distinct isoforms of GATA-5. The major isoform, which we described previously, has two CXNCX(17)CNXC zinc fingers typical of a vertebrate GATA factor, The minor isoform, on the other hand, has only one such zinc finger, We show that this novel isoform localizes within the nuclei of transfected cells and can bind to a consensus GATA site, This truncated isoform of GATA-5 is compromised in its ability to transactivate a simple target gene, however, and thus is functionally distinct from the major isoform of GATA-5.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; PHS HHS [35535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABEL T, 1993, DEVELOPMENT, V119, P623; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FU YH, 1990, P NATL ACAD SCI USA, V87, P5331, DOI 10.1073/pnas.87.14.5331; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEORGE KM, 1994, DEVELOPMENT CAMB, V120, P2637; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KELLEY C, 1993, DEVELOPMENT, V118, P817; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 2002, MOL CLONING LAB MANU; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201; ZIMMER A, 1994, J CELL BIOL, V127, P111	37	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8396	8401		10.1074/jbc.272.13.8396	http://dx.doi.org/10.1074/jbc.272.13.8396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079664	hybrid			2022-12-27	WOS:A1997WQ63500047
J	Yamagishi, S; Yonekura, H; Yamamoto, Y; Katsuno, K; Sato, F; Mita, I; Ooka, H; Satozawa, N; Kawakami, T; Nomura, M; Yamamoto, H				Yamagishi, S; Yonekura, H; Yamamoto, Y; Katsuno, K; Sato, F; Mita, I; Ooka, H; Satozawa, N; Kawakami, T; Nomura, M; Yamamoto, H			Advanced glycation end products-driven angiogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; DIABETIC-RETINOPATHY; VASCULAR PERICYTES; HYPOXIC INDUCTION; MAILLARD REACTION; MESSENGER-RNA; FACTOR FAMILY; FACTOR VEGF; CELLS; RECEPTOR	This study was undertaken to determine whether and how advanced glycation end products (AGE), senescent macroproteins accumulated in various tissues under hyperglycemic states, cause angiogenesis, the principal vascular derangement in diabetic microangiopathy. We first prepared AGE-bovine serum albumin (BSA) and anti-AGE antiserum using AGE-RNase A. Then AGE-BSA was administered to human skin microvascular endothelial cells in culture, and their growth was examined. The AGE-BSA, but not nonglycated BSA, was found to induce a statistically significant increase in the number of viable endothelial cells as well as their synthesis of DNA. The increase in DNA synthesis by AGE-BSA was abolished by anti-AGE antibodies. AGE-BSA also stimulated the tube formation of endothelial cells on Matrigel. We obtained the following evidence that it is vascular endothelial growth factor (VEGF) that mainly mediates the angiogenic activities of AGE. (1) Quantitative reverse transcription-polymerase chain reaction analysis of poly(A)(+) RNA from microvascular endothelial cells revealed that AGE-BSA up-regulated the levels of mRNAs for the secretory forms of VEGF in time- and dose-dependent manners, while endothelial cell expression of the genes encoding the two VEGF receptors, kinase insert domain-containing receptor and fms-like tyrosine kinase 1, remained unchanged by the AGE treatment. Immunoprecipitation analysis revealed that AGE-BSA did increase de novo synthesis of VEGF. (2) Monoclonal antibody against human VEGF completely neutralized both the AGE-induced DNA synthesis and tube formation of the endothelial cells. The results suggest that AGE can elicit angiogenesis through the induction of autocrine vascular VEGF, thereby playing an active part in the development and progression of diabetic microangiopathies.	KANAZAWA UNIV,SCH MED,DEPT BIOCHEM,KANAZAWA,ISHIKAWA 920,JAPAN; KISSEI PHARMACEUT CO LTD,DISCOVERY RES LAB 3,HOTAKA 39983,JAPAN; MITSUI PHARMACEUT INC,INST BIOL SCI,MOBARA 297,JAPAN; MITSUI TOATSU CHEM CO LTD,LIFE SCI LAB,MOBARA 297,JAPAN	Kanazawa University; Kissei Pharmaceutical Co Ltd								ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AHMED MU, 1986, J BIOL CHEM, V261, P4889; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CHO HK, 1991, OPHTHALMIC SURG LAS, V22, P44; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DolhoferBliesener R, 1996, EUR J CLIN CHEM CLIN, V34, P355; DORCHY H, 1993, DIABETES CARE, V16, P1212, DOI 10.2337/diacare.16.8.1212; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FELDTRASMUSSEN B, 1986, DIABETOLOGIA, V29, P282, DOI 10.1007/BF00452063; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GRANT DS, 1991, IN VITRO CELL DEV B, V27, P327; Gugliucci A, 1996, DIABETOLOGIA, V39, P149, DOI 10.1007/BF00403957; HAMMES HP, 1995, DIABETOLOGIA, V38, P656, DOI 10.1007/s001250050333; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JOHNSON PC, 1982, ARCH PATHOL LAB MED, V106, P214; Joukov V, 1996, EMBO J, V15, P290; KROLEWSKI AS, 1991, AM J MED, V90, pS56, DOI 10.1016/0002-9343(91)90040-5; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; KUWABARA T, 1960, ARCH OPHTHALMOL-CHIC, V64, P904, DOI 10.1001/archopht.1960.01840010906012; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MICHEEL F, 1959, CHEM BER, V90, P2836; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; NAKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P740, DOI 10.1016/0006-291X(89)92372-3; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OOKA H, 1992, MICROBIOL IMMUNOL, V36, P1305, DOI 10.1111/j.1348-0421.1992.tb02132.x; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; SATO F, 1996, DIABETS S2, V45, P264; SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VRIES CD, 1992, SCIENCE, V255, P989; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; Yamamoto Y, 1996, BIOCHEM BIOPH RES CO, V222, P700, DOI 10.1006/bbrc.1996.0807	51	285	293	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8723	8730		10.1074/jbc.272.13.8723	http://dx.doi.org/10.1074/jbc.272.13.8723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079706	hybrid			2022-12-27	WOS:A1997WQ63500089
J	Hoskins, LC; Boulding, ET; Larson, G				Hoskins, LC; Boulding, ET; Larson, G			Purification and characterization of blood group A-degrading isoforms of alpha-N-acetylgalactosaminidase from Ruminococcus torques strain IX-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON ECOSYSTEMS; HUMAN FECAL FLORA; MUCIN DEGRADATION; CLOSTRIDIUM-PERFRINGENS; GROUP-O; GROUP-B; GEL-ELECTROPHORESIS; GROUP SPECIFICITY; HEXOSAMINIDASE-C; GROUP ANTIGENS	To cleave blood group A immunodeterminants from erythrocytes (Hoskins, L, C,, Larson, Gr,, and Naff, G. B, (1995) Transfusion 35, 813-821), we purified and characterized alpha-N-acetylgalactosaminidase (EC 3.2.1.49) activity from culture supernatants of the human fecal bacterium Ruminococcus torques strain IX-70, Three isoforms separated during hydrophobic interaction chromatography, Hydroxyapatite chromatography further resolved the most hydrophilic, isoform I, into isoforms IA and IB, The most hydrophobic, isoform III, differed from IA and IB by a more acidic pH optimum, greater heat resistance, greater sensitivity to alkylating agents, and anomalous retardation during gel filtration chromatography, Isoform IB differed from IA and III in N-terminal amino acid sequence and in sensitivity to EDTA inhibition, Each cleaved nonreducing alpha(1-->3)-N-acetylgalactosamine residues from human blood group A and AB mucin glycoproteins, Forssman hapten, and blood group A lacto series glycolipids, The apparent molecular mass of denatured isoform subunits of IA, IB, and III-PII (158, 173, and 201 kDa, respectively) bore no integer relationship to the apparent molecular mass of the native isoforms (265, 417, and 530 kDa), but the latter bore a ratio of 1.96:3.09:3.93 to the weight-average apparent molecular mass of native IA (135 kDa), suggesting that the isoforms are multimers of a 135-kDa sequence, Isoforms IA and III-PII had an identical N-terminal amino acid sequence which showed homologies to the N-terminal sequence of sialidases produced by Bacteroides fragilis SBT3182, another commensal enteric bacterium.	CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM & TRANSFUS MED, S-41345 GOTHENBURG, SWEDEN	Case Western Reserve University; Sahlgrenska University Hospital; University of Gothenburg	Hoskins, LC (corresponding author), VA MED CTR 541 111EW, DEPT MED, 10701 E BLVD, CLEVELAND, OH 44106 USA.		Larson, Göran/AAF-3404-2019		NCI NIH HHS [P30 CA43703] Funding Source: Medline; NHLBI NIH HHS [R01-HL45659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMINOFF D, 1970, J BIOL CHEM, V245, P1659; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; BELL WC, 1978, CARBOHYD RES, V61, P447, DOI 10.1016/S0008-6215(00)84504-8; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRAIDMAN I, 1974, BIOCHEM J, V143, P295, DOI 10.1042/bj1430295; BRAIDMAN I, 1974, FEBS LETT, V41, P181, DOI 10.1016/0014-5793(74)81206-8; BROWN WC, 1970, BIOCHIM BIOPHYS ACTA, V198, P308, DOI 10.1016/0005-2744(70)90063-X; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; DEAN KJ, 1979, J BIOL CHEM, V254, P6; DEAN KJ, 1979, J BIOL CHEM, V254, P1001; FALK P, 1991, BIOCHIM BIOPHYS ACTA, V1084, P139, DOI 10.1016/0005-2760(91)90212-Z; FALK P, 1990, J BIOCHEM-TOKYO, V108, P466, DOI 10.1093/oxfordjournals.jbchem.a123223; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; FINCH PR, 1969, ANAL BIOCHEM, V31, P296, DOI 10.1016/0003-2697(69)90269-3; FURUKAWA K, 1970, BLOOD TISSUE ANTIGEN, P415; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOLDSTEIN J, 1982, SCIENCE, V215, P168, DOI 10.1126/science.6274021; Goldstein J, 1989, Transfus Med Rev, V3, P206, DOI 10.1016/S0887-7963(89)70080-8; GOLDSTEIN J, 1983, PROGR CLIN RES, V65, P139; HATA J, 1992, BIOCHEM INT, V28, P77; HOLDEMAN LV, 1974, INT J SYST BACTERIOL, V24, P260, DOI 10.1099/00207713-24-2-260; HOLDEMAN LV, 1976, APPL ENVIRON MICROB, V31, P359, DOI 10.1128/AEM.31.3.359-375.1976; HOSKINS L C, 1992, Microbial Ecology in Health and Disease, V5, P193; HOSKINS LC, 1985, J CLIN INVEST, V75, P944, DOI 10.1172/JCI111795; HOSKINS LC, 1995, TRANSFUSION, V35, P813, DOI 10.1046/j.1537-2995.1995.351096026361.x; HOSKINS LC, 1976, J CLIN INVEST, V57, P63, DOI 10.1172/JCI108270; HOSKINS LC, 1993, EUR J GASTROEN HEPAT, V5, P205, DOI 10.1097/00042737-199304000-00004; HOSKINS LC, 1981, J CLIN INVEST, V67, P163, DOI 10.1172/JCI110009; HOWE C, 1953, J AM CHEM SOC, V75, P5542, DOI 10.1021/ja01118a022; HUANG CC, 1972, J BIOL CHEM, V247, P6737; HUANG CC, 1974, BIOCHIM BIOPHYS ACTA, V371, P462, DOI 10.1016/0005-2795(74)90042-7; HUTTON DA, 1990, CLIN SCI, V78, P265, DOI 10.1042/cs0780265; ITOH T, 1984, J BIOCHEM-TOKYO, V95, P959, DOI 10.1093/oxfordjournals.jbchem.a134723; JOHANSSON BL, 1988, J CHROMATOGR, V457, P205, DOI 10.1016/S0021-9673(01)82068-9; KADOWAKI S, 1989, AGR BIOL CHEM TOKYO, V53, P111, DOI 10.1080/00021369.1989.10869270; KARLSSON KA, 1981, J BIOL CHEM, V256, P3512; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON G, 1988, J BIOL CHEM, V263, P10790; LENNY LL, 1991, BLOOD, V77, P1383; LENNY LL, 1994, TRANSFUSION, V34, P209, DOI 10.1046/j.1537-2995.1994.34394196617.x; LEVY GN, 1980, J BIOL CHEM, V255, P1737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE GT, 1988, J APPL BACTERIOL, V64, P37, DOI 10.1111/j.1365-2672.1988.tb02427.x; Maizel JV, 1971, METHOD VIROL, V5, P179; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; McDonald M.J., 1972, METHODS ENZYMOL    B, V28, P734; MCGUIRE EJ, 1972, METHOD ENZYMOL, V28, P755; MCKIBBIN JM, 1969, BIOCHEMISTRY-US, V8, P679, DOI 10.1021/bi00830a033; MILLER RS, 1981, GASTROENTEROLOGY, V81, P759; MOKRASCH LC, 1954, J BIOL CHEM, V208, P55; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; MURAMATSU T, 1968, J BIOCHEM, V64, P521, DOI 10.1093/oxfordjournals.jbchem.a128925; NAKAGAWA H, 1987, J BIOCHEM-TOKYO, V101, P855, DOI 10.1093/oxfordjournals.jbchem.a121952; ORTIZ JM, 1972, BIOCHIM BIOPHYS ACTA, V289, P174, DOI 10.1016/0005-2744(72)90120-9; OVERDIJK B, 1975, BIOCHEM J, V151, P257, DOI 10.1042/bj1510257; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SIEGEL S., 1956, NONPARAMETRIC STAT B; *SIGM CHEM CO, 1986, TECHN B; *SIGM CHEM CO, 1982, TECHN B; SIZMANN D, 1990, EUR J BIOCHEM, V192, P143, DOI 10.1111/j.1432-1033.1990.tb19207.x; SUNG SSJ, 1980, J BIOL CHEM, V255, P6589; TANAKA H, 1994, J BIOCHEM-TOKYO, V115, P318, DOI 10.1093/oxfordjournals.jbchem.a124335; TUPPY H, 1966, BIOCHEMISTRY-US, V5, P1742, DOI 10.1021/bi00869a042; UDA Y, 1977, J BIOL CHEM, V252, P5194; VALLEE BL, 1992, FARADAY DISCUSS, V93, P47, DOI 10.1039/fd9929300047; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Weber K., 1975, PROTEINS, VI, P179; WIESSMANN B, 1969, BIOCHEMISTRY-US, V8, P2034; YAGI F, 1990, ARCH BIOCHEM BIOPHYS, V280, P61, DOI 10.1016/0003-9861(90)90518-4; YAMADA M, 1973, J BIOCHEM-TOKYO, V73, P69; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	76	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7932	7939		10.1074/jbc.272.12.7932	http://dx.doi.org/10.1074/jbc.272.12.7932			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065462	hybrid			2022-12-27	WOS:A1997WP59200056
J	Sullivan, W; Stensgard, B; Caucutt, G; Bartha, B; McMahon, N; Alnemri, ES; Litwack, G; Toft, D				Sullivan, W; Stensgard, B; Caucutt, G; Bartha, B; McMahon, N; Alnemri, ES; Litwack, G; Toft, D			Nucleotides and two functional states of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PROGESTERONE-RECEPTOR COMPLEXES; GLUCOCORTICOID RECEPTOR; HYDROPHOBIC REGION; STEROID-RECEPTORS; BINDING; INHIBITION; TRANSFORMATION; HETEROCOMPLEX; GELDANAMYCIN	Previous studies have demonstrated the ATP-dependent formation of a complex containing the heat shock protein hsp90, the unique hsp90 binding protein p23, and one of three high molecular weight immunophilins. In the present study, hsp90 and p23 are shown 60 form a complex that requires elevated temperature and ATP/Mg2+. Complex formation is strongly promoted by molybdate and by the nonionic detergent Nonidet P-40. ADP and the benzoquinone ansamycin, geldanamycin, are potent inhibitors of complex formation. The ATP-dependent process alters the state of hsp90, not p23, and influences the ability of hsp90 to bind to phenyl-Sepharose. Conversion of hsp90 to the ATP-bound state lowers its affinity for phenyl-Sepharose. These results show that hsp90 can exist in at least two functional states, one able to bind p23 and the other with a high affinity for hydrophobic resins. A model is presented where these states are dictated by the binding of either ATP or ADP.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107	Mayo Clinic; Jefferson University			Alnemri, Emad S/B-4526-2010					ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HOUSLEY PR, 1990, BIOCHEMISTRY-US, V29, P3578, DOI 10.1021/bi00466a022; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NIELSEN CJ, 1977, CANCER RES, V37, P3421; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; NISHIGORI H, 1980, ARCH BIOCHEM BIOPHYS, V203, P600, DOI 10.1016/0003-9861(80)90217-9; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WRIGHT LS, 1993, PROTEIN EXPRES PURIF, V4, P417, DOI 10.1006/prep.1993.1055; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532	46	223	228	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8007	8012		10.1074/jbc.272.12.8007	http://dx.doi.org/10.1074/jbc.272.12.8007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065472	hybrid			2022-12-27	WOS:A1997WP59200066
J	vanderVliet, A; Eiserich, JP; Halliwell, B; Cross, CE				vanderVliet, A; Eiserich, JP; Halliwell, B; Cross, CE			Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite - A potential additional, mechanism of nitric oxide-dependent toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LUNG INJURY; HYDROGEN-PEROXIDE; HUMAN-NEUTROPHILS; HORSERADISH-PEROXIDASE; ANTIMICROBIAL ACTIVITY; EOSINOPHIL PEROXIDASE; CHLORINATING ACTIVITY; THYROID PEROXIDASE; AQUEOUS-SOLUTION; SYNOVIAL-FLUID	Involvement of peroxynitrite (ONOO-) in inflammatory diseases has been implicated by detection of 3-nitrotyrosine, an allegedly characteristic protein oxidation product, in various inflamed tissues, We show here that nitrite (NO2-), the primary metabolic end product of a nitric oxide (NO.), can be oxidized by the heme peroxidases horseradish peroxidase, myeloperoxidase (MPO), and lactoperoxidase (LPO), in the presence of hydrogen peroxide (H2O2), to most likely form NO2., which can also contribute to tyrosine nitration during inflammatory processes. Phenolic nitration by MPO-catalyzed NO2- oxidation is only partially inhibited by chloride (Cl-), the presumed major physiological substrate for MPO. In fact, low concentrations of NO2- (2-10 mu M) catalyze MPO-mediated oxidation of Cl-, indicated by increased chlorination of monochlorodimedon or 4-hydroxyphenylacetic acid, most likely via reduction of MPO compound II, Peroxidase-catalyzed oxidation of NO-2, as indicated by phenolic nitration, was also observed in the presence of thiocyanate (SCN-), an alternative physiological substrate for mammalian peroxidases, Collectively, our results suggest that N--(O), at physiological or pathological levels, is a substrate for the mammalian peroxidases MPO and lactoperoxidase and that formation of NO-2 via peroxidase-catalyzed oxidation of NO. may provide an additional pathway contributing to cytotoxicity or host defense associated with increased NO' production.	UNIV LONDON KINGS COLL,NEURODEGENERAT DIS RES CTR,PHARMACOL GRP,LONDON SW3 6LX,ENGLAND	University of London; King's College London	vanderVliet, A (corresponding author), MED SPONSORED PROGRAMS,UNIV CALIF DAVIS,DEPT INTERNAL MED,PULM RES LAB,DIV PULM CRIT CARE MED,DAVIS,CA 95616, USA.		Halliwell, Barry/C-8318-2009		NHLBI NIH HHS [HL47628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMADO R, 1984, METHOD ENZYMOL, V107, P377; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; Buttery LDK, 1996, LAB INVEST, V75, P77; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; COHEN G, 1964, BIOCHEMISTRY-US, V3, P901, DOI 10.1021/bi00895a007; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Doyle M P, 1985, J Free Radic Biol Med, V1, P145, DOI 10.1016/0748-5514(85)90019-4; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FARHANGRAZI ZS, 1995, BIOCHEMISTRY-US, V34, P2866, DOI 10.1021/bi00009a017; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRISHAM MB, 1990, AM J PHYSIOL, V258, pC115, DOI 10.1152/ajpcell.1990.258.1.C115; Haas P, 1924, BIOCHEM J, V18, P614, DOI 10.1042/bj0180614; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEPPEL LA, 1949, J BIOL CHEM, V178, P549; HOSKINS JA, 1988, J CHROMATOGR-BIOMED, V426, P155, DOI 10.1016/S0378-4347(00)81937-4; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MARTIN H, 1963, NATURE, V200, P898, DOI 10.1038/200898a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOODIE RB, 1979, J CHEM SOC PERK T 2, P133, DOI 10.1039/p29790000133; NAKAMURA M, 1986, J BIOL CHEM, V261, P13923; PARKS NJ, 1981, SCIENCE, V212, P58, DOI 10.1126/science.7209517; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SALATHE M, 1995, AM J RESP CRIT CARE, V151, P1543, DOI 10.1164/ajrccm.151.5.7735613; Sampson JB, 1996, METHOD ENZYMOL, V269, P210; SHIBATA H, 1995, BBA-BIOENERGETICS, V1230, P45, DOI 10.1016/0005-2728(95)00031-D; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; TANNENBAUM SR, 1976, FOOD COSMET TOXICOL, V14, P549, DOI 10.1016/S0015-6264(76)80006-5; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	75	679	697	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7617	7625		10.1074/jbc.272.12.7617	http://dx.doi.org/10.1074/jbc.272.12.7617			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065416	hybrid			2022-12-27	WOS:A1997WP59200010
J	Koda, Y; Soejima, M; Kimura, H				Koda, Y; Soejima, M; Kimura, H			Structure and expression of H-type GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase gene (FUT1) - Two transcription start sites and alternative splicing generate several forms of FUT1 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE; BLOOD-GROUP ANTIGENS; HUMAN GASTRIC-MUCOSA; MOLECULAR-CLONING; HUMAN-SERUM; ALPHA-2,6-SIALYLTRANSFERASE GENE; HUMAN COLON; CELL-LINE; PURIFICATION; ORGANIZATION	The expression of the ABO antigens on erythrocyte membranes is regulated by H gene (FUT1)-encoded alpha(1,2)fucosyltransferase activity. We have examined the expression of the FUT1 in several tumor cell lines, including erythroid lineage and normal bone marrow cells, by Northern blot and/or reverse transcription-polymerase chain reaction (RT-PCR) analyses. RT-PCR indicated that bone marrow cells, erythroleukemic cells (HEL), and highly undifferentiated leukemic cells (K562) that have erythroid characteristics expressed the FUT1 mRNA while four leukemic cell lines did not. The FUT1 mRNA was also demonstrated in gastric, colonic, and ovarian (MCAS) cancer cell lines by RT-PCR. Northern blot analysis indicated that a 4.0-kilobase FUT1 transcript was expressed in some of these tumor cell lines, Rapid amplification of 5' cDNA end (RACE) analysis suggested that the FUT1 transcript had several forms generated by two distinct transcription start sites and alternative splicing, The results of RT-PCR using specific primers for each starting exon suggested that two transcription initiation sites (exon 1A and exon 2A) of the FUT1 were identified in gastric cancer cells and in ovarian cancer cells. Only exon 1A was identified as a transcription start site in another gastric cancer cell line, two colonic cancer cell lines, and in K562 cells, whereas only exon 2A was identified in HEL cells and in bone marrow cells. These two transcription start sites were located 1.8 kilobases apart, Therefore, two distinct promoters appeared to be present in the FUT1. The distinct promoters of the FUT1 and alternative splicing of the FUT1 mRNA may be associated with time- and tissue-specific expression of the FUT1.	KURUME UNIV, SCH MED, DEPT FORENS MED, DIV HUMAN GENET, KURUME, FUKUOKA 830, JAPAN	Kurume University			Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Furukawa K, 1996, J BIOL CHEM, V271, P20836, DOI 10.1074/jbc.271.34.20836; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; JOHNSON PH, 1994, VOX SANG S2, V67, P25; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; Koda Y, 1996, AM J HUM GENET, V59, P343; KODA Y, 1993, BLOOD, V82, P2915; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MASUTANI H, 1995, J BIOCHEM-TOKYO, V118, P541, DOI 10.1093/oxfordjournals.jbchem.a124942; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; ORNTOFT TF, 1991, GUT, V32, P287, DOI 10.1136/gut.32.3.287; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; Szulman A E, 1980, Curr Top Dev Biol, V14, P127; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wang BJ, 1997, VOX SANG, V72, P31, DOI 10.1046/j.1423-0410.1997.00031.x; WANG BJ, 1994, FORENSIC SCI INT, V67, P1, DOI 10.1016/0379-0738(94)90405-7; WANG XC, 1993, J BIOL CHEM, V268, P4355; Watkins W.M., 1995, GLYCOPROTEINS, P313; WEN DX, 1992, J BIOL CHEM, V267, P2512	40	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7501	7505		10.1074/jbc.272.11.7501	http://dx.doi.org/10.1074/jbc.272.11.7501			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054453	hybrid			2022-12-27	WOS:A1997WN14700092
J	Mira, JP; Dubois, T; Oudinet, JP; Lukowski, S; RussoMarie, F; Geny, B				Mira, JP; Dubois, T; Oudinet, JP; Lukowski, S; RussoMarie, F; Geny, B			Inhibition of cytosolic phospholipase A(2) by annexin V in differentiated permeabilized HL-60 cells - Evidence of crucial importance of domain I type II Ca2+-binding site in the mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; TIGHT-BINDING INHIBITORS; MEMBRANE-BINDING; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; ANTICOAGULANT PROTEIN; MOLECULAR-STRUCTURE; MONONUCLEAR-CELLS; CALCIUM IONOPHORE; HUMAN NEUTROPHILS	Annexin V belongs to a family of proteins that interact with phospholipids in a Ca2+-dependent manner. This protein has been demonstrated to have anti-phospholipase A(2) activity, However, this effect has never yet been reported with the 85-kDa cytosolic PLA(2) (cPLA(2)), We studied, in a model of differentiated and streptolysin O-permeabilized HL-60 cells, the effect of annexin V on cPLA(2) activity after stimulation by calcium, GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)), formyl-Met-Leu-Phe, or phorbol 12-myristate 13-acetate, Both recombinant and human placental purified annexin V inhibit cPLA(2) activity whatever the stimulus used, The decrease of arachidonic acid release is of 40 and 50%, respectively, at [Ca2+] of 3 and 10 mu M. The mechanism of inhibition was also analyzed, cPLA(2) requires calcium and protein kinase C (PKC) or mitogen activated protein kinase phosphorylation for its activation, As annexin V was shown to be an endogenous inhibitor of PKC, PKC-stimulated cPLA(2) activity was analyzed, Using GF109203x, a specific PKC inhibitor, we demonstrated that this pathway is of minor importance in our model, cPLA(2) inhibition by annexin V is not linked to PKC inhibition, To test the hypothesis of phospholipid depletion, mutants of annexin V were constructed using mutagenesis directed to Ca2+ site, We demonstrate that the Ca2+ site located in domain I is necessary for the inhibitory effect of annexin V on cPLA(2) activity, The site in domain IV is also involved but with less efficiency. In contrast, mutations in site II and III do not modify this effect, Moreover, annexin V mutated on all sites does not inhibit cPLA(2), Thus, we propose a predominant role of module (I/IV) in the biological action of annexin V, which, in physiological conditions, may control cPLA(2) activity by depletion of the phospholipid substrate.	INST COCHIN GENET MOL, INSERM, UNITE 332, F-75014 PARIS, FRANCE; COCHIN UNIV HOSP, MED INTENS CARE UNIT, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Dubois, Thierry/D-2852-2017	Dubois, Thierry/0000-0003-4739-6164				AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARROWMAN MM, 1987, J PHYSIOL-LONDON, V383, P115; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Barwise JL, 1996, J CELL SCI, V109, P247; BASTIAN BC, 1993, J INVEST DERMATOL, V101, P359, DOI 10.1111/1523-1747.ep12365541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURACK WR, 1994, CHEM PHYS LIPIDS, V73, P209, DOI 10.1016/0009-3084(94)90182-1; BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; CHAKRABORTI S, 1992, EUR J BIOCHEM, V206, P965, DOI 10.1111/j.1432-1033.1992.tb17007.x; CHAPLINSKI TJ, 1986, LEUKEMIA RES, V10, P611, DOI 10.1016/0145-2126(86)90263-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Croxtall JD, 1996, BIOCHEM BIOPH RES CO, V220, P491, DOI 10.1006/bbrc.1996.0432; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUBOIS T, 1995, J RHEUMATOL, V22, P1230; DUBOIS T, 1995, BIOCHEM J, V310, P243, DOI 10.1042/bj3100243; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1989, CELL SIGNAL, V1, P165, DOI 10.1016/0898-6568(89)90006-5; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOOSSENS ELJ, 1995, FEBS LETT, V359, P155, DOI 10.1016/0014-5793(95)00032-5; HAYASHI H, 1990, BIOCHEM J, V269, P709, DOI 10.1042/bj2690709; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KIM KM, 1994, FEBS LETT, V343, P251, DOI 10.1016/0014-5793(94)80566-0; KOSTER JJ, 1993, BIOCHEM J, V291, P595, DOI 10.1042/bj2910595; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; Liemann S, 1996, J MOL BIOL, V258, P555, DOI 10.1006/jmbi.1996.0268; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Maniatis T, 1989, MOL CLONING; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; NELSON MR, 1995, BIOCHEMISTRY-US, V34, P3121, DOI 10.1021/bi00009a044; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NIELSON CP, 1991, BIOCHIM BIOPHYS ACTA, V1095, P83, DOI 10.1016/0167-4889(91)90048-3; PALMI M, 1995, EUR J PHARMACOL, V281, P97, DOI 10.1016/0014-2999(95)00304-4; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; ROTHHUT B, 1987, FEBS LETT, V219, P169, DOI 10.1016/0014-5793(87)81211-5; RUSSOMARIE F, 1991, PROSTAG LEUKOTR ESS, V42, P83, DOI 10.1016/0952-3278(91)90072-D; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; RZIGALINSKI BA, 1994, BBA-MOL CELL RES, V1223, P219, DOI 10.1016/0167-4889(94)90229-1; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SierraHonigmann R, 1996, LAB INVEST, V74, P684; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; TATHAM PER, 1990, PEPTIDE HORMONES PRA, P257; THIEL C, 1991, J BIOL CHEM, V266, P14732; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROTTER PJ, 1995, BIOCHEM J, V308, P591, DOI 10.1042/bj3080591; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; XING MZ, 1992, J BIOL CHEM, V267, P25966; XING MZ, 1992, J BIOL CHEM, V267, P6602; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719	72	100	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10474	10482						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099690				2022-12-27	WOS:A1997WV26200024
J	Han, YQ; Brasier, AR				Han, YQ; Brasier, AR			Mechanism for biphasic Rel A center dot NF-kappa B1 nuclear translocation in tumor necrosis factor alpha-stimulated hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACUTE-PHASE RESPONSE; SIGNAL-INDUCED PHOSPHORYLATION; DNA-BINDING; ANGIOTENSINOGEN GENE; TRANSCRIPTIONAL ACTIVATION; PROTEIN; PROTEOLYSIS; EXPRESSION; SUBUNITS	The proinflammatory cytokine, tumor necrosis factor alpha (TNF alpha), is a potent activator of angiotensinogen gene transcription in hepatocytes by activation of latent nuclear factor-kappa B (NF-kappa B) DNA binding activity. In this study, we examine the kinetics of TNF alpha-activated translocation of the 65-kDa (Rel A) and 50-kDa (NF-kappa B1) NF-kappa B subunits mediated by inhibitor (I kappa B) proteolysis in HepG2 hepatoblastoma cells. HepG2 cells express the I kappa B members I kappa B alpha, I kappa B beta, and I kappa B gamma. In response to TNF alpha, Rel A.NF-kappa B1 translocation and DNA binding activity follows a biphasic profile, with an ''early'' induction (15-30 min), followed by a nadir to control levels at 60 min, and a ''late'' induction (>120 min). The early phase of Rel A NF-kappa B1 translocation depends on simultaneous proteolysis of both I kappa B alpha and I kappa B beta isoforms; I kappa B gamma is inert to TNF alpha treatment. The 60-min nadir is due to a rapid I kappa B alpha resynthesis that reassociates with Rel A and completely inhibits its DNA binding activity; the 60-min nadir is not observed when I kappa B alpha resynthesis is prevented by cycloheximide treatment. By contrast, selective inhibition of I kappa B beta proteolysis by pretreatment of HepG2 cells with the peptide aldehyde N-acetyl-Leu-Leu-nor-leucinal completely blocks the late phase of Rel A.NF-kappa B1 translocation. These studies indicate the presence of inducible and constitutive cytoplasmic NF-kappa B pools in hepatocytes. TNF alpha induces a coordinated proteolysis and resynthesis of I kappa B isoforms to produce dynamic changes in NF-kappa B nuclear abundance.	UNIV TEXAS,MED BRANCH,DIV ENDOCRINOL,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					PHS HHS [1R01 55630-01A1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRASIER AR, 1996, J HYPERTENS, V27, P1009; BRASIER AR, 1996, J HYPERTENS, V27, P465; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN JZ, 1996, CELL, V84, P853; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ITOH N, 1994, NUCLEIC ACIDS RES, V22, P3787; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RON D, 1990, MOL CELL ENDOCRINOL, V74, pC97, DOI 10.1016/0303-7207(90)90221-S; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHAFFER CD, 1994, METHOD CELL BIOL, V44, P185, DOI 10.1016/S0091-679X(08)60913-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	40	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9825	9832						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092517				2022-12-27	WOS:A1997WU03900036
J	Ory, J; Kane, CD; Simpson, MA; Banaszak, LJ; Bernlohr, DA				Ory, J; Kane, CD; Simpson, MA; Banaszak, LJ; Bernlohr, DA			Biochemical and crystallographic analyses of a portal mutant of the adipocyte lipid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; RETINOIC ACID; CRYSTAL-STRUCTURES; CRYSTALLIZATION; PURIFICATION; REFINEMENT; AFFINITY; RESIDUES; CAVITY	A number of crystallographic studies of the adipocyte lipid-binding protein have established that the fatty acid binding site is within an internalized water-filled cavity. The same studies have also suggested the existence of a region physically distinct from the fatty acid-binding site which connects the cavity of the protein with the external solvent, hereafter referred to as the portal. In an effort to examine the portal region, we have used site-directed mutagenesis to introduce the mutations V32D/F57H into the murine ALBP cDNA. Mutant protein has been isolated, crystallized, and its stability and binding properties studied by biochemical methods. As assessed by guanidine-HCl denaturation, the mutant form exhibited a slight overall destabilization relative to the wild-type protein under both acid and alkaline conditions. Accessibility to the cavity in both the mutant and wild-type proteins was observed by stopped-flow analysis of the modification of a cavity residue, Cys(117), by the sulfhydryl reactive agent 5,5'-dithiobis(2-nitrobenzoic acid) at pH 8.5, Cys(117) Of V32D/F57H ALBP was modified 7-fold faster than the wild type protein. The ligand binding properties of both the V32D/F57H mutant and wild-type proteins were analyzed using a fluorescent probe at pH 6.0 and 8.0. The apparent dissociation constants for 1-anilinonaphthalene-8-sulfonic acid were approximately 9-10-fold greater than the wild-type protein, independent of pH. In addition, there is a 6-fold increase in the K-d for oleic acid for the portal mutant relative to the wild type at pH 8.0. To study the effect of pH on the double mutant, it was crystallized and analyzed in two distinct space groups at pH 4.5 and 6.4. While in general the differences in the overall main chain conformations are negligible, changes were ob served in the crystallographic structures near the site of the mutations. At both pH values, the mutant side chains are positioned somewhat differently than in wild-type protein. To ensure that the mutations had not altered ionic conditions near the binding site, the crystallographic coordinates were used to monitor the electrostatic potentials from the head group site to the positions near the portal region. The differences in the electrostatic potentials were small in all regions, and did not explain the differences in ligand affinity. We present these results within the context of fatty acid binding and suggest lipid association is more complex than that described within a single equilibrium event.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA; UNIV MINNESOTA, COLL BIOL SCI, ST PAUL, MN 55108 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Kane, Christopher/C-8256-2019	Kane, Christopher/0000-0002-0469-1668; Ory, Jeramia/0000-0002-5867-007X	NIGMS NIH HHS [GM 08277, GM 13925] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925, T32GM008277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; CARTER CW, 1979, J BIOL CHEM, V254, P2219; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kim K, 1996, BIOCHEMISTRY-US, V35, P7553, DOI 10.1021/bi9529115; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LALONDE JM, 1994, FASEB J, V8, P1240, DOI 10.1096/fasebj.8.15.8001736; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Prinsen CFM, 1996, BIOCHEM J, V314, P253, DOI 10.1042/bj3140253; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SHA RS, 1993, J BIOL CHEM, V268, P7885; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XU ZH, 1991, J BIOL CHEM, V266, P14367; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202	32	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9793	9801						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092513				2022-12-27	WOS:A1997WU03900032
J	Walker, KW; Gilbert, HF				Walker, KW; Gilbert, HF			Scanning and escape during protein-disulfide isomerase-assisted protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYSIS; THIOREDOXIN; SITES; BONDS	During oxidative protein folding, efficient catalysis of disulfide rearrangements by protein-disulfide isomerase is found to involve an escape mechanism that prevents the enzyme hom becoming trapped in covalent complexes with substrates that fail to rearrange in a timely fashion. Protein-disulfide isomerase mutants with only a single active-site cysteine catalyze slow disulfide rearrangements and become trapped in a covalent complex with substrate. Escape is mediated by the second, more carboxyl-terminal cysteine at the active site. A glutathione redox buffer increases the k(cat) for single-cysteine mutants by 20-40-fold, but the presence of the second cysteine at the active site in the wild-type enzyme increases the k(cat) by over 200-fold. A model is developed in which kinetic scanning for disulfides of increasing reactivity is timed against an intramolecular clock provided by the second cysteine at the active site. This provides an alternative, more efficient mechanism for rearrangement involving the reduction and reoxidation of substrate disulfides.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; PLOWMAN KM, 1972, ENZYME KINETICS, P98; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0	20	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8845	8848						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9082998				2022-12-27	WOS:A1997WU03700003
J	Webster, JC; Jewell, CM; Bodwell, JE; Munck, A; Sar, M; Cidlowski, JA				Webster, JC; Jewell, CM; Bodwell, JE; Munck, A; Sar, M; Cidlowski, JA			Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; ANTIPEPTIDE ANTIBODIES; THYROID-HORMONE; GENE-EXPRESSION; NUCLEAR; ACTIVATION; CELLS; TRANSCRIPTION; SUPERFAMILY; SITES	Although studies have shown that the mouse glucocorticoid receptor (mGR) contains eight phosphorylation sites (Bodwell, J. E., Orti, E., Coull, J. M., Pappin, D. J. C., Smith, L. I., and Swift, F. (1991) J. Biol. Chem. 266, 7549-7555), the effect of phosphorylation on receptor function is unclear, We have examined the consequences of single or multiple phosphorylation site mutations on several properties of mGR including receptor expression, ligand-dependent nuclear translocation, hormone-mediated transactivation, ligand-dependent down-regulation of mGR, and receptor protein half-life. Mutations had little effect on receptor expression, subcellular distribution, ligand-dependent nuclear translocation, or on the ability to activate hormone-mediated transcription from a complex (murine mammary tumor virus) promoter. In contrast, the phosphorylation status of the mGR had a profound effect on the ability to transactivate a minimal promoter containing simple glucocorticoid response elements after hormone administration. Similarly, ligand-dependent down-regulation by glucocorticoids of both receptor mRNA and protein was abrogated in mutants containing three or more phosphorylation site alterations. Finally, we show that the phosphorylation status of mGR has a profound effect on the stability of the glucocorticoid receptor protein, Receptors containing seven or eight mutated sites have a markedly extended half-life and do not show the ligand-dependent destabilization seen with wild type receptor, These data show that receptor phosphorylation may play a crucial role in regulating receptor levels and hence control receptor functions.	NIEHS,LAB SIGNAL TRANSDUCT,MOL ENDOCRINOL GRP,NIH,RES TRIANGLE PK,NC 27709; DARTMOUTH COLL,SCH MED,DEPT PHYSIOL,LEBANON,NH 03756	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dartmouth College			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NIDDK NIH HHS [DK 03535, DK 45337, DK 47329] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047329, R01DK003535, R01DK045337] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; ELIASSON E, 1994, J BIOL CHEM, V269, P18378; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HU LM, 1994, J BIOL CHEM, V269, P6571; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASON SA, 1993, J BIOL CHEM, V268, P21501; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MCGIMSEY WC, 1991, ENDOCRINOLOGY, V129, P3064, DOI 10.1210/endo-129-6-3064; MCINTYRE WR, 1985, J BIOL CHEM, V260, P418; MUELLER SG, 1995, J BIOL CHEM, V270, P10439, DOI 10.1074/jbc.270.18.10439; Oakley Robert H., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P63; ONATE SA, 1995, SCIENCE, V270, P1354; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEBSTER JC, 1994, ENDOCRINE, V2, P967; WEIGEL NL, 1994, 9 INT C HORM STER SE, pS148; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	37	205	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9287	9293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083064				2022-12-27	WOS:A1997WU03700069
J	Zhang, JG; Hilton, DJ; Willson, TA; McFarlane, C; Roberts, BA; Moritz, RL; Simpson, RJ; Alexander, WS; Metcalf, D; Nicola, NA				Zhang, JG; Hilton, DJ; Willson, TA; McFarlane, C; Roberts, BA; Moritz, RL; Simpson, RJ; Alexander, WS; Metcalf, D; Nicola, NA			Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein - Evidence that it is distinct from the cloned IL-13 receptor and IL-4 receptor alpha-chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; GAMMA-CHAIN; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; B-CELLS; SUBUNIT; EXPRESSION; COMPONENT; RESPONSES; MECHANISM	Interleukin-4 (IL-4) and interleukin-13 (IL-13) are structurally and functionally related cytokines which play an important role in the regulation of the immune response to infection, The functional similarity of IL-4 and IL-13 can be explained, at least in part, by the common components that form their cell surface receptors, namely the IL-4 receptor alpha-chain (IL-4R alpha) and the IL-13 receptor alpha-chain (IL-13R alpha), Soluble forms of the IL-4R alpha have also been described and implicated in modulating the effect of IL-4. In this paper we describe the presence of a 45,000-50,000 M(r) IL-13-binding protein (IL-13BP) in the serum and urine of mice, This protein binds IL-13 with a 100-300-fold higher affinity (K-D = 20-90 pM) than does the cloned IL-13R alpha (K-D = 3-10 nM). In addition to this functional difference, the IL-13BP appears to be structurally and antigenically distinct from the IL-13R alpha. Finally, unlike the cloned receptor, the IL-13BP acts as a potent inhibitor of IL-13 binding to its cell surface receptor, raising the possibility that it may be used to modulate the effects of IL-13 in vivo.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,COOPERAT RES CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Walter & Eliza Hall Institute; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Moritz, Robert L/B-9222-2011; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Simpson, Richard/0000-0002-9834-0796				BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHRISTIE G, 1995, CYTOKINE, V7, P305, DOI 10.1006/cyto.1995.0038; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DEVRIES JE, 1995, INT ARCH ALLERGY IMM, V106, P175, DOI 10.1159/000236842; FANSLOW W C, 1990, Cytokine, V2, P398, DOI 10.1016/1043-4666(90)90047-W; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; HE YW, 1995, J IMMUNOL, V155, P9; HE YW, 1995, J IMMUNOL, V154, P1596; HEAKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; Howard M, 1994, GUIDEBOOK CYTOKINES, P44; KEEGAN AD, 1991, J IMMUNOL, V146, P2272; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Luttmann W, 1996, J IMMUNOL, V157, P1678; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; McKenzie ANJ, 1994, GUIDEBOOK CYTOKINES, P92; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; REID GE, 1995, ELECTROPHORESIS, V16, P1120, DOI 10.1002/elps.11501601189; SATO TA, 1993, J IMMUNOL, V150, P2717; SEMPOWSKI GD, 1994, J IMMUNOL, V152, P3606; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAGA T, 1989, COLD SH Q B, V54, P713; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TOMIDA M, 1993, FEBS LETT, V334, P193, DOI 10.1016/0014-5793(93)81710-H; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	35	134	145	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9474	9480						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083087				2022-12-27	WOS:A1997WU03700092
J	Oulmouden, A; Wierinckx, A; Petit, JM; Costache, M; Palcic, MM; Mollicone, R; Oriol, R; Julien, R				Oulmouden, A; Wierinckx, A; Petit, JM; Costache, M; Palcic, MM; Mollicone, R; Oriol, R; Julien, R			Molecular cloning and expression of a bovine alpha(1,3)-fucosyltransferase gene homologous to a putative ancestor gene of the human FUT3-FUT5-FUT6 cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; STAGE-SPECIFIC EXPRESSION; BLOOD-GROUP ANTIGENS; GDP-L-FUCOSE; HUMAN-SERUM; ACCEPTOR SPECIFICITY; DETERMINES EXPRESSION; ELAM-1 LIGAND	Only one bovine gene, corresponding to the human cluster of genes FUT3-FUT5-FUT6, was found by Southern blot analysis. The cognate bovine alpha(1,3)-fucosyltransferase shares 67.3, 69.0, and 69.3% amino acid sequence identities with human FUC-T3, FUC-T5, and FUC-T6 enzymes, respectively. As revealed by protein sequence alignment, potential sites for asparagine-linked glycosylation and conserved cysteines, the bovine enzyme is an intermediate between FUC-T3, FUC-T5, and FUC-T6 human enzymes. Transfected into COS-7 cells, the bovine gene induced the synthesis of an alpha(1,3)-fucosyltransferase enzyme with type 2 substrate acceptor pattern specificity and induced expression of fucosylated type 2 epitopes (Le(x) and sialyl-Le(x)), but not of type 1 structures (Le(a) or sialyl-Le(a)), suggesting that it has an acceptor specificity similar to the human plasma FUC-T6. However, no enzyme activity was detected in bovine plasma. Gene transcripts are detected on tissues such as bovine liver, kidney, lung, and brain. The type 2 sialyl-Le(x) epitope was found in renal macula densa and biliary ducts, and Le(x) and Le(y) epitopes were detected on the brush border of epithelial cells of small and large intestine, suggesting a tissue distribution closer to human FUC-T3, but fucosylated type 1 structures (Le(a), Le(b) or sialyl-Le(a)) were not detected at all in any bovine tissue. Analysis of genetic distances on a combined phylogenetic tree of fucosyltransferase genes suggests that the bovine gene is the orthologous homologue of the ancestor of human genes constituting the present FUT3-FUT5-FUTG cluster.	UNIV LIMOGES, FAC SCI, INST BIOTECHNOL, F-87060 LIMOGES, FRANCE; UNIV PARIS SUD XI, INSERM U178, F-94807 VILLEJUIF, FRANCE; UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2G2, CANADA	Universite de Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Alberta			Wierinckx, Anne/AAF-5233-2021; Costache, Marieta D/F-2806-2016	Wierinckx, Anne/0000-0002-0186-6645; Costache, Marieta D/0000-0002-8103-3693; Ahmad, oulmouden/0000-0002-2920-2226				BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Borson N D, 1992, PCR Methods Appl, V2, P144; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CANDELIER JJ, 1993, LAB INVEST, V69, P449; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; CHENCHIK A, 1995, CLONTECHNIQUES X, P5; CHESTER MA, 1990, P 2 INT WORKSH MON A, P207; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Fitch W.M., 1970, EVOL BIOL, V4, P67; GAILLARD C, 1981, NUCLEIC ACIDS RES, V9, P6069, DOI 10.1093/nar/9.22.6069; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; ITO N, 1992, PROG HISTOCHEM CYTOC, V25, P1; ITO N, 1993, HISTOCHEM J, V25, P242, DOI 10.1007/BF00163820; JOZIASSE DH, 1993, BIOCHEM BIOPH RES CO, V194, P358, DOI 10.1006/bbrc.1993.1828; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KODA Y, 1993, BLOOD, V82, P2915; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MIYAKE M, 1988, CANCER RES, V48, P7150; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; MOLLICONE R, 1985, LAB INVEST, V53, P219; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; ORIOL R, 1992, APMIS, V100, P28; Oriol R, 1996, TRANSPLANT P, V28, P794; OULMOUDEN A, 1995, MAMM GENOME, V6, P760, DOI 10.1007/BF00354308; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; TUO XH, 1992, CANCER RES, V52, P5744; Watkins W.M., 1995, GLYCOPROTEINS, P313; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YAGO K, 1993, CANCER RES, V53, P5559	66	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8764	8773		10.1074/jbc.272.13.8764	http://dx.doi.org/10.1074/jbc.272.13.8764			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079712	hybrid			2022-12-27	WOS:A1997WQ63500095
J	Ruff, AL; Guarnieri, FG; StaveleyOCarroll, K; Siliciano, RF; August, JT				Ruff, AL; Guarnieri, FG; StaveleyOCarroll, K; Siliciano, RF; August, JT			The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT VACCINIA VIRUS; T-CELLS; ENVELOPE PROTEIN; NEUTRALIZING ANTIBODIES; ANTIGEN PRESENTATION; NONHUMAN-PRIMATES; DNA INOCULATION; DENDRITIC CELLS	The lysosome-associated membrane proteins (LAMP), found in the outer membrane of lysosomes and also in a multilaminar compartment that contains major histocompatibility complex class II (MHC LI) proteins, are directed to their localization by a cytoplasmic carboxyl-terminal sequence. Our studies of the immune response to LAMP-targeted proteins has led to the application of a HIV-1 gp160/LAMP chimeric gene as a novel means to enhance the MHC II presentation of gp160. Immunofluorescence microscopy confirmed that the gp160/LAMP protein had a cellular localization corresponding to that of lysosomes. Pulse-chase analysis confirmed that the rates of synthesis of gp160/LAMP and wild type gp160 were comparable and that both proteins were processed to gp120 at similar rates. However, the gp160/LAMP was degraded more rapidly than the wild type gp160. MHC II-mediated T cell proliferation assays performed with cloned human cell lines showed that gp160/LAMP stimulated greater responses than did the wild type gp160. Moreover, mice vaccinated with recombinant vaccinia expressing gp160/LAMP had greater gp160-specific lymphoproliferation responses and higher titers of anti-V3 loop antibodies than mice vaccinated with recombinant vaccinia expressing wild type gp160.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI28108] Funding Source: Medline; NICHD NIH HHS [NP1-HD-6-2915] Funding Source: Medline; NIGMS NIH HHS [5.T32.GM07626] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028108, R37AI028108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P116; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ARKEMA JMS, 1994, HISTOCHEM J, V26, P95, DOI 10.1007/BF00157956; CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DOLIN R, 1995, J INFECT DIS, V172, P1175, DOI 10.1093/infdis/172.5.1175; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; EAGER KB, 1989, J IMMUNOL, V143, P2328; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; ELDAHER N, 1993, J INFECT DIS, V168, P306, DOI 10.1093/infdis/168.2.306; FULLER DH, 1994, AIDS RES HUM RETROV, V10, P1433, DOI 10.1089/aid.1994.10.1433; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; GRAHAM BS, 1994, J INFECT DIS, V170, P782, DOI 10.1093/infdis/170.4.782; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; HATHCOCK KS, 1991, CURRENT PROTOCOLS IM, V1; HAYNES JR, 1994, AIDS RES HUM RETROV, V10, pS43; HU SL, 1991, AIDS RES HUM RETROV, V7, P615, DOI 10.1089/aid.1991.7.615; HUGHES EN, 1981, J BIOL CHEM, V256, P664; KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715; Lin KY, 1996, CANCER RES, V56, P21; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MCELRATH MJ, 1994, J INFECT DIS, V169, P41, DOI 10.1093/infdis/169.1.41; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MONTEFIORI DC, 1992, J CLIN IMMUNOL, V12, P429, DOI 10.1007/BF00918855; MOSS B, 1993, CURRENT PROTOCOLS MO, V2; MOSS B, 1991, CURRENT PROTOCOLS MO, V2; NATUK RJ, 1993, AIDS RES HUM RETROV, V9, P395, DOI 10.1089/aid.1993.9.395; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PARRY C, 1994, AIDS RES HUM RETROV, V10, P205, DOI 10.1089/aid.1994.10.205; PERALES MA, 1995, J ACQ IMMUN DEF SYND, V10, P27; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PINCUS SH, 1989, J IMMUNOL, V142, P3070; POLYDEFKIS M, 1990, J EXP MED, V171, P875, DOI 10.1084/jem.171.3.875; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROWELL JF, 1995, J IMMUNOL, V155, P473; ROWELL JF, 1995, J IMMUNOL, V155, P1818; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	59	56	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8671	8678		10.1074/jbc.272.13.8671	http://dx.doi.org/10.1074/jbc.272.13.8671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079699	hybrid			2022-12-27	WOS:A1997WQ63500082
J	Wendler, WMF; Kremmer, E; Forster, R; Winnacker, EL				Wendler, WMF; Kremmer, E; Forster, R; Winnacker, EL			Identification of Pirin, a novel highly conserved nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; RNA-POLYMERASE-II; RAT MONOCLONAL-ANTIBODIES; EUKARYOTIC MESSENGER-RNAS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; PREINITIATION COMPLEX; SECONDARY STRUCTURE; SEQUENCE; CLONING	In this article we describe the molecular cloning of Pirin, a novel highly conserved 32-kDa protein consisting of 290 amino acids. Pirin was isolated by a yeast two-hybrid screen as an interactor of nuclear factor I/CCAAT box transcription factor (NFI/CTF1), which is known to stimulate adenovirus DNA replication and RNA polymerase II-driven transcription. Pirin mRNA is expressed weakly in all human tissues tested. About 15% of all Pirin cDNAs contain a short 34-base pair insertion in their 5'-untranslated regions, indicative of alternative splicing processes. Multiple Pirin transcripts are expressed in skeletal muscle and heart. Western blots and immunoprecipitations employing monoclonal anti-Pirin antibodies reveal that Pirin is a nuclear protein. Moreover, confocal immunofluorescence experiments demonstrate a predominant localization of Pirin within dot-like subnuclear structures. Homology searches using the BLAST algorithm indicate the existence of Pirin homologues in mouse and rat. The N-terminal half of Pirin is significantly conserved between mammals, plants, fungi, and even prokaryotic organisms, Genomic Southern and Western blots demonstrate the presence of Pirin genes and their expression, respectively, in all mammalian cell lines tested. The expression pattern, the concentrated localization in subnuclear structures, and its interaction with NFI/CTF1 in the two-hybrid system classify Pirin as a putative NFI/CTF1 cofactor, which might help to gain new insights in NFI/CTF1 functions.	UNIV MUNICH,INST BIOCHEM,GENZENTRUM,D-81377 MUNICH,GERMANY; GESELL STRAHLEN & UMWELTFORSCH MBH,NATL RES CTR ENVIRONM & HLTH,INST IMMUNOL,D-81377 MUNICH,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	University of Munich; University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Förster, Reinhold/D-6770-2011	Forster, Reinhold/0000-0001-6190-7923				ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; CHEN M, 1990, J BIOL CHEM, V265, P18634; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; EDELMAN I, 1994, WISOCNSIN SEQUENCE A; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLAGHER SR, 1992, CURRENT PROTOCOLS MO, V2; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GONDOLF C, 1995, BERL MUNCH TIERARZTL, V108, P47; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRONOSTAJSKI RM, 1988, NUCLEIC ACIDS RES, V5, P2087; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; KARAGHIOSOFF M, 1994, THESIS LUDWIGMAXIMIL; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; MURPHY AJM, 1992, METHODS COMPANION ME, V4, P11; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OLIVA D, 1995, EUR J BIOCHEM, V232, P141, DOI 10.1111/j.1432-1033.1995.tb20792.x; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; QUERTEMOUS T, 1992, CURRENT PROTOCOLS MO, V1; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; SPRINGER TA, 1982, HYBRIDOMA, V1, P257, DOI 10.1089/hyb.1.1982.1.257; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRAUSS WM, 1992, CURRENT PROTOCOLS MO, V2; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; 1995, QIAESPRESSIONIST, P35	50	95	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8482	8489		10.1074/jbc.272.13.8482	http://dx.doi.org/10.1074/jbc.272.13.8482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079676	hybrid			2022-12-27	WOS:A1997WQ63500059
J	Colombo, MI; Beron, W; Stahl, PD				Colombo, MI; Beron, W; Stahl, PD			Calmodulin regulates endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-II; CELL-CYCLE; SYNAPSIN-I; TRANSPORT; MEMBRANE; CALCIUM; SECRETION; ENDOCYTOSIS; EXOCYTOSIS; VESICLES	Calmodulin (CaM) has previously been implicated in regulated exocytosis, transcytosis, and receptor recycling. We have investigated the role of CaM in endocytic transport by examining the effects of several CaM antagonists in intact cells. We present evidence indicating that the mixing of sequentially internalized ligands is inhibited by CaM antagonists, indicating that CaM may play a general role in regulating endosomal membrane trafficking. To address the specific events that are affected by CaM we studied its role in an in vitro assay that reconstitutes fusion among endosomes. CaM antagonists inhibited endosome fusion, and the inhibition was reversed by the addition of CaM. Moreover, we found that Ca2+ stimulates fusion among endosomes and that addition of CaM stimulates fusion beyond that produced by Ca2+ alone, Our data indicate that one of the possible targets for CaM in endosome fusion is the CaM-dependent kinase II. We propose that CaM regulates endocytic transport by modulating an essential component(s) of the membrane traffic machinery.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Stahl, Philip/D-6315-2012					APODACA G, 1994, J BIOL CHEM, V269, P19005; ARTALEJO CR, 1996, NEURON, V16, P1; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; COLOMBO MI, 1994, MOL MEMBR BIOL, V11, P93, DOI 10.3109/09687689409162226; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; COOPERSTEIN SJ, 1995, BIOCHEM BIOPH RES CO, V215, P75, DOI 10.1006/bbrc.1995.2435; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; DIAZ R, 1991, EUR J CELL BIOL, V56, P223; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIPAOLA M, 1984, J CELL PHYSIOL, V118, P193, DOI 10.1002/jcp.1041180212; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; ENRICH C, 1988, BIOCHEM J, V255, P999, DOI 10.1042/bj2550999; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Fournier S., 1988, J NEUROCHEM, V50, P20; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; HORWITZ SB, 1981, J CELL BIOL, V91, P798, DOI 10.1083/jcb.91.3.798; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KERBOEUF D, 1993, EMBO J, V12, P3385, DOI 10.1002/j.1460-2075.1993.tb06012.x; KIBBLE AV, 1996, EUR J PHYSL, V431, P464; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MAYORGA LS, 1995, J NIH RES, V7, P57; MEANS AR, 1982, J CELL BIOCHEM, V20, P317, DOI 10.1002/jcb.240200402; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; OKABE T, 1992, BIOCHEM BIOPH RES CO, V186, P1006, DOI 10.1016/0006-291X(92)90846-D; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	54	116	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7707	7712		10.1074/jbc.272.12.7707	http://dx.doi.org/10.1074/jbc.272.12.7707			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065429	hybrid			2022-12-27	WOS:A1997WP59200023
J	Reseland, JE; Larsen, F; Solheim, J; Eriksen, JA; Hanssen, LE; Prydz, H				Reseland, JE; Larsen, F; Solheim, J; Eriksen, JA; Hanssen, LE; Prydz, H			A novel human chymotrypsin-like digestive enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SYNTHESIS; PROTEOLYTIC-ENZYMES; SEQUENCE; GENE; POLYMERASE; PROTEINS; CLONING; ACIDS; CDNA	The gene of a novel chymotrypsin-like serine protease has been cloned from human pancreas. The chymotrypsin-like enzyme-1 gene is located on chromosome 16q22.1 in a tight cluster with four unrelated genes. The gene has seven exons with the signal and activation peptide and the three main catalytic residues forming the active site encoded by separate exons. Northern blots of pancreatic mRNA showed a major transcript of 1.0 kilobases and a minor transcript of 1.3 kilobases due to alternative polyadenylation. No transcript was found in other tissues. Its presence in pancreatic tissue, duodenal juice, and urine was demonstrated with antisera raised against synthetic peptides from the derived amino acid sequence of the gene, The peptide sequences were chosen for being most dissimilar to chymotrypsin, and the antisera obtained did not react with purified human chymotrypsin. The proteolytically active CTRL-1 has been identified in pancreatic homogenate, duodenal juice, and urine, and a recombinant CTRL-1 has been characterized. Increased pancreatic secretion of CTRL-1 was induced by protease inhibitors indicating that the enzyme is secreted from pancreas upon feedback stimulation. Both native and recombinant CTRL-1 displayed chymotrypsin- and elastase-2-like activities and hydrolyzed the amide bonds of substrates having tyrosine, phenylalanine, or leucine residues at the p(1) position. The enzyme was active over a broad pH range (6.5-9.0), with a maximum at pH 8.0-8.5. CTRL-1 was produced as a zymogen of 264 amino acids as deduced from the gene sequence, with a sequence identity of 54% with human chymotrypsin B. The number and location of intron/exon junctions as well as the sequence similarity to chymotrypsin both at the DNA and protein level and the presence in duodenal juice indicate that this is a novel digestive enzyme of the chymotrypsin superfamily, albeit one with distinct physiological and biochemical features.	UNIV OSLO,NATL HOSP,CTR BIOTECHNOL,N-0317 OSLO,NORWAY; UNIV OSLO,NATL HOSP,DEPT ANIM,N-0317 OSLO,NORWAY; NORSK HYDRO AS,RES CTR,N-3901 PORSGRUNN,NORWAY; NATL HOSP NORWAY,DEPT MED,N-0027 OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Norsk Hydro ASA; University of Oslo; National Hospital Norway								ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; ATHERTON E, 1983, J CHEM SOC CHEM COMM, P1060, DOI 10.1039/c39830001060; AZOULAY M, 1987, ANN HUM GENET, V51, P129, DOI 10.1111/j.1469-1809.1987.tb01054.x; BELL GI, 1984, J BIOL CHEM, V259, P4265; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; COAN MH, 1971, BIOCHEMISTRY-US, V10, P2711; COAN MH, 1972, BIOCHIM BIOPHYS ACTA, V268, P207, DOI 10.1016/0005-2744(72)90216-1; de Haen C, 1975, J Mol Biol, V92, P225, DOI 10.1016/0022-2836(75)90225-9; DECARO A, 1975, BIOCHIM BIOPHYS ACTA, V379, P431, DOI 10.1016/0005-2795(75)90150-6; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINSTEIN G, 1974, EUR J BIOCHEM, V43, P569, DOI 10.1111/j.1432-1033.1974.tb03444.x; GALAU GA, 1986, PLANT MOL BIOL, V7, P155, DOI 10.1007/BF00021327; HARRISON J, 1994, ANAL BIOCHEM, V216, P235, DOI 10.1006/abio.1994.1033; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KISFALUDY L, 1983, SYNTHESIS-STUTTGART, P325; KRISTENSEN T, 1988, NUCLEIC ACIDS RES, V16, P3487, DOI 10.1093/nar/16.8.3487; LARSEN F, 1993, HUM MOL GENET, V2, P775, DOI 10.1093/hmg/2.6.775; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; NEURATH H, 1967, SCIENCE, V158, P1638, DOI 10.1126/science.158.3809.1638; PINSKY SD, 1983, P NATL ACAD SCI-BIOL, V80, P7486, DOI 10.1073/pnas.80.24.7486; RESELAND JE, 1995, SCAND J GASTROENTERO, V30, P72, DOI 10.3109/00365529509093239; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANDERS TG, 1974, J BIOL CHEM, V249, P3500; SMILLIE LB, 1968, NATURE, V218, P343, DOI 10.1038/218343a0; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; VANNEST GA, 1980, J CELL BIOL, V86, P784, DOI 10.1083/jcb.86.3.784	30	16	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8099	8104		10.1074/jbc.272.12.8099	http://dx.doi.org/10.1074/jbc.272.12.8099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065485	hybrid			2022-12-27	WOS:A1997WP59200079
J	Sarvazyan, NA; Ivanov, A; Modyanov, NN; Askari, A				Sarvazyan, NA; Ivanov, A; Modyanov, NN; Askari, A			Ligand-sensitive interactions among the transmembrane helices of Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; CATION OCCLUSION; BETA-SUBUNIT; ALPHA-SUBUNIT; K+-ATPASE; NA+,K+-ATPASE; NA,K-ATPASE; SITES; (NA++K+)-ATPASE	An extensively trypsin-digested Na+/K+-ATPase, which retains the ability to bind Na+, K+, and ouabain, consists of four fragments of the alpha-subunit that contain all 10 transmembrane a domains, and the beta-subunit, a fraction of which is cleaved at Arg(142)-Gly(143). In previous studies, we solubilized this preparation with a detergent and mapped the relative positions of several transmembrane helices of the subunits by chemical cross-linking, To determine if these detected helix-helix proximities were representative of those existing in the bilayer prior to solubilization, we have now done similar studies on the membrane-bound preparation of the same digested enzyme, After oxidative sulfhydryl cross-linking catalyzed by Cu2+-phenanthroline, two prominent products were identified by their mobilities and the analyses of their N termini, One was a dimer of a 11-kDa alpha-fragment containing the H-1-H-2 helices and a 22-kDa alpha-fragment containing the H-7-H-10 helices, This dimer seemed to be the same as that obtained in the solubilized preparation, The other product was a trimer of the above two alpha-fragments and that fraction of beta whose extracellular domain was cleaved at Arg(142)-Gly(143). This product was different from a similar one of the solubilized preparation in that the latter contained the predominant fraction of beta without the extracellular cleavage, The cross-linking reactions of the membrane preparation, but not those of the solubilized one, were hindered specifically by Na+, K+, and ouabain, These findings indicate that (a) the H-1-H-2 transmembrane helices of alpha are adjacent to some of its H-7-H-10 helices both in solubilized and membrane-bound states, (b) the alignment of the residues of the single transmembrane helix of beta with the interacting H-1-H-2 and H-7-H-10 helices of a is altered by detergent solubilization and by structural changes in the extracellular domain of beta, and (c) the three-dimensional packing of the interacting transmembrane helices of alpha and beta are regulated by the specific ligands of the enzyme.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EFREMOV RG, 1993, J PROTEIN CHEM, V12, P143, DOI 10.1007/BF01026035; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FARLEY RA, 1980, J BIOL CHEM, V255, P860; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P1566; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7855	7858		10.1074/jbc.272.12.7855	http://dx.doi.org/10.1074/jbc.272.12.7855			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065451	hybrid			2022-12-27	WOS:A1997WP59200045
J	Giorgino, F; Pedrini, MT; Matera, L; Smith, RJ				Giorgino, F; Pedrini, MT; Matera, L; Smith, RJ			Specific increase in p85 alpha expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PDGF BETA-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; BOVINE BRAIN; BINDING-SITE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; DNA-SYNTHESIS; CDNA CLONING	The stimulation of phosphatidylinositol (PI) 3-kinase by insulin-like growth factor I (IGF-I) in L6 cultured skeletal muscle cells is inhibited by the glucocorticoid dexamethasone. The objective of this study was to investigate the mechanism of dexamethasone action by determining its effects on the expression of the p85 alpha and p85 beta regulatory subunit isoforms of PI 3-kinase, their coupling with the p110 catalytic subunit, and their association with insulin receptor substrate 1 (IRS-1) in response to ICE-I stimulation. Dexamethasone induced a 300% increase in p85 alpha protein content in the L6 cultured myoblast cell line, whereas it increased p110 content by only 38% and had no effect on p85 beta. The increase in p85 alpha protein was associated with a coordinate increase in p85 alpha mRNA. Stimulation with IGF-I induced the association of p85 alpha and p85 beta with IRS-1, and this was accompanied by increased amounts of the p110 catalytic subunit and markedly increased PI 3-kinase activity in IRS-1 immunoprecipitates. In cells treated with dexamethasone, greater amounts of p85 alpha and lower amounts of p85 beta, respectively, were found in IRS-l immunoprecipitates, such that the alpha/beta ratio was markedly higher than in control cells. In spite of the increase in both total and IRS-1-associated p85 alpha following dexamethasone treatment, IRS-1-associated p110 catalytic subunit and PI 3-kinase activity were decreased by approximately 50%. Thus, dexamethasone induces a specific increase in expression of the p85 alpha regulatory subunit that is not associated with a coordinate increase in the p110 catalytic subunit of PI 3-kinase. As a consequence, in dexametbasone-treated cells, p85 alpha that is not coupled with p110 competes with both p85 alpha p110 and p85 beta p110 complexes for association with IRS-1, leading to increased p85 alpha but decreased p85 beta, p110, and PI 3-kinase activity in IRS-1 immunoprecipitates.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215; UNIV BARI,SCH MED,IST CLIN MED ENDOCRINOL & MALATTIE METAB,I-70124 BARI,ITALY	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universita degli Studi di Bari Aldo Moro			Giorgino, Francesco/K-7262-2016	Giorgino, Francesco/0000-0001-7372-2678	NIDDK NIH HHS [DK43038, DK50411, DK48503] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048503, R01DK050411, R01DK043038] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; GOULD GW, 1994, J BIOL CHEM, V269, P26622; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEDRINI MT, 1994, BIOCHEM BIOPH RES CO, V202, P1038, DOI 10.1006/bbrc.1994.2033; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REIF K, 1993, J BIOL CHEM, V268, P10780; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1994, ONCOGENE, V9, P651; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	54	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7455	7463		10.1074/jbc.272.11.7455	http://dx.doi.org/10.1074/jbc.272.11.7455			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054447	hybrid			2022-12-27	WOS:A1997WN14700086
J	Kosako, H; Amano, M; Yanagida, M; Tanabe, K; Nishi, Y; Kaibuchi, K; Inagaki, M				Kosako, H; Amano, M; Yanagida, M; Tanabe, K; Nishi, Y; Kaibuchi, K; Inagaki, M			Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT; SEPARATION; BINDING; INVITRO; CELLS; AREA; RAS	Site- and phosphorylation state-specific antibodies are useful to analyze spatiotemporal distribution of site-specific phosphorylation of target proteins in vivo. Using several polyclonal and monoclonal antibodies that can specifically recognize four phosphorylated sites on glial fibrillary acidic protein (GFAP), we have previously reported that Thr-7, Ser-13, and Ser-34 on this intermediate filament protein are phosphorylated at the cleavage furrow during cytokinesis. This observation suggests that there exists a protein kinase named cleavage furrow kinase specifically activated at metaphase-anaphase transition (Matsuoka, Y., Nishizawa, K., Yano, T., Shibata, M., Ando, S., Takahashi, T., and Inagaki, M. (1992) EMBO J. 11, 2895-2902; Sekimata, M., Tsujimura, a, Tanaka, J., Takeuchi, Y., Inagaki, N., and Inagaki, M. (1996) J. Cell Biol; 132, 635-641). Here we report that GFAP is phosphorylated specifically at Thr-7, Ser-13, and Ser-34 by Rho-associated kinase (Rho-kinase), which binds to the small GTPase Rho in its GTP-bound active form. The kinase activity of Rho-kinase toward GFAP is dramatically stimulated by guanosine 5'-(3-O-thio)-triphosphate-bound RhoA. Furthermore, the phosphorylation of GFAP by Rho-kinase results in a nearly complete inhibition of its filament formation in vitro. The possibility that Rho-kinase is a candidate for cleavage furrow kinase is discussed.	AICHI CANC CTR,RES INST,BIOCHEM LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,BIOPHYS UNIT,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nara Institute of Science & Technology			Amano, Mutsuki/M-4820-2014; Inagaki, Masaki/B-9920-2016	Amano, Mutsuki/0000-0002-0662-1524; 				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ANDREASSEN PR, 1991, J CELL SCI, V99, P523; Beavo J A, 1974, Methods Enzymol, V38, P299; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; FUCKS E, 1994, ANN REV BIOCH, V63, P345; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1995, FEBS LETT, V377, P343; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6	33	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	1997	272	16					10333	10336						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WV262	9099667				2022-12-27	WOS:A1997WV26200001
J	Symes, A; Gearan, T; Eby, J; Fink, JS				Symes, A; Gearan, T; Eby, J; Fink, JS			Integration of Jak-Stat and AP-1 signaling pathways at the vasoactive intestinal peptide cytokine response element regulates ciliary neurotrophic factor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; NEUROBLASTOMA CELL-LINE; CULTURED SYMPATHETIC NEURONS; TRIPARTITE CNTF RECEPTOR; C-FOS; JUN-B; ONCOSTATIN-M; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; TRANSDUCER GP130	Ciliary neurotrophic factor (CNTF)-dependent induction of expression of the neuropeptide vasoactive intestinal peptide (VIP) gene is mediated by a 180-base pair cytokine response clement (CyRE) in the VIP promoter, To elucidate the molecular mechanisms mediating the transcriptional activation by CNTF, intracellular signaling to the CyRE has been studied in a neuroblastoma cell line, It has been shown previously that CNTF induces Stat proteins to bind to a site within the CyRE, CNTF also induces a second protein to bind to a C/EBP-like site within the CyRE. In this report, we show that this inducible CyRE binding protein is composed of the AP I proteins c-Fos, JuuB, and JunD., These proteins bind to a non-canonical AP-P site located near the previously characterized C/EBP site, The serine/threonine kinase inhibitor H7 prevents CNTF-dependent induction of AP-1 binding and CyRE-mediated transcription, suggesting that an H7-sensitive kinase is important to mediating CNTF effects on VIP transcription, The integration at the VIP CyRE of the Jak-Stat and AP-I signaling pathways with other pre-existing proteins provides a cellular mechanism for cell- and cytokine-specific signaling.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,MOL NEUROBIOL LAB,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital			Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27514] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI N, 1992, PHARMACOL THERAPEUT, V55, P303, DOI 10.1016/0163-7258(92)90054-4; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1995, ONCOGENE, V10, P985; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NARANJO JR, 1991, ONCOGENE, V6, P223; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEAVER DR, 1995, DEV BRAIN RES, V85, P293, DOI 10.1016/0165-3806(95)00016-7; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; YAMAMORI T, 1991, NEUROREPORT, V2, P173, DOI 10.1097/00001756-199104000-00003; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	70	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9648	9654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092493				2022-12-27	WOS:A1997WU03900012
J	Gayraud, B; Hopfner, B; Jassim, A; Aumailley, M; BrucknerTuderman, L				Gayraud, B; Hopfner, B; Jassim, A; Aumailley, M; BrucknerTuderman, L			Characterization of a 50-kDa component of epithelial basement membranes using GDA-J/F3 monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; TUBULOINTERSTITIAL NEPHRITIS ANTIGEN; VII COLLAGEN; ANCHORING FIBRILS; CELLULAR INTERACTIONS; CUTANEOUS CELLS; FIBROUS SHEATH; GENE LAMC2; HUMAN-SKIN; PROTEIN	Using the monoclonal antibody GDA-J/F3, a 50-kDa noncollagenous component of human skin basement membrane zone was identified. Immunofluorescence stainings of normal human skin with the GDA-J/F3 antibody showed a linear fluorescence decorating the basement membrane zone. With immunoelectron microscopy, the epitope was localized to the insertion points of the anchoring fibrils into the lamina densa The antigen is distinct from collagen VII, from the main structural protein of the anchoring fibrils, and from several other structural molecules of the basement membrane zone, because the GDA-J/F3 antibody did not react with purified basement membrane components in vitro. In serum-free cultures, the antigen was synthesized and secreted by normal and transformed human keratinocytes and to a lesser extent by normal human skin fibroblasts. Immunoprecipitation of radiolabeled epithelial cell-conditioned medium with the GDA-J/F3 antibody yielded two polypeptides that migrated on SDS-polyacrylamide gel electrophoresis with apparent molecular masses of 46 and 50 kDa under nonreducing conditions. Using reducing gels, only the 50-kDa polypeptide was observed. The antigen was resistant to digestion with bacterial collagenase but sensitive to trypsin and pepsin. It also bound to heparin and DEAE cellulose at low ionic strength and alkaline pH. These findings indicate that the GDA-J/F3 antigen is a small globular disulphide-bonded protein with a potential to interact with basement membrane proteoglycans. Integration of the GDA-J/F3 antigen into the histoarchitecture of the dermo-epidermal junction is dependent on the presence of collagen VII, because the GDA-J/F3 epitope was missing in several patients with a genetic blistering disorder of the skin, epidermolysis bullosa dystrophica, who lacked collagen VII and anchoring fibrils.	UNIV MUNSTER, DEPT DERMATOL, D-48149 MUNSTER, GERMANY; CNRS, INST BIOL & CHIM PROT, F-69367 LYON 07, FRANCE; UNIV LONDON LONDON HOSP, COLL MED, DEPT IMMUNOL, LONDON E1 2AD, ENGLAND	University of Munster; Centre National de la Recherche Scientifique (CNRS); University of London; University College London			Jassim, Alaa/AHD-6184-2022	Jassim, Alaa/0000-0002-6700-5426; Gayraud-Morel, Barbara/0000-0002-1168-8504				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Bruckner-Tuderman Leena, 1993, P507; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; BURGESON RE, 1995, EXTRACELLULAR MATRIX, P119; BUTKOWSKI RJ, 1990, J BIOL CHEM, V265, P21091; BUTKOWSKI RJ, 1991, KIDNEY INT, V40, P838, DOI 10.1038/ki.1991.283; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; FLEISCHMAJER R, 1995, J INVEST DERMATOL, V105, P597, DOI 10.1111/1523-1747.ep12323604; GAMMON WR, 1984, J INVEST DERMATOL, V82, P139, DOI 10.1111/1523-1747.ep12259692; GAMMON WR, 1993, J INVEST DERMATOL, V100, P1618; GOLDSMITH LA, 1983, J INVEST DERMATOL, V81, P464, DOI 10.1111/1523-1747.ep12522669; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Harlow E., 1988, ANTIBODIES LAB MANUA; HECKMANN M, 1989, EUR J BIOCHEM, V182, P719, DOI 10.1111/j.1432-1033.1989.tb14884.x; JASSIM A, 1987, J REPROD IMMUNOL, V12, P173, DOI 10.1016/0165-0378(87)90022-2; JASSIM A, 1991, BRIT J DERMATOL, V125, P101, DOI 10.1111/j.1365-2133.1991.tb06055.x; JASSIM A, 1994, HUM REPROD, V9, P1452, DOI 10.1093/oxfordjournals.humrep.a138728; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; KIRTSCHIG G, 1995, J INVEST DERMATOL, V105, P543, DOI 10.1111/1523-1747.ep12323431; KONIG A, 1994, J INVEST DERMATOL, V102, P155, DOI 10.1111/1523-1747.ep12371754; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MARINKOVICH MP, 1993, ARCH DERMATOL, V129, P1557, DOI 10.1001/archderm.129.12.1557; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MCGRATH JA, 1994, INT CONGR SER, V1045, P199; NELSON TR, 1995, J BIOL CHEM, V270, P16265, DOI 10.1074/jbc.270.27.16265; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Pleyer U, 1996, IMMUNOL TODAY, V17, P111, DOI 10.1016/0167-5699(96)80601-3; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; REGAUER S, 1990, J CELL BIOL, V111, P2109, DOI 10.1083/jcb.111.5.2109; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; ZENG L, 1995, J INVEST DERMATOL, V104, P582; [No title captured]	48	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9531	9538						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083095				2022-12-27	WOS:A1997WU03700100
J	Semizarov, DG; Arzumanov, AA; Dyatkina, NB; Meyer, A; VichierGuerre, S; Gosselin, G; Rayner, B; Imbach, JL; Krayevsky, AA				Semizarov, DG; Arzumanov, AA; Dyatkina, NB; Meyer, A; VichierGuerre, S; Gosselin, G; Rayner, B; Imbach, JL; Krayevsky, AA			Stereoisomers of deoxynucleoside 5'-triphosphates as substrates for template-dependent and -independent DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; L-THYMIDINE 5'-TRIPHOSPHATE; NUCLEOSIDE 5'-TRIPHOSPHATES; SYNTHETIC NUCLEOSIDES; ALPHA; BETA; ENANTIOMERS; NUCLEOTIDES; TRANSFERASE	All four possible stereoisomers of dNTP with regard to deoxyribofuranose C-1' and C-4' carbon atoms were studied as substrates for several template-dependent DNA polymerases and template-independent terminal deoxynucleotidyl transferase. It was shown that DNA polymerases alpha, beta, and epsilon from human placenta and reverse transcriptases of human immunodeficiency virus and avian myeloblastosis virus incorporate into the DNA chain only natural beta-D-dNTPs, whereas calf thymus terminal deoxynucleotidyl transferase incorporates two nucleotide residues of alpha-D-dNTP and extends the resulting oligonucleotide in the presence of beta-D-dNTPs. The latter enzyme also extended alpha-anomeric D-oligodeoxynucleotide primers in the presence of beta-D-dNTPs. None of the studied enzymes utilized L-dNTPs. These data indicate that template-dependent DNA polymerases are highly stereospecific with regard to dNTPs, whereas template-independent terminal deoxynucleotidyl transferase shows less stereodifferentiation. It is likely that the active center of the latter enzyme forms no specific contacts with the nucleic bases of both nucleotide substrate and oligonucleotide primer.	UNIV MONTPELLIER 2,CHIM BIOORGAN LAB,CNRS,UMR 5625,F-34095 MONTPELLIER 5,FRANCE; RUSSIAN ACAD SCI,ENGELHARDT INST MOL BIOL,MOSCOW 117984,RUSSIA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS			MEYER, albert Louis/E-1744-2013	MEYER, albert Louis/0000-0003-3909-0894				BEABEALASHVILLI RS, 1986, BIOCHIM BIOPHYS ACTA, V868, P136, DOI 10.1016/0167-4781(86)90016-3; CHANG CN, 1992, J BIOL CHEM, V267, P22414; DEBART F, 1994, BIOORG MED CHEM LETT, V4, P1041, DOI 10.1016/S0960-894X(01)80678-8; DYATKINA N, 1987, FEBS LETT, V219, P151, DOI 10.1016/0014-5793(87)81208-5; FOCHER F, 1995, NUCLEIC ACIDS RES, V23, P2840, DOI 10.1093/nar/23.15.2840; GENUDELLAC C, 1991, NUCLEOS NUCLEOT, V10, P1345, DOI 10.1080/07328319108047067; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; Kolocheva T. I., 1993, Molekulyarnaya Biologiya (Moscow), V27, P1368; KRAEV A S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1164; KRAYEVSKY AA, 1993, NUCLEOS NUCLEOT, V12, P649, DOI 10.1080/07328319308019019; KRAYEVSKY AA, 1990, SOV SCI REV D, V9, P179; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; MERLO V, 1994, J CHEM SOC PERK T 1, P1477, DOI 10.1039/p19940001477; MORVAN F, 1988, NUCLEIC ACIDS RES, V16, P833, DOI 10.1093/nar/16.3.833; Mozzherin D. Yu., 1992, Molekulyarnaya Biologiya (Moscow), V26, P999; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PYRINOVA GB, 1989, FEBS LETT, V247, P57, DOI 10.1016/0014-5793(89)81240-2; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROZOVSKAYA TA, 1992, MOL BIOL RUSIAN, V27, P618; SEMIZAROV DG, 1994, FEBS LETT, V354, P187, DOI 10.1016/0014-5793(94)01123-0; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; SPADARI S, 1992, J MED CHEM, V35, P4214, DOI 10.1021/jm00100a029; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; VANDRAANEN NA, 1992, J BIOL CHEM, V267, P25019; WILSON JE, 1993, ANTIMICROB AGENTS CH, V37, P1720, DOI 10.1128/AAC.37.8.1720; YAMAGUCHI T, 1984, CHEM PHARM BULL, V32, P1441; YAMAGUCHI T, 1994, BIOCHEM BIOPH RES CO, V200, P1023, DOI 10.1006/bbrc.1994.1552; [No title captured]	29	37	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9556	9560						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083099				2022-12-27	WOS:A1997WU03700104
J	Wu, V; Yang, M; McRoberts, JA; Ren, J; Seensalu, R; Zeng, NX; Dagrag, M; Birnbaumer, M; Walsh, JH				Wu, V; Yang, M; McRoberts, JA; Ren, J; Seensalu, R; Zeng, NX; Dagrag, M; Birnbaumer, M; Walsh, JH			First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B GASTRIN RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; BETA-2-ADRENERGIC RECEPTOR; CHROMOSOMAL LOCALIZATION; CA2+ MOBILIZATION; ADENYLYL CYCLASE; CLONAL GROWTH; RAT PANCREAS; LUNG-CANCER	Cholecystokinin (CCK)-A and CCK-B receptors are highly homologous members of the seven transmembrane domain G-protein-coupled receptor superfamily. Genes of both receptors contain five exons and share a similar exon-intron organization. To determine the structural basis of CCK-A receptor (CCK-AR) functionally coupled to G(s), a series of chimeric mutants were constructed by replacing exons of human CCK-B receptor (CCR-BR), from the second to the fifth (last) exon, with human CCK-AR counterparts. Binding and signal transduction properties of wild-type and chimeric receptors were examined in stably transfected HEK-293 cells, Chimeric receptors that maintained high affinity binding to CCK exhibited dose-dependent increases in intracellular calcium mobilization similar to both wildtype receptors. However; only the wild-type CCK-AR and chimeric mutants containing the second exon of CCK-AR were able to mediate significantly greater in: creases in intracellular cAMP content and adenylyl cyclase activity compared with wild-type CCK-BR, A CCK-BR mutant was further constructed by replacing five amino acids, Gly-Leu-Ser-Arg-(Arg)-Leu, in the first intracellular loop with the corresponding five CCK-AR specific amino acids, Ile-Arg-Asn-Lys-(Arg)-Met. The resultant receptor maintained high affinity binding to both CCK and gastrin and dose-dependent calcium responses similar to wild-type CCK-BR. However, this first intracellular loop mutant also gained positive cAMP responses to both sulfated CCK-8 and gastrin-17 with EC(50) values of 8.5 +/- 1 nm and 23 +/- 7 nnn, respectively. These data suggest that the first intracellular loop of CCK-AR is essential for coupling to G(s) and activation of adenylyl cyclase signal transduction cascade.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV DIGEST DIS,DIGEST DIS RES CTR,CURE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT ANESTHESIOL,LOS ANGELES,CA 90024; VET ADM MED CTR,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK-40301, DK-17294, DK-10054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK017294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; Beinborn M, 1996, GASTROENTEROLOGY, V110, pA1059; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; GALAS MC, 1992, EUR J PHARMACOL, V22, P35; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HERGET T, 1994, ANN NY ACAD SCI, V713, P283, DOI 10.1111/j.1749-6632.1994.tb44076.x; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; LEE YM, 1993, J BIOL CHEM, V268, P8164; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MANTAMADIOTIS T, 1994, BIOCHEM BIOPH RES CO, V201, P1382, DOI 10.1006/bbrc.1994.1856; MARINO CR, 1993, FEBS LETT, V316, P48, DOI 10.1016/0014-5793(93)81734-H; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MILLER LJ, 1995, GASTROENTEROLOGY, V109, P1375, DOI 10.1016/0016-5085(95)90601-0; MITSUHASHI M, 1992, J NEUROSCI RES, V32, P437, DOI 10.1002/jnr.490320315; MIYAKE A, 1995, BIOCHEM BIOPH RES CO, V208, P230, DOI 10.1006/bbrc.1995.1328; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; PRINZ C, 1994, GASTROENTEROLOGY, V107, P1067, DOI 10.1016/0016-5085(94)90231-3; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SETHI T, 1993, CANCER RES, V53, P5208; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SONG I, 1993, P NATL ACAD SCI USA, V90, P9085, DOI 10.1073/pnas.90.19.9085; TAKATA Y, 1995, BIOCHEM BIOPH RES CO, V213, P958, DOI 10.1006/bbrc.1995.2222; TANIGUCHI T, 1994, ONCOGENE, V9, P861; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Walsh John H., 1994, P1; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; XIONG YT, 1995, ENDOCRINOLOGY, V136, P1828, DOI 10.1210/en.136.5.1828; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999	36	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9037	9042						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083028				2022-12-27	WOS:A1997WU03700033
J	Zako, M; Shinomura, T; Kimata, K				Zako, M; Shinomura, T; Kimata, K			Alternative splicing of the unique ''PLUS'' domain of chicken PG-M/versican is developmentally regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MOUSE INTERPHOTORECEPTOR MATRIX; DEDUCED PRIMARY STRUCTURE; COMPLETE CODING SEQUENCE; CORE PROTEIN; PIGMENT-EPITHELIUM; IMMUNOCYTOCHEMICAL LOCALIZATION; CARTILAGE PROTEOGLYCAN; CONE PHOTORECEPTORS; HUMAN VERSICAN	We investigated the occurrence of alternatively spliced forms (V0, V1, V2, and V3) of PG-M/versican, a large chondroitin sulfate proteoglycan in developing chicken retinas, using the reverse transcription-polymerase chain reaction. We characterized the PLUS domain, which is apparently unique to the chicken molecule and is regulated by alternative splicing. PG-M in chicken retinas consisted of four forms with (V0, V1, V2, and V3) and two forms without (V1 and V3) the PLUS domain (PG-M(+) and PG-M(-), respectively). The four forms of PG-M(+) were found in all samples examined, but the occurrence of the two PG-M(-) forms was regulated developmentally. Genomic analysis has revealed that the PLUS and CS-alpha domains are encoded by a single exon, and this exon has an internal alternative 5'-splice donor site, allowing alternative spliced forms that do not include the 3'-end of the exon. Sequences corresponding to the chicken PLUS domain (plus) were not found in mouse and human and may have disappeared during evolution. Sequence similarity suggests that the PLUS domain corresponds to the keratan sulfate attachment domain of aggrecan and that it has a distinct function in the chicken eye.	AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN	Aichi Medical University								AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; FULOP C, 1993, J BIOL CHEM, V268, P17377; HAGEMAN GS, 1987, CURR EYE RES, V6, P639, DOI 10.3109/02713688709025225; HOLLYFIELD JG, 1989, RETINA-J RET VIT DIS, V9, P59, DOI 10.1097/00006982-198909010-00008; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; IWASAKI M, 1992, EXP EYE RES, V54, P415, DOI 10.1016/0014-4835(92)90054-V; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDERS RA, 1991, EXP EYE RES, V52, P65, DOI 10.1016/0014-4835(91)90129-3; LANDERS RA, 1992, EXP EYE RES, V55, P345, DOI 10.1016/0014-4835(92)90199-3; LAZARUS HS, 1992, INVEST OPHTH VIS SCI, V33, P364; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Li H, 1995, J MOL EVOL, V41, P878; LI H, 1993, J BIOL CHEM, V268, P23504; McKeown M, 1990, Genet Eng (N Y), V12, P139; MORRIS JE, 1984, J NEUROCHEM, V42, P798, DOI 10.1111/j.1471-4159.1984.tb02752.x; MORRIS JE, 1981, J NEUROCHEM, V37, P1594, DOI 10.1111/j.1471-4159.1981.tb06332.x; MORRIS JE, 1987, ARCH BIOCHEM BIOPHYS, V258, P206, DOI 10.1016/0003-9861(87)90337-7; MORRIS JE, 1984, ARCH BIOCHEM BIOPHYS, V235, P127, DOI 10.1016/0003-9861(84)90261-3; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NASO MF, 1994, J BIOL CHEM, V269, P32999; NEEDHAM LK, 1988, DEV BIOL, V126, P304, DOI 10.1016/0012-1606(88)90140-6; PORELLO K, 1989, INVEST OPHTH VIS SCI, V30, P638; PORRELLO K, 1986, CURR EYE RES, V5, P981, DOI 10.3109/02713688608995180; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHINOMURA T, 1995, J BIOL CHEM, V270, P10328, DOI 10.1074/jbc.270.17.10328; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRAMM LE, 1987, INVEST OPHTH VIS SCI, V28, P618; TAWARA A, 1990, EXP EYE RES, V51, P301, DOI 10.1016/0014-4835(90)90027-R; TAWARA A, 1989, EXP EYE RES, V48, P815, DOI 10.1016/0014-4835(89)90066-3; UJITA M, 1994, J BIOL CHEM, V269, P27603; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; VARNER HH, 1987, EXP EYE RES, V44, P633, DOI 10.1016/S0014-4835(87)80135-5; WALCZ E, 1994, GENOMICS, V22, P364, DOI 10.1006/geno.1994.1396; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9325	9331						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083069	hybrid			2022-12-27	WOS:A1997WU03700074
J	Azam, N; Dixon, JE; Sadowski, PD				Azam, N; Dixon, JE; Sadowski, PD			Topological analysis of the role of homology in Flp-mediated recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; SACCHAROMYCES-CEREVISIAE; 2-MU-M PLASMID; BACTERIOPHAGE-LAMBDA; INTEGRATIVE RECOMBINATION; HOLLIDAY JUNCTIONS; SUBSTRATES REVEAL; STRAND EXCHANGE; CIRCLE PLASMID; CHI-STRUCTURES	Recombination by the Flp recombinase of Saccharomyces cerevisiae is known to be inhibited by heterology of the overlap regions of the two recombining DNA targets (FRT sites). We have used topological analysis to show that Flp can promote two rounds of intramolecular recombination between heterologous FRT sites contained within the same supercoiled plasmid. The products are in parental nonrecombinant configuration. Thus, heterology may appear to ''block'' recombination by rendering the heteroduplex recombinant products unstable, thus favoring a second round of recombination to homoduplex (but parental) products. Hence, homology in the core region is not a requirement for the recombination reaction by Flp but for the formation of recombinant products.	UNIV TORONTO, DEPT MED GENET & MICROBIOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARCISZEWSKA L, 1995, EMBO J, V14, P2651, DOI 10.1002/j.1460-2075.1995.tb07263.x; BABINEAU D, 1985, J BIOL CHEM, V260, P2313; BAUER CE, 1985, J MOL BIOL, V181, P187, DOI 10.1016/0022-2836(85)90084-1; BEATTY LG, 1986, J MOL BIOL, V188, P529, DOI 10.1016/S0022-2836(86)80003-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GRIFFITH JD, 1985, P NATL ACAD SCI USA, V82, P3124, DOI 10.1073/pnas.82.10.3124; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; LEE JH, 1995, J BIOL CHEM, V270, P19086, DOI 10.1074/jbc.270.32.19086; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MCLEOD M, 1986, MOL CELL BIOL, V6, P3357, DOI 10.1128/MCB.6.10.3357; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PAN H, 1991, J BIOL CHEM, V266, P11347; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; QIAN XH, 1990, J BIOL CHEM, V265, P21779; REYNOLDS AE, 1987, MOL CELL BIOL, V7, P3566, DOI 10.1128/MCB.7.10.3566; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SADOWSKI PD, 1987, DNA REPLICATION RECO, P691; SAMBROOK J, 1989, MOL CLONING LAB MANU, P938; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; UMLAUF SW, 1988, EMBO J, V7, P1845, DOI 10.1002/j.1460-2075.1988.tb03017.x; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; WAITE LL, 1995, J BIOL CHEM, V270, P23409, DOI 10.1074/jbc.270.40.23409; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646	54	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8731	8738		10.1074/jbc.272.13.8731	http://dx.doi.org/10.1074/jbc.272.13.8731			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079707	hybrid			2022-12-27	WOS:A1997WQ63500090
J	GeddeDahl, M; Freisewinkel, I; Staschewski, M; Schenck, K; Koch, N; Bakke, O				GeddeDahl, M; Freisewinkel, I; Staschewski, M; Schenck, K; Koch, N; Bakke, O			Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; MEMBRANE INSERTION; SURFACE EXPRESSION; CYTOPLASMIC TAIL; GAMMA-CHAIN; CDNA CLONE	Invariant chain (Ii) is a transmembrane type II protein that forms a complex with the major histocompatibility complex (MHC) class II molecules in the endoplasmic reticulum (ER). The membrane proximal luminal region of Ii is responsible for the non-covalent association with MHC class II molecules. Chemical cross-linking in COS cells was used to study the effect of luminal and cytoplasmic deletions on trimerization of Ii. We demonstrate that trimerization of Ii is independent of the cytosolic tail of Ii, whereas residues 162-191 (the sequence encoded by exon 6) in the luminal part of Ii are essential for trimer formation. Immunofluorescence studies of the transfected luminal deletion constructs show that the amino acids encoded by exon 6 of Ii are also essential for the induction of large endosomal vesicles. The data suggest that Ii must be in a trimeric form to modify the endosomal pathway.	UNIV OSLO, DEPT BIOL, DIV MOL CELL BIOL, N-0316 OSLO, NORWAY; UNIV BONN, INST ZOOL, IMMUNOBIOL SECT, D-53117 BONN, GERMANY	University of Oslo; University of Bonn				Bakke, Oddmund/0000-0003-4843-7626				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENHAM A, 1995, IMMUNOL TODAY, V16, P359, DOI 10.1016/0167-5699(95)80157-X; BERTOLINO P, 1995, J IMMUNOL, V154, P5620; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BREMNES B, 1994, J CELL SCI, V107, P2021; Busch R, 1996, CURR OPIN IMMUNOL, V8, P51, DOI 10.1016/S0952-7915(96)80105-1; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CLAESSON L, 1993, BIOCHEMISTRY-US, V22, P3206; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GAMBARI R, 1987, ANN NY ACAD SCI, V511, P292, DOI 10.1111/j.1749-6632.1987.tb36258.x; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; HENKES W, 1988, NUCLEIC ACIDS RES, V16, P11822, DOI 10.1093/nar/16.24.11822; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; OSULLIVAN DM, 1986, P NATL ACAD SCI USA, V83, P4484, DOI 10.1073/pnas.83.12.4484; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PIETERS J, 1993, J CELL SCI, V106, P831; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SENGUPTA DJ, 1994, EMBO J, V13, P982, DOI 10.1002/j.1460-2075.1994.tb06343.x; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STANG E, 1993, J CELL BIOCHEM, P29; STORRIE B, 1984, J CELL BIOL, V98, P108, DOI 10.1083/jcb.98.1.108; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; SUNG E, 1981, MOL IMMUNOL, V18, P899, DOI 10.1016/0161-5890(81)90013-4; Tjelle TE, 1996, J CELL SCI, V109, P2905	52	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8281	8287		10.1074/jbc.272.13.8281	http://dx.doi.org/10.1074/jbc.272.13.8281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079649	hybrid			2022-12-27	WOS:A1997WQ63500032
J	Horwitz, SB; Shen, HJ; He, LF; Dittmar, P; Neef, R; Chen, JH; Schubart, UK				Horwitz, SB; Shen, HJ; He, LF; Dittmar, P; Neef, R; Chen, JH; Schubart, UK			The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAGE-SPECIFIC EXPRESSION; ENCODING PHOSPHOPROTEIN P19; ACTIVATED PROTEIN-KINASE; MAJOR CYTOSOLIC TARGET; MASS-SPECTROMETRY; MAMMALIAN-CELLS; GROWTH-FACTOR; RAT-BRAIN; IDENTIFICATION; ONCOPROTEIN-18	Metablastin (also called p19, stathmin, prosolin, p18, Lap18, and oncoprotein 18) is a highly conserved, cytosolic 149-amino acid polypeptide that is expressed in immature vertebrate cells and undergoes extracellular factor- and cell cycle-regulated serine phosphorylation. The protein was shown recently to destabilize microtubules in vitro (Belmont, L., and Mitchison, T. J. (1996) Cell 84, 623-631). Here we demonstrate that microinjection of recombinant metablastin induces a loss of microtubules in COS-7 cells. This effect is enhanced by serine-to-alanine mutations at several phosphorylation sites and virtually abolished by aspartate substitution at a single site, Ser-63. We also show that stoichiometric amounts of metablastin prevent assembly and promote disassembly of microtubules in vitro. Interestingly, the phosphorylation site mutations of metablastin that have dramatic differential effects in intact cells do not alter the ability of metablastin to block tubulin assembly in vitro. The data suggest that phosphorylation of metablastin controls its microtubule-destabilizing activity in vivo but that this regulation may require additional cellular factors. This control mechanism is poised to play a critical role in the dynamic reorganization of the cellular microtubule network that occurs during morphogenesis and mitosis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [R35CA039821, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026333] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA13330, CA39821] Funding Source: Medline; NINDS NIH HHS [NS26333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; AMAT JA, 1990, MOL REPROD DEV, V26, P383, DOI 10.1002/mrd.1080260414; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRATTIN WJ, 1981, MOL CELL ENDOCRINOL, V23, P77, DOI 10.1016/0303-7207(81)90118-0; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; COOPER HL, 1989, J IMMUNOL, V143, P956; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOYE V, 1990, J BIOL CHEM, V265, P11650; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; SAHAI A, 1986, CANCER RES, V46, P4143; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; WANG YK, 1993, J BIOL CHEM, V268, P14269	35	120	124	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8129	8132		10.1074/jbc.272.13.8129	http://dx.doi.org/10.1074/jbc.272.13.8129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079624	hybrid			2022-12-27	WOS:A1997WQ63500007
J	Iwatsuki, K; Endo, T; Misawa, H; Yokouchi, M; Matsumoto, A; Ohtsubo, M; Mori, KJ; Yoshimura, A				Iwatsuki, K; Endo, T; Misawa, H; Yokouchi, M; Matsumoto, A; Ohtsubo, M; Mori, KJ; Yoshimura, A			STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of all erythroleukemia cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA CHAIN; INTERLEUKIN-3; PROLIFERATION; REQUIRES; SIGNALS; REGION	Interaction between erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. EPO has been shown to activate the JAK2-STAT5 pathway in various hematopoietic cell lines, although the physiological role of this pathway is unclear. We have previously shown that epidermal growth factor activates a chimeric receptor bearing the extracellular domain of the epidermal growth factor receptor linked to the cytoplasmic domain of the EPO receptor, resulting in proliferation of interleukin-3-dependent hematopoietic cells and erythroid differentiation (globin synthesis) of EPO-responsive erythroleukemia cells. In the present study, we introduced various deletion and tyrosine to phenylalanine substitution in the cytoplasmic domain of the chimeric receptor and expressed these mutant chimeras in an EPO-responsive erythroleukemia cell line, ELM-I-1. Mutant chimeric receptors retaining either Tyr(343) or Tyr(401) could activate STATE, judged by tyrosine-phosphorylation of STATE and induction of CIS, a target gene of STAT5, These mutants were able to induce erythroid differentiation. However, a chimeric receptor containing both Y343F and Y401F mutations could not activate STAT5 nor induce erythroid differentiation. Thus, Tyr(343) Or Tyr(401) Of the EPO receptor are independently necessary for erythroid differentiation as well as STAT5 activation. Moreover, exogenous expression of dominant-negative STAT5 suppressed EPO-dependent erythroid differentiation. These findings suggest that STAT5 plays an important role in erythroid differentiation through the EPO receptor cytoplasmic domain.	KURUME UNIV, INST LIFE SCI, KURUME, FUKUOKA 839, JAPAN; UNIV TOKYO, BUNKYO KU, TOKYO 113, JAPAN; NIIGATA UNIV, FAC SCI, DEPT BIOL, LAB MOL & CELLULAR SCI, NIIGATA 95021, JAPAN	Kurume University; University of Tokyo; Niigata University			Yoshimura, Akihiko/K-5515-2013	ohtsubo, motoaki/0000-0002-2479-3178				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CARROLL M, 1995, P NATL ACAD SCI USA, V92, P2869, DOI 10.1073/pnas.92.7.2869; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITHO K, 1988, LEUKEMIA RES, V12, P471; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; KROSL J, 1995, BLOOD, V85, P50, DOI 10.1182/blood.V85.1.50.bloodjournal85150; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA O, 1994, J BIOL CHEM, V269, P614; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	34	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8149	8152		10.1074/jbc.272.13.8149	http://dx.doi.org/10.1074/jbc.272.13.8149			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079629	hybrid			2022-12-27	WOS:A1997WQ63500012
J	Koli, KM; Ramsey, TT; Ko, Y; Dugger, TC; Brattain, MG; Arteaga, CL				Koli, KM; Ramsey, TT; Ko, Y; Dugger, TC; Brattain, MG; Arteaga, CL			Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; DEPENDENT KINASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; CANCER-CELLS; TGF-BETA; II RECEPTOR; DIFFERENTIAL REGULATION; EXPRESSION; LINES; TAMOXIFEN	We have studied the role of autocrine transforming growth factor-beta (TGF-beta) signaling on antiestrogen mediated growth inhibition of hormone-dependent T47D and MCF-7 human breast carcinoma cells, Tamoxifen treatment increased the secretion of TGF-beta activity into serum-free cell medium and the cellular content of affinity cross-linked type I and III TGF-beta receptors in both cell lines, Anti-pan-TGF-beta antibodies did not block antiestrogen-induced recruitment in G(1) and inhibition of anchorage-dependent and -independent growth of both cell lines, Early passage MCF-7 cells, which exhibit de detectable type II TGF-beta receptors at the cell surface and exquisite sensitivity to exogenous TGF-beta 1, were transfected with a tetracycline-controllable dominant-negative TGF-beta RII (Delta RII) construct, Although the TGF-beta 1 response was blocked by removal of tetracycline in MCF-7/Delta RII cells, tamoxifen-mediated suppression of Rb phosphorylation, recruitment in G(1), and inhibition of cell proliferation were identical in the presence and absence of tetracycline. TGF-beta 1 treatment up-regulated the Cdk inhibitor p21 and induced its association with Cdk2 in MCF-7 cells; these responses were blocked by the Delta RII transgene product, In MCF-7 cells with a functional TGF-P signaling pathway, tamoxifen did not upregulate p21 nor did it induce association of p21 with Cdk2, suggesting alternative mechanisms for antiestrogen-mediated cytostasis, Finally, transfection of late-passage, TGF-beta 1 unresponsive MCF-7 cells with high levels of TGF-beta RII restored TGF-beta 1-induced growth inhibition but did not enhance tamoxifen response in culture, Taken together these data strongly argue against any role for TGF-beta signaling on tamoxifen-mediated growth inhibition of hormone-dependent breast cancer cells.	VANDERBILT UNIV, DIV MED ONCOL, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA; VANDERBILT CANC CTR, NASHVILLE, TN 37232 USA; MED COLL OHIO, DEPT BIOCHEM & MOL BIOL, TOLEDO, OH 43699 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University					NATIONAL CANCER INSTITUTE [R37CA038173, R01CA054807, R01CA062212, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA62212, CA38173, CA54807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARRICK BA, 1990, CANCER RES, V50, P299; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARTEAGA CL, 1991, REGULATORY MECHANISM, P289; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; BUTTA A, 1992, CANCER RES, V52, P4261; CHEN AR, 1993, BLOOD, V81, P2539; COHEN PS, 1995, CANCER RES, V55, P2380; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JENG MH, 1993, MOL CELL ENDOCRINOL, V97, P115, DOI 10.1016/0303-7207(93)90217-8; JENG MH, 1991, MOL ENDOCRINOL, V5, P1120, DOI 10.1210/mend-5-8-1120; JI HJ, 1994, J CELL BIOCHEM, V54, P332, DOI 10.1002/jcb.240540309; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KAREY KP, 1988, CANCER RES, V48, P4083; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; Koli KM, 1996, J MAMMARY GLAND BIOL, V1, P373, DOI 10.1007/BF02017393; KOPP A, 1995, CANCER RES, V55, P4512; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LUCAS C, 1990, J IMMUNOL, V145, P1415; LYONS RM, 1991, MOL ENDOCRINOL, V5, P1887, DOI 10.1210/mend-5-12-1887; MACCALLUM J, 1996, BRIT J CANCER, V74, P464; MOSES HL, 1990, KAR INS NCS, P141; MOSES HL, 1985, CANCER CELL, V3, P65; MURRAY PA, 1994, EUR J CANCER, V30A, P1218, DOI 10.1016/0959-8049(94)90161-9; NORGAARD P, 1994, BRIT J CANCER, V69, P802, DOI 10.1038/bjc.1994.158; OSBORNE CK, 1983, CANCER RES, V43, P3583; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SUN LZ, 1994, J BIOL CHEM, V269, P26449; THOMPSON AM, 1991, BRIT J CANCER, V63, P609, DOI 10.1038/bjc.1991.140; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	54	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8296	8302		10.1074/jbc.272.13.8296	http://dx.doi.org/10.1074/jbc.272.13.8296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079651	hybrid			2022-12-27	WOS:A1997WQ63500034
J	Mueller, SG; White, JR; Schraw, WP; Lam, V; Richmond, A				Mueller, SG; White, JR; Schraw, WP; Lam, V; Richmond, A			Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; INTERLEUKIN-8 RECEPTOR; NONHEMATOPOIETIC CELLS; PROTEIN-KINASE; PHOSPHORYLATION; SEQUESTRATION; EXPRESSION	We have characterized the ligand-enhanced phosphorylation of the CXC chemokine receptor-2 (CXCR2) in a series of clonal 3ASubE cell lines expressing receptors truncated or mutated in the carboxyl-terminal domain. Truncation of CXCR2 by substitution of a stop codon for Ser-342 (342T) or Ser-331 (331T) results in total loss of melanoma growth stimulatory activity/growth-related protein (MGSA/GRO)-enhanced receptor phosphorylation, which cannot be explained based upon altered ligand binding affinity or receptor number. 3ASubE cells expressing 342T or CXCR2 with mutation of Ser-342, -346, -347, and -348 to alanine (4A) exhibit strong mobilization of Ca2+ in response to ligand (interleukin-8 or MGSA/GRO), with a recovery phase significantly slower than that of cells expressing wild type (WT) CXCR2, In contrast to the WT CXCR2, which is 93% desensitized by 20 nM ligand, the 331T, 342T, and 4A CXCR2 mutants do not undergo significant ligand-induced desensitization, and respond to a second ligand challenge by mobilizing Ca2+. The 3ASubE cells expressing CXCR2 with mutation of Ser-346, -347, and -348 to alanine, or with mutation of only one serine in this domain, continue to be phosphorylated in response to ligand and are 60-70% desensitized following the initial ligand challenge. WT CXCR2 phosphorylation and desensitization occur in <1 min, while receptor sequestration is a much later event (30-60 min). However, mutant receptors that are neither phosphorylated nor desensitized in response to ligand are <10% sequestered 60 min following ligand challenge. These data demonstrate for the first time that ligand binding to CXCR2 results in receptor phosphorylation, desensitization, and sequestration and that serine residues 342 and 346-348 participate in the desensitization and sequestration processes.	VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37212; SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOL,KING OF PRUSSIA,PA 19406	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; GlaxoSmithKline			Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X; White, John R/0000-0003-2998-1626	NATIONAL CANCER INSTITUTE [R01CA034590, R23CA034590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NCI NIH HHS [CA34590] Funding Source: Medline; NIAMS NIH HHS [5P30 AR41943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Franci C, 1996, J IMMUNOL, V157, P5606; Hoffman JF, 1996, J BIOL CHEM, V271, P18394, DOI 10.1074/jbc.271.31.18394; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; LATTION AL, 1994, J BIOL CHEM, V269, P22887; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; MUELLER SG, 1995, J BIOL CHEM, V270, P10439, DOI 10.1074/jbc.270.18.10439; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; RICHMOND A, 1996, CHEMOATTRACTANT LIGA, P87; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; YU SS, 1993, J BIOL CHEM, V268, P337	23	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8207	8214		10.1074/jbc.272.13.8207	http://dx.doi.org/10.1074/jbc.272.13.8207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079638	hybrid			2022-12-27	WOS:A1997WQ63500021
J	Worthylake, R; Wiley, HS				Worthylake, R; Wiley, HS			Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; TYROSINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; BREAST-CANCER; POSTENDOCYTIC TRAFFICKING; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; PROTO-ONCOGENE; NEU-ONCOGENE; MICE LACKING	The epidermal growth factor receptor (EGF-R) is known to transmodulate the activity and level of the erbB-2/neu protein in several epithelial cell lines. We therefore determined which structural features of the EGF-R were important in transmodulating erbB-2, We found that the addition of EGF to nontransformed epithelial cells resulted in down-regulation of erbB-2 with the same kinetics and similar extent as the EGF-R. By using cells expressing a series of EGF-R modified by site-directed mutagenesis, we found that EGF-R tyrosine kinase activity was not necessary for down-regulation of erbB-2, but receptor sequences between 899 and 958 in the EGF-R were required, To determine whether transmodulation was associated with activation of erbB-2, tyrosine phosphorylation of erbB-2 was determined following addition of EGF, Again, phosphorylation of erbB-2 following EGF addition did not require the intrinsic tyrosine kinase activity of the EGF-R, but did require sequences between 899 and 958. To determine the localization of EGF-R and erbB-2 following EGF addition, the relative distribution of the two receptors was evaluated by fluorescence microscopy, Surprisingly, the majority of erbB-2 was found in small cytoplasmic vesicles, whereas the EGF-R was predominantly found on the cell surface. Addition of EGF resulted in a redistribution and consequent colocalization of both receptors in endosomal and lysosomal structures. We conclude that activation and transmodulation of erbB-2 does not require intrinsic tyrosine kinase activity of the EGF-R, but does require sequences in the EGF-R which regulate its trafficking.			Worthylake, R (corresponding author), UNIV UTAH,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132, USA.			Wiley, Steven/0000-0003-0232-6867	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA 42014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baulida J, 1996, J BIOL CHEM, V271, P5251; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DAVIES RL, 1980, P NATL ACAD SCI-BIOL, V77, P4188, DOI 10.1073/pnas.77.7.4188; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DSOUZA B, 1993, ONCOGENE, V8, P1797; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAMPS MP, 1988, ONCOGENE, V2, P305; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARTH C, 1992, INT J CANCER, V52, P311, DOI 10.1002/ijc.2910520226; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Will B H, 1995, Tissue Eng, V1, P81, DOI 10.1089/ten.1995.1.81; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8594	8601		10.1074/jbc.272.13.8594	http://dx.doi.org/10.1074/jbc.272.13.8594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079690	hybrid			2022-12-27	WOS:A1997WQ63500073
J	Guan, ZH; Baier, LD; Morrison, AR				Guan, ZH; Baier, LD; Morrison, AR			p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E(2) biosynthesis stimulated by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GENE DISRUPTION; MAP KINASES; HEAT-SHOCK; SYNTHASE; PHOSPHORYLATION; EXPRESSION; INDUCTION; CYCLOOXYGENASE; CLONING	The inflammatory cytokine interleukin 1 beta (IL-1 beta) induces both cyclooxygenase-2 (Cox-2) and the inducible nitric-oxide synthase (iNOS) with increases in the release of prostaglandins (PGs) and nitric oxide (NO) from glomerular mesangial cells. However, the intracellular signaling mechanisms by which IL-1 beta induces iNOS and Cox-a expression is obscure, Our current studies demonstrate that IL-1 beta produces a rapid increase in p38 mitogen-activated protein kinase (MAPK) phosphorylation and activation. Serum starvation and SC68376, a drug which selectively inhibits p38 MAPK in mesangial cells, were used to investigate whether p38 MAPK contributes to the signaling mechanism of IL-1 beta induction of NO and PG; synthesis. Serum starvation and SC68376 selectively inhibited IL-1 beta-induced activation of p38 MAPK. Both SC68376 and serum starvation enhanced NO biosynthesis by increasing iNOS mRNA expression, protein expression, and nitrite production. In contrast, both SC68376 and serum starvation suppressed PO release by inhibiting Cox-a mRNA, protein expression, and PGE, synthesis. These data demonstrate that IL-1 beta phosphorylates and activates p38 MAPK in mesangial cells, The activation of p38 MAPK may provide a crucial signaling mechanism, which mediates the up-regulation of PG synthesis and the down-regulation of NO biosynthesis induced by IL-1 beta.	ST LOUIS UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL & MED, ST LOUIS, MO 63110 USA	Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUAN Z, 1996, AM J PHYSIOL, V270, pF738; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P44; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RZYMKIEWICZ DM, 1995, KIDNEY INT, V47, P1354, DOI 10.1038/ki.1995.191; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	34	167	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					8083	8089		10.1074/jbc.272.12.8083	http://dx.doi.org/10.1074/jbc.272.12.8083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065483	hybrid			2022-12-27	WOS:A1997WP59200077
J	Schmidt, U; Darke, PL				Schmidt, U; Darke, PL			Dimerization and activation of the herpes simplex virus type 1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLEAVAGE SITES; ACTIVE-SITE; MATURATIONAL PROTEINASE; IDENTIFICATION; SUBSTRATE; PEPTIDE; GENE; PURIFICATION; EXPRESSION	The quaternary state of the herpes simplex virus type 1 (HSV-1) protease has been analyzed in relation to its catalytic activity, The dependence of specific activity upon enzyme concentration indicated that association of the 27-kDa subunits strongly increased activity, Size-exclusion chromatography identified the association as a monomer-dimer equilibrium, Isolation of monomeric and dimeric species from a size-exclusion column followed by immediate assay identified the dimer as the active form of the enzyme. Activation of the protease by antichaotropic cosolvents correlated with changes in the monomer dimer equilibrium, Thus, dimerization of the enzyme was enhanced in solvents containing glycerol or the anions citrate or phosphate, These are substances previously identified as activators of HSV-1 protease (Hall, D. L., and Darke, P. L. (1995) J. Biol, Chem, 270, 22697-22700), The relative potencies of these cosolvents as enzyme activators correlated with their efficiency in promoting dimerization, Under all solvent conditions examined, the dependence of specific activity upon enzyme concentration was consistent with a kinetic model in which only the dimer is active, Dissociation constants for the HSV-1 protease dimer determined with this model at 15 degrees C, pH 7.5, were 964 and 225 nM in 20% glycerol with 0.2 and 0.5 M citrate present, respectively, The activation of the HSV-1 protease by antichaotropic cosolvents was hereby shown to be similar in nature to the activation of the other well characterized herpesvirus protease, that from human cytomegalovirus.	MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486	Merck & Company								BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DARKE PL, 1994, J BIOL CHEM, V269, P18708; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DIIANNI CL, 1993, J BIOL CHEM, V268, P2048; DIIANNI CL, 1994, J BIOL CHEM, V269, P12672; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; GIBSON W, 1974, J VIROL, V13, P155, DOI 10.1128/JVI.13.1.155-165.1974; HALL DL, 1995, J BIOL CHEM, V270, P22697, DOI 10.1074/jbc.270.39.22697; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993; YAMANAKA G, 1995, J BIOL CHEM, V270, P30168	24	49	53	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 21	1997	272	12					7732	7735		10.1074/jbc.272.12.7732	http://dx.doi.org/10.1074/jbc.272.12.7732			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WP592	9065433	hybrid			2022-12-27	WOS:A1997WP59200027
J	Gramatikova, SI; Christen, P				Gramatikova, SI; Christen, P			Monoclonal antibodies against N-alpha-(5'-phosphopyridoxyl)-L-lysine - Screening and spectrum of pyridoxal 5'-phosphate-dependent activities toward amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ANALOGY; PHOSPHOPYRIDOXYLTYROSINE; LYSINE	Cofactors may be expected to expand the range of reactions amenable to antibody-assisted catalysis. The biological importance of pyridoxal 5'-phosphate (PLP) as enzymic cofactor in amino acid metabolism and its catalytic versatility make it an attractive candidate for the generation of cofactor-dependent abzymes. Here we report an efficient procedure to screen antibodies for PLP dependent catalytic activity and detail the spectrum of catalytic activities found in monoclonal antibodies elicited against N-alpha-(5'-phosphopyridoxyl)-L-lysine. This hapten is a nonplanar analog of the planar, resonance-stabilized coenzyme substrate adducts formed in the PLP-dependent reactions of amino acids. The hapten-binding antibodies were screened for binding of the planar Schiff base formed from PLP and D- or L-norleucine by competition enzyme-linked immunosorbent assay, The Schiff base (external aldimine) is an obligatory intermediate in all PLP dependent reactions of amino acids. This simple, yet highly discriminating screening step eliminated most of the total 24 hapten-binding antibodies. Three positive clones bound the Schiff base with L-norleucine, two preferred that with the D-enantiomer. The positive clones were assayed for catalysis of Schiff base formation and of the alpha,beta-elimination reaction with the D and L-enantiomers of beta-chloroalanine. Three antibodies were found to accelerate aldimine formation, and two of these catalyzed the PLP-dependent alpha,beta-elimination reaction. One of the alpha,beta-elimination-positive antibodies catalyzed the transamination reaction with hydrophobic D-amino acids and oxoacids (Gramatikova, S.I., and Christen, P. (1996) J. Biol. Chem. 271, 30583-30586). All catalytically active antibodies displayed continuous turnover. No PLP-dependent reactions other than aldimine formation, alpha,beta-elimination of beta-chloroalanine and transamination were detected. The successive screening steps plausibly simulate the functional selection pressures having been operative in the molecular evolution of primordial PLP-dependent protein catalysts to reaction- and substrate-specific enzymes.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; AULD DS, 1967, J AM CHEM SOC, V89, P2083, DOI 10.1021/ja00985a020; Christen P, 1996, FEBS LETT, V389, P12, DOI 10.1016/0014-5793(96)00298-0; CHRISTEN P, 1994, BIOCH VITAMIN B6 PQQ, P9; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FREEDMAN MH, 1968, BIOCHEMISTRY-US, V7, P1941, DOI 10.1021/bi00845a044; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GRABER R, 1995, EUR J BIOCHEM, V232, P686, DOI 10.1111/j.1432-1033.1995.tb20861.x; Gramatikova SI, 1996, J BIOL CHEM, V271, P30583, DOI 10.1074/jbc.271.48.30583; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; HUBER B, 1996, THESIS U ZURICH; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P133; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; KOCHHAR S, 1989, ANAL BIOCHEM, V178, P17, DOI 10.1016/0003-2697(89)90348-5; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MORINO Y, 1974, J BIOL CHEM, V249, P6684; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; RASO V, 1973, J AM CHEM SOC, V95, P1621, DOI 10.1021/ja00786a043; RASO V, 1975, BIOCHEMISTRY-US, V14, P584, DOI 10.1021/bi00674a019; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; SCHONBECK ND, 1975, J BIOL CHEM, V250, P5343; TUBUL A, 1994, TETRAHEDRON LETT, V35, P5865, DOI 10.1016/S0040-4039(00)78204-9; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	25	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9779	9784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092511				2022-12-27	WOS:A1997WU03900030
J	Hu, SM; Vincenz, C; Buller, M; Dixit, VM				Hu, SM; Vincenz, C; Buller, M; Dixit, VM			A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSCUM CONTAGIOSUM; DNA-SEQUENCE; INTERACTS; PROTEIN; GENOME	Molluscum contagiosum virus proteins MC159 and MC160 and the equine herpesvirus 2 protein E8 share substantial homology to the death effector domain present in the adaptor molecule Fas-associated death domain protein (FADD) and the initiating death protease FADD-like interleukin-1 beta-converting enzyme (FLICE) (caspase-8). FADD and FLICE participate in generating the death signal from both tumor necrosis factor receptor-1 (TNFR-1) and the CD-95 receptor, The flow of death signals from TNFR-1 occurs through the adaptor molecule tumor necrosis factor receptor associated death domain protein (TRADD) to FADD to FLICE, whereas for CD-95 the receptor directly communicates with FADD and then FLICE, MC159 and E8 inhibited both TNFR-1- and CD-95-induced apoptosis as well as killing mediated by overexpression of the downstream adaptors TRADD and FADD, Neither viral molecule, however, inhibited FLICE-induced killing, consistent with an inhibitory action upstream of the active death protease, These data suggest the existence of a novel strategy employed by viruses to attenuate host immune killing mechanisms, Given that bovine herpesvirus 4 protein E1.1 and Kaposi's sarcoma associated herpesvirus protein K13 also possess significant homology to the viral inhibitory molecules MC159, MC160, and E8, it may be that this class of proteins is used ubiquitously by viruses to evade host defense.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; ST LOUIS UNIV,HLTH SCI CTR,DEPT MOL MICROBIOL & IMMUNOL,ST LOUIS,MO 63104	University of Michigan System; University of Michigan; Saint Louis University			Hu, Shimin/H-3427-2019; dixit, vishva m/A-4496-2012	Hu, Shimin/0000-0001-7110-3814; dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [AG13671] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAXBY D, 1988, EPIDEMIOL INFECT, V100, P321, DOI 10.1017/S0950268800067078; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; LOMONTE P, 1995, J GEN VIROL, V76, P1835, DOI 10.1099/0022-1317-76-7-1835; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314	23	253	263	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9621	9624						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092488				2022-12-27	WOS:A1997WU03900007
J	Iversen, PO; Hercus, TR; Zacharakis, B; Woodcock, JM; Stomski, FC; Kumar, S; Nelson, BH; Miyajima, A; Lopez, AF				Iversen, PO; Hercus, TR; Zacharakis, B; Woodcock, JM; Stomski, FC; Kumar, S; Nelson, BH; Miyajima, A; Lopez, AF			The apoptosis-inducing granulocyte-macrophage colony-stimulating factor (GM-CSF) analog E21R functions through specific regions of the heterodimeric GM-CSF receptor and requires interleukin-1 beta-converting enzyme-like proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL-TRANSDUCTION; COMMON BETA-SUBUNIT; CYTOPLASMIC DOMAINS; HEMATOPOIETIC-CELLS; ALPHA CHAIN; B-CELLS; IL-5; DEATH	The granulocyte macrophage colony-stimulating factor (GM-CSF) analog E21R induces apoptosis of hemopoietic cells. We examined the GM-CSF receptor subunit requirements and the signaling molecules involved. Using Jurkat T cells transfected with the GM-CSF receptor we found that both receptor subunits were necessary for E21R-induced apoptosis. Specifically, the 16 membrane-proximal residues of the alpha subunit were sufficient for apoptosis. This sequence could be replaced by the corresponding sequence from the interleukin-2 receptor common gamma subunit, identifying this as a conserved cytokine motif necessary for E21R-induced apoptosis. Cells expressing the alpha subunit and truncated beta c mutants showed that the 96 membrane-proximal residues of beta c were sufficient for apoptosis, E21R, in contrast to GMCSF, did not alter tyrosine phosphorylation of beta c, suggesting that receptor-associated tyrosine kinases were not activated. Consistent with this, E21R decreased the mitogen-activated protein kinase ERK (extracellular signal-regulated kinase). E21R-induced apoptosis was independent of Fas/APO-1 (CD95) and required interleukin-1 beta-converting enzyme (ICE)-like proteases. In contrast, Bcl-2, which protects cells from growth factor deprivation-induced cell death, did not prevent this apoptosis. These findings demonstrate the GM-CSF receptor and ICE-like protease requirements for E21R-induced apoptosis.	INST MED & VET SCI,DIV HUMAN IMMUNOL,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HUMAN IMMUNOL,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,TOKYO 113,JAPAN	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; Fred Hutchinson Cancer Center; University of Tokyo			Lopez, Angel F/E-2260-2011; Nelson, Brad H/K-2622-2014	Woodcock, Joanna/0000-0001-5127-9687; Lopez, Angel F/0000-0001-7430-0135; Kumar, Sharad/0000-0001-7126-9814; Nelson, Brad/0000-0002-4445-5539				BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Iversen PO, 1996, P NATL ACAD SCI USA, V93, P2785, DOI 10.1073/pnas.93.7.2785; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KUMAR S, 1997, IN PRESS CELL GROWTH; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LOTEM J, 1991, BLOOD, V78, P953; METCALF D, 1984, HEMOPOIETIC COLONIES; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	39	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9877	9883						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092524				2022-12-27	WOS:A1997WU03900043
J	Mei, BS; Kennedy, MW; Beauchamp, J; Komuniecki, PR; Komuniecki, R				Mei, BS; Kennedy, MW; Beauchamp, J; Komuniecki, PR; Komuniecki, R			Secretion of a novel, developmentally regulated fatty acid-binding protein into the perivitelline fluid of the parasitic nematode, Ascaris suum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2 MYELIN PROTEIN; SECONDARY STRUCTURE; 3-DIMENSIONAL STRUCTURE; TRANSPORT PROTEINS; BOVINE HEART; RAT-LIVER; SEQUENCE; GENE; POLYPEPTIDE; EXPRESSION	Early development of the parasitic nematode, Ascaris suum, occurs inside a highly resistant eggshell, and the developing larva is bathed in perivitelline fluid. Two-dimensional gel analysis of perivitelline fluid from infective larvae reveals seven major proteins; a cDNA encoding one of these, As-p18, has been cloned, sequenced, and protein expressed in Escherichia coli. The predicted amino acid sequence of As-p18 exhibits similarities to the intracellular lipid-binding protein (iLBP) family including retinoid- and fatty acid-binding proteins (FABP), As-p18 is unusual in that it possesses a hydrophobic leader that is not present in the mature protein, the developmental regulation of its expression, and in terms of its predicted structure. Recombinant As-p18 is a functional FABP with a high affinity for both a fluorescent fatty acid analog (11-(((5-(dimethylamino)-1-naphthalenyl)sulfonyl)amino) undecanoic acid) and oleic acid, but not retinol. Circular dichroism of rAs-p18 reveals a high beta-sheet content (62%), which is consistent with secondary structure for the protein predicted from sequence algorithms, and the structure of iLBPs, Unusual features are apparent in a structural model of As-p18 generated from existing crystal structures of iLBPs. As-p18 is not found in unembryonated eggs, begins to be synthesized at about day 3 of development, reaches a maximal concentration with the formation of the first stage larva and remains abundant in the perivitelline fluid of the second-stage larva. Since As-p18 is not present in the post-infective third-stage larva or adult worm tissues, it appears to be exclusive to the egg. Surprisingly, however, Northern blot analysis yields mRNA for As-p18 not only in the early larval stages, but also the unembryonated egg, third-stage larvae, and ovaries of adult worms, even though the protein is not detectable from any of those sources. As-p18 may play a role in sequestering potentially toxic fatty acids and their peroxidation products, or it may be involved in the maintenance of the impermeable lipid layer of the eggshell.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606; UNIV GLASGOW,INST BIOMED & LIFE SCI,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,INST PROT CRYSTALLOG,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Toledo; University of Glasgow; University of Glasgow					NIAID NIH HHS [AI 18427] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BARRETT J, 1976, PARASITOLOGY, V73, P109, DOI 10.1017/S0031182000051374; BARRETT J, 1970, COMP BIOCHEM PHYSIOL, V35, P577, DOI 10.1016/0010-406X(70)90974-6; BARRETT J, 1981, BIOCH PARASITIC HELM, P107; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BRUNGR AT, 1987, XPLOR MANUAL VERSION; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AJ, 1980, PARASITOLOGY, V80, P447, DOI 10.1017/S0031182000000913; CLEAVINGER PJ, 1989, DEV BIOL, V133, P600, DOI 10.1016/0012-1606(89)90062-6; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Diaz F, 1995, MOL BIOCHEM PARASIT, V75, P87, DOI 10.1016/0166-6851(95)02498-0; DOUVRES FW, 1969, J PARASITOL, V55, P689, DOI 10.2307/3277198; ESTEVES A, 1993, MOL BIOCHEM PARASIT, V58, P215, DOI 10.1016/0166-6851(93)90043-W; FAIRBAIRN D, 1961, CAN J ZOOLOG, V39, P153, DOI 10.1139/z61-020; FAIRBAIRN DONALD, 1957, EXPTL PARASITOL, V6, P491, DOI 10.1016/0014-4894(57)90037-1; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FRAPIN D, 1993, J PROTEIN CHEM, V12, P443, DOI 10.1007/BF01025044; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAUNERLAND NH, 1993, MOL CELL BIOCHEM, V123, P153, DOI 10.1007/BF01076487; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; JI H, 1994, ELECTROPHORESIS, V15, P391, DOI 10.1002/elps.1150150158; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEDY MW, 1995, J BIOL CHEM, V270, P19277, DOI 10.1074/jbc.270.33.19277; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; KENT UM, 1994, IMMUNOCYTOCHEMICAL M, P29; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MOSER D, 1991, J BIOL CHEM, V266, P8447; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NARAYANAN V, 1988, J BIOL CHEM, V263, P8332; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Roberts LS, 1996, FDN PARASITOLOGY, P419; RODRIGUEZPEREZ J, 1992, EXP PARASITOL, V74, P400, DOI 10.1016/0014-4894(92)90202-L; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TARR GE, 1973, LIPIDS, V8, P7, DOI 10.1007/BF02533232; Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TOMLINSON LA, 1989, J IMMUNOL, V143, P2349; URBAN JF, 1981, P HELM SOC WASH, V48, P241; VANOVERDETTLING L, 1989, MOL BIOCHEM PARASIT, V36, P29, DOI 10.1016/0166-6851(89)90197-7; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Westermeier R., 1993, ELECTROPHORESIS PRAC, P197; WHARTON D, 1980, PARASITOLOGY, V81, P447, DOI 10.1017/S003118200005616X; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419	59	71	74	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9933	9941						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092532	hybrid			2022-12-27	WOS:A1997WU03900051
J	Wiesner, DA; Kilkus, JP; Gottschalk, AR; Quintans, J; Dawson, G				Wiesner, DA; Kilkus, JP; Gottschalk, AR; Quintans, J; Dawson, G			Anti-immunoglobulin-induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; PROTEIN-KINASE; HL-60 CELLS; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION; FACTOR-ALPHA; FREE SYSTEM; DEATH; PATHWAY	Prolonged (>24 h) exposure to anti-IgM tan antigen surrogate that induces membrane cross linking and apoptosis) induced a 3-fold increase in the mass of endogenous ceramide measured by P-32 labeling by diacylglycerol kinase and a 4-fold increase in ceramide as measured by metabolic labeling with [H-3]palmitate in a B-lymphocyte cell line, WEHI 231. This correlated with the induction of apoptosis. Shorter exposure times to anti-IgM (up to 8 h) failed to elicit apoptosis and did not elicit increased ceramide formation, After 8 h, apoptosis occurs concomitantly with ceramide formation over the next 10 h. Further, we showed that exogenous ceramide mimicked anti-IgM-induced apoptosis and that apoptosis was potentiated in serum-free media. Treatment of cells with an inhibitor of ceramide catabolism, N-oleoylethanolamine, increased both ceramide formation and apoptosis and accelerated apoptosis induced by anti-IgM. To examine further how ceramide metabolism is involved in apoptosis, we derived cell lines from a small population of cells resistant to N-oleoylethanolamine. These cell lines were selected based on an altered ceramide metabolic pathway, were resistant to apoptosis induced by anti-IgM, and showed no significant increase in ceramide when challenged with anti-IgM. The basis of this resistance was shown to be the failure to activate neutral sphingomyelinase activity following 24-h treatment with anti-IgM, in contrast to the 2-fold increase in neutral sphingomyelinase activity observed in wild type cells. We have shown previously that transfection of WEHI cells with bcl-x(L) conferred resistance to anti-IgM-induced apoptosis, whereas transfection with bcl-2 did not (Gottschalk, A., Boise, L., Thompson, C., and Quintans, J. (1994) Proc. Natl. Acad. Sci, U. S. A. 91, 7350-7354). In this study, these bcl-x(L) transfectants also displayed increased resistance to exogenous N-acetylsphingosine (C-2-ceramide) or N-hexanoylsphingosine (C-6-ceramide). However, when challenged with anti-IgM the bcl-x(L) transfectants produced levels of ceramide similar to wild type cells, suggesting that ceramide formation is upstream of bcl-x(L) and that it is a major determinant of B-cell death.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,CANC RES CTR,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; University of Chicago					NCI NIH HHS [P0-CA-19266] Funding Source: Medline; NICHD NIH HHS [HD-06426] Funding Source: Medline; NIGMS NIH HHS [T32GM-07281] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006426] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA019266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BANERJEE P, 1992, BIOCHIM BIOPHYS ACTA, V1110, P65, DOI 10.1016/0005-2736(92)90295-W; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DABROWSKY R, 1995, SCIENCE, V265, P1596; DBAIBO GS, 1995, BIOCHEM J, V310, P453, DOI 10.1042/bj3100453; FERRARI G, 1993, J NEUROSCI, V13, P1879; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOTTSCHALK AR, 1993, EUR J IMMUNOL, V23, P2011, DOI 10.1002/eji.1830230843; GOTTSCHALK AR, 1994, INT IMMUNOL, V6, P121, DOI 10.1093/intimm/6.1.121; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Higuchi M, 1996, J IMMUNOL, V157, P297; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITO A, 1995, J NEUROCHEM, V65, P463; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; Kwon G, 1996, BBA-LIPID LIPID MET, V1300, P63, DOI 10.1016/0005-2760(95)00223-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15283; PAVLOVICSURJANCEV B, 1993, J NEUROCHEM, V61, P697; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RENSINGEHL A, 1995, J INFLAMM, V45, P161; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1996, GLYCOCONJUGATE J, V13, P327, DOI 10.1007/BF00731508; WIESNER DA, 1996, J NEUROCHEM, V66, P1414; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	62	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9868	9876						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092523				2022-12-27	WOS:A1997WU03900042
J	Yoneyama, T; Brewer, JM; Hatakeyama, K				Yoneyama, T; Brewer, JM; Hatakeyama, K			GTP cyclohydrolase I feedback regulatory protein is a pentamer of identical subunits - Purification, cDNA cloning, and bacterial expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOSYNTHESIS; BINDING; TETRAHYDROBIOPTERIN; DEFICIENCY; BIOPTERIN; SEQUENCES; ENZYME	GTP cyclohydrolase I feedback regulatory protein (GFRP) mediates feedback inhibition of GTP cyclohydrolase I activity by tetrahydrobiopterin and also mediates the stimulatory effect of phenylalanine on the enzyme activity. To characterize the molecular structure of GFRP, we have purified it from rat liver using an efficient step of affinity chromatography and isolated cDNA clones, based on partial amino acid sequences of peptides derived from purified GFRP, Comparison between the amino acid sequence deduced from the cDNA and the N-terminal amino acid sequence of purified GFRP showed that the mature form of GFRP consists of 83 amino acid residues with a calculated M(r) of 9,542. The isolated GFRP cDNA was expressed in Escherichia coli as a fusion protein with six consecutive histidine residues at its N terminus. The fusion protein was affinity-purified and digested with thrombin to remove the histidine tag, The resulting recombinant GFRP showed kinetic properties similar to those of GFRP purified from rat liver, Cross Linking experiments using dimethyl suberimidate indicated that GFRP was a pentamer of 52 kDa. Sedimentation equilibrium measurements confirmed the pentameric structure of GFRP by giving an average M(r) of 49,734, which is 5 times the calculated molecular weight of the recombinant GFRP polypeptide. Based on the pentameric structure of GFRP, we have proposed a model for the quaternary structure of GFRP and CTP cyclohydrolase I complexes.	UNIV PITTSBURGH, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; OSAKA MED COLL, DEPT BIOCHEM, OSAKA 569, JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Georgia; University of Georgia; Osaka Medical College			Yoneyama, Tohru/ABG-2670-2020					BENESADOUN A, 1976, ANAL BIOCHEM, V70, P241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DHONDT JL, 1983, EUR J PEDIATR, V141, P92, DOI 10.1007/BF00496797; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; KATZENMEIER G, 1991, BIOL CHEM H-S, V372, P991, DOI 10.1515/bchm3.1991.372.2.991; KAUFMAN S, 1978, NEW ENGL J MED, V299, P673, DOI 10.1056/NEJM197809282991301; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCINNES RR, 1984, J CLIN INVEST, V73, P458, DOI 10.1172/JCI111232; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANFORD C, 1961, PHYSICAL CHEM MACROM, P346; Weber K., 1975, PROTEINS, VI, P179; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	25	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	1997	272	15					9690	9696						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU039	9092499				2022-12-27	WOS:A1997WU03900018
J	Jardim, A; Ullman, B				Jardim, A; Ullman, B			The conserved serine-tyrosine dipeptide in Leishmania donovani hypoxanthine-guanine phosphoribosyltransferase is essential for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; OROTATE PHOSPHORIBOSYLTRANSFERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING-SITE; SEQUENCE; IDENTIFICATION; EXPRESSION; MECHANISM; PROTEINS	Crystal structures of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) proteins have implied that the translocation of a flexible loop containing a highly conserved Ser-Tyr dipeptide is necessary for the protection of the proposed oxocarbonium ion transition state of the enzyme (Eads, J. C., Scapin, G. T., Xu, Y., Grubmeyer. C., and Sacchettini, J. C. (1994) Cell 78, 325-334; Schumacher, M. A., Carter, D., Roos, D. S., Ullman, B., and Brennan, R. G. (1996) Nature Struct. Biol. 3, 881-887). An essential role for this Ser-Tyr dyad in HGPRT catalysis has now been verified biochemically and genetically for the Leishmania donovani HGPRT employing a combination of protein modifying reagents and site-directed mutagenesis. Incubation of HGPRT with either tetranitromethane or diethyl pyrocarbonate inactivated the enzyme completely, and peptide sequence analysis revealed that tetranitromethane treatment modified the Tyr residue within the Ser(95)-Tyr(96) dipeptide. Analysis of site-directed mutants confirmed that both amino acids were vital for phosphoribosylation activity. Mutant HGPRTs, S95A, S95E, Y96F, and Y96V, exhibited dramatic reductions in their catalytic capabilities of 2-3 orders of magnitude, whereas HGPRTs containing conservative substitutions, S95C and S95T, displayed only a 2-3-fold decrease in k(cat). K-m values for the substrates of the forward and reverse reactions were largely unchanged for all HGPRT constructs, except for a 4-5-fold decrease in the K-m value of the Y96F and Y96V mutants for phosphoribosylpyrophosphate. Expression of L. donovani hgprt constructs in Escherichia cell indicated that wild type and S95T HGPRTs complemented bacterial phosphoribosyltransferase deficiencies, whereas the S95A and S95C mutants complemented weakly, and the S95E, Y96F, and Y96V HGPRT did not support bacterial growth. These data authenticate that the Ser-Tyr dipeptide that is conserved among all members of the HGPRT family is essential for phosphoribosylation of purine nucleobases by HGPRT.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University					NIAID NIH HHS [AI-23682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R37AI023682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; Bergmann M, 1928, H-S Z PHYSIOL CHEM, V175, P145, DOI 10.1515/bchm2.1928.175.3-4.145; BRAY MR, 1995, BIOCHEMISTRY-US, V34, P2006, DOI 10.1021/bi00006a022; BUNTON CA, 1958, J CHEM SOC, P3588, DOI 10.1039/jr9580003588; CHEN HY, 1995, BIOCHEMISTRY-US, V34, P12276, DOI 10.1021/bi00038a023; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FREE ML, 1990, BIOCHIM BIOPHYS ACTA, V1087, P205, DOI 10.1016/0167-4781(90)90206-H; GIACOMELLO A, 1978, J BIOL CHEM, V253, P6038; GLAZER AN, 1976, PROTEINS, V2, P1; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; Henriksen A, 1996, BIOCHEMISTRY-US, V35, P3803, DOI 10.1021/bi952226y; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KANAANI J, 1995, BIOCHEMISTRY-US, V34, P14987, DOI 10.1021/bi00046a005; KEOUGH DT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P95, DOI 10.1016/0925-4439(91)90045-B; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; Means GE, 1971, CHEM MODIFICATION PR, P105; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MUSHEGIAN AR, 1994, PROTEIN SCI, V3, P1081, DOI 10.1002/pro.5560030711; OZTURK DH, 1995, BIOCHEMISTRY-US, V34, P10764, DOI 10.1021/bi00034a008; PRATT D, 1983, NUCLEIC ACIDS RES, V11, P8817, DOI 10.1093/nar/11.24.8817; Richards PG, 1996, BIOCHEM J, V315, P473, DOI 10.1042/bj3150473; Riordan J F, 1972, Methods Enzymol, V25, P515, DOI 10.1016/S0076-6879(72)25048-0; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; SMITH JC, 1994, SCIENCE, V264, P1327; SOKOLOVSKY M, 1967, BIOCHEM BIOPH RES CO, V27, P20, DOI 10.1016/S0006-291X(67)80033-0; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILSON JM, 1986, J CLIN INVEST, V77, P188, DOI 10.1172/JCI112275; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P426, DOI 10.1021/bi00002a006	43	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					8967	8973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083019	hybrid			2022-12-27	WOS:A1997WU03700024
J	Siegenthaler, G; Roulin, K; ChatellardGruaz, D; Hotz, R; Saurat, JH; Hellman, U; Hagens, G				Siegenthaler, G; Roulin, K; ChatellardGruaz, D; Hotz, R; Saurat, JH; Hellman, U; Hagens, G			A heterocomplex formed by the calcium-binding proteins MRP8 (S100A8) and MRP14 (S100A9) binds unsaturated fatty acids with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOMONOCYTIC ANTIGEN L1; DIFFERENTIATION; EXPRESSION; EPIDERMIS; COMPLEX; KERATINOCYTES; LOCALIZATION; PSORIASIS; MEMBRANE; CLONING	We show that unsaturated fatty acids (FAs) bind reversibly and with high affinity to a heterocomplex of 34 kDa (FA-p34) formed by the non-covalent association of two calcium-binding proteins of the S100 family: MRP8 (S100A8) and MRP14 (S100A9). Fatty acid-competition studies on the [H-3]oleic acid-FA-p34-complex show that oleic, alpha-linoleic, gamma-linolenic, and arachidonic acids have IC50 values of about 1 mu M, whereas palmitic and stearic acids are poor competitors. The binding of arachidonic acid is saturable with a single class of binding site per FA-p34, and a dissociation constant (K-d) of 0.13 mu M is calculated. The individual subunits MRP8 and MRP14 show no binding properties for fatty acids, whereas a p34 complex reconstituted in vitro by the recombinant molecules exhibits binding properties, suggesting that the fatty acid-binding site of FA-p34 is created through heterocomplex formation. Furthermore, we demonstrate that lowering free Ca2+ levels to 16 nM results in a loss of the fatty acid-binding capacity of purified FA-p34. In calcium-induced differentiating keratinocytes, the amounts of FA-p34 are increased in the particulate (2.0 +/- 0.5 pmol of [H-3]oleic acid/mg protein) and in the cytosolic (4.5 +/- 0.6 pmol of [H-3]oleic acid/mg protein) fractions, whereas no FA-p34 can be detected in non-differentiated cultured keratinocytes. In abnormally differentiated keratinocytes (psoriasis) and in human polymorphonuclear leukocytes, FA-p34 is highly expressed (31.35 +/- 1.6 and 349.8 +/- 17.9 pmol of [H-3]oleic acid/mg protein, respectively), pointing toward a role for this heteromer in mediating effects of unsaturated fatty acids in a calcium-dependent way during cell differentiation and/or inflammation.	LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research	Siegenthaler, G (corresponding author), HOP CANTONAL UNIV GENEVA, DERMATOL CLIN, CH-1211 GENEVA 14, SWITZERLAND.							BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; CHAPKIN RS, 1986, J LIPID RES, V27, P945; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; FEINGOLD KR, 1991, ADV LIPID RES, V24, P57; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GABRIELSEN TO, 1986, J AM ACAD DERMATOL, V15, P173, DOI 10.1016/S0190-9622(86)70152-7; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; Hagens G, 1996, GWUMC DEPT, P61; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; HOGG N, 1985, IMMUNOLOGY, V56, P673; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Masouye I, 1996, DERMATOLOGY, V192, P208, DOI 10.1159/000246367; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PARKER CW, 1984, FUNDAMENTAL IMMUNOLO, P697; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; SAINTIGNY G, 1992, J INVEST DERMATOL, V99, P639, DOI 10.1111/1523-1747.ep12668098; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIEGENTHALER G, 1988, EXP CELL RES, V178, P114, DOI 10.1016/0014-4827(88)90383-7; SIEGENTHALER G, 1993, BIOCHEM BIOPH RES CO, V190, P482, DOI 10.1006/bbrc.1993.1073; SIEGENTHALER G, 1994, BIOCHEM J, V302, P363, DOI 10.1042/bj3020363; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; VEERKAMP JH, 1995, P NUTR SOC, V54, P23, DOI 10.1079/PNS19950035; WATANABE N, 1986, CLIN CHEM, V32, P1551; WILKINSON MM, 1988, J CELL SCI, V91, P221; ZWALDO G, 1988, CLIN EXP IMMUNOL, V72, P510	38	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	1997	272	14					9371	9377						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WU037	9083074				2022-12-27	WOS:A1997WU03700079
J	Haltiwanger, RS; Philipsberg, GA				Haltiwanger, RS; Philipsberg, GA			Mitotic arrest with nocodazole induces selective changes in the level of O-linked N-acetylglucosamine and accumulation of incompletely processed N-glycans on proteins from HT29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC PROTEINS; PHOSPHORYLATION SITE; EPITHELIAL-CELLS; HUMAN KERATIN-18; GLYCOSYLATION; NUCLEAR; GLCNAC; GLYCOPROTEINS; OLIGOSACCHARIDES; IDENTIFICATION	O-Linked N-acetylglucosamine (O-GlcNAc) is a ubiquitous and abundant protein modification found on nuclear and cytoplasmic proteins. Several lines of evidence suggest that it is a highly dynamic modification and that the levels of this sugar on proteins may be regulated, Previous workers (Chou, C. F., and Omary, M. B. (1993) J. Biol. Chem. 268, 4465-4472) have shown that mitotic arrest with microtubule-destabilizing agents such as nocodazole causes an increase in the O-GlcNAc levels on keratins in the human colon cancer cell line HT29. We have sought to determine whether this increase in glycosylation is a general (i.e. occurring on many proteins) or a limited (i.e. occurring only on the keratins) process. A general increase would suggest that the microtubule-destabilizing agents were somehow affecting the enzymes responsible for addition and/or removal of O-GlcNAc. Our results suggest that the changes in O-GlcNAc induced by nocodazole are selective for the keratins. The levels of O-GlcNAc on other proteins, including the nuclear pore protein p62 and the transcription factor Spl, are not significantly affected by this treatment. In agreement with these findings, nocodazole treatment caused no change in the activity of the enzymes responsible for addition or removal of O-GlcNAc as determined by direct in vitro assay. Interestingly, nocodazole treatment did cause a dramatic increase in modification of N-glycans with terminal GlcNAc residues on numerous proteins. Potential mechanisms for this and the change in glycosylation of the keratins are discussed.			Haltiwanger, RS (corresponding author), SUNY STONY BROOK,INST CELL & DEV BIOL,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048666] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02427] Funding Source: Medline; NIGMS NIH HHS [GM 48666] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU CF, 1994, J CELL SCI, V107, P1833; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DONG DLY, 1994, J BIOL CHEM, V269, P19321; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HALTIWANGER RS, 1997, IN PRESS BIOCH BIOPH; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KOBATA A, 1994, METHOD ENZYMOL, V230, P200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; STULTS NL, 1989, J BIOL CHEM, V264, P19956; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WICE BM, 1985, J BIOL CHEM, V260, P139	34	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8752	8758		10.1074/jbc.272.13.8752	http://dx.doi.org/10.1074/jbc.272.13.8752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079710	hybrid			2022-12-27	WOS:A1997WQ63500093
J	Valentini, RP; Brookhiser, WT; Park, J; Yang, TX; Briggs, J; Dressler, G; Holzman, LB				Valentini, RP; Brookhiser, WT; Park, J; Yang, TX; Briggs, J; Dressler, G; Holzman, LB			Post-translational processing and renal expression of mouse Indian hedgehog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CLEAVAGE PRODUCT; POLARITY GENE HEDGEHOG; SONIC-HEDGEHOG; SCLEROTOME INDUCTION; PROTEIN; AUTOPROTEOLYSIS; TRANSCRIPTION; HOMOLOG; SOMITES; CLONING	The full-length mouse Indian hedgehog (Ihh) cDNA was cloned from an embryonic 17.5-day kidney library and was used to study the post-translational processing of the peptide and temporal and spatial expression of the transcript, Sequence analysis predicted two putative translation initiation sites. Ihh translation was initiated at both initiation sites when expressed in an in vitro transcription/translation system. Expression of an Ihh mutant demonstrated that the internal translation initiation site was sufficient to produce the mature forms of Ihh, Ihh post-translational processing proceeded in a fashion similar to Sonic and Drosophila hedgehog; the unprocessed form underwent signal peptide cleavage as well as internal proteolytic processing to form a 19-kDa amino-terminal peptide and a 26-kDa carboxyl-terminal peptide. This processing required His(313) present in a conserved serine protease motif. Ihh transcript was detected by in situ RNA hybridization as early as 10 days postcoitum (dpc) in developing gut, as early as 14.5 dpc in the cartilage primordium, and in the developing urogenital sinus, In semiquantitative reverse transcription-polymerase chain reaction experiments, Indian hedgehog transcript was first detected in the mouse metanephros at 14.5 dpc; transcript abundance increased with gestational age, becoming maximal in adulthood, In adult kidney, Ihh transcript was detected only in the proximal convoluted tubule and proximal straight tubule.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PEDIAT UROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Briggs, Josephine P/B-9394-2009	Briggs, Josephine P/0000-0003-0798-1190; Holzman, Lawrence/0000-0002-8961-234X	NIDDK NIH HHS [DK-47566, DK-09375] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047566, F32DK009375] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BUMEROT DA, 1995, MOL CELL BIOL, V15, P2294; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kretzler M, 1996, AM J PHYSIOL-RENAL, V271, pF770; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS DJ, 1995, DEVELOPMENT CAMB, V121, P3168; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Yang TX, 1996, HYPERTENSION, V27, P541, DOI 10.1161/01.HYP.27.3.541	31	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	1997	272	13					8466	8473		10.1074/jbc.272.13.8466	http://dx.doi.org/10.1074/jbc.272.13.8466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WQ635	9079674	hybrid			2022-12-27	WOS:A1997WQ63500057
J	Kaytor, EN; Shih, HM; Towle, HC				Kaytor, EN; Shih, HM; Towle, HC			Carbohydrate regulation of hepatic gene expression - Evidence against a role for the upstream stimulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; TRANSCRIPTION FACTOR USF; LIPOPROTEIN RECEPTOR GENE; GLUCOSE RESPONSE COMPLEX; ACID SYNTHASE PROMOTER; MAJOR LATE PROMOTER; LOOP-HELIX PROTEIN; LIVER S14 GENE; RAT-LIVER; FACTOR BINDS	Hepatic expression of the genes encoding L-type pyruvate kinase (L-PR) and S-14 is induced in rats upon feeding them a high carbohydrate, low fat diet. A carbohydrate response element (ChoRE) containing two CACGTG-type E boxes has been mapped in the 5'-flanking region of both of these genes. The nature of the ChoRE suggests that a member of the basic/helix-loop-helix/leucine zipper family of proteins may be responsible for mediating the response to carbohydrate. Indeed, the upstream stimulatory factor (USF), a ubiquitous basic/helix-loop-helix/leucine zipper protein, is present in hepatic nuclear extracts and binds to the ChoREs of L-PK and S-14 in vitro. We have conducted experiments to determine whether USF is involved in the carbohydrate-mediated regulation of L-PH and S-14. For this purpose, dominant negative forms of USF that are capable of heterodimerizing with endogenous USF but not of binding to DNA were expressed in primary hepatocytes. Expression of these forms did not block either S-14 Or L-PK induction by glucose. In addition, we have constructed mutant ChoREs that retain their carbohydrate responsiveness but have lost the ability to bind USF. Together, these data suggest that USF is not the carbohydrate-responsive factor that stimulates S-14 and L-PK expression and that a distinct hepatic factor is likely to be responsible for the transcriptional response.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007323] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07323] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1988, J BIOL CHEM, V263, P7254; KIM KS, 1992, BIOCHEM BIOPH RES CO, V189, P264, DOI 10.1016/0006-291X(92)91553-3; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MARIASH CN, 1986, METABOLISM, V35, P452, DOI 10.1016/0026-0495(86)90137-X; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIN DH, 1991, J BIOL CHEM, V266, P23834; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WANG XD, 1993, J BIOL CHEM, V268, P14497; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	58	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	1997	272	11					7525	7531		10.1074/jbc.272.11.7525	http://dx.doi.org/10.1074/jbc.272.11.7525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WN147	9054457	hybrid			2022-12-27	WOS:A1997WN14700096
